<SEC-DOCUMENT>0001019056-22-000444.txt : 20220606
<SEC-HEADER>0001019056-22-000444.hdr.sgml : 20220606
<ACCEPTANCE-DATETIME>20220606163424
ACCESSION NUMBER:		0001019056-22-000444
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		75
FILED AS OF DATE:		20220606
DATE AS OF CHANGE:		20220606

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Modular Medical, Inc.
		CENTRAL INDEX KEY:			0001074871
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870620495
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-265444
		FILM NUMBER:		22998502

	BUSINESS ADDRESS:	
		STREET 1:		16772 WEST BERNARDO DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-800-3500

	MAIL ADDRESS:	
		STREET 1:		16772 WEST BERNARDO DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BEAR LAKE RECREATION INC
		DATE OF NAME CHANGE:	19981208
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>modular_s1.htm
<DESCRIPTION>FORM S-1
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:modd="http://modular-medical.com/20211231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_modd_modular%2Dmedical.com_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_049_20210401_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001074871 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_068_Number_5_Number -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-04-01to2021-12-31" name="dei:EntityCentralIndexKey">0001074871</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-01to2021-12-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:UnsecuredDebtCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0074" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:PromissoryNotePayable" contextRef="AsOf2021-03-31" id="xdx2ixbrl0078" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0092" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31" id="xdx2ixbrl0104" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-03-31" id="xdx2ixbrl0105" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:CommonStockIssuable" contextRef="AsOf2021-03-31" id="xdx2ixbrl0130" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-10-012020-12-31" id="xdx2ixbrl0172" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-04-012020-12-31" id="xdx2ixbrl0174" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-10-012021-12-31" id="xdx2ixbrl0176" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-10-012020-12-31" id="xdx2ixbrl0177" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-04-012020-12-31" id="xdx2ixbrl0179" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-10-012021-12-31" id="xdx2ixbrl0186" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-10-012020-12-31" id="xdx2ixbrl0187" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-012021-06-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0225" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0226" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0230" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2021-04-012021-06-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-012021-06-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0238" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0239" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0243" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0244" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0251" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-07-012021-09-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0257" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0258" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0262" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0270" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-10-012021-12-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-10-012021-12-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:SharesIssuableForServices" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:SharesIssuableForServices" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:SharesIssuableForServices" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:SharesIssuedForReverseStockSplit" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:SharesIssuedForReverseStockSplit" contextRef="From2021-10-012021-12-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:SharesIssuedForReverseStockSplit" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-10-012021-12-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-04-012020-06-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-07-012020-09-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_custom_CommonStockIssuableMember" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-10-012020-12-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-10-012020-12-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012020-12-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:GainOnPPPNoteForgiveness" contextRef="From2020-04-012020-12-31" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-04-012020-12-31" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2020-04-012020-12-31" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:SharesIssuableForServices" contextRef="From2020-04-012020-12-31" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2020-04-012020-12-31" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2020-04-012020-12-31" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:ProceedsFromIssuanceOfPromissoryNote" contextRef="From2020-04-012020-12-31" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2021-04-01to2021-12-31" id="xdx2ixbrl0466" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2020-04-012020-12-31" id="xdx2ixbrl0488" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2021-04-012021-12-31_srt_MinimumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P3Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-012021-12-31_srt_MaximumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P5Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2020-04-02" name="us-gaap:LesseeOperatingLeaseTermOfContract">P39M</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-01to2021-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P5Y9M</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-04-01to2021-12-31" id="xdx2ixbrl0568" decimals="INF" unitRef="Pure">0</ix:nonFraction>
  <ix:nonNumeric contextRef="From2021-04-01to2021-12-31" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">P2Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-012021-12-31_us-gaap_StockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">P8Y1M17D</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:UnsecuredDebtCurrent" contextRef="AsOf2020-03-31" id="xdx2ixbrl0749" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShortTermBankLoansAndNotesPayable" contextRef="AsOf2020-03-31" id="xdx2ixbrl0752" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-03-31" id="xdx2ixbrl0772" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2020-03-31" id="xdx2ixbrl0773" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:CommonStockIssuable" contextRef="AsOf2021-03-31" id="xdx2ixbrl0797" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0831" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-04-012020-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0861" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-04-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0862" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-04-012020-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0864" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2019-04-012020-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0870" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0871" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-04-012020-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0874" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-04-012020-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0876" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-04-012020-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0877" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012020-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0880" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0881" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012020-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0882" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0896" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0902" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0903" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0907" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0909" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0910" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0913" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0914" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0915" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_custom_CommonStockIssuableMember" id="xdx2ixbrl0921" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0939" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0942" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="modd:IncreaseDecreaseInLeaseLiability" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0945" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0948" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0951" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInSecurityDeposits" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0959" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0984" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0987" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2020-04-012021-03-31_srt_MinimumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P3Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2020-04-012021-03-31_srt_MaximumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P5Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2020-03-31_custom_AccruedPlacementFeesMember" id="xdx2ixbrl1075" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2020-03-31_custom_AccruedInterestMember" id="xdx2ixbrl1078" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2020-04-02" name="us-gaap:LesseeOperatingLeaseTermOfContract">P39M</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">P8Y4M</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">P3Y11M16D</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="modd-20211231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-04-01to2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CommonStockIssuableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-232021-11-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-23</xbrli:startDate>
        <xbrli:endDate>2021-11-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-10-28_us-gaap_RevolvingCreditFacilityMember_custom_SecuredPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">modd:SecuredPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-10-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-272021-10-28_us-gaap_RevolvingCreditFacilityMember_custom_SecuredPromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">modd:SecuredPromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-27</xbrli:startDate>
        <xbrli:endDate>2021-10-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_us-gaap_CommonStockMember_us-gaap_EmployeeStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_us-gaap_StockOptionMember_us-gaap_EmployeeStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_StockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_StockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CEOAndInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-31_custom_MemberOfBoardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:MemberOfBoardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MemberOfBoardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:MemberOfBoardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-10-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-10-31_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-10-31_srt_BoardOfDirectorsChairmanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-02-14_us-gaap_SubsequentEventMember_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-02-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-092022-02-10_us-gaap_SubsequentEventMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-09</xbrli:startDate>
        <xbrli:endDate>2022-02-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_AccruedWagesAndBonusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedWagesAndBonusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_AccruedWagesAndBonusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedWagesAndBonusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_AccruedPlacementFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedPlacementFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_AccruedPlacementFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedPlacementFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_AccruedInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_AccruedInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_AccruedOtherExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedOtherExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_AccruedOtherExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedOtherExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_StockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_StockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Number">
      <xbrli:measure>modd:Number</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
No. 333-</b></span><span style="font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90D_edei--DocumentType_c20210401__20211231_zOlUlMve8dIj"><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" name="dei:DocumentType">S-1</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1pt; width: 100%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 24pt"><b><span id="xdx_90A_edei--EntityRegistrantName_c20210401__20211231_zU8aqJIPoHd6"><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" name="dei:EntityRegistrantName">MODULAR MEDICAL, INC.</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Exact
    name of registrant as specified in its charter)</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1pt; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20210401__20211231_zJ8u91u7u9J1"><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.5pt; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1pt; width: 37%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3841</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.5pt; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1pt; width: 31%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20210401__20211231_zSy01qjDV446"><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" name="dei:EntityTaxIdentificationNumber">87-0620495</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(State
    or other jurisdiction of <br />
    incorporation or organization)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Primary
    Standard Industrial <br />
    Classification Code Number)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(I.R.S.
    Employer <br />
    Identification Number)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityAddressAddressLine1_c20210401__20211231_z183Zt0E5Bsb"><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" name="dei:EntityAddressAddressLine1">16772 W. Bernardo Drive</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityAddressCityOrTown_c20210401__20211231_zUkWAQAK9bWc"><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" name="dei:EntityAddressCityOrTown">San Diego</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20210401__20211231_zARiT28GgUKk"><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_900_edei--EntityAddressPostalZipCode_c20210401__20211231_z1tLdH5fDuS9"><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" name="dei:EntityAddressPostalZipCode">92127</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--CityAreaCode_c20210401__20211231_zB1iIMIyqY2l"><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" name="dei:CityAreaCode">(858)</ix:nonNumeric></span>
<span id="xdx_903_edei--LocalPhoneNumber_c20210401__20211231_zSoiIrAjKwgi"><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" name="dei:LocalPhoneNumber">800-3500</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Address,
including zip code, and telephone number, including</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>area
code, of registrant&#8217;s principal executive offices)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>James
E. Besser<br />
Chief Executive Officer<br />
16772 W. Bernardo Drive </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>San
Diego, California 92127</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(858)
800-3500</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Name, address, including zip code, and telephone number, including</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>area code, of agent for service)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b><i>With copies to:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Joseph M. Lucosky, Esq.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lawrence Metelitsa, Esq. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lucosky Brookman LLP</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>101 Wood Avenue South, 5</b></span><span style="font-size: 10pt">th <span style="font-family: Times New Roman, Times, Serif"><b>Floor</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Woodbridge, New Jersey 08830</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tel. No.: (732) 395-4400</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fax No.: (732) 395-4401 </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 100%; font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.25pt 0.5pt; text-align: center"><span style="font-size: 10pt"><b>From
    time to time after the effective date of this registration statement</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-size: 10pt"><i>(Approximate
    date of commencement of proposed sale to the public)</i></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If any of the securities
being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933,
check the following box. <span style="font-family: Wingdings">x</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If this Form is filed
to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <span style="font-family: Wingdings">o</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If this Form is a post-effective
amendment filed pursuant to rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. <span style="font-family: Wingdings">o</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If this Form is a post-effective
amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. <span style="font-family: Wingdings">o</span></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->



<!-- Field: Page; Sequence: 2 -->

    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See
definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging
growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-size: 10pt">Large accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Wingdings">o</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-size: 10pt">Accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Wingdings">o</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><span id="xdx_904_edei--EntityFilerCategory_c20210401__20211231_zLIonbZPRmXh"><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated Filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Wingdings">x</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Smaller reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Wingdings"><span id="xdx_905_edei--EntitySmallBusiness_c20210401__20211231_ze4j2yzmFddb"><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">x</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Emerging growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Wingdings"><span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20210401__20211231_zxIa9sBQRY4b"><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">x</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If an emerging growth
company, indicate by checkmark if the registrant has not elected to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <span style="font-family: Wingdings"><span id="xdx_907_edei--EntityExTransitionPeriod_c20210401__20211231_zLVOSCAEgKb4"><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">o</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 10pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date
as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</b></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red"></p>

<!-- Field: Page; Sequence: 3 -->

    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red"><span style="font: 10pt Times New Roman, Times, Serif"><b>PRELIMINARY
PROSPECTUS SUBJECT TO COMPLETION DATED JUNE 6, 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"><span style="font-size: 10pt">The information
in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting offers
to buy these securities in any jurisdiction where the offer or sale is not permitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: Red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="modular001.jpg" alt="" /></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">This prospectus relates
to the resale of up to 1,438,202 shares of common stock, par value $0.001 per share, of Modular Medical, Inc. (&#8220;we,&#8221; &#8220;us,&#8221;
&#8220;our,&#8221; or the &#8220;Company&#8221;), consisting of up to 1,438,202 shares of common stock issuable upon exercise of warrants
(the &#8220;May Warrants&#8221;) to purchase shares of common stock at an exercise price of $6.60 per share originally issued by us on
May 5, 2022 in a private placement of warrants that occurred concurrently with a registered offering of shares of common stock (the &#8220;May
Offering&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">This registration does
not mean that the selling stockholder named herein will actually offer or sell any of these shares. We will not receive any proceeds
from the resale of any of the shares of common stock being registered hereby sold by the selling stockholders. However, we may receive
proceeds from the exercise of the May Warrants held by the selling stockholders exercised, other than pursuant to any applicable cashless
exercise provisions of such warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our common stock
is listed on the Nasdaq Capital Market, or Nasdaq, under the symbol &#8220;MODD.&#8221; On June 2, 2022, the last reported sale
price of our common stock was $4.75 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Following the effectiveness
of the registration statement of which this prospectus forms a part, the sale and distribution of securities offered hereby may be effected
from time to time in one or more transactions that may take place on Nasdaq (or such other market or quotation system on which our common
stock is then listed or quoted), including ordinary brokers&#8217; transactions, privately negotiated transactions or through sales to
one or more dealers for resale of such securities as principals, at market prices prevailing at the time of sale, at prices related to
such prevailing market prices or at negotiated prices. Usual and customary or specifically negotiated brokerage fees or commissions may
be paid by the selling stockholders. The selling stockholders and intermediaries through whom such securities are sold may be deemed
&#8220;underwriters&#8221; within the meaning of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), with respect
to the securities offered hereby, and any profits realized or commissions received may be deemed underwriting compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">This prospectus describes
the general manner in which shares of common stock may be offered and sold by any selling stockholders. When the selling stockholders
sell shares of common stock under this prospectus, we may, if necessary and required by law, provide a prospectus supplement that will
contain specific information about the terms of that offering. Any prospectus supplement may also add to, update, modify or replace information
contained in this prospectus. We urge you to read carefully this prospectus, any accompanying prospectus supplement and any documents
we incorporate by reference into this prospectus and any accompanying prospectus supplement before you make your investment decision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are an &#8220;emerging
growth company&#8221; under applicable Securities and Exchange Commission rules and will be subject to reduced public company reporting
requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investing
in our common stock is highly speculative and involves a significant degree of risk. See &#8220;<span style="text-decoration: underline">Risk Factors</span>&#8221; beginning
on page 14 of this prospectus for a discussion of information that should be considered before making a decision to purchase our common
stock.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
date of this prospectus is June 6, 2022.</b></span></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>



<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 94%"><a href="#modulara001">Prospectus Summary</a></td>
    <td style="vertical-align: bottom; width: 6%; text-align: right">1</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#modulara002">Risk Factors</a></td>
    <td style="vertical-align: bottom; text-align: right">14</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#modulara003">Cautionary Note Regarding Forward-Looking Statements</a></td>
    <td style="vertical-align: bottom; text-align: right">34</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#modulara004">Use of Proceeds</a></td>
    <td style="vertical-align: bottom; text-align: right">35</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#modulara005">Determination of Offering Price</a></td>
    <td style="vertical-align: bottom; text-align: right">36</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#modulara006">Selling Stockholders</a></td>
    <td style="vertical-align: bottom; text-align: right">88</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#modulara007">Plan of Distribution</a></td>
    <td style="vertical-align: bottom; text-align: right">89</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#modulara008">Market for Our Common Stock and Related Stockholder Matters</a></td>
    <td style="vertical-align: bottom; text-align: right">36</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#modulara009">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></td>
    <td style="vertical-align: bottom; text-align: right">36</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#modulara010">Business</a></td>
    <td style="vertical-align: bottom; text-align: right">41</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#modulara016">Directors, Executive Officers and Key Employees</a></td>
    <td style="vertical-align: bottom; text-align: right">71</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#modulara011">Executive Compensation</a></td>
    <td style="vertical-align: bottom; text-align: right">80</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#modulara012">Security Ownership of Certain Beneficial Owners and Management</a></td>
    <td style="vertical-align: bottom; text-align: right">86</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#modulara013">Certain Relationships and Related Party Transactions</a></td>
    <td style="vertical-align: bottom; text-align: right">85</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#modulara017">Description of Capital Stock</a></td>
    <td style="vertical-align: bottom; text-align: right">87</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#modulara018">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></td>
    <td style="vertical-align: bottom; text-align: right">92</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#modulara019">Interests of Named Experts and Counsel</a></td>
    <td style="vertical-align: bottom; text-align: right">92</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#modulara014">Where You Can Find More Information</a></td>
    <td style="vertical-align: bottom; text-align: right">92</td></tr>
  <tr style="vertical-align: bottom">
    <td><a href="#modulara015">Index to Consolidated Financial Statements</a></td>
    <td style="vertical-align: bottom; text-align: right">F-1</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Please read this prospectus
carefully. It describes our business, our financial condition and our results of operations. We have prepared this prospectus so that
you will have the information necessary to make an informed investment decision. You should rely only on the information contained in
this prospectus. We have not authorized anyone to provide you with any information or to make any representations about us, the securities
being offered pursuant to this prospectus or any other matter discussed in this prospectus, other than the information and representations
contained in this prospectus. If any other information or representation is given or made, such information or representation may not
be relied upon as having been authorized by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The information contained
in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any
sale of our common stock. Neither the delivery of this prospectus nor any distribution of securities in accordance with this prospectus
shall, under any circumstances, imply that there has been no change in our affairs since the date of this prospectus. This prospectus
will be updated and made available for delivery to the extent required by the federal securities laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We further note that
the representations, warranties and covenants made by us in any document that is filed as an exhibit to the registration statement of
which this prospectus is a part were made solely for the benefit of the parties to such agreement, including, in some cases, for the
purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant
to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations,
warranties and covenants should not be relied on as accurately representing the current state of our affairs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
and Other Industry Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Unless otherwise indicated,
market data and certain industry forecasts used throughout this prospectus were obtained from various sources, including internal surveys,
market research, consultant surveys, publicly available information and industry publications and surveys. Industry surveys, publications,
consultant surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be
reliable, but that the accuracy and completeness of such information is not guaranteed. We have not independently verified any of the
data from third-party sources nor have we ascertained the underlying economic assumptions relied upon therein. Similarly, internal surveys,
industry forecasts and market research, which we believe to be reliable based upon our management&#8217;s knowledge of the industry,
have not been independently verified. The future performance of the industry and markets in which we operate and intend to operate is
necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the sections titled
&#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-looking Statements&#8221; and elsewhere in this prospectus. These
and other factors could cause results to differ materially from those expressed in these publications and reports.</span></p>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><span id="modulara001"></span>PROSPECTUS SUMMARY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
summary highlights selected information contained elsewhere in this prospectus and does not contain all the information that you should
consider before making your investment decision. Before investing in our securities, you should carefully read this entire prospectus,
including the information set forth under the &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations&#8221; sections of this prospectus and our consolidated financial statements and the accompanying
notes included in this prospectus. Except as otherwise indicated herein or as the context otherwise requires, references in this prospectus
to &#8220;Modular Medical,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Modular
Medical, Inc. and its wholly-owned subsidiary, Quasuras, Inc.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Modular Medical is
a development stage medical device company focused on the design, development, and commercialization of an innovative insulin pump using
modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part patch pump, our
MODD1 product candidate, or MODD1, the Company seeks to fundamentally alter the trade-offs between cost and complexity and access to
the higher standards of care that presently available insulin pumps provide. By simplifying and streamlining the user experience from
introduction, prescription, reimbursement, training and day-to-day use, we seek to expand the wearable insulin delivery device market
beyond the highly motivated &#8220;super users&#8221; and expand the category into the mass market. The product candidate seeks to serve
both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Differentiation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We believe that there
are a number of shortcomings and issues with currently available insulin pumps that prevent a substantial number of people who require
insulin on a daily basis from choosing an insulin pump to treat their diabetes. We believe that by tailoring our insulin pump to address
such factors, we can expand the scope and adoption rate of insulin pump usage. We believe that to achieve broader market acceptance,
an insulin pump must be easier to learn to use, less time consuming to operate, more intuitive to both patients and physicians, and meet
the standards for coverage by insurance providers so that co-payments required from patients are affordable and the hurdles to insurance
coverage are significantly reduced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Among the more prominent
issues are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Complexity</i></span><span style="font-size: 10pt">:
    Many existing pumps are highly complex and require significant technical expertise to use effectively. We believe such pumps were
    designed for &#8220;super users,&#8221; who have high levels of motivation and technical competence. The complexity of pumps proves daunting to less technically inclined users.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cumbersome</i></span><span style="font-size: 10pt">:
    We believe that a majority of existing pumps are bulky and difficult to manage, in many cases requiring additional equipment to introduce
    a catheter to the patient&#8217;s body and up to 48 inches of tubing, which must be replaced frequently, to connect the catheter
    to a pump. This requires users to carry spare parts and other equipment adding to the difficulty of using the pump.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cost</i></span><span style="font-size: 10pt">:
    Costs associated with insulin pump therapy are high and can be prohibitive, especially for those on fixed or limited incomes. These
    costs vary by pump, but multi-thousand-dollar upfront payments, often with substantial co-payments in addition to possible daily
    co-payments on consumables, can easily place current pumps out of reach for patients. This makes insurance providers hesitant to
    pay for them, leading to limited or absent reimbursement/coverage and high hurdles for patients to gain access.</span></td></tr>
  </table>
<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our team has substantial
knowledge of the diabetes industry and experience in developing, obtaining regulatory authorization for, and bringing insulin pumps to
market. Based on this experience, we believe that our innovative insulin pump, using a new and proprietary method of pumping insulin,
can address most or all of these shortcomings. It provides a state-of-the-art insulin pump capable of both basal (steady flow) and bolus
(mealtime dosing) insulin disbursement. It also has been designed considering a natural migration path to multi-chamber/multi-liquid
pumps, potentially offering an exciting array of new therapies to patients with diabetes and other conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our goal is to become
the leader in expanding access to insulin pump technology to a wider portion of diabetes sufferers and provide not just care for the
super users, but &#8220;diabetes care for the rest of us.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The MODD1 is a high-precision,
first-line pump that we believe represents the best choice for new pump patients because it is easy to afford, easy to learn, easy to
use, and has a revolutionary design and technology that enable precision with low-cost manufacture and high reproducibility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Key features include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 8pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Two parts - one reusable,
    one disposable - snap together to form the working system</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">One button interface, easy
    to learn and use</span></td></tr>
  </table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 8pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">90-day reusable, 3-day disposable
    cartridges</span></td></tr>
  </table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Removable at any time from
    an adhesive bracket</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 8pt">&#160;</span></td></tr>
  </table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">No external controller required,
    no charging, no battery replacement</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 8pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 8pt">&#160;</span></td></tr>
  </table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Slim profile, lighter weight</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">A proprietary
survey of American healthcare payors representing 50 million covered lives (approximately 1/3 of U.S. covered lives) performed for us
by industry leading survey firm ISA has demonstrated that a majority of payors are willing to grant equivalent or preferential coverage
for a product with this feature set at launch in exchange for about a 20% rebate. These costs are built into all of our models.</span></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Diabetes
Classifications and Therapies</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Diabetes is typically classified
as either type 1, or T1D, or type 2, or T2D:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 13.5pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">T1D is an auto-immune condition
    characterized by the body&#8217;s nearly complete inability to produce insulin. It is frequently diagnosed during childhood or adolescence.
    Individuals with T1D require daily insulin therapy to survive.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.75pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">T2D represents over 90% of
    all individuals diagnosed with diabetes and is characterized by the body&#8217;s inability to either properly utilize insulin or
    produce sufficient insulin. Initially, many people with T2D attempt to manage their condition with improvements in diet and exercise
    and/or the use of oral medications and/or injection of glucagon-like peptide-1 (GLP-1) drugs. However, as their diabetes advances,
    patients often progress to requiring insulin therapies such as once-daily long-acting insulin and ultimately to intensified mealtime
    rapid-acting insulin therapy. This represents an important portion of the diabetes market with an estimated 1.6 million T2D intensively
    treated with insulin currently in the United States.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 13.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Glucose, the primary
source of energy for cells, must be maintained at certain levels in the blood in order to permit optimal cell function and health. In
people with diabetes, blood glucose levels are not well controlled and frequently become very high, a condition known as hyperglycemia,
and very low, a condition called hypoglycemia. Hyperglycemia can lead to serious long-term complications, including blindness, kidney
disease, nervous system disorders, occlusive vascular diseases, lower-limb amputation, stroke, cardiovascular disease, and death. Hypoglycemia
can lead to confusion or loss of consciousness, often requiring a visit to the emergency room or, in certain cases, result in seizures,
coma, and/or death.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">All people with T1D,
which is our primary market, require daily insulin. According to the Seagrove 2021 Diabetes Blue Book, approximately 18% of people with
T2D in the United States, or 4.7 million people, require insulin (basal (steady supply) alone represents 3.1 million and basal plus mealtime
represent 1.6 million) to manage their diabetes. In this prospectus, we refer to people with T1D and people with T2D who require mealtime
insulin as &#8220;insulin-requiring people with diabetes.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Currently, there are
two primary therapies available for insulin-requiring people with diabetes: multiple daily insulin injections directly into the body
through syringes or insulin pens, referred to as Multiple Daily Injection, or MDI therapy, or the use of an insulin pump to deliver mealtime
insulin boluses (single doses) to help with glucose absorption after carbohydrate consumption and a continuous subcutaneous insulin infusion,
or CSII therapy, into the body. Generally, CSII therapy is considered to provide a number of advantages over MDI therapy, primarily an
improvement in glycemic control, as measured by certain diabetes management tests such as hemoglobin A1c (HbA1c) measure and more recently
Time in Range (TIR) where a continuous glucose measuring device is used to calculate this test. Among other medical benefits, it has
been demonstrated that insulin pump use can decrease glucose variability, reduce the number of hypoglycemia, decrease the daily doses
of insulin and reduce the fear of hypoglycemia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Notwithstanding these
advantages, the difficulty in use resulting from the complexity and cumbersome design of available insulin pumps as well as high and
often prohibitive costs for both the patient and insurance provider has resulted not only in dissatisfaction among many existing pump
users (fewer than half purchase a new pump after the warranty expires per Seagrove Partners estimate), but also has severely limited
the adoption rate of insulin pumps by a large segment of the MDI diabetes population, who we refer to in this prospectus as &#8220;Almost
Pumpers.&#8221;</span></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><img src="modular002.jpg" alt="(Graphic)" style="float: right; margin-left: 20pt" /></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"></span><span style="font-size: 10pt">We define Almost Pumpers as individuals who treat their diabetes with MDI. These individuals
are aware of pumps and the potential benefits, however, for a variety of reasons, they choose to continue giving themselves shots. We
undertook one-on-one interviews with over 200 of these individuals to understand their past experiences on or considering pumps, existing
pump shortcomings, the cost and insurance hurtles challenges, complexity to learn and time and complexity to operate that drives them
to remain on MDI. With this detailed understanding, we brought a series of prototype models to them to react to, so we could refine the
design and include features that would motivate them to be able to use this technology to better care for their diabetes. To date, the
MODD1 pump has been well received by these individuals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">It is estimated that
32% of Americans with T1D use insulin pump therapy. Clinicians were surveyed on potential pump users and identified that 28% of Americans
with T1D, including 44% of those who currently utilize MDI, can be classified as i) having an interest in pump adoption and ii) meeting
the American Diabetes Association guidelines for required glucose control. These individuals do not want to closely manage their glucose
levels and incur the associated time and effort involved - they are the Almost Pumpers. We have developed what we believe to be the most
technologically advanced delivery system to overcome their objections and provide motivation. We believe that there are four addressable
hurdles to adoption:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Usability: the device needs
    to be easy to learn and to operate;</span></td></tr>
    <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Affordability: we will focus
    on overcoming copay and insurance hurdles rather than leaving the &#8220;insurance journey&#8221; to the clinician and patient;</span></td></tr>
    <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Accessibility and Education:
    we will seek to engage patients to sample this new technology by supplying clinicians with free samples and simple training to allow
    people to see first-hand the typical barriers to adoption that have been overcome; and</span></td></tr>
    <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Service and Support: we will
    have a support network available to address their questions and concerns.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 13.5pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our initial
focus for our insulin pump is the almost pumper segment population located in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.75pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We believe this conversion
process, engaging people to try and thereby receive the benefits of our technology will substantially increase adoption of insulin pumps
among both those with T1D and T2D who remain reliant upon multiple daily injections. Diabetes is a disease that appears throughout the
world. Therefore, we cannot segment the market by socioeconomics, education or level of care. We intend to create an insulin pump that
appeals to all Almost Pumpers.</span></p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Insulin Pump</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0; text-align: justify"><span style="font-size: 10pt">Instead
of building complex, bespoke, and difficult to manufacture and maintain pumping and control systems, we began with the technology and
the user in mind. Using proprietary and patented methods of insulin measurement, we were able to eschew the complex mechanisms used today
and instead build a product candidate using only parts from high volume consumer electronics manufacturing lines, breaking the cost vs.
functionality curve that has existed in the insulin pump space and representing the first truly modern insulin pump design.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0; text-align: justify"><span style="font-size: 10pt">The pre-production
models of our low-cost insulin pump are now undergoing the testing required to submit to the Food and Drug Administration, or FDA, for
clearance to market them in the United States. We expect to submit our product candidate to the FDA in March 2022 through a premarket
notification (or 510(k)) process (see the section titled <span style="font-family: Times New Roman, Times, Serif"><i>Government Regulation
</i></span>below for a discussion of the FDA submission process and requirements). After submission, we expect to receive two rounds
of comments from the FDA, and we believe it will take approximately six months to obtain clearance from the FDA. After we obtain clearance
from the FDA, we can commence our commercialization process, as discussed in the section titled <span style="font-family: Times New Roman, Times, Serif"><i>Commercialization
Strategy: Overcoming the Insurance Hurdles </i></span>below. We continue to devote substantial time and resources to better understand
the needs and preferences of Almost Pumpers and the specific patent/provider/payor requirements to motivate change from MDI patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 13.5pt 0 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">MODD1 has several distinguishing
features:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<img src="modular003.jpg" alt="" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">1 - The pump has a
simple button to press to deliver insulin as the patient requires it. The electronic pump uses a simple motor and rotating cam to motivate
the insulin into the patient along with low power Bluetooth (LPBT) and near field communication (NFC) chips to allow the patient to communicate
with their smart phone, tablet, or other mobile computing platform, as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">2 - The pump snaps
together with a three-day disposable cartridge that is patient filled with insulin for delivery. It includes the power source and a simple
coin cell that allows it to run through the 80-hour life of the cartridge.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">3 - There is a set
(not shown) that contains a soft 6 mm cannula and an introducer for insertion into the skin and removal of the needle used to transfer
insulin to the body.</span></p>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">4 - MODD1 comes with
a variety of methods for the patient to wear the pump. Options include: a base plate with adhesive (shown) for attaching to the body
that has features for holding the pump to the patient; overwraps to hold the product candidate to the patient; and a velcro strap
with a base plate suitable for wrapping around the arm or leg of the patient. The system will deliver a small continuous rate, called
a basal, that will provide approximately 50% of the total daily dose required and the user will use the on-pump button to administer
boluses, typically before and after meals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The objective is to
make the product candidate simple to acquire and take home, simple to learn and most importantly, simple to use to expand the pump market,
drive adoption and ultimately better clinical outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Technological
Advantages </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The adoption of new
ultra-high volume technologies will result in far easier manufacturing scale up as parts sourcing and assembly processes are far easier.
The MODD1 was designed from the beginning for mass manufacturing processes and fully automated production assembly lines. This advantage
is compounded by the high availability and already optimized cost reduction in its components. This has resulted in a cost of goods,
estimated on our competitors&#8217; announced margins and sales, 50% lower than our closest patch pump competitor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The adoption of modern,
miniaturized technologies has led to numerous other advantages as well. The MODD1 pump is smaller in overall volume than Insulet&#8217;s
popular Omnipod product and has a lower profile to the skin. Despite this, it holds a full 3mL (300 units) of insulin in line with full
sized pumps such as Tandem and Medtronic, 50% more than the 2mL reservoir in the Omnipod. We believe that this volume advantage over
other patch pumps will be significant as 24% of type 1 and over 50% of the rapidly growing type 2 market require more than 2 milliliters
of insulin every 3 days (the expected wear time of patch pumps).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In addition, our new
and patented pumping modality will provide what we believe is the most even (and thus closest to the function of a healthy pancreas)
delivery of basal insulin in the industry. Basal rate can be delivered almost continuously while other pumps are delivering micro-boluses
every five minutes for the Tandem, Omnipod and Medtronic pumps. We plan to demonstrate the impact of our system on glycemic control in
a future clinical study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The technology allows
the patient to simply add insulin and operate. The battery is included in each cartridge and the device is operated without a controller.
Nothing requires charging. MODD1 has been made push button simple to appeal to a wider audience of users.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">This new technology
has also made the MODD1 lighter than existing offerings. Compared to the Insulet Omnipod pump, MODD1 weighs 20 grams (vs. 26 grams) empty
and 23 grams (vs. 28 grams) fully filled (despite carrying 50% more insulin), a reduction of 23% and 18% respectively. Also, unlike existing
patch pumps, the MODD1 can be removed from the needle and taken off and replaced later if the user desires. This avoids loss of insulin
in a pump due to accidental dislodging of the soft canula, an issue that users have expressed considerable dissatisfaction with on other
patch pumps.</span></p>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">This technology is
also uniquely suited to dual (or more) chamber pumps. We believe that such pumps will be integral to the realization of high time in
range artificial pancreas solutions that require no human intervention, the next step forward from the cumbersome and awkward solutions
today that require the user to announce meals, count and input carbs, and adjust delivery for exercise and sleep. The advantages of cost
and miniaturization are multiplied in a multi-chamber setup and we expect to be able to reach price points, ease of use, and form factor
unlike anything seen in the industry thus far. We believe that a prefilled, multi-hormone peel and stick-patch pump able to function
in a fully autonomous closed loop system with CGM&#8217;s represents the next generation of diabetes care. We believe that we have demonstrated
our technology and are securing the intellectual property on our approach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We believe this technology,
especially in dual chamber, will open up numerous applications outside of diabetes where medication compliance of complex therapy regimes
is difficult, addressing such spaces as weight loss and fertility, and simplifying complex delivery of multi-drug cocktails, especially
those with diverse and challenging dosing schedules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commercialization
Strategy: Overcoming the Insurance Hurdles</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our goal is to establish
MODD1 as the best option for new pump patients as we expand the market into the Almost Pumpers (Type 1 and Type 2) and the newly motivated
CGM users. We seek to grow the market by providing first-line insulin pump therapy that is well suited to meet the needs of both diabetes
patients requiring insulin and their clinicians.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">According to Insulet&#8217;s
    published costs of goods, MODD1 is approximately 50% less expensive to manufacture than Omnipod. This low cost allows us to spend
    more on patients and sampling. This will save money for payers. We can offer the pump with no upfront cost to patients. Benefits
    of MODD1 include:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.75pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">20% discount vs. Insulet (PODD) will drive preferred status</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Designed to use pharmacy benefits manager (PBM) codes as a disposable</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">No new code needed to be reimbursed at launch</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Saves provider an estimated $1062/patient/year vs. Omnipod</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">MODD1 will be sampled and
    given to patients by the doctor or diabetes nurse educator at the time of the patient visit. When a patient is motivated to make
    change, our starter kit will make it easy for the clinician to initiate the new therapy that same day. We seek to eliminate the currently
    challenging &#8220;insurance journey&#8221; and product acquisition timeline and significantly reduce training time for the busy
    clinician, all major hurdles to pump adoption. We intend to add telehealth support to help the patient throughout adoption and use
    and to facilitate greater collaboration between patients and their physicians.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Europe represents
another large potential market for MODD1. Sixty million people in Europe live with diabetes, and approximately $161 billion is spent
annually on diabetes healthcare costs in Europe. At present, cost containment is restricting pump uptake across Europe. Current pump
usage across Europe hovers between 10% and 20% in many markets. Single payor healthcare systems across Europe traditionally attempt to
contain costs in the short term and seek low price technologies with moderate medical benefits. MODD1 will offer a rebalance of this
risk/reward strategy in that payors will incur only minor incremental short-term costs with the benefit of longer-term cost savings associated
with reliable pump use. We intend to employ a partnership strategy across Europe following in-house managed regulatory and pricing activities
in the major markets (e.g., the United Kingdom) and more cost receptive markets (e.g., Nordics). We are targeting European and United
Kingdom approval towards early 2023.</span></p>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our success
depends in part on our ability to obtain patents and trademarks, maintain trade secrets and know-how protection, enforce our proprietary
rights against infringers, and operate without infringing on the proprietary rights of third parties. Because of the length of time and
expense associated with developing new products and bringing them through the regulatory approval process, the health care industry places
considerable emphasis on obtaining patent protection and maintaining trade secret protection for new technologies, products, processes,
know-how, and methods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As of May 31,
2022, we had one issued U.S. utility patent, five published U.S. utility patents, two pending foreign patent applications, and two pending
international Patent Cooperation Treaty (PCT) patent applications covering various aspects of our technology, including our proprietary
fluid movement technology. There can be no assurance that our pending patent applications will result in the issuance of patents, that
patents issued to or licensed by us will not be challenged or circumvented by competitors, or that these patents will be found to be
valid or sufficiently broad to protect our technology or provide us with a competitive advantage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">On
May 2, 2022, we entered into a securities purchase agreement (the &#8220;May 2022 Purchase Agreement&#8221;) with Sio Capital Management,
LLC, an institutional investor (the &#8220;Investor&#8221;), pursuant to which we agreed to sell, in a registered direct offering
(the &#8220;May 2022 Registered Offering&#8221;), an aggregate of 449,438 shares (the &#8220;Shares&#8221;) of our common stock, at a
purchase price per Share of $4.45 and pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase an aggregate of 1,348,314
shares of common stock at a purchase price per Pre-Funded Warrant of $4.44. The Pre-Funded Warrants will be exercisable immediately on
the date of issuance at an exercise price of $0.01 per share and may be exercised at any time until all of the Pre-Funded Warrants are
exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">In
a concurrent private placement (the &#8220;May 2022 Private Placement&#8221; and together with the Registered Offering, the &#8220;May
2022 Offerings&#8221;) under the May 2022 Purchase Agreement, we issued to the Investor warrants (the &#8220;Private Placement Warrants&#8221;)
to purchase an aggregate of 1,438,202 shares of our common stock at an exercise price of $6.60 per share. The May 2022 Private Placement
Warrants will be exercisable six months from date of issuance and have a five-year term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our business
is subject to many significant risks, as more fully described in the section entitled &#8220;Risk Factors&#8221; immediately following
this prospectus summary. You should read and carefully consider these risks, together with the risks set forth under the section entitled
&#8220;Risk Factors&#8221; and all of the other information in this prospectus, including the financial statements and the related notes
included elsewhere in this prospectus, before deciding whether to invest in our common stock. If any of the risks discussed in this prospectus
actually occur, our business, financial condition or operating results could be materially and adversely affected. In particular, our
risks include, but are not limited to, the following:</span></p>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.75pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Even if we are able to obtain
    all regulatory approvals and have completed all other steps needed to be taken to commercialize our insulin pump, if we or any contract
    manufacturers we select fails to comply with the FDA&#8217;s quality system regulations, the manufacturing and distribution of our
    product candidate could be interrupted, and our product sales and operating results could suffer.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">We will need to outsource
    and rely on third parties for various aspects relating to the development, manufacture, sales and marketing of our insulin pump as
    well as in connection with assisting us in the preparation and filing of our FDA submission, and our future success will be dependent
    on the timeliness and effectiveness of the efforts of these third parties.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">We are a developmental-stage
    medical device company and have a history of significant operating losses; we expect to continue to incur operating losses for the
    foreseeable future, and we may never achieve or maintain profitability.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.25pt; text-align: justify"><span style="font-size: 10pt">We
    may not receive the necessary regulatory clearance or approvals for our insulin pump, and failure to timely obtain necessary clearances
    and/or approvals could harm our then operations, including our ability to commercialize our product candidate.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.75pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Obtaining marketing authorization
    in the United States will not obviate the need to obtain marketing authorization in other jurisdictions We must obtain approval from
    foreign regulatory authorities before we can market and sell any of our product candidates in countries outside the United States.
    We will incur additional costs in seeking such approvals, may experience delays in obtaining such approvals and cannot be certain
    that such approvals will be granted.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.75pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Although our product candidate
    does not presently require clinical trials to apply to the FDA for clearance, and even if a clinical trial is conducted, the results
    of our clinical testing may not demonstrate the safety and efficacy of the device or may be equivocal or otherwise not be sufficient
    for us to obtain approval of our product candidate.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.75pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">We require additional capital
    to fund our growth, operations, and obligations, and our growth may be limited.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.75pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Any outbreak or worsening
    of an outbreak of contagious diseases, or other adverse public health developments, could have a material and adverse effect on our
    business operations, financial condition and results of operations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.75pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Our competitors may develop
    products that are more effective, safer and less expensive than ours.</span></td></tr>
  </table>
<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Sales of a significant number
    of shares of our Common Stock in the public markets, or the perception that such sales could occur, could depress the market price
    of our Common Stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.75pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">We have limited internal
    research and development personnel, making us dependent on consulting relationships.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.75pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Technological breakthroughs
    in diabetes monitoring, treatment or prevention could render our insulin pump obsolete.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.75pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">We may not be able to identify,
    negotiate and maintain the strategic alliances necessary to develop and commercialize our products and technologies, and we will
    be dependent on our corporate partners if we do.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.75pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Implications
of Being an Emerging Growth Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are an &#8220;emerging
growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. We will remain an emerging
growth company until the earlier of (1) December 31, 2024 (2) the last day of the fiscal year in which we have total annual gross revenue
of at least $1.07 billion, (3) the last day of the fiscal year in which we are deemed to be a &#8220;large accelerated filer&#8221; as
defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur on the date on which
we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. An emerging growth company
may take advantage of specified reduced reporting requirements and is relieved of certain other significant requirements that are otherwise
generally applicable to public companies. As an emerging growth company, we may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.75pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">present only two years of
    audited financial statements, plus unaudited condensed financial statements for any interim period, and related management&#8217;s
    discussion and analysis of financial condition and results of operations in this prospectus;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.75pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">avail ourselves of the exemption
    from the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial
    reporting pursuant to the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.75pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.25pt; text-align: justify"><span style="font-size: 10pt">provide
    reduced disclosure about our executive compensation arrangements; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.75pt"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">not require stockholder non-binding
    advisory votes on executive compensation or golden parachute arrangements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.75pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In addition,
under the JOBS Act, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise
apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period, and, as a result we
will adopt new or revised accounting standards on relevant dates on which adoption of such standards is required for other public companies.</span></p>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are also
a &#8220;smaller reporting company&#8221; as defined in Rule 12b-2 of the Exchange Act and have elected to take advantage of certain
of the scaled disclosure available to smaller reporting companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our principal
executive offices are located at 16772 West Bernardo Drive, San Diego, CA 92127 and our telephone number is (858) 800-3500. We maintain
a website at www.modular-medical.com to which we regularly post copies of our press releases, as well as additional information about
us. Our filings with the Securities and Exchange Commission, or SEC, will be available free of charge through the website as soon as
reasonably practicable after being electronically filed with or furnished to the SEC. Information contained on, or accessible through,
our website does not constitute a part of this prospectus or our other filings with the SEC, and you should not consider any information
contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">All brand names
or trademarks appearing in this prospectus are the property of their respective holders. Use or display by us of other parties&#8217;
trademarks, trade dress, or products in this prospectus is not intended to, and does not, imply a relationship with, or endorsements
or sponsorship of, us by the trademark or trade dress owners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY
RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
business is subject to a number of risks, including risks that could prevent us from achieving our business objectives or financial goals
or that otherwise could adversely affect our business, results of operations, financial condition and liquidity, that you should carefully
consider before making a decision to invest in our common stock. These risks are discussed more fully in &#8220;Risk Factors.&#8221;
These risks include the following:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 1pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">We
                                            are a developmental stage medical device company and have a history of significant operating
                                            losses; we expect to continue to incur operating losses, and we may never achieve or maintain
                                            profitability;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 1pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The
                                            full effects of COVID-19 and other potential future public health crises, epidemics, pandemics
                                            or similar events are uncertain and could have a material and adverse effect on our business,
                                            financial condition, operating results and cash flows;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 1pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">We
                                            will need substantial additional funding to complete subsequent phases of our insulin pump
                                            product candidate and to operate our business and such funding may not be available or, if
                                            it is available, such financing is likely to substantially dilute our existing shareholders;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 1pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">We
                                            have a limited operating history and historical financial information upon which you may
                                            evaluate our performance;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 1pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">We
                                            may not be able to meet our future capital needs;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 1pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Technological
                                            breakthroughs in diabetes monitoring, treatment or prevention could render our insulin pump
                                            obsolete;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 1pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">We
                                            have limited internal research and development personnel, making us dependent on consulting
                                            relationships;</span></td></tr></table>
<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 1pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">We
                                            may not receive the necessary regulatory clearance or approvals for our insulin pump, and
                                            failure to timely obtain necessary clearances and/or approvals could harm our then operations,
                                            including our ability to commercialize our product candidate;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 1pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Our
                                            competitors may develop products that are more effective, safer and less expensive than ours;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 1pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">We
                                            may be subject to potential product liability and other claims that could materially impact
                                            our business and financial condition;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 1pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">We
                                            are subject to extensive regulation by the U.S. Food and Drug Administration, which could
                                            restrict the sales and marketing of our insulin pump and could cause us to incur significant
                                            costs;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 1pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">If
                                            we are sued for infringing on third-party intellectual property rights, it will be costly
                                            and time-consuming, and an unfavorable outcome would have a significant adverse effect on
                                            our business;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 1pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">If
                                            we are unable to protect the confidentiality of our proprietary information, the value of
                                            our technology and products could be adversely affected;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 1pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Healthcare
                                            reform laws could adversely affect our product candidate and financial condition; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 1pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">We
                                            are a &#8220;smaller reporting company&#8221; and, as a result of the reduced disclosure
                                            and governance requirements applicable to smaller reporting companies, our Common Stock may
                                            be less attractive to investors.</span></td></tr></table>

					    <!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<div style="border: black 1px solid; padding: 6pt; width: 98%">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0pt"><span style="font-size: 10pt"><b>THE OFFERING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
    Stock Offered by the Selling Stockholders</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 63%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #565656; background-color: white">1,438,202
    </span><span style="font-size: 10pt">shares of Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
    Stock Outstanding Before the Offering</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">10,911,684 shares of Common Stock as of June 2,
    2022.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
    Stock Outstanding After the Offering(1)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">12,349,886 shares of Common
    Stock (assuming exercise of all May Warrants).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Terms
    of the Offering</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The Selling Stockholders
    will determine when and how they will sell the Common Stock offered in this prospectus.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
</table>



<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
    of Proceeds</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 63%"><span style="font-size: 10pt">We will not receive any proceeds
    from the sale of the common stock by the selling stockholders. We may receive proceeds upon the exercise of the May Warrants (to
    the extent the registration statement of which this prospectus is a part is then effective and, if applicable, the &#8220;cashless
    exercise&#8221; provision is not utilized by the holder). Any proceeds will be used for general corporate and working capital or
    for other purposes that the board of directors, in their good faith, deems to be in the best interest of the Company. No assurances
    can be given that any of such warrants will be exercised. See &#8220;Use of Proceeds.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
    Factors</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The Common Stock offered
    hereby involves a high degree of risk and should not be purchased by investors who cannot afford the loss of their entire
    investment. See &#8220;Risk Factors&#8221; beginning on page 14.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Listing
    of Securities</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Our common stock is listed
    on the Nasdaq Capital Market under the symbol &#8220;MODD.&#8221;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.5pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;The
number of shares of our Common Stock to be outstanding after this offering is based on 10,911,684 shares of our Common Stock outstanding
as of June 2, 2022, and excludes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">767,796
    shares of our Common Stock issuable upon the exercise of warrants with an exercise price of $6.00 per share;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,011,276
    shares of our Common Stock issuable upon the exercise of warrants with an exercise price of $6.60 per share;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 48px"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">1,348,314
                                            s</span><span style="font-size: 10pt">hares of our Common Stock issuable upon exercise of
                                            pre-funded warrants with an exercise price of $0.01 per share;</span></td></tr>
                                                                                                                           </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 48px"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">1,847,735
                                            shares of our Common Stock issuable upon exercise of outstanding stock options with a weighted
                                            average exercise price of approximately $8.14 per share; and</span></td></tr>
                                                                                                                         </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 48px"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">792,435</span><span style="font-size: 10pt">
                                                                                                                                                                                           shares of our Common Stock reserved for issuance pursuant to future awards under our Amended 2017 Equity Incentive Plan, or the 2017
                                                                                                                                                                                           Plan.</span></td></tr></table></div>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modulara002"></span>RISK
FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
in our common stock involves a great deal of risk. Careful consideration should be made of the following factors as well as other information
included in this prospectus before deciding to purchase our common stock. There are many risks that affect our business and results of
operations, some of which are beyond our control. Our business, financial condition or operating results could be materially harmed by
any of these risks. This could cause the trading price of our common stock to decline, and you may lose all or part of your investment.
Additional risks that we do not yet know of or that we currently think are immaterial may also affect our business and results of operations.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
Related To Our Operations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a developmental stage medical device company and have a history of significant operating losses; we expect to continue to incur operating
losses, and we may never achieve or maintain profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As a development-stage
enterprise, we do not currently have revenues to generate cash flows to cover operating expenses. Since our inception, we have incurred
operating losses in each year due to costs incurred in connection with research and development activities and general and administrative
expenses associated with our operations. For the years ended March 31, 2021 and 2020, we incurred net losses of approximately $7.4 million
and $5.3 million, respectively. At March 31, 2021, we had an accumulated deficit of approximately $15.9 million. For the nine months
ended December 31, 2021, we incurred a net loss of approximately $4.8 million. At December 31, 2021, we had an accumulated deficit of
approximately $30 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We expect to incur
losses for the foreseeable future, as we continue the development of, and seek regulatory clearance and approvals for, our insulin pump.
As our prototype insulin pump is currently our only product candidate, if it fails to gain regulatory approval and market acceptance,
we will not be able to generate any revenue or explore other opportunities to enhance shareholder value, such as through a sale. If we
fail to generate revenue and eventually become profitable, or if we are unable to fund our continuing losses, our shareholders could
lose all or a substantial part of their investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
might not be able to continue as a going concern which would likely cause our stockholders to lose most or all of their investment.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">Our audited
financial statements for the year ended March 31, 2021 were prepared under the assumption that we would continue as a going concern.
However, our independent registered public accounting firm included a &#8220;going concern&#8221; explanatory paragraph in its report
on our financial statements for the year ended March 31, 2021, indicating that, without additional sources of funding, our cash at March
31, 2021 was not sufficient for us to operate as a going concern for a period of at least one year from the date of issuance of the financial
statements. Management&#8217;s plans concerning these matters, including our need to raise additional capital, are described in Management&#8217;s
Discussion and Analysis of Financial Conditions and Results of Operations included in this prospectus and in Note 1 to our audited consolidated
financial statements included in this prospectus. However, we cannot assure you that our plans will be successful. In light of the foregoing,
there is substantial doubt about our ability to continue as a going concern. If we cannot continue as a viable entity, our stockholders
would likely lose most or all of their investment in us.</span></p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
full effects of COVID-19 and other potential future public health crises, epidemics, pandemics or similar events are uncertain and could
have a material and adverse effect on our business, financial condition, operating results and cash flows.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The global outbreak
of the coronavirus disease 2019, or COVID-19, was declared a pandemic by the World Health Organization and a national emergency by the
U.S. government in March 2020. This has negatively affected the world economy, disrupted global supply chains, significantly restricted
travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in-place&#8221; and created significant disruption
of the financial markets. The extent of the impact on our operational and financial performance will depend on future developments, including
the duration and spread of the pandemic and related actions taken by U.S. and foreign government agencies to prevent disease spread,
all of which are uncertain, out of our control and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">We have been
complying with county and state orders and, until May 2021, had implemented a teleworking policy for our employees and contractors and
significantly minimized the number of employees who visit our office. However, a facility closure, work slowdowns or temporary stoppage
at one of our suppliers could occur, which could have a longer-term impact and could delay our prototype production and ability to conduct
business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If our workforce is
unable to work effectively, including because of illness, quarantines, absenteeism, government actions, facility closures, travel restrictions
or other restrictions in connection with the COVID-19 pandemic, our operations will be negatively impacted. We may be unable to develop
our product candidate, and our costs may increase as a result of the COVID-19 outbreak. The impacts could worsen if there is an extended
duration of any COVID-19 outbreak or a resurgence of COVID-19 infection in affected regions after they have begun to experience improvement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">We rely on other
companies to provide components and to perform services for us. An extended period of supply chain disruption caused by the response
to COVID-19 could impact our ability to produce our initial product quantities and, if we are not able to implement alternatives or other
mitigations, product deliveries would be adversely impacted and negatively impact our business, financial condition, operating results
and cash flows. Limitations on government operations can also impact regulatory approvals that are necessary for us to operate our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The continued
spread of COVID-19 has also led to disruption and volatility in the global capital markets. We were recently able to raise additional
capital through equity offerings in February 2022 and May 2022, however, we will need to raise additional capital to support our operations
in the future. We may be unable to access the capital markets, and additional capital may only be available to us on terms that could
be significantly detrimental to our existing stockholders and to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need substantial additional funding to complete subsequent phases of our insulin pump product candidate and to operate our business
and such funding may not be available or, if it is available, such financing is likely to substantially dilute our existing shareholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The discovery, development,
and commercialization of new medical devices, such as our insulin pump, entails significant costs. While we believe that we have generally
completed the engineering and mechanical aspects of our insulin pump prototype, we still must modify, refine and finalize our insulin
pump to, among other things, meet the general needs and preferences of the almost pumper marketplace and the guidelines of third-party
payors. To enable us to accomplish these and other related items and continue to operate our business, we will need to raise substantial
additional capital and/or enter into strategic partnerships or joint ventures to enable us to:</span></p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">fund clinical
    studies and seek regulatory approvals;</span></td></tr>
  </table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">build or
    access manufacturing and commercialization capabilities;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">develop,
    test, and, if approved, market our product candidate;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">acquire or
    license additional internal systems and other infrastructure; and</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">hire and
    support additional management, engineering and scientific personnel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Until we can generate
a sufficient amount of product revenue to finance our cash requirements, which we may never achieve, we expect to finance our cash needs
primarily through public or private equity offerings, debt financings or through the establishment of possible strategic alliances. We
may in the future seek additional capital from public or private offerings of our capital stock or borrow additional amounts under new
credit lines or from other sources. If we issue equity or debt securities to raise additional funds, our existing stockholders may experience
dilution, we may incur significant financing costs, and the new equity or debt securities may have rights, preferences and privileges
senior to those of our existing stockholders. In addition, if we raise additional funds through collaborations, licensing, joint ventures,
strategic alliances, partnership arrangements or other similar arrangements, it may be necessary to relinquish valuable rights to our
potential future products or proprietary technologies or grant licenses on terms that are not favorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We cannot be certain
that additional funding will be available on acceptable terms, or at all. If we are not able to secure additional equity funding when
needed, we may have to delay, reduce the scope of, or eliminate one or more of our clinical studies, development programs or future commercialization
initiatives. In addition, any additional equity funding that we do obtain will dilute the ownership held by our existing equity holders.
The amount of this dilution may be substantially increased if the trading price of our Common Stock is lower at the time of any financing.
Regardless, the economic dilution to shareholders will be significant if our stock price does not increase significantly, or if the effective
price of any sale is below the price paid by a particular shareholder. Any debt financing that we obtain in the future could involve
substantial restrictions on activities and creditors could seek a pledge of some or all of our assets. We have not identified potential
sources for such financing that we will require, and we do not have commitments from any third parties to provide any future debt financing.
If we fail to obtain funding as needed, we may be forced to cease or scale back operations, and our results, financial condition and
stock price would be adversely affected.</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 100%; text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a limited operating history and historical financial information upon which you may evaluate our performance.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">You should consider,
among other factors, our prospects for success in light of the risks and uncertainties encountered by companies that, like us, are in
their early stages of development. We may not successfully address these risks and uncertainties or successfully complete our studies
and/or implement our existing and new products. If we fail to do so, it could materially harm our business and impair the value of our
Common Stock. Unanticipated problems, expenses and delays are frequently encountered in establishing a new business, conducting research,
and developing new products. These include, but are not limited to, inadequate funding, failure to obtain regulatory approval, unforeseen
research issues, lack of consumer acceptance, competition, sluggish product development, and inadequate sales and marketing. The failure
by us to meet any of these conditions would have a materially adverse effect upon us and may force us to reduce or curtail operations.
No assurance can be given that we can or will ever operate profitably.</span></p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to meet our future capital needs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">To date, we have no
revenue and we have limited cash liquidity and capital resources. We will need additional capital in the near future. Any equity financings
will result in dilution and may contain other terms that are not favorable to our then-existing stockholders. We currently have debt
financing, and any additional sources of debt financing that we may obtain in the future may result in a high interest expense. Any financing,
if available, may be on unfavorable terms. If adequate funds are not obtained, we will be required to reduce or curtail operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
amount of financing we require will depend on a number of factors, many of which are beyond our control. Our results of operations, financial
condition and stock price are likely to be adversely affected if our funding requirements increase or are otherwise greater than we expect.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our future funding
requirements will depend on many factors, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">the testing
    costs for our insulin pump product candidate and other development activities conducted by us directly, and our ability to successfully
    conclude the studies and activities and achieve favorable results;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">our ability
    to attract future strategic partners to pay for or share costs related to our product development efforts;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">the costs
    and timing of seeking and obtaining regulatory clearance and approvals for our product candidate;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">the costs
    of filing, prosecuting, maintaining and enforcing any patents and other intellectual property rights that we may have and defending
    against potential claims of infringement;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">decisions
    to hire additional scientific, engineering or administrative personnel or consultants;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">our ability
    to manage administrative and other costs of our operations; and</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">the presence
    or absence of adverse developments in our research program.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If any of these factors
cause our funding needs to be greater than expected, our operations, financial condition, ability to continue operations and stock price
may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
future cash requirements may differ significantly from our current estimates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our cash requirements
may differ significantly from our estimates from time to time, depending on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">the costs and results of our clinical
    studies regarding our insulin pump product candidate;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">the time and costs involved in
    obtaining regulatory clearance and approvals;</span></td></tr>
  </table>
<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">whether we are able to obtain
    funding under future licensing agreements, strategic partnerships, or other collaborative relationships, if any;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">the costs
    of compliance with laws, regulations, or judicial decisions applicable to us; and</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">the costs
    of general and administrative infrastructure required to manage our business and protect corporate assets and shareholder interests.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If we fail to raise
additional funds on a timely basis, we will need to scale back our business plans, which would adversely affect our business, financial
condition, and stock price, and we may even be forced to discontinue our operations and liquidate our assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Technological
breakthroughs in diabetes monitoring, treatment or prevention could render our insulin pump obsolete.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The diabetes treatment
market is subject to rapid technological change and product innovation. Our insulin pump is based on our proprietary technology, but
a number of companies, medical researchers and existing pharmaceutical companies are pursuing new delivery devices, delivery technologies,
sensing technologies, procedures, drugs and other therapeutics for the monitoring, treatment and/or prevention of insulin-dependent diabetes.
Any technological breakthroughs in diabetes monitoring, treatment or prevention could render our insulin pump obsolete, which, since
our insulin pump is our only product candidate, would have a material adverse effect on our business, financial condition and results
of operations and could result in shareholders losing their entire investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
failure to attract and retain skilled directors, executives, employees and consultants could impair our product development and commercialization
activities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our business depends
on the skills, performance, and dedication of our directors, executive officers and key engineering, scientific and technical advisors.
Many of our current engineering or scientific advisors are independent contractors and are either self-employed or employed by other
organizations. As a result, they may have conflicts of interest or other commitments, such as consulting or advisory contracts with other
organizations, which may affect their ability to provide services to us in a timely manner. We will need to recruit additional directors,
executive management employees, and advisers, particularly engineering, scientific and technical personnel, which will require additional
financial resources. In addition, there is currently intense competition for skilled directors, executives and employees with relevant
engineering, scientific and technical expertise, and this competition is likely to continue. If we are unable to attract and retain persons
with sufficient engineering, scientific, technical and managerial experience, we may be forced to limit or delay our product development
activities or may experience difficulties in successfully conducting our business, which would adversely affect our operations and financial
condition.</span></p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have limited internal research and development personnel, making us dependent on consulting relationships.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We consider research
and development to be an important part of the process of designing, developing, obtaining regulatory required approvals and the eventual
commercialization of our insulin pump. We continue to incur increased research and development expenditures, which are attributable to
effort and expenses incurred in designing and developing our innovative insulin pump. We expect to continue to incur substantial costs
related to research and development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to outsource and rely on third parties for various aspects relating to the development, manufacture, sales and marketing of
our insulin pump as well as in connection with assisting us in the preparation and filing of our FDA submission, and our future success
will be dependent on the timeliness and effectiveness of the efforts of these third parties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are dependent on
consultants for important aspects of our product development strategy. We do not have the required financial resources and personnel
to carry out independently the development of our product candidate, and do not have the capability or resources to manufacture, market
or sell our current product candidate. As a result, we contract with and rely on third parties for important functions, including in
connection with the development and finalization of our insulin pump, the preparation and filing of our FDA submission and eventual manufacturing
and commercialization of our product candidate. We have recently entered into several agreements with third parties for such services.
If problems develop in our relationships with third parties, or if such parties fail to perform as expected, it could lead to delays
or lack of progress in obtaining FDA clearance, significant cost increases, changes in our strategies, and even failure of our product
initiatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to identify, negotiate and maintain the strategic alliances necessary to develop and commercialize our products and technologies,
and we will be dependent on our corporate partners if we do.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We may seek to enter
into a strategic alliance with a diabetes related service providing company for the further development and approval of our insulin pump
product candidate. At this time, we have not entered into any such strategic alliance. Strategic alliances, if entered into, could potentially
provide us with additional funds, expertise, access, and other resources in exchange for exclusive or non-exclusive licenses or other
rights to the product that we are currently developing or a product we may explore in the future. We cannot give any assurance that we
will be able to enter into strategic relationships with a diabetes related service providing company or others in the near future or
at all. In addition, we cannot assure you that any agreements that we do reach will achieve our goals or be on terms that prove to be
economically beneficial to us. When we do enter into strategic or contractual relationships, we become dependent on the successful performance
of our partners or counter-parties. If they fail to perform as expected, such failure could adversely affect our financial condition,
lead to increases in our capital needs, or hinder or delay our development efforts.</span></p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not receive the necessary regulatory clearance or approvals for our insulin pump, and failure to timely obtain necessary clearances
and/or approvals could harm our then operations, including our ability to commercialize our product candidate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Before we can market
a new medical device, such as our insulin pump, we must first receive clearance under Section 510(k) of the Federal Food, Drug, and Cosmetic
Act, or the FDCA. In the 510(k) clearance process, before a device may be marketed, the FDA must determine that such proposed device
is &#8220;substantially equivalent&#8221; to a legally-marketed &#8220;predicate&#8221; device, which includes a device that has been
previously cleared through the 510(k) process, a device that was legally marketed prior to May 28, 1976 (pre-amendments device), a device
that was originally on the U.S. market pursuant to a premarket approval (PMA) and later down-classified, or a 510(k)-exempt device. To
be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have
the same technological characteristics as the predicate device or have different technological characteristics and not raise different
questions of safety or effectiveness than the predicate device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Certain future modifications
made to our product candidate, which we currently expect to be cleared through 510(k), may require a new 510(k) clearance. The 510(k)
clearance process can be expensive, lengthy and uncertain. The FDA&#8217;s 510(k) clearance process usually takes from three to 12 months,
but can last longer. Despite the time, effort and cost, a device may not be approved or cleared by the FDA. Any delay or failure to obtain
necessary regulatory authorizations could harm our business, including our ability to commercialize our product candidate and our shareholders
could lose their entire investment. Furthermore, even if we are granted the required regulatory authorizations, such authorizations may
be subject to significant limitations on the indicated uses for the device, which may limit the market for our product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If the FDA requires
us to go through a lengthier, more rigorous examination for our product candidate than we had expected, product introductions or modifications
could be delayed or canceled, which could adversely affect our ability to grow our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The FDA can delay,
limit or deny clearance or approval for our insulin pump medical device for many reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">our inability
    to demonstrate to the satisfaction of the FDA that our product candidate is substantially equivalent to the proposed predicate device;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">the disagreement
    of the FDA with the design or implementation of our performance testing protocols or the interpretation of data from our performance
    testing;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">the data
    from performance testing may be insufficient to support a determination of substantial equivalence or that our device meets required
    special controls or applicable performance standards;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">our inability
    to demonstrate that the benefits of our pump outweigh the risks;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">the manufacturing
    process or facilities we intend to use may not meet applicable requirements; and</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">the potential
    for approval policies or regulations of the FDA to change significantly in a manner rendering our data or regulatory filings insufficient
    for clearance or approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In addition, the FDA
may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which
may prevent or delay approval or clearance of our product candidate or impact our ability to modify our product candidate after clearance
on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain
clearance for our pump, increase the costs of compliance or restrict our ability to maintain our current approval.</span></p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As a general rule,
demonstration of conformity of medical devices and their manufacturers with the essential requirements must be based, among other things,
on the evaluation of data supporting the safety and performance of the product candidates during normal conditions of use. Specifically,
a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use, that the known and
foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance,
and that any claims made about the performance and safety of the device are supported by suitable evidence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
marketing authorization in the United States will not obviate the need to obtain marketing authorization in other jurisdictions We must
obtain approval from foreign regulatory authorities before we can market and sell any of our product candidates in countries outside
the United States. We will incur additional costs in seeking such approvals, may experience delays in obtaining such approvals and cannot
be certain that such approvals will be granted.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The development, manufacture,
and marketing of our product candidates outside the United States is subject to government regulation. In most foreign countries, we
must complete rigorous pre-clinical testing and extensive human clinical trials that demonstrate the safety and efficacy of a product
in order to apply for regulatory approval to market the product. If foreign regulatory authorities grant regulatory approval of a product,
the approval may be limited to specific indications or limited with respect to its distribution. Expanded or additional indications for
approved devices may not be approved, which could limit our potential revenues. Foreign regulatory authorities may refuse to grant any
approval. Consequently, even if we believe that pre-clinical and clinical data are sufficient to support regulatory approval for our
products, foreign regulatory authorities may not ultimately grant approval for commercial sale in any jurisdiction. If our product candidates
are not approved in such jurisdictions, our ability to generate revenues will be limited and our business will be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
competitors may develop products that are more effective, safer and less expensive than ours.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Existing insulin pumps
are expensive, with the more popular models having purchase prices exceeding $4,000 for individuals without health insurance and often
require significant patient copays. Others have daily use costs that exceed the reimbursement rates of many health insurance plans, forcing
some users to spend thousands of dollars a year in copays. We believe this makes insurers hesitant to pay for any pumps and places pumps
out of reach for many patients whom cannot afford such out of pocket expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are engaged in the
diabetes treatment sector of the healthcare marketplace, which is intensely competitive. There are current products that are quite effective
at addressing the effects of diabetes, and we expect that new developments by other companies and academic institutions in the areas
of diabetes treatment will continue. If approved for marketing by the FDA, depending on the approved clinical indication, our product
will be competing with existing and future products related to treatments for diabetes.</span></p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our competitors may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">develop product
    candidates and market products that increase the levels of safety or efficacy that our product candidates will need to show in order
    to obtain regulatory approval;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">develop product
    candidates and market products that are less expensive or more effective than ours;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">commercialize
    competing products before we can launch any products we are working to develop;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">hold or obtain
    proprietary rights that could prevent us from commercializing our products; or</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">introduce
    therapies or market medical products that render our potential product candidates obsolete.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We expect to compete
against large medical device companies, such as Medtronic, Inc., Tandem Diabetes Care, Inc. and Insulet Corporation and smaller companies
that are collaborating with larger medical device companies, new companies, academic institutions, government agencies and other public
and private research organizations. These competitors, in nearly all cases, produce similar products relative to the treatment of diabetes
that have substantially greater financial resources than we do. Our competitors also have significantly greater experience in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">developing
    medical device and other product candidates;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">undertaking
    testing and clinical studies;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">building
    relationships with key customers and opinion-leading physicians;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">obtaining
    and maintaining FDA and other regulatory approvals;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">formulating
    and manufacturing medical devices;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">launching,
    marketing and selling medical devices; and</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">providing
    management oversight for all of the above-listed operational functions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If we fail to achieve
superiority over other existing or newly developed products, we may be unable to obtain regulatory approval. If our competitors&#8217;
market medical devices that are less expensive, safer or more effective than our insulin pump, or that gain or maintain greater market
acceptance, we may not be able to compete effectively. See &#8220;Business &#8211; Competition.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect to rely on third-party manufacturers and will be dependent on their quality and effectiveness.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our insulin pump requires
precise, high-quality manufacturing. The failure to achieve and maintain high manufacturing standards, including failure to detect or
control anticipated or unanticipated manufacturing errors or the frequent occurrence of such errors, could result in patient injury or
death, discontinuance or delay of ongoing or planned clinical studies, delays or failures in product testing or delivery, cost overruns,
product recalls or withdrawals and other problems that could seriously hurt our business. Contract medical device manufacturers often
encounter difficulties involving production yields, quality control and quality assurance and shortages of qualified personnel. These
manufacturers are subject to stringent regulatory requirements, including the FDA&#8217;s current good-manufacturing-practices regulations.
If our contract manufacturers fail to maintain ongoing compliance at any time, the production of our product could be interrupted, resulting
in delays or discontinuance of our clinical studies, additional costs and loss of potential revenues.</span></p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to successfully scale-up manufacturing of our product candidate in sufficient quality and quantity, which would delay
or prevent us from developing our product candidate and commercializing our product candidate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In order to conduct
larger-scale or late-stage clinical studies and for commercialization of our insulin pump, if 510(k) clearance is granted, we will need
to manufacture it in larger quantities. We may not be able to successfully increase the manufacturing capacity for our product candidate
in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If we are unable to
successfully scale up the manufacture of our product candidate in sufficient quality and quantity, the development and testing of our
product candidate and regulatory approval or commercial launch may be delayed, which could significantly harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to potential product liability and other claims that could materially impact our business and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The development and
sale of our insulin pump exposes us to the risk of significant damages from product liability and other claims, and the use of our product
candidate in clinical studies may result in adverse effects. We cannot predict all the possible harms or adverse effects that may result.
We maintain a modest amount of product liability insurance to provide some protection from claims. Nonetheless, we may not have sufficient
resources to pay for any liabilities resulting from a personal injury or other claim, even if it is partially covered by insurance. In
addition to the possibility of direct claims, we may be required to indemnify third parties against damages and other liabilities arising
out of our development, commercialization and other business activities, which would increase our liability exposure. If third parties
that have agreed to indemnify us fail to do so, we may be held responsible for those damages and other liabilities as well.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legislative,
regulatory, or medical cost reimbursement changes may adversely impact our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">New laws, regulations
and judicial decisions, or new interpretations of existing laws, regulations and decisions, that relate to the health care system in
the U.S. and in other jurisdictions may change the nature of and regulatory requirements relating to innovations in medical devices,
testing and regulatory approvals, limit or eliminate payments for medical procedures and treatments, or subject the pricing of medical
devices to government control. In addition, third-party payors in the U.S. are increasingly attempting to contain health care costs by
limiting both coverage and the level of reimbursement of new products. Consequently, significant uncertainty exists as to the reimbursement
status of newly approved health care products. Significant changes in the health care system in the U.S. or elsewhere, including changes
resulting from adverse trends in third-party reimbursement programs, could have a material adverse effect on our projected future operating
results and our ability to raise capital, commercialize products, and remain in business.</span></p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to extensive regulation by the U.S. Food and Drug Administration, which could restrict the sales and marketing of our insulin
pump and could cause us to incur significant costs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our insulin pump is
subject to extensive regulation by the FDA. These regulations relate to manufacturing, labeling, sale, promotion, distribution and shipping.
Before a new medical device, or a new intended use of a legally marketed device, can be marketed in the United States, it must be cleared
or approved by FDA through the applicable premarket review process (510(k), PMA, or de novo classification), unless an exemption applies.
If we receive 510(k) clearance for our insulin pump, we may be required to obtain new 510(k) clearances for significant post-market modifications
to the pump. Each premarket submission and review process can be expensive and lengthy, and entail significant user fees, unless exempt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Medical devices may
be marketed only for the indications for which they are approved or cleared. Further, 510(k) clearances can be revoked if safety or effectiveness
problems develop once the device is on the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The current regulatory
requirements to which we are subject may change in the future in a way that adversely affects us. If we fail to comply with present or
future regulatory requirements that are applicable to us, we may be subject to enforcement action by the FDA, which may include any of
the following sanctions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">untitled
    letters, warning letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr>
  </table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">customer
    notification, or orders for repair, replacement or refunds;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">voluntary
    or mandatory recall or seizure of our current or future products;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">administrative
    detention by the FDA of medical devices believed to be adulterated or misbranded;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">imposing
    operating restrictions, suspension or shutdown of production;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">refusing
    our requests for 510(k) clearance, PMA or <span style="font-family: Times New Roman, Times, Serif"><i>de novo</i></span> classification
    of any new products, new intended uses or modifications to our insulin pump;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">rescinding
    510(k) clearance that has already been granted; and</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">criminal
    prosecution.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The occurrence of any
of these events would have a material adverse effect on our business, financial condition and results of operations and could result
in shareholders losing their entire investment.</span></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Although
our system does not presently require clinical trials to apply to the FDA for clearance and even if a clinical trial is completed, the
results of our clinical testing may not demonstrate the safety and efficacy of the device or may be equivocal or otherwise not be sufficient
for us to obtain approval of our product candidate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Clinical trials are
almost always required to support a PMA application and may also be required to support 510(k) submissions although at this time ours
does not require a PMA. If the device presents a &#8220;significant risk&#8221; to human health as defined by the FDA, the FDA requires
the study sponsor to submit an investigational device exemption (&#8220;IDE&#8221;) application and obtain IDE approval prior to commencing
human clinical trials. The IDE must be supported by appropriate data, such as animal and laboratory testing results, showing that it
is safe to test the device in humans and that the testing protocol is scientifically sound. An IDE will automatically become effective
30 days after receipt by the FDA, unless the FDA denies the application or notifies the sponsor that the investigation is on hold and
may not begin until the sponsor provides supplemental information about the investigation that satisfies the agency&#8217;s concerns.
The FDA may also notify the sponsor that the study is approved as proposed. If the FDA determines that there are deficiencies or other
concerns with an IDE that require modification of the study, the FDA may permit a clinical trial to proceed under a conditional approval.
Furthermore, the agency may withdraw approval of an IDE under certain circumstances. Clinical trials for a significant risk device may
begin once an IDE is approved by the FDA and the appropriate Institutional Review Board (&#8220;IRB&#8221;) at each clinical trial site.
If the product is deemed a &#8220;non-significant risk&#8221; device, IDE approval from the FDA would not be required, but the clinical
trial would need to meet other requirements including IRB approval. Our clinical trials must be conducted in accordance with FDA regulations
and federal and state regulations concerning human subject protection, including informed consent and healthcare privacy. A clinical
trial may be suspended by the FDA or at a specific site by the relevant IRB at any time for various reasons, including a determination
that the risks to the trial participants outweigh the benefits of participation in the clinical trial. Even if a clinical trial is completed,
the results of our clinical testing may not demonstrate the safety and efficacy of the device or may be equivocal or otherwise not be
sufficient for us to obtain approval of our product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
success depends substantially upon our ability to obtain and maintain intellectual property protection relating to our product candidate
and research technologies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have applied to
the U.S. Patent and Trademark Office for patents on our proprietary fluid movement technology and the configuration of our insulin pump.
There is no assurance that these patents will be issued, and no assurance that they will prevent other companies from competing with
us. We will continue to attempt to patent our innovations as appropriate to help ensure a sustainable competitive advantage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Due to evolving legal
standards relating to the patentability, validity and enforceability of patents covering health care product inventions, our ability
to enforce our existing patents and to obtain and enforce patents that may issue from any pending or future patent applications is uncertain
and involves complex legal, scientific and factual questions. To date, no consistent policy has emerged regarding the breadth of claims
allowed in medical device patents. Thus, we cannot be sure that any patents will issue from any pending or future patent applications
owned by or licensed to us. Even if patents do issue, we cannot be sure that the claims of these patents will be held valid or enforceable
by a court of law, will provide us with any significant protection against competing products, or will afford us a commercial advantage
over competitive products. If, at some point in the future, one or more products resulting from our product candidates is approved for
sale by the FDA and we do not have adequate intellectual property protection for those products, competitors could duplicate them for
approval and sale in the United States without repeating the extensive testing required of us to obtain FDA approval.</span></p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are sued for infringing on third-party intellectual property rights, it will be costly and time-consuming, and an unfavorable outcome
would have a significant adverse effect on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our ability to commercialize
our product candidate depends on our ability to use, manufacture and sell our product candidate without infringing the patents or other
proprietary rights of third parties. Numerous U.S. and foreign issued patents and pending patent applications owned by third parties
exist in the diabetes medical device area. There may be existing patents, unknown to us, on which our activities with our insulin pump
candidate could infringe.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If a third party claims
that our actions infringe on its patents or other proprietary rights, we could face a number of issues that could seriously harm our
competitive position, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">infringement
    and other intellectual property claims that, even if meritless, can be costly and time-consuming, delay the regulatory approval process
    and divert management&#8217;s attention from our core business operations;</span></td></tr>
  </table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">substantial
    damages for infringement, including consequential damages for lost of profits or market share, if a court determines that our products
    or technologies infringe on a third party&#8217;s patent or other proprietary rights;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">a court prohibiting
    us from selling or licensing our products or technologies unless the holder licenses the patent or other proprietary rights to us,
    which it is not required to do; and</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">even if a
    license is available from a holder, we may have to pay substantial royalties or grant cross-licenses to our patents or other proprietary
    rights.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If any of these events
occur, it could significantly harm our operations and financial condition and negatively affect our stock price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely
affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In addition to patented
technology, we rely on our unpatented technology, trade secrets and know-how. We generally seek to protect this information by confidentiality,
non-disclosure and assignment of invention agreements with our officers, employees, contractors and other service providers and with
parties with which we do business. These agreements may be breached, which breach may result in the misappropriation of such information,
and we may not have adequate remedies for any such breach. We cannot be certain that the steps we have taken will prevent unauthorized
use or reverse engineering of our technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Moreover, our trade
secrets may be disclosed to or otherwise become known or be independently developed by competitors. To the extent that our officers,
employees, contractors, other service providers, or other third parties with whom we do business use intellectual property owned by others
in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. If, for any of the above reasons,
our intellectual property is disclosed or misappropriated, it would harm our ability to protect our rights and have a material adverse
effect on our business, financial condition, and results of operations.</span></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property rights do not necessarily address all potential threats to our competitive advantage.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The degree of future
protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not
adequately protect our business, or permit us to gain and maintain a competitive advantage. The following examples are illustrative:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">others may
    be able to make devices that are similar to our insulin pump but that are not covered by the claims of the patents that we own;</span></td></tr>
  </table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">we or any
    collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications that
    we own;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">we might
    not have been the first to file patent applications covering certain of our inventions;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">others may
    independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual
    property rights;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">it is possible
    that our pending patent applications will not lead to issued patents;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">issued patents
    that we own may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">our competitors
    might conduct research and development activities in the U.S. and other countries that provide a safe harbor from patent infringement
    claims for certain research and development activities, as well as in countries where we do not have patent rights, and then use
    the information learned from such activities to develop competitive products for sale in our major commercial markets; and</span></td></tr>
  </table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">we may not
    develop additional proprietary technologies that are patentable.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
reform laws could adversely affect our product candidate and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the United States,
there have been, and continue to be, a number of legislative initiatives to contain healthcare costs. In March 2010, the Patient Protection
and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (ACA), was enacted in the United
States, which made a number of substantial changes in the way healthcare is financed by both governmental and private insurers. Among
other ways in which it may affect our business, the ACA implemented payment system reforms, including a national pilot program on payment
bundling to encourage hospitals, physicians, and other providers to improve the coordination, quality, and efficiency of certain healthcare
services through bundled payment models and expanded the eligibility criteria for Medicaid programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Since its enactment,
there have been judicial, executive, and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court
dismissed the most recent judicial challenge to the ACA without specifically ruling on the constitutionality of the ACA. Prior to the
Supreme Court&#8217;s decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021
through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed
certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among
others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary
barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures
of the Biden administration or other efforts, if any, to challenge, repeal, or replace the ACA will impact the ACA or our business.</span></p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In addition, other
legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed
into law, which, among other things, reduced Medicare payments to providers by 2% per fiscal year, effective on April 1, 2013 and, due
to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension
implemented under various COVID-19 relief legislation from May 1, 2020 through the end of 2021, unless additional Congressional action
is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced
Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover
overpayments to providers from three to five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Further, the Bipartisan
Budget Act of 2018 among other things, amended the Medicare statute, effective January 1, 2019, to reduce the coverage gap in most Medicare
drug plans, commonly known as the &#8220;donut hole,&#8221; by raising the manufacturer discount under the Medicare Part D coverage gap
discount program to 70%. It is unclear how the ACA and its implementation, as well as efforts to repeal or replace, or invalidate, the
ACA, or portions thereof, will affect our insulin pump or our business. Additional legislative changes, regulatory changes, and judicial
challenges related to the ACA remain possible. It is possible that the ACA, as currently enacted or as it may be amended in the future,
and other healthcare reform measures that may be adopted in the future, could have an adverse effect on our industry generally and on
our ability to commercialize our insulin pump and achieve profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we are able to obtain all regulatory approvals and have completed all other steps needed to be taken to commercialize our insulin
pump, if we or any contract manufacturers we select fails to comply with the FDA&#8217;s quality system regulations, the manufacturing
and distribution of our product candidate could be interrupted, and our product sales and operating results could suffer.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">A material step in
the process of the commercialization of our product candidate will involve selecting a manufacturer or manufacturers for our pump. We
and any future contract manufacturers of our insulin pump will be required to comply with the FDA&#8217;s quality system regulations,
which impose a complex regulatory framework that covers the procedures and documentation of the design, testing, production, control,
quality assurance, labeling, packaging, sterilization, storage and shipping of medical devices. The FDA enforces its quality system regulations
through periodic unannounced inspections. We cannot assure you that, in the future, any manufacturing facilities owned by us or any contract
manufacturer will pass any quality system inspection. In the event that our or any contract manufacturer&#8217;s facilities fails a quality
system inspection, the manufacturing or distribution of our product candidate could be interrupted and our operations disrupted. Failure
to take adequate and timely corrective action in response to an adverse quality system inspection could force a suspension or shutdown
of any packaging and labeling operations or then manufacturing operations of any contract manufacturers, or a recall of our insulin pump.
If any of these events were to occur, we at such time would not be able to provide our customers with the quantity of insulin pumps that
they require on a timely basis, our reputation could be harmed and we could lose any customers we then have, any or all of which could
have a material adverse effect on our business, financial condition and results of operations.</span></p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may undertake infringement or other legal proceedings against third parties, causing us to spend substantial resources on litigation
and exposing our own intellectual property portfolio to challenge.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We may come to
believe that third parties are infringing on our patents or other proprietary rights. To prevent infringement or unauthorized use,
we may need to file infringement and/or misappropriation suits, which are very expensive and time-consuming, could result in
meritorious counterclaims against us and would distract management&#8217;s attention. Also, in an infringement or misappropriation
proceeding, a court may decide that one or more of our patents is invalid, unenforceable, or both, in which case third parties may
be able to use our technology without paying license fees or royalties. Even if the validity of our patents is upheld, a court may
refuse to stop the other party from using the technology at issue on the grounds that the other party&#8217;s activities are not
covered by our patents. See &#8220;Business &#8211; Patents,&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may become involved in disputes with our present or future contract partners over intellectual property ownership or other matters, which
would have a significant effect on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Inventions discovered
in the course of performance of contracts with third parties or contractors may become jointly owned by such third party contractors
and us, in some cases, and the exclusive property of one of us, in other cases. Under some circumstances, it may be difficult to determine
who owns a particular invention or whether it is jointly owned, and disputes could arise regarding ownership or use of those inventions
or jointly developed improvements thereto. Other disputes may also arise relating to the performance or alleged breach of our agreements
with third parties. Any disputes could be costly and time-consuming, and an unfavorable outcome could have a significant adverse effect
on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Assuming
our insulin pump receives FDA clearance or approval, our insulin pump will still be subject to recalls, which would harm our reputation,
business operations and financial results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Even assuming we obtain
FDA approval or clearance with regard to our insulin pump, the FDA has the authority to require the recall of our pump if we commence
manufacturing of our insulin pump and we or any contract manufacturers we retain fail to comply with relevant regulations pertaining
to manufacturing practices, labeling, advertising or promotional activities, or if new information is obtained concerning the safety
or efficacy of the device. A government-mandated recall could occur if the FDA finds that there is a reasonable probability that our
device would cause serious, adverse health consequences or death. A voluntary recall by us could occur as a result of manufacturing defects,
labeling deficiencies, packaging defects or other failures to comply with applicable regulations. Any recall would divert management&#8217;s
attention and financial resources and harm our reputation with customers. A recall involving our insulin pump would be particularly harmful
to our business, financial condition and results of operations because it is currently our only product candidate.</span></p>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
disruption and/or instability in economic conditions and capital markets could adversely affect our ability to access the capital markets,
and thus adversely affect our business and liquidity.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Negative economic conditions
and issues with regard to the financial markets, could have a negative impact on our ability to access the capital markets, and thus
have a negative impact on our then operations and liquidity. A general shortage of liquidity and credit combined with the substantial
losses in worldwide equity markets could lead to an extended worldwide recession in the future. If such occurred, we would face significant
challenges if conditions in the capital markets did not improve. Our ability to access the capital markets under such circumstances could
be severely restricted at a time when we need to access such markets, which could have a negative impact on our business plans. Even
if we are able to raise capital under such circumstances, it may not be at a price or on terms that are favorable to us. We cannot predict
the occurrence of future disruptions or how long such negative conditions might continue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
our current insulin pump prototype is still in the development stage, it does not have reimbursement and is not approved for insurance
coverage. If in the future we are approved for and are otherwise able to commercialize our insulin pump, but are unable to obtain adequate
reimbursement or insurance coverage for such product candidate from third-party payors, we will be unable to generate significant revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Because our current
insulin pump prototype is still in the development stage, it does not have reimbursement and is not approved for insurance coverage.
The future availability of insurance coverage and reimbursement for newly approved medical devices is highly uncertain. In the United
States, patients using insulin pumps are generally reimbursed for all or part of the product cost by Medicare or other third-party payors.
Any future commercial success of our insulin pump will be substantially dependent on whether third-party coverage and reimbursement is
available for future customers. Medicare, Medicaid, health maintenance organizations and other third-party payors are increasingly attempting
to contain healthcare costs by limiting both coverage and the level of reimbursement of new medical devices, and, as a result, they may
not cover or provide adequate reimbursement for our insulin pump, assuming we are able to fully develop and obtain all regulatory approval
to market it in the United States. In addition, in certain countries, no uniform policy of coverage and reimbursement for medical device
products and services exists among third-party payors. Therefore, coverage and reimbursement for medical device products and services
can differ significantly from payor to payor. In addition, payors continually review new technologies for possible coverage and can,
without notice, deny coverage for these new products and procedures. As a result, the coverage determination process is often a time-consuming
and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately,
with no assurance that coverage and adequate reimbursement will be obtained, or maintained if obtained. Reimbursement systems in international
markets vary significantly by country and by region within some countries, and reimbursement approvals must be obtained on a country-by-country
basis. In many international markets, a product must be approved for reimbursement before it can be approved for sale in that country.
Further, many international markets have government-managed healthcare systems that control reimbursement for new devices and procedures.
Accordingly, unless government and other third-party payors provide coverage and reimbursement for our insulin pump, patients may not
use it, which would cause investors to lose their entire investment.</span></p>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to the oversight of the SEC and other regulatory agencies. Investigations by those agencies could divert management&#8217;s
focus and could have a material adverse effect on our reputation and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are subject to the
regulation and oversight of the SEC and state regulatory agencies, in addition to the FDA. As a result, we may face legal or administrative
proceedings by these agencies. We are unable to predict the effect of any investigations on our business, financial condition or reputation.
In addition, publicity surrounding any investigation, even if ultimately resolved in our favor, could have a material adverse effect
on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are a &#8220;smaller reporting company&#8221; and, as a result of the reduced disclosure and governance requirements applicable to smaller
reporting companies, our Common Stock may be less attractive to investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are a &#8220;smaller
reporting company,&#8221; and are subject to lesser disclosure obligations in our SEC filings compared to other issuers. Specifically,
&#8220;smaller reporting companies&#8221; are able to provide simplified executive compensation disclosures in their filings, are exempt
from the provisions of Section 404(b) of the Sarbanes-Oxley Act requiring that independent registered public accounting firms provide
an attestation report on the effectiveness of internal control over financial reporting and have certain other decreased disclosure obligations
in their SEC filings, including, among other things, only being required to provide two years of audited financial statements in annual
reports. Decreased disclosures in our SEC filings due to our status as a &#8220;smaller reporting company&#8221; may make it harder for
investors to analyze our operating results and financial prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not expect any cash dividends to be paid on our shares of Common Stock for the foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have never declared
or paid a cash dividend and we do not anticipate declaring or paying dividends on our Common Stock for the foreseeable future. We expect
to use future financing proceeds and earnings, if any, to fund operating expenses. Consequently, shareholders&#8217; only opportunity
to achieve a return on their investment is if the price of our stock appreciates and they sell their shares at a profit. We cannot assure
shareholders of a positive return on their investment when they sell their shares or that shareholders will not lose the entire amount
of their investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the beneficial ownership of our Common Stock continues to be highly concentrated, it may prevent our shareholders from influencing significant
corporate decisions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our executive officers,
directors and certain persons who may be deemed affiliates beneficially own in excess of 50% of our issued and outstanding Common Stock.
As a result, such persons may exercise substantial influence over the outcome of corporate actions requiring shareholder approval including,
without limitation, the election of directors, certain mergers, consolidations and sales of all or substantially all of our assets or
any other significant corporate transactions. Such persons may also vote against a change of control, even if such a change of control
would benefit our other shareholders.</span></p>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sale
of our Common Stock by shareholders could encourage short sales by third parties, which could contribute to the further decline of our
stock price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The significant downward
pressure on the price of our Common Stock that would be caused by the sale of material amounts of our Common Stock could encourage short
sales by third parties. Such an event could place further downward pressure on the price of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies
will make our Common Stock less attractive to investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are an &#8220;emerging
growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). For as long as we continue to be
an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public
companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of
Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in this prospectus and our periodic
reports and proxy statements and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and
stockholder approval of any golden parachute payments not previously approved. We will remain an emerging growth company until the earlier
of (i) the last day of the fiscal year (a) following the fifth anniversary of the completion of the first sale of shares covered by this
prospectus, (b) in which we have total annual gross revenue of at least $1.07 billion or (c) in which we are deemed to be a large accelerated
filer, which requires the market value of our Common Stock that is held by non-affiliates to exceed $700.0 million as of the prior September
30<span style="font-family: Times New Roman, Times, Serif"><sup>th</sup></span>, and (ii) the date on which we have issued more than
$1.0 billion in non-convertible debt during the prior three-year period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
sales of our securities could adversely affect the market price of our Common Stock and our future capital-raising activities could involve
the issuance of equity securities, which would dilute your investment and could result in a decline in the trading price of our Common
Stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We may sell securities
in the public or private equity markets at prices per share below the current market price of our Common Stock, even if we do not have
an immediate need for additional capital at that time. Sales of substantial amounts of shares of our Common Stock, or the perception
that such sales could occur, could adversely affect the prevailing market price of our shares and our ability to raise capital. We may
issue additional shares of Common Stock in future financing transactions or as incentive compensation for our executive management and
other key personnel, consultants and advisors. Issuing any equity securities would be dilutive to the equity interests represented by
our then-outstanding shares of Common Stock. Moreover, sales of substantial amounts of shares in the public market, or the perception
that such sales could occur, may adversely affect the prevailing market price of our Common Stock and make it more difficult for us to
raise additional capital.</span></p>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
articles of incorporation allow for our board of directors to create new series of preferred stock without further approval by our shareholders,
which could adversely affect the rights of the holders of our Common Stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our board of directors
has the authority to fix and determine the relative rights and preferences of preferred stock. Currently, our board of directors has
the authority to designate and issue up to 5,000,000 shares of our preferred stock without further shareholder approval. In the future,
our board of directors could authorize the issuance of one or more series of preferred stock that would grant to holders, among other
rights, the preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to
the holders of Common Stock and the right to the redemption of our preferred shares acquired by such persons, together with a premium,
prior to the redemption of our Common Stock. In addition, our board of directors could authorize the issuance of a series of preferred
stock that has greater voting power than our Common Stock or that is convertible into our Common Stock, which could decrease the relative
voting power of our Common Stock or result in dilution to our existing shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to establish and maintain an effective system of internal controls, we may not be able to report our financial results accurately
or prevent fraud. Any inability to report and file our financial results accurately and timely could harm our reputation and adversely
affect the trading price of our Common Stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Effective internal
controls are necessary for us to provide reliable financial reports and prevent fraud. If we cannot provide reliable financial reports
or prevent fraud, we may not be able to manage our business as effectively as we would if an effective control environment existed, and
our business and reputation with investors may be harmed. If we are unable to maintain effective internal controls, we may not have adequate,
accurate or timely financial information, and we may be unable to meet our reporting obligations as a public company, including the requirements
of the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act). In addition, we may be unable to accurately report our financial results
in future periods, or report them within the timeframes required by the requirements of the SEC or the Sarbanes-Oxley Act. Failure to
comply with the Sarbanes-Oxley Act, when and as applicable, could also potentially subject us to sanctions or investigations by the SEC
or other regulatory authorities. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter
in their implementation, could result in identification of additional material weaknesses or significant deficiencies, cause us to fail
to meet our reporting obligations or result in material misstatements in our financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">Furthermore, Section
404 of the Sarbanes-Oxley Act and related regulations require our management to evaluate the effectiveness of our internal control over
financial reporting as of the end of each fiscal year. Based on its evaluation, our management concluded that our internal controls over
financial reporting were effective as of March 31, 2021. We cannot provide assurance that, in the future, a material weakness or significant
deficiency will not exist or otherwise be discovered. If that were to happen, it could harm our operating results and cause shareholders
to lose confidence in our reported financial information. Any such loss of confidence would have a negative effect on the trading price
of our securities.</span></p>
<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
board of directors is able to adopt recapitalizations through forward or reverse splits of our outstanding shares of Common Stock without
shareholder approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt">Pursuant to our
amended and restated articles of incorporation, our board of directors has the power, without obtaining shareholder approval, to effectuate
recapitalizations of us through forward or reverse splits of our outstanding Common Stock. As a result of such provision, our board of
directors can implement recapitalizations of us by effectuating a forward or reverse stock split of our outstanding Common Stock, which
would increase or decrease each of our shareholder&#8217;s number of shares owned, and our shareholders will have no right to approve
or disapprove any such action even if such actions have a material adverse effect on them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modulara003"></span>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">This prospectus includes
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, which we refer to as the Securities
Act, and Section 21E of the Securities Exchange Act of 1934, as amended, which we refer to as the Exchange Act, that relate to future
events or to our future operations or financial performance. Any forward-looking statement involves known and unknown risks, uncertainties
and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future
results, levels of activity, performance or achievements expressed or implied by such forward-looking statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Words such as, but
not limited to, &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;forecast,&#8221;
&#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;targets,&#8221;
&#8220;likely,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; &#8220;scheduled&#8221;
and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying words. Although we believe that we have a reasonable basis for
each forward-looking statement contained in this registration statement, we caution you that these statements are based on our estimates
or projections of the future that are subject to known and unknown risks and uncertainties and other important factors that may cause
our actual results, level of activity, performance, experience or achievements to differ materially from those expressed or implied by
any forward-looking statement. Actual results, level of activity, performance, experience or achievements may differ materially from
those expressed or implied by any forward-looking statement as a result of various important factors, including our critical accounting
policies and risks and uncertainties relating, to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our strategies, prospects,
    plans, expectations, forecasts or objectives;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our ability to achieve a
    marketable product (i.e., our insulin pump) and the costs and timing thereof;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">acceptance of our product
    candidate by our target market and our ability to compete in such market;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our ability to raise additional
    financing when needed and the terms and timing thereof;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our ability to expand, protect
    and maintain our intellectual property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our future operations, financial
    position, revenues, costs, expenses, uses of cash, capital requirements, our need for additional financing or the period for which
    our existing cash resources will be sufficient to meet our operating requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our analysis of the target market for our insulin pump;</span></td></tr>
  </table>
<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the impact of COVID-19 and
    other adverse public health developments on our operations and our industry:</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our ability to obtain all
    regulatory approvals and clearances relating to our insulin pump including those of the United States Food and Drug Administration,
    or FDA;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">regulatory developments in
    the United States and other countries;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the timing and costs of our
    obtaining all regulatory approvals and clearances identified immediately above;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our compliance with all applicable
    laws, rules and regulations, including those of the Securities and Exchange Commission, or SEC, and the FDA;</span></td></tr>
  </table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our ability to compete in
    the diabetes marketplace with larger and more substantial medical device companies;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">general economic, business,
    political and social conditions;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our reliance on and our ability
    to retain (and if necessary, timely recruit and replace) our officers, directors and key employees and their ability to timely and
    competently perform at levels expected of them;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our ability to generate significant
    revenues and achieve profitability;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our ability to manage the
    growth of our business;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our commercialization, marketing
    and manufacturing capabilities and strategies;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our ability to expand, protect
    and maintain our intellectual property position;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt; width: 24px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-top: 0.25pt; padding-bottom: 0.25pt; text-align: justify"><span style="font-size: 10pt">the success
    of competing third-party products;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our ability to fully remediate
    our identified internal control material weaknesses;</span></td></tr>
  </table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">our ability to comply with
    regulatory requirements relating to our business, and the costs of compliance with those requirements, including those on data privacy
    and security;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the specific risk factors
    discussed under the heading &#8220;Risk Factors&#8221; set forth in this prospectus; and</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">various other matters, many
    of which are beyond our control.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modulara004"></span>USE
OF PROCEEDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We will not receive
any proceeds from the sale of the common stock by the selling stockholders. We may receive proceeds upon the exercise of the May Warrants
(to the extent the registration statement of which this prospectus is a part is then effective and, if applicable, the &#8220;cashless
exercise&#8221; provision is not utilized by the holder). Any proceeds will be used for general corporate and working capital or for
other purposes that our board of directors, in its good faith, deems to be in the best interest of the Company. No assurances can be
given that any of such May Warrants will be exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;<span style="font-family: Times New Roman, Times, Serif"><b>DIVIDEND
POLICY</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have never declared
or paid any cash dividend on our capital stock. We do not anticipate paying any cash dividends in the foreseeable future and we intend
to retain all of our earnings, if any, to finance our growth and operations and to fund the expansion of our business. Payment of any
dividends will be made in the discretion of our board of directors, after its taking into account various factors, including our financial
condition, operating results, current and anticipated cash needs and plans for expansion. Any dividends that may be declared or paid
on our common stock, must also be paid in the same consideration or manner, as the case may be, on our shares of preferred stock, if
any.</span></p>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modulara005"></span>DETERMINATION
OF OFFERING PRICE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The selling stockholders
will offer common stock at the prevailing market prices or privately negotiated price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 46.05pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The offering price
of our common stock by the selling stockholders does not necessarily bear any relationship to our book value, assets, past operating
results, financial condition or any other established criteria of value. The facts considered in determining the offering price were
our financial condition and prospects, our limited operating history and the general condition of the securities market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 46.05pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In addition, there
is no assurance that our common stock will trade at market prices in excess of the offering price as prices for common stock in any public
market will be determined in the marketplace and may be influenced by many factors, including the depth and liquidity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modulara008"></span>MARKET
FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our common stock began
trading on Nasdaq under the symbol &#8220;MODD&#8221; on February 10, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders
of Record</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On June 2,
2022, the closing price per share of our common stock was $4.75 as reported on The Nasdaq Capital Market, and we had approximately
80 stockholders of record. On June 2, 2022 there were 10,911,684 shares of our common stock issued and outstanding. In addition,
we believe that a significant number of beneficial owners of our common stock hold their shares in street name.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modulara009"></span>MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND
RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following discussion and analysis is based on, and should be read in conjunction with our financial statements, which are included elsewhere
in this prospectus. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contains statements that
are forward-looking. These statements are based on current expectations and assumptions that are subject to risk, uncertainties and other
factors. These statements are often identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221;
&#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; or &#8220;continue,&#8221;
and similar expressions or variations. Actual results could differ materially because of the factors discussed in &#8220;Risk Factors&#8221;
elsewhere in this prospectus, and other factors that we may not know.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-size: 10pt">Our
fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in this Report, refers to the fiscal year ended March
31 of the calendar year indicated (for example, fiscal 2022 refers to the fiscal year ending March 31, 2022). Unless the context requires
otherwise, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and the &#8220;Company&#8221; refer to Modular Medical,
Inc. and its consolidated subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; background-color: white"><span style="font-size: 10pt">We
are a development stage medical device company focused on the design, development, and commercialization of an innovative insulin pump
using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part patch pump,
our MODD1 product, the Company seeks to fundamentally alter the trade-offs between cost and complexity and access to the higher standards
of care that presently-available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription,
reimbursement, training and day-to-day use, we seek to expand the wearable insulin delivery device market beyond the highly motivated
&#8220;super users&#8221; and expand the category into the mass market. The product seeks to serve both the type 1 and the rapidly growing,
especially in terms of device adoption, type 2 diabetes markets.</span></p>
<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; background-color: white"><span style="font-size: 10pt">Historically,
we have financed our operations principally through private placements of our common stock and convertible promissory notes. Based on
our current operating plan, substantial doubt about our ability to continue as a going concern for a period of at least one year from
the date that the financial statements included in Item 1 of this Report are issued exists. Our ability to continue as a going concern
depends on our ability to raise additional capital, through the sale of equity or debt securities, to support our future operations.
If we are unable to secure additional capital, we will be required to curtail our research and development initiatives and take additional
measures to reduce costs. We have provided additional disclosure in Note 1 to the condensed consolidated financial statements in Item
1 of this Report and under&#160;<span style="font-family: Times New Roman, Times, Serif"><i>Liquidity</i></span>&#160;below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impacts
of COVID-19</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-size: 10pt">The
global outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains, significantly
restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in-place&#8221; and created significant
disruption of the financial markets. The full extent of the COVID-19 impact on our operational and financial performance will depend
on future developments, including, without limitation, the duration and spread of the pandemic and related actions taken by U.S. and
foreign government agencies to prevent disease spread, all of which are uncertain, out of our control, and cannot be predicted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-size: 10pt">In
March 2020, Santa Diego County in California, where we are based, and the state of California issued &#8220;shelter-in-place&#8221; orders
(the Orders). We complied with the Orders and minimized business activities at our San Diego facility from March 2020 until May 2021.
During that time, we implemented a teleworking policy for our employees and contractors to reduce on-site activity at our facility. In
May 2021, our employees and certain contractors returned to work in our office. We have and continue to experience longer lead times
for certain components used to manufacture initial quantities of our products for our submission to the FDA. We remain diligent in continuing
to identify and manage risks to our business given the changing uncertainties related to COVID-19. While we believe that our operations
personnel are currently in a position to build an adequate supply of products for our FDA submission, we recognize that unpredictable
events could create difficulties in the months ahead. We may not be able to address these difficulties in a timely manner, which could
delay our submission to the FDA and negatively impact our business, results of operations, financial condition and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; background-color: white"><span style="font-size: 10pt">The
continued spread of COVID-19 has also led to disruption and volatility in the global capital markets. We were recently able to raise
additional capital in a private placement of convertible promissory notes (see discussion below under&#160;<span style="font-family: Times New Roman, Times, Serif"><i>Liquidity</i></span>).
However, we need to raise additional capital to support our operations in the future. We may be unable to access the capital markets
or additional capital may only be available to us on terms that could be significantly detrimental to our existing stockholders and holders
of the convertible promissory notes and to our business.</span></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-size: 10pt">The
discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements,
which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires
us to make certain estimates and judgments that affect the reported amounts of assets, liabilities, and expenses. On an ongoing basis,
we make these estimates based on our historical experience and on assumptions that we consider reasonable under the circumstances. Actual
results may differ from these estimates and reported results could differ under different assumptions or conditions. Our significant
accounting policies and estimates are disclosed in Note 1 of the Notes to Consolidated Financial Statements in our Annual Report on Form
10-K for the year ended March 31, 2021. As of December 31, 2021, there have been no material changes to our significant accounting policies
and estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Change</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020 to 2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 48%">Research and development &#8211; Three months ended</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,849,399</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,086,669</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">762,730</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">70.2</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Research and development &#8211; Nine months ended</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,742,911</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,150,149</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,592,762</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-size: 10pt">Our
research and development expenses include personnel, consulting, materials and other costs associated with the development of our insulin
pump product. We expense research and development costs as they are incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Research
and development, or R&amp;D, expenses increased for the three months ended December 31, 2021 as compared with the prior period of fiscal
2021 primarily due to increased engineering and manufacturing consulting costs, as we have increased our development and manufacturing
activities. R&amp;D expenses increased for the nine months ended December 31, 2021 as compared with the prior period of fiscal 2021 primarily
due to increased engineering and manufacturing personnel and consulting costs, protype and production component and material costs and
stock-based compensation expenses. R&amp;D expenses included non-cash, stock-based compensation expenses of $204,962 and $96,127 for
the three months ended December 31, 2021 and 2020, respectively, and $459,989 and $301,767 for the nine months ended December 31, 2021
and 2020, respectively. We expect R&amp;D expenses to remain flat for the remainder of fiscal 2022, as we continue to advance the development
of our pump product and develop an initial low-volume manufacturing process.</span></p>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Change</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020 to 2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 48%">General and administrative &#8211; Three months ended</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,981,665</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">783,898</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,197,767</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">152.8</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>General and administrative &#8211; Nine months ended</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,156,152</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,453,808</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,702,344</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-size: 10pt">General
and administrative expenses consist primarily of personnel and related overhead costs for facilities, marketing, finance, human resources
and general management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-size: 10pt">General
and administrative, or G&amp;A, expenses, increased for the three and nine months ended December 31, 2021 as compared with the prior
periods of fiscal 2021 primarily as a result of increased stock-based compensation expense and increased consulting and legal fees. G&amp;A
expenses included stock-based compensation expenses of $1,016,774 and $198,926 for the three months ended December 31, 2021 and 2020,
respectively, and $2,280,098 and $638,607 for the nine months ended December 31, 2021 and 2020, respectively. We expect G&amp;A expenses
to increase for the remainder of fiscal 2022, as we pursue a public offering of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Expense</i></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
    30,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Change</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020
    to 2021</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEECC">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48%"><span style="font-size: 10pt">Interest expense &#8211; Three months
    ended</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt">1,010,247</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt">(1,010,247</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Interest expense &#8211; Nine months ended</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">2,204,917</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">(2,204,917</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-size: 10pt">Interest
expense consisted of interest expense incurred from our convertible promissory notes, including amortization of debt issuance costs,
and our promissory (bridge) note. See Notes 4 and 5 to the condensed consolidated financial statements included in Item 1 of this Report
for additional disclosure.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">As
a development-stage enterprise, we do not currently have revenues to generate cash flows to cover operating expenses. Since our inception,
we have incurred operating losses and negative cash flows in each year due to costs incurred in connection with R&amp;D activities and
G&amp;A expenses associated with our operations. For the nine months ended December 31, 2021, we incurred a net loss of approximately
$14.1 million. For the years ended March 31, 2021 and 2020, we incurred net losses of approximately $7.4 million and $5.3 million, respectively.
At December 31, 2021, we had a cash balance of approximately $0.2 million and an accumulated deficit of approximately $29.9 million.
When considered with our current operating plan and the requirement to repay the Notes (as defined below) and the draws under the Bridge
Note (as defined below) by May 2022, these conditions raise substantial doubt about our ability to continue as a going concern for a
period of at least one year from the date that of issuance of the consolidated financial statements included in Item 1 of this Report.
Our consolidated financial statements do not include adjustments to the amounts and classification of assets and liabilities that may
be necessary should we be unable to continue as a going concern. Our ability to continue as a going concern depends on our ability to
raise additional capital through the sale of equity or debt securities to support our future operations, and we are currently seeking
such additional financing. As discussed in Note 3 to our condensed consolidated financial statements in Item 1 of this Report, we obtained
forgiveness of the $368,000 principal balance and interest on the PPP Note we received from Silicon Valley Bank in April 2020 under the
U.S. Small Business Administration Paycheck Protection Program. As discussed in Note 4 to our condensed consolidated financial statements
in Item 1 of this Report, in May 2021, we completed a private placement of $6,610,500 aggregate principal amount of our convertible promissory
notes (the Notes). The Notes are unsecured obligations of ours with each Note having a stated maturity date of 12 months from its issue
date (the Issue Date). The Notes bear interest at a rate of 12% per annum, payable on maturity, provided that, if we fail to pay any
amounts when due under a Note, the interest rate increases to the greater of 16% or the maximum amount permitted by law. Each Note may
be prepaid at our option during the first 270 calendar days following its Issue Date (the 270<span style="font-family: Times New Roman, Times, Serif"><sup>th</sup></span>&#160;day,
the Trigger Date), subject to a 110% prepayment penalty on all principal and accrued interest then outstanding. No Notes may be prepaid
in whole or in part after the Trigger Date. As discussed in Note 9 to our condensed consolidated financial statements in Item 1 of this
Report, on October 28, 2021, we sold $250,000 of shares of our common stock to officers, and we issued a secured promissory note (the
Bridge Note) to an investor. The Bridge Note provides us with a $3,000,000 revolving credit facility with all amounts being drawn down
by the Company thereunder being due and payable, subject to acceleration in the event of a default, on March 15, 2022. For the three
months ended December 31, 2021, we drew down $1,500,000 under the Bridge Note.</span></p>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-size: 10pt">Our
operating needs include the planned costs to operate our business, including amounts required to fund research and development activities,
including clinical studies, working capital and capital expenditures. Our future capital requirements and the adequacy of our available
funds will depend on many factors, including our ability to successfully commercialize our product, competing technological and market
developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or
complement our product offering. If we are unable to secure additional capital, we will be required to curtail our research and development
initiatives and take additional measures to reduce costs in order to conserve our cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-size: 10pt">For
the nine months ended December 30, 2021, we used $7,128,787 in operating activities, which primarily resulted from our net loss of $14,058,155
increased for a non-cash gain on the PPP Note extinguishment of $368,780 and net changes in operating lease assets and liabilities of
$34,422, as adjusted for changes to operating assets and liabilities of $1,197,989, a loss on debt extinguishment of $1,321,450 stock-based
compensation expenses of $2,740,086, $388,021 for issuances of shares of common stock in exchange for services, $149,994 for issuable
shares of common stock in exchange for services, depreciation and amortization expenses of $80,268, and interest expense of $1,454,762
for amortization of debt discount. For the nine months ended December 31, 2020, we used $4,570,713 in operating activities, which primarily
resulted from our net loss of $5,605,431 and changes to operating assets and liabilities of $107,758, as adjusted for stock-based compensation
expenses of $940,374, depreciation and amortization expenses of $82,016, net changes in lease assets and liabilities of $120,085.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; background-color: white"><span style="font-size: 10pt">For
the nine months ended December 31, 2021 and 2020, cash used in investing activities of $22,779 and $109,541, respectively was due to
the purchase of property and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; background-color: white"><span style="font-size: 10pt">Cash
provided by financing activities of $6,037,199 for the nine months ended December 31, 2021 primarily attributable to net proceeds from
the issuance of our Notes of $5,637,199 and net proceeds of $250,000 from the sale of shares of common stock to officers of the Company.&#160;Cash
provided by financing activities of $2,154,662 for the nine months ended December 31, 2020 was attributable to net proceeds of $1,785,882
from the sale of shares of our common stock in a private placement that was initiated in March 2020 and $368,780 in proceeds from the
PPP Note.</span></p>
<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual
Obligations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
a &#8220;smaller reporting company&#8221; as defined by Item 10 of Regulation S-K, we are not required to provide the information requested
by paragraph (a)(5) of this Item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modulara010"></span>BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Modular Medical is
a development stage medical device company focused on the design, development, and commercialization of an innovative insulin pump using
modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part patch pump, the
Company seeks to fundamentally alter the trade-offs between cost and complexity and access to the higher standards of care that presently
available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription, reimbursement,
training and day-to-day use, we seek to expand the wearable insulin delivery device market beyond the highly motivated &#8220;super users&#8221;
and expand the category into the mass market. The product candidate seeks to serve both the type 1 and the rapidly growing, especially
in terms of device adoption, type 2 diabetes markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Differentiation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We believe that there
are a number of shortcomings and issues with currently available insulin pumps that prevent a substantial number of people who require
insulin on a daily basis from choosing an insulin pump to treat their diabetes. We believe, that by tailoring our insulin pump to address
such factors, we can expand the scope and adoption rate of insulin pump usage. We believe that to achieve broader market acceptance,
an insulin pump must be easier to learn to use, be less time consuming to operate, more intuitive to both patients and physicians, and
meet the standards for coverage by insurance providers so that co-payments required from patients are affordable and the hurdles to insurance
coverage are significantly reduced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Among the more
prominent issues are:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 74px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Complexity</i></span><span style="font-size: 10pt">:
    Many existing pumps are highly complex and require significant technical expertise to use effectively. We believe such pumps were
    designed for &#8220;super users,&#8221; who have high levels of motivation and technical competence. The complexity of pumps proves
    daunting to less technically inclined users.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 74px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cumbersome</i></span><span style="font-size: 10pt">:
    We believe that a majority of existing pumps are bulky and difficult to manage, in many cases requiring additional equipment to introduce
    a catheter to the patient&#8217;s body and up to 48 inches of tubing, which must be replaced frequently, to connect the catheter
    to a pump. This requires users to carry spare parts and other equipment adding to the difficulty of using the pump.</span></td></tr>
  </table>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->




<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 74px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cost</i></span><span style="font-size: 10pt">:
    Costs associated with insulin pump therapy are high and can be prohibitive, especially for those on fixed or limited incomes. These
    costs vary by pump, but multi-thousand-dollar upfront payments, often with substantial co-payments in addition to possible daily
    co-payments on consumables, can easily place current pumps out of reach for patients. This makes insurance providers hesitant to
    pay for them, leading to limited or absent reimbursement/coverage and high hurdles for patients to gain access.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Outdated
    style</i></span><span style="font-size: 10pt">: Consumer electronics devices have evolved in both form and function. Diabetes pumps
    have not experienced similar progress. We believe that consumers will be more receptive of products designed with the user experience
    in mind and that many have low tolerance for complex, difficult procedures for use and maintenance of products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pump
    mechanism limitations</i></span><span style="font-size: 10pt">: Traditional pumps generally utilize a syringe and plunger mechanism
    to deliver insulin. We believe this design limits the ability to reduce the size of the pump, and also potentially exposes the user
    to the unintended delivery of the full volume of insulin within the pump, which can cause hypoglycemia or death. We believe that
    the fear of adverse health events due to technical malfunctions related to traditional pump mechanism limitations deters the adoption
    of insulin pump therapy.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our team has substantial
knowledge of the diabetes industry and experience in developing, obtaining marketing authorization for, and bringing insulin pumps to
market. Based on this experience, we believe that our innovative insulin pump, using a new and proprietary method of pumping insulin,
can address most or all of these shortcomings. It provides a state-of-the-art insulin pump capable of both basal (steady flow) and bolus
(mealtime dosing) insulin disbursement. It also has been designed considering a natural migration path to multi-chamber/multi-liquid
pumps, potentially offering an exciting array of new therapies to patients with diabetes and other conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our goal is to become
the leader in expanding access to insulin pump technology to a wider portion of diabetes sufferers and provide not just care for the
super users, but &#8220;diabetes care for the rest of us.&#8221; We believe there is a substantial opportunity to penetrate the type
2 MDI marketplace, whether through this new insulin pump or further simplification of pumps for the type 2 marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The MODD1 is a high-precision,
first-line pump that we believe represents the best choice for new pump patients because it is easy to afford, easy to learn, easy to
use, and has a revolutionary design and technology that enable precision with low-cost manufacture and high reproducibility.</span></p>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Key features include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Two parts &#8211;
    one reusable, one disposable &#8211; snap together to form the working system;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">One button interface, easy
    to learn and use;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">90-day reusable, 3-day disposable;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Removable at any time from
    an adhesive bracket;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">No external controller required,
    no charging, no battery replacement; and</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Slim profile, lighter weight.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">A proprietary survey
of American healthcare payors representing 50 million covered lives (approximately 1/3 of U.S. covered lives) performed for us by industry
leading survey firm ISA has demonstrated that payors are willing to grant equivalent or preferential coverage for a product with this
feature set at launch in exchange for rebates of about 20%. These costs are built into all of our models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Diabetes
Classifications and Therapies</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Diabetes is typically classified as either
type 1 or type 2:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">T1D is an
    auto-immune condition characterized by the body&#8217;s nearly complete inability to produce insulin. It is frequently diagnosed
    during childhood or adolescence. Individuals with T1D require daily insulin therapy to survive.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">T2D represents
    over 90% of all individuals diagnosed with diabetes and is characterized by the body&#8217;s inability to either properly utilize
    insulin or produce sufficient insulin. Initially, many people with T2D attempt to manage their condition with improvements in diet
    and exercise and/or the use of oral medications and/or injection of glucagon-like peptide-1 (GLP-1) drugs. However, as their diabetes
    advances, patients often progress to requiring insulin therapies such as once-daily long-acting insulin and ultimately to intensified
    mealtime rapid-acting insulin therapy. This represents an important portion of the diabetes market with an estimated 1.6 million
    T2D intensively treated with insulin currently in the United States.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Glucose, the primary
source of energy for cells, must be maintained at certain levels in the blood in order to permit optimal cell function and health. In
people with diabetes, blood glucose levels are not well controlled and frequently become very high, a condition known as hyperglycemia,
and very low, a condition called hypoglycemia. Hyperglycemia can lead to serious long-term complications, including blindness, kidney
disease, nervous system disorders, occlusive vascular diseases, lower-limb amputation, stroke, cardiovascular disease, and death. Hypoglycemia
can lead to confusion or loss of consciousness, often requiring a visit to the emergency room or, in certain cases, result in seizures,
coma, and/or death.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">All people with T1D,
which is our primary market, require daily insulin. According to the Seagrove 2021 Diabetes Blue Book, approximately 18% of people with
T2D in the United States, or 4.7 million people, require insulin (basal alone represent 3.1 million and basal plus mealtime represent
1.6 million) to manage their diabetes. In this prospectus, we refer to people with T1D and people with T2D who require mealtime insulin
as &#8220;insulin-requiring people with diabetes.&#8221;</span></p>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Currently, there are
two primary therapies available for insulin-requiring people with diabetes: multiple daily insulin injections directly into the body
through syringes or insulin pens, referred to as Multiple Daily Injection, or MDI therapy, or the use of an insulin pump to deliver mealtime
insulin boluses to help with glucose absorption after carbohydrate consumption and a continuous subcutaneous insulin infusion, or CSII
therapy, into the body. Generally, CSII therapy is considered to provide a number of advantages over MDI therapy, primarily an improvement
in glycemic control, as measured by certain diabetes management tests such as hemoglobin A1c (HbA1c) measure and more recently Time in
Range (TIR) where a continuous glucose measuring device is used to calculate this test. Among other medical benefits, it has been demonstrated
that insulin pump use can decrease glucose variability, reduce the number of hypoglycemia, decrease the daily doses of insulin and reduce
the fear of hypoglycemia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Notwithstanding
these advantages, the difficulty in use resulting from the complexity and cumbersome design of available insulin pumps as well as high
and often prohibitive costs for both the patient and insurance provider has resulted not only in dissatisfaction among many existing
pump users (fewer than half purchase a new pump after the warranty expires per Seagrove Partners estimate), but also has severely limited
the adoption rate of insulin pumps by a large segment of the MDI diabetes population, who we refer to in this prospectus as &#8220;Almost
Pumpers.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We define Almost Pumpers
as insulin-requiring people with diabetes who are aware of pumps and their potential benefits but because of past experiences, pump shortcomings,
cost, complexity, and time and learning required to adopt and utilize currently available insulin pumps, continue to receive their daily
insulin through MDI therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Our initial
focus for our insulin pump is the almost pumper segment population located in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><img src="modular004.jpg" alt="(Graphic)" style="float: right; margin-left: 25pt" /></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our research, along
with marketplace data, estimates that 32% of Americans with T1D use insulin pump therapy and 28% of Americans with T1D (44% of those
who currently utilize MDI) can be classified as having an interest in pump adoption and meeting the American Diabetes Association guidelines
of glucose control if their objections to the currently available suite of products can be overcome. They do not want to closely manage
their glucose levels and incur the associated time and effort involved. They are the Almost Pumpers. We have developed what we believe
to be the most technologically advanced delivery system overcome the objections and provided motivation for this market. We believe that
there are four addressable hurdles to adoption:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 10pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Usability: the device needs
    to be easy to learn and to operate;</span></td></tr>
  </table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Affordability: we will focus
    on overcoming copay and insurance hurdles rather than leaving the &#8220;insurance journey&#8221; to the clinician and patient;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Accessibility and Education:
    we will seek to engage patients to sample this new technology by supplying clinicians with free samples and simple training to allow
    people to see first-hand the typical barriers to adoption that have been overcome; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Service and Support: where
    we will answer their questions and concerns during this diabetes experience.</span></td></tr>
  </table>
<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We believe this conversion
process, engaging people to try and thereby receive the benefits of our technology will substantially increase adoption of insulin pumps
among both those with T1D and T2D who remain reliant upon multiple daily injections. Diabetes is a disease that appears throughout the
world. Therefore, we cannot segment the market by socioeconomics, education or level of care. We intend to create an insulin pump that
appeals to all Almost Pumpers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The International Diabetes
Federation, or IDF, estimates that, in 2019, approximately 460 million people were living with diabetes worldwide and, that by 2045,
this number will increase to approximately 700 million people</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">An estimated 34 million
people in the United States live with diabetes. Within this group, T1D accounts for approximately 1.8 million people (7% of total) with
the remainder being T2D. All people with T1D require daily insulin. However, of the approximately 25.5 million people with T2D, about
1.6 million of them require intensive insulin treatments to manage their diabetes. This represents a large and growing market with the
effects of diabetes accounting for roughly 25% of all healthcare dollars spent annually in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">According to
the National Diabetes HCP Survey conducted by Seagrove Partners, approximately 25% of the 1.6 million highly insulin intensive T2D have
considered going &#8220;on pump.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Insulin pumps have
been shown to provide a higher level of care for insulin dependent people with diabetes and result in better glycemic control, fewer
comorbidities, fewer trips to the emergency room, and higher overall quality of life. They also result in lower overall costs to the
healthcare system, reducing typical expense per patient year from $27,195 to $16,992.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Despite these
benefits, only 1 in 3 (32%) of the 1.8 million Americans with T1D and very few of the 1.6 million T2D intensively treated with insulin
currently use an insulin pump, for a total of approximately 670,000 current users, with only a slow increase of insulin pump use. The
remaining 68% of T1D&#8217;s and virtually all of the T2D&#8217;s rely on multiple daily injections (MDI) for glucose control. Decades
of advances in technology advances have left these non-pumpers at a significant disadvantage from a control perspective versus their
&#8220;pumping&#8221; counterparts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have identified
a large segment of the market that we refer to as &#8220;Almost Pumpers.&#8221; Almost Pumpers are those insulin-requiring people with
diabetes (T1D and T2D) who feel that they would adopt the pump if it were less expensive, less time consuming, less technically intimidating,
and if there was no separate controller. They represent approximately 32% of the T1D market correlating to a $1.9 billion growth opportunity.</span></p>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Insulin pumps on the
market today require a substantial amount of time to manage the therapy, have high out of pocket costs that place these technologies
out of reach for a large part of the population, and are feature-heavy with complex systems that have hampered adoption and intimidated
many users. The most commonly used insulin pumps today require extensive training and hours of daily management. The average pump user
must go through 42 steps of setup and refill process every 72 hours to &#8220;stay on track.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><img src="modular005.jpg" alt="(Graphic)" style="float: left; margin-right: 25pt" />&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The current reluctance
to adopt the insulin pump has had serious consequences on the healthcare system. In the United States, people living with T1D have struggled
to attain glycemic targets. A 2019 analysis of the large T1D Exchange clinical registry found that only 21% of U.S. adults with T1D achieved
the ADA A1c goal (&lt;7.0%). Further, according to a study published in JAMA Internal Medicine, researchers found no significant improvements
in diabetes care between 2005 and 2016, with persistent gaps in care related to socioeconomic status.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The recent introduction
and rapid adoption of Abbott Labs Freestyle Libre has made Continuous Glucose Monitoring (CGM) easier and more affordable, expanding
the product category, and doubling its size. Now for the first time, there is an easy, less painful-no more finger sticks&#8211;way
for patients to have the data they need to understand more about their glucose levels and their insulin requirements. Access to such
data has motivated patients to ask their diabetes clinician how they can achieve better glycemic control and made them more comfortable
with using technology and wearables to treat their diabetes. Pumps offer a clear pathway to better control and better overall care. We
believe that the insulin pump market is ready for a similar transition as that experienced in the CGM space. MODD1 pump represents a
new and better offering to assist and induce a wide variety of patients to make the transition and bridge the void to superior control
by becoming a &#8220;pumper.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We believe the present
pump marketplace is approximately a $1.9 billion market, comprising 32% of T1D pumpers and a small group of T2D pumpers. Seagrove Partners
estimates that 28% of T1D patients and 25% of T2D patients would adopt technology that was easier to use, access and pay for. We believe
the total addressable market approximates $3 billion, assuming revenue of $4,128 per patient, per year. We expect to spend approximately
15% of our total revenue on discounts and free samples to encourage adoption of our pump product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are dedicated to
helping all people with diabetes gain access to high quality care. We aim to help people with diabetes &#8211; especially Almost
Pumpers and the historically underserved communities &#8211; gain access to insulin pump technology by making it affordable and easy
to use.</span></p>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Diabetes
Care is at an Inflection Point</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">We believe that
the insulin pump market stands at a crossroads as a confluence of events makes the timing for a new product introduction ideal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">2020 was a very
difficult year in diabetes. Between COVID-19 and a loss of glycemic control during quarantines and isolation, deaths from diabetes rose
by 17% in 2020 versus the prior year. This was sharpest among the young who saw deaths rise 29% in the 25-44 year old demographic. This
has created a pain point and a desire to find new and better solutions and has raised awareness among patients, caregivers, payors, and
policy makers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">COVID-19 also
encouraged (and required) trial and adoption of telehealth models and a great many people have found them to their liking with a high
proportion of patients and of health care providers (HCPs) that want to continue to use these technologies. We expect much of this shift
and newfound comfort with distance care models to persist and believes that this can provide a patient acquisition and engagement model
for insulin pumps and diabetes care, especially for pumps optimized for free trial and easy learning.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">At the same
time, reimbursement for patch pumps has been increasingly moving to a pharmacy benefits manager (PBM) model, which simplifies reimbursement
which will further aid in a &#8220;frictionless launch.&#8221; This represents a fundamental shift in the insulin pump market, making
onboarding rapid and simplifying a previously complex and time-consuming &#8220;insurance journey.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The continuous
glucose monitoring (CGM) space (wearable devices that monitor blood glucose levels) has been experiencing explosive growth largely driven
by a new product introduction from Abbott Labs called the &#8220;libre.&#8221; This product was a more affordable, easier to use version
of the popular Dexcom CGM. Not only is it now a larger (by revenues) product than Dexcom, but it accomplished this without seeming to
slow Dexcom&#8217;s growth but rather by growing a new category with a new type of user.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">These users
are increasingly interested in adopting technology and wearables to manage their diabetes. We believe they are a natural market for a
new type of pump if it can meet their needs and address their objections and that the conjunction of the above trends represents a unique
opportunity in the insulin pump market&#8217;s history.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Diabetes technology
companies understand that we are at a turning point with new markets (T2D, T1D that are currently not using technologies). This can be
seen with increased discussion around this topic during recent national diabetes conferences, as well as but also an increase in marketing
promotion. For example, Dexcom purchased a $5.5 million 30-second spot during the 2021 Super Bowl.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">All these recent changes
support the high proportion of T1D and T2D intensively treated with insulin that are considered as Almost Pumpers, number that may grow
in the next years and that may be more reachable with adequate marketing strategies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Insulin Pump </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Instead of building
complex, bespoke, and difficult to manufacture and maintain pumping and control systems, we began with the technology and the user in
mind. Using proprietary and patented methods of insulin measurement, we were able to eschew complex mechanisms and instead built a product
candidate using only parts from high volume consumer electronics manufacturing lines, breaking the cost vs functionality curve that has
existed in the insulin pump space and representing the first truly modern insulin pump design. This is a new kind of product for a new
kind of patient.</span></p>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The pre-production
models of our low-cost insulin pump are now undergoing the testing required to submit to the FDA for clearance to market them in the
United States. We continue to devote, substantial time and resources to better understand the needs and preferences of Almost Pumpers
and the specific patent/provider/payor requirements to motivate change from MDI.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">MODD1 has several distinguishing
features:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="modular006.jpg" alt="" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">1 &#8211; The pump
has a simple button to press to deliver insulin as the patient requires it. The electronic pump uses a simple motor and rotating cam
to motivate the insulin into the patient along with a low power Bluetooth (LPBT) and near field communication (NFC) chips to allow the
patient to communicate with their smart phone, tablet, or other mobile computing platform, as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">2 &#8211; The pump
snaps together with a three-day disposable cartridge that is patient filled with insulin for delivery. It includes the power source and
a simple coin cell that allows it to run through the 80-hour life of the cartridge.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">3 &#8211; There is
a set (not shown) that contains a soft 6 mm cannula and an introducer for insertion into the skin and removal of the needle used to transfer
insulin to the body.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">4 &#8211; MODD1
comes with a variety of methods for the patient to wear the pump. Options include: a base plate with adhesive (shown) for attaching
to the body that has features for holding the pump to the patient; overwraps to hold the product candidate to the patient; and
a velcro strap with a base plate suitable for wrapping around the arm or leg of the patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The system will deliver
a small continuous rate called a basal that will provide approximately 50% of the total daily dose required and the user will use the
on-pump button to administer boluses, typically before and after meals.</span></p>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The objective is to
make the product candidate simple to acquire and take home, simple to learn and most importantly, simple to use to expand the pump market,
drive adoption and ultimately better clinical outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Technological
Advantages</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The adoption of new
ultra-high volume technologies will result in far easier manufacturing scale up as parts sourcing and assembly processes are far easier.
The MODD1 was designed from the beginning for mass manufacturing processes and &#8220;lights out&#8221; or near lights out production
assembly lines. This advantage is compounded by the high availability and already optimized cost reduction in its components. This has
resulted in a cost of goods, estimated on the competitors&#8217; announced margins and sales, 50% lower than our closest patch pump competitor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The adoption
of modern, miniaturized technologies has led to numerous other advantages as well. The MODD1 pump is smaller in overall volume than Insulet&#8217;s
popular Omnipod product and has a lower profile to the skin. Despite this, it holds a full 3mL (300 units) of insulin in line with full
sized pumps such as Tandem and Medtronic, 50% more than the 2mL reservoir in the Omnipod. We believe that this volume advantage over
other patch pumps will be significant as 24% of type 1 and over 50% of the rapidly growing type 2 market require more than 2mL of insulin
every three days (the expected wear time of patch pumps).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In addition,
our new and patented pumping modality will provide what we believe is the most even (and thus closest to the function of a healthy pancreas)
delivery of basal insulin in the industry. Basal rate can be delivered almost continuously while other pumps are delivering micro-boluses
every 5 minutes for the Omnipod, Tandem and Medtronic pumps. We plan to demonstrate the impact of our system on glycemic control in a
future clinical study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The technology
allows the patient to simply add insulin and operate. The battery is included in each cartridge and the device is operated without a
controller. Nothing needs charging. MODD1 has been made push button simple to appeal to a wider audience of users.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">This new technology
has also made the MODD1 lighter than existing offerings. Compared to the Insulet Omnipod, MODD1 weighs 20 grams (vs. 26 grams) empty
and 23 grams (vs. 28 grams) fully filled (despite carrying 50% more insulin), a reduction of 23% and 18%, respectively. Also, unlike
existing patch pumps, the MODD1 can be removed from the needle and taken off and replaced later if the user desires. This avoids loss
of insulin in a pump due to accidental dislodging of the soft canula, an issue that users have expressed considerable dissatisfaction
with on other patch pumps.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">This technology
is also uniquely suited to dual (or more) chamber pumps. We believe that such pumps will be integral to the realization of high time
in range artificial pancreas solutions that require no human intervention, the next step forward from the cumbersome and awkward solutions
today that require the user to announce meals, count and input carbs, and adjust delivery for exercise and sleep. The advantages of cost
and miniaturization are multiplied in a multi-chamber setup and we expect to be able to reach price points, ease of use, and form factor
unlike anything seen in the industry thus far. We believe that a prefilled, multi-hormone peel and stick patch pump able to function
in a fully autonomous closed loop system with CGM&#8217;s represents the next generation of diabetes care. We believe that we have demonstrated
our technology and are securing intellectual property protection on our approach.</span></p>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">We believe this
technology, especially in dual chamber, will open up numerous applications outside of diabetes where medication compliance of complex
therapy regimes is difficult addressing such spaces as weight loss, fertility, and simplifying complex delivery of multi-drug cocktails,
especially those with diverse and challenging dosing schedules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Solution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt">Our proposed
pump is being designed and developed to address the aforementioned shortcomings of the existing pump market and to appeal to: (i) the
substantial group of &#8220;Almost-Pumpers&#8221; who are currently interested in using an insulin pump, but have not done so because
of the complexity, cost or cumbersome nature of existing products, and (ii) people who are using one of the currently available insulin
pumps but are dissatisfied with such products. We believe that, owing to our new proprietary technology, our proposed insulin pump will
be the simplest and least expensive product on the market and the easiest for providers to prescribe.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our current pump prototype
of our proposed pump has been built to test what we believe to be our novel approach to insulin pumps. By providing a pump that we believe
will establish industry standards in terms of technology, simplicity to understand, ease of use and price, we believe our proposed pump
will offer the vast majority of benefits afforded by more expensive and complex pumps but remain accessible to a substantially greater
percentage of diabetes sufferers requiring daily insulin therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 0; text-align: justify"><span style="font-size: 10pt">We believe
people generally will not use technology that intimidates them and physicians are hesitant to prescribe such technology. We believe mass
market products, such as is intended for our proposed pump, must be &#8220;user friendly&#8221; and affordable. We believe this approach
is fundamentally different from that applied to the existing pump market today where most pumps are continuously adding complex features
and are &#8220;user friendly&#8221; to only the most technically astute.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our current goal is
to successfully design, develop and obtain all required regulatory approvals for our proposed insulin pump, and, thereafter, commercialize
the finished product. Our long-term goal is to become a leading provider of insulin pump therapy by focusing on both consumer and clinical
needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">To achieve our above
stated immediate and current goals, we intend to pursue the following business strategies:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use
    of innovative proprietary technology. </i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Based upon the substantial
experience of Paul DiPerna, our President, Chief Financial Officer, Treasurer and Chairman of our Board of Directors, in engineering
design and innovative technology in the medical device industry and, in particular, with insulin pumps, we have generated proprietary
technology that has been incorporated into our proposed insulin pump. Generally, this technology is involved in the delivery of insulin
to the user at the appropriate and necessary times. We believe this technology will greatly assist us in creating a simpler, user-friendly
pump. We believe the proposed design, engineering and technology being incorporated into our proposed pump will make it substantially
simpler and more affordable than those currently available. These features, together with the safety and reliability of our proposed
pump, are designed to create the next generation of insulin pumps that will feature important and well-differentiated attributes compared
to those currently available and make it available to consumers across mostly all socioeconomic groups in the United States and around
the world.</span></p>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Keep
    costs low during our design and development process. </i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">To attempt to ensure
that we have sufficient funds to design, develop, and obtain all required regulatory approvals for our proposed insulin pump without
having to sacrifice quality and efficiency, we intend to maintain a tight budget and limit expenditures where possible. We believe this
will be possible because of the extensive knowledge and experience of Mr. DiPerna, not only in the diabetes industry and more specifically
in the insulin pump device market, but also his experience in designing and developing insulin pumps and other medical devices and his
ability to manage a small, focused development team. We currently expect that various other expenses, such as product scale up, and sales
and marketing costs, will not be incurred until such time as development work is completed and regulatory approvals obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employ
    experienced engineers selected, supervised, and led by Mr. DiPerna, a highly experienced and respected engineer and executive in
    the insulin pump industry. </i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">To attempt to ensure
our proposed insulin pump is &#8220;state of the art,&#8221; functional, and efficient, as well as to conserve funds, substantially all
of our employees will initially be hand-picked engineers under the leadership of Mr. DiPerna. We believe that there is a strong pool
of engineers with significant applicable experience and knowledge who we will be able to initially employ on a contract and/or outsource
basis to help us design and develop our proposed insulin pump. We believe by hiring such persons on an out-source basis, we will save
substantial resources and by having Mr. DiPerna lead and focus the team on technological and mechanical aspects of our proposed insulin
pump, we believe our team will be well guided, focused, cost efficient, and able to efficiently design and develop our product candidate
that we believe can eventually be a competitive and popular choice for people with insulin requiring diabetes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commercialization
Strategy: Overcoming the Insurance Hurdles</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our goal is to establish
MODD1 as the best option for new pump patients as we expand the market into the Almost Pumpers (Type 1 and Type 2) and the newly motivated
CGM users. We seek to grow the market by providing first-line insulin pump therapy that is well suited to meet the needs of both diabetes
patients requiring insulin and their clinicians.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">MODD1 is approximately 50%
    less expensive to manufacture than Omnipod. This low cost allows us to spend more on patients and sampling. This will save money
    for payers. We can offer the pump with no upfront cost to patients. Benefits of MODD1 include:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">20% discount vs Insulet (PODD) will drive preferred status;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Designed to use PBM codes as a disposable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">No new code needed to be reimbursed at launch; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Saves provider an estimated $1062/patient/year vs Omnipod.</span></td></tr>
  </table>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The MODD1 will be sampled
    and given to patients by the doctor or diabetes nurse educator at the time of the patient visit. When a patient is motivated to make
    change, our starter kit will make it easy for the clinician to initiate the new therapy that same day. We seek to eliminate the currently
    challenging &#8220;insurance journey&#8221; and product acquisition timeline and significantly reduce training time for the busy
    clinician, all major hurdles to pump adoption. We intend to add telehealth support to help the patient throughout adoption and use
    and to facilitate greater collaboration between patients and their physicians.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Europe represents another
large potential market for MODD1. Approximately 60 million people in Europe live with diabetes. ($161 billion is spent annually in diabetes
healthcare costs in the Europe). At present, cost containment is restricting pump uptake across Europe. Current pump usage hovers between
10% and 20% in many markets. Single payor healthcare systems across the Europe traditionally attempt to contain costs in the short term
and seek low price technologies with moderate medical benefits. MODD1 will offer a rebalance of this risk/reward strategy in that payors
will incur only minor incremental short-term costs with the benefit of longer -term cost savings associated with reliable pump use. We
intend to employ a partnership strategy across Europe following in-house managed regulatory and pricing activities in the major markets
(e.g., UK) and more cost receptive markets (e.g., Nordics). We are targeting European and United Kingdom approval towards early 2023.
Our initial target market for our insulin pump is the Almost Pumper population located in the United States followed quickly by an effort
to obtain CE mark approval for distribution throughout Europe.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Marketing
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">MODD1 tackles the most
significant barriers to pump use-access and affordability-and makes it easier for clinicians, caregivers and individuals to manage diabetes
care. Our commercialization plan will drive adoption and is designed to expand the market and is intended to do the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Maximize
    adoption with a comprehensive frictionless launch program. </b></span><span style="font-size: 10pt">We will seek to decrease the
    level of reimbursement effort and cost to encourage HCPs to offer our pumps and encourage patient trials. Our product candidate reduces
    the technical hurdles to widen appeal, new starts and increase adherence. We will encourage MDI patients who want or need more control
    to make the switch to the pump earlier in their treatment-ideally right at diagnosis.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leverage
    technology to support sales and new patient acquisition</b></span><span style="font-size: 10pt">. We intend to set up tech enabled
    sales teams backed with a full omnichannel program to drive awareness and trial with HCPs and patients. We will focus on educating
    providers that our product candidate is simple to teach and easy to support making it an ideal front line offering.</span></td></tr>
  </table>
<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Facilitate
    patient trials. To facilitate patient trials, we intend to:</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Provide a free pump and a
    30-day supply of cartridges, insurance verification, co-pay coupons and telehealth support to patients thereby reducing outlay of time and money</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Partner with connected care companies to provide superb support of patients from trial through the first year</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-size: 10pt">We believe
that MODD1 will be the only insulin pump that patients can take home immediately from the doctor&#8217;s office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leverage
MODD1 300-unit chamber to increase adoption with Type 2 patients</b></span><span style="font-size: 10pt">. MODD1 has a major advantage
over existing patch pumps in that the chamber carries enough insulin to meet the high doses many Type 2 patients need. We intend to promote
this advantage and capture a significant share of the existing Type 2 pump users as well as new starts.</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Work
    with key organizations and policy makers to pave the way for greater access to pumps. </b></span><span style="font-size: 10pt">We
    will<span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span>promote MODD1 technology among the underserved,
    who are typically low users of health technology. We will identify individuals, patient organizations, professional societies, and
    policy and DEI organizations that are critically important to the adoption of new technologies in the diabetes space and build relationships
    with these influential stakeholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Initiate
    a clinical study program (with key diabetes centers</b></span><span style="font-size: 10pt">) to provide additional clinical support
    for MODD1 in special patient types and clinical setting. After obtaining 510(k) clearance, we intend to conduct a soft launch and
    clinical research program in major markets to pave the way for the full launch in late 2022. We will work with our advisors and key
    diabetes associations to educate the community about the MODD1. In addition, we will conduct clinical studies to develop competitive
    claims and market expansion.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Work
    with major health plans to establish MODD1 as the first line pump for Type 2 patients</b></span><span style="font-size: 10pt">. We
    believe MODD1 will be payor preferred for both Type 1 and Type 2 patients. It was designed to attain preferential reimbursement and
    avoid the coverage pitfalls many other pumps have experienced.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Payors want a simple product
    that is less expensive. We will launch with a discount program for payers of 20% payers less than Omnipod to drive uptake.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Designed to use existing PBM codes as a disposable</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">No new code: Reimbursed at launch</span></td></tr>
  </table>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tie-in
with the massive movement to telehealth. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">2020 saw personal telehealth
go from beta test to mainstream. Customers and providers have become comfortable with it. There are only 4,000 patient-facing endocrinologists
in the United States. The treatment of diabetes will be significantly enhanced with telehealth to drive more volume and clinical enhancements
through their practices. Telemedicine is a force multiplier for a small group of doctors to better serve a large market. MODD1 was designed
to be affordable enough for free sampling and trial, and simple enough for self-guided user training. We believe that by combining telehealth
support with MODD1, we will decrease the burden of diabetes care and improve the lives of people with diabetes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red">&#160;<img src="modular007.jpg" alt="" /></p>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Launch/Trial</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We intend to initiate
a &#8220;soft launch&#8221; following FDA clearance of the MODD1 device. Our plan is to select a group of clinicians who are well trained,
experienced and have the support infrastructure to take on initial patients and monitor them carefully to provide clinical feedback on
our performance to further refine our product candidate and support infrastructure prior to full commercial launch. Many of these clinicians
will have been those who assisted in the development of the MODD1 offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We intend to continue
to modify, refine and finalize our system to best meet:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The general needs and preferences
    of our almost pumper target market based upon our knowledge of the diabetes industry and information available and/or obtained by
    us from Almost Pumpers and their caregivers; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The general guidelines of
    third-party payors, private and public insurance companies, preferred provider organizations and other managed care providers with
    particular focus on the guidelines established by the Center for Medicare and Medicaid Services, or CMS which administrates the United
    States Medicare program, or Medicare. To assist us in making such modifications and refinements, we have retained independent consultants
    to focus on ensuring that our product candidate satisfies the existing coverage and reimbursement criteria of such third-party payors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Manufacturing requires
the production of pumps, cartridges, and baseplates as well as assembly with sets. In connection therewith:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">We plan to build an automation
    machine for implementation in Southern California, close to the design engineers, that will be capable of assembling the cassettes
    at a rate sufficient to supply 50,000 patients in a single shift (500,000 per month). This equipment will require nine months to
    design and build and three months to verify and validate into our manufacturing process.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The packaging equipment and
    boxing will start as manual operations while the automation is refined. This equipment will be purchased and implemented as the second
    phase of automation of the cassette.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The sets will be purchased
    through third party suppliers with expertise in the product to time and cost-effectively introduce the product and focus on our core
    expertise.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The standard cost of the
    cartridge is estimated to be $7.68 at the point we are manufacturing for 3,000 users or more. The pump is estimated to cost $34.00
    at similar volumes.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Our internal estimates project
    potential gross margins as high as 78% and a 20% operating margin, approximately 30 months after launch.</span></td></tr>
  </table>
<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The pumps will be built
and tested in our San Diego facility while we build volume and expertise. When the production methodology has matured and the volumes
have risen, we will consider a transition to outside and offshore manufacturing, as appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FDA
Clearance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The FDA requires us
to meet all applicable regulations for insulin pumps, a subcategory of infusion pumps, which are generally considered Class 2 devices.
The design of the MODD1 pump has been completed, units have been built and testing is underway to verify that the design meets all FDA
requirements. There are 17 specific tests required to submit for 510(k) clearance. We break these required tests into four testing categories:
wetted surface, electrical safety, usability and internal. Appropriate design control and standard operating procedures have been implemented
to allow us, when testing is completed, to submit for clearance under the premarket notification (or 510(k)) process. To achieve this,
we will continue to work closely with our regulatory consultants to complete, finalize and file our submission to the FDA for 510(k)
clearance and all other documentation necessary to obtain marketing authorization of our insulin pump.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">We have engaged the FDA in
    two pre-submission conferences to ensure that we understand and meet the FDA&#8217;s requirements, expectations and standards with
    regard to clearance of our product candidate. At these meetings, our team, including our FDA regulatory consultant, received FDA
    comments and guidance regarding our proposed submission during the pre-market notification period for 510(k) clearance (including
    any suggested modifications to the device description, indications for use or summary of supporting data contained in the notification);</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">We are currently preparing
    and ensuring that our premarket notification, which will be part of our FDA submission in order to demonstrate that our insulin pump
    is substantially equivalent to an insulin pump previously cleared by the FDA and legally marketed to the public and generally safe
    and effective for its intended use. We are also preparing our submission to the FDA, which will include the relevant results of our
    performance and human factor tests (relating to, among other things, user effectiveness, sterility, pump efficiency and shipping
    compatibility) demonstrating the accuracy and usability of our insulin pump, which we believe will satisfy the mandates of the FDCA
    and any applicable performance standards.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commercialization
Steps</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">While we have substantially
completed the general engineering and mechanical aspects of our insulin pump prototype, prior to commercializing, we still must successfully
complete a number of material steps including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">Continue
    to modify, refine and finalize our prototype so that it meets:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 50px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">the general
    needs and preferences of our almost-pumper target market based upon our knowledge of the diabetes industry and information available
    and/or obtained by us from Almost Pumpers and their caregivers; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 50px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">the general
    guidelines of third-party payors, private and public insurance companies, preferred provider organizations and other managed care
    providers with particular focus on the guidelines established by the Center for Medicare and Medicaid Services, or CMS which administrates
    the United States Medicare program, or Medicare. To assist us in making such modifications and refinements, we have retained independent
    consultants to focus on ensuring that our product candidate satisfies the existing coverage and reimbursement criteria of such third-party
    payors.</span></td></tr>
  </table>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">Refine our
    manufacturing process during the submission process to identify and select a manufacturer of our insulin pump through a competitive
    bidding process, as we prepare for our product introduction;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">Take such
    actions, if any, as may be required by the FDA as a condition to granting approval and providing 510(k) clearance for our insulin
    pump; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Hire and retain
    appropriate sales and marketing personnel to develop, implement and launch a promotional campaign for our insulin pump substantially
    focused on our target market.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As with any medical
device attempting to enter and successfully compete with existing products in an established and competitive marketplace, we will face
significant hurdles to accomplish the above steps to commercialization including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">Obtaining
    FDA 510(k) clearance to market and sell our insulin pump to the public;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">Obtaining
    any other FDA-required authorizations with regard to our product candidate, as required by the FDCA;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">Educating
    endocrinologists, physician&#8217;s assistants, nurse practitioners and nurse educators, who typically prescribe pump usage, and
    certified diabetes educators and dieticians, who provide education and guidance to diabetes patients, as to what we believe to be
    the superior qualities of our product candidate;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">Demonstrating
    to select general practitioners, who have historically been skeptical of the heightened support inherent in insulin pumps, our product
    candidate&#8217;s ease of use and convenience;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">Ensuring
    that our final product does, in fact, meet the needs of Almost-Pumpers;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">Overcoming
    the historic obstacles and reluctance of Almost-Pumpers to using insulin pumps to treat their diabetes; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">Ensuring
    that third party payors agree to cover all or a substantial portion of the purchase price and recurring costs of the use of our insulin
    pump.</span></td></tr>
  </table>
<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Looking
Forward</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Going forward, we expect
to continue to evolve the MODD1 pumps and their capabilities and functionality both in response to patient needs and as part of our current
platform roadmap.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">With MODD1+, we will seek
    to add phone-based control and ACE and AID capability to allow integration with popular continuous glucose monitors. This will expand
    our available market to include many existing pumpers. The new model has the same modular design and low-cost components as MODD1
    and provides a much desired breakthrough for patients &#8211; two-factor command authentication that allows the wearer to use his/her
    own cell phone as the controller.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 72px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Additionally, adds AID control functionality via
    an &#8220;ACE&#8221; Designation</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Any approved algorithm controller can drive insulin
    delivery in &#8220;auto&#8221; mode</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">CGM integration allows the controller to potentially
    adjust basal insulin rate for meals and exercise with an approved algorithm.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">With MOD2, we will seek to
    move to a full featured multi chamber pump optimized for high time in range fully autonomous close loop insulin delivery utilizing
    the form factor and cost advantages of its pumping designs to create an affordable, easy to use drug delivery system to realize the
    aspiration of true &#8220;artificial pancreas&#8221; systems. We envision moving to a drug prefill model such that cartridges can
    be filled with therapeutics and shipped cold chain to patients, further simplifying the use process.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: Red">&#160;<img src="modular008.jpg" alt="" /></p>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">Our operations
are subject to comprehensive federal, state, and local laws and regulations in the jurisdictions in which we or our research and development
partners do business. The laws and regulations governing our business and interpretations of those laws and regulations and are subject
to frequent change. Our ability to operate profitably will depend in part upon our ability, and that of our research and development
partners and affiliates, to operate in compliance with applicable laws and regulations. The laws and regulations relating to medical
products and healthcare services that apply to our business and that of our partners and affiliates continue to evolve, and we must,
therefore, devote significant resources to monitoring developments in legislation, enforcement, and regulation in such areas. As the
applicable laws and regulations change, we are likely to make conforming modifications in our business processes from time to time. We
cannot provide assurance that a review of our business by courts or regulatory authorities will not result in determinations that could
adversely affect our operations or that the regulatory environment will not change in a way that restricts our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>FDA
Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">In the United
States, medical devices are strictly regulated by the FDA. Under the FDCA, a medical device is defined as &#8220;an instrument, apparatus,
implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component, part or accessory
which is, among other things: intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment,
or prevention of disease, in man or other animals; or intended to affect the structure or any function of the body of man or other animals,
and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which
is not dependent upon being metabolized for the achievement of any of its primary intended purposes.&#8221; This definition provides
a clear distinction between a medical device and other FDA regulated products such as drugs. If the primary intended use of a medical
product is achieved through chemical action or by being metabolized by the body, the product is usually a drug or biologic. If not, it
is generally a medical device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">We are currently
developing an insulin pump delivery system, which is regulated by the FDA as a medical device under the FDCA, as implemented and enforced
by the FDA. The FDA regulates the development, testing, manufacturing, labeling, packaging, storage, installation, servicing, advertising,
promotion, marketing, distribution, import, export, and market surveillance of our medical devices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Device
Premarket Regulatory Requirements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">Before being
introduced into the U.S. market, each medical device must obtain marketing clearance or approval from the FDA through the premarket notification
(or 510(k)) process, the <span style="font-family: Times New Roman, Times, Serif"><i>de novo</i></span> classification process, or the
premarket approval, or PMA, process, unless they are determined to be Class I devices or to otherwise qualify for an exemption from one
of these available forms of premarket review and authorization by the FDA. Under the FDCA, medical devices are classified into one of
three classes &#8211; Class I, Class II or Class III &#8211; depending on the degree of risk associated with each medical device
and the extent of control needed to provide reasonable assurance of safety and effectiveness. Classification of a device is important
because the class to which a device is assigned determines, among other things, the necessity and type of FDA review required prior to
marketing the device. Class I devices are those for which reasonable assurance of safety and effectiveness can be maintained through
adherence to general controls which include compliance with the applicable portions of the FDA&#8217;s Quality System Regulation, or
the QSR, as well as regulations requiring facility registration and product listing, reporting of adverse medical events, and appropriate,
truthful and non-misleading labeling, advertising, and promotional materials. The Class I designation also applies to devices for which
there is insufficient information to determine that general controls are sufficient to provide reasonable assurance of the safety and
effectiveness of the device or to establish special controls to provide such assurance, but that are not life-supporting or life-sustaining
or for a use which is of substantial importance in preventing impairment of human health, and that do not present a potential, unreasonable
risk of illness or injury.</span></p>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Class II devices are
those for which general controls alone are insufficient to provide reasonable assurance of safety and effectiveness and there is sufficient
information to establish &#8220;special controls.&#8221; These special controls can include performance standards, post-market surveillance
requirements, patient registries and FDA guidance documents describing device-specific special controls. While most Class I devices are
exempt from the premarket notification requirement, most Class II devices require a premarket notification prior to commercialization
in the United States; however, the FDA has the authority to exempt Class II devices from the premarket notification requirement under
certain circumstances. As a result, manufacturers of most Class II devices must submit premarket notifications to the FDA under Section
510(k) of the FDCA (21 U.S.C. &#167; 360(k)) in order to obtain the necessary clearance to market or commercially distribute such devices.
To obtain 510(k) clearance, manufacturers must submit to the FDA adequate information demonstrating that the proposed device is &#8220;substantially
equivalent&#8221; to a &#8220;predicate device&#8221; that is already on the market. A predicate device is a legally marketed device
that is not subject to PMA, meaning, (i) a device that was legally marketed prior to May 28, 1976 (&#8220;pre-amendments device&#8221;)
and for which a PMA is not required, (ii) a device that has been reclassified from Class III to Class II or I or (iii) a device that
was found substantially equivalent through the 510(k) process. If the FDA agrees that the device is substantially equivalent to the predicate
device identified by the applicant in a premarket notification submission, the agency will grant 510(k) clearance for the new device,
permitting the applicant to commercialize the device. Premarket notifications are subject to user fees, unless a specific exemption applies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">If there is
no adequate predicate to which a manufacturer can compare its proposed device, the proposed device is automatically classified as a Class
III device. In such cases, a device manufacturer must then fulfill the more rigorous PMA requirements or can request a risk-based classification
determination for its device in accordance with the de novo classification process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0pt; text-align: justify"><span style="font-size: 10pt">Devices that
are intended to be life sustaining or life supporting, devices that are implantable, devices that present a potential unreasonable risk
of harm or are of substantial importance in preventing impairment of health, and devices that are not substantially equivalent to a predicate
device and for which safety and effectiveness cannot be assured solely by the general controls and special controls are placed in Class
III. Such devices generally require FDA approval through the PMA process, unless the device is a pre-amendments device not yet subject
to a regulation requiring premarket approval. The PMA process is more demanding than the 510(k) process. For a PMA, the manufacturer
must demonstrate through extensive data, including data from preclinical studies and one or more clinical trials, that the device is
safe and effective for its proposed indication. The PMA must also contain a full description of the device and its components, a full
description of the methods, facilities and controls used for manufacturing, and proposed labeling. Following receipt of a PMA submission,
the FDA determines whether the application is sufficiently complete to permit a substantive review. If the FDA accepts the application
for review, it has 180 days under the FDCA to complete its review and determine whether the proposed device can be approved for commercialization,
although in practice, PMA reviews often take significantly longer, and it can take up to several years for the FDA to issue a final decision.
Before approving a PMA, the FDA generally also performs an on-site inspection of manufacturing facilities for the product to ensure compliance
with the QSR.</span></p>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The <span style="font-family: Times New Roman, Times, Serif"><i>de
novo</i></span> classification process allows a manufacturer whose novel device is automatically classified into Class III to request
down-classification of its device to Class I or Class II, on the basis that the device presents low or moderate risk, as an alternative
to following the typical Class III device pathway requiring the submission and approval of a PMA application. Under the Food and Drug
Administration Safety and Innovation Act of 2012, the FDA is required to classify a device within 120 days following receipt of the <span style="font-family: Times New Roman, Times, Serif"><i>de
novo</i></span> classification request from an applicant; however, the most recent FDA premarket review goals state that in fiscal year
2021, FDA will attempt to issue a decision within 150 days of receipt on 65% of all <span style="font-family: Times New Roman, Times, Serif"><i>de
novo </i></span>classification requests received during the year and on 70% of <span style="font-family: Times New Roman, Times, Serif"><i>de
novo</i></span> requests received during fiscal year 2022. If the manufacturer seeks reclassification into Class II, the classification
request must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness
of the medical device. The FDA may reject the classification request if it identifies a legally marketed predicate device that would
be appropriate for a 510(k) notification or determines that the device is not low to moderate risk or that general controls would be
inadequate to control the risks and special controls cannot be developed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">Clinical trials are
almost always required to support PMAs and are sometimes required to support 510(k) and de novo classification submissions. All clinical
investigations of devices to determine safety and effectiveness must be conducted in accordance with the FDA&#8217;s investigational
device exemption, or IDE, regulations that govern investigational device labeling, prohibit promotion of investigational devices, and
specify recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a
&#8220;significant risk,&#8221; as defined by the FDA, the agency requires the study sponsor to submit an IDE application to the FDA,
which must become effective prior to commencing human clinical trials. The IDE will automatically become effective 30 days after receipt
by the FDA, unless the FDA denies the application or notifies the sponsor that the investigation is on hold and may not begin until the
sponsor provides supplemental information about the investigation that satisfies the agency&#8217;s concerns. If the FDA determines that
there are deficiencies or other concerns with an IDE that require modification of the study, the FDA may permit a clinical trial to proceed
under a conditional approval. The FDA may also notify the sponsor that the study is approved as proposed or approved with specific requested
modification. Furthermore, the agency may withdraw approval of an IDE under certain circumstances. In addition, the study must be approved
by, and conducted under the oversight of, an institutional review board, or IRB, for each clinical site. If the device presents a non-significant
risk to the patient according to criteria established by the FDA as part of the IDE regulations, a sponsor may begin the clinical trial
after obtaining approval for the trial by one or more IRBs without separate authorization from the FDA, but must still comply with abbreviated
IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping
requirements.</span></p>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Post-Marketing
Restrictions and Enforcement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">After a device
is placed on the market, numerous regulatory requirements apply. These include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">submitting and updating establishment
    registration and device listings with the FDA;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">compliance with the QSR,
    which requires manufacturers to follow stringent design, testing, control, documentation, record maintenance, including maintenance
    of complaint and related investigation files, and other quality assurance controls during the manufacturing process;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">unannounced routine or for-cause
    device facility inspections by the FDA, which may include our suppliers&#8217; facilities; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">labeling regulations, which
    prohibit the promotion of products for uncleared or unapproved (or &#8220;off-label&#8221;) uses and impose other restrictions relating
    to promotional activities;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">corrections and removal reporting
    regulations, which require that manufacturers report to the FDA field corrections or removals if undertaken to reduce a risk to health
    posed by a device or to remedy a violation of the FDCA that may present a risk to health; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">post-market surveillance
    regulations, which apply to certain Class II or III devices when necessary to protect the public health or to provide additional
    safety and effectiveness data for the device.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">In addition,
under the FDA medical device reporting, or MDR, regulations, medical device manufacturers are required to report to the FDA information
that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause
or contribute to death or serious injury if the malfunction of the device or a similar device of such manufacturer were to recur. The
decision to file an MDR involves a judgment by the manufacturer. If the FDA disagrees with the manufacturer&#8217;s determination, the
FDA can take enforcement action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">The MDR requirements
also extend to health care facilities that use medical devices in providing care to patients, or &#8220;device user facilities,&#8221;
which include hospitals, ambulatory surgical facilities, nursing homes, outpatient diagnostic facilities, or outpatient treatment facilities,
but not physician offices. A device user facility must report any device-related death to both the FDA and the device manufacturer, or
any device-related serious injury to the manufacturer (or, if the manufacturer is unknown, to the FDA) within 10 days of the event. Device
user facilities are not required to report device malfunctions that would likely cause or contribute to death or serious injury if the
malfunction were to recur but may voluntarily report such malfunctions through MedWatch, the FDA&#8217;s Safety Information and Adverse
Event Reporting Program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The FDA also has the
authority to require the recall of commercialized medical device products in the event of material deficiencies or defects in design
or manufacture. The authority to require a recall must be based on an FDA finding that there is a reasonable probability that the device
would cause serious adverse health consequences or death. Manufacturers may, under their own initiative, recall a product if any distributed
devices fail to meet established specifications, are otherwise misbranded or adulterated under the FDCA, or if any other material deficiency
is found. The FDA requires that certain classifications of recalls be reported to the FDA within ten working days after the recall is
initiated.</span></p>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The failure
to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include any of the following
sanctions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">warning letters, fines, injunctions
    or civil penalties;</span></td></tr>
  </table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">recalls, detentions or seizures
    of products;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">operating restrictions;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">delays in the introduction
    of products into the market;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">total or partial suspension
    of production;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">delay or refusal of the FDA
    or other regulators to grant 510(k) clearance, PMA approvals, or other marketing authorization to new products;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">withdrawals of marketing
    authorizations; or</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">in the most serious cases,
    criminal prosecution.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">To ensure compliance
with regulatory requirements, medical device manufacturers are subject to market surveillance and periodic, pre-scheduled and unannounced
inspections by the FDA, and these inspections may include the manufacturing facilities of subcontractors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Federal
Trade Commission Regulatory Oversight</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">Our advertising
for our products and services is subject to federal truth-in-advertising laws enforced by the Federal Trade Commission, or the FTC, as
well as comparable state consumer protection laws. Under the Federal Trade Commission Act, or FTC Act, the FTC is empowered, among other
things, to (a) prevent unfair methods of competition and unfair or deceptive acts or practices in or affecting commerce; (b) seek monetary
redress and other relief for conduct injurious to consumers; and (c) gather and compile information and conduct investigations relating
to the organization, business, practices, and management of entities engaged in commerce. The FTC has very broad enforcement authority,
and failure to abide by the substantive requirements of the FTC Act and other consumer protection laws can result in administrative or
judicial penalties, including civil penalties, injunctions affecting the manner in which we would be able to market services or products
in the future, or criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
Law and Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>United
States</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0pt; text-align: justify"><span style="font-size: 10pt">If our MODD1
product candidate or our other future product candidates are approved in the United States, we will have to comply with various U.S.
federal and state laws, rules and regulations pertaining to healthcare fraud and abuse, including anti-kickback laws and physician self-referral
laws, rules and regulations. Violations of the fraud and abuse laws are punishable by criminal and civil sanctions, including, in some
instances, exclusion from participation in federal and state healthcare programs, including Medicare and Medicaid. These laws include
the following:</span></p>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the federal Anti-Kickback
    Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration,
    directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order
    or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program
    such as Medicare and Medicaid;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the federal False Claims
    Act imposes civil penalties, and provides for civil whistleblower or qui tam actions, against individuals or entities for knowingly
    presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false
    statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the federal Health Insurance
    Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any
    healthcare benefit program or making false statements relating to healthcare matters;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">HIPAA, as amended by the
    Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including
    mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health
    information;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the federal false statements
    statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement
    in connection with the delivery of or payment for healthcare benefits, items or services;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">the federal transparency
    requirements under the Physician Payments Sunshine Act require manufacturers of FDA-approved drugs, devices, biologics and medical
    supplies covered by Medicare or Medicaid to report, on an annual basis, to the Department of Health and Human Services information
    related to payments and other transfers of value to physicians, teaching hospitals, and certain advanced non-physician health care
    practitioners and physician ownership and investment interests; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">analogous state and foreign
    laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims
    involving healthcare items or services reimbursed by nongovernmental third-party payors, including private insurers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Some state laws require
pharmaceutical or medical device companies to comply with the relevant industry&#8217;s voluntary compliance guidelines and the relevant
compliance guidance promulgated by the federal government in addition to requiring drug and device manufacturers to report information
related to payments to physicians and other health care providers or marketing expenditures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">State and foreign
laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant
ways and often are not preempted by HIPAA, thus complicating compliance efforts. We also may be subject to, or may in the future become
subject to, U.S. federal and state, and foreign laws and regulations imposing obligations on how we collect, use, disclose, store and
process personal information. Our actual or perceived failure to comply with such obligations could result in liability or reputational
harm and could harm our business. Ensuring compliance with such laws could also impair our efforts to maintain and expand our customer
base and thereby decrease our future revenues.</span></p>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The European Union
approves the use of medical devices in a very different way. They have similar regulations and requirements to adhere to, however a Notified
Body, in the form of a private company, will represent their interests and is required to have sufficient expertise to review all applications
and the company&#8217;s internal processes to ensure the safety of the product for which approval is being requested. We are in the process
of identifying a Notified Body to represent us, and we will follow our FDA submission process with regard to preparing the materials
and processes required to meet the regulations and gain clearance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>European
Union</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">EEA</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the European Economic
Area, (which is comprised of the 27 member states of the European Union plus Norway, Iceland and Liechtenstein), or EEA, manufacturers
of medical devices need to comply with the Essential Requirements laid out in Annex I to the EU Medical Devices Directive (Council Directive
93/42/EEC) or with the General Safety and Performance Requirements (GSPR) of the new EU Medical Devices Regulation (EU 2017/745). Compliance
with these requirements is a prerequisite to be able to affix the CE mark to medical devices, without which they cannot be marketed or
sold in the EEA. To demonstrate compliance with the Essential Requirements and the GSPR and obtain the right to affix the CE Mark, manufacturers
of medical devices must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification.
Except for low-risk medical devices (Class I with no measuring function and which are not sterile), where the manufacturer can issue
an EC Declaration of Conformity based on a self-assessment of the conformity of its products with the Essential Requirements and the
GSPR, a conformity assessment procedure requires the intervention of a Notified Body, which is an organization designated by a competent
authority of an EEA country to conduct conformity assessments. Depending on the relevant conformity assessment procedure, the Notified
Body would audit and examine the Technical File and the quality system for the manufacture, design and final inspection of the devices.
The Notified Body issues a CE Certificate of Conformity following successful completion of a conformity assessment procedure conducted
in relation to the medical device and its manufacturer and their conformity with the Essential Requirements and GSPR. This Certificate
entitles the manufacturer to affix the CE mark to its medical devices after having prepared and signed a related EC Declaration of Conformity.
As a general rule, demonstration of conformity of medical devices and their manufacturers with the Essential Requirements and GSPR must
be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal
conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions
of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits
of its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence.</span></p>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">All manufacturers placing
medical devices into the market in the EEA must comply with the EU Medical Device Vigilance System. Under this system, incidents must
be reported to the relevant authorities of the member states of the EEA, and manufacturers are required to take Field Safety Corrective
Actions, or FSCAs, to reduce a risk of death or serious deterioration in the state of health associated with the use of a medical device
that is already placed on the market. An incident is defined as any malfunction or deterioration in the characteristics and/or performance
of a device, as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, might lead to or might
have led to the death of a patient or user or of other persons or to a serious deterioration in their state of health. An FSCA may include
the recall, modification, exchange, destruction or retrofitting of the device. FSCAs must be communicated by the manufacturer or its
legal representative to its customers and/or to the end users of the device through Field Safety Notices. Where appropriate, our products
commercialized in Europe are CE marked and classified as either Class I or Class II.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In 2017, the European
Parliament passed the Medical Devices Regulation, which repeals and replaces the EU Medical Devices Directive. Unlike directives, which
must be implemented into the national laws of the EEA member states, the regulations would be directly applicable (i.e., without the
need for adoption of EEA member State laws implementing them) in all EEA member states and are intended to eliminate current differences
in the regulation of medical devices among EEA member States. The Medical Devices Regulation, among other things, is intended to establish
a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices and in vitro diagnostic devices
and ensure a high level of safety and health while supporting innovation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Medical Device
Regulation was meant to become applicable three years after publication (in May 2020). However, in April 2020, to allow EEA national
authorities, notified bodies, manufacturers and other actors to focus fully on urgent priorities related to the COVID-19 pandemic, the
European Council and Parliament adopted Regulation 2020/561, postponing the date of application of the Medical Device Regulation by one
year. The Medical Device Regulation became applicable on May 26, 2021. Devices lawfully placed on the market pursuant to the EU Medical
Devices Directive prior to May 26, 2021 may generally continue to be made available on the market or put into service until May 26, 2025.
The Medical Devices Regulation, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 7.4pt; text-align: justify"><span style="font-size: 10pt">strengthens
    the rules on placing devices on the market and reinforces surveillance once they are available;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 7.4pt; text-align: justify"><span style="font-size: 10pt">establishes
    explicit provisions on manufacturers&#8217; responsibilities for the follow-up of the quality, performance and safety of devices placed
    on the market;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 7.4pt; text-align: justify"><span style="font-size: 10pt">improves
    the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 7.4pt; text-align: justify"><span style="font-size: 10pt">sets
    up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available
    in the EU; and</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 7.4pt; text-align: justify"><span style="font-size: 10pt">strengthens
    rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts
    before they are placed on the market.</span></td></tr>
  </table>
<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Today, in the United
States, only three companies are commercializing insulin pumps to T1D patients and insulin treated T2D patients:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Medtronic &#8211; that commercializes
    the durable Minimed 770G also offering older durable pumps still used (670G, 630G etc.). In 2020, they held approximately 51% of
    the US insulin pump market.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Tandem &#8211;
    that commercializes the durable t:slim X2 pump (with or without algorithms &#8211; Basal-IQ and Control-IQ). In
    2020, they held approximately 28% of the US insulin pump market.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Insulet &#8211; that commercializes
    the disposable Omnipod patch pump with about 19% of the US market in 2020.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Older insulin pumps
are also still being used by a minority of patients previously provided by Roche or Animas though these pumps are not commercialized
any longer. To a lesser extent, the pumps described below are also used in small numbers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><img src="modular009.jpg" alt="" /></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: right"><img src="modular010.jpg" alt="" /></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">These three insulin
pump offerings are vying for the attention of the most motivated and well insured in hope of converting them away from their reliance
on multi-day insulin injections. The t:slim X2 and Minimed 770G each have a ~$5,000 list price that is covered through Durable Medical
Equipment (DME) reimbursement; daily consumables and insulin are also required to complete these offerings. These products have controllers
integrated into the pump, making them cumbersome and bulky, along with long (&gt;20 inch) tubing between the pump and the cannular site.
The Omnipod is the third offering, a patch pump that attaches to your body for 72 hours and uses a separate controller to manage the
insulin delivery process. Insurance coverage can be provided via DME but also via Pharmacy Benefit (PB). The Omnipod patch pump is more
expensive per day and less accurate than other insulin pumps. Around 32% of people living with T1D are currently using insulin pumps;
of these, the vast majority are using one of these three offerings, a statistic that has not changed significantly over the last 5+ years.</span></p>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 69.2pt"><img src="modular011.jpg" alt="" /></td><td style="width: 17.3pt; text-align: left"><span style="font-size: 10pt"></span></td><td style="vertical-align: middle; text-align: left"><span style="font-size: 10pt">All of these pump products require
extensive training to initiate, two to four hours per day to use and manage on an ongoing basis. This level of sophistication and effort
along with the cost and awkwardness of these products contribute to the limited uptake.</span></td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Although there are
purely mechanical pumps available to patients with a small percentage of T2D patients are using the Zealand V-Go patch pump, a fixed
basal rate and a button to deliver small boluses. This pump is simple to use though gives little performance decision to the user (no
possibility to change the basal rate, no possibility to stop bolus doses, small reservoir, pump that needs to be changed every day, etc.).
The last available patch pump is provided by Cequr, called Simplicity, a bolus only delivery option without basal delivery that is yet
to be available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the future, Medtronic
intends to launch a new version of their insulin pump, the Minimed 780G, already available in some European countries with an advanced
algorithm, but no obvious change in hardware. Tandem is currently developing a patch pump called t:sport, coupled with an algorithm with
potential launch expected in summer 2022. The t:sport should have a small 2mL reservoir and would be controlled by a separate unit as
is the current Omnipod. Insulet should launch in the coming quarters the Omnipod 5, a similar patch pump to their offering today, that
includes an algorithm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Approximately 71% of
the people who rely upon MDI choose to not administer a shot outside of their house, which creates a poorly controlled group. MOD is
designed to focus upon a segment of these people and mobilize them via a simple, easy to use, affordable product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; color: Red">&#160;<img src="modular012.jpg" alt="" /></p>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our success depends
in part on our ability to obtain patents and trademarks, maintain trade secret and know-how protection, enforce our proprietary rights
against infringers, and operate without infringing on the proprietary rights of third parties. Because of the length of time and expense
associated with developing new products and bringing them through the regulatory approval process, the health care industry places considerable
emphasis on obtaining patent protection and maintaining trade secret protection for new technologies, products, processes, know-how,
and methods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As of December 31,
2021, we had one issued U.S. utility patent, five published U.S. utility patents, two pending foreign patent applications, and two pending
international PCT patent applications covering various aspects of our technology, including our proprietary fluid movement technology.
There can be no assurance that the pending patent applications will result in the issuance of patents, that patents issued to or licensed
by us will not be challenged or circumvented by competitors, or that these patents will be found to be valid or sufficiently broad to
protect our technology or provide us with a competitive advantage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Available
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our annual reports
on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to such reports filed or furnished pursuant
to section 13(a) or 15(d) of the Securities Exchange Act of 1934, as well as section 16 reports on Form 3, 4, or 5, are available free
of charge on our website at www.modular-medical.com. as soon as it is reasonably practicable after they are filed or furnished with the
SEC. Our Code of Business Conduct and Ethics and the charters for the Audit Committee, Compensation Committee and Nominating and Governance
Committee are also available on our website. The Code of Business Conduct and charters are also available in print to any shareholder
upon request without charge. Requests for such documents should be directed to James Sullivan, at Modular Medical, Inc., 16772 W. Bernardo
Drive, San Diego CA 92127. Our Internet website and the information contained on it or connected to it are not part of, or incorporated
by, reference into this prospectus. Our filings with the SEC are also available on the SEC&#8217;s website at http://www.sec.gov.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
History and Background</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We were formed as a
corporation under the laws of the State of Nevada in October 1998 under the name Bear Lake Recreation Inc. We had no material business
operations from 2002 until July 2017, when we acquired Quasuras, Inc., a Delaware corporation, in the Control Block Acquisition (as defined
below). Prior to the Control Block Acquisition, and, since at least 2002, we were a shell company, as defined in Rule 12b-2 promulgated
under the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Control Block Acquisition.</i></b><i>&#160;</i></span><span style="font-size: 10pt">On April 26, 2017, pursuant to a Common Stock Purchase
Agreement, dated as of April 5, 2017, by and among Manchester Explorer, LP, a Delaware limited partnership, we and certain persons named
therein, Manchester Explorer, LP purchased from us 966,667 shares of our Common Stock representing in excess of a majority of our then
issued and outstanding Common Stock, for a purchase price of $375,000 (the &#8220;Control Block Acquisition&#8221;), resulting in a change
in control of the Company. In connection with the Control Block Acquisition, James E. Besser was appointed president and a director and
Morgan C. Frank was appointed the chief executive officer, chief financial officer, secretary, treasurer and a director of ours and immediately
following such appointments, our then officers and directors resigned. Mr. Besser is the managing member of and Mr. Frank is the portfolio
manager and a consultant to Manchester Management Company, LLC, a Delaware limited liability company also referred to herein as MMC.
MMC is the general partner of Manchester Explorer, LP and Jeb Partners, L.P. (Jeb Partners, and together with Manchester Explorer, LP,
collectively, the Purchasing Funds).</span></p>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Acquisition. </i></b></span><span style="font-size: 10pt">On July 24, 2017, pursuant to a Reorganization and Share Exchange Agreement,
by and among us, Paul M. DiPerna, the sole officer, director and a controlling stockholder of Quasuras, Messrs. Besser and Frank (Messrs.
Besser, Frank and DiPerna, collectively, the &#8220;3 Quasuras Shareholders&#8221;), and Quasuras, Inc. (the &#8220;Share Exchange Agreement&#8221;),
we acquired all of the issued and outstanding shares of Quasuras, Inc. owned by the 3 Quasuras Shareholders, resulting in Quasuras, Inc.
becoming our wholly-owned subsidiary (the &#8220;Acquisition&#8221;). Simultaneously with the closing of the Acquisition, Manchester
Explorer, LP cancelled the 2,900,000 shares of our Common Stock purchased in the Control Block Acquisition, Mr. Besser resigned as our
president and a director and Mr. Frank resigned as our chief executive officer, chief financial officer, secretary, and treasurer, but
remained a director, and Mr. DiPerna was appointed our chairman of the board of directors, chief executive officer, chief financial officer,
president, secretary and treasurer. Mr. DiPerna served as our chief executive officer until August 2021 and as our secretary until October
2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Quasuras, Inc., a Delaware
corporation, is our only subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As of May 31, 2022,
we had 29 employees all of whom are located in the United States, consisting of 26 in research and development and manufacturing operations
and 3 in general and administrative functions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Properties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In January 2020, we
executed a lease for a corporate facility located at 16772 West Bernardo Drive, San Diego, CA 92127 and paid a $100,000 security deposit.
The 39-month lease term commenced April 1, 2020, and provides for an initial monthly rent of approximately $12,400 with annual rent increases
of approximately 3%. In addition to the minimum lease payments, we are responsible for property taxes, insurance and certain other operating
costs. We believe that our existing facility is adequate to meet our current needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are a Nevada corporation.
Our corporate headquarters and operating facilities are located at 16772 West Bernardo Drive, San Diego, CA 92127 Our telephone number
is (858) 800-3500. We maintain a website at www.modular-medical.com.</span></p>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modulara016"></span>MANAGEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following
table sets forth information on our executive officers and directors as of June 2, 2022. The term for each of our directors
is generally three years or until their successors are duly elected and qualified. We do not have any promoters or control persons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.25pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.25pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 68%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">James Besser</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">46</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Paul DiPerna</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">63</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Chief Financial Officer, President, Treasurer
    and Director (Chairman of the Board of Directors)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Ellen O&#8217; Connor Vos</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">66</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">William J. Febbo(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Morgan C. Frank</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Carmen Volkart(1)(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">61</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Steven Felsher(2)(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">73</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Philip Sheibley(2)(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">63</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 23px"><span style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Member of Compensation Committee</span></td></tr>
  </table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 23px"><span style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Member of Audit Committee</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Member of Nominating and
    Governance Committee</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">There are no family
relationships between our officers and members of our Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The principal occupations
and positions for at least the past five years of our directors are described below. There are no family relationships among any of our
directors or executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>James
&#8220;Jeb&#8221; Besser</i>. Mr. Besser has served as our chief executive officer since February 23, 2022 and combines over 25 years
of experience in alternative investments, strategic advisory, corporate strategy and corporate governance. Since 1999, he has been a
Managing Member at Manchester Management Company, LLC (&#8220;Manchester&#8221;), an investment management firm. James Besser is also
currently a director of River Stone Biotech, a development stage specialty bioprocessing company. He holds a B.A. in history from Brown
University. We believe that Mr. Besser is qualified to serve as member of our board of directors due to his extensive prior experience
conducting financial analysis of public companies (certain of which were in the development stage), including such public companies&#8217;
management teams, products, including products in the development stage, the potential markets for such products and other factors that
could affect the likelihood and timing of success and market penetration of such entities&#8217; products as well as his capital raising
activities. We believe this provides us with valuable insights into the financial markets and investment criteria of institutional and
other investors as well as capital raising activities.</span></p>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Paul
DiPerna. </i></span><span style="font-size: 10pt">Mr. DiPerna has been our chairman, chief financial officer, president, and treasurer
since we acquired Quasuras, Inc. in July 2017. He also served as our chief executive officer from July 2017 until August 2021. In 2015,
he founded Quasuras, Inc., an early-stage medical device company developing an insulin pump product, and, until its acquisition by us,
he served as its chief executive officer and chairman. Prior to that, Mr. DiPerna founded Fuel Source Partners, LLC to incubate early
stage medical device products and accumulate technical talent. Our current pump product was one of such proposed products and was spun-out
to Quasuras in 2015. From 2012 to 2015, he served as a co-inventor at a private company with property rights in a medical device used
for blood borne infection control called the Curos Cap, which was acquired by 3M Corporation. In 2003, Mr. DiPerna founded Tandem Diabetes
Care, Inc. (&#8220;Tandem&#8221;) and held various positions, including as director, chief executive officer and chief technology officer
and was primarily responsible for the design concept and development of Tandem&#8217;s initial insulin pump. Prior to that, he held executive
and management positions at Baxter Healthcare Corporation (&#8220;Baxter&#8221;) where he was tasked with identifying synergistic opportunities
in the diabetes industry. As a result, Mr. DiPerna developed substantial expertise and knowledge in the diabetes industry and led attempts
by Baxter to acquire three insulin pump manufacturers. Previously, he held mechanical design engineering positions in the automated test
equipment and blood separation sciences industries. Mr. DiPerna holds 70 patents in medical device and microfluidic technology and has
achieved numerous product clearances from the FDA. He has also achieved multiple successful exits with previous companies. Mr. DiPerna
received a Masters in Engineering Management from Northeastern University and a B.S. in Mechanical Engineering from the University of
Massachusetts and has spent over 35 years in the medical-device industry. We believe that Mr. DiPerna is qualified to serve as the chairman
of our board of directors due to his extensive knowledge and experience in the medical device industry generally, and, in particular,
with regard to insulin pumps and the diabetes industry, as well as his management and leadership experience from holding director and
senior executive positions in other public and private companies and leading project development teams of medical device companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Ellen
O&#8217;Connor Vos. </i></span><span style="font-size: 10pt">Ms. Vos was appointed to our board of directors in May 2021 and served as
our chief executive officer from August 2021 until February 23, 2022. Ms. Vos has served as a member of VosHealth LLC since November
2020. Prior to that, she served as the president and chief executive officer of the Muscular Dystrophy Association from October 2017
to November 2020. Previously, Ms. Vos had been chief executive officer of ghg | greyhealth group from 1996 to 2017, and she has been
a champion of using digital capabilities to improve the public health. Ms. Vos also serves on the board of OptimizeRX Corporation, a
publicly-traded digital health company, and the Jed Foundation, a leading nonprofit dedicated to protecting the emotional health of college
students, and was a founding board member of MMRF, a pioneering cancer research foundation. Ms. Vos holds a B.S. in nursing from Alfred
University. We believe that Ms. Vos is qualified to serve on our board of directors because of her executive experience and extensive
executive skills in digital marketing, commercialization and communications in the healthcare industry.<span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>William
J. Febbo.</i><b>&#160;</b></span><span style="font-size: 10pt">Mr. Febbo was appointed to our board of directors in January 2020. He
is currently the Chief Executive Officer and a director of OptimizeRx Corporation, a digital health company focused on bringing life
sciences support to patients and providers, having joined us in 2016. Mr. Febbo founded Plexuus, LLC, a payment processing business for
medical professionals in September 2015 and remained its Chairman from September 2015 to December 2020. From April 2007 to September
2015, he served as Chief Operating Officer of Merriman Holdings, Inc., an investment banking firm, where he assisted with capital raises
in the technology, biotechnology, clean technology, consumer and resources industries. Mr. Febbo was a co-founder of, and from September
2013 to September 2015 served as Chief Executive Officer of, Digital Capital Network, Inc. a transaction platform for institutional and
accredited investors. He was a co-founder of, and from January 1999 to September 2015 was Chief Executive Officer of, MedPanel, LLC,
a provider of market intelligence and communications for the pharmaceutical, biomedical, and medical device industries. Since 2017, Mr.
Febbo has been a faculty member of the Massachusetts Institute of Technology&#8217;s linQ program, which is a collaborative initiative
focused on increasing the potential of innovative research to benefit society and the economy. Since 2004, he has been a board member
of the United Nations Association of Greater Boston, a resource for the citizens of Greater Boston on the broad agenda of critical global
issues addressed by the United Nations and its agencies. He holds a B.A. in international studies and Spanish from Dickinson College.</span></p>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On January 29, 2018,
the Financial Industry Regulatory Authority (FINRA) accepted a Letter of Acceptance, Waiver and Consent (the Consent) submitted by Mr.
Febbo. Without admitting or denying the findings, Mr. Febbo consented to the sanctions and to the entry of findings that he permitted
Merriman Capital, Inc. to conduct a securities business while below its net capital requirement. From August 2012 to October 2015, he
was the Financial and Operations Principal (FinOp) for a registered broker-dealer, Merriman Capital, Inc. (Merriman). During certain
months, while Mr. Febbo was FinOp, FINRA found that certain of Merriman&#8217;s net capital filings with FINRA were inaccurate because
of the method by which Merriman calculated net capital and that, when corrected, it was retroactively determined that Merriman had operated
below its minimum net capital requirements. Mr. Febbo, as FinOp, signed certain of these reports and was thus held responsible. Based
on the Consent, in settlement, Mr. Febbo, who was then no longer registered with any broker-dealer, accepted a fine of $5,000, a 10-business
day suspension from acting as FinOp for any FINRA member and required to requalify by examination for the Series 27 license before again
acting in a FinOp capacity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We believe that Mr.
Febbo is qualified to serve on our board of directors because of his wealth of experience in building and managing health services and
financial businesses. Mr. Febbo brings more than 20 years of experience in building and managing health services and financial businesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Morgan
C. Frank. </i></span><span style="font-size: 10pt">Mr. Frank was appointed to our board of directors in April 2017. Mr. Frank has worked
with Manchester Explorer, LP since May 2002, and, prior to such time, he was a founder and managing director at First Principles Group,
a boutique consultancy and principal investor specializing in corporate restructuring, restarts, intellectual property assessment and
salvage, and spin outs. Prior to such time, Mr. Frank spent approximately five years as an analyst and portfolio manager at Hollis Capital,
a San Francisco based hedge fund and prior thereto, Mr. Frank worked for an independent private client group at Paine Webber specializing
in primary research to develop investment ideas (particularly short sale ideas) for institutional clients. Prior to his employment at
Paine Webber, Mr. Frank was a currency trader for Eastern Vanguard. Mr. Frank holds a BA in Economics and in Political Science from Brown
University. We believe that Mr. Frank is qualified to serve as member of our board of directors due to his extensive prior experience
conducting financial analysis of public companies (certain of which were in the development stage), including such public companies&#8217;
management teams, products, including products in the development stage, the potential markets for such products and other factors that
could affect the likelihood and timing of success and market penetration of such entities&#8217; products as well as his capital raising
activities. We believe this provides us with valuable insights into the financial markets and investment criteria of institutional and
other investors as well as capital raising activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Carmen
Volkart. </i></span><span style="font-size: 10pt">Ms. Volkart<span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span>was
appointed to our board of directors in December 2019. She has served as chief financial officer of Natureworks LLC, an advanced materials
company offering a portfolio of renewably-sourced polymers, since October 2018. From October 2012 to July 2018, Ms. Volkart served as
chief financial officer and, for a portion of that time, as senior vice president of commercialization for NxThera, Inc., a medical device
company pioneering the application of convective radiofrequency thermotherapy to treat endurological conditions. She served as global
chief financial officer of Tornier N.V. from 2010 to 2012, and was chief operating and financial officer, corporate secretary, compliance
officer and treasurer of Spine Wave, Inc. from 2006 to 2010. Prior to 2006, Ms. Volkart held various executive and financial positions
at American Medical Systems, Inc., Medtronic, Inc. and Honeywell, Inc. She holds a B.S. in accounting from the University of North Dakota
and an MBA with a concentration in strategic management from the University of Minnesota. We believe that Ms. Volkart is qualified to
serve on our board of directors because of her substantial financial and public company experience, as she has served as chief financial
officer at multiple medical device and other companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Steven
Felsher. </i></span><span style="font-size: 10pt">Mr. Felsher was appointed to our board of directors in November 2021. Mr. Felsher is
an experienced executive with respect to finance, administration, governance and other aspects of public and private company management.
He has served as a member of the board of directors of Signal Hill Acquisition Corp., a special purpose acquisition company, since March
2021. From August 2018 to July 2020, he served as a member of the board of directors of Sito Mobile, Inc., a publicly-traded company
that provided customized, data-driven solutions for brands spanning all forms of media. From January 2011 to June 2019, Mr. Felsher was
a senior advisor at Quadrangle Group LLC, a private investment firm focused on the information and communications technology sectors.
He spent a substantial portion of his career with Grey Global Group Inc., a global marketing services company, where he served as a senior
executive from 1979 until 2007, most recently as vice chairman and chief financial officer. He holds a BA in classical Greek from Dickinson
College and a J.D. from Yale University School of Law. We believe that Mr. Felsher is qualified to serve on our board of directors because
of his extensive business experience with administration, governance, capital allocation and other aspects of public and private company
management.</span></p>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Philip
Sheibley. </i></span><span style="font-size: 10pt">Mr. Sheibley was appointed to our board of directors in November 2021. Mr. Sheibley
is an experienced executive and venture capitalist. Since 2011, he has served as a principal at Alumni Investment Partners, a private
equity firm. From 1981 to 2010, Mr. Sheibley served as a management and technology consultant with Accenture, where he focused on the
life sciences area, holding a variety of leadership positions, including North American industry director for life sciences and global
lead for management consulting. Mr. Sheibley holds a B.S. in industrial and systems engineering with a business minor from Lehigh University.
We believe that Mr. Sheibley is qualified to serve on our board of directors because of his extensive business experience in the life
sciences area and experience with venture capital investment and consulting, including financing transactions for early-stage and scale-up
stage companies, assisting with scale-up strategy/execution, and participating as a board member in the medical products industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Involvement
in Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Except as described
above with regard to Mr. Febbo, to our knowledge, none of our executive officers or our directors has, during the last ten years:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">had any bankruptcy
    petition filed by or against the business or property of the person, or of any partnership, corporation or business association of
    which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that
    time;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">been subject
    to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal
    or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type
    of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated
    with persons engaged in any such activity;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">been found
    by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated
    a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">been the
    subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently
    reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged
    violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions
    or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution,
    civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting
    mail or wire fraud or fraud in connection with any business entity; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">been the
    subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization
    (as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange
    Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons
    associated with a member.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">To our knowledge, there
are no material proceedings to which any director, officer or affiliate of ours, any owner of record or beneficially of more than 5%
of any class of voting securities of us, or any associate of any such director, officer, affiliate of ours, or security holder is a party
adverse to us or any of our subsidiaries or has a material interest adverse to us or any of our subsidiaries.</span></p>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Arrangements
for Appointment of Directors and Officers </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Pursuant to the Reorganization
and Share Exchange Agreement, hereinafter referred to as the Share Agreement, dated as of July 24, 2017, by and among us, Quasuras, Inc.,
Mr. DiPerna and the other stockholders of Quasuras, Inc., until July 24, 2022, our board of directors shall consist of no more than five
and no less than two directors of which (i) Manchester Explorer, LP has the right to appoint two directors, pursuant to which Manchester
Explorer, LP appointed Mr. Frank and Ms. Volkart and (ii) Mr. DiPerna, in addition to being our chairman of the board, had the right
to appoint two additional directors, pursuant to which he appointed Liam Burns, who resigned from our board of directors in December
2021, and Mr. Febbo. In May 2021, the parties amended the Share Agreement and removed Manchester Explorer, LP&#8217;s and Mr. DiPerna&#8217;s
rights to appoint directors. In addition, the parties agreed that Mr. DiPerna shall remain chairman of our board of directors until July
2022; provided, that in the event Mr. DiPerna resigns or is otherwise replaced as our chief executive officer, Mr. DiPerna shall remain
as chairman of our board of directors for an additional period of three years. Following such amendment, our board of directors increased
the size of the board to six members and, on May 18, 2021, appointed Ms. Vos as a director to our board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
DiPerna Employment and Related Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We entered into an
employment agreement dated August 1, 2018, with Mr. DiPerna pursuant to which Mr. DiPerna is employed by us as our president for an initial
two-year term with automatic one-year renewals. Pursuant to such agreement, we agreed to pay Mr. DiPerna: i) an annual salary of $200,000
in cash, ii) $100,000 per year in fully-vested stock options granted monthly at an exercise price determined by our board of directors
in its sole discretion and iii) an annual bonus of $300,000, payable at the discretion of our board of directors, either in shares or
in cash. If the board chooses to pay the bonus in shares, such shares will be valued at a price determined by our board of directors.
Pursuant to such employment agreement (i) if (a) we terminate Mr. DiPerna&#8217;s employment without cause or he resigns with good reason,
we will pay Mr. DiPerna a lump sum of $200,000, and (b) we terminate Mr. DiPerna&#8217;s employment for cause, we are not obligated to
make any severance payment and Mr. DiPerna will receive only his base compensation through the last day of his employment, (ii) upon
Mr. DiPerna&#8217;s death or disability, he will receive his base compensation through the last day of his employment and will remain
eligible for all applicable benefits relative to death or disability pursuant to any plans that we have in place at such time, and (iii)
upon a change of control (as defined in the employment agreement), Mr. DiPerna will be paid a lump sum of $100,000 within sixty days
of the time at which such change of control takes place.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In May 2020,
we amended our employment agreement with Mr. DiPerna to provide that in the event of a change in control:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">within 60
    days of the date the change in control occurs, Mr. DiPerna shall be paid by us or our successor in interest a lump sum cash payment
    equal to 12 months of Mr. DiPerna&#8217;s then annual Base Compensation (as defined in the employment agreement); and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">immediately
    prior to such change of control, any unvested stock options or other unvested securities of ours issued to Mr. DiPerna shall automatically
    accelerate and immediately become fully vested and exercisable.</span></td></tr>
  </table>
<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In June 2020, our board
of directors approved an amendment to the employment agreement to provide that Mr. DiPerna&#8217;s base salary would be paid entirely
in cash commencing July 1, 2020. The payment of the additional cash component of Mr. DiPerna&#8217;s annual base salary ($8,333.33 per
month) was initially deferred (the &#8220;Deferred Salary&#8221;) and accrue for Mr. DiPerna&#8217;s benefit until we have received $5,000,000
of cumulative gross proceeds of financing, at which time the Deferred Salary shall be paid to Mr. DiPerna and the salary deferrals will
cease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On April 15, 2021,
our board of directors authorized a $50,000 bonus for Mr. DiPerna for fiscal 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If a change of control
occurred on March 31, 2021, under his employment agreement, Mr. DiPerna would be entitled to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">payment of
    a lump sum of $300,000 within 60 days of the time at which such change of control takes place; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">accelerated
    vesting of 61,111 shares of Common Stock under an unvested stock option. The value of the shares subject to accelerated vesting is
    calculated as the intrinsic value per share multiplied by the number of shares that would become fully vested upon a change of control.
    The intrinsic value per share would be calculated as the excess of the closing price of the Common Stock of $15.75 on the OTCQB Venture
    Market on March 31, 2021 over the exercise price of the option. As of March 31, 2021, the intrinsic value was approximately $550,000.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In connection with
our acquisition of Quasuras, we entered into an Intellectual Property Transfer Agreement dated as of July 24, 2017, with Quasuras and
Mr. DiPerna, pursuant to which Mr. DiPerna transferred to us all intellectual property rights owned directly and/or indirectly by him
related to our business. Separately, we agreed to pay Mr. DiPerna, as part of his compensation for services to be performed for us, pursuant
to a royalty agreement, certain fees based upon future sales, if any, of our potential product subject to a maximum $10,000,000 cap on
the aggregate amount of fees that Mr. DiPerna could earn from such arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Vos Employment Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On August 11, 2021,
we entered into a two-year employment agreement (the &#8220;Agreement&#8221;) with Ms. Vos for her service as our chief executive officer,
and the Agreement renews for one-year terms, unless either party provides the other with 90-day prior written notice of termination.
The Agreement provided that Ms. Vos was entitled to total base compensation of $300,000 annually, as follows: a cash salary of $250,000
per year (the &#8220;Cash Salary&#8221;), plus deferred salary of $50,000 per year (the &#8220;Deferred Salary&#8221; and, together with
the Cash Salary, the &#8220;Base Compensation&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
February 23, 2022, Ellen O&#8217;Connor Vos informed the board of directors the Company that she was resigning from her position as chief
executive officer of the Company, effective immediately (the &#8220;Resignation&#8221;). In connection with the Resignation, the Company
and Ms. Vos entered into a Severance and Release Agreement dated February 23, 2022 (the &#8220;Separation Agreement&#8221;). Pursuant
to the Separation Agreement, Ms. Vos is entitled to receive separation payments in an aggregate gross amount of $375,000. Under the terms
of the Separation Agreement, the vesting of an option to purchase 362,452 shares of the Company&#8217;s common stock, which was granted
to Ms. Vos on August 11, 2021, will cease on May 24, 2022 and the remaining unvested shares will be forfeited.</span></p>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>James
Besser</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
compensation for his services as Chief Executive Officer, Mr. Besser is paid de minimis compensation of $1.00 per year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Communications
with our Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Stockholders who desire
to communicate with the board of directors, or a specific director, may do so by sending the communication addressed to either the board
of directors or any individual director, c/o Modular Medical, Inc., 16772 West Bernardo Drive, San Diego, California 92127. These communications
will be delivered to the board of directors, or any individual director, as specified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Governance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our Board has undertaken
a review of the independence of our directors and considered whether any director has a material relationship with us that could compromise
his ability to exercise independent judgment in carrying out his responsibilities. As a result of this review, our Board has determined
that William Febbo, Steven Felsher, Philp Sheibley and Carmen Volkart are &#8220;independent directors&#8221; as defined under the rules
of Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Board
Leadership Structure and Role in Risk Oversight</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Due to our small size
and early stage, we have not adopted a formal policy on whether the chairman and chief executive officer positions should be separate
or combined. Since August 11, 2021, Mr. DiPerna has been serving as our chairman, and since February 23, 2022, Mr. Besser has been serving
as our chief executive officer. Our board of directors has oversight responsibility for our risk management processes. Our board of directors
receives and reviews periodic reports from management, auditors, legal counsel, and others, as considered appropriate, regarding our
assessment of risks. Our board of directors will focus on the most significant risks facing us and our general risk management strategy,
and also ensure that risks undertaken by us are consistent with our appetite for risk. While our board of directors oversees our risk
management processes, management is responsible for day-to-day risk management processes. We believe this division of responsibilities
is the most effective approach for addressing the risks facing us and that the leadership structure of our board of directors supports
this approach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-size: 10pt">We have established
an audit committee, a compensation committee, and a nominating and governance committee. Each committee&#8217;s members and functions
are described below.</span></p>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt">Our board of
directors established the audit committee (the &#8220;Audit Committee&#8221;) for the purpose of overseeing the accounting and financial
reporting processes and audits of our financial statements. The Audit Committee also is charged with reviewing any internal control violations
under our whistleblower policy. The responsibilities of our audit committee are described in the Audit Committee Charter adopted by our
board of directors, a current copy of which can be found on the investors section of our website, www.modular-medical.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Ms. Volkart, Mr. Felsher
and Mr. Sheibley are the current members of the Audit Committee. Mr. Felsher serves as the chairperson and has been designated by the
board of directors as the &#8220;audit committee financial expert,&#8221; as defined by Item 407(d)(5) of Regulation S-K under the Securities
Act of 1933, as amended, and the Exchange Act. That status does not impose duties, liabilities or obligations that are greater than the
duties, liabilities or obligations otherwise imposed on her as a member of the audit committee and the board of directors, however. Our
board of directors has determined that each of our Audit Committee members satisfies the &#8220;independence&#8221; requirements of the
Nasdaq listing rules and meets the independence standards under Rule 10A-3 under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our board of directors
established the compensation committee for the purpose of reviewing, recommending and approving our compensation policies and benefits,
including the compensation of all of our executive officers and directors. Mr. Febbo and Ms. Volkart are the current members of the compensation
committee, and Mr. Febbo serves as the chairperson. Each of our Compensation Committee members satisfies the &#8220;independence&#8221;
requirements of the Nasdaq listing rules and meets the independence standards under Rule 10A-3 under the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our compensation committee
is responsible for reviewing, recommending and approving our compensation policies and benefits, including the compensation of all of
our executive officers and directors, and it also has the principal responsibility for the administration of our equity incentive plan.
The responsibilities of our compensation committee are more fully described in the Compensation Committee Charter adopted by our board
of directors, a current copy of which can be found on the investors section of our website, www.modular-medical.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nominating
and Corporate Governance Committee</i>. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The Nominating
and Governance Committee consists of Mr. Sheibley and Mr. Felsher, and Mr. Sheibley serves as the chairperson. Each of the members of
our Nominating and Governance Committee satisfies the &#8220;independence&#8221; requirements of the Nasdaq listing rules and meets the
independence standards under Rule 10A-3 under the Exchange Act. The Nominating and Governance Committee will consider persons recommended
by stockholders for inclusion as nominees for election to our board of directors if the information required by our bylaws is submitted
in writing in a timely manner addressed and delivered to our secretary at the address of our executive offices.</span></p>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Nominating and
Governance Committee will identify and evaluate nominees for our board of directors, including nominees recommended by stockholders,
based on numerous factors it considers appropriate, some of which may include strength of character, mature judgment, career specialization,
relevant technical skills, diversity, and the extent to which the nominee would fill a present need on our board of directors. The responsibilities
of our Nominating and Governance committee are more fully described in the Nominating and Governance Committee Charter adopted by our
board of directors, a current copy of which can be found on the investors section of our website, www.modular-medical.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Business Conduct and Ethics for Employees, Executive Officers and Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have adopted a Code
of Business Conduct and Ethics, or the Code of Conduct, applicable to all of our employees, executive officers and members of our board
of directors. The Code of Conduct is available on our website at www.modular-medical.com. Our Nominating and Governance Committee is
responsible for overseeing the Code of Conduct, and our board of directors must approve any waivers of the Code of Conduct. In addition,
we intend to post on our website all disclosures that are required by law concerning any amendments to, or waivers from, any provision
of the Code of Conduct.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Board
Diversity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We seek diversity in
experience, viewpoint, education, skill, and other individual qualities and attributes to be represented on our board of directors. We
believe directors should have various qualifications, including individual character and integrity; business experience; leadership ability;
strategic planning skills, ability, and experience; requisite knowledge of our industry and finance, accounting, and legal matters; communications
and interpersonal skills; and the ability and willingness to devote time to our company. We also believe the skill sets, backgrounds,
and qualifications of our directors, taken as a whole, should provide a significant mix of diversity in personal and professional experience,
background, viewpoints, perspectives, knowledge, and abilities. Nominees are not to be discriminated against on the basis of race, religion,
national origin, sex, sexual orientation, disability, or any other basis proscribed by law. The assessment of prospective directors is
made in the context of the perceived needs of our board of directors from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">All of our directors
have held high-level positions in business or professional service firms and have experience in dealing with complex issues. We believe
that all of our directors are individuals of high character and integrity, are able to work well with others, and have committed to devote
sufficient time to the business and affairs of our company. In addition to these attributes, the description of each director&#8217;s
background set forth above indicates the specific qualifications, skills, perspectives, and experience necessary to conclude that each
individual should continue to serve as a director of ours.</span></p>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modulara011"></span>Executive
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY
COMPENSATION TABLE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following table
sets forth compensation information for the years ended March 31, 2021 and March 31, 2020 for each of our named executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name and Principal<br /> Position</b></span></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary<br /> ($)</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock<br /> Awards<br /> ($)</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br /> Awards<br /> ($)(1)</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Equity<br /> Incentive<br /> Plan<br /> Compensation<br /> ($)</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All<br /> Other<br /> Compensation<br /> ($)</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total<br /> ($)</b></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 31%; text-align: left; text-indent: -8.65pt; padding-left: 8.9pt">Paul DiPerna, CEO, CFO, Secretary,</td><td style="width: 2%">&#160;</td>
    <td style="width: 6%; text-align: center">2021</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">200,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">25,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">50,000</td><td style="width: 1%; text-align: left">(3)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">275,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.9pt">Treasurer and Director(2)</td><td>&#160;</td>
    <td style="text-align: center">2020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">584,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">280,000</td><td style="text-align: left">(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,064,200</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.9pt">Stephen Daly, Chief Commercial Officer(5)</td><td>&#160;</td>
    <td style="text-align: center">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">234,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">234,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">2020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,833</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">355,240</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">376,073</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Award amounts reflect the
    aggregate grant date fair value with respect to awards granted, as determined pursuant to FASB ASC Topic 718. The assumptions used
    to calculate the aggregate grant date fair value of option awards are set forth in the notes to the consolidated financial statements
    included in item 8 of this Report. These amounts do not reflect actual compensation earned or to be earned by our named executive
    officers.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Mr. DiPerna&#8217;s annual
    salary base was increased from $180,000 to $300,000 in August 2018, under the terms of an employment agreement between us and Mr.
    DiPerna. From August 2018 until June 30, 2020, Mr. DiPerna&#8217;s $300,000 annual salary was paid $200,000 in cash and $100,000
    in fully-vested stock options granted monthly. In June 2020, our board of directors amended the salary payment composition effective
    July 1, 2020, such that the $100,000 component of Mr. DiPerna&#8217;s salary would be deferred until we have achieved $5,000,000
    in financing proceeds from a subsequent financing. On August 11, 2021, Mr. DiPerna resigned as our chief executive officer and continues
    to serve as Chairman of our board of directors and as our President and Chief Financial Officer.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Earned as a bonus of which
    $22,000 was paid on April 30, 2021, and the remainder will be paid in four quarterly installments commencing on July 15, 2021.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Earned as a bonus, and is
    being paid in quarterly installments over the 24-month period that commenced on March 31, 2020.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Mr. Daly became our Chief
    Commercial Officer in March 2020 at an annual base salary of $250,000. In February 2021, Mr. Daly converted to part time and his
    annual base salary was reduced to $125,000. Mr. Daly resigned as our Chief Commercial Officer effective September 24, 2021, and we
    and Mr. Daly entered into a consulting arrangement pursuant to which Mr. Daly provides transitional services to us on a part-time,
    interim basis.</span></td></tr>
  </table>
<!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt">The following
table shows certain information regarding outstanding equity awards held by our named executive officers as of March 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Name</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br /> Securities<br /> Underlying<br /> Unexercised<br /> Options (#)<br /> Exercisable</b></span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: left">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br /> Securities<br /> Underlying<br /> Unexercised<br /> Options (#)<br /> Unexercisable</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br /> Exercise<br /> Price($)</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br /> Expiration<br /> Date(1)</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 47%; text-align: justify; padding-left: 0.5pt">Paul DiPerna</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">1,155</td>
    <td style="vertical-align: bottom; width: 2%; text-align: left">(2)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">9.48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 10%; text-align: right">6/1/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,168</td>
    <td style="vertical-align: bottom; text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">5/1/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,169</td>
    <td style="vertical-align: bottom; text-align: left">(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">4/1/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,660</td>
    <td style="vertical-align: bottom; text-align: left">(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/2/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,745</td>
    <td style="vertical-align: bottom; text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">2/1/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,727</td>
    <td style="vertical-align: bottom; text-align: left">(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/1/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,808</td>
    <td style="vertical-align: bottom; text-align: left">(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/1/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,811</td>
    <td style="vertical-align: bottom; text-align: left">(6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">11/1/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,721</td>
    <td style="vertical-align: bottom; text-align: left">(7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">10/1/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,662</td>
    <td style="vertical-align: bottom; text-align: left">(8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">9/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,666</td>
    <td style="vertical-align: bottom; text-align: left">(9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">8/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,660</td>
    <td style="vertical-align: bottom; text-align: left">(10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">7/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,650</td>
    <td style="vertical-align: bottom; text-align: left">(11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">6/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,676</td>
    <td style="vertical-align: bottom; text-align: left">(12)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">5/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,623</td>
    <td style="vertical-align: bottom; text-align: left">(13)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">4/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,694</td>
    <td style="vertical-align: bottom; text-align: left">(14)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,641</td>
    <td style="vertical-align: bottom; text-align: left">(15)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">2/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,603</td>
    <td style="vertical-align: bottom; text-align: left">(16)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1/15/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.775</td>
    <td style="vertical-align: bottom; text-align: left">(17)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">12/28/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.775</td>
    <td style="vertical-align: bottom; text-align: left">(18)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">11/14/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,005</td>
    <td style="vertical-align: bottom; text-align: left">(19)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">10/14/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,005</td>
    <td style="vertical-align: bottom; text-align: left">(20)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">09/14/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,005</td>
    <td style="vertical-align: bottom; text-align: left">(21)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">08/14/2028</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.5pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,889</td>
    <td style="vertical-align: bottom; text-align: left">(22)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: bottom; text-align: right">61,111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">11/25/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: justify; padding-left: 0.5pt">Stephen Daly</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,223</td>
    <td style="vertical-align: bottom; text-align: left">(23)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,445</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">3/3/2030</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 31px; text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The standard
    option term is ten years, but all of the options expire automatically unless exercised within 90 days after the cessation of service
    as an employee, director or consultant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on June 1, 2020, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on May 1, 2020, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on April 1, 2020, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on March 2, 2020, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on February 1, 2020, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on January 1, 2020, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
</table>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify; width: 31px"><span style="font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on December 1, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on November 1, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on October 1, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on September 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(12)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on August 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(13)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on July 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(14)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on June 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(15)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on May 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  </table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 31px; text-align: justify"><span style="font-size: 10pt">(16)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on April 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(17)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on March 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(18)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on February 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(19)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on January 15, 2019, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(20)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on December 15, 2018, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(21)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on November 15, 2018, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(22)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on October 15, 2018, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(23)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on September 15, 2018, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  </table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 31px; text-align: justify"><span style="font-size: 10pt">(24)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on August 15, 2018, and the shares subject to this option were fully vested on the grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(25)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">The option
    was granted on November 25, 2019, and the shares subject to this option vest monthly over three years commencing January 1, 2020,
    subject to continued service as an employee, director or consultant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">(26)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">This option
    was granted on March 3, 2020, and the shares subject to this option vest as to 1/3<sup>rd</sup> of the shares the annual anniversary
    of the grant date and as to 1/36<sup>th</sup> of the shares subject to the option on each monthly anniversary thereafter,
    subject to continued service as an employee, director or consultant.</span></td></tr>
  </table>
<!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have entered into
our standard form of employment, confidential information and invention assignment agreement with each of our named executive officers.
We also have entered into agreements to indemnify our directors and certain executive officers, in addition to the indemnification provided
for in our articles of incorporation and bylaws. These agreements, among other things, provide for indemnification of our directors and
certain executive officers for many expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by any
such person in any action or proceeding, including any action by or in the right of us, arising out of such person&#8217;s services as
a director or executive officer of ours, any subsidiary of ours or any other company or enterprise to which such person provided services
at our request.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following table
summarizes the compensation we paid to our non-employee directors for the year ended March 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 0; white-space: nowrap; font-weight: bold; text-align: center">Fee</td><td style="padding-bottom: 0; white-space: nowrap; font-weight: bold">&#160;</td><td style="padding-bottom: 0; white-space: nowrap">&#160;</td>
    <td colspan="2" style="padding-bottom: 0; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restricted <br /> Stock</b></span></td><td style="padding-bottom: 0; white-space: nowrap">&#160;</td><td style="padding-bottom: 0; white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 0; white-space: nowrap; font-weight: bold; text-align: center">Option</td><td style="padding-bottom: 0; white-space: nowrap; font-weight: bold">&#160;</td><td style="padding-bottom: 0; white-space: nowrap">&#160;</td>
    <td colspan="2" style="padding-bottom: 0; white-space: nowrap; text-align: center">&#160;</td><td style="padding-bottom: 0; white-space: nowrap">&#160;</td><td style="padding-bottom: 0; white-space: nowrap">&#160;</td>
    <td colspan="2" style="padding-bottom: 0; white-space: nowrap; text-align: center">&#160;</td><td style="padding-bottom: 0; white-space: nowrap">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0; white-space: nowrap; text-align: center">&#160;</td><td style="padding-bottom: 0; white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 0; white-space: nowrap; font-weight: bold; text-align: center">Compensation</td><td style="padding-bottom: 0; white-space: nowrap; font-weight: bold">&#160;</td><td style="padding-bottom: 0; white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 0; white-space: nowrap; font-weight: bold; text-align: center">Awards</td><td style="padding-bottom: 0; white-space: nowrap; font-weight: bold">&#160;</td><td style="padding-bottom: 0; white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 0; white-space: nowrap; font-weight: bold; text-align: center">Awards</td><td style="padding-bottom: 0; white-space: nowrap; font-weight: bold">&#160;</td><td style="padding-bottom: 0; white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 0; white-space: nowrap; font-weight: bold; text-align: center">All Other</td><td style="padding-bottom: 0; white-space: nowrap; font-weight: bold">&#160;</td><td style="padding-bottom: 0; white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 0; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 0; white-space: nowrap; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; padding-bottom: 0; white-space: nowrap; font-weight: bold; text-align: left">Name</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 0">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 0; white-space: nowrap; font-weight: bold; text-align: center">($)</td><td style="white-space: nowrap; padding-bottom: 0; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 0">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 0; white-space: nowrap; font-weight: bold; text-align: center">($)</td><td style="white-space: nowrap; padding-bottom: 0; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 0">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 0; white-space: nowrap; font-weight: bold; text-align: center">($)(1)(2)</td><td style="white-space: nowrap; padding-bottom: 0; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 0">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 0; white-space: nowrap; font-weight: bold; text-align: center">Compensation</td><td style="white-space: nowrap; padding-bottom: 0; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 0">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; padding-bottom: 0; white-space: nowrap; font-weight: bold; text-align: center">($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 35%; text-align: justify; padding-left: 0.5pt">Liam Burns(3)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">10,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">10,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 0.5pt">William Febbo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: justify; padding-left: 0.5pt">Morgan Frank(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">375,105</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">375,105</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 0.5pt">Carmen Volkart</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 23px"><span style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Award amounts reflect the
    aggregate grant date fair value with respect to awards granted, as determined pursuant to FASB ASC Topic 718. The assumptions used
    to calculate the aggregate grant date fair value of option awards are set forth in the notes to the consolidated financial statements
    included in Item 8 of this Annual Report on Form 10-K. These amounts do not reflect actual compensation earned or to be earned by
    our directors.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 23px"><span style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As of March 31, 2021, our
    non-employee directors each held outstanding options to purchase the following number of shares of our Common Stock: Liam Burns,
    65,688; William Febbo, 66,667; Morgan Frank, 50,000; Carmen Volkart, 50,000.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 23px"><span style="font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Mr. Burns resigned as a member of our Board on
    December 31, 2021.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 23px"><span style="font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Mr. Frank was granted an
    option to purchase 50,000 shares of our Common Stock in May 2020.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 2pt 0 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 2pt 0 0; text-align: justify"><span style="font-size: 10pt">During the year
ended March 31, 2021, our board of directors had authorized an annual cash retainer fee of $10,000, payable in quarterly installments,
for our non-employee directors, with the exception of Mr. Frank, as compensation for their service. Effective April 1, 2021, our board
of directors approved our outside (non-employee) director compensation plan (the Director Plan). Pursuant to the Director Plan, outside
directors will be paid the following annual retainers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 2pt 0 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 50px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; vertical-align: top; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; vertical-align: top; text-align: justify"><span style="font-size: 10pt">$30,000
    for service as a member of the board of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; vertical-align: top; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; vertical-align: top; text-align: justify"><span style="font-size: 10pt">$5,000
    for service as chair of the audit committee; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; vertical-align: top; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; vertical-align: top; text-align: justify"><span style="font-size: 10pt">$5,000
    for service as chair of the compensation committee.</span></td></tr>
  </table>
<!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The retainers will
be paid in quarterly installments in either cash or in shares of our Common Stock, as directed by each director based on an annual election.
In addition, under the Director Plan, each director will also receive an annual service equity award of $100,000 paid in quarterly installments
in either options to purchase shares our Common Stock or shares of our Common Stock, as directed by each director based on an annual
election.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In addition, upon appointment
to our board of directors, we award our non-employee directors a stock option grant under our Amended 2017 Equity Incentive Plan, hereinafter
referred to as the 2017 Plan, ranging from 16,667 to 66,667 shares of our Common Stock. These options vest annually over three years
from the date of appointment to our board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In connection with
her May 2021 appointment and service as a non-employee director, Ms. Vos has entered into our standard form of indemnification agreement.
We also awarded Ms. Vos an initial option to purchase 16,667 shares of our Common Stock vesting over three years, with one-third of the
shares subject to the option vesting on each one-year anniversary of the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Compensation Plan Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The following table
shows the number of securities to be issued upon exercise or vesting of outstanding equity awards under the 2017 Plan as of March 31,
2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Plan Category</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of <br /> securities to be<br /> issued upon exercise<br /> or vesting of <br /> outstanding <br /> equity awards <br /> (a)</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-<br /> average <br /> exercise price <br /> of outstanding <br /> options <br /> (b)</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of securities <br /> remaining available<br />
    for future issuance under <br /> equity compensation plans<br />
    (excluding securities<br /> reflected in column(a)) &#169;</b></span></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%; text-align: left; text-indent: -8.65pt; padding-left: 9.15pt">Equity compensation plans not approved by security holders</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: center">1,197,252</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: center">$5.25</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: center">136,082</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>

    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif"><b><span id="modulara013"></span>CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Party Transaction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Manchester
Management Company LLC (&#8220;Manchester&#8221;) as the general partner of Manchester Explorer, L.P. (&#8220;Explorer&#8221;), combined
with the holdings of its affiliates, JEB Partners LP, Mr. Besser and Mr. Frank, owns approximately 25% of the Company&#8217;s outstanding
shares of common stock. Mr. Besser is our chief executive officer and a managing member of Manchester. Mr. Frank is one of our directors
and serves as the portfolio manager of Explorer and as a managing member of Manchester.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">In
October 2021, we issued a secured promissory note (the &#8220;Bridge Note&#8221;) to Explorer that provided the Company with a $3,000,000
revolving credit facility with all amounts being drawn down by us thereunder being due and payable, subject to acceleration in the event
of a default, on March 15, 2022. Interest at the rate of 12% was payable on each amount drawn down without regard to the draw-down date
or the date when interest is paid. During the period from October 2021 to February 2022, we made draws of $2,100,000 on the Bridge Note,
and we repaid to Explorer the draws and accrued interest in the amount of $2,352,000 in February 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">In
May 2021, we issued a convertible promissory note (the &#8220;Febbo Convertible Note&#8221;) in the amount of $200,000 to William Febbo,
a member of our board of directors. On February 14, 2022, in accordance with the terms of the Manchester Convertible Note, principal
and accrued interest of $273,507 for the Febbo Convertible Note was converted into 45,586 shares of our common stock. In addition, in
connection with the conversion, Mr. Febbo received a five-year warrant to purchase 45,586 shares of our common stock at a price of $6.60
per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">In
April 2021, we issued a convertible promissory note (the &#8220;Manchester Convertible Note&#8221;) in the amount of $1,026,630 to Explorer.
On February 14, 2022, in accordance with the terms of the Manchester Convertible Note, principal and accrued interest of $1,124,511 for
the Manchester Convertible Note was converted into 234,274 shares of our common stock. In addition, in connection with the conversion,
Explorer received a five-year warrant to purchase 234,274 shares of our common stock at a price of $6.60 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">In
April 2021, we issued a convertible promissory note (the &#8220;DiPerna Convertible Note&#8221;) in the amount of $102,663 to Explorer.
On February 14, 2022, in accordance with the terms of the DiPerna Convertible Note, principal and accrued interest of $112,451 for the
DiPerna Convertible Note was converted into 23,429 shares of our common stock. In addition, in connection with the conversion, Mr. DiPerna
received a five-year warrant to purchase 23,429 shares of our common stock at a price of $6.60 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">See &#8220;Management&#8221;
above for other related party transactions involving our executive officers and directors.</span></p>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modulara012"></span>SECURITY
OWNERSHIP OF CERTAIN<br />
BENEFICIAL OWNERS AND MANAGEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0; text-align: justify"><span style="font-size: 10pt">The following
table sets forth certain information as of May 31, 2022 concerning the ownership of our Common Stock by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 0 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">each shareholder
    known by us to be the beneficial owner of more than 5% of the outstanding shares of our Common Stock (currently our only class of
    voting securities);</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">each of our
    directors;</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">each of our
    executive officers; and</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 26px; text-align: justify"><span style="font: 10pt Symbol">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: justify"><span style="font-size: 10pt">all directors
    and executive officers as a group.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Beneficial ownership
is determined in accordance with Rule 13d-3 of the Exchange Act, and includes all shares over which the beneficial owner exercises voting
or investment power. Shares that are issuable upon the exercise of options, warrants and other rights to acquire Common Stock that are
presently exercisable or exercisable within 60 days of May 31, 2022 are reflected in a separate column in the table below. These shares
are taken into account in the calculation of the total number of shares beneficially owned by a particular holder and the total number
of shares outstanding for the purpose of calculating percentage ownership of the particular holder. We have relied on information supplied
by our officers, directors and certain stockholders and on information contained in filings with the SEC. Except as otherwise indicated,
and subject to community property laws where applicable, we believe, based on information provided by these persons, that the persons
named in the table have sole voting and investment power with respect to all shares of Common Stock shown as beneficially owned by them.
The percentage of beneficial ownership is based on 10,911,684 shares of Common Stock outstanding as of May 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0; text-align: justify"><span style="font-size: 10pt">Unless otherwise
stated, the business address of each of our directors and executive officers listed in the table is 16772 West Bernardo Drive, San Diego,
California 92127.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>
<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">Name and principal position</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Number
    of Shares<br /> Beneficially Owned<br /> (Excluding<br /> Outstanding<br /> Options)(1)</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Number
    of<br /> Shares Issuable<br /> on Exercise of<br /> Outstanding<br /> Options and Warrants(2)</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Percent
    of<br /> Class</b></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 66%; font-size: 10pt; text-align: left; text-indent: -8.65pt; padding-left: 8.9pt">JEB Partners, L.P.</td><td style="width: 3%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 7%; font-size: 10pt; text-align: right">2,720,577</td><td style="width: 1%; font-size: 10pt; text-align: left">(3)</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 7%; font-size: 10pt; text-align: right">653,511</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 7%; font-size: 10pt; text-align: right">29.17</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: -8.65pt; padding-left: 8.9pt">Manchester Explorer, L.P.</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">2,720,577</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">(3)</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">653,511</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">29.17</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-size: 10pt; text-align: left; text-indent: -8.65pt; padding-left: 8.9pt">Manchester Management LLC</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,720,577</td><td style="font-size: 10pt; text-align: left">(3)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">653,511</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">29.17</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Sio
                                            Capital Management, LLC</span></p></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;&#160;</span></td><td style="font-size: 10pt; text-align: right"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">449,438</span></p></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">(4)</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">712,000</span></p></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">(5)</span></td><td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">9.99</span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 8.9pt">Directors and Officers:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">James Besser</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,720,577</td><td style="font-size: 10pt; text-align: left">(3)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">653,511</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">29.17</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-size: 10pt; text-align: left; text-indent: -8.65pt; padding-left: 8.9pt">Paul DiPerna</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,553,586</td><td style="font-size: 10pt; text-align: left">(6)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">186,862</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">24.69</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: -8.65pt; padding-left: 8.9pt">Ellen O&#8217;Connor Vos</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">18,519</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">95,206</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1.03</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-size: 10pt; text-align: left; text-indent: -8.65pt; padding-left: 8.9pt">William J. Febbo</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">79,105</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">113,260</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">1.74</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: -8.65pt; padding-left: 8.9pt">Morgan C. Frank</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,720,577</td><td style="font-size: 10pt; text-align: left">(3)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">443,836</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">27.87</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-size: 10pt; text-align: left; text-indent: -8.65pt; padding-left: 8.9pt">Carmen Volkart</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">3,999</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">73,892</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">*</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: -8.65pt; padding-left: 8.9pt">Steven Felsher</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">2,174</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">21,417</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="font-size: 10pt">*</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.9pt">Philip Sheibley</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,139</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="font-size: 10pt">*</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: -8.65pt; padding-left: 8.9pt">All current directors and executive officers as a group (8) persons</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">5,386,099</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">934,473</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">56.34</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.35pt 0 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 23px"><span style="font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Represents less than 1%</span></td></tr>
  </table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 23px"><span style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Excludes shares subject to
    outstanding options and warrants to acquire Common Stock that are exercisable within 60 days of May 31, 2022.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 23px"><span style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Represents the number of
    shares subject to outstanding options to acquire Common Stock that are exercisable within 60 days of May 31, 2022.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 23px"><span style="font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Includes (i) 124,750 shares
    directly held by Mr. Besser, of which: (a) 60,277 shares were received in exchange for Mr. Besser&#8217;s shares as a result of our
    acquisition of Quasuras; (b) 29,630 shares purchased in a private placement in 2018 (the &#8220;2018 Placement&#8221;) and (c) 34,843
    shares were purchased in a private placement in 2020 (the &#8220;2020 placement&#8221;); (ii) 2,218,077 held by Manchester Explorer,
    L.P. of which: (a) 1,515,152 shares were purchased in a private placement in 2017 (the &#8220;2017 Placement&#8221;), (b) 157,037
    shares were purchased in the 2018 Placement, (c) 11,614 were purchased in the 2020 Placement, (d) 300,000 shares were purchased in
    a public offering in February 2022, and (e) 234,274 shares were acquired upon the conversion of a convertible note in February 2022;
    (iii) 317,473 shares held by JEB Partners, L.P. of which (a) 252,526 shares were purchased in the 2017 Placement, (b) 53,333 shares
    were purchased in the 2018 Placement and (c) 11,614 shares were purchased in the 2020 Placement; and (iv) 60,277 shares held by Mr.
    Frank, which shares were received in our acquisition of Quasuras in exchange for Mr. Frank&#8217;s shares of Quasuras. Mr. Besser,
    as the managing member, and Mr. Frank, as the portfolio manager and consultant of Manchester Management, LLC, (&#8220;MMC&#8221;)
    the general partner of Manchester Explorer, L.P. and JEB Partners, L. P., have shared voting and dispositive power over shares held
    by Manchester Explorer, L.P. and JEB Partners, L.P. The address for Manchester Explorer, L.P is c/o MMC, 2 Calle Candina, No. 1701,
    San Juan, Puerto Rico 00907.</span></td></tr>
  </table>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 23px"><span style="font-size: 10pt">(4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; background-color: white">Consists
                                            of the following shares of Common Stock acquired in the Offering: (i) 144,438 shares of Common
                                            Stock held by Sio Partners LP (&#8220;Partners&#8221;), (ii) 85,000 shares of Common Stock
                                            held by Sio Partners Offshore LTD (&#8220;Offshore&#8221;), (iii) 81,000 shares of Common
                                            Stock held by Compass MAV LLC (&#8220;Compass&#8221;), (iv) 49,000 shares of Common Stock
                                            held by Compass Offshore MAV LTD (&#8220;Compass Offshore&#8221;), (v) 27,000 shares of Common
                                            Stock held by Walleye Manager Opportunities LLC (&#8220;Walleye Manager&#8221;) and (vi)
                                            63,000 shares of Common Stock held by Walleye Opportunities Master Fund Ltd. (Walleye Master&#8221;).
                                            Sio Capital Management, LLC&#160;(&#8220;Sio Management&#8221;) is the investment manager
                                            of Partners, Offshore, Compass, Compass Offshore, Walleye Manager and Walleye Master, and
                                            Michael Castor is the sole owner and Managing Member of Sio Management. Sio Management and
                                            Mr. Castor may be deemed to beneficially own the securities held by Partners, Offshore, Compass,
                                            Compass Offshore, Walleye Manager, and Walleye Master. Each of Sio Management and Mr. Castor
                                            disclaim beneficial ownership of any of the shares of our Common Stock they may be deemed
                                            to beneficially own except to the extent of their respective pecuniary interest therein.
                                            The address for Sio Management, Mr. Castor, Partners, Offshore, Compass, Compass Offshore,
                                            Walleye Manager and Walleye Master is 600 Third Avenue, New York, New York 10016.</span></td></tr></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 23px"><span style="font-size: 10pt">(5)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">These
                                            shares are issuable upon exercise of outstanding pre-funded warrants to purchase shares of
                                            our Common Stock. As of May 31, 2022, Sio Management held 1,348,314 pre-funded warrants to
                                            purchase shares of Common Stock.&#160;&#160;Pursuant to the terms of the pre-funded warrants,
                                            Sio Management cannot exercise such pre-funded warrants if Sio Management would beneficially
                                            own, after such exercise, more than 9.99% of the outstanding shares of our Common Stock.
                                            Accordingly, pre-funded warrants to purchase 636,314 shares of our Common Stock have been
                                            excluded from the table above.</span></td></tr></table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 23px"><span style="font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Includes (i) 2,000,000
    shares directly held by the Paul DiPerna Irrevocable Trust, (ii) 333,334 shares directly held by Mr. DiPerna&#8217;s adult daughters,
    Kelsie DiPerna and Alaria DiPerna, which shares Mr. DiPerna has sole voting power over; (iii) 207,906 shares directly held by the
    Paul DiPerna Trust, of which 101,010 shares were purchased in the 2017 Placement and 23,429 shares were acquired upon the conversion
    off a convertible note in February 2022 and (iv) 12,346 shares held by Mr. DiPerna. The 2,000,000 shares held by the Paul DiPerna
    Irrevocable Trust, 333,334 shares held by Mr. DiPerna&#8217;s adult daughters and 73,480 shares held by the Paul DiPerna Trust that
    were issued in 2017 to Mr. DiPerna in the Control Block Acquisition and transferred to such persons in December 2020 by Mr. DiPerna.
    Mr. DiPerna is the chairman of our board of directors, and also serves as our president, chief financial officer and treasurer. Mr.
    DiPerna is the trustee of both the Paul DiPerna Irrevocable Trust and the Paul DiPerna Trust.</span></p>
</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  </table>


    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modulara017"></span>DESCRIPTION
    OF SECURITIES TO BE REGISTERED</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">We
    are authorized to issue up to 50,000,000 shares of Common Stock, par value $0.001 per share and up to 5,000,000 shares of
    preferred stock, par value $0.001 per share. As of June 2, 2022, we had 10,911,684 shares of our Common Stock outstanding.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On November 29,
    2021, we effected a 1-for-3 reverse stock split of our outstanding Common Stock, which caused our then outstanding Common Stock to
    decrease from 19,100,154 to 6,366,736 shares while keeping our authorized capital unchanged.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
    description is a summary, does not purport to be complete and is subject to and qualified in its entirety by reference to our second
    amended and restated articles of incorporation, and our bylaws, as amended, each of which is incorporated herein by reference and
    are exhibits to the registration statement of which this prospectus forms a part. We encourage you to read our articles of incorporation,
    our bylaws and the applicable provisions of the Nevada Revised Statutes (the &#8220;NRS&#8221;) for additional information.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
    Stock</i></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Each holder of
    our Common Stock is entitled to a pro rata share of any cash distributions made to shareholders, including any dividend payments.
    The holders of our Common Stock are entitled to one vote for each share or record on all matters to be voted on by our shareholders.
    There is no cumulative voting with respect to the election of our directors or any other matter. Therefore, under our charter documents,
    the holders of more than 50% of the shares voted for the election of those directors can elect all of the directors. Our board of
    directors currently are elected as a single class. Our board of directors may from time to time declare dividends on our outstanding
    shares. In the event of our liquidation, dissolution or winding up, the holders of our Common Stock are entitled to share ratably
    in all assets remaining available for distribution to them after payment of our liabilities and after provision has been made for
    each class of stock, if any, having any preference in relation to our Common Stock. Holders of shares of our Common Stock have no
    conversion, preemptive or other subscription rights, and there are no redemption provisions applicable to our Common Stock.</span></p>

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exchange Listing</b></span></p>

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our common stock is listed on the Nasdaq under the symbol &#8220;MODD&#8221;.</span></p>

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><i>Transfer Agent and Registrar</i></b></span></p>

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The transfer agent and registrar for our Common Stock is Colonial Stock Transfer Company, Inc., 7840 S 700 E, Sandy, UT 84070. Its telephone number is 801-355-5740.</span></p>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modulara006"></span>SELLING STOCKHOLDERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
shares of common stock being registered for resale hereby consist of shares that have been issued or are issuable upon exercise of outstanding
warrants that were issued to the selling stockholders in a past private placement of the Company. We are registering the shares of common
stock in order to permit the selling stockholders to offer the shares for resale from time to time. Except as set forth in this prospectus
and except for certain ownership of our securities, the selling stockholders have not had any material relationship with us within the
past three years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The
table below lists the selling stockholders and other information regarding the ownership of the shares of common stock (including shares
of common stock issuable upon conversion or exercise of outstanding securities registered hereunder) by the selling stockholders. The
second column lists the number of shares of common stock (including shares of common stock issuable upon conversion or exercise of outstanding
securities registered hereunder) owned by the selling stockholders prior to this offering. The third column lists the shares of common
stock (including shares of common stock issuable upon conversion or exercise of outstanding securities registered hereunder) being offered
by this prospectus by the selling stockholders. The fourth and fifth columns list the number and percentage, respectively, of shares
of common stock owned by the selling stockholders after the closing of the offering, based on their ownership as of the date of this
prospectus, based on 10,911,684 shares of common stock outstanding, and assuming the sale of all of the shares offered by the selling
stockholders pursuant to this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Name of Selling Stockholder</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<br />
 Shares Owned <br />
Prior to<br />
 Offering(1)</td><td style="white-space: nowrap; white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Maximum Number <br />
of Shares to be Sold <br />
Pursuant to this <br />
Prospectus(1)</td><td style="white-space: nowrap; white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of <br />
Shares <br />
Owned After<br />
 Offering(2)</td><td style="white-space: nowrap; white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Percentage
    of <br />
    Shares Owned <br />
    After Offering(3)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 48%; text-align: left">Sio Capital Management, LLC</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">2,599,640</td><td style="width: 1%; text-align: left">(4)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">1,438,202</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">1,161,438</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">9.99</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 23px"><span style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The number of shares is based
    upon the number of shares of our Common Stock and shares convertible into Common Stock (including shares of
    common stock issuable upon exercise of outstanding warrants registered hereby) held by each selling stockholder based upon information supplied by the Selling Stockholder. </span></td></tr>
</table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 23px"><span style="font-size: 10pt">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 7.9pt"><span style="font-size: 10pt">Assumes
                                            that all securities registered within this offering will be sold. </span></td></tr></table>



<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 23px"><span style="font-size: 10pt">(3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 7.9pt"><span style="font-size: 10pt">Percentages
                                            are based on 10,911,684 shares of our Common Stock outstanding as of May 31, 2022.</span></td></tr>
                                                                                                                                                   </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 23px"><span style="font-size: 10pt">(4)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; background-color: white">The
                                            shares reported consist of the following securities held by the Selling Stockholder: (i)
                                            449,438 shares of our Common Stock, (ii) 712,000 pre-funded warrants to purchase our Common
                                            Stock and (iii) 1,438,202 warrants to purchase our Common Stock (registered hereby). The
                                            Selling Stockholder cannot exercise such pre-funded warrants </span><span style="font-size: 10pt">if
                                            the Selling Stockholder would beneficially own, after such exercise, more than 9.99% of the
                                            outstanding shares of our Common Stock. Accordingly, 636,314 pre-funded warrants to purchase
                                            shares of our Common Stock have been excluded from the ownership of the Selling Stockholder
                                            in the table above.</span></td></tr></table>
<!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modulara007"></span>PLAN
OF DISTRIBUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We are registering
the shares of common stock to permit the resale of these shares of common stock (including shares of common stock issuable upon conversion
or exercise of outstanding securities) by the holders thereof (and such holders&#8217; successors and assigns) from time to time after
the date of this prospectus. We will not receive any of the proceeds from the sale by the selling stockholders of the shares of common
stock. We will bear all fees and expenses incident to our obligation to register the shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 46.05pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The selling stockholders
may sell all or a portion of the shares of common stock owned by them and offered hereby from time to time directly or through one or
more underwriters, broker-dealers or agents. If the shares of common stock are sold through underwriters or broker-dealers, the selling
stockholders will be responsible for underwriting discounts or commissions or agent&#8217;s commissions. The shares of common stock may
be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined
at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 94%; text-align: justify"><span style="font-size: 10pt">on any national
    securities exchange or quotation service on which the securities may be listed or quoted at the time of sale;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">in the over-the-counter market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 94%"><span style="font-size: 10pt">in transactions otherwise
    than on these exchanges or systems or in the over-the-counter market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">through the writing of options,
    whether such options are listed on an options exchange or otherwise;</span></td></tr>
</table>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 94%"><span style="font-size: 10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">block trades in which the
    broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate
    the transaction;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">purchases by a broker-dealer
    as principal and resale by the broker-dealer for its account;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">an exchange distribution
    in accordance with the rules of the applicable exchange;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">privately negotiated transactions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">short sales;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">sales pursuant to Rule 144;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">broker-dealers may agree
    with the selling stockholders to sell a specified number of such shares at a stipulated price per share;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">a combination of any such
    methods of sale; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">any other method permitted
    pursuant to applicable law.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 46.05pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If the selling stockholders
effect such transactions by selling shares of common stock to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers
or agents may receive commissions in the form of discounts, concessions or commissions from the selling stockholders or commissions from
purchasers of the shares of common stock for whom they may act as agent or to whom they may sell as principal (which discounts, concessions
or commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary in the types of transactions
involved). In connection with sales of the shares of common stock or otherwise, the selling stockholders may enter into hedging transactions
with broker-dealers, which may in turn engage in short sales of the shares of common stock in the course of hedging in positions they
assume. The selling stockholders may also sell shares of common stock short and deliver shares of common stock covered by this prospectus
to close out short positions and to return borrowed shares in connection with such short sales. The selling stockholders may also loan
or pledge shares of common stock to broker-dealers that in turn may sell such shares.</span></p>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The selling stockholders
may pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance
of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock from time to time pursuant
to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act, amending,
if necessary, the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders
under this prospectus. The selling stockholders also may transfer and donate the shares of common stock in other circumstances in which
case the transferees, donees, pledgees or other successors in interest will be the selling owners for purposes of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 46.05pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The selling stockholders
and any broker-dealer participating in the distribution of the shares of common stock may be deemed to be &#8220;underwriters&#8221;
within the meaning of the Securities Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer
may be deemed to be underwriting commissions or discounts under the Securities Act. At the time a particular offering of the shares of
common stock is made, a prospectus supplement, if required, will be distributed which will set forth the aggregate amount of shares of
common stock being offered and the terms of the offering, including the name or names of any broker-dealers or agents, any discounts,
commissions and other terms constituting compensation from the selling stockholders and any discounts, commissions or concessions allowed
or reallowed or paid to broker-dealers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 46.05pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Under the securities
laws of some states, the shares of common stock may be sold in such states only through registered or licensed brokers or dealers. In
addition, in some states the shares of common stock may not be sold unless such shares have been registered or qualified for sale in
such state or an exemption from registration or qualification is available and is complied with.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 46.05pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">There can be no assurance
that any selling stockholder will sell any or all of the shares of common stock registered pursuant to the registration statement, of
which this prospectus forms a part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 46.05pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The selling stockholders
and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act and the rules and
regulations thereunder, including, without limitation, Regulation M of the Exchange Act, which may limit the timing of purchases and
sales of any of the shares of common stock by the selling stockholders and any other participating person. Regulation M may also restrict
the ability of any person engaged in the distribution of the shares of common stock to engage in market-making activities with respect
to the shares of common stock. All of the foregoing may affect the marketability of the shares of common stock and the ability of any
person or entity to engage in market-making activities with respect to the shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 46.05pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Once sold under the
registration statement, of which this prospectus forms a part, the shares of common stock will be freely tradable in the hands of persons
other than our affiliates.</span></p>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modulara018"></span>LEGAL
MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Certain legal matters
with respect to the shares of common stock offered hereby will be passed upon by Lucosky Brookman LLP, Woodbridge, New Jersey.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modulara019"></span>EXPERTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The consolidated balance
sheets of Modular Medical, Inc. as of March 31, 2021 and March 31, 2020, and the related consolidated statements of operations, changes
in stockholders&#8217; equity (deficit) and cash flows for the years then ended have been audited by Farber Hass Harley LLP, an independent
registered public accounting firm, as stated in their report which is incorporated herein. Such consolidated financial statements have
been incorporated herein in reliance on the report of such firm given upon their authority as experts in accounting and auditing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modulara014"></span>WHERE
YOU CAN FIND MORE INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have filed with
the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of our common stock offered by this
prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth
in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and regulations
of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement, including the
exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract
or any other document is not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement,
please see the copy of the contract or document that has been filed. Each statement is this prospectus relating to a contract or document
filed as an exhibit is qualified in all respects by the filed exhibit. The SEC maintains an Internet website that contains reports, proxy
statements and other information about issuers, like us, that file electronically with the SEC. The address of that website is&#160;<span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration: underline">www.sec.gov</span></span>.</span></p>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modulara015"></span>INDEX
TO FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 95%"><span style="font-size: 10pt; color: Black">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%; text-align: center"><span style="font-size: 10pt; color: Black">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Nine
    Months ended December 31, 2021 and 2020</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; color: Black"><a href="#modularb001"><span style="font-family: Times New Roman, Times, Serif"><b>Condensed
    Consolidated Balance Sheets as of December 31, 2021 (Unaudited) and March 31, 2021</b></span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; color: Black">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; color: Black"><a href="#modularb002"><span style="font-family: Times New Roman, Times, Serif"><b>Condensed
    Consolidated Statements of Operations for the Three and Nine Months Ended December 31, 2021 and 2020</b></span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; color: Black">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; color: Black"><a href="#modularb003"><span style="font-family: Times New Roman, Times, Serif"><b>Condensed
    Consolidated Statements of Stockholders&#8217; Equity (Deficit) for the Three and Nine Months Ended December 31, 2021 and 2020 (Unaudited)</b></span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; color: Black">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; color: Black"><a href="#modularb004"><span style="font-family: Times New Roman, Times, Serif"><b>Condensed
    Consolidated Statements of Cash Flows for the Nine Months Ended December 31, 2021 and 2020 (Unaudited)</b></span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; color: Black">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; color: Black"><a href="#modularb005"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
    to Condensed Consolidated Financial Statements (Unaudited)</b></span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; color: Black">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Years
    ended March 31, 2021 and March 31, 2020</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; color: Black">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-size: 10pt; color: Black">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Report
    of Independent Registered Public Accounting Firm</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; color: Black"><a href="#modularb006"><span style="font-family: Times New Roman, Times, Serif"><b>Consolidated
    Balance Sheets as of March 31, 2021 and March 31, 2020 </b></span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; color: Black">F-19</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; color: Black"><a href="#modularb007"><span style="font-family: Times New Roman, Times, Serif"><b>Consolidated
    Statements of Operations for the Years Ended March 31, 2021 and March 31, 2020</b></span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; color: Black">F-20</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; color: Black"><a href="#modularb008"><span style="font-family: Times New Roman, Times, Serif"><b>Consolidated
    Statements of Stockholders&#8217; Equity (Deficit) for the Years Ended March 31, 2021 and March 31, 2020 </b></span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; color: Black">F-21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; color: Black"><a href="#modularb009"><span style="font-family: Times New Roman, Times, Serif"><b>Consolidated
    Statements of Cash Flows for the Years Ended March 31, 2021 and March 31,2020, </b></span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; color: Black">F-22</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; color: Black"><a href="#modularb010"><span style="font-family: Times New Roman, Times, Serif"><b>Notes
    to Consolidated Financial Statements</b></span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; color: Black">F-23</span></td></tr>
  </table>
<!-- Field: Page; Sequence: 98; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modularb001"></span>Modular
Medical, Inc.<br />
Condensed Consolidated Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_111_zt01t10WSKq4" summary="xdx: Statement - Condensed Consolidated Balance Sheets (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20211231_zXxqNLk9cLgh" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,<br /> 2021<br /> (Unaudited)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210331_zXxNuQvG0yhh" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,<br /> 2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--AssetsAbstract_iB_ziZMWgXQdCDa" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; padding-left: 8.65pt; text-indent: -8.65pt">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--AssetsCurrentAbstract_i01B_zQeXkBpoJe5k" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">CURRENT ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzxrg_zxrdll7FmZpc" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Cash and cash equivalents</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">204,098</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,468,465</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--PrepaidExpenseCurrent_i02I_maCzxrg_zIK8kryr9Oib" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,607</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,158</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--OtherAssetsCurrent_i02I_maCzxrg_z9ZkzqqjwIPe" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">946</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,466</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--AssetsCurrent_i02TI_mtCzxrg_maCzjVt_zImNaUNHXeL2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 34.6pt">TOTAL CURRENT ASSETS</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">268,651</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,649,089</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_i02I_maCzhYT_zhEk3pdFIUB6" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">241,468</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">298,958</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maCzhYT_zf4A7zEybUn2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Right of use asset, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141,720</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,124</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--DepositsAssets_i02I_maCzhYT_zr6q5IvHUGW7" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Security deposit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--AssetsNoncurrent_i02TI_mtCzhYT_maCzjVt_zqDFkv2M1eA7" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 34.6pt">TOTAL NON-CURRENT ASSETS</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">483,188</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">599,082</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--Assets_i02TI_mtCzjVt_zIoXUoSWkVo1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 25.95pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">751,839</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,248,171</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zQnUNPE73p48" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--LiabilitiesCurrentAbstract_i01B_zWTmwnWap7Vi" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maCzdlD_zXLSJvlpMW12" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">671,363</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,284</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_i02I_maCzdlD_zqwE0M9q7zB" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,124,499</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,948</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzdlD_zIqrBu4QQueh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Short-term lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,817</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--UnsecuredDebtCurrent_i02I_maCzdlD_zQS6FM8bubJh" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">PPP note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0074">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:UnsecuredDebtCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">368,780</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_ecustom--PromissoryNotePayable_i02I_maCzdlD_zbWsjU2UDiQ4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Promissory note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:PromissoryNotePayable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0078">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--ShortTermBankLoansAndNotesPayable_i02I_maCzdlD_zTjTJ6MmMGf1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Convertible notes payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShortTermBankLoansAndNotesPayable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,485,583</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShortTermBankLoansAndNotesPayable" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,133,453</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--LiabilitiesCurrent_i02TI_mtCzdlD_maCzwHb_z1hlcqXpvSE2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 25.95pt">TOTAL CURRENT LIABILITIES</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,921,262</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,296,965</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zTk3LdPCDko5" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; padding-left: 8.65pt; text-indent: -8.65pt">LONG-TERM LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maCzwHb_zyIGRDTOSeUh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Long-term lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,212</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">184,355</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--OtherLiabilitiesNoncurrent_i02I_maCzwHb_zMYh0RasbUs2" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Bonus payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0092">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--Liabilities_i01TI_mtCzwHb_maCzvCw_zWnsxi0fB7Ob" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">TOTAL LIABILITIES</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,998,474</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,523,320</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--CommitmentsAndContingencies_i01I_zpBzme5l9xDk" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Commitments and Contingencies (Note 9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B_zljSUFPUjtJ5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">STOCKHOLDERS&#8217; DEFICIT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--PreferredStockValue_i02I_maCzgzJ_zQ7deegF0dh" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Preferred Stock, $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231_zL4oZIsTXTfe"><span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210331_zDVddJr2tX9b"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_zPGmQMXBAo6i"><span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20210331_zPFo01plDzwk"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_dn_c20211231_zwXquVTNT0Sf"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20211231_zO7rqMNIGqd8"><span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_dn_c20210331_zDB4QImxzv0d"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20210331_zXpIOiFRste1"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0104">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0105">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--CommonStockValue_i02I_maCzgzJ_zfnZZ4sGKRcl" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 17.3pt">Common Stock, $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_zq99cT2Te7ll"><span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210331_zWiW42MHCqGh"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zxi6QHSBTCde"><span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20210331_zcm9JMHYRCK7"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_c20211231_znOIFXquAl6"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zoYLKCNlX5Il"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,373,706</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20210331_zGVSbBdGpStf"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20210331_z19WHBToqvd"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,302,050</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of December 31, 2021 and March 31, 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,374</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,302</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AdditionalPaidInCapital_i02I_maCzgzJ_zvAEqH9xf8F" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,602,162</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,665,559</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_ecustom--CommonStockIssuable_i02I_maCzgzJ_z0OdsvEhD6p7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Common stock issuable </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:CommonStockIssuable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,994</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0130">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzgzJ_zXO3tGStc497" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,005,165</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,947,010</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_403_eus-gaap--StockholdersEquity_i02TI_mtCzgzJ_maCzvCw_zLo43ED4Dkii" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 34.6pt">TOTAL STOCKHOLDERS&#8217; DEFICIT</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,246,635</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,275,149</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtCzvCw_zFJhA6zrMGmb" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 25.95pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">751,839</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,248,171</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center; background-color: white"><span style="font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Modular
Medical, Inc.</b></span><span style="font-size: 10pt"><br />
<span style="font-family: Times New Roman, Times, Serif"><b><span id="modularb002"></span>Condensed Consolidated Statements of Operations</b></span><br />
<span style="font-family: Times New Roman, Times, Serif"><b>(Unaudited)</b></span></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_113_zJrLed6hoIBf" summary="xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_498_20211001__20211231_z94ulBZgaCt7" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_499_20201001__20201231_zuKX8zotoBf2" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_49E_20210401__20211231_zgZqK6zwfti8" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_492_20200401__20201231_zxi6QHSBTCde" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended<br /> December 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended<br /> December 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--OperatingExpensesAbstract_iB_zL4oZIsTXTfe" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzq99_zvrFO9uL6CCc" style="vertical-align: bottom; background-color: White">
    <td style="width: 48%; text-align: left; padding-left: 8.65pt">Research and development</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,849,399</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,086,669</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,742,911</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,150,149</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzq99_zAMKyl6QiN13" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,981,665</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">783,898</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,156,152</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,453,808</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--OperatingExpenses_i01T_mtCzq99_msCzO7r_zsUYAaY0wEHa" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 25.95pt">Total operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,831,064</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,870,567</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,899,063</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,603,957</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--OperatingIncomeLoss_i01T_mtCzO7r_maCzwXq_zfGX6cyaYqGc" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,831,064</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,870,567</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,899,063</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,603,957</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--InterestIncomeExpenseNet_maCzwXq_ziw37vCvbkd1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">368,876</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--InterestExpense_iN_di_msCzwXq_zPS8ovpdpbU8" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,010,247</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0172">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,204,917</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0174">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--GainsLossesOnExtinguishmentOfDebt_maCzwXq_zUsNO4vRL1Ac" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Loss on debt extinguishment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0176">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0177">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,321,450</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0179">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzwXq_maCzPGm_zFi3SL1ZLIPg" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,841,307</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,870,545</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,056,554</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,603,831</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_msCzPGm_z91kNmWqsMS8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Provision for income taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0186">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0187">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--NetIncomeLoss_iT_mtCzPGm_zU8CVXxNBkz8" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 17.3pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,841,307</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,870,545</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,058,155</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,605,431</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zc4259O95h59" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_i01_zgeYzeLVm6J4" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.76</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.30</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.22</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.91</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_iB_zTZkMMJLSWa9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Shares used in computing net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_zVIckvqwXEne" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,354,145</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,249,038</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,331,982</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,187,526</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Modular
Medical, Inc.</b></span><span style="font-size: 10pt"><br />
<span style="font-family: Times New Roman, Times, Serif"><b><span id="modularb003"></span>Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit)</b></span><br />
<span style="font-family: Times New Roman, Times, Serif"><b>(Unaudited)</b></span></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_114_zbXCmW4waTu8" summary="xdx: Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Deficit) (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zfiHlonx8tt" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zJSsMYQ3DrN6" style="white-space: nowrap; font-weight: bold; text-align: center">Additional</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_custom--CommonStockIssuableMember_zJVsBBNOk9m8" style="white-space: nowrap; font-weight: bold; text-align: center">Common</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_za8iydTWal7k" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" id="xdx_4B9_zE3GLL1fpKO" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Paid-In</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Stock</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Accumulated</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Stockholders&#8217;</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Issuable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_430_c20210401__20210630_eus-gaap--StockholdersEquity_iS_zGH7G3RXd7c6" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 28%; text-indent: -8.65pt; padding-left: 8.65pt">Balance as of March 31, 2021</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zckKi8tF7tj1" style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,302,050</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,302</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,665,559</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0218">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,947,010</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,275,149</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_434_c20210401__20210630_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zx6I8wPtH281" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Shares issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zubCD2VydHPb" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">172,180</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0225">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0226">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">172,200</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_431_c20210401__20210630_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_zbIBTURHBef4" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Warrants issued with convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0230">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,700,632</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0232">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0233">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,700,632</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_439_c20210401__20210630_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zrVDvJBut1k4" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7J36NC5iawl" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,836</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">655,918</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0238">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0239">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">655,920</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_437_c20210401__20210630_eus-gaap--NetIncomeLoss_zNdUZ1YSW5Bj" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0243">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0244">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0245">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,835,091</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,835,091</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_433_c20210401__20210630_eus-gaap--StockholdersEquity_iE_z31i8Uva5wS2" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Balance as of June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,323,886</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,324</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,194,289</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0251">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,782,101</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,581,488</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_438_c20210701__20210930_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_z1fbKdTOrjxe" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zctVnNOZN8If" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,635</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">862,427</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0257">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0258">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">862,431</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_439_c20210701__20210930_eus-gaap--NetIncomeLoss_zXzgNkgsi7a8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0262">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0263">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0264">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,381,757</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,381,757</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_437_c20210701__20210930_eus-gaap--StockholdersEquity_iE_z6cvtvoZbSFj" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Balance as of September 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgRAnywtoz02" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,327,521</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,328</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,056,716</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0270">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,163,858</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,100,814</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43E_c20211001__20211231_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zq02eRSCuUv5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Private placement of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSGDyj5iGaA" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,865</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">249,969</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43B_c20211001__20211231_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zmp6GezQNSa4" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Shares issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRsA9Gr1fCv7" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,748</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0285">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,756</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_434_c20211001__20211231_ecustom--SharesIssuableForServices_zVVReHIWhded" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Shares issuable for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0290">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:SharesIssuableForServices" contextRef="From2021-10-012021-12-31_custom_CommonStockIssuableMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,994</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0292">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:SharesIssuableForServices" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,994</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_433_c20211001__20211231_ecustom--SharesIssuedForReverseStockSplit_znbbCYjDBqRb" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Shares issued for reverse stock split</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zj4qhd6LmZv5" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,211</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:SharesIssuedForReverseStockSplit" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:SharesIssuedForReverseStockSplit" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43D_c20211001__20211231_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_z5Gzbu584HW3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zm8h0HhVIfkh" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,775</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,221,729</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0304">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0305">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,221,735</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43F_c20211001__20211231_eus-gaap--NetIncomeLoss_zuzyKiJvTh6h" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0309">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,841,307</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,841,307</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_431_c20211001__20211231_eus-gaap--StockholdersEquity_iE_zOkcBH6vtw16" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Balance as of December 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_c20211001__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6xhqfKiVEpc" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,373,706</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,374</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,602,162</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_CommonStockIssuableMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,994</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,005,165</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,246,635</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Additional</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Common</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b>Stockholders&#8217;</b></td><td style="white-space: nowrap">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Paid-In</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Stock</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Accumulated</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Equity</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Issuable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Deficit)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_43F_c20200401__20200630_eus-gaap--StockholdersEquity_iS_zL9lDPFyXGDd" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Balance as of March 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTbReoxPzMZa" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,956,754</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,957</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,517,505</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_custom_CommonStockIssuableMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">923,994</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,569,034</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,878,422</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_430_c20200401__20200630_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zdLB5XGEJkUl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Private placement of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJlU2bmt06c1" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">243,299</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,042,385</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30_custom_CommonStockIssuableMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">923,994</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0332">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,118,634</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43D_c20200401__20200630_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zzymjlX4W9Ij" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">344,716</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0338">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0339">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">344,716</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43D_c20200401__20200630_eus-gaap--NetIncomeLoss_z9KbJV0NJrmi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0344">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,874,157</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,874,157</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_438_c20200401__20200630_eus-gaap--StockholdersEquity_iE_zX1hDvorIxu1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Balance as of June 30, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMjEBOGlSPbk" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,200,053</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,200</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,904,606</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0350">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,443,191</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,467,615</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_437_c20200701__20200930_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zY3K8FbFFEHb" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,604</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,604</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_434_c20200701__20200930_eus-gaap--NetIncomeLoss_zvMq5ck7CG5b" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,860,729</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,860,729</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_43B_c20200701__20200930_eus-gaap--StockholdersEquity_iE_zQnJaiJktPY8" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Balance as of September 30, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_c20200701__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVo7q5jJSUjg" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,200,053</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,200</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,205,210</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0369">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,303,920</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">907,490</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_439_c20201001__20201231_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zzJvvgfFS02h" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Private placement of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201001__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z33sa4B3IYSk" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">77,497</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">667,171</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0376">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">667,248</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43B_c20201001__20201231_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zaQBksh6AJq6" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0381">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,054</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,054</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_437_c20201001__20201231_eus-gaap--NetIncomeLoss_zPr9UTReLyEc" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0388">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,870,545</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,870,545</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_43D_c20201001__20201231_eus-gaap--StockholdersEquity_iE_zVFtp8CQtQsb" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Balance as of December 31, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_c20201001__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zq2jgRXI0pkd" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,277,550</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,277</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,167,435</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,174,465</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">753</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Modular
Medical, Inc.</b></span><span style="font-size: 10pt"><br />
<span style="font-family: Times New Roman, Times, Serif"><b><span id="modularb004"></span>Condensed Consolidated Statements of Cash Flows</b></span><br />
<span style="font-family: Times New Roman, Times, Serif"><b>(Unaudited)</b></span></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_112_zVn1nqSKR3Bg" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_499_20210401__20211231_zuTBzG66M3xl" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_493_20200401__20201231_zljSUFPUjtJ5" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended <br /> December 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--NetIncomeLoss_z5J0zyDYQl3a" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Net loss</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,058,155</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,605,431</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_40B_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_iB_zopuRrW1jxO3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_ecustom--GainOnPPPNoteForgiveness_i01_zo5lr6S4obpl" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Gain on PPP note forgiveness</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="modd:GainOnPPPNoteForgiveness" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">368,780</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0407">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01N_di_zoRHLFuYxou1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Loss on debt extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,321,450</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0410">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_i01_zFUPEGwXQlI" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,740,086</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">940,374</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--DepreciationAndAmortization_i01_zf2gMxVci9m8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,268</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,016</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i01_znkMRFK5hv1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Shares issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">388,021</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_ecustom--SharesIssuableForServices_i01_zwZgTGAVEuif" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Shares issuable for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:SharesIssuableForServices" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,994</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i01_zldEw3p3upkc" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Amortization of lease right-to-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,404</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,994</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--IncreaseDecreaseInLeaseLiability_i01_zOtWM8c1TMP3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Change in lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="modd:IncreaseDecreaseInLeaseLiability" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">92,826</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:IncreaseDecreaseInLeaseLiability" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,092</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--AmortizationOfDebtDiscountPremium_i01_zX4Cg5lzZ8e" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Amortization of debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,454,762</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_i01B_zpZkplMaTDUh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes in assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i01_zVH00prj37E1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,995</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,964</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i01_zcrcu0ZLLqci" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Accounts payable and accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,223,983</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">123,722</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_maCACEPzPvN_zMJRKDXRSxTg" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Net cash used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,128,787</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,570,713</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zUT7cEpnoPte" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCzzNy_zPXmtf6s6rJl" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Purchase of property and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,779</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,541</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzzNy_maCACEPzPvN_zGoq40zlwYO5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22,779</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">109,541</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zLwHiRFjvKy8" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_i01_maCzhPL_z5Fa3vWc3Vng" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Proceeds from private placement, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,785,882</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--ProceedsFromConvertibleDebt_i01_maCzhPL_z2QQHCLQPtx3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Proceeds from issuance of convertible notes, net of placement fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,137,199</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0461">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--ProceedsFromIssuanceOfPromissoryNote_i01_maCzhPL_zQmnc2ThUHj1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Proceeds from issuance of promissory note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:ProceedsFromIssuanceOfPromissoryNote" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0464">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--ProceedsFromNotesPayable_i01_maCzhPL_zPEqGKLUumg2" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Proceeds from issuance of PPP note payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0466">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">368,780</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzhPL_maCACEPzPvN_zUFtUJlJJ9i5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,887,199</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,154,662</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCACEPzPvN_z19pu41qgmKk" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Net decrease in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,264,367</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,525,592</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iS_z0zvflS8bS3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash and cash equivalents at beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,468,465</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,122,134</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iE_zsKg2GITRxt8" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Cash and cash equivalents at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">204,098</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">596,542</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_iB_zzdmlRpi0e8a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Supplemental disclosure:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_i01B_zgKlgExPCGJ8" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Noncash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_i02_z2Odo9XlGBy4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Fair value of detachable warrants issued with convertible notes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,700,632</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0488">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><span style="font-size: 10pt">The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></p>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MODULAR
MEDICAL, INC.</b></span><span style="font-size: 10pt"><br />
<span style="font-family: Times New Roman, Times, Serif"><b>F/K/A BEAR LAKE RECREATION, INC.</b></span><br />
<span style="font-family: Times New Roman, Times, Serif"><b><span id="modularb005"></span>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span><br />
<span style="font-family: Times New Roman, Times, Serif"><b>(UNAUDITED)</b></span></span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zdcuY53cetG" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
1 &#8211; <span id="xdx_826_zOZwgRE2vlhh">THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Modular
Medical, Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had
no material business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of
Quasuras, Inc., a Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and
Quasuras, the share exchange was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities
of Quasuras acquired in the merger, at their historical carrying amounts. Prior to the acquisition of Quasuras and since at least
2002, the Company was a shell company, as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange
Act). In June 2017, the Company changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
is a development-stage, medical-device company focused on the design, development, and commercialization of an innovative insulin
pump using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part,
patch pump product, the Company seeks to fundamentally alter the trade-offs between cost and complexity and access to the higher
standards of care that presently available insulin pumps provide. By simplifying and streamlining the user experience from introduction,
prescription, reimbursement, training and day-to-day use, the Company seeks to expand the wearable insulin delivery device market
beyond the highly motivated &#8220;super users&#8221; and expand the category into the mass market. The Company&#8217;s pump product
seeks to serve both the type 1 and type 2 diabetes markets.</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="modd:LiquidityPolicyTextBlock"><p id="xdx_840_ecustom--LiquidityPolicyTextBlock_z9z2ekIUfun5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86B_zSn8fkw1P1Oc">Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Financial
Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15), <i>Going Concern</i>, requires management
to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#8217;s
ability to continue as a going concern within one year after the date that the financial statements are issued. If management
identifies conditions or events that raise substantial doubt about an entity&#8217;s ability to continue as a going concern, management
must consider if there are plans that are probable to be implemented, and whether it is probable that the plans will mitigate
the conditions or events raising the substantial doubt about the entity&#8217;s ability to continue as a going concern. If the
substantial doubt is not alleviated after consideration of management&#8217;s plans, the entity must include a statement in the
notes to the financial statements indicating that there is substantial doubt about the entity&#8217;s ability to continue as a
going concern within one year after the date that the financial statements are issued including: 1) the principal conditions or
events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern, 2) management&#8217;s evaluation
of the significance of those conditions or events in relation to the entity&#8217;s ability to meet its obligations, and 3) management&#8217;s
plans to attempt to mitigate the conditions or events causing the substantial doubt about the entity&#8217;s ability to continue
as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development
and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant
product revenues to achieve profitability. The Company&#8217;s expected operating losses and cash burn and the need to repay the
convertible promissory notes and accrued interest in the first half of 2022 raise substantial doubt about the Company&#8217;s
ability to continue as a going concern within one year after the date that these financial statements are issued. Implementation
of the Company&#8217;s plans and its ability to continue as a going concern will depend upon the Company&#8217;s ability to raise
additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no
assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and,
if available, that such capital will be offered on terms and conditions acceptable to the Company. As disclosed in note 9, the
Company recently sold shares of its common stock to two of its officers, obtained access to a credit facility and filed a registration
statement to offer shares of its common stock. The Company&#8217;s operating needs include the planned costs to operate its business,
including amounts required to repay its convertible promissory notes (if not converted), fund working capital and capital expenditures.
The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many factors, including
the Company&#8217;s ability to successfully commercialize its product, competing technological and market developments, and the
need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its
product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash. These condensed consolidated financial
statements do not include any adjustments that might result from this uncertainty.</span></p>


<ix:exclude><!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>



</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zg1kLg1u7ymh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: left"><span style="font-size: 10pt"><b><span id="xdx_866_zzUiA2s82eS6">Basis
of Presentation </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">The Company&#8217;s
fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in these notes to the condensed consolidated
financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2022 refers
to the fiscal year ending March 31, 2022). The condensed consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">The accompanying
condensed consolidated financial statements of the Company have been prepared without audit. The condensed consolidated balance
sheet as of March 31, 2021 has been derived from the audited consolidated financial statements at that date. Certain information
and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted
in the United States (GAAP) have been condensed or omitted in accordance with these rules and regulations of the Securities and
Exchange Commission (SEC).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">In the
opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting
only of normal recurring adjustments) necessary to summarize fairly the Company&#8217;s financial position, results of operations
and cash flows for the interim periods presented. The operating results for the three months ended December 31, 2021 are not necessarily
indicative of the results that may be expected for the year ending March 31, 2022 or for any other future period.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="modd:ReverseStockSplitPolicyTextBlock"><p id="xdx_843_ecustom--ReverseStockSplitPolicyTextBlock_zLxBVkzxzg51" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><span style="font-size: 10pt"><b><i><span id="xdx_868_zzQnHUeQsOQa">Reverse Stock Split</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20211123__20211124_zbRbXZoxiQj8"><ix:nonNumeric contextRef="From2021-11-232021-11-24" name="us-gaap:StockholdersEquityReverseStockSplit">On November
24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary
of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company&#8217;s shares of common stock.</ix:nonNumeric></span> Such amendment
and ratio were previously approved by a majority of the Company&#8217;s stockholders and the board of directors. As a result of
the reverse stock split, which was effective November 29, 2021, every three shares of the Company&#8217;s pre-reverse split outstanding
common stock were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common
stock holders were not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Split
were rounded up to the nearest whole share. All stock options outstanding and common stock reserved for issuance under the
Company&#8217;s equity incentive plans and warrants outstanding immediately prior to the reverse stock split were adjusted by
dividing the number of affected shares of common stock by three (3) and, as applicable, multiplying the exercise price by three
(3), as a result of the reverse stock split.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>



</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_84D_eus-gaap--UseOfEstimates_zoPl13e0kP2d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_869_zxNVb9p9jHN6">Use
of Estimates </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">The preparation
of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of
the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates
may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWeoFIr7QlXe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_863_zvh4FPiSwkPe">Reportable
Segment </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">The Company
operates in <span id="xdx_906_eus-gaap--NumberOfOperatingSegments_dc_uNumber_c20210401__20211231_zevLYwcoxte5"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2021-04-01to2021-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Number">one</ix:nonFraction></span> business segment and uses one measurement of profitability for its business.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zZZNMr8lQ3V2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_865_zTNsevdrL2h3">Research
and Development</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">The Company
expenses research and development expenditures as incurred.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock"><p id="xdx_841_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z58yieOnj0u9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86A_zpfdCgZFzn8">General
and Administrative </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting
fees, and office and other administrative expenses.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zzo1rW1DtNX7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86E_zPLJpIi6iP3g">Concentration
of Credit Risk </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Financial
instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains
its cash balances at high-quality financial institutions within the United States, which are insured by the Federal Deposit Insurance
Corporation up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss
due to financial institution failure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="modd:RisksAndUncertaintiesPolicyTextBlock"><p id="xdx_847_ecustom--RisksAndUncertaintiesPolicyTextBlock_z5k8Yx9Zt5I5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_861_zA1ZtrM00522">Risks
and Uncertainties </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing technology and customer requirements, limited operating history and the volatility
of public markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><i>COVID-19</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">The global
outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains,
significantly restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in-place&#8221;
and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#8217;s operational
and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions
taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company&#8217;s
control, and cannot be predicted.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>



</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zKjab441Int8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_865_zwxlbtu427x1">Cash
and Cash Equivalents </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Cash
and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and highly liquid debt instruments
with original maturities of three months or less.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z9QabmbzvQBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86F_zJqlZcaMfrYg">Property
&amp; Equipment </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Property
and equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful
lives of the assets, generally <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxH_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_zaJ33kMbcei9" title="::XDX::P3Y">three</span> to <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxH_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_z7a40rLLRfAk" title="::XDX::P5Y">five</span> years. Depreciation is recorded in operating expenses in the condensed consolidated
statements of operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of
their estimated useful life or the lease term, and amortization is recorded in operating expenses in the condensed consolidated
statements of operations.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z6gGPV0CA5hh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86A_zU4nuxpUaHsj">Fair
Value of Financial Instruments </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Level
                                         1 inputs to the valuation methodology are quoted prices for identical assets or liabilities
                                         in active markets.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Level
                                         2 inputs to the valuation methodology include quoted prices for similar assets and liabilities
                                         in active markets, and inputs that are observable for the asset or liability, either
                                         directly or indirectly, for substantially the full term of the financial instrument.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Level
                                         3 inputs to the valuation methodology are unobservable and significant to the fair value
                                         measurement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Due to
their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses approximate fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zo9FYsK7bo2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_861_zUBEGqHISegh">Per-Share
Amounts </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Basic
net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding
during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period.
For the nine months ended December 31, 2021 and 2020, outstanding options to purchase <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20211231_zjB5ywqmGkoe"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,967,188</ix:nonFraction></span> and <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20201231_zHT92n9jnntk"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,170,863</ix:nonFraction></span> shares of common
stock, respectively, were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_844_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zKt0uGP8yu0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_862_zncbUgeI7kCi">Reclassification
</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no
effect on the reported results of operations or cash flows.<b> </b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>



</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zI1mPvysuMpd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_864_zjEy9Mo68f6d">Comprehensive
Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly,
comprehensive loss may include certain changes in equity that are excluded from net loss. For the three and nine months ended
December 31, 2021 and 2020, the Company&#8217;s comprehensive loss was the same as its net loss.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zcNdW5Ao75f6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Recently
Adopted Accounting Pronouncement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In August
2020, the FASB issued ASU No. 2020-06, <i>Debt</i> <i>with Conversion and Other Options</i> <i>(Subtopic 470-20) and Derivatives
and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments and Contracts in an
Entity&#8217;s Own Equity </i>(ASU 2020-06)<i>.</i> ASU 2020-06 simplifies the accounting for convertible instruments by removing
major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single
liability instrument with no separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions
that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts
to qualify for it. ASU 2020-06 also simplifies the diluted net income per share calculation in certain areas. The new guidance
is effective for annual and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years
beginning after December 15, 2020, and interim periods within those fiscal years. The Company early adopted ASU 2020-06 effective
April 1, 2021, and the impact of the adoption was not material to the Company&#8217;s consolidated financial statements.</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:LeasesOfLesseeDisclosureTextBlock"><p id="xdx_809_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zffH278fS3Q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
2 &#8211; <span id="xdx_829_z4AbZHRlLxEk">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Effective April
1, 2019, the Company adopted ASU No. 2016-02, <i>Leases </i>(ASC 842),<i> </i>and related ASUs, as amended, using the alternative
transition method, which allowed the Company to initially apply the new lease standard at the adoption date (the &#8220;effective
date method&#8221;). In January 2020, the Company executed a lease for a new, larger corporate facility in San Diego, California
and paid a $100,000 security deposit. The <span id="xdx_908_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxH_c20200402_zyp6c5dcFNR5" title="::XDX::P39M">39</span>-month lease
term commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $<span id="xdx_908_eus-gaap--LeaseAndRentalExpense_c20200401__20200430_zW6ATisQmqil" title="Monthly Rent"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2020-04-012020-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,400</ix:nonFraction></span> annual rent increases of approximately <span id="xdx_90D_ecustom--OperatingLeasesAnnualRentIncreasePercentange_iI_c20200402_zNBNpGf376D4" title="Operating Lease Annual Rent Increase Percentage"><ix:nonFraction name="modd:OperatingLeasesAnnualRentIncreasePercentange" contextRef="AsOf2020-04-02" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction>%</span>.&#160;In addition to the minimum lease payments, the Company
is responsible for property taxes, insurance and certain other operating costs. The right-to-use asset and corresponding liability
for the facility lease have been measured at the present value of the future minimum lease payments. A discount rate of 11%, which
approximated the Company&#8217;s incremental borrowing rate, was used to measure the lease asset and liability. Lease expense
is recognized on a straight line basis over the lease term.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">The Company
obtained a right-of-use asset of $<span id="xdx_905_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20210401__20211231_zC45oVTDftc8"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">270,950</ix:nonFraction></span> in exchange for its obligations under the operating lease. The landlord also provided
a lease incentive of approximately $<span id="xdx_909_ecustom--LeaseIncentiveReceived_iI_c20200930_z7w1C4Im8Qc7"><ix:nonFraction name="modd:LeaseIncentiveReceived" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,000</ix:nonFraction></span>, which was paid to the Company in June 2020, for the Company to make improvements
to the leased space.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 107; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>



<ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zJmxZubEG2ql" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8B0_zxWDKwGCiRO8">Future
minimum payments under the facility operating lease</span>, as of December 31, 2021, are listed in the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="modd:DisclosureLeaseDetailsAbstract"><table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--DisclosureLeaseDetailsAbstract_zI3Kg6Yps0F5" summary="xdx: Disclosure - LEASES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Annual Fiscal Years</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20211231_z2XAUWdNaUfg" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating<br /> lease</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_maOLFMPz6XG_zdjbLZgmxOe3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 87%; text-align: left">2022</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,358</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_maOLFMPz6XG_zqAa2Rf3FnEd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,028</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_maOLFMPz6XG_zzhclJCqGXo3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,692</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_ecustom--OperatingLeasesImputedInterest_iI_maOLFMPz6XG_z073Amdjcmm7" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt; padding-bottom: 1pt">Imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="modd:OperatingLeasesImputedInterest" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,049</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">)</td></tr>
<tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iTI_mtOLFMPz6XG_zN6ZgoIM8uQf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">217,029</ix:nonFraction></td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table></ix:nonNumeric>




<p id="xdx_8A3_zPArM1EYkdH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Cash
paid for amounts included in the measurement of lease liabilities was $<span id="xdx_90F_ecustom--CashPaidforLeaseLiabilities_iI_c20211231_zPgsconRLJA2"><ix:nonFraction name="modd:CashPaidforLeaseLiabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,073</ix:nonFraction></span> for the nine months ended December 31, 2021. Rent
expense was $<span id="xdx_907_eus-gaap--LeaseAndRentalExpense_c20210401__20211231_z9BHbeDJ2Tal"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,698</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--LeaseAndRentalExpense_c20200401__20201231_z5l2mr1N2Rke"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2020-04-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,654</ix:nonFraction></span> for the nine months ended December 31, 2021 and 2020, respectively, and $<span id="xdx_90A_eus-gaap--LeaseAndRentalExpense_c20211001__20211231_zcADFxelGKi5"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2021-10-012021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,930</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--LeaseAndRentalExpense_c20201001__20201231_z4Wt8IcRaChh"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,844</ix:nonFraction></span> for
the three months ended December 31, 2021 and 2020, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="modd:PPPNotesPayableTextBlock"><p id="xdx_805_ecustom--PPPNotesPayableTextBlock_z1pYskgfGTY9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
3 &#8211; <span id="xdx_82B_zu9sua4qxjwh">PPP NOTE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">On April
24, 2020, the Company received a $<span id="xdx_902_eus-gaap--UnsecuredDebtCurrent_iI_c20200424_zuS4y3ofPMQa"><ix:nonFraction name="us-gaap:UnsecuredDebtCurrent" contextRef="AsOf2020-04-24" format="ixt:numdotdecimal" decimals="0" unitRef="USD">368,780</ix:nonFraction></span> unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which
was established under the U.S. government&#8217;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP
Note to the Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration
Paycheck Protection Program Note with the Lender evidencing the PPP Note. The full amount of the PPP Note was due in April 2022
and interest accrued on the outstanding principal balance of the PPP Note at a fixed rate of 1.0% per annum, which was deferred
for 10 months after the covered period during which the Company used the proceeds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
applied to the Lender for forgiveness of the PPP Note in October 2020, and, in May 2021, the Company was notified by the Lender
and the U.S. Small Business Administration that the outstanding principal and accrued interest for the PPP Note was forgiven in
full. The Company accounted for the forgiveness of the PPP Note in accordance with Accounting Standards Codification Topic 470:
Debt (ASC 470), and the amount forgiven was recorded as a gain on extinguishment and recognized in the other income line of the
condensed consolidated statement of operations.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80C_eus-gaap--DebtDisclosureTextBlock_zAiJa8bB4pD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
4 &#8211; <span id="xdx_82B_zDANrQwEOcLj">CONVERTIBLE PROMISSORY NOTES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">From
February through April 2021, the Company sold $2,310,000 of convertible promissory notes (each an Original Notes and, collectively,
the Original Notes), at par in a private placement transaction effected pursuant to an exemption from the registration requirements
under the Securities Act of 1933, as amended. Effective April 30, 2021, pursuant to a revocation and replacement agreement between
each holder of an Original Note and the Company (the Revocation Agreement), the $2,310,000 of Original Notes and accrued interest
thereon as of April 30, 2021 were replaced with $2,360,550 aggregate principal amount of new Notes (as defined below). The Company
accounted for the replacement of the Original Notes in accordance with ASC 470 and recorded a loss on extinguishment of $<span id="xdx_900_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20210401__20211231_z7Gjzm5a3EVg"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,321,450</ix:nonFraction></span>
and interest expense of $<span id="xdx_906_eus-gaap--AmortizationOfFinancingCosts_c20210401__20211231_zshpgyKP037h"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,647</ix:nonFraction></span> for unamortized debt issuance costs as of April 30, 2021.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 108; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In April
and May 2021, pursuant to a Securities Purchase Agreement by and between the Company and each investor (the SPA), the Company
sold to investors $<span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_c20210531__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zaxJPRzXweH3"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2021-05-31_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,250,000</ix:nonFraction></span> aggregate principal amount of convertible promissory notes (the Notes) and warrants to purchase shares
of its common stock (the Warrants). The Notes are unsecured obligations of the Company with each Note having a stated maturity
date of 12 months from its issue date (the Issue Date). The Notes bear interest at a rate of 12% per annum, payable on maturity,
provided that, if the Company fails to pay any amounts when due under a Note, the interest rate increases to the greater of 16%
or the maximum amount permitted by law. Each Note may be prepaid at the Company&#8217;s option during the first 270 calendar days
following its Issue Date (the 270<sup>th</sup> day, the Trigger Date), subject to a 110% prepayment penalty on outstanding principal
and accrued interest then outstanding. No Note may be prepaid in whole or in part after the Trigger Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Notes
outstanding after the Trigger Date may be converted into shares of the Company&#8217;s common stock at an initial conversion price
of $8.61 per share; provided that a Note holder may not convert any portion of its Note that would cause it to beneficially own
in excess of 4.99% of the Company&#8217;s outstanding common stock. The conversion price and number of shares of Company common
stock issuable upon conversion of the Notes are subject to adjustment from time to time for subdivisions and consolidations of
shares and other standard dilutive and corporate events, as provided in the Notes. Subject to certain Exempt Issuances (as defined
in the Notes), if while a Note is outstanding, the Company sells, issues or grants any shares of its common stock or other securities
to acquire shares of common stock at a price per share less than the then conversion price, such conversion price shall be reduced
to such lesser price, and the number of conversion shares issuable upon conversion of the Notes shall be increased, as provided
in the Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">If the
Company completes an offering of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified
Capital Raise, as defined in the Notes), each Note holder will be required to convert its Adjusted Note Amount (as defined below)
into the securities of such Qualified Capital Raise. Adjusted Note Amount equals the product of (i) the sum of all outstanding
principal plus accrued interest on a Note, multiplied by (ii) 1.25.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Notes
contain a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal
or interest thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting
requirements under the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement,
(v) material restatements of the Company&#8217;s consolidated financial statements filed with the SEC, (vi) a holder&#8217;s inability
to rely on Rule 144 for sales of shares underlying the Notes, (vii) the Company&#8217;s common stock is suspended or halted from
trading and/or fails to be quoted or listed (as applicable) on the OTCQB, OTCQX, any tier of the NASDAQ Stock Market, the New
York Stock Exchange, or the NYSE American within 10 days thereafter, (viii) failure to file with the SEC a registration statement
covering the resale of shares of common stock underlying the Notes and Warrants within 60 calendar days following the Issue Date,
(ix) failure to cause such registration statement to become effective within 120 calendar days following the Issue Date, or (x)
certain mergers consolidations, business combinations and sales of all or substantially all of the Company&#8217;s assets in the
event the Company is not the survivor of such transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">Upon
an Event of Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will
be required to pay such Note holder the sum of (i) the product of (a) all then outstanding principal amount and accrued interest
thereon, multiplied by (b) 125%; and (ii) all collection costs including legal fees and expenses in connection therewith. At the
option of a Note holder, in the event the Company receives cash proceeds as a result of certain events, including, but not limited
to, payments from customers, issuances of debt or equity securities, exercise of warrants or asset sales, the Company will be
required to use such proceeds to repay all or any lesser outstanding amounts due under such holder&#8217;s Note.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 109; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Notes
include covenants, representations, warranties, other payment obligations and agreements by the Company including, without limitation,
most-favored nation rights, rights of participation and first refusal and exchange rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In connection
with the issuance of the Notes, the Company issued Warrants to purchase in the aggregate 767,796 shares of its common stock at
an initial exercise price of $24.00 per share. The Warrants may be exercised for a period of five years from the Trigger Date,
provided that, if prior to the Trigger Date, the Company (i) completes a Qualified Capital Raise, the outstanding Warrants shall
be cancelled or (ii) prepays a holder&#8217;s Note(s) in whole or in part, such holder&#8217;s pro-rata number of Warrants shall
be cancelled. The fair value of the Warrants was $3,700,632, of which $2,379,182 was recorded as a debt discount, which is being
amortized to interest expense over the term of the Warrants, and $1,321,450 was recorded as a loss on debt extinguishment. The
Company calculated the fair value of the Warrants utilizing the Black-Scholes valuation model with the following assumptions:
volatility of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_c20210401__20211231_zsRt4WHqRwy2"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">88.98</ix:nonFraction>%</span>, risk-free interest rate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20211231_zLknLX55GhKe"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-04-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.86</ix:nonFraction>%</span>, a term of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20211231_zGJvvNpm3bWh" title="::XDX::P5Y9M">5.75</span> years and a dividend yield of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dcpxH_c20210401__20211231_zLx04zbKA4ge" title="::XDX::0">zero</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In connection
with the April and May 2021 sales of the $4,250,000 aggregate principal amount of the Notes, the Company incurred debt issuance
costs of $116,000, which were recorded as a debt discount and are being amortized to interest expense over the term of the Notes
using the effective interest rate method. The interest expense attributable to the debt discount, comprising the debt issuance
costs and Warrants, during the three and nine months ended December 31, 2021 was $630,323 and $1,454,762, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The $6,610,550
aggregate principal amount of Notes are due and payable in full in the first quarter of fiscal 2023. Subsequent to the Trigger
Date, the Notes can be converted into <span id="xdx_90C_ecustom--NotesAndAccuredInterestCouldBeConvertedIntoCommonStock_iI_c20211231_zAX49DWsrmre"><ix:nonFraction name="modd:NotesAndAccuredInterestCouldBeConvertedIntoCommonStock" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">767,783</ix:nonFraction></span> shares of common stock at a conversion price of $8.61 per share.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="modd:PromissoryNoteTextBlock"><p id="xdx_804_ecustom--PromissoryNoteTextBlock_zZLKfUWSVEFc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
5 &#8211; <span id="xdx_82A_zXncvbeBDPdf">PROMISSORY NOTE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">On
October 28, 2021, the Company issued a secured promissory note (the Bridge Note) to Manchester Explorer, L.P. (&#8220;Manchester&#8221;)
that provides the Company with a $<span id="xdx_90E_eus-gaap--LineOfCredit_iI_c20211028__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--InvestmentTypeAxis__custom--SecuredPromissoryNotesMember_zEh8GdOS7zXk"><ix:nonFraction name="us-gaap:LineOfCredit" contextRef="AsOf2021-10-28_us-gaap_RevolvingCreditFacilityMember_custom_SecuredPromissoryNotesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span> revolving credit facility with all amounts being drawn down by the Company thereunder
being due and payable, subject to acceleration in the event of a default, on <span id="xdx_90A_eus-gaap--LineOfCreditFacilityExpirationDate1_c20211027__20211028__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--InvestmentTypeAxis__custom--SecuredPromissoryNotesMember_zDtbfLEgLYo2" title="Maturity Date"><ix:nonNumeric contextRef="From2021-10-272021-10-28_us-gaap_RevolvingCreditFacilityMember_custom_SecuredPromissoryNotesMember" format="ixt:datemonthdayyearen" name="us-gaap:LineOfCreditFacilityExpirationDate1">March 15, 2022</ix:nonNumeric></span> (the &#8220;Maturity Date&#8221;).
Interest at the rate of <span id="xdx_90E_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_c20211027__20211028__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--InvestmentTypeAxis__custom--SecuredPromissoryNotesMember_zV3wKkgD9ZS"><ix:nonFraction name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" contextRef="From2021-10-272021-10-28_us-gaap_RevolvingCreditFacilityMember_custom_SecuredPromissoryNotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction>%</span> is payable on each drawn down without regard to the draw down date or the date when interest is paid.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The
principal amount of the Bridge Note and interest due thereon is payable to Manchester no later than the earlier of: (i) the Maturity
Date and (ii) the date on which the Company has received proceeds in excess of $12,000,000 from a transaction or series of related
transactions occurring prior to the Maturity Date, which such transactions constitute equity financings or other issuances of
the Company&#8217;s equity securities. Provided that no Event of Default (as such term is defined in the Bridge Note) has occurred,
on any date prior to the Maturity Date, upon no less than three days written notice by the Company specifying the draw amount,
Manchester will advance the draw amount to the Company. No draw amount can be in an amount less than $100,000 or exceed an amount
equal to $3,000,000 minus the aggregate principal amount outstanding under the Bridge Note at the time of such draw request. If
an Event of Default occurs and is continuing, Manchester may declare all of the Bridge Note, including any interest and other
amounts due, to be due and payable immediately.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 110; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In
connection with the issuance of the Note, on October 28, 2021, the Company entered into a Security Agreement with Manchester (the
&#8220;Security Agreement&#8221;) under which the Company granted Manchester a continuing and unconditional first priority security
interest in and to any and all of the Company&#8217;s property of any kind or description, tangible or intangible, wheresoever
located and whether now existing or hereafter arising or acquired.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
the quarter ended December 31, 2021, the Company made draws on the Bridge Note of $<span id="xdx_90C_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_c20211001__20211231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zosYE3aCBPLk"><ix:nonFraction name="us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet" contextRef="From2021-10-012021-12-31_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500,000</ix:nonFraction></span> and incurred interest charges of
$<span id="xdx_90E_eus-gaap--LineOfCreditFacilityIncreaseAccruedInterest_c20211001__20211231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zGfFez5D3hHk"><ix:nonFraction name="us-gaap:LineOfCreditFacilityIncreaseAccruedInterest" contextRef="From2021-10-012021-12-31_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,000</ix:nonFraction></span>.</span></p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock"><p id="xdx_80A_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zQz1HdeI7FFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
6 &#8211; <span id="xdx_82D_z6GULZVoIzo8">STOCKHOLDERS&#8217; DEFICIT AND STOCK-BASED COMPENSATION</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
the three months ended December 31, 2021, the Company sold 30,865 shares of common stock to its chief executive officer and its
chairman of the board of directors, president, chief financial officer and treasurer, issued 8,334 shares of common stock to a
service provider and issued 5,775 shares to its non-employee directors under the Company&#8217;s outside director compensation
plan. At December 31, 2021, the Company had an obligation to issue 16,666 shares of common stock to service providers, and the
value of these shares was recorded as common stock issuable in the condensed consolidated balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Amended
2017 Equity Incentive Plan </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In October
2017, the Company&#8217;s board of directors (the Board) approved the 2017 Equity Incentive Plan (the Plan) with <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20171031_ztEmafj12tal"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2017-10-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares
of common stock reserved for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved
for issuance under the Plan by <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200131_zlXA0kJN12F2"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2020-01-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">333,334</ix:nonFraction></span> and <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200831_zMSDt8zLhQSk"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2020-08-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,333,334</ix:nonFraction></span> shares, respectively. Under the Plan, eligible employees, directors and consultants
may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based
awards and restricted stock units. The Plan is administered by the Board or, in the alternative, a committee designated by the
Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Stock-Based
Compensation Expense</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The expense
relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period,
based on the grant date fair value. The unamortized compensation cost, as of December 31, 2021, was $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20211231_zlB1owsTyga"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,419,022</ix:nonFraction></span> related to stock
options and is expected to be recognized as expense over a weighted-average period of approximately <span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dxH_c20210401__20211231_zHpVu1aRNWu" title="::XDX::P2Y">two</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">During
the nine months ended December 31, 2021, the Company granted options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zoRiL3V4EeLf"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-04-012021-12-31_us-gaap_CommonStockMember_us-gaap_EmployeeStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">723,269</ix:nonFraction></span> shares of its common stock to employees,
directors and consultants. The options had 10-year terms, and <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zUHxuUD5tbBj"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-04-012021-12-31_us-gaap_StockOptionMember_us-gaap_EmployeeStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">85,484</ix:nonFraction></span> options vested immediately when granted. The fair value of
the options was determined to be $<span id="xdx_909_ecustom--FairValueofOptionGranted_c20210401__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMgkdlr2ZUMk"><ix:nonFraction name="modd:FairValueofOptionGranted" contextRef="From2021-04-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,108,043</ix:nonFraction></span> of which $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20210401__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfNzWohm5oJ"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2021-04-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,769,805</ix:nonFraction></span> was recorded as stock-based compensation expense and included
in the condensed consolidated statement of operations for the nine months ended December 31, 2021.</span></p>



<ix:exclude><!-- Field: Page; Sequence: 111; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>



<ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zvoaga1a89yd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
assumptions were used in the fair value method calculations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BC_zoHpYNToBpPe" style="display: none">Schedule of Fair Value Assumptions</span></p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="modd:DisclosureStockBasedCompensationDetailsAbstract"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zBie8INYQvq1" summary="xdx: Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Three
    Months Ended<br /> December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Nine
    Months Ended<br /> December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: left"><span style="font-size: 10pt">Risk-free
    interest rates</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_zJhiCTvtdor5"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-10-012021-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.26</ix:nonFraction>%</span> - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zFYXEYTjgfXj"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-10-012021-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.36</ix:nonFraction>%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20201001__20201231_zgrZ8UmxTHRa"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.38</ix:nonFraction>%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_z8xm6yEUn6ze"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-04-012021-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.8</ix:nonFraction>%</span> - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_z4F0L9F5VYCg"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-04-012021-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.36</ix:nonFraction>%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20201231__srt--RangeAxis__srt--MinimumMember_zMAGWA6uQjTh"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-04-012020-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.28</ix:nonFraction>%</span> - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20201231__srt--RangeAxis__srt--MaximumMember_zmxRF2Rnv4Gk"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-04-012020-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.38</ix:nonFraction>%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_zzxbc1ec0iya"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-10-012021-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">197</ix:nonFraction>%</span>
                                         - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zX9wuplYzrge"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-10-012021-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">253</ix:nonFraction>%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20201001__20201231_zzEbfdv7ehvb"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-10-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">87</ix:nonFraction>%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_zmHwQ5WCgu2d"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-04-012021-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">89</ix:nonFraction>%</span>
                                         - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_zgALPDHRxh5b"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-04-012021-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">370</ix:nonFraction>%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20201231__srt--RangeAxis__srt--MinimumMember_z3J24CnpuBAf"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-04-012020-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">87</ix:nonFraction>%</span>
                                         - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20201231__srt--RangeAxis__srt--MaximumMember_zTf56EI8vHUa"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-04-012020-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">127</ix:nonFraction>%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Expected life (years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_z3uH1IqRNXW8"><ix:nonNumeric contextRef="From2021-10-012021-12-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric></span>
                                         &#8211; <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zUli8eAzzafj"><ix:nonNumeric contextRef="From2021-10-012021-12-31_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.0</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231__srt--RangeAxis__srt--MinimumMember_zRuCprlQIXoe"><ix:nonNumeric contextRef="From2020-10-012020-12-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.2</ix:nonNumeric></span>
                                         &#8211; <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231__srt--RangeAxis__srt--MaximumMember_zOj6Ji4p1sYa"><ix:nonNumeric contextRef="From2020-10-012020-12-31_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.7</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_zy0bHBwbcbmj"><ix:nonNumeric contextRef="From2021-04-012021-12-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric></span>
                                         - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_zu1julJ9OpCf"><ix:nonNumeric contextRef="From2021-04-012021-12-31_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.2</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20201231__srt--RangeAxis__srt--MinimumMember_zgqyty753UOh"><ix:nonNumeric contextRef="From2020-04-012020-12-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric></span>
                                         - <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20201231__srt--RangeAxis__srt--MaximumMember_z5K54pvMIsg"><ix:nonNumeric contextRef="From2020-04-012020-12-31_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.0</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20211001__20211231_zm1YAE8gfGAg"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-10-012021-12-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20201001__20201231_zc9a5wEnzU71"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-10-012020-12-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20210401__20211231_zWrUnJCVcVV8"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-04-01to2021-12-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20201231_zgll00aypvEi"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-04-012020-12-31" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table></ix:nonNumeric>





<p id="xdx_8A0_zt8mvG0EWljf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The fair
values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods
to establish the fair term of options as well as average volatility of three comparable organizations. The risk-free interest
rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant
date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never
paid dividends and has no intention to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company
accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zgPewvRZSuA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">A summary
of stock option activity under the Plan is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BF_zMfIkSaPKpo3" style="display: none">Schedule of Stock Option activity</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="modd:DisclosureStockBasedCompensationDetails2Abstract"><table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zJgKjtBn1Yde" summary="xdx: Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares<br /> Available<br /> for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br /> Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br /> Average<br /> Exercise<br /> Prices</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2021</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zwC7l1Fa7005" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">136,082</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmpnLVcwY3H" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,197,252</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5b8iKkQzy1l" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.25</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zczvsn3JQKFi" style="text-align: right">(<ix:nonFraction name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">60,774</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoueppVNmd15" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,774</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSqVkRYMnjPh" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.69</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKnwKSq88j1h" style="text-align: right">(<ix:nonFraction name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">1,836</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgshN5RbEzDh" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,547</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3cy1HgyK8jh" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,547</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT43tyNwyf" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.61</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Balance at June 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLN21uVqY9e3" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">81,089</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWS7z1Hgdljk" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,479</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziGgmlnX6b1i" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.58</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztHm9HiOjxM" style="text-align: right"><ix:nonFraction name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant" contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,333,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zw75AdIoqDyd" style="text-align: right">(<ix:nonFraction name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">396,384</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAUosEMtvCBd" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">396,384</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyFNIXkQzrj5" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.15</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRLRhaCnjRf6" style="text-align: right">(<ix:nonFraction name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">3,636</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyad6u5ObVd3" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,213</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zTxde3atswIb" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,213</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQHd0IPPrYek" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.02</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at September 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2QiQGPgV8T3" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,063,546</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5KsGdZdFMok" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,597,650</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zr46KajKTuM2" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.17</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLCJHdBqM5kc" style="text-align: right">(<ix:nonFraction name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">266,112</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5ZRQE89Yb73" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">259,559</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBSJy6ClQVAc" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.99</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx4DAV7jxxii" style="text-align: right">(<ix:nonFraction name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,775</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmghZMF6l164" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,073</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zV9lNSrU3La7" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,256</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBuKoN8LsIr9" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.24</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at December 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zApvYc0926E8" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">820,732</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziAAAHiBLCc3" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,845,953</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDJsNb4lL4fc" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.57</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<ix:exclude><!-- Field: Page; Sequence: 112; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">There were no stock options exercised during the nine months ended December 31, 2021 and 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_zHfLqyJ8vjpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table summarizes the range of outstanding and exercisable options as of December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B0_zjWp49Tt5yt7" style="display: none">Schedule of
Outstanding and Exercisable Option, Range</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="modd:DisclosureStockBasedCompensationDetails3Abstract"><table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zhuv6eC9oSy" summary="xdx: Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number<br /> Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br /> Average<br /> Remaining<br /> Contractual<br /> Life<br /> (in Years)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br /> Average<br /> Exercise<br /> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number<br /> Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br /> Average<br /> Exercise<br /> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br /> Intrinsic<br /> value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%; padding-bottom: 1pt">$<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zfOh8Nh6lWy3"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.98</ix:nonFraction></span> - $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zxbrZpd0Al24"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.70</ix:nonFraction></span></td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDlPIupeKgEh" style="border-bottom: Black 1pt solid; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,845,953</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxH_c20210401__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGGy1zqdjbL1" title="::XDX::P8Y1M17D" style="width: 8%; padding-bottom: 1pt; text-align: right">8.13</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVj3UdAANCp3" style="width: 8%; padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.57</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zketqRJJRft7" style="border-bottom: Black 1pt solid; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,011,586</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znJSsM8zPE36" style="width: 8%; padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.10</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6lN4x67ZMvb" style="border-bottom: Black 1pt solid; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,564,268</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p id="xdx_8A4_z8FJHdEPWO81" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The intrinsic
value per share is calculated as the excess of the closing price of the common stock on the Company&#8217;s principal trading
market over the exercise price of the option at December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise
of stock options as financing cash flows in the consolidated statements of cash flows. For the nine months ended December 31,
2021 and 2020, there were no such tax benefits associated with the exercise of stock options.<b> </b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_zUEqCSby3s5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
7 &#8211; <span id="xdx_82D_zxkyS1vMVZte">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#8217;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to
affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that
all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management
believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company
has recorded a full valuation allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. All tax returns for fiscal
2016 to fiscal 2021 may be subject to examination by the U.S. federal and state tax authorities. As of December 31, 2021, the
Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80F_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zl0wjrUeuXPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
8 &#8211; <span id="xdx_82B_z5GWTZLhenl5">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt"><span style="font-size: 10pt">In
February 2021, the Company&#8217;s chairman of the board of directors and president and an existing investor, who is represented by
a member of the Company&#8217;s board of directors, purchased $100,000 and $1,000,000, aggregate principal amount of the Original
Notes, respectively. Effective April 30, 2021, the related party holders entered into revocation agreements with the Company
pursuant to which their collective $<span id="xdx_907_ecustom--NotesCancelled_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember_zpEpvhCm5JPg"><ix:nonFraction name="modd:NotesCancelled" contextRef="AsOf2021-12-31_custom_CEOAndInvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,100,000</ix:nonFraction></span>
aggregate principal amount of Original Notes and accrued interest of $<span id="xdx_904_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember_zcyifl49Z55f"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2021-12-31_custom_CEOAndInvestorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,091</ix:nonFraction></span>
were replaced with Notes. At December 31, 2021, the investor and executive officer held Notes in an aggregate principal amount of
$<span id="xdx_902_eus-gaap--NotesPayable_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_z3CkvCUhqox5"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,026,630</ix:nonFraction> </span></span><span style="font-size: 10pt; background-color: white">and
$<span id="xdx_906_eus-gaap--NotesPayable_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_z11Y8PN1Hqul"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,663</ix:nonFraction></span></span><span style="font-size: 10pt; background-color: white">,
respectively, with $<span id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_z2tgfwXqwLbf"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,693</ix:nonFraction> </span></span><span style="font-size: 10pt; background-color: white">and
$<span id="xdx_905_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_zOOV3VE30ppc"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,269</ix:nonFraction> </span></span><span style="font-size: 10pt; background-color: white">of
interest payable thereon. For the three months ended December 31, 2021, the Company incurred interest expense of approximately
$<span id="xdx_906_eus-gaap--InterestExpense_c20211001__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zJlsPLO8Ucc3"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-10-012021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,052</ix:nonFraction></span>
and $<span id="xdx_90E_eus-gaap--InterestExpense_c20201001__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zm29wzzYRPh5"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-10-012020-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,105</ix:nonFraction></span>,
respectively, and for the nine months ended December 31, 2021, the Company incurred interest expense of approximately $<span id="xdx_90F_eus-gaap--InterestExpense_c20200401__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zduk0yOy6uCg"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-04-012020-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,693</ix:nonFraction></span>
and $<span id="xdx_90C_eus-gaap--InterestExpense_c20210401__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zWDYuGmYOvei"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-04-012021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8</ix:nonFraction></span>,269,
respectively, on the related party holder Notes.</span></span></p>

<ix:exclude><!-- Field: Page; Sequence: 113; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In May
2021, a member of the Board purchased $<span id="xdx_901_eus-gaap--NotesPayable_iI_c20210531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember_zCkH58G40yP9"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-05-31_custom_MemberOfBoardMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span> aggregate principal amount of Notes (the Director Note). For the three and nine
months ended December 31, 2021, the Company incurred expense of approximately $<span id="xdx_90A_eus-gaap--InterestExpense_c20211001__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_zdzZyZbvd3t4"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-10-012021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,049</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--InterestExpense_c20200401__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_zFDOKrRi1Gb4"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-04-012020-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,110</ix:nonFraction></span>, respectively, on the Director
Note. At December 31, 2021, approximately $<span id="xdx_90F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember_z7AmrHnUNT13"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2021-12-31_custom_MemberOfBoardMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,110</ix:nonFraction></span> of interest was payable by the Company on the Director Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In
October 2021, the Company entered into purchase agreements with <span id="xdx_91E_esrt--ChiefExecutiveOfficerMember_zehMJcD8lkOc">Ellen O&#8217;Connor (Lynn) Vos</span>, the Company&#8217;s chief executive
officer, and <span id="xdx_916_esrt--BoardOfDirectorsChairmanMember_zy02JHBnJS12">Paul DiPerna</span>, the chairman of the Company&#8217;s board of directors and its president, chief financial officer and
treasurer, providing for the sale and issuance by the Company of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20211031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9rvwpXchzH8"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-10-012021-10-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,864</ix:nonFraction></span> shares of the Company&#8217;s common stock, par value
$0.001 per share at the closing market price on October 28, 2021 of $8.10 per share. The Company received proceeds of approximately
$250,000 from the sale of the shares, comprising $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20211031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zUBpGab4RsSe"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-10-012021-10-31_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span> from Ms. Vos and $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20211031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--BoardOfDirectorsChairmanMember_z80d6un24TL6"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-10-012021-10-31_srt_BoardOfDirectorsChairmanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> from Mr. DiPerna.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zbceCCTkrLKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
9 &#8211; <span id="xdx_824_zaPq6zvWTJl9">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><i>Litigations,
Claims and Assessments </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In the
normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course
of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable
settlements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt"><i>Indemnification</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In the
ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties
from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims
and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising
from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses.
The Company has also entered into indemnification agreements with its officers and directors. No amounts were reflected in the
Company&#8217;s consolidated financial statements for the nine months ended December 31, 2021 and 2020 related to these indemnifications.
The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited
history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has
not made any payments related to these indemnification agreements, and no claims for payment have been made under such agreements.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2021-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_znpdYl2pAO33" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
10 &#8211; <span id="xdx_823_zAU6dGNwHE6e">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 9.05pt 0 0; text-align: justify"><span style="font-size: 10pt"><i>Bridge
Note</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 9.05pt 0 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 9.05pt 0 0; text-align: justify"><span style="font-size: 10pt">Subsequent
to December 31, 2021, the Company made additional draws totaling $<span id="xdx_901_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_c20220101__20220214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z7zukpg0ljG8"><ix:nonFraction name="us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet" contextRef="From2022-01-012022-02-14_us-gaap_SubsequentEventMember_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></span> under the Bridge Note.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 114; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 9.05pt 0 0; text-align: justify"><span style="font-size: 10pt"><i><span id="xdx_91F_eus-gaap--IPOMember_zixvTgUUY3Zg">Public
Offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 9.05pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On February
9, 2022, the Company entered into an underwriting agreement (the Underwriting Agreement), with Oppenheimer &amp; Co. Inc.,
which acted as the representative of the several underwriters (the &#8220;Representative&#8221;), in a firm commitment underwritten
public offering (the Offering) pursuant to which the Company agreed to sell to the Representative an aggregate of 2,500,000 shares
of the Company&#8217;s common stock, par value $0.001 per share (the Common Stock), and 2,500,000 warrants (Warrants and, collectively
with the Common Stock, the Units), each to purchase one share of Common Stock, at a public offering price of $6.00 per Unit. The
Warrants included in the Units are exercisable immediately, have an exercise price of $6.60 per share and expire five years from
the date of issuance. The Common Stock was approved to list on the Nasdaq Capital Market under the symbol &#8220;MODD&#8221; and
began trading there on February 10, 2022. The gross proceeds from the Offering were $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_pdp0_dm_c20220209__20220210__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zj4ohTeyRNYf"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-02-092022-02-10_us-gaap_SubsequentEventMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">15</ix:nonFraction> million</span>, before deducting underwriting
discounts and commissions and other offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Units were
offered and sold to the public pursuant to the Company&#8217;s registration statement on Form S-1 (File No. 333-260682), initially
filed by the Company with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the Securities
Act), on November 2, 2021, and declared effective on February 9, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Underwriting
Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification
obligations of the Company and the Representative, including for liabilities under the Securities Act of 1933, as amended,
other obligations of the parties and termination provisions. In addition, pursuant to the terms of the Underwriting Agreement and
related &#8220;lock-up&#8221; agreements, the Company, each director and executive officer of the Company, and certain stockholders
have agreed with the Representative not to offer for sale, issue, sell, contract to
sell, pledge or otherwise dispose of any of our Common Stock or securities convertible into Common Stock for a period of 180 days
after February 9, 2022, the date of the final prospectus.</span></p>

</ix:nonNumeric><p id="xdx_819_zeTcgYKG7Kr9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Modular
Medical, Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modularb006"></span>Consolidated
Balance Sheets</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_111_zLuwwfeNOBfg" summary="xdx: Statement - Condensed Consolidated Balance Sheets (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_49B_20210331_zJsknetPv7Cd" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_498_20200331_z7CjDOSb5Cvb" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AssetsAbstract_iB_zrzqEGjdDjt2" style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">ASSETS</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--AssetsCurrentAbstract_i01B_zMPwF46GGM7h" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">CURRENT ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzxQb_zaTozqaAC46k" style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Cash and cash equivalents</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,468,465</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,122,134</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--PrepaidExpenseCurrent_i02I_maCzxQb_zSrEH8722Wne" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,158</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,853</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--OtherAssetsCurrent_i02I_maCzxQb_zOSRT2Tf79re" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,466</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">306</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--AssetsCurrent_i02TI_mtCzxQb_maCzI4V_zbOlcYP8O6nk" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 34.6pt; text-indent: -8.65pt">TOTAL CURRENT ASSETS</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,649,089</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,186,293</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_i02I_maCzBrL_zpMRFpm4IVKa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Property and equipment,&#160;net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">298,958</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">301,308</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maCzBrL_zryZZsVHcGSa" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Right of use asset, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,124</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">270,950</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--DepositsAssets_i02I_maCzBrL_zrmvtnb2AeWj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Security deposit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--AssetsNoncurrent_i02TI_mtCzBrL_maCzI4V_zLvsw7kIkdE4" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 34.6pt; text-indent: -8.65pt">TOTAL NON-CURRENT ASSETS</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">599,082</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,258</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--Assets_i02TI_mtCzI4V_zuBF0cmvrh01" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 25.95pt; text-indent: -8.65pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,248,171</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,858,551</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zzna8HPNs2c4" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--LiabilitiesCurrentAbstract_i01B_zTkgdSek77Rj" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maCzPnu_z7niGuU3IjXb" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,284</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">367,019</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_i02I_maCzPnu_zr0zUsmrKdli" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,948</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,160</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzPnu_zTph6Riok0L2" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Short-term lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,214</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--UnsecuredDebtCurrent_i02I_maCzPnu_z25kXtNmVWs1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">PPP note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:UnsecuredDebtCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">368,780</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0749">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--ShortTermBankLoansAndNotesPayable_i02I_maCzPnu_zOp1kxGVhed9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Convertible notes payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShortTermBankLoansAndNotesPayable" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,133,453</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0752">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--LiabilitiesCurrent_i02TI_mtCzPnu_maCzs7u_zIXSbOMbtVMh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 25.95pt; text-indent: -8.65pt">TOTAL CURRENT LIABILITIES</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,296,965</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">661,393</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maCzs7u_zGsGSdw9U7K3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Long-term lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">184,355</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,736</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--OtherLiabilitiesNoncurrent_i02I_maCzs7u_zqTpEA1HTKea" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Bonus payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">140,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--Liabilities_i02TI_mtCzs7u_maCztDH_zQoI8dYSpqQh" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 25.95pt; text-indent: -8.65pt">TOTAL LIABILITIES</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,523,320</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">980,129</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--CommitmentsAndContingencies_iI_zmJWRikcS7xj" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 34.6pt; text-indent: -8.65pt">Commitments and Contingencies (Note 10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--StockholdersEquityAbstract_iB_zoZ2A0jzdLgc" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--PreferredStockValue_i02I_maCz5oc_z7ogGekcbRGf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Preferred Stock, $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210331_z9BJIVBGq3L4"><span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20200331_zlmFxHU2syvh"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>&#160;par value, <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20210331_zTBi0OeRBQud"><span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20200331_zOyqD7GoacRg"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_dn_c20210331_zcnH0nSl3nP4"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20210331_zBt30owpjWe1"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_dn_c20200331_zybn0oRExgAi"><span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_dn_c20200331_zAwTgXPSLsN7"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2020-03-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0772">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0773">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--CommonStockValue_i02I_maCz5oc_zRwXmcGQUNeh" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 17.3pt; text-indent: -8.65pt">Common Stock, $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210331_z4X7b7210PTb"><span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20200331_zJnAAdxjedM5"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>&#160;par value, <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20210331_zlxlX5oNLqJ3"><span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20200331_zvYH68dbudFe"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20210331_zFRrCu0NBcGh"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_c20210331_zK01T81Gc3Q8"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,302,050</ix:nonFraction></ix:nonFraction></span></span> shares and <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20200331_zdrLOog7IUNb"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20200331_zLFmJ6EG8N92"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,956,754</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of March 31, 2021 and 2020, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,302</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,957</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AdditionalPaidInCapital_i02I_maCz5oc_ztezYCWvxNVj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,665,559</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,517,505</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--CommonStockIssuable_i02NI_di_msCz5oc_zcVjMfktiwH" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Common stock issuable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0797">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:CommonStockIssuable" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">923,994</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCz5oc_zOCxFQiAiBie" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt; text-indent: -8.65pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,947,010</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,569,034</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_405_eus-gaap--StockholdersEquity_i02I_mtCz5oc_maCztDH_zjjQchjDfDIl" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 34.6pt; text-indent: -8.65pt">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,275,149</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,878,422</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquity_iI_mtCztDH_z3ZtIBRvOg8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 25.95pt; text-indent: -8.65pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,248,171</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,858,551</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">The accompanying notes
are an integral part of these audited consolidated financial statements</span></p>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Modular
Medical, Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modularb007"></span>Consolidated
Statements of Operations</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_113_zwlZnYMokX8g" summary="xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_490_20200401__20210331_zvuuGonH6Xf8" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_49B_20190401__20200331_zKMFsUZG7gjg" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--OperatingExpensesAbstract_iB_zpSQE3WkT4va" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzKWH_zSBR2Ipbscm8" style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; text-align: left; padding-left: 8.65pt">Research and development</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,083,303</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,034,152</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_i01_zdEZO3y1sLyd" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">General and administrative expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,253,412</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,313,870</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--OperatingExpenses_i01T_mtCzKWH_msCzp4b_zg93iQNZLyq5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 25.95pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,336,715</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,348,022</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_i01T_mtCzp4b_maCz4vx_zmdad6hJRyYd" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 17.3pt">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,336,715</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,348,022</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--InterestIncomeExpenseNet_i01_maCz4vx_zNm0Ezpc9LV2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--InterestIncomeOther_i01_z57yYtxPkBX4" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,749</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--InterestExpense_i01N_di_msCz4vx_zNwqhHmWVhQk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Interest expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,791</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0831">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zZ0u3YIw4ZPh" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 17.3pt">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,376,376</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,319,273</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_z5ZThIgFWBd2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Provision for income taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--NetIncomeLoss_i01T_mtCz4vx_z9RK9W8Ha5Md" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left; padding-left: 17.3pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,377,976</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,320,873</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--EarningsPerShareAbstract_iB_z7AECqWCCRH5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--EarningsPerShareBasic_i01_zptdAmdKrW0b" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.19</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.89</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_iB_zdQmUr1tuPR1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Shares used in computing net loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_zawepLOFMmbf" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,211,562</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,954,923</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">The accompanying notes
are an integral part of these audited consolidated financial statements</span></p>
<!-- Field: Page; Sequence: 117; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Modular
Medical, Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modularb008"></span>Consolidated
Statements of Stockholders&#8217; Equity (Deficit)</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_114_zDAqHQziyj64" summary="xdx: Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Deficit) (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zBiHlWtpIe09" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zMuO4TZ0jL6i" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_custom--CommonStockIssuableMember_zfVrolVFRejg" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zK3WEOE5Hywi" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B0_zPMzg2yh5eQe" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Common Stock</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Additional<br /> Paid-In</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Common Stock</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Accumulated</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Stockholders&#8217;</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; padding-left: 8.65pt; text-indent: -8.65pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Capital</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Issuable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Deficit</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Equity (Deficit)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_430_c20190401__20200331_eus-gaap--StockholdersEquity_iS_zZKYrWvRhQy1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 28%; font-weight: bold; text-indent: -8.65pt; padding-left: 8.65pt">Balance as of March 31, 2019</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_c20190401__20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNnvsVcuLQ3c" style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,946,754</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,947</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,696,471</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_custom_CommonStockIssuableMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,800</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,248,161</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,474,057</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_43A_c20190401__20200331_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zkMP52N1uWKi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Placement of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0862">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-04-012020-03-31_custom_CommonStockIssuableMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">923,994</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0864">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">923,994</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43E_c20190401__20200331_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zjeuziWSkIM5" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Shares issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20190401__20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoWyKDjupCjb" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2019-04-012020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2019-04-012020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2019-04-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,790</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2019-04-012020-03-31_custom_CommonStockIssuableMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,800</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0870">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43B_c20190401__20200331_eus-gaap--ShareBasedCompensation_zMDQfBuQLYcd" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0874">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-04-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">801,244</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0876">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0877">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">801,244</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_433_c20190401__20200331_eus-gaap--NetIncomeLoss_zF642jJfSPv1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0880">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0881">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0882">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,320,873</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,320,873</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_432_c20200401__20210331_eus-gaap--StockholdersEquity_iS_zOq31stEf0p1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-indent: -8.65pt; padding-left: 8.65pt">Balance as of March 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlh6fcmPzSa7" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,956,754</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,957</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,517,505</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_custom_CommonStockIssuableMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">923,994</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,569,034</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,878,422</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_430_c20200401__20210331_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zDVAgHPvMRni" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Placement of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXnkIjKcdFy" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">320,796</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">321</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,709,555</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">923,994</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0896">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,785,882</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43C_c20200401__20210331_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zSAzbma3F8yh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Shares issued for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z532Txk2PcQe" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,920</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0902">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0903">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,945</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_431_c20200401__20210331_eus-gaap--ShareBasedCompensation_zdF45w53Oehf" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0907">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,227,578</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0909">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0910">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,227,578</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_438_c20200401__20210331_eus-gaap--NetIncomeLoss_zWga4JDVFgkc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0913">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0914">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0915">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,377,976</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,377,976</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_435_c20200401__20210331_eus-gaap--StockholdersEquity_iE_zH9VTuTQKoH3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-indent: -8.65pt; padding-left: 8.65pt">Balance as of March 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20200401__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztrLChkzcsDf" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,302,050</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,302</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,665,559</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0921">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,947,010</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,275,149</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-indent: -8.65pt; padding-left: 8.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">The accompanying notes
are an integral part of these audited consolidated financial statements</span></p>
<!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Modular
Medical, Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modularb009"></span>Consolidated
Statements of Cash Flows</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_112_zJe7U9lWWVc" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_499_20200401__20210331_zEHxvR9gP8I9" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td>
    <td id="xdx_49E_20190401__20200331_zVtYiMeNZRtb" style="white-space: nowrap; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Cash Flows from operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--NetIncomeLoss_zNnK1fHOZ964" style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; text-align: left">Net loss</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,377,976</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,320,873</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_404_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_iB_z8BDAeWcEbk5" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i01_zcG7UsWN4YL1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,227,578</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">801,244</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DepreciationAndAmortization_i01_zufEbQLkvBZf" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,015</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,431</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i01_zWs7a9dLG4N1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Shares for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,880</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0939">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i01_z3QwLIyHYoah" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Amortization of lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,826</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0942">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_ecustom--IncreaseDecreaseInLeaseLiability_i01_zn1rV3LFrHX5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Change in lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="modd:IncreaseDecreaseInLeaseLiability" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,905</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0945">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AmortizationOfDebtDiscountPremium_i01_z3goiiZxNWr7" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Amortization of debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,253</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0948">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--IncreaseDecreaseInOtherAccountsPayable_i01_zOdkCfLm5lEg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,004</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0951">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_i01B_zVkoFcDrg1h1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Changes in assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i02N_di_zQNsIKprMygg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Other assets and prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,391</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_400_eus-gaap--IncreaseDecreaseInSecurityDeposits_i02_zBs1XCJfhtMf" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Security deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0959">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInSecurityDeposits" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">92,500</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40D_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_zlTfdqcTu5B6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Accounts payable and accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">86,747</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">530,250</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_maCzXv3_zjgDTRf90uz3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,908,662</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,094,839</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zUWTku0UgMRc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_iN_di_zRH4M5k95JX1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Purchases of property and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,669</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">260,789</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzznH_maCzXv3_z7e5llJGpko9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net cash used in investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">109,669</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">260,789</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zusB4eqLaIdl" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_i01_pp0p0_maNCPBUz69e_zFoloTADCtI5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Proceeds from private placement, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,785,882</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">923,994</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--ProceedsFromConvertibleDebt_i01_pp0p0_maNCPBUz69e_z0JU917xMfLb" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Proceeds from issuance of convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,210,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0984">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--ProceedsFromNotesPayable_i01_pp0p0_maNCPBUz69e_zQtW2i18oGKc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Proceeds from issuance of PPP note payable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">368,780</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0987">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzBRg_maCzXv3_zLA7ACprHNv" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,364,662</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">923,994</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCzEHg_zHSoS6GHUSE1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net decrease in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,653,669</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,431,634</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iS_zIrwHzsqJfg1" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Cash and cash equivalents, at beginning of year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,122,134</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,553,768</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iE_z4wi5rPn29Fc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash and cash equivalents, at end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,468,465</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,122,134</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_iB_zuiLwv581jei" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash paid for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--IncomeTaxesPaidNet_z6mmMsJUxsg2" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><span style="font-size: 10pt">The accompanying
notes are an integral part of these audited consolidated financial statements</span></p>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p id="xdx_043_c20200401__20210331_zAlUdpLZZ89i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MODULAR
MEDICAL, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="modularb010"></span>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zGT6BSgYLNs4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>Note&#160;1 &#8211; <span id="xdx_82E_zMUTozRktbd4">THE COMPANY
AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Modular Medical,
Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material
business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras,
Inc., a Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras,
the share exchange was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras,
acquired in the merger, at their historical carrying amounts. Prior to the acquisition of Quasuras and, since at least 2002, the
Company was a shell company, as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act).
In June 2017, the Company changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
is a development-stage medical device company focused on the design, development and eventual commercialization of an innovative
insulin pump to address shortcomings and problems represented by the relatively limited adoption of currently available pumps
for insulin-dependent people with diabetes. The Company has developed a hardware technology allowing people with insulin-dependent
diabetes to receive their daily insulin in two ways, through a continuous &#8220;basal&#8221; delivery allowing a small amount
of insulin to be in the blood at all times and a &#8220;bolus&#8221; delivery to address meal time glucose input and to address
when the blood glucose level becomes excessively high. By addressing the time and effort required to effectively treat their condition,
the Company believes it can address the less technically savvy, less motivated part of the market. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt">The consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United
States of America. The following summarizes the more significant of such policies:&#160;</span></p>

<ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:LiquidityPolicyTextBlock"><p id="xdx_843_ecustom--LiquidityPolicyTextBlock_z4QrIhxBDxHj" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0"><span style="font-size: 10pt"><b><span id="xdx_86D_zDQdXEmUbbvb">Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="font-size: 10pt">Financial
Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15),&#160;<i>Going&#160;</i>Concern,
requires management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt
about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are
issued.&#160;If management identifies conditions or events that raise substantial doubt about an entity&#8217;s ability to continue
as a going concern, management must consider if there are plans that are probable to be implemented, and whether it is probable
that the plans will mitigate the conditions or events raising the substantial doubt about the entity&#8217;s ability to continue
as a going concern.&#160;If the substantial doubt is not alleviated after consideration of management&#8217;s plans, the entity
must include a statement in the notes to the financial statements indicating that there is substantial doubt about the entity&#8217;s
ability to continue as a going concern within one year after the date that the financial statements are issued including: 1) the
principal conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern, 2)
management&#8217;s evaluation of the significance of those conditions or events in relation to the entity&#8217;s ability to meet
its obligations, and 3) management&#8217;s plans to attempt to mitigate the conditions or events causing the substantial doubt
about the entity&#8217;s ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The Company
expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development
and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant
product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#8217;s ability to continue
as a going concern within one year after the date that these consolidated financial statements are issued. Implementation of the
Company&#8217;s plans and its ability to continue as a going concern will depend upon the Company&#8217;s ability to raise additional
capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance
that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available,
that such capital will be offered on terms and conditions acceptable to the Company.&#160; As discussed in notes 3 and 11, in
February 2021, the Company commenced a private placement of its convertible promissory notes to investors to fund its operations.
In addition, during fiscal 2021, the Company obtained additional equity financing through a private placement of its common stock
(see note 6), and the Company obtained a loan from Silicon Valley Bank in April 2020 (see notes 3 and 12).</span></p>

<ix:exclude><!-- Field: Page; Sequence: 120; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company&#8217;s
operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital
expenditures. The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many factors,
including the Company&#8217;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement
its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash. These consolidated financial statements
do not include any adjustments that might result from this uncertainty.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z2QiEAE6btr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_862_zgcZE7UT1anf">Basis of
Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The consolidated
financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany
transactions and balances have been eliminated in consolidation. The Company&#8217;s fiscal year ends on March 31 of each calendar
year.<b>&#160;</b>Certain prior year amounts have been reclassified for consistency with the current period presentation. These
reclassifications had no effect on the reported results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_841_eus-gaap--UseOfEstimates_zjb03aSEOl9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86E_zkVTFpwCYJTh">Use of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The preparation
of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues
and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income
taxes. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zEBGwLnCl838" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_861_zYSzqPmtkea">Reportable Segment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The Company operates in one business
segment and uses one measurement of profitability for its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_z5RHgVDh9VL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_868_zhvjzB3hriT2">Concentration
of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Financial instruments
that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents. Cash and
cash equivalents are deposited with high credit-quality institutions within the United States, which are insured by the Federal
Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:RisksAndUncertaintiesPolicyTextBlock"><p id="xdx_84F_ecustom--RisksAndUncertaintiesPolicyTextBlock_zU4HzJXoI7S" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86F_zvwI2K5ZXTqd">Risks and
Uncertainties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public
markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><i>COVID-19</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The global
outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply
chains, significantly restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in-place&#8221;
and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#8217;s operational
and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions
taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company&#8217;s
control, and cannot be predicted.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 121; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>



</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zRAzlxQ0y94d" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_863_z90kSs4OLyka">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Cash and cash
equivalents include cash in hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with
original maturities of three months or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_844_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zk1Cd3Wid9k2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_867_zUcEsPUJ4DLc">Property and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Property and
equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxH_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z0PB92ihRM74" title="::XDX::P3Y">three</span> to <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxH_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zVoGulgcYkX2" title="::XDX::P5Y">five</span> years. Depreciation is recorded in operating expenses in the consolidated statements of
operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated
useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zhjQ4qzLxNwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_86B_z3q4LBjYHSv1">Fair Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs
    that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial
    instrument.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Due to their
short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIDNnS7C5Ryi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86F_zIfOdHenFOg9">Research
and Development</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
expenses research and development expenditures as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock"><p id="xdx_84A_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zslkeDbN2qj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86D_zGAah61b4eJa">General and
Administrative</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">General and
administrative expense consists primarily of payroll and benefit related costs, rent, office expenses, equipment supplies and
meetings and travel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_849_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z3Tp69wE9iP" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_869_zNRpWSNYg7F3">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the
requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock
options on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards
on the date of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number
of highly complex and subjective variables. These variables include, but are not limited to, the expected stock price&#160;volatility
over the term of the awards, and projected stock option exercise behaviors.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 122; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>



</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_z04lF1yOv96e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86B_zNciwlCAEoM4">Per-Share
Amounts&#160;</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Basic net loss
per share is computed by dividing net loss for the period by the weighted-average number of shares of common stock outstanding
during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period.
For the years ended March 31, 2021 and 2020, <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20210331_z7FZlwLQa8h7"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,197,252</ix:nonFraction></span> and <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190401__20200331_zKybxb95oDpl"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,059,315</ix:nonFraction></span> outstanding options to purchase common stock were excluded
from the calculation of diluted net loss per share because their effect would be anti-dilutive. &#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zPlCSJXYVvMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_863_zszo70i8EdZa">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#8217;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to
affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that
all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management
believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company
has recorded a full valuation allowance.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
accounts for uncertain tax positions in accordance with FASB Accounting Standards Codification (ASC) Topic 740,&#160;<i>Income
Taxes</i>. When tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing
authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that
would be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements in the period
during which, based on all available evidence, management believes it is more likely than not that the position will be sustained
upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated
with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount
of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The
portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as
a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and
penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits
is classified as interest expense and penalties are classified in selling, general and administrative expenses in the consolidated
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. All tax returns
from 2016 to 2020 may be subject to examination by the U.S. federal and state tax authorities.&#160; As of March 31, 2021, the
Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zkBl9gDn6xMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86B_z6I11cISyor1">Comprehensive&#160;Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly,
comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2021 and
2020, the Company&#8217;s comprehensive loss was the same as its net loss.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 123; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>



</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:ConsolidatedBalanceSheetDetailTextBlock"><p id="xdx_803_ecustom--ConsolidatedBalanceSheetDetailTextBlock_zFH8XpydeD68" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE&#160;2 &#8211; <span id="xdx_829_zEATFVQb0qp3">CONSOLIDATED
BALANCE SHEET DETAIL</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_892_eus-gaap--PropertyPlantAndEquipmentTextBlock_zndr6DZw71U1" style="margin: 0"><span style="font-size: 10pt"><span id="xdx_8BE_zHWRXpwdOD49" style="display: none">Schedule of
Property Plant And Equipment</span></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:DisclosureConsolidatedBalanceSheetDetailsAbstract"><table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureConsolidatedBalanceSheetDetailsAbstract_z7p2IfHAlRqh" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1pt"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_49F_20210331_zCz7v32xtXAa" style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"></td>
    <td id="xdx_49A_20200331_zD6jfVUXPyoa" style="white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: left">Property and equipment, net:</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z3BPmqjQLSv9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Leasehold improvements</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-03-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,197</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-03-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,197</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zcwACcdJH1u3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-03-31_us-gaap_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,476</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-03-31_us-gaap_OfficeEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,724</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zTWOHfvNRM33" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Computer equipment and software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-03-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,383</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-03-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,882</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zXXrzTWCcmC8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Machinery and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-03-31_us-gaap_MachineryAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,993</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-03-31_us-gaap_MachineryAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,198</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_zhStRP3g6Mdk" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td><span style="display: none">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">451,049</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">353,001</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_z8azUF3TJ1jj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,091</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,693</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td><span style="display: none">Property and equipment, net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">298,958</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">301,308</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p id="xdx_8A4_z8yDspHtdiad" style="margin: 0"></p>

<ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zizSZirDdEgi" style="margin: 0"><span id="xdx_8B4_zcJkXV60NCF2" style="display: none">Schedule of Accrued Expenses</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:DisclosureConsolidatedBalanceSheetDetails2Abstract"><table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureConsolidatedBalanceSheetDetails2Abstract_z3esqbaMX4Bg" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49D_20210331_zahbdjG7U326" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_495_20200331_z11U9drwWqZ2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>

<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: left; padding-bottom: 1pt">Accrued expenses:</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedWagesAndBonusMember_zZVbo88qYMUi" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Accrued wages and bonus</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2021-03-31_custom_AccruedWagesAndBonusMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">372,563</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2020-03-31_custom_AccruedWagesAndBonusMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">198,160</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedPlacementFeesMember_zMdz7KVF6jZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued placement fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2021-03-31_custom_AccruedPlacementFeesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1075">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedInterestMember_zjTar9XFERn" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2021-03-31_custom_AccruedInterestMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,538</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1078">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedOtherExpensesMember_zyN8mqgMrjL" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2021-03-31_custom_AccruedOtherExpensesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,047</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2020-03-31_custom_AccruedOtherExpensesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_zdCf18Aoa407" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt"><span style="display: none">Accrued expenses</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,948</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,160</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p id="xdx_8A6_zujoonP5i0A8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_z239wqwiF2ui" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 3 &#8211; <span id="xdx_82D_zcREI3129Eqe">NOTES PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>PPP Note</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On April 24,
2020, the Company received a $368,780 unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was
established under the U.S. government&#8217;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note
to the Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration
Paycheck Protection Program Note (the Agreement) with the Lender evidencing the PPP Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 73.35pt 0 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The full amount
of the PPP Note is due in April 2022. Interest will accrue on the outstanding principal balance of the PPP Note at a fixed rate
of 1.0% per annum, which shall be deferred for 10 months after the covered period during which the Company used the proceeds.
The Company may prepay principal of the PPP Note at any time in any amount without penalty. The Agreement contains customary events
of default relating to, among other things, payment defaults, breach of representations and warranties or provisions of the PPP
Note. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts
owing from the Company, and/or filing suit and obtaining judgment against the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
applied to the Lender for forgiveness of the PPP Note in October 2020, and the amount which may be forgiven will be equal to the
sum of the payroll and benefit costs and covered rent and utility payments incurred by the Company, as calculated in accordance
with the terms of the CARES Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Convertible
Promissory Notes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">In
February and March 2021, the Company sold $2,210,000 of convertible promissory notes (the Notes), at par in a private placement
transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended
(the 2021 Placement). The Notes bear interest at an annual rate of 12%, and interest is accrued or payable monthly in cash. The
Notes mature on September 30, 2021 (the Maturity Date) and may be prepaid prior to the Maturity Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">The
aggregate principal amount of the Notes plus accrued but unpaid interest thereon shall automatically convert upon the closing
of an offering of the Company&#8217;s equity securities to investors or a strategic corporate investor resulting in aggregate
gross proceeds to the Company of at least $5,000,000 (excluding conversion of the Notes or other convertible securities issued
for capital raising purposes) (a Qualified Financing). In the event of a Qualified Financing, all such outstanding principal and
accrued interest shall convert into the same equity securities purchased by and on the same terms and conditions as the other
investors in such Qualified Financing at a conversion price equal to 80% (a 20% discount) of the lowest price paid per unit or
share by investors in the Qualified Financing. In the event that additional bridge financing is obtained by the Company, the Notes
shall convert into the same securities and on the same terms and conditions as the other investors therein and all such purchases
will be treated as one, single round of financing going forward. As of March 31, 2021, the Notes could be converted into 770,305
shares of common stock, excluding the effects of any payments of interest in kind.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 124; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">At
any time on or following the Maturity Date, the holders of the Notes may demand repayment of the Notes, and the Company shall
repay the outstanding aggregate principal amount plus accrued but unpaid interest thereon. The holders of the Notes, however,
retain the right for 30 days after the Maturity Date to convert all or part of the aggregate principal amount plus accrued but
unpaid interest on the Notes into the Company&#8217;s common stock at the conversion price of $2.87 per share or at a 20% discount
to any financing consummated during the 30-day period following the Maturity Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">If
a Qualified Financing has not occurred immediately prior to the consummation of a Change of Control (as defined below), the Note
holders shall have the option of either (i) converting all or any portion of the aggregate principal amount of the Notes plus
accrued but unpaid interest thereon into common stock of the Company at a conversion price equal to $2.87 per share or (ii) having
the Company repay the aggregate principal amount of the Notes and accrued but unpaid interest. The term &#8220;Change of Control&#8221;
means (i) a consolidation or merger of the Company with or into any other corporation or other entity or person, or any other
corporate reorganization, other than any such consolidation, merger or reorganization in which the shares of capital stock of
the Company immediately prior to such consolidation, merger or reorganization continue to represent a majority of the voting power
of the surviving entity immediately after such consolidation, merger or reorganization; (ii) any transaction or series of related
transactions to which the Company is a party in which in excess of 50% of the Company&#8217;s voting power is transferred; (iii)
the sale or transfer of all or substantially all of the Company&#8217;s assets, or the exclusive license of all or substantially
all of the Company&#8217;s material intellectual property; or (iv) the dissolution and winding up of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
incurred debt issuance costs of $88,800, which were recorded as a debt discount and are being amortized to interest expense over
the term of the Notes using the effective interest rate method. The interest expense related to the debt discount during
the year ended March 31, 2021 was approximately $13,000.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:LeasesOfLesseeDisclosureTextBlock"><p id="xdx_804_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zI2D2UliU05h" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 4 &#8211; <span id="xdx_825_zi2Nz2cefmjg">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Effective April 1,
2019, the Company adopted ASC No. 842, as amended, using the alternative transition method, which allowed the Company to initially apply
the new lease standard at the adoption date (the &#8220;effective date method&#8221;). In January 2020, the Company executed a lease
for a new, larger corporate facility in San Diego, California&#160;<span style="background-color: white">and paid a $100,000 security
deposit.</span> The <span id="xdx_900_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxH_c20200402_z1KFBhPCaoOa" title="::XDX::P39M">39-month</span>
lease term commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $<span id="xdx_905_eus-gaap--LeaseAndRentalExpense_c20200401__20200430_zSDH0uPGgrS6"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2020-04-012020-04-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,400</ix:nonFraction></span></span><span style="font-size: 10pt; background-color: white">&#160;with
annual rent increases of approximately <span id="xdx_902_ecustom--OperatingLeasesAnnualRentIncreasePercentange_iI_c20200402_zZhDUxsMKzcl"><ix:nonFraction name="modd:OperatingLeasesAnnualRentIncreasePercentange" contextRef="AsOf2020-04-02" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction>%</span></span><span style="font-size: 10pt; background-color: white">.&#160;In
addition to the minimum lease payments, the Company is responsible for property taxes, insurance and certain other operating costs. The
right-to-use asset and corresponding liability for the facility lease have been measured at the present value of the future minimum lease
payments. A discount rate of 11%, which approximated the Company&#8217;s incremental borrowing rate, was used to measure the lease asset
and liability. Lease expense is recognized on a straight line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
obtained a right-of-use asset of $<span id="xdx_908_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20210401__20210630_z2G2AIje6xNg"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">270,950</ix:nonFraction></span> in exchange for its obligations under the operating lease. The landlord also provided
a lease incentive of approximately $<span id="xdx_908_ecustom--LeaseIncentiveReceived_iI_c20200630_zKiJo3oTJbY7" title="Lease Incentive Received"><ix:nonFraction name="modd:LeaseIncentiveReceived" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,000</ix:nonFraction></span>, which was paid to the Company in June 2020, for the Company to make improvements
to the leased space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>


<ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zwsEbf5hBpr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8B4_z4ymE4sowwz9">Future minimum
payments under the facility operating lease, net of the lease incentive</span>, as of March 31, 2021, are listed in the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:DisclosureLeasesDetailsAbstarct"><table cellspacing="0" cellpadding="0" id="xdx_88A_ecustom--DisclosureLeasesDetailsAbstarct_zaw73crHXSE8" summary="xdx: Disclosure - LEASES (Details)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20210331_zrL4AFPyLXnl" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Operating</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><b>Annual
    Fiscal Years</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>lease</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_zVkfNZy9FY0h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 87%"><span style="font: 10pt Times New Roman, Times, Serif">2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,432</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_znDX2jMH8Bvk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,028</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_zuf1bKMgk1Tf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,692</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Less:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_ecustom--OperatingLeasesImputedInterest_iI_zAvxbfezdWk1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Imputed
    interest</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="modd:OperatingLeasesImputedInterest" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42,297</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_zBAFDAn0JDSa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Present value
    of lease liabilities</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">309,855</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
</table></ix:nonNumeric>
<p id="xdx_8A3_zaIbd7vh93P6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Rent expense
was $<span id="xdx_90E_eus-gaap--LeaseAndRentalExpense_c20200401__20210331_zjo2lo5EhDg1"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,540</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--LeaseAndRentalExpense_c20190401__20200331_zu0OXP6pJkSg"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,766</ix:nonFraction></span> for the years ended March&#160;31, 2021 and 2020, respectively.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 125; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>



</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock"><p id="xdx_808_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zjUWhAWCd1K7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE 5 &#8211;
<span id="xdx_82A_zCTmmfmICWHf">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Equity Compensation
Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In October 2017,
the Company&#8217;s board of directors (the Board) approved the 2017 Equity Incentive Plan (the 2017 Plan) with 3,000,000 shares
of common stock reserved for issuance. In January 2020, the Board approved an amendment to the 2017 Plan to increase the number
of shares reserved for issuance by 1,000,000 shares. Under the 2017 Plan, eligible employees, directors and consultants may be
granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards
and restricted stock units. The 2017 Plan is administered by the Board or, in the alternative, a committee designated by the Board.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The exercise
or purchase price of a stock option shall be calculated as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
    the case of an incentive stock option, (a) granted to employees, who, at the time of the grant of such incentive stock option
    own stock representing more than 10% of the voting power of all classes of stock of the Company, the per share exercise price
    shall be not less than 110% of the fair market value per share on the date of grant; or (b) granted to employees, other than
    to employees, described in the preceding clause, the per share exercise price shall be not less than 100% of the fair market
    value per share on the date of grant;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
    the case of a non-qualified stock option, the per share exercise price shall be not less than 100% of the fair market value
    per share on the date of grant unless otherwise determined by the Board; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(iii) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
    the case of other grants, such price as determined by the Board.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Board
is responsible for determining the consideration to be paid for the shares of common stock to be issued upon exercise or purchase.
The 2017 Plan generally does not allow for the transfer of awards, and the Board may amend, suspend or terminate the 2017 Plan
at any time.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Stock-Based
Compensation Expense</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The expense
relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period,
based on the grant date fair value. The unamortized compensation cost, as of March 31, 2021 was $2,242,352 related to stock options
and is expected to be recognized as expense over a weighted-average period of approximately 2 years.&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
the year ended March 31, 2021, options granted to purchase shares of its common stock to employees, directors and consultants
had 10-year terms and a grant-date fair value of $1,101,737. Options to purchase 10,476 shares vested immediately on the respective
grant dates.&#160;</span></p>

<ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zvYq7IF9JyI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The following <span id="xdx_8B5_zlf1rY5Degjc">assumptions were used
in the fair-value method calculations</span>:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:DisclosureStockBasedCompensationDetailsAbstract"><table cellspacing="0" cellpadding="0" id="xdx_882_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zoHuDK6s0nT1" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Year
    ended March 31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2021</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 75%"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rates</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z3WdONB4SZo3" title="Risk-free interest rates"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-04-012021-03-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.28</ix:nonFraction>%</span>
    - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zKXqL9Ish2u2"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-04-012021-03-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.71</ix:nonFraction>%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zUL6Ejt736V7"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2019-04-012020-03-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.77</ix:nonFraction>%</span>
    - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zm1j5c8ajwF2"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2019-04-012020-03-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.37</ix:nonFraction>%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zTa7ch8pmPZj" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-04-012021-03-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">87</ix:nonFraction>%</span>
    - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_ziVZpTGts1Ki"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-04-012021-03-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">127</ix:nonFraction>%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zYHYFJV41tZa"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2019-04-012020-03-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">86</ix:nonFraction>%</span>
    - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zC5IcFOdVVE6"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2019-04-012020-03-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">103</ix:nonFraction>%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    life (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zxbZfBQ3IN0l" title="Expected Life (years)"><ix:nonNumeric contextRef="From2020-04-012021-03-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric></span>
    - <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_z1TUxfEn4EG1"><ix:nonNumeric contextRef="From2020-04-012021-03-31_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.0</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zRjo0fMiYtB4"><ix:nonNumeric contextRef="From2019-04-012020-03-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric></span>
    - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zjseC5rpXBNk"><ix:nonNumeric contextRef="From2019-04-012020-03-31_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.0</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Dividend
    yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zznV59JTlHzb"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-04-012021-03-31_srt_MinimumMember" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction>%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zzPv2kfTG5L1"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2019-04-012020-03-31_srt_MinimumMember" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction>%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table></ix:nonNumeric>
<p id="xdx_8AC_zuhRbsCVqLn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The fair values
of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to
establish the fair term of options as well as average volatility of three comparable organizations. The risk-free interest rate
was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date
for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid
dividends and has no intention to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts
for forfeitures as they occur.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 126; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>


<ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_znsC7EV5wvie" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">A summary of <span id="xdx_8BD_zo1WcKMoXVka">stock option activity
</span>under the 2017 Plan is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:DisclosureStockBasedCompensationDetails2Abstract"><table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zJSj4aqevOpc" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Available</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted Average</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2019</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331_zLweyHt3pxQh" title="Shares available for grant, beginning" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">490,031</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVmGRDLvVbFb" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">509,969</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRzl68rEqYJl" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.56</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_c20190401__20200331_zhAdxgDFNffd" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">333,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_iN_di_c20190401__20200331_zPsMwIKwoQAc" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">572,402</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMPyaRvRz9dd" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2019-04-012020-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">572,402</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zng6yBVex3Pe" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2019-04-012020-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.75</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20190401__20200331_zfYa8LQ4ZHWg" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,056</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2NYijcemSPe" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2019-04-012020-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,056</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlC05erYxvwe" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2019-04-012020-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.75</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Balance at March 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331_z15feRx4wrj7" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">274,019</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1nYosdl6G92" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,059,315</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5YLernKnlpk" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.74</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_iN_di_c20200401__20210331_zJggddizapdi" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">163,492</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLCxmcLIOV75" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">163,492</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZXcbDKJQol3" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.64</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20200401__20210331_zkXgvpN0sYMi" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,555</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZ7eE89lFage" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,555</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbhsQtPUzcSh" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.75</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at March 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331_zye6aVSk8FA5" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">136,082</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znw72iivgn5k" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,197,252</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0YFfXOhuZWl" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.25</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p id="xdx_8A4_zCZ32lEJywa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">There were no
stock options exercised during the years ended March 31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z4MDAK8NLx19" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table <span id="xdx_8BD_z7khsmxDY1Ib">summarizes the range of outstanding and exercisable options</span> as of March 31, 2021:</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:DisclosureStockBasedCompensationDetails3Abstract"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zjQ9JdEOW2z5" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br /> Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br /> Average<br /> Remaining<br /> Contractual<br /> Life<br /> (in Years)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br /> Average<br /> Exercise<br /> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br /> Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br /> Average<br /> Exercise<br /> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<br /> Intrinsic<br /> value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt">$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zzRBzMxdOvJi"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.98</ix:nonFraction></span> - $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zxDphhvUO3l4"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.48</ix:nonFraction></span></td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zs1oFVpZzC45" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,197,252</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtYxH_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDF6lDyhHc4a" title="::XDX::P8Y4M" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">8.25</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zz6JFas6hN48" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.25</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhDEwU7OVCq4" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">742,913</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtYxH_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zD0TjOxu1WX7" title="::XDX::P3Y11M16D" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">3.96</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoZStRXd9JH2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="AsOf2021-03-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,763,260</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table></ix:nonNumeric>

<p id="xdx_8AB_zRfPGIO5nMhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The intrinsic
value per share is calculated as the excess of the closing price of the common stock on the Company&#8217;s principal trading
market over the exercise price of the option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise
of stock options as financing cash flows in the consolidated statements of cash flows. For the years ended March 31, 2021 and
2020, there were no such tax benefits associated with the exercise of stock options.<b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_ziV6Qcjuipug" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 6 &#8211; <span id="xdx_820_zIsr1RW0bfL9">STOCKHOLDERS&#8217;
EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Private Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Between March
and December 2020, the Company completed a private placement of shares of its common stock (the 2020 Placement). The Company sold
<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200401__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsybujndopYi"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-04-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">320,796</ix:nonFraction></span> shares of common stock, at a purchase price of $8.61 per share, for gross proceeds of $2,762,054. The Company paid placement
agent fees on the 2020 Placement of $52,256 during fiscal 2021. Under the terms of the common stock purchase agreements between
the Company and the investors, the Company must use commercially reasonable efforts to file a registration statement with the
SEC to register for resale the shares of common stock sold.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 127; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 &#8211; INCOME TAXES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"><span style="font-size: 10pt">The income tax provision (benefit)
consisted of the following:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Current portion:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.9pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; padding-bottom: 1pt; padding-left: 8.9pt">State</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1,600</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1,600</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Deferred portion:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.9pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,931,390</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,180,434</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 1pt; padding-left: 8.9pt">State</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(576,868</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(391,865</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,508,258</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,572,299</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,508,258</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,572,299</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"><span style="font-size: 10pt">As of March 31, 2021,
the Company had net operating loss carryforwards (NOLs) of approximately $13,954,000 for federal income tax purposes and $14,019,000
for state income tax purposes. These NOLs are available to reduce future taxable income and will expire at various times from 2037 through
2041, except federal NOLs from fiscal 2018, 2019 and 2020 which will never expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"><span style="font-size: 10pt">The Company
also had federal research and development tax credit carryforwards of approximately $535,000, which will begin expiring at various times
from 2038 through 2040, and state research and development credits of approximately $141,000, which do not have an expiration date.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"><span style="font-size: 10pt">A reconciliation of
income taxes provided at the federal statutory rate (21% for fiscal 2021 and 2020) to the actual income tax provision is as follows:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Federal statutory rate</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State tax rate, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Section 179 assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">34</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">31</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Significant components of the Company&#8217;s
deferred tax assets and liabilities were:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Net operating loss carryforwards</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,909,434</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,965,118</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">554,892</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">364,989</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,039</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,842</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reserves, accruals &amp; other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(79,878</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,181</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt">Research and development tax credits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">646,296</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">237,716</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.9pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,012,705</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,567,484</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,012,705</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,567,484</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 8.9pt">Deferred tax assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Based on the available
information and other factors, management believes it is more likely than not that the net deferred tax assets at March 31, 2021 and
2020, will not be fully realizable. Accordingly, management has recorded a full valuation allowance against its net deferred tax assets
at March 31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 0.5in"><span style="font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Management has evaluated
and concluded that there were no material uncertain tax positions requiring recognition in the Company&#8217;s consolidated financial
statements at March 31, 2021 and 2020. The Company does not expect any significant changes in its unrecognized tax benefits within twelve
months of the reporting date.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 128; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>



</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:RoyaltyAgreementDisclosureTextBlock"><p id="xdx_803_ecustom--RoyaltyAgreementDisclosureTextBlock_zkaeltItnZK7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 8 &#8211; <span id="xdx_825_zCbrVhHYqJ95">ROYALTY AGREEMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In July 2017,
the Company entered into a royalty agreement with its founder, chief executive officer and major shareholder (the Founder). Pursuant
to the agreement, the Founder assigned and transferred all of his rights in the intellectual property of Quasuras in return for
future royalty payments on the Company&#8217;s product. The Company is obligated to make royalty payments under the agreement
to the Founder on any sales of the royalty product sold or otherwise commercialized by the Company equal to (a) $0.75 on each
sale of a royalty product or (b) 5% of the gross sale price of the royalty product, whichever is less. The royalty payments will
cease, and the agreement will terminate, at such time as the total sum of royalty payments actually paid to the Founder, pursuant
to the agreement, reaches $10,000,000. The Company has the option to terminate the agreement at any time upon payment, to the
Founder, of the difference between total royalty payments actually made to him to date and the sum of $10,000,000. All payments
of the royalties, if due, for the preceding quarter, will be made by the Company to the Founder within thirty days after the end
of each calendar quarter.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="modd:RetirementSavingsPlanDisclosureTextBlock"><p id="xdx_802_ecustom--RetirementSavingsPlanDisclosureTextBlock_zX9EcFTxDFYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 9 &#8211; <span id="xdx_822_zQx4uQmdvPXg">RETIREMENT SAVINGS
PLAN</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Effective March
2020, the Company adopted the Modular Medical, Inc. 401(k) Plan (the Savings Plan), which qualifies as a thrift plan under Section&#160;401(k)
of the Internal Revenue Code. Full-time and part-time employees who are at least 21&#160;years of age are eligible to participate
in the Savings Plan at the time of hire. Participants may contribute up to 15% of their earnings to the Savings Plan. The Plan
became effective and began accepting participant contributions in April 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zeBo7ziYRPG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE 10 &#8211;
<span id="xdx_820_zkGXOVMGfxh7">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Litigations,
Claims and Assessments&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the normal
course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of
business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable
settlements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Indemnification</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the ordinary
course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties
from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims
and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising
from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses.
The Company has also entered into indemnification agreements with its officers and directors. No amounts were reflected in the
Company&#8217;s consolidated financial statements for the years ended March&#160;31, 2021 and 2020 related to these indemnifications.
The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited
history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has
not made any payments related to these indemnification agreements.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z5zBxWgYBylj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE&#160;11
&#8211; <span id="xdx_827_zfZkjWzcwctc">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Consulting
Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">During the year
ended March 31, 2020, the Company entered into consulting agreements with a member of its board of directors. Under the consulting
agreements, during the year ended March 31, 2020, the Company paid the director consulting fees of $140,625<span style="color: red">&#160;</span>in
cash, and the director was granted stock options with a fair value of $76,875. The options were for a total of 15,687 shares
of common stock, were fully vested on the grant dates and have terms of 10 years.<b>&#160;</b>&#160;The most recent consulting
agreement, which was entered into between the Company and the director in September 2019, was terminated in March 2020. At March
31, 2020, the Company had an outstanding payable to the director of $5,585, which was included in accounts payable in the consolidated
balance sheet. The Company paid the $5,585 to the director during fiscal 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>2021 Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">The
Company&#8217;s chief executive officer and an existing investor, which is represented by a member of the Company&#8217;s board
of directors, purchased $100,000 and $1,000,000, respectively, aggregate principal amount of the Notes (the Related Party Notes)
in the 2021 Placement. As of March 31, 2021, $1,677 and $16,767 of interest was payable by the Company on the Related Party Notes
to its chief executive officer and to the investor, respectively.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 129; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>



</ix:nonNumeric><ix:nonNumeric contextRef="From2020-04-012021-03-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zJZhTqL9Pnwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE 12 &#8211;
<span id="xdx_822_zye6Msj6Q1d7">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Convertible
Promissory Notes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Subsequent to
March 31, 2021, the Company issued an additional $4,250,000 of the Notes in the 2021 Placement pursuant to a Securities Purchase
Agreement between the Company and each investor (the SPA) and warrants to purchase shares of its common stock (the Warrants).
The Notes are unsecured obligations of the Company with each Note having a stated maturity date of 12 months from its issue date
(the Issue Date). The Notes bear interest at a rate of 12% per annum, payable on maturity, provided that, if the Company fails
to pay any amounts when due under a Note, the interest rate increases to the greater of 16% or the maximum amount permitted by
law. Each Note may be prepaid at the Company&#8217;s option during the first 270 calendar days following its Issue Date (the 270<sup>th</sup>&#160;day,
the Trigger Date), subject to a 110% prepayment penalty on all principal and accrued but unpaid interest then outstanding. No
Notes may be prepaid in whole or in part after the Trigger Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If the Notes
remain outstanding after the Trigger Date, the Notes may be converted into shares of the Company&#8217;s common stock at an initial
conversion price of $8.61 per share; provided, that a Note holder may not convert any portion of its Note that would cause it
to beneficially own in excess of 4.99% of the Company&#8217;s outstanding common stock. The conversion price and number of
shares of Company common stock issuable upon conversion of the Notes will be subject to adjustment from time to time for any subdivision
or consolidation of shares and other standard dilutive and certain other corporate events, as provided in the Notes. Subject to
certain Exempt Issuances (as defined in the Notes), if at any time while a Note is outstanding, the Company sells, issues or grants
any shares of its common stock or other securities entitling the holder to acquire shares of the Company&#8217;s common stock
at a price per share less than the then conversion price, such conversion price shall be reduced to such lesser price, and the
number of shares of the Company&#8217;s common stock issuable upon conversion of the Notes shall be increased, as provided in
the Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If the Company
completes an offering of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified Capital
Raise), each Note holder will be required to convert its Adjusted Note Amount into the securities of such Qualified Capital Raise.
For purposes hereof, Adjusted Note Amount equals the product of (i) the sum of all outstanding principal plus accrued but unpaid
interest on a Note, multiplied by (ii) 1.25.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Notes contain
a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal or interest
thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting requirements
under the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement, (v)
material restatements of the Company&#8217;s consolidated financial statements filed with the SEC, (vi) a holder&#8217;s inability
to rely on Rule 144 for sales of shares underlying the Notes, (vii) the Company&#8217;s common stock is suspended or halted from
trading and/or fails to be quoted or listed (as applicable) on the OTCQB, OTCQX, any tier of the Nasdaq Stock Market, the New
York Stock Exchange, or the NYSE American within 10 days thereafter, (viii) failure to file with the SEC a registration statement
covering the resale of shares of common stock underlying the Notes and Warrants within 60 calendar days following the Issue Date,
(ix) failure to cause such registration statement to become effective within 120 calendar days following the Issue Date, or (x)
certain merger consolidations, business combinations and sales of all or substantially all of the Company&#8217;s assets in the
event the Company is not the survivor of such transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Upon an Event
of Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will be required
to pay such Noteholder the product of (i) all then outstanding principal amount and accrued but unpaid interest thereon, multiplied
by (ii) 125%; and all collection costs including legal fees and expenses in connection therewith. At the option of a Note holder,
in the event the Company receive cash proceeds as a result of certain events including, but not limited to, from customers, issuances
of debt or equity securities, exercise of warrants or asset sales, the Company will be required to use such proceeds to repay
all or any lesser outstanding amounts due under such holder&#8217;s Note.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Notes also
includes various covenants, including negative covenants, representations, warranties, other payment obligations and agreements
by the Company including, without limitation, most-favored nation clauses, rights of participation and first refusal and exchange
rights. In connection with the issuance of the Notes, the Company issued Warrants to purchase 761,912 shares of its common
stock (Warrant Shares) at an initial exercise price of $24.00 per share. The Warrants may be exercised for a period of 5 years
from the Trigger Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the event
that, prior to the Trigger Date, the Company (i) completes a Qualified Capital Raise, the outstanding Warrants shall be cancelled
or (ii) prepays a holder&#8217;s Note(s) in whole or in part, such holder&#8217;s pro-rata number of its Warrants shall be cancelled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Effective April
30, 2021, each of the holders of the $2,210,000 of Notes outstanding at March 31, 2021 entered into a revocation and replacement
agreement with the Company (the Revocation Agreement). Under the terms of the Revocation Agreement, the $2,210,000 of Notes and
accrued interest of $50,091 were replaced with new Notes consistent with the terms described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In May 2021,
a member of the Board purchased $200,000 of the Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>PPP Note</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As a result
of the Company&#8217;s request for loan forgiveness, on May 29, 2021, the Company was notified that the outstanding principal
and accrued interest for the PPP Note was forgiven in full by the U.S. Small Business Administration.</span></p>

</ix:nonNumeric><p id="xdx_81B_zqsVc2a73tKb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 130; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants
to Purchase up to 1,438,202 Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: Red">&#160;<img src="modular001.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MODULAR
MEDICAL, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">June 6, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 131 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INFORMATION
NOT REQUIRED IN PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
13. Other Expenses of Issuance and Distribution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The registrant estimates
that expenses payable by the registrant in connection with the offering described in this Registration Statement will be as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; margin-top: 0; margin-bottom: 0">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Securities and Exchange Commission registration fee</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">$</span></td>
    <td style="vertical-align: bottom; text-align: right">880</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; text-align: left">Accounting fees and expenses *</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="vertical-align: bottom; width: 7%; text-align: right">2,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Legal fees and expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="vertical-align: bottom; text-align: right">25,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">28,380*</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-right: 0; margin-bottom: 0">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Estimated expenses.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
14. Indemnification of Directors and Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our Second Amended
and Restated Articles of Incorporation and our Amended and Restated Bylaws provide that each person who was or is made a party or is
threatened to be made a party to or is otherwise involved (including, without limitation, as a witness) in any action, suit or proceeding,
whether civil, criminal, administrative or investigative, by reason of the fact that he or she is or was one of our directors or officers
or is or was serving at our request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust
or other enterprise, whether the basis of such action, suit or proceeding is alleged action in an official capacity as a director, officer
or trustee or in any other capacity while serving as a director, officer or trustee, shall be indemnified and held harmless by us to
the fullest extent authorized by the Nevada Revised Statutes, or NRS, against all expense, liability and loss (including attorneys&#8217;
fees and amounts paid in settlement) reasonably incurred or suffered by such.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">NRS 78.7502 permits
a corporation to indemnify any director or officer of the corporation against expenses (including attorneys&#8217; fees) and amounts
paid in settlement actually and reasonably incurred in connection with any action, suit or proceeding brought by reason of the fact that
such person is or was a director or officer of the corporation, if such person (i) is not liable pursuant to NRS 78.138 and (ii) acted
in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation, and,
with respect to any criminal action or proceeding, had no reasonable cause to believe the conduct was unlawful. In a derivative action
(i.e., one brought by or on behalf of the corporation), indemnification may be provided only for expenses actually and reasonably incurred
by any director or officer in connection with the defense or settlement of such an action or the suit if such person (i) is not liable
pursuant to NRS 78.138 and (ii) acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the
best interests of the corporation, except that no indemnification shall be provided if such person shall have been adjudged to be liable
to the corporation, unless and only to the extent that the court in which the action or suit was brought or some other court of competent
jurisdiction determines that such person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.</span></p>

<!-- Field: Page; Sequence: 132; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Our Second Amended
and Restated Articles of Incorporation provide that the liability of our directors and officers shall be eliminated or limited to the
fullest extent permitted by the NRS. NRS 78.138(7) provides that, subject to limited statutory exceptions and unless the articles of
incorporation or an amendment thereto (in each case filed on or after October 1, 2003) provide for greater individual liability, a director
or officer is not individually liable to a corporation or its shareholders or creditors for any damages as a result of any act or failure
to act in his or her capacity as a director or officer unless it is proven that: (i) the act or failure to act constituted a breach of
his or her fiduciary duties as a director or officer and (ii) the breach of those duties involved intentional misconduct, fraud or a
knowing violation of law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The foregoing discussion
of our Second Amended and Restated Articles of Incorporation, Amended and Restated Bylaws and Nevada law is not intended to be exhaustive
and is qualified in its entirety by such Second Amended and Restated Articles of Incorporation, Amended and Restated Bylaws, indemnification
agreements, indemnity agreement, or law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Nevada Revised Statutes
provide that a corporation may purchase and maintain insurance or make other<span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span>financial
arrangements on behalf of any person who is or was a director, officer, employee or agent of<span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span>the
corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise for any liability asserted against him and liability and expenses incurred by him
in his capacity as a director, officer, employee or agent, or arising out of his status as such, whether or not the corporation has the
authority to indemnify him against such liability and expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">We have been advised
that in the opinion of the SEC, insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors,
officers and other persons pursuant to the foregoing provisions, or otherwise, such indemnification is against public policy as expressed
in the Securities Act and is therefore unenforceable. In the event a claim for indemnification against such liabilities (other than payment
of expenses incurred or paid by a director or officer in the successful defense of any action, suit or proceeding) is asserted by such
director, officer or other person in connection with the securities being registered, we will, unless in the opinion of our counsel the
matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification
is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
15. Recent Sales of Unregistered Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Set
forth below is information regarding shares of Common Stock, convertible notes and warrants issued, and options granted, by us within
the past three years that were not registered under the Securities Act. Also included is the consideration, if any, received by us for
such shares, convertible notes, warrants and options, and information relating to the section of the Securities Act, or rule of the Securities
and Exchange Commission, under which exemption from registration was claimed.</span></p>

<!-- Field: Page; Sequence: 133; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Director
Compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">On
March 31, 2022, we issued 15,250 shares of our Common Stock to non-employee members of our board of directors for service as directors
in accordance with the Director Plan. On December 31, 2021, we issued 5,775 shares of our Common Stock to non-employee members of our
board of directors for service as directors in accordance with the Director Plan. On September 30, 2021, we issued 3,636 shares of our
Common Stock to non-employee members of our board of directors for service as directors in accordance with the Director Plan. On June
30, 2021, we issued 1,836 shares of our Common Stock to non-employee members of our board of directors for service as directors in accordance
with our Outside Director Compensation Plan (the Director Plan).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Service
Providers</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
March 23, 2022 we issued 45,000 shares of our Common Stock to a service provider. On January 5, 2022, we issued 16,666 shares of our
Common Stock to service providers. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Officer
Purchases of Common Stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">On
October 28, 2021, we sold to two of our executive officers a total of 30,864 shares of our Common Stock at a purchase price of $8.10
per share, which resulted in gross proceeds to us of $250,000.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2021
Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Between
February and May 2021, we issued to accredited investors in a private placement (the &#8220;2021 Placement&#8221;) $6,610,550 aggregate
principal amount of our 12% unsecured convertible promissory notes, due 12 months from each respective issuance date, at par and warrants
to purchase in the aggregate 761,912 shares of our Common Stock at an exercise price of $24.00 per share, exercisable for a 5-year period,
as provided in such warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2020
Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Between
March and December 2020, we sold to accredited investors in a private placement (the 2020 Placement) a total of 320,796 shares of our
Common Stock at a purchase price of $8.61 per share. The 2020 Placement resulted in gross proceeds to us of $2,762,054.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Transactions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">In
2021, we issued a total of 52,836 shares of our Common Stock to five service providers in exchange for services rendered. In 2019, we
issued 10,000 shares of our Common Stock for cash to a service provider.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2018
Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Between
November 2018 and March 2019, we sold to accredited investors in a private placement (the 2018 Placement) a total of 618,996 shares of
our Common Stock at a purchase price of $6.75 per share, resulting in gross proceeds to us of $4,142,666.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">The
above sales of our securities were made pursuant to exemptions from registration pursuant to Section 4(2) and/or Rule 506 of Regulation
D of the Securities Act. We made such determinations based upon representations by the purchasers of such securities including, without
limitation, that such purchasers were &#8220;accredited investors&#8221; as defined in the Securities Act.</span></p>

<!-- Field: Page; Sequence: 134; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
16. Exhibits and Financial Statement Schedules</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">(a) <span style="font-family: Times New Roman, Times, Serif"><b>Exhibits</b></span></span></p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 10%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Exhibit
    No.</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Description</span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">1.1(18)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000180/ex1_1.htm" style="font: 10pt Times New Roman, Times, Serif">Form
    of Underwriting Agreement</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">2.1(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex2_1.htm" style="font: 10pt Times New Roman, Times, Serif">Reorganization
    and Share Exchange Agreement dated as of July 24, 2017, by and among the Registrant, Quasuras, Inc., Paul DiPerna and the other stockholders
    of Quasuras, Inc.</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">2.2(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex2_2.htm" style="font: 10pt Times New Roman, Times, Serif">Addendum
    No. 1 to Reorganization and Share Exchange Agreement dated as of July 24, 2017, by and among the Registrant, Quasuras, Inc., Paul
    DiPerna and the other Stockholders of Quasuras, Inc. dated May 3, 2021</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">3.1(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000593/ex3_1.htm" style="font: 10pt Times New Roman, Times, Serif">Third
    Amended and Restated Articles of Incorporation, as filed with the Secretary of State of Nevada on June 27, 2017</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">3.2(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000620/ex3_1.htm" style="font: 10pt Times New Roman, Times, Serif">Certificate
    of Amendment to the Amended and Restated Articles of Incorporation of Modular Medical, Inc., filed with the Secretary of State of
    the State of Nevada on November 24, 2021</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">3.3(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101041209000212/ex32amendedbylaws.htm" style="font: 10pt Times New Roman, Times, Serif">Amended
    Bylaws</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">4.1(6) +</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905618000822/ex4_1.htm" style="font: 10pt Times New Roman, Times, Serif">2017
    Equity Incentive Plan, as amended</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">4.2(18)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000142/ex4_2.htm" style="font: 10pt Times New Roman, Times, Serif">Form
    of Warrant to Purchase Common Stock</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">4.3(20)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000371/ex4_1.htm" style="font: 10pt Times New Roman, Times, Serif">Form of Pre-Funded Warrant dated May 2, 2022</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">4.4(20)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000371/ex4_2.htm" style="font: 10pt Times New Roman, Times, Serif">Form of Private Placement Warrant dated May 2,
    2022</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">5.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="ex5_1.htm" style="font: 10pt Times New Roman, Times, Serif">Opinion
    of Lucosky Brookman LLP</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.1(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101041217000014/stockpurchaseagreementbearla.htm" style="font: 10pt Times New Roman, Times, Serif">Common
    Stock Purchase Agreement, dated as of April 5, 2017, by and among Bear Lake Recreation, Inc., Manchester Explorer, LP, a Delaware
    limited partnership, and certain persons named therein</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.2(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex10_2.htm" style="font: 10pt Times New Roman, Times, Serif">Form
    of Common Stock Purchase Agreement, dated as of July 24, 2017, by and between the Registrant and the purchaser named therein</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.3(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905618001091/ex99_1.htm" style="font: 10pt Times New Roman, Times, Serif">Form
    of Common Stock Purchase Agreement dated as of November 19, 2018 among the Registrant and the Investors named therein</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.4(9) +</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905619000388/ex10_4.htm" style="font: 10pt Times New Roman, Times, Serif">Employment
    Agreement dated August 1, 2018, by and between the Registrant and Paul DiPerna</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.5(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex10_3.htm" style="font: 10pt Times New Roman, Times, Serif">Intellectual
    Property Assignment Agreement dated July 24, 2017, by and between the Registrant, Quasuras, Inc. and Paul DiPerna</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.6(1) +</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905617000628/ex10_4.htm" style="font: 10pt Times New Roman, Times, Serif">Technology
    Royalty Agreement dated as of July 24, 2017, by and between the Registrant, Quasuras, Inc. and Paul DiPerna</a></span></span></td></tr>
</table>




<!-- Field: Page; Sequence: 135; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 10%"><span style="font-size: 10pt">10.7(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905619000388/ex10_7.htm" style="font: 10pt Times New Roman, Times, Serif">Service
    Agreement effective January 16, 2019 between the Registrant and Liam Burns</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.8(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905619000388/ex10_8.htm" style="font: 10pt Times New Roman, Times, Serif">Standard
    Sublease Agreement, dated August 21, 2017, between the Registrant and Western Education Corporation</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.9(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_9.htm" style="font: 10pt Times New Roman, Times, Serif">Lease
    between MCP Socal Industrial &#8212; Bernardo, LLC and the Registrant dated January 10, 2020</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.10(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_10.htm" style="font: 10pt Times New Roman, Times, Serif">Consulting
    Agreement between the Registrant and Liam Burns dated April 15, 2019</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.11(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_11.htm" style="font: 10pt Times New Roman, Times, Serif">Consulting
    Agreement between the Registrant and Liam Burns dated July 15, 2019</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.12(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_12.htm" style="font: 10pt Times New Roman, Times, Serif">Consulting
    Agreement between the Registrant and Liam Burns dated September 3, 2019</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.13(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_13.htm" style="font: 10pt Times New Roman, Times, Serif">Service
    Agreement effective December 31, 2019 between the Registrant and Carmen Volkart</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.14(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_14.htm" style="font: 10pt Times New Roman, Times, Serif">Service
    Agreement effective January 23, 2020 between the Registrant and William Febbo</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.15(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_15.htm" style="font: 10pt Times New Roman, Times, Serif">Form
    of Indemnification Agreement between the Registrant and each of its directors and officers used from January 23, 2020</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.16(10) +</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000112/ex10_16.htm" style="font: 10pt Times New Roman, Times, Serif">Form
    of Notice of Stock Option Grant and Stock Option Agreement under the Amended 2017 Equity Incentive Plan</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.17(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000268/ex10_17.htm" style="font: 10pt Times New Roman, Times, Serif">Form
    of Common Stock Purchase Agreement dated March 2020 by and between the Registrant and the Investors named therein</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.18(12) +</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000364/ex10_18.htm" style="font: 10pt Times New Roman, Times, Serif">First
    Amendment to Employment Agreement between the Registrant and Paul DiPerna effective as of May 12, 2020</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.19(13)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905620000315/ex10_1.htm" style="font: 10pt Times New Roman, Times, Serif">U.S.
    Small Business Administration Paycheck Protection Program Note dated April 23, 2020</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.20(14)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000102/ex10_21.htm" style="font: 10pt Times New Roman, Times, Serif">Form
    of Promissory Note dated February 8, 2021</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.21(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_21.htm" style="font: 10pt Times New Roman, Times, Serif">Form
    of Convertible Promissory Note issued in the 2021 Private Placement</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.22(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_22.htm" style="font: 10pt Times New Roman, Times, Serif">Form
    of Common Stock Purchase Warrant issued in the 2021 Private Placement</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.23(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_23.htm" style="font: 10pt Times New Roman, Times, Serif">Form
    of Securities Purchase Agreement for the 2021 Private Placement</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.24(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000292/ex10_24.htm" style="font: 10pt Times New Roman, Times, Serif">Form
    of Registration Rights Agreement for the 2021 Private Placement</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.25(15) +</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000387/ex10_26.htm" style="font: 10pt Times New Roman, Times, Serif">Service
    Agreement effective May 18, 2021 between the Registrant and Ellen O&#8217;Connor Vos</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.26(16) +</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000475/ex10_27.htm" style="font: 10pt Times New Roman, Times, Serif">Employment
    Agreement between the Registrant and Ellen O&#8217;Connor Vos dated August 11, 2021</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.27(17)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000551/ex10_27.htm" style="font: 10pt Times New Roman, Times, Serif">Promissory
    Note dated October 28, 2021 between the Registrant and Manchester Explorer, L.P.</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.28(17)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000551/ex10_28.htm" style="font: 10pt Times New Roman, Times, Serif">Security
    Agreement dated October 28, 2021 between the Registrant and Manchester Explorer, L.P.</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.29(17)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000551/ex10_29.htm" style="font: 10pt Times New Roman, Times, Serif">Form
    of Common Stock Purchase Agreement dated October 28, 2021 between the Registrant and Investors</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.30(18)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000180/ex10_1.htm" style="font: 10pt Times New Roman, Times, Serif">Form of Warrant Agency Agreement</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.31(19)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000142/ex10_31.htm" style="font: 10pt Times New Roman, Times, Serif">Form
    of Warrant Omnibus Amendment Agreement</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.32(20)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905622000371/ex10_1.htm" style="font: 10pt Times New Roman, Times, Serif">Form of Securities Purchase
    Agreement dated May 2, 2022</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">10.33*+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="ex10_33.htm" style="font: 10pt Times New Roman, Times, Serif">Severance and Release Agreement
    between the Registrant and Ellen O&#8217;Connor Vos dated February 23, 2022</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000101905621000387/modular_10k.htm" style="font: 10pt Times New Roman, Times, Serif">Sole
    Subsidiary of the Registrant (as disclosed in the Notes to Consolidated Financial Statements as of March 31, 2021 in the Registrant&#8217;s
    Annual Report on Form 10-K)</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="ex23_1.htm" style="font: 10pt Times New Roman, Times, Serif">Consent
    of Farber Hass Hurley LLP</a></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">23.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="ex5_1.htm" style="font: 10pt Times New Roman, Times, Serif">Consent of Lucosky Brookman
    LLP (included in Exhibit 5.1)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">107*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><span style="text-decoration: underline"><a href="ex_107.htm" style="font: 10pt Times New Roman, Times, Serif">Calculation
    of Filing Fee Tables</a></span></span></td></tr>
  </table>



<!-- Field: Page; Sequence: 136; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29px"><span style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
    Current Report on Form 8-K filed July 28, 2017, and incorporated herein by reference.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29px"><span style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
    Current Report on Form 8-K filed May 12, 2021, and incorporated herein by reference.</span></td></tr>
  </table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29px"><span style="font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
    Current Report on Form 8-K filed June 29, 2017, and incorporated herein by reference.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29px"><span style="font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
    Current Report on Form 8-K filed December 1, 2021, and incorporated herein by reference.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29px"><span style="font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
    Annual Report on Form 10-K/A for the year ended June 30, 2008, and incorporated herein by reference.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29px"><span style="font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
    Quarterly Report on Form 10-Q filed November 12, 2018, and incorporated herein by reference.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29px"><span style="font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
    Current Report on Form 8-K filed April 5, 2017, and incorporated herein by reference.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29px"><span style="font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
    Current Report on Form 8-K filed November 20, 2018 and incorporated herein by reference.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29px"><span style="font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
    Registration Statement on Form S-1, as amended, originally filed June 27, 2019, declared effective October 22, 2019 (Commission File
    No. 333-232377).</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29px"><span style="font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
    Quarterly Report on Form 10-Q for the quarter ended December 31, 2019, and incorporated herein by reference.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29px"><span style="font-size: 10pt">(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
    Registration Statement on Form S-1, as amended, originally filed April 9, 2020, declared effective May 11, 2020 (Commission File
    No. 333-237615).</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29px"><span style="font-size: 10pt">(12)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
    Current Report on Form 8-K filed May 27, 2020, and incorporated herein by reference.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29px"><span style="font-size: 10pt">(13)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
    Current Report on Form 8-K filed May 12, 2020, and incorporated herein by reference.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29px"><span style="font-size: 10pt">(14)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
    Quarterly Report on Form 10-Q for the quarter ended December 31, 2020, and incorporated herein by reference.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29px"><span style="font-size: 10pt">(15)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
    Annual Report on Form 10-K filed June 29, 2021, and incorporated herein by reference.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29px"><span style="font-size: 10pt">(16)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
    Current Report on Form 8-K filed August 16, 2021, and incorporated herein by reference.</span></td></tr>
  </table>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29px"><span style="font-size: 10pt">(17)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
    Current Report on Form 8-K filed October 29, 2021, and incorporated herein by reference.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(18)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
    Current Report on Form 8-K filed February 14, 2022, and incorporated herein by reference.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(19)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
    Registration Statement on Form S-1 filed February 9, 2022, and incorporated herein by reference.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(20)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">As filed with the Registrant&#8217;s
    Current Report on Form 8-K filed May 5, 2022, and incorporated herein by reference.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-size: 10pt">*&#160;&#160;Filed
herewith</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-size: 10pt">+&#160;Management
contract, compensatory plan or arrangement.</span></p>

<!-- Field: Page; Sequence: 137; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)
Financial statement schedules.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">All schedules have
been omitted because either they are not required, are not applicable or the information is otherwise set forth in the financial statements
and related notes thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
17. Undertakings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The undersigned registrant
hereby undertakes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25px"><span style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">To file, during any period
    in which offers or sales are being made, a post-effective amendment to this registration statement:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25px"><span style="font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">To include any prospectus
    required by Section 10(a)(3) of the Securities Act of 1933;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">To reflect in the prospectus
    any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof)
    which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement.
    Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
    offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering
    range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes
    in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation
    of Registration Fee&#8221; table in the effective registration statement; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">To include any material information
    with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information
    in the registration statement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25px"><span style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">That for the purpose of determining
    any liability under the Securities Act of 1933 each such post-effective amendment shall be deemed to be a new registration statement
    relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona
    fide offering thereof.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">To remove from registration
    by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</span></td></tr>
  </table>
<!-- Field: Page; Sequence: 138; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25px"><span style="font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">That, for the purpose of
    determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of
    a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses
    filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first
    used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the
    registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or
    prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first
    use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration
    statement or made in any such document immediately prior to such date of first use.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25px"><span style="font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">That, for the purpose of
    determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The undersigned registrant
    undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless
    of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser
    by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered
    to offer or sell such securities to such purchaser:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25px"><span style="font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Any preliminary prospectus
    or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Any free writing prospectus
    relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The portion of any other
    free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities
    provided by or on behalf of the undersigned registrant; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(iv)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Any other communication that
    is an offer in the offering made by the undersigned registrant to the purchaser.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25px"><span style="font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The undersigned Registrant
    hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations
    and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.</span></td></tr>
</table>

<!-- Field: Page; Sequence: 139; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25px"><span style="font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Insofar as indemnification
    for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant
    pursuant to the provisions described in Item 14 above, or otherwise, the Registrant has been advised that in the opinion of the SEC
    such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that
    a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a
    director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted
    by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in
    the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
    question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the
    final adjudication of such issue.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The undersigned Registrant
    hereby undertakes:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49px"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25px"><span style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">That for purposes of determining
    any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement
    in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4), or 497(h)
    under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">That for the purpose of determining
    any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a
    new registration statement relating to the securities offered therein, and this offering of such securities at that time shall be
    deemed to be the initial bona fide offering thereof.</span></td></tr>
  </table>



<!-- Field: Page; Sequence: 140; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form S-1 and has duly caused this registration statement to be signed on its
behalf by the undersigned, thereunto duly authorized, thereto duly authorized, in the City of San Diego, State of California,
on June 6, 2022.</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MODULAR
    MEDICAL, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 52%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; width: 45%"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt"><span style="font-size: 10pt">By:&#160;&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0.5pt; padding-right: 0.5pt; padding-left: 0.5pt"><span style="font-size: 10pt">/<span style="font-family: Times New Roman, Times, Serif"><i>s/
    James E. Besser</i></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">James E. Besser</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>POWER
OF ATTORNEY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">KNOW
ALL PERSONS BY THESE PRESENTS that each of the undersigned directors and officers of Modular Medical, Inc. hereby appoints James E. Besser,
as his or her true and lawful attorney-in-fact and agent, for him or her and in his or her name, place and stead, with full power to
act alone, to sign on his or her behalf and in the capacity set forth below, any and all amendments and post-effective amendments and
supplements to this Registration Statement on Form S-1 and to file each such amendment and post-effective amendment and supplements to
this Registration Statement, with all exhibits thereto, and any and all other documents in connection therewith, with the Securities
and Exchange Commission, hereby granting unto said attorney-in-fact and agent full power and authority to do and perform any and all
acts and things requisite and necessary or appropriate to be done in and about the premises as fully to all intents and purposes as he
or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause
to be done by virtue hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in
the capacities and on the dates indicated.</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 23%; padding-top: 0.5pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt; width: 4%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%; padding-top: 0.5pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt; width: 4%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 23%; padding-top: 0.5pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
    <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1pt; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt 0.5pt 1.25pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0.5pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><span style="font-size: 10pt">/<span style="font-family: Times New Roman, Times, Serif"><i>s/
    James E. Besser</i></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt; text-align: center"><span style="font-size: 10pt">Chief Executive
    Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt 0.5pt 1.25pt"><span style="font-size: 10pt">&#160;June
    6, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-size: 10pt">James E. Besser</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span><span style="font-size: 10pt">(<span style="font-family: Times New Roman, Times, Serif"><i>Principal
    Executive Officer</i></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0.5pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Paul DiPerna</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt; text-align: center"><span style="font-size: 10pt">Chairman,
    President, and Chief Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt 0.5pt 1.25pt"><span style="font-size: 10pt">&#160;June
    6, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-size: 10pt">Paul DiPerna</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span><span style="font-size: 10pt">(<span style="font-family: Times New Roman, Times, Serif"><i>Principal
    Financial and Accounting Officer</i></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-top: 0.5pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    William J. Febbo</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt; vertical-align: top; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt; vertical-align: top; text-align: center"><span style="font-size: 10pt">June
    6, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-size: 10pt">William J.
    Febbo</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0.5pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Steven     Felsher</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt; text-align: center"><span style="font-size: 10pt">June
    6, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-size: 10pt">Steven Felsher</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0.5pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Morgan C. Frank</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt; text-align: center"><span style="font-size: 10pt">June
    6, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-size: 10pt">Morgan C.
    Frank</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0.5pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Philip Sheibley</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt; text-align: center"><span style="font-size: 10pt">June
    6, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-size: 10pt">Philip Sheibley</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0.5pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Carmen Volkart</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt; text-align: center"><span style="font-size: 10pt">June
    6, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-size: 10pt">Carmen Volkart</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0.5pt; padding-right: 0.5pt; padding-left: 0.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Ellen O&#8217;Connor Vos</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt 0.5pt 1.25pt; text-align: center"><span style="font-size: 10pt">June
    6, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-size: 10pt">Ellen O&#8217;Connor
    Vos</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding: 0.5pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  </table>

<div style="border-bottom: Black 2pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ex5_1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML STYLE="font: 10pt Times New Roman, Times, Serif">
<HEAD STYLE="font: 10pt Times New Roman, Times, Serif">
     <TITLE STYLE="font: 10pt Times New Roman, Times, Serif"></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0 0 10pt; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="modular013.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">June 6, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">Modular Medical, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">16772 W. Bernardo Drive</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">San Diego, California 92127</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RE:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares
    to be registered on Form S-1</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">We have acted
as counsel to Modular Medical, Inc., a Nevada corporation, (the &ldquo;Company&rdquo;) in connection with the Company&rsquo;s Registration
Statement on Form S-1 filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) pursuant to the Securities Act
of 1933, as amended (the &ldquo;Securities Act&rdquo;) on June 6, 2022 (the &ldquo;Registration Statement&rdquo;) with respect to the
registration of 1,438,202 shares of the Company&rsquo;s common stock, $0.001 par value per share (the &ldquo;Common Stock&rdquo;), that
may be issued from time to time upon exercise of warrants (the &ldquo;Warrant Shares&rdquo;). This opinion is being furnished in accordance
with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; border-right-width: 0in; border-right-color: Black; border-left-width: 0in; border-left-color: Black"><FONT STYLE="font-size: 10pt">As
such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter.
With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters
without having independently verified such factual matters. We are opining herein as to the laws of the State of Nevada, including the
Constitution of the State of Nevada, and we express no opinion with respect to any other laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">Based upon the
foregoing and in reliance thereon, and subject to the qualifications, limitations, exceptions and assumptions set forth herein, we are
of the opinion that, when issued and sold in exchange for payment in full to the Company of all consideration required therefor as applicable,
and as described in the Registration Statement, the Common Shares will be validly issued, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; border-right-width: 0in; border-right-color: Black; border-left-width: 0in; border-left-color: Black"><FONT STYLE="font-size: 10pt">This
opinion letter speaks only as of the date hereof and we assume no obligation to update or supplement this opinion letter if any applicable
laws change after the date of this opinion letter or if we become aware after the date of this opinion letter of any facts, whether existing
before or arising after the date hereof, that might change the opinions expressed above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; border-right-width: 0in; border-right-color: Black; border-left-width: 0in; border-left-color: Black"><FONT STYLE="font-size: 10pt">This
opinion letter is furnished in connection with the filing of the Registration Statement and may not be relied upon for any other purpose
without our prior written consent in each instance. Further, no portion of this letter may be quoted, circulated or referred to in any
other document for any other purpose without our prior written consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; border-right-width: 0in; border-right-color: Black; border-left-width: 0in; border-left-color: Black"><FONT STYLE="font-size: 10pt">We
hereby consent to the filing of this opinion with the Commission as an exhibit to the Registration Statement and to the use of our name
as it appears in the prospectus included in the Registration Statement. In giving such consent, we do not thereby admit that we come
within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission
promulgated thereunder. This opinion is expressed as of the date hereof unless otherwise expressly stated, and we disclaim any undertaking
to advise you of any subsequent changes in the facts stated or assumed herein or of any subsequent changes in applicable laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">Very Truly Yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/<FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Lucosky
    Brookman LLP</I></FONT></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Lucosky Brookman LLP</FONT></TD></TR>
  </TABLE>

<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>3
<FILENAME>ex10_33.htm
<DESCRIPTION>EXHIBIT 10.33
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: right"><FONT STYLE="font-size: 10pt"><B>Exhibit 10.33</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SEVERANCE
AGREEMENT AND GENERAL RELEASE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">This Severance
Agreement and General Release (the &ldquo;Agreement&rdquo;) dated February 23, 2022, is entered into by and between Ellen (Lynn)
O&rsquo;Connor Vos (&ldquo;Vos&rdquo;) and Modular Medical, Inc., a Nevada corporation (the &ldquo;Company&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 10pt"><FONT STYLE="font-size: 10pt"><B><U>RECITALS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to an Employment Agreement effective August 11, 2021 (the &ldquo;Employment Agreement&rdquo;), Vos has been employed as Company&rsquo;s
Chief Executive Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vos
and the Company now desire to terminate Vos&rsquo;s employment relationship with the Company upon the terms and conditions hereinafter
set forth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">NOW, THEREFORE,
in consideration of the mutual covenants contained herein, the parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 1in"><FONT STYLE="font-size: 10pt">1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Recitals</U>.
The Recitals set forth above are hereby expressly made a part of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 1in; text-align: justify"><FONT STYLE="font-size: 10pt">2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Resignation
and Termination of Employment</U>. Concurrently with the execution of this Agreement, Vos agrees to submit her voluntary resignation
as an employee and as the Company&rsquo;s Chief Executive Officer, effective February 23, 2022 at 8:00 a.m. Vos&rsquo;s employment
with Company is deemed terminated effective February 23, 2022 at 8:00 a.m. (the &ldquo;Termination Date&rdquo;), and the Employment
Agreement shall be deemed terminated as of 90 days following the Termination Date (&ldquo;Effective Date of Termination&rdquo;).
For the avoidance of doubt, Vos&rsquo; separation from the Company shall be treated as a Termination of the Company Without Cause
or by Executive With Good Reason other than in conjunction with a Change of Control as set forth in Section 5(c)(ii) of the Employment
Agreement dated August 11, 2021 (&ldquo;Employment Agreement&rdquo;)..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0; text-align: justify"><FONT STYLE="font-size: 10pt">3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Final
Paycheck</U>. On February 23, 2022, Company shall pay Vos the sum of $32,500.24, constituting Vos&rsquo;s earned but unpaid salary
through February 23, 2022, and the sum of $7,931.21,constituting all of Vos&rsquo;s accrued and unused paid time off. By executing
this Agreement, Vos agrees that upon payment of the sums set forth in this Section 3, she has received all wages, salary, bonuses,
and other compensation due her through the Termination Date pursuant to the Employment Agreement and her employment with the Company,
excepting only such payments by and obligations of Company as are set forth in this Agreement, including but not limited to Section
4 hereof. Nothwithstanding the foregoing, nothing in this Agreement is intended to or does negate rights Vos has to stock options
granted to her as a Board Member or as CEO except as expressly provided herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Severance
Benefits. In further consideration of Vos&rsquo;s acceptance of this Agreement, Company shall provide Vos with the following Severance
Benefits:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A lump sum cash payment of $75,000, less applicable withholding, representing Vos&rsquo;s Cash Salary for the 90 day period from
the Termination Date (the &ldquo;Notice Period Compensation&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
cash severance payment of $300,000.00 (the &ldquo;Severance Payment&rdquo;), which Severance Payment shall be payable as follows:</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 2in"><FONT STYLE="font-size: 10pt">(i)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The sum of $150,000.00 shall be payable on or before May 25, 2022; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 2in"><FONT STYLE="font-size: 10pt">(ii)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The remaining balance of $150,000.00 shall be payable on or
before</FONT> November 25, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(c)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reimbursement or continuation of Vos&rsquo;s healthcare coverage premiums for 15 months from the Termination Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(d)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Notice Period Compensation and the Severance Payment shall be subject to applicable withholdings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(e)
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A grant pursuant to the August 11, 2021 CEO option grant of
20,711 vested Incentive Stock Options with an Exercise Price of $12.18 representing the equity incentive compensation due to Vos
for the Notice Period as set forth in Section 3(c) of the Employment Agreement. For the purposes of clarity, this vesting shall
be the final vesting of Incentive Options under the August 11, 2021 CEO option grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The foregoing Severance Benefits will be become payable or otherwise effective within two (2) business days of the &ldquo;Effective
Date&rdquo; of this Agreement as defined in Section 16 below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 1in; text-align: justify"><FONT STYLE="font-size: 10pt">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Return
of Company Property</U>. On or before February 23, 2022, Vos shall have returned to Company all property of Company that is in
her possession including, without limitation, Company-owned equipment, office keys and access cards, and all Company documents
including electronic and print versions, and all other materials belonging to Company, except that Vos may retain any such property
provided to other members of the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 1in; text-align: justify"><FONT STYLE="font-size: 10pt">6. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Continuation
as a Member of the Board of Directors and Option Exercise Right</U>. Vos shall continue to serve as a member of Company&rsquo;s
Board of Directors subject to reelection by the Company&rsquo;s shareholders in the normal course. Regardless of any contrary
provisions in any other agreement, including but not limited to the Employment Agreement, any Notice of Stock Option Grant or
any other documents related to the grant and exercise of stock options, all options granted to Vos as a Board Member and/or as
CEO shall be exercisable for three months after Vos ceases to provide Continuous Service as a Board Member, unless such termination
is due to Vos&rsquo;s death or Disability, in which case any and all options awarded to Vos in any capacity shall be exercisable
for 12 months after Vos ceases to provide Continuous Service as a Board Member. As of the date of this Agreement, Vos&rsquo;s
Option Grants (with the exception of the additional 20,711 shares to be awarded in accordance with Section 3(e) above, are set
forth on Exhibit A hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 1in; text-align: justify"><FONT STYLE="font-size: 10pt">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Release
of Claims By Vos</U>. Vos agrees that by signing this Agreement, and in exchange for the benefits provided by it, she is waiving
and giving up any and all right to bring any legal claim against the Company of any nature including, but not limited to, claims
related in any way, directly or indirectly, to Vos&rsquo;s employment relationship with the Company, including her separation
from employment. The release of claims in this Agreement is intended to be interpreted in the broadest possible manner to include
all actual or potential legal claims that Vos may have against the Company, except as specifically provided otherwise in this
Agreement.</FONT></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Specifically,
Vos agrees to fully and forever release all of her legal rights and claims against the Company, whether or not presently known
to her and including future legal rights and claims if based in whole or in part on acts or omissions occurring before Vos delivers
this signed Agreement to the Company. Vos agrees that the legal rights and claims that she is giving up include, but are not limited
to, her rights, if any, under all State and federal statutes that protect her from discrimination in employment, such as the Age
Discrimination in Employment Act (the &ldquo;ADEA&rdquo;), Title VII of the Civil Rights Act of 1964, as amended, the Rehabilitation
Act of 1973, the Americans With Disabilities Act, the Equal Pay Act, the California Fair Employment and Housing Act and any similar
State or local statute, regulation or order. Vos also agrees that the legal rights and claims that she is giving up include her
rights, if any, for unpaid wages including overtime and other benefits under all State and federal statutes such as but not limited
to the Fair Labor Standards Act, the Family and Medical Leave Act, the Employee Retirement and Income Security Act (ERISA), and
any similar State or local statute, regulation or order. Vos further agrees that the legal rights and claims that she is giving
up include any claims relating to any contract for past employment, any failure to offer employment, any representations or commitments
made by the Company regarding future employment, the termination and conclusion of her employment with the Company, benefits payable
by the Company, any representations or commitments made by the Company regarding grants of or rights to receive securities of
Company except as set forth in this Agreement, or any other Company benefit policy or plan. Vos understands and agrees that the
release provided in this Agreement includes, without limitation, any and all claims under municipal, state and federal contract
or tort law, such as claims of wrongful discharge, constructive discharge, retaliation, negligent or intentional infliction of
emotional distress, defamation, failure of due process, breach of the covenant of good faith and fair dealing, intentional interference
with contract, and any claims for attorneys&rsquo; fees that exist or may exist as of the date of the signing of this Agreement.
Vos also agrees that she is giving up and forever releasing any right that she may have to attorneys&rsquo; fees for any of the
foregoing rights and claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">Vos
further agrees that the release described in this Section 7 applies not only to Company, but also to Company&rsquo;s predecessors
and all of Company&rsquo;s past, current and future subsidiaries, related entities, officers, directors, shareholders, members,
partners, owners, agents, attorneys, employees, successors, or assigns. Vos agrees that this Agreement may be used as a complete
defense in the future in the event she brings or asserts any claim that she has released in this Section 7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">The
foregoing release <U>does not</U> include or affect Vos&rsquo;s vested rights, if any, under any stock grant or option agreement
with the Company, and Vos&rsquo;s COBRA, unemployment compensation and worker&rsquo;s compensation rights, if any. In addition, this
release does not affect any rights expressly created by this Agreement, and does not limit Vos&rsquo;s ability to enforce this
Agreement. Notwithstanding any other provision of this Section 7 or this Agreement, nothing in this Section 7 or this Agreement
is intended to waive, release or limit Vos&rsquo;s indemnification rights, if any, against Company, whether contractual, statutory
or arising by operation of law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 1in; text-align: justify"><FONT STYLE="font-size: 10pt">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Release
of Claims By Company</U>. Company hereby releases and discharges Vos and her successors, assigns, attorneys, agents, heirs and
representatives from and against any and all claims, damages, representations, obligations, losses, liabilities, judgments, awards,
actions, demands and causes of action which Company may now or hereinafter have or claim to have against her arising out of or
related to Vos&rsquo;s employment with Company; provided, however, that nothing in this Section 8 is intended to constitute a
release of claims arising out of or related to Vos&rsquo;s past, present or future service as a member of Company&rsquo;s Board
of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 1in; text-align: justify"><FONT STYLE="font-size: 10pt">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>1542
Waiver</U>. Each of the parties hereto hereby waives any and all rights which it may have as to the other under the provisions
of Section 1542 of the Civil Code of the State of California, which section reads as follows:</FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1in 10pt"><FONT STYLE="font-size: 10pt">
 &ldquo;A general release
does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time
of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor
or released party.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">It is understood by each of
the parties hereto that if the facts or law with respect to which the foregoing release is given hereafter turn out to be other
than or different from the facts or law in that connection now known to be or believed by such party to be true, then said party
expressly assumes the risk of the facts or law turning out to be so different, and agrees that the foregoing release shall be
in all respects effective and not subject to termination or rescission on account of any such difference in facts or law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Trade
Secrets and Proprietary Information</U>. Vos agrees that she will not, unless required or otherwise permitted by law, disclose
to others any information regarding Company&rsquo;s sales, products, markets, technology, marketing strategies, research, sales
and purchasing practices, procedures, trade secrets, vendor lists, purchasing terms, customer lists, or pricing. Vos agrees to
keep and treat all such information as proprietary and confidential.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Actions Filed</U>. Vos represents that she has not filed any action, charge, suit, or claim against Company with any federal,
state, or local agency or court, and has not initiated any mediation or arbitration proceeding. Vos agrees not to file or initiate
a lawsuit in any court or initiate a mediation or arbitration proceeding asserting any claim released pursuant to this Agreement.
Vos further agrees that she will not permit herself to be a member of any class action and/or collective action in any court or
in any mediation or arbitration proceeding seeking relief based on any claim(s) released pursuant to this Agreement. Vos further
agrees that she shall not receive or be entitled to any monetary damages, recovery, and/or relief of any type in connection with
any charge, administrative action, or legal proceeding pursued by Vos, by any governmental agency, person, group, or entity regarding
and/or relating to any claim(s) released pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Disparagement</U>.
The Company agrees that it shall not make any statement about Vos which disparages Vos or suggests that Vos engaged in any conduct
warranting her removal from the CEO position. In the event, the Company receives inquiries from any third party about the reasons
for Vos&rsquo;s separation from the Company as its CEO, the Company shall respond by stating that the decision was made solely
for reasons unrelated to Vos&rsquo;s performance, that Vos&rsquo;s performance was not a factor in the decision and that Vos remains
a highly valued resource to the Company and a member of its Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidentiality</U>.
The terms of this Agreement, the benefits being paid under it and the fact of their payment, are confidential and may not be disclosed
by Vos except that Vos may disclose this information to her spouse or domestic partner, and to her attorney, accountant or other
professional advisor to whom she must make the disclosure in order for them to render professional services to her. Vos shall
instruct such advisors and her spouse to maintain the confidentiality of such information. Nothing in this Section 11 shall prevent
either party from making any disclosures required under applicable securities laws and regulations.</FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. The rights and benefits of Company under this Agreement shall be transferable to or enforceable by or against
Company&rsquo;s successors and assigns. This Agreement also binds all persons who might assert a legal right or claim on Vos&rsquo;s
behalf, including, without limitation, Vos&rsquo;s heirs, personal representatives and assigns, now and in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Partial
Invalidity</U>. The invalidity or unenforceability of any particular provision of this Agreement shall not affect the other provisions
hereof, and this Agreement shall be construed in all respects as if such invalid or unenforceable provision were omitted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement</U>. Vos agrees that no promise, inducement or other agreement not expressly contained in this Agreement or referred
to in this Agreement, has been made conferring any benefit upon her. This Agreement contains the entire agreement between Vos
and Company with respect to any benefit conferred upon Vos, and Vos expressly agrees that she is not relying on any representations
that are not contained in this Agreement. This Agreement is entered into and governed by the laws of the State of California.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Right
to Counsel; Revocation; Effective Date</U>. Vos acknowledges that she has been advised to consult with an attorney regarding her
rights before executing this Agreement and that she has had full opportunity to do so. In entering into this Agreement, Vos represents
that she is competent, that she has read the terms of this Agreement, and that she has relied upon the advice of her attorney,
who is the attorney of her choice. By executing this Agreement, Vos specifically acknowledges:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in; text-align: justify"> <FONT STYLE="font-size: 10pt">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> <FONT STYLE="font-size: 10pt">That she has read and understands the terms of this Agreement and has been advised to consult with an attorney and has either done so or chosen not to prior to signing this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in; text-align: justify"> <FONT STYLE="font-size: 10pt">b.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">That she is signing this Agreement voluntarily and understands that it contains a full and final release of all claims that she has or may have against the Company up to the present;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in"><FONT STYLE="font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in; text-align: justify"> <FONT STYLE="font-size: 10pt">c.</FONT> <FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That she may take up to twenty-one (21) calendar days from the date this Agreement is provided to her to consider it before signing it and returning it to the Company; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in; text-align: justify"> <FONT STYLE="font-size: 10pt">d.</FONT> <FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That she has seven (7) days after the date of her execution of this Agreement in which to revoke this Agreement by asking for its return and revocation. Vos understands and agrees that the terms of this Agreement shall not be effective until at least seven (7) days after she has executed this Agreement. To revoke this Agreement, Vos must send Company a written statement of revocation by registered mail, return receipt requested. If Vos does not revoke this Agreement, the 8<SUP>th</SUP> day after the date of his acceptance will be the &ldquo;Effective Date&rdquo; of the Agreement, and she may not thereafter revoke it. &#9;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 1in"><FONT STYLE="font-size: 10pt">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Attorney&rsquo;s
Fees</U>. In the event of litigation relating to or arising out of this Agreement, the prevailing party shall be entitled to reasonable
attorneys&rsquo; fees and costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">WHEREFORE,
the parties have executed this Agreement as of February 23, 2022.</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/
    Ellen (Lynn) O&rsquo;Connor Vos</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">ELLEN (LYNN) O&rsquo;CONNOR
    VOS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 3%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 47%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">MODULAR MEDICAL, INC.,</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">a Nevada corporation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT>/s/ Paul M. DiPerna</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Paul M. DiPerna, Board Member</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex23_1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 2.2pt 9.05pt 0 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: right; margin-top: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-top: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: center; margin-top: 0"><FONT STYLE="font-size: 10pt">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-top: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: justify; margin-top: 0"><FONT STYLE="font-size: 10pt">We consent to the inclusion in this Registration Statement on Form S-1, as filed with the Securities and Exchange Commission, of our report dated June 29, 2021, with respect to the consolidated balance sheets of Modular Medical, Inc. as of March 31, 2021 and 2020 and the related consolidated statements of operations, stockholders&rsquo; equity/(deficit), and cash flows for the years then ended. Our report dated June 29, 2021, relating to those consolidated financial statements, includes an emphasis of matter paragraph relating to uncertainty as to Modular Medical, Inc.&rsquo;s ability to continue as a going concern. We also consent to the reference to us under the heading &ldquo;Experts&rdquo; in such Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-top: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; text-align: justify; margin-top: 0"><FONT STYLE="font-size: 10pt">/s/
Farber Hass Hurley LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-top: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-top: 0"><FONT STYLE="font-size: 10pt">Chatsworth, California</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-bottom: 0; margin-top: 0"><FONT STYLE="font-size: 10pt">June 6,
2022</FONT></P>

    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>ex_107.htm
<DESCRIPTION>EXHIBIT 107
<TEXT>
<HTML STYLE="font: 10pt Times New Roman, Times, Serif">
<HEAD STYLE="font: 10pt Times New Roman, Times, Serif">
     <TITLE STYLE="font: 10pt Times New Roman, Times, Serif"></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
107</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Calculation
of Filing Fee Tables</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">Form S-1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">(Form Type)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">MODULAR MEDICAL, INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">(Exact Name of Registrant
as Specified in its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Table
1: Newly Registered Securities</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 23%; border: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 6%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Security
    <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Type</B></FONT></TD>
    <TD NOWRAP STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 6%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Security
    <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Class <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Title</B></FONT></TD>
    <TD NOWRAP STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 7%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fee
    <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Calculation <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    or Carry <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Forward Rule</B></FONT></TD>
    <TD NOWRAP STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 8%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount
    <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Registered</B></FONT></TD>
    <TD NOWRAP STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 6%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed
    <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Maximum <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Offering <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Price Per <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Unit</B></FONT></TD>
    <TD NOWRAP STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 6%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Maximum
    <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Aggregate <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Offering <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Price</B></FONT></TD>
    <TD NOWRAP STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 6%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fee
    <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Rate</B></FONT></TD>
    <TD NOWRAP STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 7%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount
    of <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Registration <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Fee(1)</B></FONT></TD>
    <TD NOWRAP STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 6%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Carry
    <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Forward <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Form <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Type</B></FONT></TD>
    <TD NOWRAP STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 6%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Carry
    <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Forward <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    File <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Number</B></FONT></TD>
    <TD NOWRAP STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 6%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Carry
    <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Forward <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Initial <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    effective <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    date</B></FONT></TD>
    <TD NOWRAP STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 7%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filing
    Fee <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Previously <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Paid In <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Connection <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    with <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Unsold <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Securities <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    to be<BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Carried <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Forward</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="13" STYLE="font: 10pt Times New Roman, Times, Serif; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 3pt; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Newly
    Registered Securities</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees
    to Be <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Paid</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock underlying Warrants</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(g)</FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,438,202
    (1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><FONT STYLE="font-size: 10pt">$6.60
                                            (2)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$9,492,133.20</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0000927</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$879.92</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees
    <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Previously<BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Paid</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="13" STYLE="font: 10pt Times New Roman, Times, Serif; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 3pt; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Carry
    Forward Securities</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carry
    <BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Forward<BR STYLE="font: 10pt Times New Roman, Times, Serif">
    Securities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    Offering Amounts</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$9,492,133.20</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$879.92</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    Fees Previously Paid</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    Fee Offsets</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="4" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
    Fee Due</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$879.92</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 3pt; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
                                            the resale of 1,438,202 warrants.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
                                            solely for purposes of calculating the registration fee pursuant to Rule 457(g) under the
                                            Securities Act, based on exercise price applicable to shares issuable upon exercise of warrants.</FONT></TD></TR></TABLE>

<DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>modular001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ :P"3 P$1  (1 0,1 ?_$ *,  0 !!0$!
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M*H @" ( @" ( @" M.]81E$3S5_1+GW5#S?I)&']:-!=8R-QD>0BV.$FAQ'
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M@0! $ 0%*#H0%=B I0=" KL0"@0! $ 0! $ 0! $ 0! $ 0! "@" ( @" (
%@" __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>modular002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular002.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ JP"? P$1  (1 0,1 ?_$ *P   $$ P$
M       !!08( @,$!P$!  ,! 0$               $" P0&!1   0,# 00#
M"0L("00#     0(#!  1!08A,1('05$382)SLQ0T=%46T3)"DB.3)*1E-A=Q
M@9&Q4C,5"*'!8G*R8X,F-_""4R5#5#41  (! @0%! (" P$!       ! A$#
M(3$2$T%Q! 4546&A8C,4(C*Q4B-"-/_:  P# 0 "$0,1 #\ L'C\1C9TJ>_,
MC-/N]HD!2T]'9(K63,U;J=XTQIVW_P"='/\ V)K/46TT :8T]ZMC_$33415L
M7V8T[ZMC_$33431A[,:>]6Q_B)IJ%&)[,:>]6Q_B)IK(HP]F-/>K8_Q$TUBC
M%]F-.^K8_P 1--1-&'LQIWU;'^(FFH48>S&G?5L?XB::A1A[,:=]6Q_B)IJ%
M&'LQI[U;'^(FFLBC$]F-/>K8_P 1--8HP]F-/>K8_P 1--8HQ?9C3OJV/\1-
M-1-&'LQIWU;'^(FFH48>S&G?5L?XB::A1A[,:=]6Q_B)IJ%&)[,:>]6Q_B)J
M=8Q1PY?3V";88+<!E!5)CI59 %TJ>2% _E%6A+,JYLQ:S&/Q*,A*R,E$:,E]
M">U=(0FZFD6VJM1HR=W3BS6GF7H6P_\ =Q/R]JC^HU50J9KKX&7XE:&.[-Q/
MG4^[4[3+/KK:$_$G0WKJ+\XGW:;;(_?MB_B5H;UU%^<3[M-MCR%L/Q*T/ZZB
M_.I]VFVR/(6Q/Q+T-ZZB?.I]VFV/(0#\2=#>NHOSB?=IMLG]^V'XE:&]=Q/G
M4^[3;'D(!^)6AO7<3YU/NTVQY" ?B5H;UW$^=3[M-L>0@'XE:&]=Q/G4^[3;
M(\A /Q+T-Z[B?.I]VFV/(0#\2]#>NHGSJ?=IMCR$ _$K0WKJ)\ZGW:;9/D(!
M^)6AO7<3YU/NTVQY" ?B3H;UW%^<3[M-MC]^V'XDZ&]=1?G$^[3;8_?M@.96
MAKC_ -W$^=3[M';=!Y"WD;<IGL3(P;648E-N8]N1'<<DI4"@(0\DJ)/< I"&
M9MN1:U$$YNI3[#94='ET<V_TTUK%59P]XGHMUB5]C(2[)9:6=BRD&Q%[$VK;
M2ED>7MK5)#Y)TQVNKIV$@N)0U&>>2'GU<*0VTH@E2NH6_+5=7J;NQ)LWIY=Y
MIR0EF.MI\+4T&W6R2A2'TA;;G]T\5J:D2NED90N7.<E.!%T,J2VEUU+E[M\2
MBA"%A-[%5K_DI41Z9UQ.#):5EXS'"7-D--2%*<0F"2>W):<4TLV&RP4@TQ*R
MZ>G$[)F)T[ Q$1N27U9:=%$ME]'[M*E[4-*1OVBW13$TATR?$W_AIF#*CQ42
M([C[KG82$(6%%AP)XE(7PWNH#JJ-1;]%_P"R!&@UF%,5Y:V9K$AB.RV;H2M3
M]@+\824D<6XTU$?HO_9#9GM,2<)E&H,M]"E.^^59: C;8WXPD_GW5.HR?3M2
MIF/$SES*3EYL.).86W'?,:/VJPA;S@3Q=FD?M6V'NTJ:/IL!LT_IA[,XG)NL
M))G1.Q+3:E!";+6$JXBHCH-0V5M64ZU3'K)Z5TY@E27LJ)#C#+C$8H94+H6X
MT''%DWVA-]E*LTA9@UDQETYB,/D,T]'?>4J,E+BH3:U)9,A2;\#?&HI""KNF
MIQ,K=I2=*,ZY.B)\C(*;@1U1&TNMLN-/K"B@.)X@Z5@E):_M7J-1>72,W0>7
MDDS,0B;+;;8RCC2$\(5?A=M92%$<*K@]!V4U$+I6<BM!Y0XB3EV5MO1&.T4B
MU[N-M*X5+3[F\]%3J)71OU1V*Y8Y,++2)\-Q]+IC]BESOR^D%796/PB!343/
MHFO_ $B(;4W '2=N\;*ALY)PT/%U/>,6!^ $H_Y+OZZS69Z/I_\ YY/ZO_ Y
M\TH<V;H[+1X<=R2]Y:P0TTDN*L&D=";TBZ,Z.YVM=K \+;TKJUIQ*T8>;Q(4
M%)O&=WCK'#6NL\U&S*$T2-Z9K9>2.2;TNMB8M2S(=1#<^62Y[]#G>[0:J\3H
ME*XG@C4J3S%#LQ;.'E1TRX[<,--174H;8:2$H2@!.RP%10G<O>GR;AE.9!R$
MR:[A9#ZIJ&VWFEQ'"CY%(2V;<.\6J5@5UW>*^1EGX?6LYF*R]A9?!$#B6;1G
M;@..*<5\']I1JVI%).;X'<D:[&)1CE8%]:FFC&9F*B.%Y#))/ E7#LWTU$*4
MUP.N3/U_*<94]IYQ7 YV\@>1N6?>(X2XX.':;5%$:ZI&N7)Y@2G'E.X%]3;W
M8CLO)7>%(C@! '>]2=O72B&N1RYV-K?,*B]M@I++<._8M-174@$JXB?>]?14
MT*/=;P0XIRG,,2)$G^ /%]]SREMPPW+M2"GA4\CO??*Z:FB+UO>GR,4?"ZUC
MXZ7 ;PTSL9JD+>^C.WNVH+%CP]8JKP*PW%6J'=$WF"''5/8!V2AWLE!MZ&XL
M)<90$(<3=/OK"H4BUJ4Z/ ;8F)U9'GO3'].O33))+[3\1Q23Q&Y([W8;U;4C
M*U*=<$/D>7K,1\NX[B)S<N?#1CXD=F*X&4-6";CO=A2FHHCHW+SX?)SQYW,"
M-&AQXV >93#=:?XDQ'+N+9(*>+O>L;:415W+WI\FEUW7SF+<QIP,CL%*66CY
M*[Q-I<5Q*2@\.ZIHC)SG7$5,GF&F8)8PLD."69P BN@=J04_L[K&IHB'*;&#
MV3U47%$X:8.(WL([HWG^[48(R=B<\3VO'X^>UR*DPW(SJ):FEI3'4@APJ4;)
M2$[[FLZ_R/1]/;:Z:2^K_P 'I.$1Q2,@#;]\BY_T45G)GT(+"C'8,#>0+C=L
MJFHL[46ZT,DM@#</T5#;)44LA>S3U#]%*LM00M C</T4395H3L$]0J:BC#L$
M=0IJ),NS3U#]%5Q)H@[-/4/T4Q(HA"VGJ'Z*58H'9)ZA4U8H!0.H?HI5BB,"
M$CX.RU]U*B,4@^3[@ZB;5-2(P2$*4GH!N-HZMG35:LLC+Y,6V 7Z2*59#0O>
M7M;;U6IB-*,NS3U#]%*L41BID$C8+5*;$H)H;<XVD18XL/.XH_2^BK1=2FFB
MH8X+SG(^&1XE%3(F(\"LRXA4!O\ T#;4@ M)-@;GJH!;B@$*TC>;4 <0H!:
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M))C2GU91PE+:&VFD-HXN+OP%FZMNT[Z;0\TO0L+B,DWDL7%GH!0B4TAU*3O
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MDCIO>YJ9%FJ.I<K1OW3P_H<?Q::X6>ZL9#T.BJFK$.^I068E00LRO/\ ,?\
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-A?LWV7J8T]ODHS__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>modular003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular003.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ Z@)3 P$1  (1 0,1 ?_$ +L  0 !!0$!
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M\;4&:PH,:U@*MX> M_GH+D$$4%UA0+"@6% L*!84"PH%A0+"@L=)2FZ1QH+
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MM;0-/@IDPR$)3QO;HIEJ+.T(3PZ:F3(B6E2M)X&BY;%ZJE H%!R'>W_<*?\
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M_@L>(<!MGLK$( DIB14A#;8/XH"0D?@I69$HD62*15:"BN8H/GS^O_\ FO\
MV-0?0E H% H% H% H% H% H*&@B-P9Z/B8I4JRY#ATM-7L23R^"I:U-7(/;L
M<$E:YJ2ZJWF,H59"?+;G6<M6+FMZ/']$EMMA!Z&Q84RYW6MMC-Q7S<JTD]*C
M?C\-=)LSBM]*T*3J2=5^D4[H87M1W'2-*233*8;:,-UK:DR#P5P*?AO40.WP
MFW99#C !Y"R@?@(J85E3CLBD6$W2?#H23_!3*X9F(I8U*>D+?4;$ V _ *95
MF7()\55AA4_X316%3E^1J4PL4\!T^=X*BL+C^GBM03Y:&&G(RC;9.CSU'GQI
ME>U'R,LZNZ2YYO2GE:AAH#*$/H#9NH'HK2O0X#BW(;2U<R 30;(Y4"@Y#O;_
M +A3_P">A?TUF@ZY/*@K0#06@'IM>LX%-!^'PU4JX)(M56*%)O\ P4(IH^+X
M;_'4P*=6>/@\'"U4 A73X*!U:@.'3SY?YJ"FDWX\CT5DJ.SV?QNW\4_DLBX6
MXD8:G5A.L_$.FEVQ.6IKEGQV0CY+'QI\<GL\MI#[14+'0XD*3<>,&M;ZV7#E
MX_)-YF-D$#A6(Z88U/M:2K4 D$I)N.8-B+UO+/NT)&"PLN<W/D0(S\UD -2W
M&6UNHTGAI<4-8MXC3/*;<Z_ZI *L> !\ Z?&:DVS&K,5<%60"HWX <N)/_34
MHM2M"AJ00H D$CB"0;6Y\ZLHT1@\*WDE9-,",G(D>=,#* ]RMQ< UGAXZDED
ML-N8U<#O#"YV9DX6.6MQS$O=GF!22D!RUR$D\3:]:[;MX^Z=-C\>$R>-R.9'
M"]B.58SB?9.M0TO=V$C;FB;<6XOZTG(6ZRA*+I"$"Y)4>7*M2=9Z'3'NF0H
M'A>W*W/\-1>Y46U\.'0.'"]:M23ZKBV3T7L;CX.-9UBVY5ZM7/IM^&M(J$*Y
M4 M]%KCRT5:&U)Y6/AO0Q%5-D^7HJ7(U<AB(.1CJC9"*S,CK(*F'T)<;-C?Y
MJP13 R1<?'B,-QHK+<:,T-+3#*0A"4CD D"P'DJC/H-N%AQN:05TGQ 4HN'*
M@4%%<Q0?/G]?_P#-?^QJ#Z$H% H% H% H% H% H%2BAJH\-WIF7Y6YI%E']"
MHH:23P'17/9VU:C0=)*ROSE$:KF]9RUAMV5YI!X^.F6<*I<6@:3\8IW,V)K&
M;B<C#2HZD>"G<S8Z[%[K@NH"7/-\8X5J;)A.QYD1U.IMP+2>7'C6Y4L7&4#<
M(X6YU<LV,+CQ)YU$RPJ= \OAH98UOH'3>IE<,#DM '@\9IEJ1IR,DRV 2O5_
M%34M7#3D9G@0V D>'F:93",E9--KN.7)\?&BQI=L+RBIM9"1SHK')5J9U7(/
MA%4,<RZ[);2V@J/\47K2/5X*%(AM((LH) (H,XY4"@Y#O;_N%/\ YZ%_36:#
MKD\J"M H% H% H% H% H+>FLWZI?HY7O'(^Y.;(L5",L\:QY_P 8Z>&\UP4&
M;NG%-[=A,9MYZ%F\/<-!N-KA.,1T*2MD]5Q2;\>L"N->CSWG:O-_$UQKK"#N
MG<CT'94B1GW$?6[#[4] 3&2''$"Z7/.;40OCQ"2!XJFL^4G[<NNU^.U]-L.1
MA1,\K8>)>^]61!E[A>87J$4D SG4%7%F_$IOQ)3?HM85F=(U>FWM'<S,[NC(
MO;A.-SRX"]K%#33"T,+;EE+*'"Y)NWJ 65?^$45,\9]\+)SK/75KL[JWQFLB
MMM.2&(CR,!'RK+,=E!?9=<2=:5*?#J5><G\GEPY\:ZW3%PY6YTUOO79[4R\_
M</=MCLF\\J//G8]MYR0SIUI<6T"I2=25(O?^+6+&WFNQ<MGHVT=LXH9Z496Y
M)#^O(NB.I<8 E2@S=JQ4X>/Z0*X_%20>@;$RVX',KG<#E)1R'U*^A$?*+2A+
MCJ'&TN?I0T&V]8U6.E('BK5C,O%<0^,Y'S/>%E<5EU8MW&RF9!:2AI;;P1%0
M>K=+J%JL?XA2:QXKCP:STM:W_*_9+-[HW-N>7-;B9)>WW<1#CRNRI;:4'UO,
MI=4'@ZE:NK!5I\Q25?QJQM^%ON3C:?9HP,WD-QY_8.6E#L4V?CI#JBR!="EQ
MR=2->K_]UZZ;S&_ED_3'*7X:?W+L;NO<S>'VS*EY]:W7,RJ!/4M$=*9#8?+?
MZ2S8M8=*--8UYNO]K7DXFWW3.W]SYM&^%8S.S9,8R9+X@QEM,J@O-(OU8CO)
M2' JP"E!9/BKKMJ:;</3@I/AK+6J^HI0*!0*!0*!0*!0*"BN8H/GS^O_ /FO
M_8U!]"4"@4"@4"@4"@4"@4"I115])JH^=<ZI?UU*4K@OK%*X_P"E7/9VU8.V
M/I).KA<5S=&RQE5)='6)%CRJL5NMSVU"WAJX&5(1S;5<](IA+&1MQT+3I)N3
M8"B82\/,SH;MG"01R\%JLJ6.FA[G;>"0I-E=*JU*Q8W',F.1('2#6F>UJ/95
MI)N5%1H=K37F'%"S:=/X:QEN1J2)KN@K=<ZM(Z/#3+4C05E&-)ZM*EJ/*_*H
M6-=<A]P66>'Y*:,M21:Z0+>(=-ZL$CA<;,F*+;#:EWYJ/S16AU4/8RW+&<[^
MC_5IX?!0=-!Q4& V&XK24 =/,_&:TC='*@4"@Y#O;_N%/_GH7]-9H.N3RH*T
M"@4"@4"@4"@4"@M'*GU37HTYL6/)CNL2&DO,NW2XVL72I)Z"#7+^3^,9\-^5
M0^&V/MO#J<5!A%*U@I"G'77U)0>:&R\ISJT?Q$V3XJ[>3FWW/'Q)[-.+W7;&
MBNLN-8I*U1G5R(R7''GD-..&ZBVVZM:4 _DI 'BJ3;%SZ3#=F99ZW+(>[39H
MQSV/&.TQ'I/;%M!UZX>4KK%*2HKU(\]1-D$"I+Q]DO2^Z^;W>[2GSD3I, ]H
M2E"%*;=>:2M+8 2EYMM:&W0D"WZ1*N%/;UY)MQ+Z3#%-[MMH3LK(RDB(Z9DM
MCLKKK<J8T.HTZ= 0V\A"1;EI JS?//J;:\2>B5V_MK#X##M8?$QE,8YH*#;"
MW'72D*)X:G%+58>7A4M5&CNXV6,6<2C':8!>,A"$N/!3;Q.K4VZ%]:UYW+JU
M"U)1*X7;^+PT8QL<R66B=2EJ6MUQ9\*W'"M:SXU$FG=Q23A'S]B;6GY)>1E0
M=<IT7>(<=2V[;EUK*5!IRW\=)K/].$VORJN6V)MC+2VY\V$52V4A"7&7GHY4
M@<DKZE;86G^*JXK?].$OTJR5L+:LG+P<PN&I,_&)",>IIYYE#:1P"0RVM+5O
M%IX]-6<YOZC;CC]/+7]U^QU.+<7BTNA;YF=6ZMYQI+Y.HK2VM:D(N>-DI K,
MF-I[)MSK]TBUL[;[66&41$/;4!75%3KJD(*OG*0TI9:2H^$)O5VV:UUX2./Q
MT6#$3'C=9U*%$I*W''E<3<W6ZI:_PTAJD**4"@4"@4"@4"@4"@HKF*#Y\_K_
M /YK_P!C4'T)0*!0*!0*!0*!0*!0*"BA<4'%[M[N8.:4J7'7V:<>:T\$*\HI
M1Y5G<%D\)*4Q.;)2I0"'4))2?+7"QUE<INA.5[(ES'E86RK6\AL7)38_@KT^
M&X>;S3*0PTB6YCV'Y0+;Y&E8'3PX&U<_)^5=?%KQ$FB:L6!-K<U#A>L._:E(
M60;UMAVRM2@E(Y&YZ2:,6))4N XTXAV0OK6^"6[W%_%4J8:;<I:57"RGP &U
M9IA(?6Z4H%U%Q7EO2;':N&8L0H(NK\E7$5KN.UB>RTYU/%8;2?Q4#2/P5C*X
M84DJ/G75_I&]:E,,[++SSH2TVIT^!/&MQ708[9N7DI"W+1T$_.5Q-O)PK6'/
M:NE@['PS"T..I4^L?.UFZ;^2D93S$5AAL-LMI;0#P2@6%:&<"U H% H%!R'>
MW_<*?_/0OZ:S0=<GE05H% H% H% H% H% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H**YB@^?/Z__P":_P#8U!]"4"@4"@4"@4"@4"@4"@4 @6Y<
M*#"_%CR$Z7VD.I_)6D*'X:S@RB1M/ -2G)C,-M#SC9;-A9%B+?-Y59<%F7E.
MX]@Y^ ^Z['8[1&6HJ"F>)2GQWO6+>732X<P0L<% A5R"E0((M4=<KVP H$#C
M?C1.JJ5J"SIX<ZE,+>L67#<DUBF$I%L&A;D1Q%)$RVV&'WEA+396>@)%_P""
MM8,N@A[+W!(" 6.J23Q6Y86'D%JO:QW.H@=WV,:0E4Q:GW!S -DW^"MS5.YT
ML'&0(;83'80W;I2!?X^=:D9M;5A516PH% H% H% H(#?6!EY_;,O$Q'FXTB0
M6EMONH4XA)9>0\-24J03?1X:",$;O=OPR6 /_L9GTN@N[-WO?:. ]1F_2Z!V
M;O>^T<!ZC-^ET#LW>]]HX#U&;]+H'9N][[1P'J,WZ70.S=[WVC@/49OTN@=F
M[WOM' >HS?I= [-WO?:. ]1F_2Z!V;O>^T<!ZC-^ET#LW>]]HX#U&;]+H'9N
M][[1P'J,WZ70.S=[WVC@/49OTN@=F[WOM' >HS?I= [-WO?:. ]1F_2Z!V;O
M>^T<!ZC-^ET#LW>]]HX#U&;]+H'9N][[1P'J,WZ70.S=[WVC@/49OTN@=F[W
MOM' >HS?I= [-WO?:. ]1F_2Z!V;O>^T<!ZC-^ET#LW>]]HX#U&;]+H'9N][
M[1P'J,WZ70.S=[WVC@/49OTN@=F[WOM' >HS?I= [-WO?:. ]1F_2Z!V;O>^
MT<!ZC-^ET#LW>]]HX#U&;]+H'9N][[1P'J,WZ70.S=[WVC@/49OTN@=F[WOM
M' >HS?I= [-WO?:. ]1F_2Z!V;O>^T<!ZC-^ET#LW>]]HX#U&;]+H'9N][[1
MP'J,WZ70.S=[WVC@/49OTN@=F[WOM' >HS?I= [-WO?:. ]1F_2Z"U4;O=N+
MY' 7Z/\ 89OTR@XOW3]X7:^U?7&)ZS[P_>BW8Y-NV=F[+U?^\_R>CCX;]-![
M-0*!0*!0*!0*!0*!0*!0*!0-(J8%-";6MP\%.V&49DMMX2>VI$F(VK5S4E(2
MKCXQ8T[8O=7'2^Z*$5GL<Q;*+W2VI.NQ\O.G;%FU1J^Z')!1T3FR/"4'Y:EU
M:[ZJSW/S=0+D]"$]-D&_X2:QVI=ZZ3$]W&)AV7*6J8L#AJLE/Q)M5D3+IHV/
M@QDI###;5N6A('_36Y(99U/LH^>M*?*1598Q+AW/Z9OAS\Y/RT&5MU"Q="@H
M>+C07:_@\M!4$T%:!0*!0*!016Y\_"P&&?R\U+BX\;3K2RC6X>L6EM(2FXXE
M2A002>\8@_W9SY'_ *#_ +]!=[QO\,;@]0/IT#WC?X8W!Z@?3H'O&_PQN#U
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M"I#Q(2ESB"15P9=/ W#*:LF1^D0#:_(BF%E=)%F,26NL:4%>$=(K#HS@WH%
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M=%G&7D)<;6#T*2H$&LX^C>?JT!L_:S<-R&C#PDQ'DI;>C=F:ZI:4"R0M.FQ
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M6V&D,H1P2E"0D#R6%8MR,^FW*LX H%45H*6H*6Z!044 38]-,*QN/L-)/6+
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MH9?OH 6WK!.GCTUQ\FW;F^EPWK,V1QNU=\[OD;;VUC[1)6Y,M 1-ZYTN]6&
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M0FT.RM)8)!+B6 I:N">.BMXYOV3.;ADB]YV['&\4W*VXY$EY"8J$M4D+BIL
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MR\=::RJ D&XY^6C.%=0HJNJ@:J!JH+5+\8'EH.2[H?\ ZWP7_IS_ *Q5!V%
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M\)J97#?2@#HX5%5 M0+&BJT0H% H% H% H% H% H% H% H% H% H% H% H%
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H*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>modular004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular004.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ K "? P$1  (1 0,1 ?_$ *D   $$ P$
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M0E9\(.(603LZ4B]2" PF(UME)!$R1)1"@S7X@X72WS8L?P6W5;?"*R-M #V
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@I\9)BY#WZY3?G7(X><SRN'A_:<Q/!>W1Q6J5H*,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>modular005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular005.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ R@#; P$1  (1 0,1 ?_$ *X  0 !!0$
M       % 0(#! 8' 0$! 0$! 0               0(#! 40  $# P(#! 4%
M!P\("P    $" P0 $042!B$Q$T%1(@=A<8$R%"-S%18VD:%"4K(ST['!T6)R
MPD.S)#24)74F-_#Q@I*#DU87X5.C1%1D=#551@@1 0 " @(! P,"!P
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M_'Q9S)8E-)=9/-"JN6;4BWE&#9>V;6^CV@!R'$_KU=G.?CT5^I6V/_CVOO\
M[--B.BI]2]L]F/:^_P#LTV/PPWY&-;>@.0DJ4RVM!;"FS920?Q3V5F9ETK$P
MAT[$Q22#U7[AHM7UIXDH4WU/=]\)<4+^GE1I6+L7$,S&Y2U./N(;#9ZI20JW
M(JTI2?9>WHH+'-B8YQ2U+?D*4X[UEJ*TW[BV"$#P$=E <V)BWBDO..KZ<GXM
ML%0TA=DC@ D6%DCT^F@Z'X=-K<?=T\SRO>@RU! ;[^RN0^;-2S,IQL@)%2BP
MNN*VH3V=M!:I)([QW4%@0LVU#_./7>@TL^#]"9 _^7<_)-$K*(\L /\ EUMR
MPX?1\>WJZ8H6C+1Q_P#5N_9<8BS>2;+R!R&H>(VKI'AX8G3MR[5-K<*YR]T3
MGE<!VT7'*M H% H% H% H% H% H% H% H%00&^_LKD/FS4LS*9U!*0H\+"]_
M94H9<ZK>T<*/1QTR0TA10IY#:4H*OVNM8)K:;)K%92-D8Z9# 6E)X%+B=*@>
MY0-%B6VX\RT 7'$H!X J( )]M&AU]EI(4ZXEM)-@5$ 7]M!H9\@X.?8\X[MO
M]4T,(7RJ>9<\N=N]-:5Z<?'"M)!L0V.!M1,M;S :7%<@9QD75"=2';=J":W7
MP\7S(QB760WT/QVG4&Z7$A2?4169>KIG-(EL)-ZC<3F%:*4"@4"@4"@4"@4"
M@4"@4"@4"H(#??V5R'S9J69E*ND!JY!(">2>9X5.M?1Y(6LSFBK0E].+CK*U
M-!1<?8#O8DV1=3=^ ))'>:[O/,<O6F%)#2-*B1I X\2>ST<:Q+TQX>=^<BY!
M;QZ&#I40_P 7-?1]PV'R?$.?B'E>H*[Q?B2-MX^4AX?$XP!SZ/FI=67G%-<&
M7.F4>/\ ;#D:"9W3*W><,VO$P8IBN1E&:W*<4E;5T\0C2./#OI"6C+QS;FWM
M][ VSB-W;4D.Y;!2HC4G+81\ZBD*0%+4S;E;_*]=(EQM75[-MS=&W_,':BWX
M"[I?04/L+X.-.$6LH?M31,[UF%VP,@LP7L9(),K'J*"%<RD<J6<_B6QFKK6T
M@$US>JL8C"^C10*!0*!0*!0*!0*!0*!0*!0*@@-]_97(?-FI9F4QXM( Y$<>
MX5FBPY=W;\9HRE1<W-@QV#KE16UMN)1<:C=3K:UBX/8JNV6,)["0(L*&AJ,X
MMU!\1==6IQ2BKC?4HUETAOK::6 %H2H W (!L?;044PPHA2FTE23J22!<'O%
M!H;@ .#G_P#IW?R318X0GEBE*_+G;H5X@K'QP0>7YL<*N6;?<\RW=!5Y5[^B
M;KQ@*-K9EY+&:AI]QI:S^< ' =_WJW7EYK?ZY_5WN3=;Q.Z(6;9-X&2"6GU#
MW;J]U56?#S]DZ7BSN6N5P;BW UR?1\SEDHI0*!0*!0*!0*!0*!0*!0*!0*@@
M-]_97(?-FI9F4SJ"47[A?AZ*E%>7Y[+;>R3<_(L?2Z&G$%$^+&0D-O%GP$+*
M@I0/AM=!%=<.4VEZ5 4TJ$PIE);;+:5(0>:4D<O7676&P7+&Q-CWFBFL\;FW
M"]J#2SPOA9PO8=!RY_T30GE#>5P!\N=N<.>.C_Q8H1PN\Q-I,;KVED,(YP5)
M;(:5^*X.*#_K6K43AR[J;0\Z\M,J_NCRVD[>GDC<&WKQG4GW]3'YL_Z6FUZZ
M.'=6+5Q/F'INRLP<EAFE+/R[(Z;P_;)X5B\.GQ[S,8ET%8>@H% H% H% H%
MH% H% H% H%00&^_LKD/FS4LS*8MX0;7X6MW\*E%>;9C-[K3DFH4U@8/$NR"
MAV1';2_J:/X1<4"A)5V_)UV<?5Z1'*.BUI5J2 -*^6H=]A85B7:'G?F_,FMH
M@-PW5I<*'UJ;ZBF4V2V?%J1:ZTGBE/::*Q;@RT>8<2Q*R,AG'*@NN.R M3#I
MD!HE'4+>DA5O%IY7H-Z5G-UHV3!T8KZ0<DX\&>^IX,EI11Q.DI5JH)OROO\
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M7'C3X<E>IJ7'Z+6IQ)1TBI"EI4JQ2.5Z]'H\T^7K$)E+$=EE%PAM("$F^H)
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M8*8J\F"T\2[UUA:0H%P?A'OH,N= &#G(0 FT==DC@ -)H(GRN_PYVW_9\?\
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=O3451'OG]R*0D^&5/(>O]:J59*-24"@4"@4'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>modular006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular006.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ Z@)3 P$1  (1 0,1 ?_$ +L  0 !!0$!
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MX_$0,>T$1F@FWTK7-:1OCE0*!0<;WM?Y0;_FV%_Q:+0=BGD*"M H% H% H%
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M;CV5J#1![W;\!@#[\WY*"M^][ZN _.F?)0+][WU<!^=,^2@7[WOJX#\Z9\E
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M\>H)DL(>9DI 4 4J2['4XVH<>A5,-9=G44H**H/F;^V_]9_[K0?35 H% H%
MH% H% H% H!( N:!>@U9>1BQA=UP)\'3\%61E#S-R'3:,DC^FH6^*M=J=R)?
MFR7E:G'%$_5OPJ]K%K7*A;@>-;D9M6J6>L"KG#.,M3(Q(LZ*MB2V'&B.*3_H
M-9M;D<EN'8V/RL[SYV:LN#@E2_VA_./&L-JM8W#8YU,EIL/36TZ$O\R/<'14
MJRN3W8VC)RDO)95VR3;6@Z#\7"LM91B&);#"A&\>Z;!MQ0/#W2:F5PT7]N3Y
M1(<=9CLGYQU:C3*8;N)V3MIE85D'?.0.*4)'"],MSH[G'YC$8Z/V.-@#6."3
MIO;W:LKGM&14O/374JD.]BT>*D)Y^ "U:C&,.MP*I$>)VJ%*0^H@!?$7%7!E
MU$#<;R;)E#4F]M0YW\-+%E=#'E,OMAQI04#SM6'1FH% H.-[VO\ *#?\VPO^
M+1:#L4\A05H!Y&@YK=^.W9.BMQL(80;6O_C4S%O(UMV^8"TE7!7TO!0;.W(F
MX68BD9E,1#B2$1V(&OL4-@<KN!*B?>JHHULK;#6:7G&\5'3EUG4N>E #RKBQ
MNKG6:KGV-K[T;[PW-P*5CCBG(_FA927A([,*UA7S=!5JZ+U9T23YLHS-;$WU
M,RVZI3#^-3'S\)N%&2M3X6V&=8"G E)!NEY?+IM6M=L-^2YQ[,<+8&^V]P[?
MR+[^,+.(QKV.=0@OE2R]V=U@%%O]BG@:9ZUCR\ZR>^4EM?N[R&'W5+S 5&B1
M'VBVJ%"+B4/K4H*[9YL@("TVLG3UFL^'Y93S?-A?G-G[KF]X&,W!%>A)QV/B
M2(O9/%TO$R2@J4 $E'BEI/3QK.DQ:UY+G613:W=[D,1NV3F0J-#B/M*;=A0=
M81(<4I*@\\E02D+1I(&GZQK7CXUP;,^X=HY^3O.'N/%R([?F\&3">;D:^)=4
MVM!24@]+?C5G'S937ARS'=IOU.%P6,<DXL_9>1?G/K0J3X[;VOQ$^)S_ &Z[
M^X/#76[$O+H]F;*W/@#]GNOP9&&9=<<B2-"O/ AQ166U73HL%*^=>]2U-IRE
M=Y[6R681CY>+D-L9;$R/.8BWK]DNZ2E3;FD$Z5 ]%8L:1V<VWO[,08*'I4%E
M:'E*R4%I3PCO,J3ITZ]/:&W.Q%C2(YC']T^]L8S@(L67CE0L)D'YR6U]JE6A
MY:BE"2E/0E==-;RY^69UL3&9[O\ =+N>W!DL5)AAK.0&8G9R>TNVMKM!]!)\
M4AVO/ISI9]^73:YD]HU<AW>[U?V/MS;[;V.1)Q#S3DEXE[LUI8N$! TW\8'Q
MKUW\F_=Y>Y+]&T]8LRW=GNQR-N&!CIT1O'[B4F1([4.%QB3I0E?9V20IL]GT
M\:Y;3C\VI<67[<.:W7"\WW#$Q\S,X^,_#Q[$)Q.0D/8T2RDJ4I* T+2&[* T
M]!\-ZW?JV]TTF--8ZN-M+<,F=C=SX=N%%D"&C'S,7*"S&4PPXLM+94$E0-ED
MCARM>KMS)&9TOXNZ<QSRL2[$>6CM7&EMJ4A(2D:@?FCJ%ZQY?F[F]+C>5YSB
M>[G?F/7MM")F.=B8%3_SNV2M:7E7%M*+<K7\-ZNOP_##%Z;3UVRO@]W^_P!F
M N$K(8_2]D7YC[+2GPV\P^LK4TM6G5XA)X<CTU+]$GHUK<;V^JV'W0[@A;9C
MXF--BH=@Y963B )6&M"GENZ%<-5_VENKA7;OYE]L,_"^]=7O_;&X,_M%[#XY
MZ,W-DI2EU^1K#8 L24A )OPX5RG%U]EGQ]W-Y'NWW3F<O/=R\B$UC9^*:QKB
M8Q>+R5MW7K3K2$E/:+/#JK4VXOOMEJWF>T;36QMXS/,W\U(@/2L-'=CXDL]L
M$+4X@-]I(ND6-A]&]3R<RP\-[:C=O]V&\<3B< XU,@?;6![5I%NU\V=8>-R%
M>+J2H7Z!5SS/[<,>.8NWOM:SX_NKS[6,S42>]C\FC*SGYPB2&U!E*GE%2;K2
MDKN":S)C61=^?);^#L=F;9GX';+.)E2_.GF^TLNY*4(6LJ2T@JXZ&P=*;] K
M6UX3#ACW7[Y8PT7%PY>.6Q$S#F4;#_;"[9DJD(0K0D^-XUC6='3/#-/[K-VY
M.9N"1+F0HZLA,8R&-=8+JEMO10E+?:!:0DI(0+VK67/#NMO8_<#;%\T(29!%
ME(@I5V1_I76E*KGJM:F3"=2+) ZATU&E:"BJ#YF_MO\ UG_NM!]-4"@4"@4"
M@4"@4"@4"@HOYM!#[CST;#P%ON*NX1^Q1UGHJ6K(\ND9EN>I<B>MQ+ZR;:+D
M6]ZI*MC:Q,QEHK EJ4V1XJ'.==)LY75+"<U;]X*WW)A:9;5KZKGP4RS=6C-S
MD=A-E'CU5+5D:'VG.E"T=@A/UU<!;WZ9,*JQQ+/:39(X<2$FPH*)RT+')TL@
M)*A<.*'QW-9JM'(-0]V,NMV0IUOB@M>(\JW/2/I>]6<M//#@UNYE<6RFV&UZ
M!J"M=NN]8;2K>SW&W%)[8EL'AK/&U7%,I6!MF-J!2E3ZO@ K4U9M=!'Q#C8"
M3I;3U#G6I&<I:#C6@0IM!41;QE5J1FI8)*0$WOQOPY54;,:.X]^[ TBY6L\A
M;I-2K'3X2,TS%(;7KU'QR.5<W5*#E0*!0<;WM?Y0;_FV%_Q:+0=BGD*"M H%
M HA15IO3XE8)#R&4%QU0;0GFI1TCCPYGPUG?TB>J%QF\($S=,W;R&WDRH3*'
MW'7$*0VI*R0GLU$ *'A%;_3E;U=%J3U^#WZR*:D]8HAK1UB_NU93/JQEQ(OQ
M\-N? TVZ-N>VSO2#GLEEH,9A]AS$/)CR/.4*:N5#5=(4 ;6IKT<L_-71I4D"
MUP+GA1:N"DWYBC2[4GKH*%0L;&@L"QROQKGXY9:N8J5)M>_#KJZWFI7-YC>>
M/QFY,9@767E2<H%F.ZE"BR-!\8%RVF_'E>NDZX8\EQIGWPG'&8ZU76A"U#B"
M0"14E=+_ *,K=@FW+J'"L_J8QQ6&4^AAI;SITMM@J4? !<UO'4GZ7/;:WBYF
MYBFAB9<>"MH/0\DO0IA]LDCQ%(*M)X<EV-<])>V_BNWUIV ])<=?$B,N.&G-
M+*UJ;4'$:00I.A2M(N;658\*L+6\%HZQ554J3UU1S^\=VP=K89W+S&7GH[:D
MA:6$*<(N;:E:0;)'2:@WFYS[CK'9Q%F,^V'3)U(TI*N(!23KO[@IK?FI>G#=
M0H:+D\[6O4USDU9$VO3XBM:JJU(A5"@4"@HJ@^9O[;_UG_NM!]-4"@4"@4"@
M4"@4"@4"@Q2W.SC..?425?!4I'SUF-S.S<D\WD7C8*/8DGQ;7K-;BYI?B@ A
M:#\TBL]R]K(MX6Y'5T]%.X[6!Z8ZSI).@*^;J-A:M39BZL4?,&2XXRU([31\
MY*#<#WZU-D[4AC910X=2$K3]99Y5K)8WI>5DMQBXVWJ93])M))'N6IEFM93R
M\A%#L"6A+]K%J19))/A/#X:92(G)"$MH-95XP)5AH,=6M*B1<7"+I-1IR(SL
MS$/+0M)2ML%,:5Q"".BY_)6<#=QN_H:Y#:,D^7%N*\9U"=1!_I6JR+8[[$IQ
M,UM+L>0A^X')0)]]/172.=J=8A-<KZ;=0M5M9RVVXT= OI*E="E5,KEM]DI"
M>T?6EE/0I1L/^VF0:6MY79XN,J6KZ3Y&EL?#4RL="U@W9"65S%E&D>,TC@">
MJF6HFV6DMMI0V-*$_1K+3+0*!0<;WM?Y0;_FV%_Q:+0=BGD*"M H% H% Z:E
M'GG?HPIW8KA$AZ/HE1+K8<+1\:2V@W*>/TK@==36?]FJN5F0G!N7,B%EY2!$
MVVTZB0T\3(4ME3BTE3U[FQ%B.GE6L_+_ ,A=%R.XLQNG:4&1G)36/RN&D293
M$50867H[C("]:#J.KM#?_MI9Q?88,#*[P\YE).7AYJ-$C8N<8LN%)DR+AAOQ
M4H<C:"CM'+W2OIJ3C_PDZJ[0D]X>X<FG<:,Q$C08TUV-.@N27R VE92ELQM'
M9(</ @WO3QS$GNGEYM]G;]XN:F0U8/'-R%P6,Q-$23.2=*FD]FM8TN?04HI
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M@C<.GQ^C_6H [IN[2U_L"/;W%_K43*_V0]VWW!&_3_6HJWV1]VM[?8$;]/\
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M+C*O%/FKJ&%+TV\;2D@CKK6M<ZC,T_/D;<PLK(XI]R7&S;3L69"Q\M"G8Z7
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M4F_7RKI(S5K<68\L.SI*I"QQ[,<$BMLMT("0+#AU5,KD)\2]N'7TT,KD$ I
M/%0-DCF:N21T6"A+::[=SFK@!7.NFJ$[V?\ *+?\VPO^+1:RT[)/(4%:!0*"
ME2WX$>;9K=FZX?>@C&(3$^P&L8_.DEQUQ*PAIQO4H -J&L \$WMSXUC6\;;?
MM_W6Q1OO,RR'<3D9^+;:VYFI'FD&6TZI<A"UZNS5(:TA*4J*+>(M7,5UWUS&
M/BN[XHZ%87&2BSVLB-DXIC@$ ZE+TD"Y X@]-<?',^33\\GDO_7O^2Y/>/*@
ML9M.8@MLS<8]'CLMLN*<;>,I12R I2$$&X.KA;PFNO=+KG[F=>=\?:U<MNN;
M,B9K:>YL<W%GOXM^;#5'=4^PZR@65=12TXE;:E)U#3;B+$USL^7>SK'3P]=?
M='[9W#*.SL)MC%0VI\Y[&KD2T272PVB,E6@\6PZHK7J\46MP-R*Z=GS3TPQX
M=NOXIGN1[1'=Q%2&PTM+TE*6R2I*;/+ &KJ'*M[K^MQ&6S&Z,YA,E*S4:*\G
M$[B98QWF[KJG I.BZ E:&T:=*[W*N=_!?GJSY/J=M)[T9.+C[@.;@)9?PJF
MVB,M;R74RB0W] +U@I.I*4GP7K5=)>6YW?\ >#/W-)G1)F,=A+AA"FI1:E-Q
MWDN7X(,IB,YK1I\8:.D6)J,[=6A-[R-S_B/.X3&8!*UX2.S,6Y*D!KMFG>TN
M6PV'N/[(Z0JU^FU6-V8L9,9WDY3)SF&8F/8\UFXQS(PW''UZ^U95I<:=2A"P
MFQZ032N>MXK48[ULXY^&V&<#VDK<"9%G.W0F,VN,M2%)U']J;<#^[Y&LY67Y
M8HCO6W"G&L9.3A641V)YQF42B25+#NJR51O$TN(M:^M2#X*N,W'MEN5:.]G<
M;C6<FL[?2B!MZ<8F02_)2)!:T-K[1I" M!/[2Y!6.%NFX&M-<R7U8VKJ]VY[
M(1]D2\UA0TN1YKV\7MU%"=*D!0-TA?'C7#;;'/OAN>CF\1OO=3N(P>/1$B2]
MS3\>C(/)4^XE@,%( 4M8:4OM%F_ ((O?C;C76:R7:?L_W9SF2_N=+L_=HW)A
MGI26#$FPWG(LR,X;A#[7 I"Q<*2>!!'1X>%3:8N?8O3\WE&6SFY=P[3S<K.1
MHSB,;F0UCNP=6I8+2PDI 6AI&GJ.J_/@*GCN=O%MZVF\Q=YZ1V\CO-DX<9].
M<@)87AVVG&?-5K>#K;]^S3Q0A7: @Z@ 1U$U9<S:_=8SX^=I^#:V#WAY#<<Z
M;"F8MV&Y&0AQF4&I2([B%WL@*ELQ5ZQ;QK)MX:NFORX3/$V]6K/[Q=TG.YS&
M8S H<.";;?=<DR UVR' 5'L@@._1'#7I]ZN?COR6_=AUVXLGK&+.]Z.68VY%
MW)C,8PK"NQ&YKDB;*$=1+G$LLI2EPK<3](*LGJ-=-XQ%N1WKO [XQD3&18[^
M'D8H9,LJ=4A]25WN -!;UBWB@K"?Z59UU::C??,VC:F-R#>*\VR.5DRV8N/T
MO.I1YL\IM1=\T:?6"=-SH0KCTUO'-3.>&>!WM9F<G$-IVY(:EY)YZ,HOE4=I
M*F5%(4.W#;Q0H65?L[VZ+\*SOXY;-,]9W,[7MTN_[;AHYCO/W<_@8SF-BPXV
M5;S?V3D&U/O%K6ATMV:7V.I25VXDI%NHTUN9W>KK9C:Z^CUB$N06VDR0E,@H
M':I;45-A5N.@D))%^D@57*=6T*-U6@4"@QR?W#G]4_DH.3[G?^5.T?Y3#_W*
M:#L*!0*!0*!0*!0*"A%^'*@XO<V'F192Y\-!?B+XR&$"ZT&WSDCXZ2I4$F4R
ML70L+OQX7U#P%-N!KIESPU92@ZT18$$<B1?X+UG*U#8[*3,#*<9"BY!?U<!Q
M*5JY6J6K$+^*YBD(BO275EX^,TFX/OJY5FMX=QM"3AWHJO-HZ6Y";]I>RR;G
MK-2:1SVB7F[@QL)02XZ%+7R:3XROBX5VFL76(>3N?+25E&/C=BV?%*WN"K#I
M %Z,U8C;^1G*US'5N'GXYLGWA3(E(^V<<T@=JE*R.-NBL[5*D8F/AQ4_\)'0
MTE7SE)2*2BS(Y"/ 8+SP64)/$(05GW@.-+2(=S([BRGC8J*(D17#SB78*/A"
M/G5BM8;+6VU.EMW)S'I4A!N$I5H:!\ K/;3"=#85?AQ^&NEC+2R&,Q\E 5,)
M3H%]14$_$3:FK41S;<%"E)C+2M*>D)(O>NN$K, .'0:N4RN#2#TU,):O TB]
MA8>]3!D*]("U62D\KU%D6^=(4X$-)4\L]#:2O_Y;CX36<M=K>CX',R7DJ641
M8XY\+NGWOFCX:9.U.0,#$C*[7BZ\>;CG&WN5G+4U2B$@"HTX_O:_R@W_ #;"
M_P"+1:#L4\A05H% H*6YUG'S9(X_-[$3D=V-9[SU338A/0)D0("@ZRZI*C9=
M_%L4=7$5C&-/)KCZL?T:J/Q/=F[#\SBRLNN9@\8^9..QRV0E39L0 MX*5V@3
MK)3XHKO=^GX88G5);XVE/W+!B18N3&-3'DMR5*[ /E9:.I*>*V](OSK&GR[I
MM,Z7W0LCNK?GR,TO)YKSEK,>;K2AJ.&5,/1%:FG$*[1=[$GA:IIQKCW-=<;9
M^UL^SS(/,S7<AF_.LS(AKQ\7(>;!"68[NG6.R[0ZE*TBYU"ICC:?N;\5Z7]K
M1QO=3/QK>-=A;@4UDL?'5"<E"*DH?C+5J"%-]IP4DBX5J]ZNG^26YG3&/S<O
M%KBV>^71[%V:WM/"JQK<UZ>VI]Q\+> &DNJU%*$CD+F]*W?K<SD.Z;)O(FL1
M-P*B1)F2&3+)BI=TN)"?%OVJ=0.@5E/)/F9Y7=5+GS<T]D\TJ0WET1RE#49+
M*F78URTM"NT7>Q4>!%5<<NJV[BLQCHH;RN5.4>2 A#@9$<:0#:Z0IRZ^M5Z)
M>KS(Q,IE^]_<C,"9)Q;$K'1(RY3D!];+H:6]VS:77 TVE:0\FR@H\^%ZL=-[
MG#K7^[8MR<9(Q&45C1CXCN/6CL0\'FG;%1-U-Z%ZA?5QI7'6<5&0NZ/)1)&#
M7$W(Z&\&N0ZPW(C)>*E2C=8OVB+)\4:1[O76+%D^6+9/='G'L-(QRMS -NY+
M[44X(()"^'B6[7EXM:FV-\_;AN1SVRL!E,]F-X07<A)A8^1DDNRV'<>\T)3:
M6&D=HT\]V80%.-+!2 K@/<K?CVQIK/1C:/6\O@V)^ >PK9[*.ZQYN@I .A&G
M2#8D<K5QVTS_ .<NFO7/LY)ONPG1V\3)A9Q<?.8B.(2<BI@+;<C@?NU,:T\K
M<#JY^[77/.U_<Q)C72>F74[:VW&P>-7%9<+KKKBY$I]8TEQYTZEKMR]P= K/
MDYF&O_;C)?=).<Q^1@1-P*C1<C/.0+9BI<*%+(647[1-[GIK&E[9XYCG3*[<
M]WW-B;W5R\G.RTG*YOSAK+1V6%M-QDLEI<<>*XA?:*^D2;6JZ<:V8_5EC68O
MY8=/MW#YK'L):RF7.4<;2$-K# 8\5/ :TA;A4H_6K>M^+.NOR2/.D0\EEN]7
M<L>%-DXR/)CL,.O.0'ELO!"=*TMO+[-"5#EJN:X^&8\6T]=\NOD^K6^FJ<RW
M<_%F@1(^45'Q(QZ,<(*F0[H#=[.(45ITJ/3XO&NUN6&XKNZE-Y+%SX^;6S*Q
MT#[.<<4R%!U'&QMJ&BQ)\7CPIEJ(O']S\V#B(,=&X%?:N,EOR\?DD10G09:R
MZZVXSVBM:5*4?I#A3.69,6U+938>>GY'#9!W<"0_BE%QP>:)*75J !TI[7]F
MFPY7-+9-YM[87R8OB[?6RHICN?G(QLN*[G^TD/Y09=F0(B4AM_M-93I[4ZDD
M^'A6=->W61O:YWNWK(]!QT7(,2G/.)GG#!0A+2"V$J24@!1*]1U7/'D+57*=
M4B*-U6@4"@QR?W#G]4_DH.3[G?\ E3M'^4P_]RF@["@4"@4"@4"@4"@4%JFT
MDW(Y\*8'/YC96'R#I>"3&DVX.M&W'K*>1JY3M<GF-G9Z$=;)&082/G) 0X/=
M23Q^&H8<J^I:"I+R%L.#Z#B"D^]J ^*A(BI:%*;L@);MR5;A\)_T5,-9::94
MN+&=CE*T*60!(:-N IAFPCYU,(!Q;I2E(\5.DN$_!>J8=EM/=$>5V;3K(;<=
ML4GB";]*@1P-7+-CK)4^+#9[:0K0V#;4+J^(7IEG"..=R4SAB(*G 3^_?LVW
M\=S6=JBW[$SDM]M[(Y-3*4F_FT461PZ-?_95@GRD*"0KWK^,>'N5O!!YYIJR
MG'$H '):@GAX;TPN4:]N* VI2&M4AP]#:21^<JPJF6HK+9Q^X:93&;/)9.HU
MJQG+6:PQ<D&3,DN2G3S039 ]P5GM:B0;90VDI1P3:]ZL2LG F_ DCDGG\=J&
M%JWV$\ K4OH0@%9_1O2[87MRW8N+S$H)4TTEAH\UO'QO>0 ?CK/?5[(E6-I1
M^U2[+>5(4GZ'S4?!QO6>YJ1--1([20EMM* .02 *9;RS:!:U3)DTBB*T'&=[
M7^46_P";87_%HM!V*5>_[E!74*!J% U"@:A06%""2;'CX:!H1U&_76;KDPKI
M1U?DJV9N3X84"$#E?XJMY7*A:;)OQO[M9FO3V9DQGW5[-OAP/"K-5G7*NE/A
MMU53XY4[-OJIA+,W*NE''AQ/31K)I1>_'XJ,V!2@\QX.BBJ!ML=!H10-M@W
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MJ2HA0X+;!Y4$,.[IX?\ Y9G_ .*:\C0/9V]ZV;@_BV?(4#V=O>MFX/XMGR%
M]G;WK9N#^+9\A0/9V]ZV;@_BV?(4#V=O>MFX/XMGR% ]G;WK9N#^+9\A0/9V
M]ZV;@_BV?(4#V=O>MFX/XMGR% ]G;WK9N#^+9\A0/9V]ZV;@_BV?(4#V=O>M
MFX/XMGR% ]G;WK9N#^+9\A0/9V]ZV;@_BV?(4#V=O>MFX/XMGR% ]G;WK9N#
M^+9\A0/9V]ZV;@_BV?(4#V=O>MFX/XMGR% ]G;WK9N#^+9\A0/9V]ZV;@_BV
M?(4#V=O>MFX/XMGR% ]G;WK9N#^+9\A0/9V]ZV;@_BV?(4#V=O>MFX/XMGR%
M ]G;WK9N#^+9\A0/9V]ZV;@_BV?(4#V=O>MFX/XMGR% ]G;WK9N#^+9\A0/9
MV]ZV;@_BV?(4#V=O>MFX/XMGR% ]G;WK9N#^+9\A0/9V]ZV;@_BV?(4#V=O>
MMFX/XMGR% ]G;WK9N#^+9\A0/9V]ZV;@_BV?(4#V=O>MFX/XMGR% ]G;WK9N
M#^+9\A047W<.J!2=UY\I(L0937&__P##0=!MW!0L!@X.&@E9AX]AN-'+IU+T
M-)"4ZB +FPZJ"1H% H% H% H% H% H% H!%Z"EJ#$_%9?;*'6T+%N2@"/@-!
MSV1V-BY"PY%O"?'-38ND^ZDF@YV=M[<&/<(\U1-BG@'63XX\)0K3\1-:RF&N
M5H;%GD.,JY66A2?CM:F6>VJMRX"SI#[5QS3K%[TE9LK.EV.K_:)]Y0JY3E4R
M(R4^.\VBW](5,C&<A )TI?0XKZK9U'XJ=RX9FTRWSIAQG9"CR!24)^%>FG<8
M347:D]YH&9(2U?YS30O^F;?DIW-]J9A[?QD9 "60M0^FYXZOA-3*X2"6P!8
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M0*!0*!0*!0*!0*!0*!0*!4"@M/.BKJH40H% H% H% H% H% H% H% H% H%
IH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>modular007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular007.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@"Z@*> P$1  (1 0,1 ?_$ ,0  0 !!0$!
M       & 0(#! 4'" $!  (# 0$               $% P0& @<0  $# P(#
M! 0("@@$! 4#!0$  @,1! 42!B$Q$T%1(@=A<9(4@9&QT3(C%1:AP4)24W-4
M-54(X6)RLM(SDR3P@D,7\6,T):*S1'0VPD5U@Z.T)C<1 0 " @$# 0,)!P0"
M @,! 0 ! A$#!"$2!3%!41-A<>$B,E(S%!7P@:&Q<J(6D<%"(]$&8C3QDB2R
MPO_:  P# 0 "$0,1 #\ ^J4! 0$!!YGA/-*^NO.3->7N0L(K:/'VGOEC?-D+
MGS B%]"RE&^&0GGV(.)Y8>?CMY^9.:V@^QBM[>P]X-A=LD<]TS;>7IDEI#0/
M":H-SRF\X\GOS>>YL0W&PVV'P+WQPWK)'NDE^N,<.II :-4;'.YH/6!(S5HU
M#72NFHK\2"XG@3V(*&1K=.HANHT;4TJ3V!!4.!)':.804ZC"XM!JYM-31Q(K
MQXH*"6,N<UK@7-^DT$$CUA!>"*(*:A6B"M4&-\C"=%07-XN;7B!WT""'8S/;
MVD\R<OA[[#"WVC:V<<V-SG$F>=PCUQGCIX$R"@%?#Z4$S:YM0VM'4J&]M!VT
M05!!-.U!6H^)!:Z5C&ZGN#6_G$T'X4$.\XMQ97;GEMG<WB9&PY&QMQ+;2N:'
M@.UM;]$\#P<>:#G>0F[LYNWRTQ^<S<[;C(SRSMED8QL8HR0AOA;0#@@]#U (
M*H*:FZM%1JI73VT[Z(*:Q0G\D<SV(#9(W-#PX%IY.!J/C04ZD>O07 /I4-)X
MT]2#S[S.W1YDX2\PK-H;=&;M[R<QY5YU$P1@MT_1/AJ'.\1KR061^<>#D\U?
M^VGN%U]L!A?[W]7[MPMO>?SM?T>'T4&;"[G\Q;KS,RV$R.WA:[0M(RZPS?B!
ME<&M(%2=)J2[D.%$$^#XQI!< Y_T03Q/J075""@D9KT:AK'-M17XD%'R,:"X
MD #FXF@^-!4N#>:#SWSXW=F]J^664SF N&PY*TD@:V4L;*&A\S6.!:ZHY'M0
M3/;]U/>;>QMW,X/N+BT@ED>!0%[XFN) '94H(A8^;N%O/-.Z\NVV5RW*VD3I
MI+L]/W<M:QKZ"CM=:/[D$^UL#2XD #F3R""X% 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!\T?S(9!NS_ #3VCO*WK!)<
M6=W97DPJ-36@L%:#B0VY/X.Y!YU!A9O+3"^67F!$'07%\+S[5EH0]QGU&,2'
MM'3=P03;RNAO=L_RO;IW/9ET.5R[KNXANA5LC8V4MXW!P!/A+7N'K00^RM]P
MWOES:_8WE_N&7=$K([BVWI'<7$CWR:PXO;I9QB+00UM4'UULJ[RUWL_"7.8A
M?;Y>:QMWY"&5I:]MPZ)IE#FGD==>"#Y;W;F=KW=]OAVVL?G]X7MG;W+KG/7E
MX&V>+E&L^\6[:5\!;X>(<0TAO>@MN]Q9[)?RM8R>[R%P^Z9G&VL=YU'=?HB2
MK1U*ZCIUGF@E?G5M#'^7?E-+?;8GOH<EF;FPMLE?R7D\TTK&LDF)+GN(:2YO
M'2 @B5U#NR.PP4^TO+?<.&SV/FMYILX))YO>V"G5Z[2T!XDYBIH@^M+LO.'F
M<X:7FW<XMY$.+"2$'S!Y 9#(3>2/F1+/=32S11S=*5\CG.;2U<1I)-1Q0<B\
MO;^?^73RW,EY<M?=[BDAGG9-(R9T;I[II&L'5P[/@03SS+VSBMG>:OEO-MT3
M8^3)WYM<BZ*:0FX8',;];J<=50\UJ@S8O+Y*U_F0\S7-N).G9;?9<00.>XQM
MD;;6;@6L/ <4$&\F,';[L\LM];PW!=7=[G[47(M+PW,H? 8[7K!T6EPTDO=Q
M[*!!";S,9<?R[XNY%]<]9VZ9F.G$S]9:+,'3JK6@[D'M?G1>7L.[?)>.&XDB
M;/?0-GT/<T/K):<' 'Q<SP*"*;EW!E<KYW[KBR6U,EO?'XEK+6RPMI(]D%L-
M+3U9(V->"7$FA[T&*SM=X6?E=YL19;#93!X*>*WGP=CE#*_I!TKFR1QOE +J
M-#.2#@W^'S$?\M^U-W8:XFMKW WUQU9('N:1%+/5I< 0"&2-',=J#T3R^RC_
M #+\]7;IAN9)-O[?Q%F\1B1_0%]-"'=)P&EI='(^4GAS95!Z;_,)--!Y,[GE
MAD=%*RWCT2,<6.:?>(QP(XH/ =];;LL7_+YM7>^-N[FSW2_W9T^09<S&6=LX
M=J8XEY^B:$=P"#?L,CE-_P#G5MK!;EO;E^&^Q;:ZFQK97QQ32^ZB1Q>QCA7J
M.\102'&^\[3_ )FF;1V]/):;?RN-,DF,;(Y\$,CH'$2,8XG3I?$'\.\]Z"(9
M&*_V;;9?%>96ULGE!-=.?'O_ !LTCIFL<[4QT<C_  ,(')A<WA4(,WG?E((L
M3Y4OV_E[ZZQEPQ_0NYYG-GECZL/"?32KV?0/=2B#.=M8.]_G FQ5W:-DQ\T<
MDLL!<[Q2?9W5+@:AU2_CP0=C9V5OK7^9S>[&S2/M[*RN)(+9SWNB:8X(BT!M
M:=G<@S^2NQL%OGR]RNXMSOGR&:OKN\8V^?/*'VK8^#3"0X:*5KP^1!Y[N#>.
MY<G_ "R8FZO,A/)=V>=DLF7?4<)'Q,B+FASZZC373U(._P"?6!L]G0; R^VW
MW&.R-\=-]=QSR]29S&PN:Y[G..IWC=Q07[JW-F,MY[;HL\EMS);TQF( MK/
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M9$.TYIG6%M;&!UK<QQM<Z+W=NENEITBA;P*#K878N'Q^QK79TC!<XJWLACY
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MMZUT9<UW@C#@ YO'F:^I9M''B;6K[H:^WR%IUZ[VCK-HP[>^=ZWF%O+7%XN
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MZ)&N/X M7@3:-T3,K7S.ONT6C&9F'EV1W#%=[#L\)':7 EL7AUS.YAZ;0"7
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M?96#]ULI[*.6^ZKK:<E\C7.!'$]QYA:M-F-MLSGHLN;Q_P#IU1KC$9_\/7J
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M\TY(;=N<]SZ!K=8+BZ@H.556\R-DSUE?^&KIZSKC%?W_ .Z<+47 @(" @("
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MAM6XN=Y8_/QS-9%91O8ZWTU+BX. H:\/I+9IR)C5.OWJW=X_NY%=L>Q(XXW
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M 0$! 0$! 0$!!0\TR8 4%5& 4@@(" @(" @(%0@I4))@J@J"@(" @(" @("
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M)W-9E(:BXB'#4/R7M'<5R_,XEM-NKZ'XCR5.3KB<_7]W[2F%5J+<0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0#R29P.5N'(_9N%O;ZH_V\+WBO>&FGX5ZT:N[;$>
M]J<S;\/3:WR/FZ:XGN)9+B=W4FF=KE>>)+CWE=MJI&NLX?+-VZ;VF9]J0;4#
M&V6;N>C#-/;VK# ;AHD:UQ>!7BJ_G5F-E8SZK/Q<1%+VF,XQ_%M:\\T$]+#4
M'<V"O#NXK6MCWRW*UM$9Q7_]G0-AC,_MZT9"RSM\V^.237#HB)>QQI$Z/Z7B
M9QJL--UM>R)QFK9MQM>_3,9B+_).4$/ </"0?AJ%T.NW=7+D;5F)G/L33RHS
M=Q:;C;8:_P#:WK7 Q]G5:*M(]:J/*Z,UBT>QTO\ Z[S)C;&J?2_\,/;6/=VC
MBN:B<R[_ #B9AF"] @(" @I51D<#>.2DM<88V'3)<'IAPY@<R?B59Y;D3KU8
MCULWO&Z?B;.O_% .'"O8.:X_9.9SZRZ>M>V.C;9B;M\;7M#>H\:XX"ZDCF]X
M!6U7ASCN:EN9$3AMV]K8106XDMWSSRQ]5SNJ(@T5(IXNW@MVNJE)B)B.ORM+
M9NO:9FLSVYQZ+I8\9%&7NL7:1STW+2?P+/;7KK[/:B+VF<9_@TLI9Q6UXZ*(
MNZ1:Q[0_B0'BM"54<[76EIB%AQ+S?7U2W9-Z9,>^W<ZKK=QT@GCI=Q"Z7Q._
MOKV3[%)Y35\.V8]J3--0K>%;"JE(@(""CD&M=W#+:WDGD(#(VE[B3PH!5*1-
MK88MUHK2;>Y\TY')3Y"_N;Z9Q=+=/+W.//36K6^H!=GHT12L?,^4<KD3MV3:
MWOEKM/B% .[CR6Q:,PP5F>Z$SNI+>SNKR>XZC<=9"VMX+2SCB#BZ2$/<][G-
M=3G\)5%-YG$1Z]9=/W1KB9F>D3$?P6Y&Q,6*W!;W3VW1L/<Y;*X?&QDK&SNK
M0Z WCI/&J]:K9O3KZYRGDZ(KKV=T9F,(<X@DBBN\9Z1T<K69BJ3^7V=FQ>Z+
M0->6VUZ6P7,=?"=9\+O6#V]RJ_(Z._7GVU7O_K_,G5LQ/I,X>^M+M7%<M$Y?
M1YCJR+TD0$! J@MUJ)$?WCDC!B^@TZ9+DZ13GI'-5?E^1.O7B/:WO&ZOB7S*
M O( U#M/8N.U^F?:ZFO3HV6XS(N <RWE<T\6NTFA"S3Q=DQ&/1K4Y6N/6>KL
M6&%N(;1\[FM-Y(POBCEC+FM#.)#NXN5QQN%\.G=/7HJ]_-B]^V)Q&6A<.;<8
M=ET8F,F;,8JQMT@@M)Y+3Y,=VJ+QTGW-W1]7;-,]'./T/E5;,>BPB<IEL;(2
M20S6<CBXQ4>ROYI-%U?A^1W9K[G.>4X_9:)CVI8TJYK.56JO0(" @L<_Q442
MB9ZO"O-'+-R&ZI8V/UP6#1 QM3I$GTGGXS1=1XO1VT[O>^>_^R<N;[YUQZ0A
M[#R [.T<.*M*].D]7.S/MAWC>LQ\>,:V*/HS6K9K@]&*21SWEU3JE#CSIP5;
M.F;S,Y])PN9W5T]L3&<QE5N?BFN;%EO;1^)\;;ML]O;EKM3@'!I8T$#C1>8X
M\Q69F?9+W',I>T5QZM#<5O#;9R_MH&AD,-Q(R-HY!H=04"W.+,S2+>V85_,_
MZ]TX]G1K6.0N[&]@O;1Y9<6[@Z-P_"T^@C@O6[1&S[3'P^3.B_?7U?2.&R<>
M1Q5I?Q?Y=S$R5OHU-!HN,V5FNR:^Y]6X^[XFNM_O-]I)7EG50$! 0$! 0$!
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MZN,N@U<_7:,S/5I_9V2KQM)J]VAWS+6_+[O<V/S.GWPVK3;V8N9 UMNY@/\
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MFMC?><.FV8D,Y\:D ]B#:CUZ&ZZ:J#53E6G&B"Y 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MK3-)]%\6;MX;5\!+7EK_  1/&IHK*XN/LE>[<S7&O$_>_P!V.O%V9[H]S1S
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M7-)@I;$Y>7W=I-9W<MO+SC<1ZQV$+A-^F==IS[W7:.1%ZQCW,3'-#FN=6C7
MDCG0%>>/>)O'SO?(SV3'R.I#969O))9[F!\#W/<&]0L=XB2.&GL6_312UIF5
M??D7K6(CHLLXXK&62:2ZAD;TGL B<7.)<-('(=ZG72-<S.39LMLBL8<MA  '
M<JS9,9Z+:(Z.OM?&2WF4:_\ Z-NX/D<?C:T>E6?B>+-K9E5^2Y,5IB/5Z,T
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MZ3E/L7B[?'6K8(&G3S+NTGM)76<?C1JKB'-;]TWG+?\ @6:)RQX57H$! 0$
MHB6.:-KXW-<-37 AS2*@@BA"G."T9C$^UY'O#RJNH'RWN"'5@),C[$_3:3SZ
M?81Z%=</R/LMT<9Y7_U^>M]?6?V^5YP^*2.1T4C#'*SZ4;P6N'K!I17==U;Q
M]6<N5W<?9KG%JS$K:$^E9K5G#6Z+HXGO>UC&E\CN#(VU+B?0!Q6*VZNN,S+)
MKU6V3BL9>A;+\K[RYN&7F=@Z5D&ZFVCOIO=V:VCDJ;F^5BU>VOJZSQ7@)[NZ
M_2/V^5Z_;Q1Q1MCC;H8P!K6CD !V*A[IM.9=K6L16(]S,$>A 0$!!0BJB8R-
M+*8NUR-N8)QPYAPY@^A:_*XT;J]LLNK;.OT0++;>R&-<7%IE@K43-%1\([%R
MW*\;?5Z1ET?&\C2_VIPY7TN*K;^Z8;_=$^G6%P J:=G-1'7I$/,TK'5L6&.O
M;Z3IVL9D/:[DT>LK;T<+9?\ XSAK[N72D>J<;?V\S&QF24A]W)P>\<@.YJZC
MA<&-=>KG>7RYVR[H 5DU%5& 4@@(" @(" @(" @(" @(" @(" @H7 ( <#RX
M^E!4F@J@M<1P/-,#!<6EM<,+)HVR,/8Y8MFFEO5ZILO7T<J79V$D-1$6<:T:
MX@+2MXS5+:KY#;#/:[9Q%JX/BMV]0<GNJX_A677P=5.K'?F;+>KJ- :/1Z%M
MUK6/1KS;*[4.U3&16O"O)2*!P/SH*H" @5XT04UC^E *&%KP.U'F9]DN5E]L
MX7+MI?VD=Q3@"X<17N(H5FIOM7T:F_@:MOK"/R>4>SG2AXAE:T?])LK]/Q56
M>?([<-+]!T3+LXC96W,3XK*RCCDY]0^)_'^LZJP;.3LOZMK1XS3K](=QK ."
MPY;\1$>B_DB5"X#@@J""*CD@(" @H7 <^'I05!!Y(+:BOI2"6*:VAF862M#V
M'\EW$+%LTQ;U>J[)KZ.1/L[!R&O2,?:=#G ?@6E;QFJ6U3G[89+?;&%MW-<V
MWU.["]Q=3X"5[KX[55YMS-MO:Z[& - :-(' !;M:Q$=&KF<]5XY!>@J@(" @
M(*:A6G:@J@HZE.)IZ41*T@'T]R=V$S&8<G+[5P>8:6Y"TCFK^611P]3A0K+J
MY-Z^C1W^/U;/M>K@_P#:+9_5$G0EH/\ IB5^GY5LSY+:TOT+1EV\1L_;F(<)
M+"RCBE H):5?0_UC4K!?D7MZRW=/C].OK6KL-;Q6&6[$^S"X</A^%0E<#5 J
M@(""CG <^WD@H96 5KP_X[.:"Z@08RP$4(J#P([%XM2+>IW3['+N]L8:X?K?
M  \\RPEOX M2_C]5FSKYFRL>K!#L[!,=JZ1?Z'.)"\5\;KB62W.V3#L6]K!;
MQAD+!&P<FMX+<IIK7T:EMDSZLE1W<EEECK"[6/4CTJ@(" @(" @(" @(" @(
M" @(" @(""*;LWU;[?O;:TDB#Y+EIH'.+3J=J;"*TT@/E:&<2.+A2O%!SH_,
MPQ7;;*]Q,QOO>Y+/1;OCE $+(3)+S:0T=<<.9 -$&UD-_7-MMVPSHQ,ONEVP
MS2 O8Y\4187Q$B,NJ9. X?1)\2"ZPWX+J&\D]WCD=;Q6LT;89V%KC>.#8XWO
M=I#'@D:J\$'/L/-O&2VUN^:T=KDQ[,C*Z%\<C6!T4<KV.%0X%K9@>(XCDHP=
M77M-]6]S:YF5ME)%<8>)TS[.:2)DL@$1E92KJ,#Z4!<:?$IP(I%Y\XQTV.@?
MBI1)>NNA<%LL1%L+..*242U(H\"<5;W>+DHP-8?S X]\3##B))9#>MLR&W$.
MGZPV38Y XGBUSLE'\13 M/GH^*2YF.(?+"QK8HK.)[#/[RV[N+68:R0PMK;$
MMX\5(W+GSTL;9]_'<XI]N;$ETK9;B$.$ ?*WKN +J,)@X_FD\>10;VV?,Z]R
M.?@Q$F*+Q>W=_#;WT#V]%D5@\-=KKQU /:?37@@]%0$!!R]Q9VWPN)N\C< N
MCMH]0:*U>]QT1QBG:YY ^%!'\+O\97)XVSB@8/>Q.V<B2ICEMC('L#2!P)B!
M%>.EP*"V/S3Q4IK'9S%C).A<DF,.BGZ;G]-S"[42-!:ZGT3S0;F*WY997(R6
MEG:R/BMX!<7-SJ86L:Z&.9K=()<YVF8#AVH.59>;&/FO(()+-T3+R:"*V/6A
M>^EPV(L>]C7$M&NX:PCF$1VPWML^8EKFKG'V;[1UK>7]D;YK.K'*UH:XM+'%
MA-#PJB<,9\R;7[LY#,PV3[B;'6MO=OL6OCCDDCN81,US=9 #>+FC4>)::(C$
M.%%Y[8^69C(<5+/$6N$MQ%)&612 N:WJ5TEK-3*/=3P=J)9,CYX6./A>+C&$
MWD9O0ZVCNK=]196;;O6U[7%I9('AH=V=J##DO.&^;?,Q\6'-O=-O["SGEED8
M^%KKNY9!)&',-0^DE6NII03#8V\XMUX5V4CLY;(-E=;OAF(U-EB:T3LX?H9B
M^(]Y:2.""2 U" @((?O/>\N"S6,QC8[:&._@NKAV2OYS;VL?NK6NZ9>T..IV
MJOJ!01'_ +[''6D\V2Q8N ^2Y^SY;*9CHY6091N-&K7I+ #*UQ>>'-!7+^>4
MD>&R>1M,0Z-N-?$R9D\T3I]3G0&1ONK3U3J9.1&X"A*#L[C\W8,+BL3?LQCK
MMN3QEUERQD\3.G!9QPR2-JX^)U+@4H@XTOGY:3$VUOBGQW+H9Z.FFBT-N(&R
M/TN:#J=$1$?K!X0>'-,#7D\\)72Q20V3&6XNK.VN6.<V0UDO+NSG,+XR6R?^
MBU1NY.'%1B#,I [SALH=BG=-SCI+9@N#;1VDLL8,CM)>#&\$M=J:. YJ1K77
MG=:0Y6[QS<6YSX)+J&*1US"QI-I'!*]\NH_4L<+D!KG=H0=:V\SH;G#X#*6^
M.>Z#.P2S1L?+%&Z-\98QL=7D-=K?)](&E!JY()%@-P1YB&X>V$PR6LYMIXR]
MD@#PQDGA>PN:X:96\0?0@ZR @500'='F2[ ;KFQ$EDR2SM\6_+3WAEZ>AL;G
MAP<VE--&?2*#G8_SNCOVP"VPLKI9;NZL7-Z\-!-;=#0T&M3U77.D<.#FT/,(
M+G>=5O-M"WW5;8N48V:]DM")9&LD='!:RSROC !JX/@=$&GFY!O8CS4;D\7?
M7%MBRZ]LKNSLO=FW$+HY'WT44T>F=I,?A;/XQV$>D(.+_P!^X'V60O(\#<&"
MP$[B]TT+0X6D=U),TDGPO#;(T!YZAZ4,-A_GE9Q7T>/EQ$HO#?>X21MFB(!<
MRW<PM-?&XF\8"P<0 3R0PPP>?=C<&V$."O)#/>&P+6.C)$L/0%TT<15T+[H-
MT\SI=1(R93^\STUKD&V8Q=[<-.FMU#&'0C5WNU#EV\$.KC[A\Q;+"WUU:SVL
MA]TB?.YU6#JLCM)[IW2%>SW8L)-/$@TY_-1MN^6&7#3MN(Y)H6Q&>V&I]N"Z
M1NHO#10#A7F@W<)Y@6^3R3+)MI)_N9I66LS35ICAC$CWR T+"T.8".][4$O!
MJ$!!Q=V9X8'%_:LK-=E;R1B_=4@L@D=H=(T#F6$@^JJ")6_FED.G#[QBFMN(
MS(W)P-G ,#XV/FHTO#0ZL72?_P _H0;5QYLV3(KB6WQL\L-J;\RO>YL?@QL+
M9IG .-:G5I [^?!!U,[ONVQ.49C3:OEE>R-_5U-;$T3R&*-SW.Y-,E 3V508
M,=OV/*W%M96EJ&7EUUR&R2C2UML(7/=6/4XM<)_"0.-/2HP&WO,&+,9PXAN/
MGAE#9)'3.+7,:UDTD3:D'\OHD\.7"JD:=GYJVT\(FFQTMM";47CY7/861QO8
MZ6,R.'8]H%*5XFB#5M?-AMZ8)K?&ET#F7;I8^LPSULG 2].,<2 *N![:(-[(
M>8S;9MC?V]J+C$WEE<7S+@2:7N9'/!!"6-IITR>]-DU./A:@ZNU]W2YZXO8V
MV#K>*Q<(GSF1CVOD(J=&FM6^E!(P@(" @(" @(" @(" @(" @(" @((CNK=V
MWL-?/L\G87$X=;PW#YHK8SQG5<-MX(O#Q,G6D\+:>E!'I_-#RQ>^:22VFEN(
M+PP3QMLGF830Q&7JN8!J#6Q1$ZCR XH+\CYH[/%BV2WQMQ?V^.R,&.UFW<R"
M*1\KH.J'N!TQQECQ]&O+A1S2@RX/S \M\N;;&8RW?*[-7$T?NHLGL#W1-9,Z
M:5I;X8W1RL>V1W CD@UKGS%\KG.D8Z"2*YD M)FQV;Q.UPGDMS;N#!5KF.M7
M.+3_ --NKD@W(MY^7%[DK7I6SI;R]EG= &VY=U'MN&XZ5[M-01KN--7?DDE!
M2\WGY<XRXR&.&/>X[>>"]D%D9&">0-#F0N IU*2-J#2HY5XH.7'YA^7,9NF8
M_ 2S6EJ&W3<A'9L;9NUV3LFQ^L>,?56W/IDU#>"#:_[C>6]Q(^U=CIGSR^%L
M,>/DD%Q*W1.Z* A@$SV>\=32WCS)0;>$W7Y;;@OS:6./ZUQ>6L>2G?)9EK0U
M^HL$KG-X24J=)]7/@@Z6"R.T,KEK#)XYTL=W-;R26UF^*6W:T3.!DE?$YK0V
M5X;S=Q<WE4<4$R0$%'.(I05J@@-[YL[0.7^S##=W$D5][E/=>[.%M#+#%+<&
M5TDA:W1$+9SG$<12O+B@P6_FQY>2%UXQD\+V,?>W$\ME*PQVQC!%W(YS1IBF
MBIHD=P=RY\$&G@-^;#N<OA[/#6<MS>9F^O'3R3Q.BEM)W1S2RNFUM.ETG0<T
M-U5T\>2#=/F5Y=89MRVRMYOJ+IUDZ.QLY'NDF:'F3I!C?K6L,3F.<RH:X40:
MF=WGL?"V-GD[+ .OHI;1F7LYK>W:V/3+<P0-J\@N$Q=(PM:&$G3V(-W [[\N
M+O-VEGCH3;Y.\,T41DM'V[FRQR/$ML]SVMT2ET;W:#SH@LO/,'8<%U+9"WCD
MQ_6GM<M<N@<RW8RQM9Y)'-JRD[&>ZR0T:3I<T_"&K'YB^53(3/)9/LO=&,MY
M6W%@^%]O'=O+ V1CVAS0[Z1X?1-?0@Z^V;G9N8QUWE(<)%86EB?=-5W:BWDZ
M!MXYC6-[0YC"V>@':./:@V#GM@N(O9>C&;F,W'ODMN^,'W4&2KI'L:.I$VKP
MTD.IQ *"S YG:NWH[/ 6YN(HI1-<-N;K47OFFDBFE-P9*2B662]#G=1HXUK0
M\"$LL;VWO;2&ZMG%\$[0^)Y#FZFGD:. /%!L("#C[G&WQ8=;.P13V<3V:&RP
M]?ZQ[@U@;&UKWESB:>$(.+]M['FB#9;9D4=Q+<V;6W%E(QKG]0]5E7QAM)9(
MSIX^-W*K@@S"XV& W)B&V=UFO#+H0$N<RR&MU':*EL89P]5!QX(,%SN?87NA
M<_ISQPL,$%H+9Y>Z-[7.+88W,!=&YMN\ES?#1CJFC#0,3]P>7WOT4#K1OO)A
MGA)]RD.B$,Z\H>>G_E/UU#AX'.X EW!!?!G-A>]XNQL+>WG?=]!MET+?ZN-O
MULD-7Z6L9IZ<I#"=?TC3F@29_P NSC763FP.L!+I]U=;2%A< 93(R,Q^)FEC
MG=1H+.!\5 4&E?X;RUM#FK2\8QTM]>&XRC"QTDKG])EP8P&M<YT?3B:X-' T
MH.(0=6YSVQ)[:&&=T%Q;L)A@C$#Y&C7$PZ(VL8[Z44S>#>^GH02#'6]G;01P
MVD @@!.B)K.D!W^ @'F@W4! /)!Q,U9;<,T-YE;2":4N;:PROAZKRZ4T#&@-
M<XUJ:@"E*D\$$;L,ML:YL7/M<>+2:+J>[MAB8+AKW,)<^,Q%VDZ8@=9<*<*T
M0787,;%L=J8:ULHC<X=X LF:'73S(US"74:'NF?U)_$Z.OBKQ0;>2W#L_;-O
M-8LM6MDM],XQ]E;.=]8X:V@=-O3$K@S4&EP=1M0*!!CM,OLR:RRF1N,8+*TC
MNGV5]<7%J6B61H,4KG#1_E_6/:Y[N%"ZI"!?[JV%:-N;Q\++BXQLLDSF0VDC
MY.O$3!))$2P!VCIZ'2 T;3Q."#:O\QLBQZ<%XR"&2./[89'T=89P?(;CP!S0
M[ZI_;4T-*H-I^[L&V[N+)CI7S645Q/,6QR=-ONE!*TRN:&:AK':@Y-SN?9NB
MZOY;&64LO68R\E=9R.>97Q4\#2S7*S0_36,.Y]J#)D;_ &%DI;6.\:VX(='=
MVD;;:9_7ZX(8YE(R)JAU7!M:<W40=# 9+ 9:]FN;!@;=6#KBUG:&Z=)?,&O!
M+?#J<;5KJ:M0;2H%0@DB @Y>XLIB<?8Z\H:VT[NATQ&Z8O<X$Z1&T.+O"TGD
M@X-OO785W<Q1Q3,,UZ\-B#K:5KWNECCT'2Z,.I(R2/2XBCN54&'[Y[0FOF00
MVC[GWN:.V+V6Y-)KDS1.$K' /:&^YD/);W<^P+X]X['OKIAF>#/>V\392^"5
M\71D#9&-?,6&%K?K&GQ$<Q6A(07Q[NVB+"US./C]Z@EN8\='+;P/,C>I]'2P
M,ZKF4H?"WB./)!7[Y[2A;;W=JW7%(0UUU'&8VLB=$;ASZN#=3>>H-K1W \4&
MY:7VT[O(R8RWBC?=PV^B9O1<&-MR\MT%Y9TZ%[31J"/YS>VP\)=7MK>XZ>&2
M."2$S6]IJZX!C9+#;OC.ISVFX;J;PY]Z#6=YK^7EC!-8FVN&''-CLFV#H(PX
M1RR^[.C:'/ :UDL.AX>6\:<ZMJ$GVMNC!9._O,=C+:6W=8,BZNN(1,.M@+0.
M.HEHH#4#T5YH)..2 @(" @(" @(" @(" @(" @(" @CV>V;A\[=0W%\93TF:
M.E'(6,>&RLG9K;3FU\0(^%!P;'R7V58F0PMNG:NI0/G+J"2WDMM(\-?#%,X-
MJ@S'RKV:VZO)Y8YIIKZ>"ZN#+.7FEI-UHF<>/3$CB34U[*TH$%=M>7&R\#)8
MW6*UUQQN'V;C*UX:VX:R*1GA U!HA:UM23WE!J1^5>TYADI\A,V:XR^7^UGW
M5L[W4MF:P0,C86.=J&@$/!)U%SCVH-K'^6FSK+.OS5K+.;EKWZ(/>=4$)=/'
M<2-CCY,'5B:2$%,SY7[*RN0OK^]?,;S)1:"XW'%C*M?JA:\.%*L!:':FM_)
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M;>Y;HD+--=/:/$'#\"#A.\N-N"^L[T=<S6$AEM6F74QCNJZ8"A%>$CB>!J>
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MX$<D'+\N]Y7V8?=8W+.!R-O1[7:1&7QN'$%K0!X:H.QN)ILKRTS$0_RG].X
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M?2??F;]G/M-_PI_D%?N?W?0?HT_?_A])]^9OV<^TW_"G^05^Y_=]!^C3]_\
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M\&_],LW'_$CYWF+>97">[YG93Z0J@(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @!!5!ZXOHSAQ 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$'/SW[HN_U3OD6IS?P;_TRS<?\2/G>8MYE<)[O
MF=E/I"J @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M$%4'KB^C.'$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0<_/?NB[_5.^1:G-_!O_3+-Q_Q(^=YBWF5PGN^9V4^D*H" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @( 050>N+Z,X<0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!S\]^Z+O]4[Y%J<W\&_]
M,LW'_$CYWF+>97">[YG93Z0J@(" @(" @(" @(" @(" @(" @(" @(" @("
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M-_=6X^V>C[N8=;3;Z>F8_HENKZ)["@YF-\D=G6$FYN-U<Q[K!^TXYI!05>9
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M(" @("!51D<_/?NB[_5.^1:O-_!O_3+-Q_Q(^=YBWF5PGN^9V4^D*H" @("
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MJ!K&R<'.)+R0>*I>#QMVSZ_=&/WK/F<G57-.WK[^B:YKCAKNGZ)WR*^Y<?\
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M/"Z?MU:V^62?:-L7"K#%1OKU+#YWNSZ9>_$8QZ]72V8R5F)G?*"V%SB6$]H
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MN[]7.J]:>1.N_=6<2;>/6]>V882YSB7.=J>>+B>9*PWOW3EFI7$8 O,LDBA
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MG%<)[(=E,^Q5 0$! 4@F 3 )@$!0" D @(" @(" @(" @(" @(" @(" @("
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MFMGYS?7J;\ZB==CXE1K@YH(X@\CS6.8F/5[K,3Z*J$B @(" @(" @(" @("
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MF:KZ8B<_*RV5I-=WL5O$TN=(0!Z&UXN]06QQ-5MNSI#7Y>RM-?5ZM$*,:.X
M?@7=TC%8CY')3.97/^B5[AXMZ(#O:&1N29.X4CE8 T^D5X?A7)>9T3-\NB\5
MNK%<. .]4T6Q.%O.)AM8FREO,G!'$"=+FN?3D&@UJ5O<#C3;9W-/F;HUZ\/4
M8A1@"[:L8ARLSE<_Z)7J'B_H\]WE;OCS3YB#HF8TL=V&@H?D7)>7TVF^<.C\
M5MK%,9<0N&FI5-696LUB74VU8S766A>QIT0N#Y']@#>-%9^*TS;=E7^1V5KK
MP]*'$579.9A:[Z*02\SW):2VV7GZC2!,\R1D\G-/<N*\GQ[QMFV'3^.WU[(C
M+G5'<J[OEO\ PX]79VK9SSY>*5C3TH"72/[JM- K;Q.B_P 3NPKO);JQ3M>B
M-YA=@YF%7_0=ZE$DSCJ\KR-K+:W\\4K=+@]Q'I#B2"%P_-T7KMF<.NX>V+ZH
M:QX<>]:4WF>C:Z._LVSF?DS<AIZ,3#5QY:G<*#X%>^)T6BV5/Y3=6:X2W-?N
MF\_5.^17W._!O_3*EXOXU?W/-&$M+7=Q!^+BN'UV[;5GW.PV1G/S/3\;>07=
MK%-$ZK9&BH[0:<0NZXNVNS7&'';M5J7ZMLD<N[DMB,0PS,SE#=\7D$DEO;,.
MJ1A+W]PX4"YKS.ZMND2O/$ZK1U1?U+GX]%\OMIFPW,,KA5L3VO('<TU6?C3$
M;*Y][!R:3;7,1ZR].L[JTN81+;O#V$GB#R*[;C[*VKB)<GNK>DXM#9-!\':L
M\1$0Q3[T6WO>Q>ZQV@=65SP_3W!O>J/S&ZO;A:^*UV[LH:.0X47+PZ1EMIA#
M<0R'E&]KCZ@5FUSBT3\L,.ZN:S'R/4+:XAGC;+$X.8_BTKO->V+QT<9;5-;=
M69Q '%>ND>I.4+WS=0R36MNUP=)#J,E.S52@_ N;\YMK:8PO?"TM6)F?:C(%
M!14$SE=Y% SM$)QDC3%I#:".0.-7.J21\ 5EHQ:O6%=NS6W26_=PV;&,UM:(
MH'Q5#'.,K0YOCZK3^"BS7UTK6)CWM6NR]K3GW+9(!)$;B)H,MRT,()T-+@3Q
MC#Z./ <J*-FC-<IU;\6PY\5LUT4D[WB.*,AKC1SG5/*@"T=7&[I;W)Y';AT3
M;NL<7<:91U)9&!K@RH+',UC@2M_X4:X:D[OB[(8,=+;MM;DNA:YT#06$EPJ2
M0./B6+@SFDW>^72<PMZ<#\/<RB.DS9F@OJ2*/KP 6.,;-%K?*]3:8WU^9GM_
M=I)HK-\7@GA;20$U!()K3X%EUQ7%?Z6+9-OK3_\ )3$V]H^SO!.T\',C9)4@
M-<\D"OPA1P]<32_RX>N9>8O2?G59:1PX>]CF:??(PU_=I!?I[>\56:G'^'IO
M5YMO^)NI)/%#/<7-D8Q&;=A?%('.J- #O$/25%M,7ECB8B,PY]RU@F86\&F-
MI ]8J5H\FO;.%CQ=F8PL6JVA 0$! 0$! 0$! 0$ (*H/67Z2P@F@Y5[>*^C.
M'13%^7ECCX\HR+*Y.49<2>]%]PW4V28>*:-S&,+) . <@L;Y<V4><GS%OE\I
M;W-U)'+<1LG9H>(:!L9U1N>(^'T=7'UH,]QY>[9NL;#CKB*2:T@OSEHVN?Q,
MYD=*X5 '@<7D.;V@T0=?$X2QQC[YUL7$Y"Z?>7&MVKZY[6M=I[AX.2#I5%$
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M#>WUK)''MCJUYY-<]%!:79 I _B.'A/$^C@O$\>T/<<BJC(+EY>&PO<6&C@
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M]D_*5T?C?PHGWJ+G]-TP[%58-3)5#*TBHH5&)1/5Y]O.GVX_]6WY%R7FJ?\
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M#*M >:B:Y,J4"R=,)R4'9^!>8@@H$PG*M F(0II;W>A1/057N,(Q)V>A>4B
M@(" @( 050>N+Z,X<0$! 0$%"VI0-*C$!1,0%$Q :0F(#2/B4AI"C$!I3$!1
M,0&D*.V!6@4X%*)B HF(#2F(#2$P% DP&E,0%$Q 43$!I"1$0&D*<!I48@-*
M8@-*8@-*G :0HF TIB TIB HF(#2$B,!I'J4X#2HQ 43$!1,0.=G /LF]_5.
M^1:O,_ O\S-QOQJO,M(X+A8M,0[&8C)I"GNDQ!I"=TF(5HWN3,F(-(43U]3"
ME%.91VQGT-(3NE.(-(3NDQ"H:$S)B"@"C)@+0353F4=L>Y32$[I3B#2$[I,0
M!HK5.Z3$*@44)"3Q]2(=ZP\/V4Z![&/Z<QK)P#G$T<W@12H5YIV?5K[.BBV1
M,VM[>O\ !@RT5S9P6TC7R6TKI)#[H7AYCK^4TCCXDYDUKV8GKE[XM8MWY],=
M&3/V]Q=7]O'%1\GN\9-3SH.-25@Y^-EXQ[F3@6KKUS,Y]67;T,L3V74C Z%K
M7@3]2@AI7@6'@ZJV>!C56TS+5\A_VVK%8:=@X65E=Y /U32O=!:]G,U+Z+7T
M;(UTFTSZRV=U9O>M8CTATL; [IX>7HF1L(>72B30UGCK5P[5O:)K%*1EH[ZY
MO?Y6G=Z#C<FXR"3_ 'H,3^ J2*_(M39%8K:?_E_LW=,S-ZQ_\?\ =Q0:_@^1
M4WK*X]BJA(@(" @(" @(" @(" @(" @!!5!ZXOHSAQ 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'/SO#$WGZIWR+4YOX-_FEFXWXM9
M>8A<)['92J@(" @(" @(" @(" @("D7&60VHMZU:U^MCNUI[AZ"LL\BTUPQ5
MTQ%L_(MN'RSR&25Q>\@#43W<$V[9M?/L>=6B*4PH=9<"7'@*!U351.Z>[+U&
MJ.W& !W*I#?S033X4^-:>D^B?A5CK$!!I3LY@=Q]2\3;/3/1/9CKCJ R#AJ(
M;W!Q^=>_C6R\?EZ89#-*;=EOPZ;"7$#\IQ[3\'!>K;LQAYIHBLY6!8:=/5GL
M!)2* 0$! 0$! 0$! 0$! 0$! ""J#UQ?1G#B @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(.?GOW1=_JG?(M3F_@W_IEFX_XD?.\Q;S*
MX3W?,[*?2%4! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$ (*H/7%]&<.(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @YV=-<3>#_RG?(M7F1G3?YI9N-/_;6'F0"X28]'8S/L51(@("@$!2"@
M$! 0%((" F 4 @(" @(" @(" @(" @(" @(" @(" @(" @!!5!ZVXD#@*KZ,
MX=QI]X[9M[B2WN,K:Q30NT2Q/E:US7=Q!(*8%GWXVC_&;/\ UF?.G:\]Q]^-
MH_QFS_UF?.G:=Q]^-H_QFS_UF?.G:=Q]^-H_QFS_ -9GSIVG<??C:/\ &;/_
M %F?.G:=Q]^-H_QFS_UF?.G:=ROWWVC_ !BS^"9A_&G:=Q]]]H_QBT_U6_.G
M:=RGWXVC_&;/_69\Z=IW'WXVC_&;/_69\Z=IW'WXVC_&;/\ UF?.G:=Q]^-H
M_P 9L_\ 69\Z=IW'WXVC_&;/_69\Z=IW'WXVC_&;/_69\Z=IW'WXVC_&;/\
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M_?VWZH_WES7G)Q>OS+WQ&)I;YVSL$_[>[)_/;_=6;P'6EIEB\U&+UPEM5?\
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M 0$! 0$! 0$!!S\]^Z+O]4[Y%J<W\&_],LW'_$CYWF+>97">[YG93Z0J@("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(""GY5?2/E4U]7FR/8*GVQ>
M>I__ ,P+HO(__6K^[^2EX/3=;]ZF6B=8Y2#(0^&.1VF9HY5//XPO/!V?&T36
M>J>73X5HM'JD+:4YU'Y)5%CMF8E<YSB8<S/RN%M';,=26[<U@;_5KQ5CXK5B
MTVG[+0\ALS3MCU7W=O';826&, ".(@>D]I4:]WQ.569]EDWU]FF8C[K#M;]V
M']8Y9O-S_P!LL7BOPXAV J5:JH/7%]&<.(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @Y^>_=%W^J=\BU.;^#?^F6;C_B1\[S%O,KA/
M=\SLI](50$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!3M^$?*IJ
MBWL1S!_OB]_Y_P"^%T7D?_K5_=_)2<+\>W[_ .;H[@_<\O\ R_*M/P/VY9_+
M?9ALXS]WV_ZL?(%H<G\2RPT?9AS,E_\ DEE_9^=6W#_ GYE3R/QH=#*?NRZ_
HL'Y%5^/_ !Z_U+'E_AV_I:FUOW6?UCEO^:_$EJ>*_#AV J9:JH/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>modular008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular008.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!E0+, P$1  (1 0,1 ?_$ *\  0 " P$! 0
M       !! (#!0<&" $!  (# 0$               $" P0&!0<0  $# P(#
M! 4*! 0#!P,% 0$  @,1! 42!B$Q$T%1(@=A<3)R%(&1H<$C,Q4U%@BQ0E)3
MT6(D5/""-.'QDK)#)1>B8QC2<T1T)S@1 0 " 0($!@$$ @(" P     ! A$#
M!"$Q$C-!43(3!144\&'Q(G&!L4)2(\'A<O_:  P# 0 "$0,1 #\ _5* @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @("""HDAS=P_E%U[GUK5WW;EFVO<AYJN&MS=C'(54B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @("#UU?1G#B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @((*B2'-W#^477N?6
MM7?=N6;:]R'FJX:W-V,<A52(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(/75]&<.(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @@J)(<W</Y1=>Y]:U=]VY9MKW(>:KAK<W8QR%5
M(@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @]=7T9PX@(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M""HDAS=P_E%U[GUK5WW;EFVO<AYJN&MS=C'(54B @(" @(" @(" @(" @("
M@(" @(" @(" @(" @("#UU?1G#B @(" @(" @(" @(" @(" @(" @(" @("
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M9CD@(" @((*B2',W'^3W7N?6M7?=N6;:]R'FHY+AK<W8QR2JI$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'KJ^C.'$! 0$'D/[J3_P#XQF.XRVHI
MZ>NQ!XW?>6/E/_\ $MMG)]SRQYDX^&YCM)+IDK&W+HP[0(.?.K?0@I;WS.:W
M%^VG;U[?0M!LKQ]L'LC$;>E%5D;M(HT5#>Q!]OYIYG$W/ESY=VEO=Q2W!O+%
MXA;(UT@:W2"2 >Q!<R /_P"6.'Y'_P!MY#_]LH/F-A,N';H\WF6U.L8;G2._
MB[A1!M\MLGMV']KNXH9KBWCORV[$T3G,$Q+@ RH/B=Z$'Q<CM/[7\01V;C=0
M5X$AA[/I0?<[G9$_]R&SV2-#VBPM2 X@MJ(S3F@Z.\(8X_W58?HQACY+4E^@
M!I<2P\32E2@J_MRNL-C]W[SM\\^.WSG7D+G7;FM?TPYQ(!<4'7_:T^WDW5OZ
M6V>U]L^]!A<SV"W6^A:@L?O)8_\ 06,>T<&Y!I>ZE:#0>9/I[$'Q_P"Y*YM+
MCRLV%);R,>RC 71N:X!W09PX'F@[_P"Y*W@9C?+J41M;*;Z!KI0 '::Q&E?0
M@^/WO^KK?]QL<L%Y9V-W)$T8JYR(U6[8M  !H.?<@]-\J-G[CM/-++Y_.9S%
MWV0N+5K+RSQKCJ;Q\+G,Y"J#']X-!Y;6>KV1D8?F -:H/E?/?);6N/(7;D%G
M-;S7\AMO@61%I>*-I+0--1PYH.AF]\9R+>VT]FX2UQV/RTF(M'7&>R4+7S-^
MPKI:YWB&D#AQYE!Q_+YMZ?W ;K;>W]ME+PXF9LUW:-:V)SPUE11O"K>1]*##
M]NUQ;Q[9W_;/>V.YK,1"YP:_V3V5XH+O[:;>WN/+#>PFB9(PR2@A[0:TB<4'
MV'[1J_\ Q8^H\(OYZ=W$-[D'!_=S1D^R97'1&S(DR//(#P&I]5"@J^:EQBF_
MN,V;D,RYAVZ^U9\-._Q0&X#I0"' Z:]0LX_.@T^;<\5]^X79K=NSQ39!L;/B
M'P%KJ4+R=99_]OO0>_[WRD6(V=E<G<6[+N.TM7ROMI*%CZ#V75[$'Y<W%N#=
M.?\ )/(YN;(8?%X.Z=IBP-G"R.0^+@#3B'E W6]EM9^2UQ,\1VT887RO-& "
M5I-2@^L\U,IC;W]QVP76=S%<-A#1*8GM?0O>X@'3RJ@V7\L-O^\"V,SF01NQ
M^D.>0UI^Q=WD<R@I>6TC++]R&ZQNB:)N1E;(ZR?*X!A82"T-+N=&(.?;OM;K
M??FE=X0N?A?PZ5L\C".D9^/'AP06=O0PL_:!DI&1M$CF3:G@ .J'@ U[T'Q6
MZ1>GR,V+-(?_ &Z/(GXD<V@FM-1[J?2@]!_=#D=KW>RML6N'EAGS#[B%V+;:
M4+Q%TRTZ=)J.);0=Z!81$_NVLFS-^T;B83(UW&CQ9-!/KJ@P\JX(#^YG>33&
MVK>N>(!()>*T]:#Y; VTC=V^;EM81D2"QE$,,0XUZIU4 Y<.Y!]=Y9Y+9<7[
M;,G;2RVT=RR"=M_%+369R#HJT\24'F5]99,?MWP-Q.TFT;ERZ-W]+20/1P)0
M>D_N'S&+N\AY916UW%/-%=P2O9&]KG!CC$ 30GM""[O#;L>4\Y[W+;!W/!8;
MUL6!F0Q=\QPB>UC:$-<X>+5VZ>2#O^06_)<[F<_C,CB+&SSF/D+;R^Q[&-;<
M$$@ZRWT]M4'N(Y! 0$! 005$D.9N+\HNO<^M:N^[<LVU[D/-EPUN;L8Y"JD0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0>NKZ,X<0$! 0<7=VT<'N
MS"S87-PFXQ]P6F6(.+*EC@YO%I!YA!\$S]L7D^QS7?A#W!IJ&.GE+?50NI1!
M]KE-A;5R6V#MBXL(_P %TM8VU8-(:&\M-.10?(V'[<?*VSZ3FXU\DEO*V:![
MY9'%CF&HTU/ >A!]3+Y=;6DW?#NYUJ3F[>+H1SZG4$=----=/)!AM_RTVC@<
MQE,MC[0LO<P2;]SG.<U^HU(TN) 0?-R?MV\JY<O-DGXHF69_5DAZCQ"7G_[=
M=/R40= ^2/EX=KP[8_#W?@\%T;R.WZCP1,135JK7D@OW/E9LZYW19[FFM"[+
M6$;(;:;6ZC6,%&C373R0;K[RYVK>;NMMVW%J79JT;HAN-;@&MI3V:Z4'B_FE
MLR:3>%SD)O+TY;XEX9:7]E=/A+C3G.QOI0?5_MX\K<[LNWS-_EXXK6YS,K9&
M8Z+B(&-)(;J[?:0>E;NVA@=V8:7#YRV%U8RN#BPFA#F\G CB"$'R!_;[Y:OP
M$.#FL9);"WG==0L=-(2)'M##0ZJTHT<$'T>Z/+G:FYH<9#E[4SLQ$@EL0'.;
MH>VE#X2*^R.:"OO?RKV7O**!F=L!.^V^YG:XLD;Z-3:% V/Y6;.V6ZXDP=H8
MY[D 33R/=(]P'(:G$FB#XG]TFW,WG=@VEGAK*2^N6WT4CX8FZCH -24&_:/[
M>_+J*#$9>[Q3OQ&***9UO*]YC9,&@G[,G2./91!]/O;R<V+O&]@R&9LB^]MV
MB-D\3W1/TCD"6$<NQ!&U_)O86U\T[,X7'FWOW0]!S];R"PTU5!-*FG$H*MOY
M%>7EKN"XSMO8NBO+K7U@R1XC/4%'58#3C5!U]J^66T=K8N^Q>&M#!9Y(EUTP
MO<_47 M/%Q-.!07=G;(V[L_$_A."MC;61D=*6%Q?XW4J:N)/8@U;WV!MG>F,
M;C\]:_$P1O$D5'%KFN':""$')O?)S85_M6RVQ>6'7QV.!%FY[W&6/4XO.F0G
M5Q)X\4#9?DSL/9^0?D<18$7[VZ#<RO=*X-'8TO)I\B#[&_Q]I?V4UE=QB:UN
M&&.:)W$.:[@04'F3/VS^4S>LTXR1T,U:PF:30">UHU<"@[>7\E]@Y7;5AMV]
ML#)CL9_T7C=K94UH'UU=J"CA?('RSPV3LLI9XYPR&/>)+>X?*]SM0Y:JGQ?*
M@Z&\/)W8^[<Q;9K+V1?DK8,:RXC>YCBUAJT.TD:OE0-Y^3NQ=W7$%WF+$OO;
M=@C9<QO='(0.6HL(K3TH-^ \I]DX';][@L;8=*QR+7-O3J<7R!W/4\G4@VV_
ME?M"WV7)LV*T(P$H<U]L7N)(>:GQ5U()B\K]EQ[1&T_P]LF$;73;2$NH7=H<
M>(*#A;?_ &_>66#RL.3ML:9;FV(=;?$2/E;$6FH+6N) (*#Z ^7&U3O;]:&U
M/Z@Z?1^)U.IH# RFFNGV0@QQ'EIM'$;GO=SV-H8\QD-7Q4Y>XAVHU/A)H$&.
M$\L=GX7/9'.V%EHR&6:6WSW.<X/#C4^$FG:@^;R'[<?*J^OY+V3&.8Z9^N6"
M.5[(G.]+&D!!];EO+_:F5VN=L7=@PX;0UC+9OA#=/(MIR(IS0?*67[<_*NUD
MM)F8Q[KFRF;<6\[I9"YKF$.:*EW*HY(.KO/R:V'N_(LR66L7?B#&AKKF%[HG
MN X4>6$:N'#B@Z6RO+?:6S+2:WP-D+?XAVJ>1Q+WO/\ F<XDH/J!R0$! 0$$
M%1)#F[A_*+KW/K6KONW+-M>Y#S5<-;F[&.0JI$! 0$! 0$! 0$! 0$! 0$!
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M0$! 002>7;V()!X("""ZA0 X(&H5H@D&H[O0@(" @(" @(%$$<!Q0"2@D&J
M@$H(#B3Z$$H" @$T%4$!U4$H!X!!CJ/H09 U0$!!&KCV<>2!4U02@(%/2@40
M*(" @(" @(" @(" @@J)(<S</Y1=>XM7?=N6;:=R'FPY+AK<W8QR%5(@()X4
M01P4H8O<UO,@=@KPX^M(I,SP1-\)!%2.T*-6)A,6RD<1Q2+9A,H4H;;2V?=7
M4<##0O(%5GV^A[EL,.OK>W7+;?8R2TR'PKG:@XM#7T["MBVSQJ=+!7>9T^IL
MN,28<E%9&349"/'3E51?:1[D5*[J?;FS<,):B\=:2W89-JTM&D\5GG8UB\0U
M_P ZTTF<,;[$V\$IMX[KJW <&=+3QJ311K[&O5B$:>\M-<RVC;I+C +AOQK6
MZC#3T _6KUV-<+_G3$9QP:[?!3SXZ6[8[QQ.+71^HT*K]=TYM!^;'5$3XJS<
M<Y^/?=:N+7Z!'3M6O;93-&3\S%UMF A8V(7-VR*:459&1QXK8G8UB(\V*/D+
M<>"+3;UQ-=S6SWZ'Q#4"!P</0GU^9Z4?8RT8_%2WF0^##])!.IU.0'H6*OQ\
MVMCR9];=Q&G,K#\"X2W<+9M4ML-6DB@<" >?RK)?91,8CFPQOIQ$JIQQ;C?C
M9'Z=1I&SM*U[[7VZ3EET-U-[84VG@M)OLD2(" @(" @("#UU?1G#B @("#D;
MHR\N)PMU>0,;)=L;ILX75 EG=PCCX?UO(:@U[6S\N7PL5U/$(;P%T5W #P9-
M&XMD;_RD(,(-Z8:6WDN0]S;=E"R4MX2 F@Z=.9J@JS[MAN!$++4R<7$<=Q#(
MW2]K)*\37U(+=AN[$W=Z+.)QZDA<+=[FT9(6>T&.]"#E7V[+B/=S[!X?;8ZR
MMA<W,Q95K@20:NKP H@Z-OO;!OCN9)'NMV6L8N']5I;6%QHV1O>UQY(-]KNS
M'7'PH#98G7DKH88Y&%KM;8S)Q_Y6H,+7>.+NWVL=L'S270+FL:WBUK7%A<ZI
MX#4$%C+[BL<8^*.;4^XFJ88(VESW@<Z#T(*5QOO!Q,A+7OF=<-<Z)D;"YQ#/
M:J.S3VH.BW/XUV,&3ZH%DYG4$IX"G+^/!!1&]L*&1NED, =,+>02MH8Y'#4U
MLG=J')!H?Y@X)L<#QU7FXC=-$QC'$F)KJ%_JIQ0;I]ZXB(P.!>^VG#'"Z:PF
M-O4II#CZ:H!WKAS>/M 7ET4O0DDT'0V0\@3Z4'.R.]H3FK6QQ[R^DKX[F0L/
M3JUA) =WA!NBWW90V=K+> R2W3)98A;L<X%D)\1H3440;LGO_!V%I'=NZEQ#
M)$V?[%FHB-[M#7.!(X%W!!.X]Y1X7\,ZEE-.,E*R)O3 JPN%?$"@K66\X6YZ
M_P =>ES-%S'!;$MHUIDB;(&N=_4=10="VWCB;B^;9QN=KD<Z.&8M(B>]GM-:
M[M(089O>N(PUT;:\ZAD$?6<(XR_3'6A<ZG8$$V.]L-?=86QD>Z*(7#6Z"#)&
M> ='7F@UR[[PL5D;N;JQALXMG0EA,HE<*M86CO'I04<7OBW?DKFRNG.=.^[,
M5G;M95[8A"R74\=@&LBJ"S)O[$?#SS6[)9S'"^>!H;3KLC]HQUYTJ@M8W=0O
M]M'-MLY8V"(RBW=360T5X(.+#O[K76,F-M-!;7D,LAMW,K(YS.5*<$'7_6^&
M^*M;2,R337;!*QK&$T830N=W 'F@FWWOA9W/T/=T],DD$I:0V5L(J_I]^E!N
M=NS$C1KD+!)9_B )%?L#05^=P0<#*^8EL;&ZDLHYH)K.6V$W6C(!CFD JWM-
M6H/I<-N&QRK91;:A);OT31R-+7-)%16O>$'40$! 0$! 0$! 0$! 0$! 005$
MD.9N'\HN?<6MO>W+-M>Y#S4'@%PUXXNQCD55%D%Q[$@X&KCPX\N2MTS/)$RU
M3WUI!43S-C(!<&DC40.=!S*M&G*LV4SF#*/]%:RW)(U,>08V$>MW^"O&G'BC
MJ<3>& W#G\/);0S1VLFIKXRPG6.\%RVMO>E/W8-6)F7<V_B7XO%P6<MQ)<S1
MM'4ED<7$DCC2JU]QJ=7@RZ<.D%K5990?1S2$3P=O;=O"#<7DSQ&V)M(WN['%
M>Q\;6E;3:9>1\AJ6M$5ANR=O&^WLKMDXN'1N:V60=O%;^I%;7ZXEIZ4VBLTP
MSOK::7<-O)&PNC.EQ?\ RT'I6"^EU:D6RRTU9C3FN%.XD;)N8.::CJ@#Y."U
M[ZDSN(CP;%-*(V\SXL;F2.'=1E=[(F:XD^A7U;8UY_\ S_\ *FG7.W_VOBTN
M3N@W0!Z /4,G81II2JR4K.>;5F<TZ6^+(?#X>ZN(11HN#5O,.!/%;UM6(HQ6
MTYM:/V8WL=K%B3/$=3)9FR.:.SO5>JDZ2:Q:+*>9M;BXR=O- TR1/:S2X"NF
MG>M2\1UQQX,U)Q6>#H37;&WUT^-_&*!H<1WA;4:L=66+HG"8^E:SLOXG#5?/
MB:WM(!]I7V]ZUOU>;'>+3'2YMY<F#=+G,_G<UKV]A:6AOUK1C5CW6Y73SIM6
MZ)JWK;9GAAA;X6#TT-2M?Y/5S.&Q\?I^+C@<5Y#UTH" @(" @(" @]=7T9PX
M@(" @X.Y-O?C5QCXYG V%O/U[B(D@N<UI$=*=SCJ]:#3MO;)P=YDF6S@,9=R
M,N(X#4N9*YH;+Q[G%H<@XS-AY"1TTDDS+=VMDT$$->D9(W$AQ:>5>X(+IVE?
M74DEU?3,^+N)8C*V.H8V.($#3Z>*#3MC8(P^1$SQ'*R!SW6]P2XR$/->(/ ?
M(@O9G:7XK=Y)\LVB&_M&6S=/M-<QQ<'?2@YMSL?+9*WO8[^Z8R26Q&/M^BWD
MUKFO#W5[26(+M[A-R7D%C=2SP,R=C<F>(-:>D6F)T1![?9<2@Y<?E_DA8XNW
M^(C9<6)J^]95LH\9<0VG @U[4'=SF"R4^1LLECIV-NK6-\3F2BK'MDI4^@A!
M3QNR76,\$G7UN8R;JN(I62?F1Z$&<VRH[K9QP%U+XB2[JLX>,.U-^E!0_P#C
M^27#MQLO2MX9IA+D3'5SGMC!T:2[M+N:"JS [HAS5G"R2-TMOC3:ONG,^S/B
MHW_FTH,,AY8WCX(;:"[$D,0MVQNEK5G0<TN#0.'BIVH.Y)M*X=;W4?5:'3W[
M+L'_ "L_E05(]E9.&_:1=,-A%<2W$;-/C+IFT(<?0@LXS:%U9NQSGRL<;."X
MA=Z3,ZH(]2#XW+X"_L[^WMIK=UPRULV16S!&Y[9WB4RZ7.'L@%!]UN'#7^7L
M<7/&6P7UE-%=N@=Q;4-\490:;G:=S-<W<O5;_J+Z"\]0B8&%OT(*6!V <9EQ
M<'IRPQ3/FBE+G&0=0DD:?9[4'9O\!/<9.\NVO:!<61M6 \?$36J#D9#9&0GM
MK=EO="WDAQXLB]O"IJPT-._31!IQNP+JU91\D9KD8L@Z,5< V.(L(\7>4%F/
M8\EON2^W!;/:+Z]F<V5SJD&U?&QA;[S71U05<!Y=.QS9().DYC;>:WANAJ,E
M)12I!.D<.Y!]%A,/>6FVQBKJ1CGLB= R1G:T@@$^E!0QNU\A#+CW7,D;C8V\
MMOX:\0\>$GTH,,-M":SO!--*',%JZUX<_$]SJ_)J05K/8M[HL;6\N6.L\9%-
M%:&-M'NZS"P.?[H*#F7^T-Q1XR[EEECN'08AV-M8HV^(@2-<PGO.EJ#7@<+<
MW]E<V4<18T/M977DD9B+W0R!Q9I/, -YH/M\7B'VF5R-V7 MO'1N8T=@8P-/
MTA!V$! 0$! 0$! 0$! 0$! 0$$.42F',W"?_ &BY]PK6WG;EDVO<AYF" T$\
M!ZUQ%ZYEV-;<%27+X^(D.F#WZ:AD?C<:=P"15$RK_B&2N ?@[,@4#FRS^$$'
MGX>:O[<3Q5S+,8Z^F<'75Z\L:[4UD0T-(( TGO"CJBIB6RUQ%A;EKHH1J:26
M.=XG"O.A*K.X6BJZ-(X  #N"I,]2>D*CC5:*I;RHHRG":)"$)");!<3" P!W
MV1-2U9JWEA]F+3F4,N)VPNA#J1.-2U7C<3"L[>&QN1OFQ=(3N#.5/^U6_-LB
M-K66ALDC) ]A(<#4'F:K#.O/7U,T:,='2F65\LADE.ISSXBFIN+3;J13;Q%>
MEO=DKXP](S.Z?=Z%L5W<Q"D;2N6MMS<"V-N'GHDU+/25A_+M,S_@C;5BV4_%
M7'P_P^L]+^E5G<6Z"VWJSAR%[#&8XYG!IY#N6>VXG$*6VT>36RXE9KTN/VHI
M(>=5BG<2O7;PD7=R!$!(:0FL8[BE=Q:)1;;58OGG?-UW/)FJ"7]O"G^"QUU9
MZLKQHQC")II9I.I*[4\\"[Y%;6U)M*^GI16.#$+$NE 0$! 0$! 0$'KJ^C.'
M$! 0$%6[O[2VE@BGD#)+EW3@:?YG4K3Y@@J/W)AH_:NF$F1T0:#Q+V<'"GH0
M3-N#$6\S89KIC9.%:GEJY5[JU0909O&W-[-9P3!]Q!PE8.33SXE!$V=Q4%T+
M6:X:R9Y#6@\!J/(5Y5*"&[BQ#I9HVW+ 8 XS.)\+=/M5/+@@P&Y<0Z#KMN&F
M.M!3F7<P .VH09NW#AZ1$7+'=<N$36FNK0=+J>HG2?2@T7.YL:VUN9X)63&V
M%7@'PUJ!2ORH*MCO"PDO+RVNI&0.MYA$RIX'4T.%?G09V&[+622^;=EL(MIS
M#&?ZP!6K4%^?.X^'%3Y36)+6%KGN='XJAO-!4LMX8.ZQME?F<117D?7B8_@X
M,'-SAW(++]P8ALD< N6.E>QKV-!KX7"K3PY:NQ!SMM[QL,M;1%\C8KN5SPV"
MO/02#0GM07[?<V"GD,<-Y&7@./$T]G@>/H05<CNRRCQEY=V3VW$EK'U S^H5
MI4(+'ZEQ+'LAFN6,GHPO83[+G"M#W%!$FZ,'#=FT?=-$VIPH"2-3 7.;7O "
M"U!E\=/)!%%<->^XBZ\31S=&' %WJ\5$$.S&/CNQ9R2AMP6Z@".!H-5*]]$&
MJVW'A;J31!=QN?I+QQX$-]H@]M$'/CW?8SY^RQ=FYLS+EDKG2#LZ8KP[P@O3
M;ALK:YNH[N1D$5OT@7N/-TQ(:"/6@'<^#$(F^+8&.E$ )-#U2*AA'.M$&?ZB
MPWPL=P+ICHIJ]+3Q+M)H^@'<>:!'N##R,D='=QNZ<77?I=RCJ17YQ1!!W%AV
MRQQ.N6M=* 8Z\ :\A7O0<VUWSB[VUNY[34[X.X%M*)!H\1=IX$H.HW/X<W1M
M?B6":I:&UYN:*N:#VD!!C8;DPU_,R*UNF2/E!=$&GVM/M4[Z(.IIJ?I00&!!
MEI]*"4! 0$! 0$! 0$! 0$$501J0:)LC9P&DTS(S0NHYP!H.VB#GS[DM:?Z2
M*2]<:$-A%10^D\%$D.3GY]S76)NBV&*QCIP,AUN+?4.16MO>W+/M8_\ 9#ST
M81KW!UW<2W#FFK?%I;0]E!V+BIOAUL5RMP6%K"/L8FL#:TH!7CZ>:CKRMTX;
M^8]'8.:QSU2GA  F+)ZH2IZ9\D3>#@HZ91UP43IE/7"4Z91UP*.F3JA%$Z9.
MJ!1T6.J!3%).N"BMTSY'7!R4XG')'5QYG-1$3$<D]<9**.F?)6+8\2B3$S&,
M$S&>911%9Z<86B\%$FMI.J)*)%9\D]4%%;$^1U04]*CHGR1UP )-9)O":%.F
M3K@3IDZX$Z).N!.B3K@3IDZX$Z9.N!1!U0BO'DG!.83VT[>Q+<),G953TI>N
MKZ(X<0$! 0?/[KPEYD#875B6&]QERRYMXY#1CR 6N:2.7A<4'S3]CYQV-?"Y
ML$EW-=SW7Q+)'1OA,[@=4;@/Y:>SVH,KKR]NGYJ6Z<YM];W@A=<NDFDB+7Q4
M!/39X7@TK0H.[9[5:69*&[)Z-Y<=:-T+RQ^D   N;0H.%E=B9J[S$=P+ELEK
M#<Q3PE\D@+8XSQ9H'A=[Q06F;/R[K"^P<LD0Q=RZ62*Y!/6U2.UZ2*<@?3Q0
M89+:&;R=M9/N!"R?%._TMO#(]@D;T^F=<C=);4>@H$^RKQECCK:PMH;9\)>Z
M6432%\+I':G%KR"9 >T.0:W[*S#QE&M,5NR\B,;(F/<8WOUAW4+:> T%."#*
M?9F<GDR%JYUN<=DI8GR/\75C$;0"1WU(X(*]]Y<WTIZT<C7R0W)GA@$CHM;7
M-TT=(WB#Z4'TN/VZR';$F(Z;;=TT;V/:U[I0'/KQUNXNXE!\L_RYR(AQ;G:)
MY;2S^ N+?K/A8YFJH>','HXMH@[&/VMD\/>SC&B!UE>"'J&4DNB,,>BC>>K5
M3O%$&JPV5?VT.&;KB;)CIIYI7=XF[N:#"?8EU/CK&T?(R,0.N.M(T\0)N1'>
M@.VEF[C'7%M<&!CX[4V=IT^(>W4#U'\!0\.2#5<;'RDCKNS;+$<??SPW,\Q)
M,L9A#?"T?S5T\T'&P%M-;[JF;) ^Y=+DYBV!\4K6112  S:R.F?#V(.]Y?X*
M:TOLK=3:G6T4SK3%,D:0^.W8=3J5['//T(#-GYUVX9K^YN1<0NDE? \R.!#)
M(] 9TQX?#WH)CV+>.LL=;/E8/AHIHYG@<?M.5/4@RP^UL[!F\9=W1MFVV-AD
MMVLBJ'.#A0/Y4^1!8RNUKZ\R%[<,,?3N9;*1C7&AI;/+G@\.%0@PN=HWLN7-
MY6(P?BD-\6__ &XK<Q4IWU*"O;[1SEC)97=K);R7-J;R)\$I(8Z.\F$H<'4-
M'-IW%!7O/+B^=!8LMKIK)>H_\4DI0OCED$I:RE. =R]:!DMC9NZS4=PVY:^T
MBN(IX29'MT,9_P"D(P-!]:#>W96699Y6Q8^)T-U>,N[>8FCJ:@YS7"G"B#8-
MI962\MXI'Q-L+*XDNK>0$F61SVD:7<. !=SKQ06,-M.\LOP#6Z/_ -J9<,N-
M-1J,H\.G@@^N;R02@(" @(" @(" @(%4$:N-*<4$=04KV=I[D',O=R8>T+F3
M7#3.QNLV\?VLNGO#&:G(*OXUF+L/&.QKJ-+2R:Z/2C>QW,M]IU1W$(#<1G+A
MP-]DRP,>2V.U8&58132XNU'Y0@WV>U<+;OCEZ'6FB),<T[C+(TDU.ESR2!5!
MU!&UH(:*#T<$DCFYVX>&(N3_ )>Q:F^[<L^U[D/-J<%PMO5AU\3B$'GZ0K:?
MJP:GIR^OQ6 QT^/@EDBU/>VI*ZG:?'UM3+G-QO;5OA;&V<5_9^DK9^LJP?GV
M/TSBO[(^<I];4_/L?IG$_P!D?.4^MJ?GV/TSBO[(^<J)^,J?GV/TSB_[ ^<J
M/K*GY]C],XK^R/G*F/C*IC?V/TUB^R$?.5/UE3\^Q^FL7VPCYRGUE2=_8_3.
M*_LCYRGUM4?GV/TSBO[(^<I];4_/L?IG%?V1\Y3ZVI^?8_3.*_LCYT^MJ?GV
M/TSBO[(^<I]94_/L?IK$_P!D?.4^LJ?GV/TSBO[(^<I]94_/L?IG%?V1\Y3Z
MRI^?8_3.*_L_24^LJG\^Q^F<5_9'SE/K*GY]C],XG^R/G*?6U1^?8_3.*_LC
MYRH^MJ?GV/TSB_[(^<J/K*GY]C],XK^R/G*?65/S['Z9Q/\ 9'SE6^MJ?GV/
MTSB?[(^<J/K:GY]C],XK^R/G*CZRI^?8_3.*_L#YRGUE3\^Q^F<5_9^DJT?&
MZ1&_LPEVWBA&XB*A -.)6/4^/THADKO[9?%2,#9'M'(.-/D7):\8ETE+9/Y5
M&>#)AZZOH;AQ 0$! (J@QT#Y$$Z>\\>] T^E!!97MX'F@G1PI\Z!I0-/I0"P
M?+WH ;1 H@%M>WAW( :0>?R(&E T\:_*@C1Z4$Z?2@:.%*\$$=,<>-:\_P#@
M()T>GO\ I0-/"E4"B!1!'3"!H[:\?K[T ,IV\.Q!.G@@:?2@:?D0-/I0-*"4
M! 0$! 0$! 01J"".H!SX>M!KFNH8(W2SN$4+!J?(\AK6C_,2@Y4^[<4V1T-K
MU+^X:&N$5JTOU-=Q!:_A&?\ Q(,#=;FNW.^'LX;&-KVELETXO<]A'$AK.#7#
MTDH$>V)IFL.3R=Q>.8\N:UIZ#-+OY'-8?$/6@Z-GA\;8QMCM+=D+& AFEHJ*
M\30FI06PWT_0@G3Z4$CD@@I)'-S-Q#_VBZ]Q:F^[<LVU[D/->2X:9Q.781&8
MPQ(\2F.%HE.<UF'H.#K^$VWN?65W.S[<.0W$_P!Y7QZ5M<6',>2>"CBB<'!.
M*. IC)P%.3@<%&93P."<3@*.)P$XHX"<3@<$XG X)Q. IXG X)Q.!P3B<!.*
M>!P3B<!.)P."CBC@<$XG 5LG X*,R<#@HXG X)Q.!P5LG 3)P*E,09AA*/LG
M^HK7U:QB62F,P\VG^^D]XKA]US==H1P8]E%A\&;/%ZZOHKAQ 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! )H@BOH^9!&O_CF@JWF7
MQUDTNNKAD+6BKM1H0.^G-!S)-T&5SF8RPGOG"E7 =*.A_F:^2@=\B"1!NBZ<
M>I<06,0=[,+3*]S3V$NT@.090[0Q8D9-=&2_N&-+#+=.+RYKOY7-%&'YD'6M
M[2&WB;% QL4;11K& -: .P <$&P,IR/R=GT(,@@(" @((*B2',W#^477N+5W
MW;EFVG<AYJ>Q<+J.RJAW.JM/.%8Y2]!P?Y3;>Y]:[G9]N'(;GURO+:8$$TH@
MFO&GS\T"O"O;V#M0*CU=Y/) )'9Q/S?Q0*CZ: >GY:<$! 0$! 0$! 0$! 0$
M! 0$! 0$! 4PK*)>$3_45@U>4LNGSAYO<??2>\5PVYYNPT.36L/@OXO75]%<
M2(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(!*""ZGUH,7
M2M:TN=P YDG@@YE_N?#6G5;).'RPM#Y((@990T]NAE2@U'*Y:XE='98]S6,D
M#73W!#&EA%=; *D^HT0:Q@LO=-!R62?2CFR06PZ4;@?G=]*"W9;:Q%FYLD5N
MUTS6Z#/)XY"WTN/%!T1$ *-H&@4H$$AG!!D$! 0$! 0$!!!420YFX?RBZ]Q:
MN^[<LVT[D/-B%PNH[&)X(=R^=6GG"MIZ8EZ!@ORFV]Q=SL^W#DMS']Y7EM-=
MR-W7=[9[;R-U92=.ZA@>^%_<X#@@\QRGF1N3]+XV&VN6MW V3_W-[:5Z4;@"
M2/\ -7@@Z<FZ=X7=OE<W;WS;:RP[F 618"9@ "_6>RM>""C#O+>.K)9]N0KC
M;.\A@_#)&- Z4P%:.YU!*#)V\=WV>.R.ZYL@9\?89/X5^*?&-+HGN8VC7<ZC
M6@^MW]?YJVQT=W87S<=8QPNDEE(UR2RN ,,+6D'F[N0=S:EWE[S;F.NLO%T<
MC-"U]S'RH_ER/*J#JH" @(" @(" @(" @(" @(" @*85E$WW;_=6#5Y2RZ?.
M'FUS]_)[Q7#;GF[#0Y,%A\%_%ZZOHKB1 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$"J!5!&L(*UUD[&T8Y]Q,R)K!5VH@$#OH@YDNYFRR"/'VL
MUZ:@.>T:6 '^:IYA!BV+=%T\=66*Q@U%KF1^-Y;V$./LE!L@VO;#0Z\N)KZ5
MK2TNF>:.![VC@@Z$&+LH.,,+&.TANIK173W5YT0;S%P KP'((-E$! 0$! 0$
M! 0$! 005$D.9N'\HNO<6KONW+-M.Y#S9<+J.Q\$'D?45:><*:OI??X+\IMO
M<7<[/MPY7=>M?6TU95<KCH<ECI["<D0W#2R0MYT/.B(A\_+Y:[;DDNY>FYLM
MXR..5[30AL5*4[JTXHE-WY<;?N+T7%)8XWD.N;>-Y;',X#@9&\CR086_EGMZ
M'+3Y ]65L\@F=9O<3!U&\G:/11!A;^6&W8\A/=R.FGCGF-RZRD>3!U:@ZM'+
ML07=V['QNYC:B[GG@9:'5$R!^D:NQU.\(.OB<<W&X^&R;+).(6Z1-,=4CO>*
M"V@(" @(" @(" @(" @(" @(" IA643?=O\ =6#5Y2RZ?.'FUS]_)[Q7#;GF
M[#0Y,%A\%_%ZZOHKB1 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$ F@
M007!!'592M>'>4'-OMQXBT);+<-+VN#2QGB<"[E4#D@J_C.5NM/P>->UA=1T
MDY# !_4 >)08C#9ZZ>TW^1Z,='-DM[5M&.#N \3O$"@M6FV,1;D.,77D#=)E
MF)D<1Z:H.D(6M:&M :T"@#> "#(-I_@@R0$! 0$! 0$! 0$! 0$!!!420YNX
M?RBZ]SZUJ[[MRS;7N0\U7"ZCL?!!Y'U%6GG"FKZ7W^"_*;;W%W.S[<.5W7K7
MUM-61$0(D_AWH)H@A 0$! KZ$"OH0$!!* @A Y<^ 0 @("!V(" @(" @*85E
M$WW;_=6#5Y2RZ?.'FUS]_)[Q7#;GF[#0Y,%A\%_%ZZOHKB1 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0":((U<T!SP!5!A+<PQ"LCPP5 J[@*E!RI]V8AKC
M';O=>2MD$4D=LTRECC_5IK0>M!7%WNB\T].TCQ["7-D-P\.D _E>UL>II]1(
M09#;-Q<!KLGD9KDEI;+%']E$ZO;05</_ !(+]AA<=8 BTMV1N(#72 5D<!RU
MO-7N^4H+V@ZJUX=R":?,@E 0$! 0$! 0$! 0$! 0$! 0$$%1)#F[A_*+KW/K
M6KONW+-M>Y#S5<+J.Q\$'D?45:><*:OI??X+\IMO<7<[/MPY7=>M?6TU9$1#
MF9_<F%P%H+O+7+;:!S@QKG=KCW (ECDL\RWQ460M(#D&3N8(61.:-6OD07%K
M?I09V.?Q]S:MN#*(:N$;XWD58\\-)]* [.V/QUO9QO$TUP_0 TUTU87AQ]!#
M2@7VX,9:0O>Z=I?&]L;F @D$N:T_-K%4&YV6QS863NN&-BD(#'$T!<>SCZD%
M1^Z,$(Y7,O(Y7PMU&-KA7EJ ^4!!$6[<"ZSBNI+V&%LK0X->\-(U<0""@L6>
M?Q%[*^.SNH[B2-NMS(SJ(!%1P'>@TX_<^*NK*&X=*V%TPJV)[@' &0QMK0TX
MN""R<WBA")Q=1]%THMVR:A0RDEH8/\U1R0:F[DPCW!K;V)Q=2E'!W,D#EZ0@
MT#<V/:UCYG""!Y>.K*YK:=-VD\*\:^A!9M<WB+LN%M=QR:*EX::D4YH(ML[8
MW,]RR-X,5LT.?/S8 :@\?11!6;NG&/R'PD3@]@TZYPYM!JC,O*M?9%>2#?-N
M#&17$43IFZ91(>I44!B<&O!](+@@UW6Z,/':SS03QW1MZ=2*)[7'VQ&>1['(
M-QW#A1*8C>1"9HJ^+4*M0=!K@X CV3Q![$$H" @("F%91-]V_P!U8-7E++I\
MX>;7/W\GO%<-N>;L-#DP6'P7\7KJ^BN)$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! J@@N'^"!J""M?97'6,74O+F.V9RU2N#./_-1!RG;IBN"&XVQN;^C]#I&Q
M].-IY@E\ND%OI;5! AW9>4ZLL&-B(<R5L59Y>/LN9(X,:VGI84&;-I8MSWOO
M>ID9)6M;,;MY>QQ9Q:[I"D0/#F&H.O%;1Q-T1-;&R@#6M%* >HH-@80:H,J(
M%4"J!5 J@50*H%4"J @("!5 0*H%4! 0$! 0$$%1)#F[A_*+KW/K6KONW+-M
M>Y#S5<+J.Q\$'D?45:><*:OI??X+\IMO<7<[/MPY7=>M?6TU9$1#B;LV;@]U
M6#+/+1%\<;P]CFFC@42WR;?M/PFWQ=LY]I!:EA@="1J&CE[2"B-FVP;$T7MP
M-+VRRT+0Z:4'A)(ZE=7J098[9MC991N1%U/<3 L%9:$4C:]K1P /\Y0;QMFU
M:V5K9Y1;RS.N'0#26ZWO#^#BW5[3:T0:\IM"SOYHY)+B>-L3PYL,9:&%PKQ(
MI_F*"O-L7$RQRQZY6B9\;S334&-F@<0/E0:I/+K$3]$WDTMX8 P1B1L>GP M
M%6Z:<B@ZN'V[9XL7 MCJ$Y&HD-:!I;I&D,H*(*<>R<='&86SS=&1C8[AATGJ
M-:\OH>'"NJG!!:EVW9R64%KU'1MMKGXN%[0VHDU%W=2AU4^M!SK;90BNI0;J
M3X,],Z*,J]S"7$N\(IS[$&V?8^.G$39;B9S(7N=$#IX:G!]#4&O$(-K=H6+8
M)HXYI8C-+),Y\9:"#)2H!IRX(,\;M/'V%K<6\4LSQ<M+)'O(+J%Q=4&G.KNY
M!5FV+:32B9]]<=9K2V.1NAI;6(PU%!_2X\^U!8FVC:RV[+<W4VAHF8^NDZV3
MR:W!W =U."#1#L'"0V]U#"#$;O[R9C6=4#7K $A:7$"E.)02[8F&ZUQ.RK;F
MX.I]P&1=0<*<'%A*#O6\(@ACB#B_0T-+SS-.1/I[T&U 0$! 4PK*)ONW^ZL&
MKREET^</-KG[^3WBN&W/-V&AR8+#X+^+UU?17$B @(" @(" @(" @(" @("
M@(" @@N"!J'#O*#%\\3!5[PP5I5QI_%!R9MT8ALCHHI3=3L?TWQ6[72EKJ$@
M/T Z>7:@U-O=R7K0VVLV6$9J#)=.U2#N+8V$@_*X(-L>%R$@K?9*:4EH#XX:
M0,)':--7CY'(-EOMK"P3OG9:L=-* )))/M'.IRJ7U*#HB("@H*#E_P!B#,-
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MP"@!H.8;[*#*TM;>UA;!!&V&(5+6-%!QXDT0;J\_1]2"1Q- 03Q^A!%10&O
M\D#_ +?EH@'A\U4 D-YFB!7Y#W<*H!-/GH?6@'@@5%=-?%V-[4#Z?4@=M$#_
M (H@(" IA643?=O]U8-7E++I\X>;7/W\GO%<-N>;L-#DP6'P7\7KJ^BN)$!
M0$! 0$! 0$! 0$#4$$:A]2"#(WO]:#GW6=Q-M*V.6X;UGDMCC;XG%W=05XH*
M+<[DKW3^'8Z30]KP)KG[,-<VE-3/:H4#\)W!> _&Y#H1O8 Z&U&DM<.T2'B@
ML6^U\3'*Z5\(GFDIU9)27EQ;R-#PJ@ZK8PT4  '<."#( H)0$! 0$! 0*H"
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M2O=G17<LCYN#G0B!@+G$!O3TN'JJ4'$M_+W*168MR^)\3=(CMNI(UG",,#^
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M:<<S6VM*I@R:AWJ"93J"291J"$3E*)$! 0$! 0#R*"A_B@40.RJ"$$T*"$!
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MDMS6^(M;21MN());N65H#F/C(;TS0\]1"",/O6WNH8V7L3XKN6[DMHFL:*/
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M>?H06+FZM;6+JW4S((J@:Y7!@J30"KJ<?0@VBG#CSY?\?(@D&O+B@(" @("
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M.WZ4 E / $]@X%!!''U<T$UX5[$"H^9 0.VB!W>GD@(%1\R"$$@'Y^2 @("
M@(+T?L#U(,D!!!420YFX?RBZ]SZUK;[MRR[3N0\V7":CLO!![?45:><*ZOI?
M?X+\IMO<7<[/MPY/=>N5];36D1$")$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MEKKEQ!Y\E$_)7D_ HI&IJ3Q/$E:-IRVH@[%CPN]=7T=PX@(""O=>VU!70$!
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M$IK754\4&#-M89L3XQ  R0ASV5/$@:?X%!!V[CQ'((FF)SXVPEP)]E@(8?\
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MX1E^V];U6S"/IN;J:&N]/LUK\J#<-GX0/:]T;GD/:\DGG0 4[>'#T(*]ML#
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M,1E#F-KJ<UNH<G$<5DBU3$) ^0GZ529CP3B(*%,R<"B<3,&G@F9.!0)GS/\
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MH+* @O1^P/4@R0$$%1)#F;A_*+KW/K6MONW++M.Y#S9<+;F[*.0JI$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$!C'22-96FH@5]:OITZK1'FK>W3$R[EQM*>&!\K
M9FO+&ZC$!QI1>Q?XZ:Z>7CT^1BVIAP&BHJ?F](*\2*3$O9ZXPR1(F!T\7@)K
MVW,YD$4==(+A6I7J;3XZ;P\W<?(12<*N3L)+"[-L]P<0-50*+6WNUG2EL;7<
MQJ0K+4;2?$I2]=7T5PP@(""O=>VU!70$'ROF1!O*?;YCVD\1Y+J-JZH:[3QY
M$H-;WY^TVMBI<OKFR4,L1O3 "YU!6O <_2@Y<N1W5>9^YCM1<P6$IC(<YIJV
MK@#IK_E0:;O(;D&3GCL;V6:2)DD<=J\$M>&@>+A_, @ZFVOU#=Y*V-U=7'PD
M<+W.+@6![Q(*-?7CR0:\[+NF$9&>V?-TS>],-;7[.V$0+71@<?;[D%?(Y/=;
M/Q)L(G> ^*DX:YNAAX.:P=I]2"PUVZB9IV3S:+>UBDCC HV1U:O!KQU40:X[
MG=)N8G3FX;/.1)! P?8AKA5S9#V40=G!?BQNIY;MTG2CB AM_987%SJN]= *
M(/ALL=TY:UF9/:SF.-US\/J!U@26TC=)]%1P0=]]YNLW%R&&X9/ V26>VT_8
MTBEU0MB/:Z1G-!49D-^'&SR7O4@E8UDH;$RKG.E.KI-IRTMH*H/JLA;3WECC
M9#&\2!T;I6UHYH(\0-$'S%_F=P07S[22XF$=M*^%Q@;J>^H+F4]2"[B[W=#\
M]9,O#+';EHJ"UQ:^/3_/3@UVI!]R4 (+-MR*#<@(" >104#]:"$! T]R 1P0
M0:H!0/%R0*('% XH'%!* @(&GOYH"!ZD#22>(KVH!]* @(+T?L#U(,D!!!42
M0YNX?RBZ]SZUJ[[MRS;7N0\U7#6YNQCD*J1 0$! 0$! 0$! 0$! 0$! 0$!
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MOI0*H%4$'CVH-7PUN).ITFZZZM7;7E5!MKSI4@\R@()""S;<B@W(" @'D4%
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:CV57;GY8WWC_ !6U\OW&'X_TNLO(>@(/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>modular009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular009.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ L@"A P$1  (1 0,1 ?_$ )(   (" P$
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MED@CBCB@54 N0JBVIZU5V\)FN:T_N^UNXS%:\WG>OU_$"B /E'SKFUC3:#6
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M+Z<K*6OU'[*  Z].-*@,C2Q-2& P70'2@,JXOPN: F3SH!=V!XZU8 <A?&@
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M;:KFS9L7LF'E]K@RYYRDF2GJ^E%H5Y6K.<>5?K82';NRXTFUX&R6L21*[<O
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M:)5 &T"1CPI4RN4H]4*RV(.M (9<:V9&OK?:32IQL,KQM[+ED;ZHDB55Z[B
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M@4'Y"? 56J=O8N9_N/L^ZKB*!_EBF2:?4/B/OH!^'\X</J'WT!;Q_0W#^Q%
?27\7SH [\!\*"#Q^/_NH(0?6OQ-,$LK\YJ"+T!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>modular010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular010.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ I "N P$1  (1 0,1 ?_$ )0   $$ P$!
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M?A4[S+7RWOY5((MKU!L1WKFV=NM/%/\  M/L-M)+JRO<?-LH <I(!/L-3O\
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MQD@WBQ* "_OK*[UT31!R()(R3WJ>QV(<BX[Z2 $WO<U2;$=L3'_A-O"U7*6
M6P.MF)7M?44=D75%?CEL=MMW<]*J;%U0Y>(W=5U[VI]DW5"F].8C'YHP1W^4
M7^VB;IZ9 /I;!W [-/#6J[CZG1V9;=BW_P#4U^VN!UK1/\\^\T LWYFI4JKL
MCO0<5SVW&G%(TWEVUJ@BR>32-$?9K>U*)JIYK;_;)]O7:UOLK2,ZL?37D?\
M+^/YMMWDIU]U.G$N/RK"UNE(V+N\U=GCK1R.$P>;<^;T[4S0LK;O/E_EMI[Z
M#5.5;:=_6E"JHG\N_:M8BHLEOX?NH)';S;]Z 3YN].&P7OK0FD&[=KTIE&=Z
$:G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>modular011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular011.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ = #$ P$1  (1 0,1 ?_$ (T   $$ P$
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MW6PIX=UC)JO<JR5H6KQMC11YBBSD9<IN>S2DI7=:N !HSY&S:.Z<]@=PL9J
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G* H"@* H"@* H"@* H"@* H,&UM:#7P6Y4!X:#>@* H"@* H/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>modular012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular012.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!40+, P$1  (1 0,1 ?_$ ,$  0 !!0$! 0
M       ! @,$!08'" D! 0$! 0$! 0             ! @,$!080  $"! ,#
M!@<+!PD&!04! 0$" P 1! 4A$@8Q41-!D2)2% =A<;$RDB,6@:'10F)3TU24
M%57PX<(SDW0VP7*BLM)S)-0(@C56%S<8\4-C@[,T9"4F)T2$$0$!  (! P(%
M @4#! ,  P   1$"$B$Q T%182(R$P2!8G&A0E(4D8(CL<'1,_#A<J*RPO_:
M  P# 0 "$0,1 #\ ^J8! (! (! (! (! (! (! (! (! (! (! (! (! (!
M(! (! (! (! (! (! (! (! (! (! (! (! (! (! (! (! (! (! (! (!
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MGWB>3ZHV/?=4536E:-+#[M.7KI;V7%,N+:46W*E"5ISME*@"DRAK?^73]?\
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M=IJ.ONEON%NNB^)=K!6.VVL=V<53,BAX#_U&U)4?#.-1G9V2)Q(D516B 0"
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M?J-?]D=^" >T;/U&O^R._! /:-GZC7_9'?@@'M&S]1K_ +([\$ ]HV?J-?\
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M1WX(![1L_4:_[([\$ ]HV?J-?]D=^" >T;/U&O\ LCOP0#VC9^HU_P!D=^"
M>T;/U&O^R._! /:-GZC7_9'?@@'M&S]1K_LCOP0#VC9^HU_V1WX(![1L_4:_
M[([\$ ]HV?J-?]D=^" >T;/U&O\ LCOP0#VC9^HU_P!D=^" >T;/U&O^R._!
M 6G-5TB'6VE4E:'70HMH-*Z"K+*<L.2<!<&HV9D=BKCXJ5T_R0$^T;/U&O\
MLCOP0#VC9^HU_P!D=^" >T;/U&O^R._! /:-GZC7_9'?@@'M&S]1K_LCOP0#
MVC9^HU_V1WX(![1L_4:_[([\$ ]HV?J-?]D=^" >T;/U&O\ LCOP0#VC9^HU
M_P!D=^" >T;/U&O^R._! /:-GZC7_9'?@@'M&S]1K_LCOP0#VC9^HU_V1WX(
M#(MMT9KV5O,I<2EM:FUH<04+"DRP*52/+ 9V,O# (! (#SSO!'_Y9K^Y'E4?
MY([^)Y_*Y@G$QZ'G(9"&0AD(9"&0AD(9"&0AD(9"&0AD(9"&0AD(9"&0AD(9
M"):L>O6S_=U+_<M_U1'AKVZUF0C1 (! (! (! (! (! (! 4NCU:O$?) :S2
MG\+V<\O8:;_XDP&U@$ @$ @-=J"_VFP6MVZ76H%+0LE(<>4%* S&0P2"=L!R
MVE.^CN[U5<V+98[HJJK*D+4PV:6J:"@TDJ6<SK2$X93C.7)!;';A1GR\T&8G
ME@JJ 0" 0" 0&HTF/_UJVG_[='D@-O* 0")1R7>#WC670UM:K[JAYY-0YPF&
M*9*"M2I3.+BFT8?SHUK+4S'G_P#W6Z)_![OX?5TO^8A9<IRBJE_U5Z!>JV6'
MJ*Y4B'5A'&=:8*4S^,I+;SCDAX$GRQ+<>C7*/:6E!: H8@X@^")+D510@$ @
M$ @$!J;B/_V"T_S*K^JB VH&,!, @$ @$ @$ @$ @$ @$ @-18 ,]T_?W?ZJ
M8#;P" 0" \][P?\ >[7]R/*J.WB>?RN7.TQZ'GB(*0" 0" 0" 0" 0" 0" 0
M" 0" 0" 0I'K]L_W=2_W+?\ 4$>'9[=69$C5(H0%))QY9<D!\UWS_4[KOVLO
M%HT]IVDJJ6TU3M*M;SAXBN$M3>;SVQTBF>R,6C4'_5;WG)6$+TY;\ZI2 <5\
M;9L=,:@R'O\ 4]WLLLJ><TQ;TMH(S*+I/G&0D$NDGFBBU3_ZI.]6H +.F:!>
M;S3G4-A ^=\,=)IF,7>1K%_ZR]=-K*%V.W!2<")O?R+,9NJYRZ7NW_U6W[46
ML+?8KK:*5EFXN!E#U,I86A9V8+*@1&6H^ETDD8[8"8! ("EW]6KQ'R0&MTI_
M"UG_ '&F_P#A3 ;2 0" 0 F0@/"/]5&J+E;-/6Z@9JT4M)7.J54H4.FYPNDE
M*5Y5E/2$\(2967#Y<;O=/:BV&67&0[.=2A3B%)+HR+(/1VIVRVQ>.''3R9VP
MZ[NX[Q-9)U/:;937NM-!]XLTR&^TO%DLJ<&8<)2BC$'=[\1UWF*^ZAR?EL@*
MH! (! (! :C2?\-6W^X1Y(#;P" 1!YOWLZ9MNI:ZQ6NY/.L4JEU3A6RG,O,E
MM,A+*O;'339SNKE/^W_NRR!QRXU;*"H(!>X34U*V <1I.V.W^3CHQQ:[5W^G
MC1MMTO>;C35=2I='05-0VE8;Q4TPM4B4H2<N8)\.WQB;?DK-7OU$"*1D';D$
M^://G/5UG9>@JDK2#(J @)"P3($& D0" 0" U-Q_B"T_S*K^JB VP@$ @$ @
M$ @$ @$ @$ @$ @-38//NG[^[_53 ;: 0" 0'GO>#_O=K^Y'E5';Q//Y7+G:
M8]#SQ$%7::F>J7.&R@K7(F0W#&%J*JBBJJ?+QVR@*GC@=A P(GOC,V:L6=V\
M[]__ (QK+.*J::<=44H25%(*C+;(;8F3%43(E/:/.'N0RN*J0VMQ>1 S$@D2
MVX"<_+#)A4PR[4.AIE!4XHR2@;=DX9,*ZBBJ:<CC(",WF@D&<O%#D86,2<HG
MF/O3_-#)BJBVOA<67JR9!?(=AY?'%S#%4R5[HG,1,PQ4[3MP\,X93%)#\QAR
M,4,I"1_EC4L"(J(! (!"D>OVS_=U+_<M_P!01X=GMU9D2-4BA 4D8P'YVZKJ
M:YC7VJ!3E82J[5F<HGL%4L\G)C'/=OPZS:XK65+]TX@X:WRF6!2%'9MQ BZW
MHZ^7QR=E)K;\Z$H6Y4K0") YY"-9>:.ITJM3U>^'QQ4-HS95++:1PU%4LR!\
M8(R[YQTF]PSMXYG+E'K%<+A<;@NE0),.JX@6<I$YF4O<BYRLUD=1W46JMMO>
MSI1%4E*5.U:%(R&<QB(S8T_0)&R,B8! ("EW]6KQ'R0&MTI_"UG_ '&F_P#A
M3 ;2 0" 0$*V0'S5_K+HZJHMVGN DK+;KBRGQ)E&]+BEF>CY\OE94W>UT5O:
MIDM+:'$6O*$&03EQ/*)QO?;+Q>'QV;LCNN0M&KK:R3-:+K23/B<Y(X>KW>67
ME'Z(#;XHJ)@$ @$ @$!J-)_PU;?[A'D@-O (! <S?_XMT](8Y:[;_=(@+-0P
M\U75*GAZU]:5,U*6@H9$$!+*LT^E,G&.DQABYRP-3,/M]WFJ"M/#9>MU<]3,
M9,BVT+I"5)7\HN*4H^.):LR[>F_^G;_FCR1AI9KW5-MS&PX& U[A9P)"B3M.
M8P$(J0AU(1,3,CC. W0@)@$ @-3<?X@M/\RJ_JH@-L(! (! ( 9R@+%16,L(
MS.*D.0<L3*L(WUK-T&U*3R' >] 9;%:R\0E*I*)EE.W"*C)@$ @$ @$!J;!Y
M]T_?W?ZJ8#;0" 0" \][P?\ >[7]R/*J.WB>?RN7.TQZ'GB(*S;55M4M0XMV
M4BRXD X@DIPF(SM%E95/>,M/4MY&VAD)IT(1AQ%+3-72*L<J8YR-VJJ.NH4T
MJ4+6E"DAP/LEO,5D^:H* ,N01NQF6+U+<J)JF2.*EI/"4VJGX>)6>7/*7OQ,
M-<HLOU%K4Q4.(6%%]IM*6@@S2I)3FQ(EL2>6&$M9;5XI&JM2D5">$X%\()9_
M5S;4 DJEOELG$L3+46NI98KT/.*!0G--4I@G*91<&5V@N%)]X(>>8;0R H=
M$"9&!(.8PP99PN%L-R+I4@ MA(6 HS5,2PR3V?)B8JRQ3>KG0OTB&Z9P94.
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M]4V33U.R]=7BPFH<X3)X:G)N920))!/)%PS:L:W#K?=_J0.K"Y6RN)6!E$N
MX0,2=@D(-2NDI?\ Z=OEZ(Q]R(,>Z(*Z<R^*9F UBSF"-Q(F!N@+:FCVEH-Y
MCF. /@@.B1/*.2 F 0" U-Q_B"T_S*K^JB VP@$ @$ )E :'5NI$6.B8?40
M^\&<Q$\LTE4Y?[,2C2T%[HKG)QM\.K5CMV'=XHSE635U]+3)FXM,]B4#E]R+
M*+UCIKK47%JM?3P*1M*BTT?.7G$ID<D:1U, @$ @$ @-38//NG[^[_53 ;:
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M"E;,SB@E(]TF+(EN%E=ZMZ%5"5U#;?9"D5*EJ"$H*Q-,U*D,01%L9^Y$&\T
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M*#& F7A@$O# )>&  R(\<!4Y/.1N,!3+PP"7A@(,AB3(;SL@'++PRE+&)DB
M9[.7P0R)QQEC*+$)C?OY.0&436Y4!F)XRPY-\-;E,F/+@-\+5/Y.2&1,CC[A
M]PDC^2+.L*2\,(0EX8!+PP"7A@*G///C\D!3+PP"7A@$O# 1CS1,AR[9C>!%
M _E/#9$B91/;X-L5:D&?CW0/7 -\\)3F801/>9?#!,I'O\HE!4R\, EX8!+P
MP'GO?H/_ -#6)X=J9G_2CMX9U>3\RWB^<C^7N1]#:='PLW)(19.B\KDD('+8
MD('/8PEX=T.B\MB0&T>'PRE.$B<MB0EX=T)C*<]LDACX,)<L6R0N^T" /SX#
M;+;$6;;(Z,I[ <03N@EWV5998$2/\F^)T.>R)"*O+8D('+8D('+8D(DG1.N7
MUAW53_Y?V3]W_25'S/)W?H/QK\KKY=&7@C#T$ @$!A7#SV_&?*(#"3YH\0BA
MRSW?EMC-'GSRN\&EO+]>DNU%OXKR:>E"^(/,]6."FF"D@J^/QC+EB^E/6,*W
MZN[RY6@OT JU5'&%8W2T%>V<P05,J4Y4H:0R@99**B2KXL2=_P#;_,]/]W\F
MWT_=M?5]IHU5@98K7:I;=2XFBJVTH8 S8MU(9<29B05,IY1$M[-2)KM0ZQ;I
M5.-42F2W4!AQ8HW7U*D)J6EII05D6< O8-IC6K-9K=;JUR]L-E!IZ!PLK?4X
MP7&P.$I;B$N H"<Q &:<@>:+LS&#J&NU,SK!AFC%:Y1<-(++++H9SD+!*E]G
M=;5+!1"GV_ #\;G'1J']5=XS"*IJF86MUEEK@FIM5;EXB@"XHN,A:'0G9)"0
M5'8)".E8>A61ZN?M-(]7!*:MQM)J$H2M"0OEDEU*'!/Y0B*S8! (! (! (!
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M!QV2P@,0<$B<E\X@)]3N5SB >IW*YQ /4[E<X@'J=RN<0#U.Y7.(!ZG<KG$
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M%Z&9KPX8[86XZ+)F9 6YRD9[IQK"2DVL,%8^&($VY3DKG@)]7X>> CU>X\\
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MZV009$1K#/7W(8.ON1).BYN7UAW5_P#3ZQ_N_P"DJ/F>3N_0?C7Y77<D8=R
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M&?MU9^9/9QU0X'7E.=+I2\\\16$OC'+Y-D>AYE$ BSL>KZP[JO\ I]8_W?\
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MVA"DIEA$WGRSWRSIW<TG07>LXJWJJ;D3P:4L5;*+G4J8<5/!3C;K;BG7)?\
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M_/'TK<Q\+U(9Z+CJ0.-0>3&1&SQ^")9EG:8[NBT,NT)O:3=BQP,JLJJIM#B
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M8[X"I:D9B"D\\!3-OJF 3;ZI@$V^J8!-OJF 3;ZI@&9J4\ID-N, *FA\4\\
MS-3EE,_' )M]4\\ FWU3# 3;ZI@$V^J8!-OJF 3;ZI@$V^J8"I:DA9!3/'?
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M<41F)<#$F^CT?5)02(YX;RJL_=]9+35*?I7'9J=#TBBG3-0F,I6AIMU8Q_\
M,4?'%U2LNNTE0UVH:.]NOOMU-'@AIDMMH7A(!Q?#+RDCJY\L^2-LX;S'P>&0
M Q./)MA2$9:(! (! (#*7YP\0\D!$ @$ @$ @.+O&L;M;+K6,N4[:J#.RS25
M24J*D.K/FO=(=%7Q3,8X1B[C*T]K15VU'<K,JF91]WYBE33_ !GAPEI0H5+*
MFT=G+F8*;&=69(G,2CIK<QB[=75#9XL)G&<H5J7)$4@$ @$ .T?ER0%3GZQ7
MC/E,!3 (! (! #L\/)X^8P'"7S6>HK(_>%.4C%53V:G[8I25<$U"'U*;IV0M
M:\K)0M"N*ZN:0E,P,3EBX83?>W4I]ETUELIF/: $5'#N-/4%E<U)2&44W&-0
ME64G.))3RD'"+$LQ'I ,Y>](?#C$VC,I%E:P0" 0" 0%3OGGQF I@$ @$ @(
MD!,RG+$^(;L-O/ <12ZXO"*I-+<:1'&=<J5T[C2%%#[#.:02)X.I(DH'P*&V
M0S:C:Z)U:O4E#4/J:IT*8<R<6CJ#5LJ$M@=+;'33L6G+T3A.-R#H_)R0LPI$
M" 0" 0'GW?I_ :_WIG]*.W@^IY/S/I?.7YX^CMV?"]2+Z%[D0(! !S^#?X-H
M@-KIZWVZXUQI*QUQDK25,OH\T91G65(\XS2DX!0QY#&;<.NDCI*ON[M@N-L:
MIK@^6;A,E(HJATM@B8R+"4I>\:91SODKK]K6N2O5L7;+I4T#A*E4Z\N8R!(Y
M)Y5.">\ D>&.FF[AY)Q8<:KGK,D%(! (!%G8]7UAW5?]/K'^[_I*CY?E[OT'
MXWTNNY(YO00" 0&%</.;\?\ *(#"3YH\4!)]X>7=$HY.HTC=WEU=,FLIFK<^
MXMY"A3GM25J&T.YRG C Y,VXQ).E/6,"V]VAH].TEG:J&F>S./.YFP\I)XS9
M;EZYQU0\Z?G2C6O6Y^&$O;_<WEXTC37>Y4U75OO!IADM\)EUUC.2<W2X:QF3
M+ I5A#U/3_<U3O=RPFBK:>D4RA=6E/&2ZV7&W"E4P'4YAG3+"4XSM]'ZM?U;
M?Q7V-!4[;]NJ77$+J[<$(8?"",@#A4XE'2FE*DG++=OC<^NIMZ+NA]&*TU]Y
M*4ZEY=QJ#4..)+TU*..98=<=3F,\<@2/!#3U2.HB:WY5P0"&#)!" 04@$ @$
M @$ @,I?G#Q#R0" B 0" 0" I*$' I$ISQ (G.)Q$!M"25A$E*'K% "<DX@'
M"-28B757^6,*LA$" 0" 0 C$?ER0%3GZQ7C/E,!3,2GR0" 0" 3'/L@&/(9'
M?$%*DH4% @*"DY53E*0GACN@<D<!F224))2>CT098\D_#"5.ZL#$S\[PPM3&
M X;8LC62 <D^2 #'9 (! 5. YSXS 1 ("(! (">48^&8@*,B9SRB8GE($CCM
ME*)A!#:4(RI "=N5("1[T7(JVX^2&53 1 (! 3 >>]^G\!K/(*IF?]*.W@^I
MY/S)\KYRCZ.UZ/AS6Y1#,P76Y[)B<H<:0S#C3PPY1>-]CEERPNT9NML$DS&4
MR.R8\,9S*NOCL2%KDF2E #S1,X>_A[D2ZQOYI<H)F2=LR9QK62)MG8Y9<NZ%
MVC/&ST(O*'&HAF'&IY)\F^+DXTB9B\;[(F(L[)BY?6'=5_T_L?[O^DJ/E^7N
M^_\ C?2Z_DC#T$ @$!AUZU)*<IE. Q>*]UO) .,]UO) 1QGNMY(E$\5W?Y(L
MD_\ GN'&>ZWDA:(X[O6\D#*>,]UO)%E#CN];R1@P<9[K>2-AQGNMY(@<9[K>
M2 <9[K>2 <9[K>2 <9[K>2 <9[K>2 <9[K>2 <9[K>2 <9[K>2 <9[K>2 <9
M[K>2 <9[K>2 R2M<T^(0$<5>\\T XJ]YYHJ9.*O>>:,UJ4XJ]_O14.*O>>:
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M[I#BKWGFCGGJU3BKER\T=-N[,.*O>>:(IQ5[SS0#BN;SS0#BKWGF@'%7O/-
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M^]<OIGNUJ'JO0]HJ:E?$?=8S.+PZ1S$<F$?.\DZON?CW.KJI="7@C+LF 0"
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MCS6PH.<0<I/1)Y91IRG=T&CJ>^4]A8:O;SS]Q3/BN5(92Z=TPPMQOF5$:;N
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MS0#AKZIYH!PU]4\T X:^J>: <-?5/- .&OJGF@'#7U3S0#AKZIYH!PU]4\T
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MZ X0&5&3D)G'72]&=N[JQ/EB5J$2+2*A (! #M'Y<D!4Y^L5XSY3 4P" 0"
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M14,B>N(!D3UQ ,B>N(!D3UQ 2$I!'3!Q@)6E)4>F 8"G(GKB 9$]<0#(GKB
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M[!$@1JA$"+ B4(1"($;DP$8T[J1;W" 06$&;2&5G8@D(-$$(#*7YP\0\D!$
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ML3YTYQCQMUTN@KY<KU9WJRO4VMSM*T-+9;<:;+80@C*EWI[2?.BV,ZUTD&B
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MX);;V(;*4XJ69QK'2_#7/ZL2_P#]L?HO:>UQK&Z-6NHK&*2C0]7+IZM#*7W
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M,R.K[\ S(ZOOP#,CJ^_ ,R.K[\ S(ZOOP%2R@+.9.,]^^ IFCJ^_ ,R.K[\
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M;8YNZ8! (#"N'GM^,^40&$GS1XA 2<1+D@(R((D4B4YGP^. A+;:0 E($MP
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2Z2H^7Y>[]!^-]+KN2.;T/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>modular013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 modular013.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!%0+, P$1  (1 0,1 ?_$ *8  0 !!0$!
M       ! P0%!@<"" $! 0$! 0$!              $" P4$!A   0,# @,%
M P8*!0@(!P   0 " Q$$!1(&(3$'05$B$Q1A,@AQ@4(C%1:1H;%28M*35)15
MP7*"LC/1DD-S)'0V-_'B-&0E11<8\*)$A#4F)Q$!  ,  @(#  (#
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MKSD_JAPTU6Y@=LZ>[[L-V[0MLZ'-C.BMXSLCD:/$'=RQ,#FVU>M&\-X]4+C
MX&V@^[MI(3-=/:72>4SAKK^F[W5!WAE=0_Z/PA!40$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M(AC!U?VX"T>)L0>3RX2#BY:5]10 "-@%  QO$<B*=BP*_! J@(" @(" @("
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M+K.T/Q6Q"GB\Z+Q'@*>0#I'Y58@?5(YE85* @(" @(" @(" @(" @(" @("
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M! 0$!!B=QL#L!D6&0QGTLY#VFCAX":@^Q!S6PN)KYOD74SFPV>$CN;234?\
M%?SD!_.]J#,;&O;V\S\DMY(XRW&(LYY8WO+AYCBX:P*^'51!K6;MKVU;E<);
M2R-GQU\W*1N+B7.M*^8YI/=V(,W9[CN1D<C=XQK6^HM1EC)*26OB;]6V-@/(
M> FH056=2KU^-DS0B:,=!.RVDM2#YSB[F6GY>2"K!E),KNG:^5<&Q,N[2[+0
M#Q#&N9I:1Q->/X4'G,[BO;;>]G/')(<42<=,TGZGS9A]7(3[)-(0>&=2,RS&
M,N);>,WD<GI,C S_ $=VZ4QM:*_1#6U05+G>6\X9I+:6W@MYHK6YNM3Q[P@(
M+12O#4"@JOZ@Y)L-W*(HM,4%E<QAQXTNV@EIX_1)07NV=UYS-WXD-HUN(>9X
MW/X5:^&E*]^KN5&M7.8NMN;@N+O*0NO+>>6:;%92)Y(?7B+>9M?H<@4&5N-]
MYNQ;$VY9#(^>&WNF.%0UL<\[(7L=0_1\UND]J"9MYYFYSAQ0;"+3S+F&5_$E
MS8V5%.-0X=J"ET\S>0MVX7$3&-]K>6MS/"176TPS@4)KX@1(H.E(.;=:^FE]
MU P5ICK2\CLG6UP)S)*TN! !%."L2DN1-^$3<0YYRVX<OJY/Z%VSN&:5F_"5
MN$?^=VQ_L2+I'/3GKAM7C^%+/L_\YMC_ &)/\BZ1VZ<==:UPSX7\XP@'+V]!
M^BY;COS$L3THF&7Q'PVF.X#LEE!-""*QPL+21W5)7;?Z-Q3Y\]&I=FP.!QV$
MQ\=C81"*",< .WVE>5S<DZEZ?%B(:GUCZ=W>^ML1XBTN8[5[9VRF21I<*#GP
M"SQ_Q=.1Q^/X6-[Q1M9%NMD40   \UH#2!PI4=JU/GRF8\-TZ;?#Q%M66]R.
M0R OLO/!)# \-+8XA(""[B27%3V6F2Z)]'\ET_GRS[V_BO?M L<P1@MTZ2ZO
M/^LDK3%[DZ%9A_4B/>FV<E%CIB]LTML]I&I]?'RX>(*6-IZI]'\)U LH_5O-
MIEK<$6M[&*CCQTNX<6I8X^?A?ZC2$V#]RQG%UII$DP 'M813\:U[#M?3/I7@
M-AXMUK9UGO)J>KO9  Z0MY:0/=:.P+,Z&J]5?AZQF[[UV:Q-S]EYNE#)I)CD
M]I TD'VJV-#M?A<WM?W$<>XMR-DQ\1%6!TLCM(/)NH !/8=:S/23''I?=[)P
M+FV;)XPT3R#55X(<7OI2JA2MTKZ;OV?LS[MY&5EZ'OE=(YK?"YLA/"A42FF;
M:Z#[AVGU!EW!MS+PQXF=[A-CI&NJ^%_$QU'#PNXA:B59+IMT7RNTM]97<=SD
M(KF#(!X9;L:YI9K<7 :BK8R.,Z.6MEU;N]]><QT$\?U-H&\63ENA\E?:UM%)
MD83>O1#/YOJ0S>&/R=O;F-K?+MY&N+@Y@I7@EI1TJZ 1[7S&2R6XIK?,RWK:
M1-<PN:QSGE[SXQS-0II6Y[WZ5;:W!M>]Q%K8VMC<W$9;;W3(6@Q//)PTBJ1(
MY!)\,>[IMO6F$FSEL;:UNGW< T/#AYC6 M%>'O-)6_;P/H#&8AEOA+;&W%)Q
M;P-@DJ/"ZC-+OF*Q8X[A?AOEP74>+<F-R,<>(AN'3Q6!:=36OJ?+#O956QW@
M$UX<>"R/2 @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @M[RSM[JVDMIP70S-+)6_G-<""#\M4&+=L_ FWM[?T^F*V8(HFAQ'U
M8^@3S+?84%>VV_B;7(NOX( V[?$V!T@)IY4?N-IRHWL059L'BYKF:ZD@:^>Y
MB\B63M,?YJ"PN]G8&=D$9@\MEM%Z>,1DBL-:^6ZGT:H/1V?M\W0NO34>-/@:
M?JR6\B6>[5!%OL_!6M_#=PPD3VY>;<ZC1@D-7-:.0%4'N?:.!N,><?+ 7VKI
MA<.87.KY@=J#JU[T"3:N >V]8;44R$HGN^]TK0 '^P^'L0>'[2P;W-?) 9I1
M$^VUR/<7&*7@]I->108BZVYLJ;*Q8R9C3>,@CB9;!SM1AB_P]0%!X>PH+[#V
M.WK/,7=I8ZH[R-K9;B $Z?'X1)IK3C3BJ+:]QVSL7>0B\+6S3ZW6]M(72 E_
M^(Z-O$<4%#$XS9&39>X^TI=,<R-L[M3O!#J+HPUQY-#V</;\B"^BV-MV.7S&
M6SA*7F0NUG47.%'5-:\0@NK#:^"L9[6:TMO+DLHWQ6CM50UDSM3VBI_. ^=0
M9WL0/+%:U*)20T *4II;W*@6A!&BG:EI,(+!V\?E6*:2&@#AP5I$%@(H5J4F
M+ P5JK:_2=(/-0265[4$>6/:@&,$4/$=Q026 BB"/*:.0IV<%F<@&- ^3M[5
M: 1-!KVGF4H/+%:]O+\*H: K8>4W\/-0/+ Y(!C:10\CP^9 # !WH)T"J Y@
M<*'B$$!@'&O$\_:@%@-0>1YH C%2>9/$H)IQ02@(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(%$#B@BB!RY(%!S0*4]B"-//V
MH)#:(&D50>) >0IQK^1!RS=>0F=D;J3$3RODN(IXKSPT= +8AHTGFWB#2G-!
MCLE<W0FR.1L[J?U-KBK.2&9I=5\C9&DZOSB.1"HV/>KKF?.;;]'*V"Z=YNB9
MS-36ZFM''A[$&-S5Q=6&YIHHGO@C>+"+)W,32TB%SY-3@X<@Y_.G>@I19;+2
MWL]M=W=Q'@81<G&7]2#*]A.@%PXFG9WH,CL>7,Y/<#I,M=7#9+2TM9FV9);&
M991*U[B.3CH#21\B@Z4@E 0$! 4 H%$@**A1  H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @$T08+)[I@Q^:LL5+!*Y]^UYAG;3R@6"I#G5X5[$%ACNH5A?V,-W!;REL
MM])CW,.D.:^&NMYX^XVG$H,W]L69@=<,GB=&TT<_4-(^5R"GE<Y%88FXR+0V
MX9#&Z1C&. \P,&HAIY<E1C\#O:SR\]Q"(S;20^66-D<VL@D;J&E!D9\[;LTL
MA+;F9SVM='$]A+6N)&LU(X"G%!;WNY8[/.V&*?'J-^V4B9KN##$TO((I7D$%
MX,UCC&9!=0N:T!SW"1I:&GZ1-> 4%2:[_P!D?<,!D:&%[!&6ES@!7P\:<?E0
M:OBMZX/)8NVRN/MGSLOIC;RL#&B:.0$M+)14>Z6D<4@7EAN3$W&+R%Z8!;6F
M.=+%<.E:--(!J>?!KX!46KM\8CRWNN;=T$T;&2P02AH=(R4^!S37A4]]$%*X
MWSB6PB22T<ZYI(^[@<&ZV1PD"1PK[^G4WD@]OWGAF7D-G-9/CLWR&&&XD8 P
MO:W5I#>= /I(+O"[JQV0R,, B,,EU$Z:Q>\ >=&TT>6$=HJ/F4&T()0$! 0$
M!0%00$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MN6W5OEO,H80^9KY6D #CI;\Y0;)N+;.<EQ%Y'#D'7KI-3X[6>-A;4-H&L('
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M5!L2"4! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MH/FV[XGBFIW<]M H.K=B"4! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MO&6<D[&74E?+A<X!SJ"O (6FUS>,NYWP6\[))H_?8UP)'S(+Y!* @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MG45U%!* @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @L<HR V\DDT
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M=CR\C\'"J#>NQ!* @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @@CB
M$"B!3C\J#P6>/7I&JE-7;1!.D]H_Z$'GRS4<!3L!%:(/=/F[D$4/<?E0-/;1
M!-.VE7=B"-- :5H>:!0_T?,@]()0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$"H0*CO0*CO0*CO0*CO0*CO0*CO0*CO0*CO0*CO0*CO0*CO0*CO0*CO0*CO0
M*CO0*CO0*CO00@E 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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*&H>[J[$%1!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>19
<FILENAME>modd-20211231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /6Ips7xRiXgen8uHZH0sSa6C+bPtzpN2SekhtWpzfelKPyMs+LvRTi8uV4mGIX0M -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:modd="http://modular-medical.com/20211231" elementFormDefault="qualified" targetNamespace="http://modular-medical.com/20211231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://modular-medical.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" id="StatementsOfStockholdersEquityDeficit">
	  <link:definition>00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" id="CompanyAndSummaryOfSignificantAccountingPolicies">
	  <link:definition>00000007 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/Leases" id="Leases">
	  <link:definition>00000008 - Disclosure - LEASES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/PppNote" id="PppNote">
	  <link:definition>00000009 - Disclosure - PPP NOTE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotes" id="ConvertiblePromissoryNotes">
	  <link:definition>00000010 - Disclosure - CONVERTIBLE PROMISSORY NOTES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/PromissoryNote" id="PromissoryNote">
	  <link:definition>00000011 - Disclosure - PROMISSORY NOTE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensation" id="StockholdersDeficitAndStock-basedCompensation">
	  <link:definition>00000012 - Disclosure - STOCKHOLDERS&#8217; DEFICIT AND STOCK-BASED COMPENSATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000013 - Disclosure - INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000014 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000016 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetail" id="ConsolidatedBalanceSheetDetail">
	  <link:definition>00000017 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/NotesPayable" id="NotesPayable">
	  <link:definition>00000018 - Disclosure - NOTES PAYABLE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
	  <link:definition>00000019 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000020 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/RoyaltyAgreement" id="RoyaltyAgreement">
	  <link:definition>00000021 - Disclosure - ROYALTY AGREEMENT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/RetirementSavingsPlan" id="RetirementSavingsPlan">
	  <link:definition>00000022 - Disclosure - RETIREMENT SAVINGS PLAN</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" id="CompanyAndSummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000023 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000024 - Disclosure - LEASES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationTables" id="StockholdersDeficitAndStock-basedCompensationTables">
	  <link:definition>00000025 - Disclosure - STOCKHOLDERS&#8217; DEFICIT AND STOCK-BASED COMPENSATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables" id="ConsolidatedBalanceSheetDetailTables">
	  <link:definition>00000026 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
	  <link:definition>00000027 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" id="CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000028 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/LeasesDetails" id="LeasesDetails">
	  <link:definition>00000029 - Disclosure - LEASES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
	  <link:definition>00000030 - Disclosure - LEASES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/PppNoteDetailsNarrative" id="PppNoteDetailsNarrative">
	  <link:definition>00000031 - Disclosure - PPP NOTE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" id="ConvertiblePromissoryNotesDetailsNarrative">
	  <link:definition>00000032 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/PromissoryNoteDetailsNarrative" id="PromissoryNoteDetailsNarrative">
	  <link:definition>00000033 - Disclosure - PROMISSORY NOTE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails" id="StockholdersEquityDeficitStock-basedCompensationDetails">
	  <link:definition>00000034 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2" id="StockholdersEquityDeficitStock-basedCompensationDetails2">
	  <link:definition>00000035 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3" id="StockholdersEquityDeficitStock-basedCompensationDetails3">
	  <link:definition>00000036 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative" id="StockholdersDeficitAndStock-basedCompensationDetailsNarrative">
	  <link:definition>00000037 - Disclosure - STOCKHOLDERS&#8217; DEFICIT AND STOCK-BASED COMPENSATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000038 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000039 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails" id="ConsolidatedBalanceSheetDetailDetails">
	  <link:definition>00000040 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2" id="ConsolidatedBalanceSheetDetailDetails2">
	  <link:definition>00000041 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails" id="Stock-basedCompensationDetails">
	  <link:definition>00000042 - Disclosure - STOCK-BASED COMPENSATION (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails2" id="Stock-basedCompensationDetails2">
	  <link:definition>00000043 - Disclosure - STOCK-BASED COMPENSATION (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails3" id="Stock-basedCompensationDetails3">
	  <link:definition>00000044 - Disclosure - STOCK-BASED COMPENSATION (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://modular-medical.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000045 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="modd_CommonStockIssuableMember" name="CommonStockIssuableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_SecuredPromissoryNotesMember" name="SecuredPromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_CEOAndInvestorMember" name="CEOAndInvestorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_NotesPayableOtherPayables1Member" name="NotesPayableOtherPayables1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_NotesPayableOtherPayables2Member" name="NotesPayableOtherPayables2Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_MemberOfBoardMember" name="MemberOfBoardMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_AccruedWagesAndBonusMember" name="AccruedWagesAndBonusMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_AccruedPlacementFeesMember" name="AccruedPlacementFeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_AccruedInterestMember" name="AccruedInterestMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_AccruedOtherExpensesMember" name="AccruedOtherExpensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="modd_PromissoryNotePayable" name="PromissoryNotePayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_CommonStockIssuable" name="CommonStockIssuable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_SharesIssuableForServices" name="SharesIssuableForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_SharesIssuedForReverseStockSplit" name="SharesIssuedForReverseStockSplit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_GainOnPPPNoteForgiveness" name="GainOnPPPNoteForgiveness" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_IncreaseDecreaseInLeaseLiability" name="IncreaseDecreaseInLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_ProceedsFromIssuanceOfPromissoryNote" name="ProceedsFromIssuanceOfPromissoryNote" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosurePppNoteAbstract" name="DisclosurePppNoteAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="modd_PPPNotesPayableTextBlock" name="PPPNotesPayableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosurePromissoryNoteAbstract" name="DisclosurePromissoryNoteAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="modd_PromissoryNoteTextBlock" name="PromissoryNoteTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureConsolidatedBalanceSheetDetailAbstract" name="DisclosureConsolidatedBalanceSheetDetailAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="modd_ConsolidatedBalanceSheetDetailTextBlock" name="ConsolidatedBalanceSheetDetailTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureRoyaltyAgreementAbstract" name="DisclosureRoyaltyAgreementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="modd_RoyaltyAgreementDisclosureTextBlock" name="RoyaltyAgreementDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureRetirementSavingsPlanAbstract" name="DisclosureRetirementSavingsPlanAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="modd_RetirementSavingsPlanDisclosureTextBlock" name="RetirementSavingsPlanDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_ReverseStockSplitPolicyTextBlock" name="ReverseStockSplitPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureLeaseDetailsAbstract" name="DisclosureLeaseDetailsAbstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureLeasesDetailsAbstarct" name="DisclosureLeasesDetailsAbstarct" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureStockBasedCompensationDetailsAbstract" name="DisclosureStockBasedCompensationDetailsAbstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureStockBasedCompensationDetails2Abstract" name="DisclosureStockBasedCompensationDetails2Abstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureStockBasedCompensationDetails3Abstract" name="DisclosureStockBasedCompensationDetails3Abstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureConsolidatedBalanceSheetDetailsAbstract" name="DisclosureConsolidatedBalanceSheetDetailsAbstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_DisclosureConsolidatedBalanceSheetDetails2Abstract" name="DisclosureConsolidatedBalanceSheetDetails2Abstract" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="modd_OperatingLeasesImputedInterest" name="OperatingLeasesImputedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_OperatingLeasesAnnualRentIncreasePercentange" name="OperatingLeasesAnnualRentIncreasePercentange" nillable="true" xbrli:periodType="instant" type="xbrli:pureItemType" substitutionGroup="xbrli:item" />
    <element id="modd_LeaseIncentiveReceived" name="LeaseIncentiveReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_CashPaidforLeaseLiabilities" name="CashPaidforLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock" name="NotesAndAccuredInterestCouldBeConvertedIntoCommonStock" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="modd_FairValueofOptionGranted" name="FairValueofOptionGranted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="modd_NotesCancelled" name="NotesCancelled" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>20
<FILENAME>modd-20211231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://modular-medical.com/role/Cover" xlink:href="modd-20211231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheets" xlink:href="modd-20211231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:href="modd-20211231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfOperations" xlink:href="modd-20211231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="modd-20211231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfCashFlows" xlink:href="modd-20211231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="modd-20211231.xsd#CompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Leases" xlink:href="modd-20211231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PppNote" xlink:href="modd-20211231.xsd#PppNote" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotes" xlink:href="modd-20211231.xsd#ConvertiblePromissoryNotes" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PromissoryNote" xlink:href="modd-20211231.xsd#PromissoryNote" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensation" xlink:href="modd-20211231.xsd#StockholdersDeficitAndStock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxes" xlink:href="modd-20211231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RelatedPartyTransactions" xlink:href="modd-20211231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CommitmentsAndContingencies" xlink:href="modd-20211231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/SubsequentEvents" xlink:href="modd-20211231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetail" xlink:href="modd-20211231.xsd#ConsolidatedBalanceSheetDetail" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/NotesPayable" xlink:href="modd-20211231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensation" xlink:href="modd-20211231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquity" xlink:href="modd-20211231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RoyaltyAgreement" xlink:href="modd-20211231.xsd#RoyaltyAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RetirementSavingsPlan" xlink:href="modd-20211231.xsd#RetirementSavingsPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="modd-20211231.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesTables" xlink:href="modd-20211231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationTables" xlink:href="modd-20211231.xsd#StockholdersDeficitAndStock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables" xlink:href="modd-20211231.xsd#ConsolidatedBalanceSheetDetailTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationTables" xlink:href="modd-20211231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="modd-20211231.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesDetails" xlink:href="modd-20211231.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesDetailsNarrative" xlink:href="modd-20211231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PppNoteDetailsNarrative" xlink:href="modd-20211231.xsd#PppNoteDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" xlink:href="modd-20211231.xsd#ConvertiblePromissoryNotesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PromissoryNoteDetailsNarrative" xlink:href="modd-20211231.xsd#PromissoryNoteDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails" xlink:href="modd-20211231.xsd#StockholdersEquityDeficitStock-basedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2" xlink:href="modd-20211231.xsd#StockholdersEquityDeficitStock-basedCompensationDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3" xlink:href="modd-20211231.xsd#StockholdersEquityDeficitStock-basedCompensationDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative" xlink:href="modd-20211231.xsd#StockholdersDeficitAndStock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="modd-20211231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/SubsequentEventsDetailsNarrative" xlink:href="modd-20211231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails" xlink:href="modd-20211231.xsd#ConsolidatedBalanceSheetDetailDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2" xlink:href="modd-20211231.xsd#ConsolidatedBalanceSheetDetailDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails" xlink:href="modd-20211231.xsd#Stock-basedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails2" xlink:href="modd-20211231.xsd#Stock-basedCompensationDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails3" xlink:href="modd-20211231.xsd#Stock-basedCompensationDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDetailsNarrative" xlink:href="modd-20211231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_us-gaapUnsecuredDebtCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapUnsecuredDebtCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_PromissoryNotePayable" xlink:label="loc_moddPromissoryNotePayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_moddPromissoryNotePayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaapShortTermBankLoansAndNotesPayable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapShortTermBankLoansAndNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_CommonStockIssuable" xlink:label="loc_moddCommonStockIssuable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_moddCommonStockIssuable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Deficit) (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_ProceedsFromIssuanceOfPromissoryNote" xlink:label="loc_moddProceedsFromIssuanceOfPromissoryNote" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_moddProceedsFromIssuanceOfPromissoryNote" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Leases" xlink:title="00000008 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PppNote" xlink:title="00000009 - Disclosure - PPP NOTE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConvertiblePromissoryNotes" xlink:title="00000010 - Disclosure - CONVERTIBLE PROMISSORY NOTES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PromissoryNote" xlink:title="00000011 - Disclosure - PROMISSORY NOTE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensation" xlink:title="00000012 - Disclosure - STOCKHOLDERS&#8217; DEFICIT AND STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RelatedPartyTransactions" xlink:title="00000014 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetail" xlink:title="00000017 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/NotesPayable" xlink:title="00000018 - Disclosure - NOTES PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensation" xlink:title="00000019 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquity" xlink:title="00000020 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RoyaltyAgreement" xlink:title="00000021 - Disclosure - ROYALTY AGREEMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RetirementSavingsPlan" xlink:title="00000022 - Disclosure - RETIREMENT SAVINGS PLAN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesTables" xlink:title="00000024 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationTables" xlink:title="00000025 - Disclosure - STOCKHOLDERS&#8217; DEFICIT AND STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables" xlink:title="00000026 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationTables" xlink:title="00000027 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000028 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesDetails" xlink:title="00000029 - Disclosure - LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_OperatingLeasesImputedInterest" xlink:label="loc_moddOperatingLeasesImputedInterest" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_moddOperatingLeasesImputedInterest" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesDetailsNarrative" xlink:title="00000030 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PppNoteDetailsNarrative" xlink:title="00000031 - Disclosure - PPP NOTE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" xlink:title="00000032 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PromissoryNoteDetailsNarrative" xlink:title="00000033 - Disclosure - PROMISSORY NOTE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails" xlink:title="00000034 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2" xlink:title="00000035 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3" xlink:title="00000036 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative" xlink:title="00000037 - Disclosure - STOCKHOLDERS&#8217; DEFICIT AND STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000038 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000039 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails" xlink:title="00000040 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2" xlink:title="00000041 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails" xlink:title="00000042 - Disclosure - STOCK-BASED COMPENSATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails2" xlink:title="00000043 - Disclosure - STOCK-BASED COMPENSATION (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails3" xlink:title="00000044 - Disclosure - STOCK-BASED COMPENSATION (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000045 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>21
<FILENAME>modd-20211231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://modular-medical.com/role/Cover" xlink:href="modd-20211231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheets" xlink:href="modd-20211231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:href="modd-20211231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfOperations" xlink:href="modd-20211231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="modd-20211231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfCashFlows" xlink:href="modd-20211231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="modd-20211231.xsd#CompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Leases" xlink:href="modd-20211231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PppNote" xlink:href="modd-20211231.xsd#PppNote" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotes" xlink:href="modd-20211231.xsd#ConvertiblePromissoryNotes" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PromissoryNote" xlink:href="modd-20211231.xsd#PromissoryNote" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensation" xlink:href="modd-20211231.xsd#StockholdersDeficitAndStock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxes" xlink:href="modd-20211231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RelatedPartyTransactions" xlink:href="modd-20211231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CommitmentsAndContingencies" xlink:href="modd-20211231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/SubsequentEvents" xlink:href="modd-20211231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetail" xlink:href="modd-20211231.xsd#ConsolidatedBalanceSheetDetail" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/NotesPayable" xlink:href="modd-20211231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensation" xlink:href="modd-20211231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquity" xlink:href="modd-20211231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RoyaltyAgreement" xlink:href="modd-20211231.xsd#RoyaltyAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RetirementSavingsPlan" xlink:href="modd-20211231.xsd#RetirementSavingsPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="modd-20211231.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesTables" xlink:href="modd-20211231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationTables" xlink:href="modd-20211231.xsd#StockholdersDeficitAndStock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables" xlink:href="modd-20211231.xsd#ConsolidatedBalanceSheetDetailTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationTables" xlink:href="modd-20211231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="modd-20211231.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesDetails" xlink:href="modd-20211231.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesDetailsNarrative" xlink:href="modd-20211231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PppNoteDetailsNarrative" xlink:href="modd-20211231.xsd#PppNoteDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" xlink:href="modd-20211231.xsd#ConvertiblePromissoryNotesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PromissoryNoteDetailsNarrative" xlink:href="modd-20211231.xsd#PromissoryNoteDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails" xlink:href="modd-20211231.xsd#StockholdersEquityDeficitStock-basedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2" xlink:href="modd-20211231.xsd#StockholdersEquityDeficitStock-basedCompensationDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3" xlink:href="modd-20211231.xsd#StockholdersEquityDeficitStock-basedCompensationDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative" xlink:href="modd-20211231.xsd#StockholdersDeficitAndStock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="modd-20211231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/SubsequentEventsDetailsNarrative" xlink:href="modd-20211231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails" xlink:href="modd-20211231.xsd#ConsolidatedBalanceSheetDetailDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2" xlink:href="modd-20211231.xsd#ConsolidatedBalanceSheetDetailDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails" xlink:href="modd-20211231.xsd#Stock-basedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails2" xlink:href="modd-20211231.xsd#Stock-basedCompensationDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails3" xlink:href="modd-20211231.xsd#Stock-basedCompensationDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDetailsNarrative" xlink:href="modd-20211231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Deficit) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_CommonStockIssuableMember" xlink:label="loc_moddCommonStockIssuableMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_moddCommonStockIssuableMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_SharesIssuableForServices" xlink:label="loc_moddSharesIssuableForServices_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_moddSharesIssuableForServices_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_SharesIssuedForReverseStockSplit" xlink:label="loc_moddSharesIssuedForReverseStockSplit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_moddSharesIssuedForReverseStockSplit_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_60" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Leases" xlink:title="00000008 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PppNote" xlink:title="00000009 - Disclosure - PPP NOTE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConvertiblePromissoryNotes" xlink:title="00000010 - Disclosure - CONVERTIBLE PROMISSORY NOTES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PromissoryNote" xlink:title="00000011 - Disclosure - PROMISSORY NOTE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensation" xlink:title="00000012 - Disclosure - STOCKHOLDERS&#8217; DEFICIT AND STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RelatedPartyTransactions" xlink:title="00000014 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetail" xlink:title="00000017 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/NotesPayable" xlink:title="00000018 - Disclosure - NOTES PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensation" xlink:title="00000019 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquity" xlink:title="00000020 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RoyaltyAgreement" xlink:title="00000021 - Disclosure - ROYALTY AGREEMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RetirementSavingsPlan" xlink:title="00000022 - Disclosure - RETIREMENT SAVINGS PLAN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesTables" xlink:title="00000024 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationTables" xlink:title="00000025 - Disclosure - STOCKHOLDERS&#8217; DEFICIT AND STOCK-BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables" xlink:title="00000026 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationTables" xlink:title="00000027 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000028 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesDetails" xlink:title="00000029 - Disclosure - LEASES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesDetailsNarrative" xlink:title="00000030 - Disclosure - LEASES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PppNoteDetailsNarrative" xlink:title="00000031 - Disclosure - PPP NOTE (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" xlink:title="00000032 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock" xlink:label="loc_moddNotesAndAccuredInterestCouldBeConvertedIntoCommonStock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_moddNotesAndAccuredInterestCouldBeConvertedIntoCommonStock_40" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PromissoryNoteDetailsNarrative" xlink:title="00000033 - Disclosure - PROMISSORY NOTE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapInvestmentTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_SecuredPromissoryNotesMember" xlink:label="loc_moddSecuredPromissoryNotesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_moddSecuredPromissoryNotesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCredit_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="loc_us-gaapLineOfCreditFacilityExpirationDate1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityExpirationDate1_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaapLineOfCreditFacilityIncreaseDecreaseForPeriodNet_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityIncreaseDecreaseForPeriodNet_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:label="loc_us-gaapLineOfCreditFacilityIncreaseAccruedInterest_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityIncreaseAccruedInterest_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails" xlink:title="00000034 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_130" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2" xlink:title="00000035 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant_80" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3" xlink:title="00000036 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_50" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative" xlink:title="00000037 - Disclosure - STOCKHOLDERS&#8217; DEFICIT AND STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapEmployeeStockMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_FairValueofOptionGranted" xlink:label="loc_moddFairValueofOptionGranted_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_moddFairValueofOptionGranted_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_90" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000038 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_CEOAndInvestorMember" xlink:label="loc_moddCEOAndInvestorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_moddCEOAndInvestorMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_MemberOfBoardMember" xlink:label="loc_moddMemberOfBoardMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_moddMemberOfBoardMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_NotesPayableOtherPayables1Member" xlink:label="loc_moddNotesPayableOtherPayables1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_moddNotesPayableOtherPayables1Member_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_NotesPayableOtherPayables2Member" xlink:label="loc_moddNotesPayableOtherPayables2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_moddNotesPayableOtherPayables2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_NotesCancelled" xlink:label="loc_moddNotesCancelled_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_moddNotesCancelled_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesPayable_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestExpense_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_150" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000039 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaapLineOfCreditFacilityIncreaseDecreaseForPeriodNet_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityIncreaseDecreaseForPeriodNet_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails" xlink:title="00000040 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2" xlink:title="00000041 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableLineItems" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableTable" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableLineItems" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaapNatureOfExpenseAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableTable" xlink:to="loc_us-gaapNatureOfExpenseAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapNatureOfExpenseAxis" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapNatureOfExpenseAxis" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_AccruedWagesAndBonusMember" xlink:label="loc_moddAccruedWagesAndBonusMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_moddAccruedWagesAndBonusMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_AccruedPlacementFeesMember" xlink:label="loc_moddAccruedPlacementFeesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_moddAccruedPlacementFeesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_AccruedInterestMember" xlink:label="loc_moddAccruedInterestMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_moddAccruedInterestMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_AccruedOtherExpensesMember" xlink:label="loc_moddAccruedOtherExpensesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_moddAccruedOtherExpensesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails" xlink:title="00000042 - Disclosure - STOCK-BASED COMPENSATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails2" xlink:title="00000043 - Disclosure - STOCK-BASED COMPENSATION (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails3" xlink:title="00000044 - Disclosure - STOCK-BASED COMPENSATION (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_50" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000045 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_20" xlink:type="arc" order="0" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>22
<FILENAME>modd-20211231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_CommonStockIssuableMember" xlink:label="modd_CommonStockIssuableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockIssuableMember" xlink:to="modd_CommonStockIssuableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CommonStockIssuableMember_lbl" xml:lang="en-US">Common Stock Issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Investment Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_SecuredPromissoryNotesMember" xlink:label="modd_SecuredPromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_SecuredPromissoryNotesMember" xlink:to="modd_SecuredPromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_SecuredPromissoryNotesMember_lbl" xml:lang="en-US">Secured Promissory Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US">Employee Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_CEOAndInvestorMember" xlink:label="modd_CEOAndInvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CEOAndInvestorMember" xlink:to="modd_CEOAndInvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CEOAndInvestorMember_lbl" xml:lang="en-US">C E O And Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_NotesPayableOtherPayables1Member" xlink:label="modd_NotesPayableOtherPayables1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NotesPayableOtherPayables1Member" xlink:to="modd_NotesPayableOtherPayables1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_NotesPayableOtherPayables1Member_lbl" xml:lang="en-US">Notes Payable Other Payables 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_NotesPayableOtherPayables2Member" xlink:label="modd_NotesPayableOtherPayables2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NotesPayableOtherPayables2Member" xlink:to="modd_NotesPayableOtherPayables2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_NotesPayableOtherPayables2Member_lbl" xml:lang="en-US">Notes Payable Other Payables 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_MemberOfBoardMember" xlink:label="modd_MemberOfBoardMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_MemberOfBoardMember" xlink:to="modd_MemberOfBoardMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_MemberOfBoardMember_lbl" xml:lang="en-US">Member Of Board [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Ellen O&#8217;Connor (Lynn) Vos</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Paul DiPerna</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">Public Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_NatureOfExpenseAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfExpenseAxis_lbl" xml:lang="en-US">Nature of Expense [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_AccruedWagesAndBonusMember" xlink:label="modd_AccruedWagesAndBonusMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AccruedWagesAndBonusMember" xlink:to="modd_AccruedWagesAndBonusMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AccruedWagesAndBonusMember_lbl" xml:lang="en-US">Accured Wages and Bonus [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_AccruedPlacementFeesMember" xlink:label="modd_AccruedPlacementFeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AccruedPlacementFeesMember" xlink:to="modd_AccruedPlacementFeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AccruedPlacementFeesMember_lbl" xml:lang="en-US">Accured Placement Fees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_AccruedInterestMember" xlink:label="modd_AccruedInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AccruedInterestMember" xlink:to="modd_AccruedInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AccruedInterestMember_lbl" xml:lang="en-US">Accured Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_AccruedOtherExpensesMember" xlink:label="modd_AccruedOtherExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_AccruedOtherExpensesMember" xlink:to="modd_AccruedOtherExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_AccruedOtherExpensesMember_lbl" xml:lang="en-US">Accrued Other Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment,&#160;net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use asset, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssets" xlink:to="us-gaap_DepositsAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssets_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">TOTAL NON-CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Short-term lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="us-gaap_UnsecuredDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebtCurrent" xlink:to="us-gaap_UnsecuredDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnsecuredDebtCurrent_lbl" xml:lang="en-US">PPP note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_PromissoryNotePayable" xlink:label="modd_PromissoryNotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PromissoryNotePayable" xlink:to="modd_PromissoryNotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PromissoryNotePayable_lbl" xml:lang="en-US">Promissory note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US">Convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG-TERM LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Bonus payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 10)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, $0.001&#160;par value, 5,000,000 shares authorized, none issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, $0.001&#160;par value, 50,000,000 shares authorized, 6,302,050 shares and 5,956,754 shares issued and outstanding as of March 31, 2021 and 2020, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_CommonStockIssuable" xlink:label="modd_CommonStockIssuable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockIssuable" xlink:to="modd_CommonStockIssuable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CommonStockIssuable_lbl" xml:lang="en-US">Common stock issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CommonStockIssuable" xlink:to="modd_CommonStockIssuable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="modd_CommonStockIssuable_2_lbl" xml:lang="en-US">Common stock issuable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on debt extinguishment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US">Shares used in computing net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Shares issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US">Warrants issued with convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Placement of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_SharesIssuableForServices" xlink:label="modd_SharesIssuableForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_SharesIssuableForServices" xlink:to="modd_SharesIssuableForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_SharesIssuableForServices_lbl" xml:lang="en-US">Shares issuable for services</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_SharesIssuedForReverseStockSplit" xlink:label="modd_SharesIssuedForReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_SharesIssuedForReverseStockSplit" xlink:to="modd_SharesIssuedForReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_SharesIssuedForReverseStockSplit_lbl" xml:lang="en-US">Shares issued for reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Shares, Outstanding, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_GainOnPPPNoteForgiveness" xlink:label="modd_GainOnPPPNoteForgiveness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_GainOnPPPNoteForgiveness" xlink:to="modd_GainOnPPPNoteForgiveness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_GainOnPPPNoteForgiveness_lbl" xml:lang="en-US">Gain on PPP note forgiveness</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Loss on debt extinguishment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Shares for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of lease right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_IncreaseDecreaseInLeaseLiability" xlink:label="modd_IncreaseDecreaseInLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_IncreaseDecreaseInLeaseLiability" xlink:to="modd_IncreaseDecreaseInLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_IncreaseDecreaseInLeaseLiability_lbl" xml:lang="en-US">Change in lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from private placement, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_ProceedsFromIssuanceOfPromissoryNote" xlink:label="modd_ProceedsFromIssuanceOfPromissoryNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ProceedsFromIssuanceOfPromissoryNote" xlink:to="modd_ProceedsFromIssuanceOfPromissoryNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ProceedsFromIssuanceOfPromissoryNote_lbl" xml:lang="en-US">Proceeds from issuance of promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from issuance of PPP note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and cash equivalents, at beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">Cash and cash equivalents, at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash investing and financing activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_2_lbl" xml:lang="en-US">Fair value of detachable warrants issued with convertible notes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets and prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xml:lang="en-US">Security deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosurePppNoteAbstract" xlink:label="modd_DisclosurePppNoteAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosurePppNoteAbstract" xlink:to="modd_DisclosurePppNoteAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosurePppNoteAbstract_lbl" xml:lang="en-US">Ppp Note</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_PPPNotesPayableTextBlock" xlink:label="modd_PPPNotesPayableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PPPNotesPayableTextBlock" xlink:to="modd_PPPNotesPayableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PPPNotesPayableTextBlock_lbl" xml:lang="en-US">PPP NOTE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE PROMISSORY NOTES</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosurePromissoryNoteAbstract" xlink:label="modd_DisclosurePromissoryNoteAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosurePromissoryNoteAbstract" xlink:to="modd_DisclosurePromissoryNoteAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosurePromissoryNoteAbstract_lbl" xml:lang="en-US">Promissory Note</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_PromissoryNoteTextBlock" xlink:label="modd_PromissoryNoteTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_PromissoryNoteTextBlock" xlink:to="modd_PromissoryNoteTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_PromissoryNoteTextBlock_lbl" xml:lang="en-US">PROMISSORY NOTE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; DEFICIT AND STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureConsolidatedBalanceSheetDetailAbstract" xlink:label="modd_DisclosureConsolidatedBalanceSheetDetailAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureConsolidatedBalanceSheetDetailAbstract" xlink:to="modd_DisclosureConsolidatedBalanceSheetDetailAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureConsolidatedBalanceSheetDetailAbstract_lbl" xml:lang="en-US">Consolidated Balance Sheet Detail</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_ConsolidatedBalanceSheetDetailTextBlock" xlink:label="modd_ConsolidatedBalanceSheetDetailTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ConsolidatedBalanceSheetDetailTextBlock" xlink:to="modd_ConsolidatedBalanceSheetDetailTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ConsolidatedBalanceSheetDetailTextBlock_lbl" xml:lang="en-US">CONSOLIDATED BALANCE SHEET DETAIL</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_2_lbl" xml:lang="en-US">NOTES PAYABLE</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_2_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureRoyaltyAgreementAbstract" xlink:label="modd_DisclosureRoyaltyAgreementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureRoyaltyAgreementAbstract" xlink:to="modd_DisclosureRoyaltyAgreementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureRoyaltyAgreementAbstract_lbl" xml:lang="en-US">Royalty Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_RoyaltyAgreementDisclosureTextBlock" xlink:label="modd_RoyaltyAgreementDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RoyaltyAgreementDisclosureTextBlock" xlink:to="modd_RoyaltyAgreementDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RoyaltyAgreementDisclosureTextBlock_lbl" xml:lang="en-US">ROYALTY AGREEMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureRetirementSavingsPlanAbstract" xlink:label="modd_DisclosureRetirementSavingsPlanAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureRetirementSavingsPlanAbstract" xlink:to="modd_DisclosureRetirementSavingsPlanAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureRetirementSavingsPlanAbstract_lbl" xml:lang="en-US">Retirement Savings Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_RetirementSavingsPlanDisclosureTextBlock" xlink:label="modd_RetirementSavingsPlanDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RetirementSavingsPlanDisclosureTextBlock" xlink:to="modd_RetirementSavingsPlanDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RetirementSavingsPlanDisclosureTextBlock_lbl" xml:lang="en-US">RETIREMENT SAVINGS PLAN</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_LiquidityPolicyTextBlock" xlink:label="modd_LiquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_LiquidityPolicyTextBlock" xlink:to="modd_LiquidityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_LiquidityPolicyTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_ReverseStockSplitPolicyTextBlock" xlink:label="modd_ReverseStockSplitPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ReverseStockSplitPolicyTextBlock" xlink:to="modd_ReverseStockSplitPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US">Reverse Stock Split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Reportable Segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US">General and Administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_RisksAndUncertaintiesPolicyTextBlock" xlink:label="modd_RisksAndUncertaintiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_RisksAndUncertaintiesPolicyTextBlock" xlink:to="modd_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_RisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Risks and Uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Per-Share Amounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassification</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Future minimum payments under the facility operating lease, net of the lease incentive</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureLeaseDetailsAbstract" xlink:label="modd_DisclosureLeaseDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureLeaseDetailsAbstract" xlink:to="modd_DisclosureLeaseDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="modd_DisclosureLeaseDetailsAbstract_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureLeasesDetailsAbstarct" xlink:label="modd_DisclosureLeasesDetailsAbstarct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureLeasesDetailsAbstarct" xlink:to="modd_DisclosureLeasesDetailsAbstarct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="modd_DisclosureLeasesDetailsAbstarct_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureStockBasedCompensationDetailsAbstract" xlink:label="modd_DisclosureStockBasedCompensationDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureStockBasedCompensationDetailsAbstract" xlink:to="modd_DisclosureStockBasedCompensationDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureStockBasedCompensationDetailsAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureStockBasedCompensationDetails2Abstract" xlink:label="modd_DisclosureStockBasedCompensationDetails2Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureStockBasedCompensationDetails2Abstract" xlink:to="modd_DisclosureStockBasedCompensationDetails2Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureStockBasedCompensationDetails2Abstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Outstanding and Exercisable Option, Range</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureStockBasedCompensationDetails3Abstract" xlink:label="modd_DisclosureStockBasedCompensationDetails3Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureStockBasedCompensationDetails3Abstract" xlink:to="modd_DisclosureStockBasedCompensationDetails3Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureStockBasedCompensationDetails3Abstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property Plant And Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureConsolidatedBalanceSheetDetailsAbstract" xlink:label="modd_DisclosureConsolidatedBalanceSheetDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureConsolidatedBalanceSheetDetailsAbstract" xlink:to="modd_DisclosureConsolidatedBalanceSheetDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="modd_DisclosureConsolidatedBalanceSheetDetailsAbstract_lbl" xml:lang="en-US">CONSOLIDATED BALANCE SHEET DETAIL</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureConsolidatedBalanceSheetDetails2Abstract" xlink:label="modd_DisclosureConsolidatedBalanceSheetDetails2Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureConsolidatedBalanceSheetDetails2Abstract" xlink:to="modd_DisclosureConsolidatedBalanceSheetDetails2Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureConsolidatedBalanceSheetDetails2Abstract_lbl" xml:lang="en-US">CONSOLIDATED BALANCE SHEET DETAIL (Details 2)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_2_lbl" xml:lang="en-US">assumptions were used in the fair-value method calculations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureStockBasedCompensationDetailsAbstract" xlink:to="modd_DisclosureStockBasedCompensationDetailsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="modd_DisclosureStockBasedCompensationDetailsAbstract_2_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2_lbl" xml:lang="en-US">stock option activity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureStockBasedCompensationDetails2Abstract" xlink:to="modd_DisclosureStockBasedCompensationDetails2Abstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="modd_DisclosureStockBasedCompensationDetails2Abstract_2_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION (Details 2)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_2_lbl" xml:lang="en-US">summarizes the range of outstanding and exercisable options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureStockBasedCompensationDetails3Abstract" xlink:to="modd_DisclosureStockBasedCompensationDetails3Abstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="modd_DisclosureStockBasedCompensationDetails3Abstract_2_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION (Details 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of Operating Segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_OperatingLeasesImputedInterest" xlink:label="modd_OperatingLeasesImputedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OperatingLeasesImputedInterest" xlink:to="modd_OperatingLeasesImputedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_OperatingLeasesImputedInterest_lbl" xml:lang="en-US">Imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Present value of lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xml:lang="en-US">Present value of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Monthly Rent</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_OperatingLeasesAnnualRentIncreasePercentange" xlink:label="modd_OperatingLeasesAnnualRentIncreasePercentange" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_OperatingLeasesAnnualRentIncreasePercentange" xlink:to="modd_OperatingLeasesAnnualRentIncreasePercentange_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_OperatingLeasesAnnualRentIncreasePercentange_lbl" xml:lang="en-US">Operating Lease Annual Rent Increase Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_LeaseIncentiveReceived" xlink:label="modd_LeaseIncentiveReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_LeaseIncentiveReceived" xlink:to="modd_LeaseIncentiveReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_LeaseIncentiveReceived_lbl" xml:lang="en-US">Lease Incentive Received</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_CashPaidforLeaseLiabilities" xlink:label="modd_CashPaidforLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_CashPaidforLeaseLiabilities" xlink:to="modd_CashPaidforLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_CashPaidforLeaseLiabilities_lbl" xml:lang="en-US">[custom:CashPaidforLeaseLiabilities-0]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebtCurrent" xlink:to="us-gaap_UnsecuredDebtCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnsecuredDebtCurrent_2_lbl" xml:lang="en-US">Unsecured Debt, Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock" xlink:label="modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock" xlink:to="modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock_lbl" xml:lang="en-US">[custom:NotesAndAccuredInterestCouldBeConvertedIntoCommonStock-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Long-term Line of Credit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xml:lang="en-US">Maturity Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xml:lang="en-US">Line of Credit Facility, Interest Rate During Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:to="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_lbl" xml:lang="en-US">Line of Credit Facility, Increase (Decrease), Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:to="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_lbl" xml:lang="en-US">Line of Credit Facility, Increase, Accrued Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_lbl" xml:lang="en-US">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_lbl" xml:lang="en-US">Cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant" xlink:to="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant_lbl" xml:lang="en-US">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_FairValueofOptionGranted" xlink:label="modd_FairValueofOptionGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_FairValueofOptionGranted" xlink:to="modd_FairValueofOptionGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_FairValueofOptionGranted_lbl" xml:lang="en-US">[custom:FairValueofOptionGranted]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3_lbl" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_NotesCancelled" xlink:label="modd_NotesCancelled" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_NotesCancelled" xlink:to="modd_NotesCancelled_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_NotesCancelled_lbl" xml:lang="en-US">Notes Cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Interest Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableTable" xlink:label="us-gaap_InterimPeriodCostsNotAllocableTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterimPeriodCostsNotAllocableTable" xlink:to="us-gaap_InterimPeriodCostsNotAllocableTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterimPeriodCostsNotAllocableTable_lbl" xml:lang="en-US">Interim Period, Costs Not Allocable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableLineItems" xlink:label="us-gaap_InterimPeriodCostsNotAllocableLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterimPeriodCostsNotAllocableLineItems" xlink:to="us-gaap_InterimPeriodCostsNotAllocableLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterimPeriodCostsNotAllocableLineItems_lbl" xml:lang="en-US">Interim Period, Costs Not Allocable [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Risk-free interest rates</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xml:lang="en-US">Volatility</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xml:lang="en-US">Expected Life (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureLeaseDetailsAbstract" xlink:to="modd_DisclosureLeaseDetailsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureLeaseDetailsAbstract_2_lbl" xml:lang="en-US">DisclosureLeaseDetailsAbstract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureLeasesDetailsAbstarct" xlink:to="modd_DisclosureLeasesDetailsAbstarct_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureLeasesDetailsAbstarct_2_lbl" xml:lang="en-US">DisclosureLeasesDetailsAbstarct</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="modd_DisclosureConsolidatedBalanceSheetDetailsAbstract" xlink:to="modd_DisclosureConsolidatedBalanceSheetDetailsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="modd_DisclosureConsolidatedBalanceSheetDetailsAbstract_2_lbl" xml:lang="en-US">DisclosureConsolidatedBalanceSheetDetailsAbstract</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>23
<FILENAME>modd-20211231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://modular-medical.com/role/Cover" xlink:href="modd-20211231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheets" xlink:href="modd-20211231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:href="modd-20211231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfOperations" xlink:href="modd-20211231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="modd-20211231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StatementsOfCashFlows" xlink:href="modd-20211231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="modd-20211231.xsd#CompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Leases" xlink:href="modd-20211231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PppNote" xlink:href="modd-20211231.xsd#PppNote" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotes" xlink:href="modd-20211231.xsd#ConvertiblePromissoryNotes" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PromissoryNote" xlink:href="modd-20211231.xsd#PromissoryNote" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensation" xlink:href="modd-20211231.xsd#StockholdersDeficitAndStock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/IncomeTaxes" xlink:href="modd-20211231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RelatedPartyTransactions" xlink:href="modd-20211231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CommitmentsAndContingencies" xlink:href="modd-20211231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/SubsequentEvents" xlink:href="modd-20211231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetail" xlink:href="modd-20211231.xsd#ConsolidatedBalanceSheetDetail" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/NotesPayable" xlink:href="modd-20211231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensation" xlink:href="modd-20211231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquity" xlink:href="modd-20211231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RoyaltyAgreement" xlink:href="modd-20211231.xsd#RoyaltyAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RetirementSavingsPlan" xlink:href="modd-20211231.xsd#RetirementSavingsPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="modd-20211231.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesTables" xlink:href="modd-20211231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationTables" xlink:href="modd-20211231.xsd#StockholdersDeficitAndStock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables" xlink:href="modd-20211231.xsd#ConsolidatedBalanceSheetDetailTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationTables" xlink:href="modd-20211231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="modd-20211231.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesDetails" xlink:href="modd-20211231.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/LeasesDetailsNarrative" xlink:href="modd-20211231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PppNoteDetailsNarrative" xlink:href="modd-20211231.xsd#PppNoteDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" xlink:href="modd-20211231.xsd#ConvertiblePromissoryNotesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/PromissoryNoteDetailsNarrative" xlink:href="modd-20211231.xsd#PromissoryNoteDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails" xlink:href="modd-20211231.xsd#StockholdersEquityDeficitStock-basedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2" xlink:href="modd-20211231.xsd#StockholdersEquityDeficitStock-basedCompensationDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3" xlink:href="modd-20211231.xsd#StockholdersEquityDeficitStock-basedCompensationDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative" xlink:href="modd-20211231.xsd#StockholdersDeficitAndStock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="modd-20211231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/SubsequentEventsDetailsNarrative" xlink:href="modd-20211231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails" xlink:href="modd-20211231.xsd#ConsolidatedBalanceSheetDetailDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2" xlink:href="modd-20211231.xsd#ConsolidatedBalanceSheetDetailDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails" xlink:href="modd-20211231.xsd#Stock-basedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails2" xlink:href="modd-20211231.xsd#Stock-basedCompensationDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/Stock-basedCompensationDetails3" xlink:href="modd-20211231.xsd#Stock-basedCompensationDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://modular-medical.com/role/StockholdersEquityDetailsNarrative" xlink:href="modd-20211231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_us-gaapUnsecuredDebtCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapUnsecuredDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_PromissoryNotePayable" xlink:label="loc_moddPromissoryNotePayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_moddPromissoryNotePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaapShortTermBankLoansAndNotesPayable" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapShortTermBankLoansAndNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_CommonStockIssuable" xlink:label="loc_moddCommonStockIssuable" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_moddCommonStockIssuable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_CommonStockIssuable" xlink:label="loc_moddCommonStockIssuable_2" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_moddCommonStockIssuable_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_2" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Deficit) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_CommonStockIssuableMember" xlink:label="loc_moddCommonStockIssuableMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_moddCommonStockIssuableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_SharesIssuableForServices" xlink:label="loc_moddSharesIssuableForServices" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_moddSharesIssuableForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_SharesIssuedForReverseStockSplit" xlink:label="loc_moddSharesIssuedForReverseStockSplit" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_moddSharesIssuedForReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_GainOnPPPNoteForgiveness" xlink:label="loc_moddGainOnPPPNoteForgiveness" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_moddGainOnPPPNoteForgiveness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_SharesIssuableForServices" xlink:label="loc_moddSharesIssuableForServices" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_moddSharesIssuableForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_IncreaseDecreaseInLeaseLiability" xlink:label="loc_moddIncreaseDecreaseInLeaseLiability" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_moddIncreaseDecreaseInLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_ProceedsFromIssuanceOfPromissoryNote" xlink:label="loc_moddProceedsFromIssuanceOfPromissoryNote" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_moddProceedsFromIssuanceOfPromissoryNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInSecurityDeposits" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInSecurityDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Leases" xlink:title="00000008 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PppNote" xlink:title="00000009 - Disclosure - PPP NOTE">
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosurePppNoteAbstract" xlink:label="loc_moddDisclosurePppNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_PPPNotesPayableTextBlock" xlink:label="loc_moddPPPNotesPayableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosurePppNoteAbstract" xlink:to="loc_moddPPPNotesPayableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConvertiblePromissoryNotes" xlink:title="00000010 - Disclosure - CONVERTIBLE PROMISSORY NOTES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PromissoryNote" xlink:title="00000011 - Disclosure - PROMISSORY NOTE">
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosurePromissoryNoteAbstract" xlink:label="loc_moddDisclosurePromissoryNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_PromissoryNoteTextBlock" xlink:label="loc_moddPromissoryNoteTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosurePromissoryNoteAbstract" xlink:to="loc_moddPromissoryNoteTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensation" xlink:title="00000012 - Disclosure - STOCKHOLDERS&#8217; DEFICIT AND STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RelatedPartyTransactions" xlink:title="00000014 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/SubsequentEvents" xlink:title="00000016 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetail" xlink:title="00000017 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL">
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureConsolidatedBalanceSheetDetailAbstract" xlink:label="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_ConsolidatedBalanceSheetDetailTextBlock" xlink:label="loc_moddConsolidatedBalanceSheetDetailTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" xlink:to="loc_moddConsolidatedBalanceSheetDetailTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/NotesPayable" xlink:title="00000018 - Disclosure - NOTES PAYABLE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensation" xlink:title="00000019 - Disclosure - STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquity" xlink:title="00000020 - Disclosure - STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RoyaltyAgreement" xlink:title="00000021 - Disclosure - ROYALTY AGREEMENT">
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureRoyaltyAgreementAbstract" xlink:label="loc_moddDisclosureRoyaltyAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_RoyaltyAgreementDisclosureTextBlock" xlink:label="loc_moddRoyaltyAgreementDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosureRoyaltyAgreementAbstract" xlink:to="loc_moddRoyaltyAgreementDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RetirementSavingsPlan" xlink:title="00000022 - Disclosure - RETIREMENT SAVINGS PLAN">
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureRetirementSavingsPlanAbstract" xlink:label="loc_moddDisclosureRetirementSavingsPlanAbstract" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_RetirementSavingsPlanDisclosureTextBlock" xlink:label="loc_moddRetirementSavingsPlanDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosureRetirementSavingsPlanAbstract" xlink:to="loc_moddRetirementSavingsPlanDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_LiquidityPolicyTextBlock" xlink:label="loc_moddLiquidityPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_moddLiquidityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_ReverseStockSplitPolicyTextBlock" xlink:label="loc_moddReverseStockSplitPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_moddReverseStockSplitPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_moddRisksAndUncertaintiesPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_moddRisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesTables" xlink:title="00000024 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureLeaseDetailsAbstract" xlink:label="loc_moddDisclosureLeaseDetailsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_moddDisclosureLeaseDetailsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureLeasesDetailsAbstarct" xlink:label="loc_moddDisclosureLeasesDetailsAbstarct" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_moddDisclosureLeasesDetailsAbstarct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationTables" xlink:title="00000025 - Disclosure - STOCKHOLDERS&#8217; DEFICIT AND STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="loc_us-gaapScheduleOfAssumptionsUsedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureStockBasedCompensationDetailsAbstract" xlink:label="loc_moddDisclosureStockBasedCompensationDetailsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_moddDisclosureStockBasedCompensationDetailsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureStockBasedCompensationDetails2Abstract" xlink:label="loc_moddDisclosureStockBasedCompensationDetails2Abstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_moddDisclosureStockBasedCompensationDetails2Abstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureStockBasedCompensationDetails3Abstract" xlink:label="loc_moddDisclosureStockBasedCompensationDetails3Abstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_moddDisclosureStockBasedCompensationDetails3Abstract" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables" xlink:title="00000026 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Tables)">
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureConsolidatedBalanceSheetDetailAbstract" xlink:label="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureConsolidatedBalanceSheetDetailsAbstract" xlink:label="loc_moddDisclosureConsolidatedBalanceSheetDetailsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" xlink:to="loc_moddDisclosureConsolidatedBalanceSheetDetailsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureConsolidatedBalanceSheetDetails2Abstract" xlink:label="loc_moddDisclosureConsolidatedBalanceSheetDetails2Abstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" xlink:to="loc_moddDisclosureConsolidatedBalanceSheetDetails2Abstract" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationTables" xlink:title="00000027 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="loc_us-gaapScheduleOfAssumptionsUsedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureStockBasedCompensationDetailsAbstract" xlink:label="loc_moddDisclosureStockBasedCompensationDetailsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_moddDisclosureStockBasedCompensationDetailsAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureStockBasedCompensationDetails2Abstract" xlink:label="loc_moddDisclosureStockBasedCompensationDetails2Abstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_moddDisclosureStockBasedCompensationDetails2Abstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureStockBasedCompensationDetails3Abstract" xlink:label="loc_moddDisclosureStockBasedCompensationDetails3Abstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_moddDisclosureStockBasedCompensationDetails3Abstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000028 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesDetails" xlink:title="00000029 - Disclosure - LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_OperatingLeasesImputedInterest" xlink:label="loc_moddOperatingLeasesImputedInterest" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_moddOperatingLeasesImputedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue_2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/LeasesDetailsNarrative" xlink:title="00000030 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_OperatingLeasesAnnualRentIncreasePercentange" xlink:label="loc_moddOperatingLeasesAnnualRentIncreasePercentange" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_moddOperatingLeasesAnnualRentIncreasePercentange" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_LeaseIncentiveReceived" xlink:label="loc_moddLeaseIncentiveReceived" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_moddLeaseIncentiveReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_CashPaidforLeaseLiabilities" xlink:label="loc_moddCashPaidforLeaseLiabilities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_moddCashPaidforLeaseLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PppNoteDetailsNarrative" xlink:title="00000031 - Disclosure - PPP NOTE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosurePppNoteAbstract" xlink:label="loc_moddDisclosurePppNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_us-gaapUnsecuredDebtCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosurePppNoteAbstract" xlink:to="loc_us-gaapUnsecuredDebtCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative" xlink:title="00000032 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock" xlink:label="loc_moddNotesAndAccuredInterestCouldBeConvertedIntoCommonStock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_moddNotesAndAccuredInterestCouldBeConvertedIntoCommonStock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/PromissoryNoteDetailsNarrative" xlink:title="00000033 - Disclosure - PROMISSORY NOTE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosurePromissoryNoteAbstract" xlink:label="loc_moddDisclosurePromissoryNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosurePromissoryNoteAbstract" xlink:to="loc_us-gaapLineOfCreditFacilityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapInvestmentTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_SecuredPromissoryNotesMember" xlink:label="loc_moddSecuredPromissoryNotesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_moddSecuredPromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="loc_us-gaapLineOfCreditFacilityExpirationDate1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaapLineOfCreditFacilityIncreaseDecreaseForPeriodNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:label="loc_us-gaapLineOfCreditFacilityIncreaseAccruedInterest" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityIncreaseAccruedInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails" xlink:title="00000034 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2" xlink:title="00000035 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant" xlink:label="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_moddShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3" xlink:title="00000036 - Disclosure - STOCKHOLDERS&apos; EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative" xlink:title="00000037 - Disclosure - STOCKHOLDERS&#8217; DEFICIT AND STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapEmployeeStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_FairValueofOptionGranted" xlink:label="loc_moddFairValueofOptionGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_moddFairValueofOptionGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000038 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_CEOAndInvestorMember" xlink:label="loc_moddCEOAndInvestorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_moddCEOAndInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_MemberOfBoardMember" xlink:label="loc_moddMemberOfBoardMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_moddMemberOfBoardMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srtBoardOfDirectorsChairmanMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtBoardOfDirectorsChairmanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_NotesPayableOtherPayables1Member" xlink:label="loc_moddNotesPayableOtherPayables1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_moddNotesPayableOtherPayables1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_NotesPayableOtherPayables2Member" xlink:label="loc_moddNotesPayableOtherPayables2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_moddNotesPayableOtherPayables2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_NotesCancelled" xlink:label="loc_moddNotesCancelled" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_moddNotesCancelled" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000039 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaapLineOfCreditFacilityIncreaseDecreaseForPeriodNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails" xlink:title="00000040 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)">
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureConsolidatedBalanceSheetDetailAbstract" xlink:label="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2" xlink:title="00000041 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)">
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_DisclosureConsolidatedBalanceSheetDetailAbstract" xlink:label="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableTable" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moddDisclosureConsolidatedBalanceSheetDetailAbstract" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableLineItems" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableTable" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaapNatureOfExpenseAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableTable" xlink:to="loc_us-gaapNatureOfExpenseAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNatureOfExpenseAxis" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_AccruedWagesAndBonusMember" xlink:label="loc_moddAccruedWagesAndBonusMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_moddAccruedWagesAndBonusMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_AccruedPlacementFeesMember" xlink:label="loc_moddAccruedPlacementFeesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_moddAccruedPlacementFeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_AccruedInterestMember" xlink:label="loc_moddAccruedInterestMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_moddAccruedInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="modd-20211231.xsd#modd_AccruedOtherExpensesMember" xlink:label="loc_moddAccruedOtherExpensesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_moddAccruedOtherExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails" xlink:title="00000042 - Disclosure - STOCK-BASED COMPENSATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails2" xlink:title="00000043 - Disclosure - STOCK-BASED COMPENSATION (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Stock-basedCompensationDetails3" xlink:title="00000044 - Disclosure - STOCK-BASED COMPENSATION (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000045 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295875094104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MODULAR MEDICAL, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001074871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0620495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">16772 W. Bernardo Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">800-3500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295876466520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 204,098<span></span>
</td>
<td class="nump">$ 1,468,465<span></span>
</td>
<td class="nump">$ 3,122,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">63,607<span></span>
</td>
<td class="nump">178,158<span></span>
</td>
<td class="nump">63,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">946<span></span>
</td>
<td class="nump">2,466<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">268,651<span></span>
</td>
<td class="nump">1,649,089<span></span>
</td>
<td class="nump">3,186,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment,&#160;net</a></td>
<td class="nump">241,468<span></span>
</td>
<td class="nump">298,958<span></span>
</td>
<td class="nump">301,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset, net</a></td>
<td class="nump">141,720<span></span>
</td>
<td class="nump">200,124<span></span>
</td>
<td class="nump">270,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssets', window );">Security deposit</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">TOTAL NON-CURRENT ASSETS</a></td>
<td class="nump">483,188<span></span>
</td>
<td class="nump">599,082<span></span>
</td>
<td class="nump">672,258<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">751,839<span></span>
</td>
<td class="nump">2,248,171<span></span>
</td>
<td class="nump">3,858,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable</a></td>
<td class="nump">671,363<span></span>
</td>
<td class="nump">169,284<span></span>
</td>
<td class="nump">367,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,124,499<span></span>
</td>
<td class="nump">499,948<span></span>
</td>
<td class="nump">202,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term lease liability</a></td>
<td class="nump">139,817<span></span>
</td>
<td class="nump">125,500<span></span>
</td>
<td class="nump">92,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebtCurrent', window );">PPP note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">368,780<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_PromissoryNotePayable', window );">Promissory note payable</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Convertible notes payable</a></td>
<td class="nump">5,485,583<span></span>
</td>
<td class="nump">2,133,453<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">8,921,262<span></span>
</td>
<td class="nump">3,296,965<span></span>
</td>
<td class="nump">661,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG-TERM LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liability</a></td>
<td class="nump">77,212<span></span>
</td>
<td class="nump">184,355<span></span>
</td>
<td class="nump">178,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Bonus payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">8,998,474<span></span>
</td>
<td class="nump">3,523,320<span></span>
</td>
<td class="nump">980,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.001&#160;par value, 5,000,000 shares authorized, none issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.001&#160;par value, 50,000,000 shares authorized, 6,302,050 shares and 5,956,754 shares issued and outstanding as of March 31, 2021 and 2020, respectively</a></td>
<td class="nump">6,374<span></span>
</td>
<td class="nump">6,302<span></span>
</td>
<td class="nump">5,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">21,602,162<span></span>
</td>
<td class="nump">14,665,559<span></span>
</td>
<td class="nump">10,517,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_CommonStockIssuable', window );">Common stock issuable</a></td>
<td class="nump">149,994<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(923,994)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(30,005,165)<span></span>
</td>
<td class="num">(15,947,010)<span></span>
</td>
<td class="num">(8,569,034)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; DEFICIT</a></td>
<td class="num">(8,246,635)<span></span>
</td>
<td class="num">(1,275,149)<span></span>
</td>
<td class="nump">2,878,422<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</a></td>
<td class="nump">751,839<span></span>
</td>
<td class="nump">2,248,171<span></span>
</td>
<td class="nump">3,858,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_CommonStockIssuable', window );">Common stock issuable</a></td>
<td class="num">(149,994)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">923,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="num">(8,246,635)<span></span>
</td>
<td class="num">(1,275,149)<span></span>
</td>
<td class="nump">2,878,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="nump">$ 751,839<span></span>
</td>
<td class="nump">$ 2,248,171<span></span>
</td>
<td class="nump">$ 3,858,551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_CommonStockIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_CommonStockIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PromissoryNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PromissoryNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295875063736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">6,373,706<span></span>
</td>
<td class="nump">6,302,050<span></span>
</td>
<td class="nump">5,956,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">6,373,706<span></span>
</td>
<td class="nump">6,302,050<span></span>
</td>
<td class="nump">5,956,754<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295876654328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,849,399<span></span>
</td>
<td class="nump">$ 1,086,669<span></span>
</td>
<td class="nump">$ 5,742,911<span></span>
</td>
<td class="nump">$ 3,150,149<span></span>
</td>
<td class="nump">$ 4,083,303<span></span>
</td>
<td class="nump">$ 3,034,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,981,665<span></span>
</td>
<td class="nump">783,898<span></span>
</td>
<td class="nump">5,156,152<span></span>
</td>
<td class="nump">2,453,808<span></span>
</td>
<td class="nump">3,253,412<span></span>
</td>
<td class="nump">2,313,870<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,831,064<span></span>
</td>
<td class="nump">1,870,567<span></span>
</td>
<td class="nump">10,899,063<span></span>
</td>
<td class="nump">5,603,957<span></span>
</td>
<td class="nump">7,336,715<span></span>
</td>
<td class="nump">5,348,022<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,831,064)<span></span>
</td>
<td class="num">(1,870,567)<span></span>
</td>
<td class="num">(10,899,063)<span></span>
</td>
<td class="num">(5,603,957)<span></span>
</td>
<td class="num">(7,336,715)<span></span>
</td>
<td class="num">(5,348,022)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Other income</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">368,876<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,010,247)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,204,917)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(39,791)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,321,450)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(4,841,307)<span></span>
</td>
<td class="num">(1,870,545)<span></span>
</td>
<td class="num">(14,056,554)<span></span>
</td>
<td class="num">(5,603,831)<span></span>
</td>
<td class="num">(7,376,376)<span></span>
</td>
<td class="num">(5,319,273)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,841,307)<span></span>
</td>
<td class="num">$ (1,870,545)<span></span>
</td>
<td class="num">$ (14,058,155)<span></span>
</td>
<td class="num">$ (5,605,431)<span></span>
</td>
<td class="num">$ (7,377,976)<span></span>
</td>
<td class="num">$ (5,320,873)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted</a></td>
<td class="num">$ (0.76)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (2.22)<span></span>
</td>
<td class="num">$ (0.91)<span></span>
</td>
<td class="num">$ (1.19)<span></span>
</td>
<td class="num">$ (0.89)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Shares used in computing net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic and diluted</a></td>
<td class="nump">6,354,145<span></span>
</td>
<td class="nump">6,249,038<span></span>
</td>
<td class="nump">6,331,982<span></span>
</td>
<td class="nump">6,187,526<span></span>
</td>
<td class="nump">6,211,562<span></span>
</td>
<td class="nump">5,954,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">$ 28,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (4,841,307)<span></span>
</td>
<td class="num">$ (1,870,545)<span></span>
</td>
<td class="num">$ (14,056,554)<span></span>
</td>
<td class="num">$ (5,603,831)<span></span>
</td>
<td class="num">$ (7,376,376)<span></span>
</td>
<td class="num">$ (5,319,273)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295872638824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Common Stock Issuable</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2019</a></td>
<td class="nump">$ 5,947<span></span>
</td>
<td class="nump">$ 9,696,471<span></span>
</td>
<td class="nump">$ 19,800<span></span>
</td>
<td class="num">$ (3,248,161)<span></span>
</td>
<td class="nump">$ 6,474,057<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Beginning Balance at Mar. 31, 2019</a></td>
<td class="nump">5,946,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">19,790<span></span>
</td>
<td class="num">(19,800)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,320,873)<span></span>
</td>
<td class="num">(5,320,873)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Placement of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">923,994<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">923,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">801,244<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">801,244<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2020</a></td>
<td class="nump">$ 5,957<span></span>
</td>
<td class="nump">10,517,505<span></span>
</td>
<td class="nump">923,994<span></span>
</td>
<td class="num">(8,569,034)<span></span>
</td>
<td class="nump">2,878,422<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Ending Balance at Mar. 31, 2020</a></td>
<td class="nump">5,956,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">344,716<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">344,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,874,157)<span></span>
</td>
<td class="num">(1,874,157)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Placement of common stock</a></td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">2,042,385<span></span>
</td>
<td class="num">(923,994)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,118,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">243,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2020</a></td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="nump">12,904,606<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,443,191)<span></span>
</td>
<td class="nump">2,467,615<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Ending Balance at Jun. 30, 2020</a></td>
<td class="nump">6,200,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2020</a></td>
<td class="nump">$ 5,957<span></span>
</td>
<td class="nump">10,517,505<span></span>
</td>
<td class="nump">923,994<span></span>
</td>
<td class="num">(8,569,034)<span></span>
</td>
<td class="nump">2,878,422<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Beginning Balance at Mar. 31, 2020</a></td>
<td class="nump">5,956,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Warrants issued with convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">940,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,605,431)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">320,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_SharesIssuableForServices', window );">Shares issuable for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 6,277<span></span>
</td>
<td class="nump">14,167,435<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(14,174,465)<span></span>
</td>
<td class="num">(753)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">6,277,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2020</a></td>
<td class="nump">$ 5,957<span></span>
</td>
<td class="nump">10,517,505<span></span>
</td>
<td class="nump">923,994<span></span>
</td>
<td class="num">(8,569,034)<span></span>
</td>
<td class="nump">2,878,422<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Beginning Balance at Mar. 31, 2020</a></td>
<td class="nump">5,956,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">210,920<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">210,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="nump">24,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,377,976)<span></span>
</td>
<td class="num">(7,377,976)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Placement of common stock</a></td>
<td class="nump">$ 321<span></span>
</td>
<td class="nump">2,709,555<span></span>
</td>
<td class="num">(923,994)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,785,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">320,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,227,578<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,227,578<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 6,302<span></span>
</td>
<td class="nump">14,665,559<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15,947,010)<span></span>
</td>
<td class="num">(1,275,149)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Ending Balance at Mar. 31, 2021</a></td>
<td class="nump">6,302,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2020</a></td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="nump">12,904,606<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,443,191)<span></span>
</td>
<td class="nump">2,467,615<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Beginning Balance at Jun. 30, 2020</a></td>
<td class="nump">6,200,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">300,604<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">300,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,860,729)<span></span>
</td>
<td class="num">(1,860,729)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2020</a></td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="nump">13,205,210<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,303,920)<span></span>
</td>
<td class="nump">907,490<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Ending Balance at Sep. 30, 2020</a></td>
<td class="nump">6,200,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">295,054<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">295,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,870,545)<span></span>
</td>
<td class="num">(1,870,545)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Placement of common stock</a></td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">667,171<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">667,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">77,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 6,277<span></span>
</td>
<td class="nump">14,167,435<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(14,174,465)<span></span>
</td>
<td class="num">(753)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">6,277,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 6,302<span></span>
</td>
<td class="nump">14,665,559<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15,947,010)<span></span>
</td>
<td class="num">(1,275,149)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Beginning Balance at Mar. 31, 2021</a></td>
<td class="nump">6,302,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">172,180<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">172,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Warrants issued with convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,700,632<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,700,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">655,918<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">655,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">1,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,835,091)<span></span>
</td>
<td class="num">(4,835,091)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">30,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 6,324<span></span>
</td>
<td class="nump">19,194,289<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(20,782,101)<span></span>
</td>
<td class="num">(1,581,488)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 6,302<span></span>
</td>
<td class="nump">14,665,559<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15,947,010)<span></span>
</td>
<td class="num">(1,275,149)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Beginning Balance at Mar. 31, 2021</a></td>
<td class="nump">6,302,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Warrants issued with convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,740,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,058,155)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_SharesIssuableForServices', window );">Shares issuable for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,994<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 6,374<span></span>
</td>
<td class="nump">21,602,162<span></span>
</td>
<td class="nump">149,994<span></span>
</td>
<td class="num">(30,005,165)<span></span>
</td>
<td class="num">(8,246,635)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">6,373,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 6,324<span></span>
</td>
<td class="nump">19,194,289<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(20,782,101)<span></span>
</td>
<td class="num">(1,581,488)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">862,427<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">862,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">3,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,381,757)<span></span>
</td>
<td class="num">(4,381,757)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2021</a></td>
<td class="nump">$ 6,328<span></span>
</td>
<td class="nump">20,056,716<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(25,163,858)<span></span>
</td>
<td class="num">(5,100,814)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Ending Balance at Sep. 30, 2021</a></td>
<td class="nump">6,327,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued for services</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">73,748<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">73,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="nump">8,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">1,221,729<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,221,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">5,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,841,307)<span></span>
</td>
<td class="num">(4,841,307)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Placement of common stock</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">249,969<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_SharesIssuableForServices', window );">Shares issuable for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">149,994<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">149,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_SharesIssuedForReverseStockSplit', window );">Shares issued for reverse stock split</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Stock Issued During Period, Shares, Reverse Stock Splits</a></td>
<td class="nump">1,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 6,374<span></span>
</td>
<td class="nump">$ 21,602,162<span></span>
</td>
<td class="nump">$ 149,994<span></span>
</td>
<td class="num">$ (30,005,165)<span></span>
</td>
<td class="num">$ (8,246,635)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding, Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">6,373,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_SharesIssuableForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_SharesIssuableForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_SharesIssuedForReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_SharesIssuedForReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295876771800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,058,155)<span></span>
</td>
<td class="num">$ (5,605,431)<span></span>
</td>
<td class="num">$ (7,377,976)<span></span>
</td>
<td class="num">$ (5,320,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_GainOnPPPNoteForgiveness', window );">Gain on PPP note forgiveness</a></td>
<td class="num">(368,780)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">1,321,450<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,740,086<span></span>
</td>
<td class="nump">940,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">80,268<span></span>
</td>
<td class="nump">82,016<span></span>
</td>
<td class="nump">111,015<span></span>
</td>
<td class="nump">35,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Shares for services</a></td>
<td class="nump">388,021<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">68,880<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_SharesIssuableForServices', window );">Shares issuable for services</a></td>
<td class="nump">149,994<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of lease right-of-use asset</a></td>
<td class="nump">58,404<span></span>
</td>
<td class="nump">52,994<span></span>
</td>
<td class="nump">70,826<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_IncreaseDecreaseInLeaseLiability', window );">Change in lease liability</a></td>
<td class="num">(92,826)<span></span>
</td>
<td class="nump">67,092<span></span>
</td>
<td class="nump">38,905<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt issuance costs</a></td>
<td class="nump">1,454,762<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,253<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(25,995)<span></span>
</td>
<td class="nump">15,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">1,223,983<span></span>
</td>
<td class="num">(123,722)<span></span>
</td>
<td class="num">(86,747)<span></span>
</td>
<td class="nump">530,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(7,128,787)<span></span>
</td>
<td class="num">(4,570,713)<span></span>
</td>
<td class="num">(5,908,662)<span></span>
</td>
<td class="num">(4,094,839)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(22,779)<span></span>
</td>
<td class="num">(109,541)<span></span>
</td>
<td class="num">(109,669)<span></span>
</td>
<td class="num">(260,789)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(22,779)<span></span>
</td>
<td class="num">(109,541)<span></span>
</td>
<td class="num">(109,669)<span></span>
</td>
<td class="num">(260,789)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement, net of issuance costs</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">1,785,882<span></span>
</td>
<td class="nump">1,785,882<span></span>
</td>
<td class="nump">923,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="nump">4,137,199<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,210,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_ProceedsFromIssuanceOfPromissoryNote', window );">Proceeds from issuance of promissory note</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of PPP note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">368,780<span></span>
</td>
<td class="nump">368,780<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">5,887,199<span></span>
</td>
<td class="nump">2,154,662<span></span>
</td>
<td class="nump">4,364,662<span></span>
</td>
<td class="nump">923,994<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(1,264,367)<span></span>
</td>
<td class="num">(2,525,592)<span></span>
</td>
<td class="num">(1,653,669)<span></span>
</td>
<td class="num">(3,431,634)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at beginning of year</a></td>
<td class="nump">1,468,465<span></span>
</td>
<td class="nump">3,122,134<span></span>
</td>
<td class="nump">3,122,134<span></span>
</td>
<td class="nump">6,553,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at end of year</a></td>
<td class="nump">204,098<span></span>
</td>
<td class="nump">596,542<span></span>
</td>
<td class="nump">1,468,465<span></span>
</td>
<td class="nump">3,122,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Fair value of detachable warrants issued with convertible notes</a></td>
<td class="nump">$ 3,700,632<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,227,578<span></span>
</td>
<td class="nump">801,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets and prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,600<span></span>
</td>
<td class="num">(48,391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Security deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(92,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_GainOnPPPNoteForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_GainOnPPPNoteForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ProceedsFromIssuanceOfPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ProceedsFromIssuanceOfPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_SharesIssuableForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_SharesIssuableForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in security deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295878712440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zdcuY53cetG" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
1 &#8211; <span id="xdx_826_zOZwgRE2vlhh">THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Modular
Medical, Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had
no material business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of
Quasuras, Inc., a Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and
Quasuras, the share exchange was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities
of Quasuras acquired in the merger, at their historical carrying amounts. Prior to the acquisition of Quasuras and since at least
2002, the Company was a shell company, as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange
Act). In June 2017, the Company changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
is a development-stage, medical-device company focused on the design, development, and commercialization of an innovative insulin
pump using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part,
patch pump product, the Company seeks to fundamentally alter the trade-offs between cost and complexity and access to the higher
standards of care that presently available insulin pumps provide. By simplifying and streamlining the user experience from introduction,
prescription, reimbursement, training and day-to-day use, the Company seeks to expand the wearable insulin delivery device market
beyond the highly motivated &#8220;super users&#8221; and expand the category into the mass market. The Company&#8217;s pump product
seeks to serve both the type 1 and type 2 diabetes markets.</span></p>

<p id="xdx_840_ecustom--LiquidityPolicyTextBlock_z9z2ekIUfun5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86B_zSn8fkw1P1Oc">Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Financial
Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15), <i>Going Concern</i>, requires management
to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#8217;s
ability to continue as a going concern within one year after the date that the financial statements are issued. If management
identifies conditions or events that raise substantial doubt about an entity&#8217;s ability to continue as a going concern, management
must consider if there are plans that are probable to be implemented, and whether it is probable that the plans will mitigate
the conditions or events raising the substantial doubt about the entity&#8217;s ability to continue as a going concern. If the
substantial doubt is not alleviated after consideration of management&#8217;s plans, the entity must include a statement in the
notes to the financial statements indicating that there is substantial doubt about the entity&#8217;s ability to continue as a
going concern within one year after the date that the financial statements are issued including: 1) the principal conditions or
events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern, 2) management&#8217;s evaluation
of the significance of those conditions or events in relation to the entity&#8217;s ability to meet its obligations, and 3) management&#8217;s
plans to attempt to mitigate the conditions or events causing the substantial doubt about the entity&#8217;s ability to continue
as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development
and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant
product revenues to achieve profitability. The Company&#8217;s expected operating losses and cash burn and the need to repay the
convertible promissory notes and accrued interest in the first half of 2022 raise substantial doubt about the Company&#8217;s
ability to continue as a going concern within one year after the date that these financial statements are issued. Implementation
of the Company&#8217;s plans and its ability to continue as a going concern will depend upon the Company&#8217;s ability to raise
additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no
assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and,
if available, that such capital will be offered on terms and conditions acceptable to the Company. As disclosed in note 9, the
Company recently sold shares of its common stock to two of its officers, obtained access to a credit facility and filed a registration
statement to offer shares of its common stock. The Company&#8217;s operating needs include the planned costs to operate its business,
including amounts required to repay its convertible promissory notes (if not converted), fund working capital and capital expenditures.
The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many factors, including
the Company&#8217;s ability to successfully commercialize its product, competing technological and market developments, and the
need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its
product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash. These condensed consolidated financial
statements do not include any adjustments that might result from this uncertainty.</span></p>






<p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zg1kLg1u7ymh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: left"><span style="font-size: 10pt"><b><span id="xdx_866_zzUiA2s82eS6">Basis
of Presentation </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">The Company&#8217;s
fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in these notes to the condensed consolidated
financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2022 refers
to the fiscal year ending March 31, 2022). The condensed consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">The accompanying
condensed consolidated financial statements of the Company have been prepared without audit. The condensed consolidated balance
sheet as of March 31, 2021 has been derived from the audited consolidated financial statements at that date. Certain information
and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted
in the United States (GAAP) have been condensed or omitted in accordance with these rules and regulations of the Securities and
Exchange Commission (SEC).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">In the
opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting
only of normal recurring adjustments) necessary to summarize fairly the Company&#8217;s financial position, results of operations
and cash flows for the interim periods presented. The operating results for the three months ended December 31, 2021 are not necessarily
indicative of the results that may be expected for the year ending March 31, 2022 or for any other future period.</span></p>

<p id="xdx_843_ecustom--ReverseStockSplitPolicyTextBlock_zLxBVkzxzg51" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><span style="font-size: 10pt"><b><i><span id="xdx_868_zzQnHUeQsOQa">Reverse Stock Split</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20211123__20211124_zbRbXZoxiQj8">On November
24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary
of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company&#8217;s shares of common stock.</span> Such amendment
and ratio were previously approved by a majority of the Company&#8217;s stockholders and the board of directors. As a result of
the reverse stock split, which was effective November 29, 2021, every three shares of the Company&#8217;s pre-reverse split outstanding
common stock were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common
stock holders were not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Split
were rounded up to the nearest whole share. All stock options outstanding and common stock reserved for issuance under the
Company&#8217;s equity incentive plans and warrants outstanding immediately prior to the reverse stock split were adjusted by
dividing the number of affected shares of common stock by three (3) and, as applicable, multiplying the exercise price by three
(3), as a result of the reverse stock split.</span></p>





<p id="xdx_84D_eus-gaap--UseOfEstimates_zoPl13e0kP2d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_869_zxNVb9p9jHN6">Use
of Estimates </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">The preparation
of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of
the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates
may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates.</span></p>

<p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWeoFIr7QlXe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_863_zvh4FPiSwkPe">Reportable
Segment </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">The Company
operates in <span id="xdx_906_eus-gaap--NumberOfOperatingSegments_dc_uNumber_c20210401__20211231_zevLYwcoxte5">one</span> business segment and uses one measurement of profitability for its business.</span></p>

<p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zZZNMr8lQ3V2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_865_zTNsevdrL2h3">Research
and Development</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">The Company
expenses research and development expenditures as incurred.</span></p>

<p id="xdx_841_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z58yieOnj0u9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86A_zpfdCgZFzn8">General
and Administrative </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting
fees, and office and other administrative expenses.</span></p>

<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zzo1rW1DtNX7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86E_zPLJpIi6iP3g">Concentration
of Credit Risk </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Financial
instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains
its cash balances at high-quality financial institutions within the United States, which are insured by the Federal Deposit Insurance
Corporation up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss
due to financial institution failure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_847_ecustom--RisksAndUncertaintiesPolicyTextBlock_z5k8Yx9Zt5I5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_861_zA1ZtrM00522">Risks
and Uncertainties </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing technology and customer requirements, limited operating history and the volatility
of public markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><i>COVID-19</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">The global
outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains,
significantly restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in-place&#8221;
and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#8217;s operational
and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions
taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company&#8217;s
control, and cannot be predicted.</span></p>





<p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zKjab441Int8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_865_zwxlbtu427x1">Cash
and Cash Equivalents </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Cash
and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and highly liquid debt instruments
with original maturities of three months or less.</span></p>

<p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z9QabmbzvQBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86F_zJqlZcaMfrYg">Property
&amp; Equipment </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Property
and equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful
lives of the assets, generally <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxH_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_zaJ33kMbcei9" title="::XDX::P3Y">three</span> to <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxH_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_z7a40rLLRfAk" title="::XDX::P5Y">five</span> years. Depreciation is recorded in operating expenses in the condensed consolidated
statements of operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of
their estimated useful life or the lease term, and amortization is recorded in operating expenses in the condensed consolidated
statements of operations.</span></p>

<p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z6gGPV0CA5hh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86A_zU4nuxpUaHsj">Fair
Value of Financial Instruments </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Level
                                         1 inputs to the valuation methodology are quoted prices for identical assets or liabilities
                                         in active markets.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Level
                                         2 inputs to the valuation methodology include quoted prices for similar assets and liabilities
                                         in active markets, and inputs that are observable for the asset or liability, either
                                         directly or indirectly, for substantially the full term of the financial instrument.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Level
                                         3 inputs to the valuation methodology are unobservable and significant to the fair value
                                         measurement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Due to
their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses approximate fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zo9FYsK7bo2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_861_zUBEGqHISegh">Per-Share
Amounts </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Basic
net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding
during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period.
For the nine months ended December 31, 2021 and 2020, outstanding options to purchase <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20211231_zjB5ywqmGkoe">1,967,188</span> and <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20201231_zHT92n9jnntk">1,170,863</span> shares of common
stock, respectively, were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.</span></p>

<p id="xdx_844_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zKt0uGP8yu0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_862_zncbUgeI7kCi">Reclassification
</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no
effect on the reported results of operations or cash flows.<b> </b></span></p>






<p id="xdx_847_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zI1mPvysuMpd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_864_zjEy9Mo68f6d">Comprehensive
Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly,
comprehensive loss may include certain changes in equity that are excluded from net loss. For the three and nine months ended
December 31, 2021 and 2020, the Company&#8217;s comprehensive loss was the same as its net loss.</span></p>

<p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zcNdW5Ao75f6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Recently
Adopted Accounting Pronouncement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In August
2020, the FASB issued ASU No. 2020-06, <i>Debt</i> <i>with Conversion and Other Options</i> <i>(Subtopic 470-20) and Derivatives
and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments and Contracts in an
Entity&#8217;s Own Equity </i>(ASU 2020-06)<i>.</i> ASU 2020-06 simplifies the accounting for convertible instruments by removing
major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single
liability instrument with no separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions
that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts
to qualify for it. ASU 2020-06 also simplifies the diluted net income per share calculation in certain areas. The new guidance
is effective for annual and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years
beginning after December 15, 2020, and interim periods within those fiscal years. The Company early adopted ASU 2020-06 effective
April 1, 2021, and the impact of the adoption was not material to the Company&#8217;s consolidated financial statements.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zGT6BSgYLNs4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>Note&#160;1 &#8211; <span id="xdx_82E_zMUTozRktbd4">THE COMPANY
AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Modular Medical,
Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material
business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras,
Inc., a Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras,
the share exchange was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras,
acquired in the merger, at their historical carrying amounts. Prior to the acquisition of Quasuras and, since at least 2002, the
Company was a shell company, as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act).
In June 2017, the Company changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
is a development-stage medical device company focused on the design, development and eventual commercialization of an innovative
insulin pump to address shortcomings and problems represented by the relatively limited adoption of currently available pumps
for insulin-dependent people with diabetes. The Company has developed a hardware technology allowing people with insulin-dependent
diabetes to receive their daily insulin in two ways, through a continuous &#8220;basal&#8221; delivery allowing a small amount
of insulin to be in the blood at all times and a &#8220;bolus&#8221; delivery to address meal time glucose input and to address
when the blood glucose level becomes excessively high. By addressing the time and effort required to effectively treat their condition,
the Company believes it can address the less technically savvy, less motivated part of the market. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font-size: 10pt">The consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United
States of America. The following summarizes the more significant of such policies:&#160;</span></p>

<p id="xdx_843_ecustom--LiquidityPolicyTextBlock_z4QrIhxBDxHj" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0"><span style="font-size: 10pt"><b><span id="xdx_86D_zDQdXEmUbbvb">Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="font-size: 10pt">Financial
Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15),&#160;<i>Going&#160;</i>Concern,
requires management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt
about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are
issued.&#160;If management identifies conditions or events that raise substantial doubt about an entity&#8217;s ability to continue
as a going concern, management must consider if there are plans that are probable to be implemented, and whether it is probable
that the plans will mitigate the conditions or events raising the substantial doubt about the entity&#8217;s ability to continue
as a going concern.&#160;If the substantial doubt is not alleviated after consideration of management&#8217;s plans, the entity
must include a statement in the notes to the financial statements indicating that there is substantial doubt about the entity&#8217;s
ability to continue as a going concern within one year after the date that the financial statements are issued including: 1) the
principal conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern, 2)
management&#8217;s evaluation of the significance of those conditions or events in relation to the entity&#8217;s ability to meet
its obligations, and 3) management&#8217;s plans to attempt to mitigate the conditions or events causing the substantial doubt
about the entity&#8217;s ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The Company
expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development
and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant
product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#8217;s ability to continue
as a going concern within one year after the date that these consolidated financial statements are issued. Implementation of the
Company&#8217;s plans and its ability to continue as a going concern will depend upon the Company&#8217;s ability to raise additional
capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance
that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available,
that such capital will be offered on terms and conditions acceptable to the Company.&#160; As discussed in notes 3 and 11, in
February 2021, the Company commenced a private placement of its convertible promissory notes to investors to fund its operations.
In addition, during fiscal 2021, the Company obtained additional equity financing through a private placement of its common stock
(see note 6), and the Company obtained a loan from Silicon Valley Bank in April 2020 (see notes 3 and 12).</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company&#8217;s
operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital
expenditures. The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many factors,
including the Company&#8217;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement
its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash. These consolidated financial statements
do not include any adjustments that might result from this uncertainty.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z2QiEAE6btr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_862_zgcZE7UT1anf">Basis of
Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The consolidated
financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany
transactions and balances have been eliminated in consolidation. The Company&#8217;s fiscal year ends on March 31 of each calendar
year.<b>&#160;</b>Certain prior year amounts have been reclassified for consistency with the current period presentation. These
reclassifications had no effect on the reported results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--UseOfEstimates_zjb03aSEOl9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86E_zkVTFpwCYJTh">Use of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The preparation
of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues
and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income
taxes. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zEBGwLnCl838" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_861_zYSzqPmtkea">Reportable Segment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The Company operates in one business
segment and uses one measurement of profitability for its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_z5RHgVDh9VL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_868_zhvjzB3hriT2">Concentration
of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Financial instruments
that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents. Cash and
cash equivalents are deposited with high credit-quality institutions within the United States, which are insured by the Federal
Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_ecustom--RisksAndUncertaintiesPolicyTextBlock_zU4HzJXoI7S" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86F_zvwI2K5ZXTqd">Risks and
Uncertainties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public
markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><i>COVID-19</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The global
outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply
chains, significantly restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in-place&#8221;
and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#8217;s operational
and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions
taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company&#8217;s
control, and cannot be predicted.</span></p>





<p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zRAzlxQ0y94d" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_863_z90kSs4OLyka">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Cash and cash
equivalents include cash in hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with
original maturities of three months or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zk1Cd3Wid9k2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_867_zUcEsPUJ4DLc">Property and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Property and
equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxH_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z0PB92ihRM74" title="::XDX::P3Y">three</span> to <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxH_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zVoGulgcYkX2" title="::XDX::P5Y">five</span> years. Depreciation is recorded in operating expenses in the consolidated statements of
operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated
useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zhjQ4qzLxNwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_86B_z3q4LBjYHSv1">Fair Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs
    that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial
    instrument.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Due to their
short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIDNnS7C5Ryi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86F_zIfOdHenFOg9">Research
and Development</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
expenses research and development expenditures as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zslkeDbN2qj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86D_zGAah61b4eJa">General and
Administrative</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">General and
administrative expense consists primarily of payroll and benefit related costs, rent, office expenses, equipment supplies and
meetings and travel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z3Tp69wE9iP" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_869_zNRpWSNYg7F3">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the
requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock
options on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards
on the date of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number
of highly complex and subjective variables. These variables include, but are not limited to, the expected stock price&#160;volatility
over the term of the awards, and projected stock option exercise behaviors.</span></p>





<p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_z04lF1yOv96e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86B_zNciwlCAEoM4">Per-Share
Amounts&#160;</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Basic net loss
per share is computed by dividing net loss for the period by the weighted-average number of shares of common stock outstanding
during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period.
For the years ended March 31, 2021 and 2020, <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20210331_z7FZlwLQa8h7">1,197,252</span> and <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190401__20200331_zKybxb95oDpl">1,059,315</span> outstanding options to purchase common stock were excluded
from the calculation of diluted net loss per share because their effect would be anti-dilutive. &#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zPlCSJXYVvMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_863_zszo70i8EdZa">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#8217;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to
affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that
all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management
believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company
has recorded a full valuation allowance.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
accounts for uncertain tax positions in accordance with FASB Accounting Standards Codification (ASC) Topic 740,&#160;<i>Income
Taxes</i>. When tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing
authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that
would be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements in the period
during which, based on all available evidence, management believes it is more likely than not that the position will be sustained
upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated
with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount
of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The
portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as
a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and
penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits
is classified as interest expense and penalties are classified in selling, general and administrative expenses in the consolidated
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. All tax returns
from 2016 to 2020 may be subject to examination by the U.S. federal and state tax authorities.&#160; As of March 31, 2021, the
Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zkBl9gDn6xMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86B_z6I11cISyor1">Comprehensive&#160;Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly,
comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2021 and
2020, the Company&#8217;s comprehensive loss was the same as its net loss.</span></p>





<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295880525832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_809_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zffH278fS3Q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
2 &#8211; <span id="xdx_829_z4AbZHRlLxEk">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Effective April
1, 2019, the Company adopted ASU No. 2016-02, <i>Leases </i>(ASC 842),<i> </i>and related ASUs, as amended, using the alternative
transition method, which allowed the Company to initially apply the new lease standard at the adoption date (the &#8220;effective
date method&#8221;). In January 2020, the Company executed a lease for a new, larger corporate facility in San Diego, California
and paid a $100,000 security deposit. The <span id="xdx_908_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxH_c20200402_zyp6c5dcFNR5" title="::XDX::P39M">39</span>-month lease
term commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $<span id="xdx_908_eus-gaap--LeaseAndRentalExpense_c20200401__20200430_zW6ATisQmqil" title="Monthly Rent">12,400</span> annual rent increases of approximately <span id="xdx_90D_ecustom--OperatingLeasesAnnualRentIncreasePercentange_iI_c20200402_zNBNpGf376D4" title="Operating Lease Annual Rent Increase Percentage">3%</span>.&#160;In addition to the minimum lease payments, the Company
is responsible for property taxes, insurance and certain other operating costs. The right-to-use asset and corresponding liability
for the facility lease have been measured at the present value of the future minimum lease payments. A discount rate of 11%, which
approximated the Company&#8217;s incremental borrowing rate, was used to measure the lease asset and liability. Lease expense
is recognized on a straight line basis over the lease term.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">The Company
obtained a right-of-use asset of $<span id="xdx_905_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20210401__20211231_zC45oVTDftc8">270,950</span> in exchange for its obligations under the operating lease. The landlord also provided
a lease incentive of approximately $<span id="xdx_909_ecustom--LeaseIncentiveReceived_iI_c20200930_z7w1C4Im8Qc7">139,000</span>, which was paid to the Company in June 2020, for the Company to make improvements
to the leased space.</span></p>





<p id="xdx_89E_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zJmxZubEG2ql" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8B0_zxWDKwGCiRO8">Future
minimum payments under the facility operating lease</span>, as of December 31, 2021, are listed in the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--DisclosureLeaseDetailsAbstract_zI3Kg6Yps0F5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Annual Fiscal Years</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20211231_z2XAUWdNaUfg" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating<br/> lease</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_maOLFMPz6XG_zdjbLZgmxOe3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 87%; text-align: left">2022</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">38,358</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_maOLFMPz6XG_zqAa2Rf3FnEd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158,028</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_maOLFMPz6XG_zzhclJCqGXo3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,692</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_ecustom--OperatingLeasesImputedInterest_iI_maOLFMPz6XG_z073Amdjcmm7" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt; padding-bottom: 1pt">Imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(20,049</td><td style="text-align: left; padding-bottom: 1pt">)</td></tr>
<tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iTI_mtOLFMPz6XG_zN6ZgoIM8uQf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">217,029</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table>




<p id="xdx_8A3_zPArM1EYkdH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Cash
paid for amounts included in the measurement of lease liabilities was $<span id="xdx_90F_ecustom--CashPaidforLeaseLiabilities_iI_c20211231_zPgsconRLJA2">115,073</span> for the nine months ended December 31, 2021. Rent
expense was $<span id="xdx_907_eus-gaap--LeaseAndRentalExpense_c20210401__20211231_z9BHbeDJ2Tal">80,698</span> and $<span id="xdx_907_eus-gaap--LeaseAndRentalExpense_c20200401__20201231_z5l2mr1N2Rke">80,654</span> for the nine months ended December 31, 2021 and 2020, respectively, and $<span id="xdx_90A_eus-gaap--LeaseAndRentalExpense_c20211001__20211231_zcADFxelGKi5">26,930</span> and $<span id="xdx_904_eus-gaap--LeaseAndRentalExpense_c20201001__20201231_z4Wt8IcRaChh">26,844</span> for
the three months ended December 31, 2021 and 2020, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_804_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zI2D2UliU05h" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 4 &#8211; <span id="xdx_825_zi2Nz2cefmjg">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Effective April 1,
2019, the Company adopted ASC No. 842, as amended, using the alternative transition method, which allowed the Company to initially apply
the new lease standard at the adoption date (the &#8220;effective date method&#8221;). In January 2020, the Company executed a lease
for a new, larger corporate facility in San Diego, California&#160;<span style="background-color: white">and paid a $100,000 security
deposit.</span> The <span id="xdx_900_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxH_c20200402_z1KFBhPCaoOa" title="::XDX::P39M">39-month</span>
lease term commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $<span id="xdx_905_eus-gaap--LeaseAndRentalExpense_c20200401__20200430_zSDH0uPGgrS6">12,400</span></span><span style="font-size: 10pt; background-color: white">&#160;with
annual rent increases of approximately <span id="xdx_902_ecustom--OperatingLeasesAnnualRentIncreasePercentange_iI_c20200402_zZhDUxsMKzcl">3%</span></span><span style="font-size: 10pt; background-color: white">.&#160;In
addition to the minimum lease payments, the Company is responsible for property taxes, insurance and certain other operating costs. The
right-to-use asset and corresponding liability for the facility lease have been measured at the present value of the future minimum lease
payments. A discount rate of 11%, which approximated the Company&#8217;s incremental borrowing rate, was used to measure the lease asset
and liability. Lease expense is recognized on a straight line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
obtained a right-of-use asset of $<span id="xdx_908_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20210401__20210630_z2G2AIje6xNg">270,950</span> in exchange for its obligations under the operating lease. The landlord also provided
a lease incentive of approximately $<span id="xdx_908_ecustom--LeaseIncentiveReceived_iI_c20200630_zKiJo3oTJbY7" title="Lease Incentive Received">139,000</span>, which was paid to the Company in June 2020, for the Company to make improvements
to the leased space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>


<p id="xdx_893_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zwsEbf5hBpr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8B4_z4ymE4sowwz9">Future minimum
payments under the facility operating lease, net of the lease incentive</span>, as of March 31, 2021, are listed in the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureLeasesDetailsAbstarct_zaw73crHXSE8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - LEASES (Details)">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20210331_zrL4AFPyLXnl" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Operating</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><b>Annual
    Fiscal Years</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>lease</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_zVkfNZy9FY0h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 87%"><span style="font: 10pt Times New Roman, Times, Serif">2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">153,432</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_znDX2jMH8Bvk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">158,028</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_zuf1bKMgk1Tf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">40,692</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Less:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_ecustom--OperatingLeasesImputedInterest_iI_zAvxbfezdWk1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Imputed
    interest</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(42,297</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_zBAFDAn0JDSa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Present value
    of lease liabilities</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">309,855</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>
<p id="xdx_8A3_zaIbd7vh93P6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Rent expense
was $<span id="xdx_90E_eus-gaap--LeaseAndRentalExpense_c20200401__20210331_zjo2lo5EhDg1">107,540</span> and $<span id="xdx_90D_eus-gaap--LeaseAndRentalExpense_c20190401__20200331_zu0OXP6pJkSg">35,766</span> for the years ended March&#160;31, 2021 and 2020, respectively.</span></p>





<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295880521960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PPP NOTE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosurePppNoteAbstract', window );"><strong>Ppp Note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_PPPNotesPayableTextBlock', window );">PPP NOTE</a></td>
<td class="text"><p id="xdx_805_ecustom--PPPNotesPayableTextBlock_z1pYskgfGTY9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
3 &#8211; <span id="xdx_82B_zu9sua4qxjwh">PPP NOTE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">On April
24, 2020, the Company received a $<span id="xdx_902_eus-gaap--UnsecuredDebtCurrent_iI_c20200424_zuS4y3ofPMQa">368,780</span> unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which
was established under the U.S. government&#8217;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP
Note to the Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration
Paycheck Protection Program Note with the Lender evidencing the PPP Note. The full amount of the PPP Note was due in April 2022
and interest accrued on the outstanding principal balance of the PPP Note at a fixed rate of 1.0% per annum, which was deferred
for 10 months after the covered period during which the Company used the proceeds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
applied to the Lender for forgiveness of the PPP Note in October 2020, and, in May 2021, the Company was notified by the Lender
and the U.S. Small Business Administration that the outstanding principal and accrued interest for the PPP Note was forgiven in
full. The Company accounted for the forgiveness of the PPP Note in accordance with Accounting Standards Codification Topic 470:
Debt (ASC 470), and the amount forgiven was recorded as a gain on extinguishment and recognized in the other income line of the
condensed consolidated statement of operations.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosurePppNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosurePppNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PPPNotesPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PPPNotesPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295880466632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PROMISSORY NOTES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE PROMISSORY NOTES</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--DebtDisclosureTextBlock_zAiJa8bB4pD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
4 &#8211; <span id="xdx_82B_zDANrQwEOcLj">CONVERTIBLE PROMISSORY NOTES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">From
February through April 2021, the Company sold $2,310,000 of convertible promissory notes (each an Original Notes and, collectively,
the Original Notes), at par in a private placement transaction effected pursuant to an exemption from the registration requirements
under the Securities Act of 1933, as amended. Effective April 30, 2021, pursuant to a revocation and replacement agreement between
each holder of an Original Note and the Company (the Revocation Agreement), the $2,310,000 of Original Notes and accrued interest
thereon as of April 30, 2021 were replaced with $2,360,550 aggregate principal amount of new Notes (as defined below). The Company
accounted for the replacement of the Original Notes in accordance with ASC 470 and recorded a loss on extinguishment of $<span id="xdx_900_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20210401__20211231_z7Gjzm5a3EVg">1,321,450</span>
and interest expense of $<span id="xdx_906_eus-gaap--AmortizationOfFinancingCosts_c20210401__20211231_zshpgyKP037h">70,647</span> for unamortized debt issuance costs as of April 30, 2021.</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In April
and May 2021, pursuant to a Securities Purchase Agreement by and between the Company and each investor (the SPA), the Company
sold to investors $<span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_c20210531__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zaxJPRzXweH3">4,250,000</span> aggregate principal amount of convertible promissory notes (the Notes) and warrants to purchase shares
of its common stock (the Warrants). The Notes are unsecured obligations of the Company with each Note having a stated maturity
date of 12 months from its issue date (the Issue Date). The Notes bear interest at a rate of 12% per annum, payable on maturity,
provided that, if the Company fails to pay any amounts when due under a Note, the interest rate increases to the greater of 16%
or the maximum amount permitted by law. Each Note may be prepaid at the Company&#8217;s option during the first 270 calendar days
following its Issue Date (the 270<sup>th</sup> day, the Trigger Date), subject to a 110% prepayment penalty on outstanding principal
and accrued interest then outstanding. No Note may be prepaid in whole or in part after the Trigger Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Notes
outstanding after the Trigger Date may be converted into shares of the Company&#8217;s common stock at an initial conversion price
of $8.61 per share; provided that a Note holder may not convert any portion of its Note that would cause it to beneficially own
in excess of 4.99% of the Company&#8217;s outstanding common stock. The conversion price and number of shares of Company common
stock issuable upon conversion of the Notes are subject to adjustment from time to time for subdivisions and consolidations of
shares and other standard dilutive and corporate events, as provided in the Notes. Subject to certain Exempt Issuances (as defined
in the Notes), if while a Note is outstanding, the Company sells, issues or grants any shares of its common stock or other securities
to acquire shares of common stock at a price per share less than the then conversion price, such conversion price shall be reduced
to such lesser price, and the number of conversion shares issuable upon conversion of the Notes shall be increased, as provided
in the Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">If the
Company completes an offering of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified
Capital Raise, as defined in the Notes), each Note holder will be required to convert its Adjusted Note Amount (as defined below)
into the securities of such Qualified Capital Raise. Adjusted Note Amount equals the product of (i) the sum of all outstanding
principal plus accrued interest on a Note, multiplied by (ii) 1.25.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Notes
contain a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal
or interest thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting
requirements under the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement,
(v) material restatements of the Company&#8217;s consolidated financial statements filed with the SEC, (vi) a holder&#8217;s inability
to rely on Rule 144 for sales of shares underlying the Notes, (vii) the Company&#8217;s common stock is suspended or halted from
trading and/or fails to be quoted or listed (as applicable) on the OTCQB, OTCQX, any tier of the NASDAQ Stock Market, the New
York Stock Exchange, or the NYSE American within 10 days thereafter, (viii) failure to file with the SEC a registration statement
covering the resale of shares of common stock underlying the Notes and Warrants within 60 calendar days following the Issue Date,
(ix) failure to cause such registration statement to become effective within 120 calendar days following the Issue Date, or (x)
certain mergers consolidations, business combinations and sales of all or substantially all of the Company&#8217;s assets in the
event the Company is not the survivor of such transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">Upon
an Event of Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will
be required to pay such Note holder the sum of (i) the product of (a) all then outstanding principal amount and accrued interest
thereon, multiplied by (b) 125%; and (ii) all collection costs including legal fees and expenses in connection therewith. At the
option of a Note holder, in the event the Company receives cash proceeds as a result of certain events, including, but not limited
to, payments from customers, issuances of debt or equity securities, exercise of warrants or asset sales, the Company will be
required to use such proceeds to repay all or any lesser outstanding amounts due under such holder&#8217;s Note.</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Notes
include covenants, representations, warranties, other payment obligations and agreements by the Company including, without limitation,
most-favored nation rights, rights of participation and first refusal and exchange rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In connection
with the issuance of the Notes, the Company issued Warrants to purchase in the aggregate 767,796 shares of its common stock at
an initial exercise price of $24.00 per share. The Warrants may be exercised for a period of five years from the Trigger Date,
provided that, if prior to the Trigger Date, the Company (i) completes a Qualified Capital Raise, the outstanding Warrants shall
be cancelled or (ii) prepays a holder&#8217;s Note(s) in whole or in part, such holder&#8217;s pro-rata number of Warrants shall
be cancelled. The fair value of the Warrants was $3,700,632, of which $2,379,182 was recorded as a debt discount, which is being
amortized to interest expense over the term of the Warrants, and $1,321,450 was recorded as a loss on debt extinguishment. The
Company calculated the fair value of the Warrants utilizing the Black-Scholes valuation model with the following assumptions:
volatility of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_c20210401__20211231_zsRt4WHqRwy2">88.98%</span>, risk-free interest rate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20211231_zLknLX55GhKe">0.86%</span>, a term of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20211231_zGJvvNpm3bWh" title="::XDX::P5Y9M">5.75</span> years and a dividend yield of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dcpxH_c20210401__20211231_zLx04zbKA4ge" title="::XDX::0">zero</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In connection
with the April and May 2021 sales of the $4,250,000 aggregate principal amount of the Notes, the Company incurred debt issuance
costs of $116,000, which were recorded as a debt discount and are being amortized to interest expense over the term of the Notes
using the effective interest rate method. The interest expense attributable to the debt discount, comprising the debt issuance
costs and Warrants, during the three and nine months ended December 31, 2021 was $630,323 and $1,454,762, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The $6,610,550
aggregate principal amount of Notes are due and payable in full in the first quarter of fiscal 2023. Subsequent to the Trigger
Date, the Notes can be converted into <span id="xdx_90C_ecustom--NotesAndAccuredInterestCouldBeConvertedIntoCommonStock_iI_c20211231_zAX49DWsrmre">767,783</span> shares of common stock at a conversion price of $8.61 per share.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_z239wqwiF2ui" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 3 &#8211; <span id="xdx_82D_zcREI3129Eqe">NOTES PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>PPP Note</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On April 24,
2020, the Company received a $368,780 unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was
established under the U.S. government&#8217;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note
to the Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration
Paycheck Protection Program Note (the Agreement) with the Lender evidencing the PPP Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 73.35pt 0 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The full amount
of the PPP Note is due in April 2022. Interest will accrue on the outstanding principal balance of the PPP Note at a fixed rate
of 1.0% per annum, which shall be deferred for 10 months after the covered period during which the Company used the proceeds.
The Company may prepay principal of the PPP Note at any time in any amount without penalty. The Agreement contains customary events
of default relating to, among other things, payment defaults, breach of representations and warranties or provisions of the PPP
Note. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts
owing from the Company, and/or filing suit and obtaining judgment against the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
applied to the Lender for forgiveness of the PPP Note in October 2020, and the amount which may be forgiven will be equal to the
sum of the payroll and benefit costs and covered rent and utility payments incurred by the Company, as calculated in accordance
with the terms of the CARES Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Convertible
Promissory Notes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">In
February and March 2021, the Company sold $2,210,000 of convertible promissory notes (the Notes), at par in a private placement
transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended
(the 2021 Placement). The Notes bear interest at an annual rate of 12%, and interest is accrued or payable monthly in cash. The
Notes mature on September 30, 2021 (the Maturity Date) and may be prepaid prior to the Maturity Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">The
aggregate principal amount of the Notes plus accrued but unpaid interest thereon shall automatically convert upon the closing
of an offering of the Company&#8217;s equity securities to investors or a strategic corporate investor resulting in aggregate
gross proceeds to the Company of at least $5,000,000 (excluding conversion of the Notes or other convertible securities issued
for capital raising purposes) (a Qualified Financing). In the event of a Qualified Financing, all such outstanding principal and
accrued interest shall convert into the same equity securities purchased by and on the same terms and conditions as the other
investors in such Qualified Financing at a conversion price equal to 80% (a 20% discount) of the lowest price paid per unit or
share by investors in the Qualified Financing. In the event that additional bridge financing is obtained by the Company, the Notes
shall convert into the same securities and on the same terms and conditions as the other investors therein and all such purchases
will be treated as one, single round of financing going forward. As of March 31, 2021, the Notes could be converted into 770,305
shares of common stock, excluding the effects of any payments of interest in kind.</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">At
any time on or following the Maturity Date, the holders of the Notes may demand repayment of the Notes, and the Company shall
repay the outstanding aggregate principal amount plus accrued but unpaid interest thereon. The holders of the Notes, however,
retain the right for 30 days after the Maturity Date to convert all or part of the aggregate principal amount plus accrued but
unpaid interest on the Notes into the Company&#8217;s common stock at the conversion price of $2.87 per share or at a 20% discount
to any financing consummated during the 30-day period following the Maturity Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">If
a Qualified Financing has not occurred immediately prior to the consummation of a Change of Control (as defined below), the Note
holders shall have the option of either (i) converting all or any portion of the aggregate principal amount of the Notes plus
accrued but unpaid interest thereon into common stock of the Company at a conversion price equal to $2.87 per share or (ii) having
the Company repay the aggregate principal amount of the Notes and accrued but unpaid interest. The term &#8220;Change of Control&#8221;
means (i) a consolidation or merger of the Company with or into any other corporation or other entity or person, or any other
corporate reorganization, other than any such consolidation, merger or reorganization in which the shares of capital stock of
the Company immediately prior to such consolidation, merger or reorganization continue to represent a majority of the voting power
of the surviving entity immediately after such consolidation, merger or reorganization; (ii) any transaction or series of related
transactions to which the Company is a party in which in excess of 50% of the Company&#8217;s voting power is transferred; (iii)
the sale or transfer of all or substantially all of the Company&#8217;s assets, or the exclusive license of all or substantially
all of the Company&#8217;s material intellectual property; or (iv) the dissolution and winding up of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
incurred debt issuance costs of $88,800, which were recorded as a debt discount and are being amortized to interest expense over
the term of the Notes using the effective interest rate method. The interest expense related to the debt discount during
the year ended March 31, 2021 was approximately $13,000.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295880533208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROMISSORY NOTE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosurePromissoryNoteAbstract', window );"><strong>Promissory Note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_PromissoryNoteTextBlock', window );">PROMISSORY NOTE</a></td>
<td class="text"><p id="xdx_804_ecustom--PromissoryNoteTextBlock_zZLKfUWSVEFc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
5 &#8211; <span id="xdx_82A_zXncvbeBDPdf">PROMISSORY NOTE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">On
October 28, 2021, the Company issued a secured promissory note (the Bridge Note) to Manchester Explorer, L.P. (&#8220;Manchester&#8221;)
that provides the Company with a $<span id="xdx_90E_eus-gaap--LineOfCredit_iI_c20211028__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--InvestmentTypeAxis__custom--SecuredPromissoryNotesMember_zEh8GdOS7zXk">3,000,000</span> revolving credit facility with all amounts being drawn down by the Company thereunder
being due and payable, subject to acceleration in the event of a default, on <span id="xdx_90A_eus-gaap--LineOfCreditFacilityExpirationDate1_c20211027__20211028__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--InvestmentTypeAxis__custom--SecuredPromissoryNotesMember_zDtbfLEgLYo2" title="Maturity Date">March 15, 2022</span> (the &#8220;Maturity Date&#8221;).
Interest at the rate of <span id="xdx_90E_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_c20211027__20211028__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--InvestmentTypeAxis__custom--SecuredPromissoryNotesMember_zV3wKkgD9ZS">12%</span> is payable on each drawn down without regard to the draw down date or the date when interest is paid.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The
principal amount of the Bridge Note and interest due thereon is payable to Manchester no later than the earlier of: (i) the Maturity
Date and (ii) the date on which the Company has received proceeds in excess of $12,000,000 from a transaction or series of related
transactions occurring prior to the Maturity Date, which such transactions constitute equity financings or other issuances of
the Company&#8217;s equity securities. Provided that no Event of Default (as such term is defined in the Bridge Note) has occurred,
on any date prior to the Maturity Date, upon no less than three days written notice by the Company specifying the draw amount,
Manchester will advance the draw amount to the Company. No draw amount can be in an amount less than $100,000 or exceed an amount
equal to $3,000,000 minus the aggregate principal amount outstanding under the Bridge Note at the time of such draw request. If
an Event of Default occurs and is continuing, Manchester may declare all of the Bridge Note, including any interest and other
amounts due, to be due and payable immediately.</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In
connection with the issuance of the Note, on October 28, 2021, the Company entered into a Security Agreement with Manchester (the
&#8220;Security Agreement&#8221;) under which the Company granted Manchester a continuing and unconditional first priority security
interest in and to any and all of the Company&#8217;s property of any kind or description, tangible or intangible, wheresoever
located and whether now existing or hereafter arising or acquired.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
the quarter ended December 31, 2021, the Company made draws on the Bridge Note of $<span id="xdx_90C_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_c20211001__20211231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zosYE3aCBPLk">1,500,000</span> and incurred interest charges of
$<span id="xdx_90E_eus-gaap--LineOfCreditFacilityIncreaseAccruedInterest_c20211001__20211231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zGfFez5D3hHk">180,000</span>.</span></p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosurePromissoryNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosurePromissoryNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_PromissoryNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_PromissoryNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295880454632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; DEFICIT AND STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">STOCKHOLDERS&#8217; DEFICIT AND STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zQz1HdeI7FFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
6 &#8211; <span id="xdx_82D_z6GULZVoIzo8">STOCKHOLDERS&#8217; DEFICIT AND STOCK-BASED COMPENSATION</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
the three months ended December 31, 2021, the Company sold 30,865 shares of common stock to its chief executive officer and its
chairman of the board of directors, president, chief financial officer and treasurer, issued 8,334 shares of common stock to a
service provider and issued 5,775 shares to its non-employee directors under the Company&#8217;s outside director compensation
plan. At December 31, 2021, the Company had an obligation to issue 16,666 shares of common stock to service providers, and the
value of these shares was recorded as common stock issuable in the condensed consolidated balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Amended
2017 Equity Incentive Plan </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In October
2017, the Company&#8217;s board of directors (the Board) approved the 2017 Equity Incentive Plan (the Plan) with <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20171031_ztEmafj12tal">1,000,000</span> shares
of common stock reserved for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved
for issuance under the Plan by <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200131_zlXA0kJN12F2">333,334</span> and <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200831_zMSDt8zLhQSk">1,333,334</span> shares, respectively. Under the Plan, eligible employees, directors and consultants
may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based
awards and restricted stock units. The Plan is administered by the Board or, in the alternative, a committee designated by the
Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Stock-Based
Compensation Expense</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The expense
relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period,
based on the grant date fair value. The unamortized compensation cost, as of December 31, 2021, was $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20211231_zlB1owsTyga">7,419,022</span> related to stock
options and is expected to be recognized as expense over a weighted-average period of approximately <span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dxH_c20210401__20211231_zHpVu1aRNWu" title="::XDX::P2Y">two</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">During
the nine months ended December 31, 2021, the Company granted options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zoRiL3V4EeLf">723,269</span> shares of its common stock to employees,
directors and consultants. The options had 10-year terms, and <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zUHxuUD5tbBj">85,484</span> options vested immediately when granted. The fair value of
the options was determined to be $<span id="xdx_909_ecustom--FairValueofOptionGranted_c20210401__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMgkdlr2ZUMk">8,108,043</span> of which $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20210401__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfNzWohm5oJ">1,769,805</span> was recorded as stock-based compensation expense and included
in the condensed consolidated statement of operations for the nine months ended December 31, 2021.</span></p>







<p id="xdx_891_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zvoaga1a89yd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
assumptions were used in the fair value method calculations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BC_zoHpYNToBpPe" style="display: none">Schedule of Fair Value Assumptions</span></p>



<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zBie8INYQvq1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Three
    Months Ended<br/> December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Nine
    Months Ended<br/> December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: left"><span style="font-size: 10pt">Risk-free
    interest rates</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_zJhiCTvtdor5">1.26%</span> - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zFYXEYTjgfXj">1.36%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20201001__20201231_zgrZ8UmxTHRa">0.38%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_z8xm6yEUn6ze">0.8%</span> - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_z4F0L9F5VYCg">1.36%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20201231__srt--RangeAxis__srt--MinimumMember_zMAGWA6uQjTh">0.28%</span> - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20201231__srt--RangeAxis__srt--MaximumMember_zmxRF2Rnv4Gk">0.38%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_zzxbc1ec0iya">197%</span>
                                         - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zX9wuplYzrge">253%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20201001__20201231_zzEbfdv7ehvb">87%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_zmHwQ5WCgu2d">89%</span>
                                         - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_zgALPDHRxh5b">370%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20201231__srt--RangeAxis__srt--MinimumMember_z3J24CnpuBAf">87%</span>
                                         - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20201231__srt--RangeAxis__srt--MaximumMember_zTf56EI8vHUa">127%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Expected life (years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_z3uH1IqRNXW8">5.0</span>
                                         &#8211; <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zUli8eAzzafj">6.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231__srt--RangeAxis__srt--MinimumMember_zRuCprlQIXoe">5.2</span>
                                         &#8211; <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231__srt--RangeAxis__srt--MaximumMember_zOj6Ji4p1sYa">5.7</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_zy0bHBwbcbmj">5.0</span>
                                         - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_zu1julJ9OpCf">6.2</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20201231__srt--RangeAxis__srt--MinimumMember_zgqyty753UOh">5.0</span>
                                         - <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20201231__srt--RangeAxis__srt--MaximumMember_z5K54pvMIsg">6.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20211001__20211231_zm1YAE8gfGAg">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20201001__20201231_zc9a5wEnzU71">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20210401__20211231_zWrUnJCVcVV8">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20201231_zgll00aypvEi">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>





<p id="xdx_8A0_zt8mvG0EWljf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The fair
values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods
to establish the fair term of options as well as average volatility of three comparable organizations. The risk-free interest
rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant
date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never
paid dividends and has no intention to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company
accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zgPewvRZSuA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">A summary
of stock option activity under the Plan is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BF_zMfIkSaPKpo3" style="display: none">Schedule of Stock Option activity</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zJgKjtBn1Yde" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares<br/> Available<br/> for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Prices</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2021</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zwC7l1Fa7005" style="width: 8%; text-align: right">136,082</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmpnLVcwY3H" style="width: 8%; text-align: right">1,197,252</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5b8iKkQzy1l" style="width: 8%; text-align: right">5.25</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zczvsn3JQKFi" style="text-align: right">(60,774</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoueppVNmd15" style="text-align: right">60,774</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSqVkRYMnjPh" style="text-align: right">12.69</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKnwKSq88j1h" style="text-align: right">(1,836</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgshN5RbEzDh" style="border-bottom: Black 1pt solid; text-align: right">7,547</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3cy1HgyK8jh" style="border-bottom: Black 1pt solid; text-align: right">(7,547</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT43tyNwyf" style="border-bottom: Black 1pt solid; text-align: right">8.61</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Balance at June 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLN21uVqY9e3" style="text-align: right">81,089</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWS7z1Hgdljk" style="text-align: right">1,250,479</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziGgmlnX6b1i" style="text-align: right">5.58</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztHm9HiOjxM" style="text-align: right">1,333,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zw75AdIoqDyd" style="text-align: right">(396,384</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAUosEMtvCBd" style="text-align: right">396,384</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyFNIXkQzrj5" style="text-align: right">12.15</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRLRhaCnjRf6" style="text-align: right">(3,636</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyad6u5ObVd3" style="border-bottom: Black 1pt solid; text-align: right">49,213</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zTxde3atswIb" style="border-bottom: Black 1pt solid; text-align: right">(49,213</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQHd0IPPrYek" style="border-bottom: Black 1pt solid; text-align: right">7.02</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at September 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2QiQGPgV8T3" style="text-align: right">1,063,546</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5KsGdZdFMok" style="text-align: right">1,597,650</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zr46KajKTuM2" style="text-align: right">7.17</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLCJHdBqM5kc" style="text-align: right">(266,112</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5ZRQE89Yb73" style="text-align: right">259,559</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBSJy6ClQVAc" style="text-align: right">9.99</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx4DAV7jxxii" style="text-align: right">(5,775</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmghZMF6l164" style="border-bottom: Black 1pt solid; text-align: right">29,073</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zV9lNSrU3La7" style="border-bottom: Black 1pt solid; text-align: right">(11,256</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBuKoN8LsIr9" style="border-bottom: Black 1pt solid; text-align: right">7.24</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at December 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zApvYc0926E8" style="border-bottom: Black 2.5pt double; text-align: right">820,732</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziAAAHiBLCc3" style="border-bottom: Black 2.5pt double; text-align: right">1,845,953</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDJsNb4lL4fc" style="border-bottom: Black 2.5pt double; text-align: right">7.57</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">There were no stock options exercised during the nine months ended December 31, 2021 and 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_zHfLqyJ8vjpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table summarizes the range of outstanding and exercisable options as of December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B0_zjWp49Tt5yt7" style="display: none">Schedule of
Outstanding and Exercisable Option, Range</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zhuv6eC9oSy" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number<br/> Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in Years)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number<br/> Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%; padding-bottom: 1pt">$<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zfOh8Nh6lWy3">1.98</span> - $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zxbrZpd0Al24">17.70</span></td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDlPIupeKgEh" style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1,845,953</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxH_c20210401__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGGy1zqdjbL1" style="width: 8%; padding-bottom: 1pt; text-align: right" title="::XDX::P8Y1M17D">8.13</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVj3UdAANCp3" style="width: 8%; padding-bottom: 1pt; text-align: right">7.57</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zketqRJJRft7" style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1,011,586</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znJSsM8zPE36" style="width: 8%; padding-bottom: 1pt; text-align: right">5.10</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6lN4x67ZMvb" style="border-bottom: Black 1pt solid; width: 8%; text-align: right">3,564,268</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A4_z8FJHdEPWO81" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The intrinsic
value per share is calculated as the excess of the closing price of the common stock on the Company&#8217;s principal trading
market over the exercise price of the option at December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise
of stock options as financing cash flows in the consolidated statements of cash flows. For the nine months ended December 31,
2021 and 2020, there were no such tax benefits associated with the exercise of stock options.<b> </b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_808_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zjUWhAWCd1K7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE 5 &#8211;
<span id="xdx_82A_zCTmmfmICWHf">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Equity Compensation
Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In October 2017,
the Company&#8217;s board of directors (the Board) approved the 2017 Equity Incentive Plan (the 2017 Plan) with 3,000,000 shares
of common stock reserved for issuance. In January 2020, the Board approved an amendment to the 2017 Plan to increase the number
of shares reserved for issuance by 1,000,000 shares. Under the 2017 Plan, eligible employees, directors and consultants may be
granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards
and restricted stock units. The 2017 Plan is administered by the Board or, in the alternative, a committee designated by the Board.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The exercise
or purchase price of a stock option shall be calculated as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
    the case of an incentive stock option, (a) granted to employees, who, at the time of the grant of such incentive stock option
    own stock representing more than 10% of the voting power of all classes of stock of the Company, the per share exercise price
    shall be not less than 110% of the fair market value per share on the date of grant; or (b) granted to employees, other than
    to employees, described in the preceding clause, the per share exercise price shall be not less than 100% of the fair market
    value per share on the date of grant;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
    the case of a non-qualified stock option, the per share exercise price shall be not less than 100% of the fair market value
    per share on the date of grant unless otherwise determined by the Board; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(iii) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
    the case of other grants, such price as determined by the Board.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Board
is responsible for determining the consideration to be paid for the shares of common stock to be issued upon exercise or purchase.
The 2017 Plan generally does not allow for the transfer of awards, and the Board may amend, suspend or terminate the 2017 Plan
at any time.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Stock-Based
Compensation Expense</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The expense
relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period,
based on the grant date fair value. The unamortized compensation cost, as of March 31, 2021 was $2,242,352 related to stock options
and is expected to be recognized as expense over a weighted-average period of approximately 2 years.&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
the year ended March 31, 2021, options granted to purchase shares of its common stock to employees, directors and consultants
had 10-year terms and a grant-date fair value of $1,101,737. Options to purchase 10,476 shares vested immediately on the respective
grant dates.&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zvYq7IF9JyI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The following <span id="xdx_8B5_zlf1rY5Degjc">assumptions were used
in the fair-value method calculations</span>:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zoHuDK6s0nT1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Year
    ended March 31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2021</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 75%"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rates</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z3WdONB4SZo3" title="Risk-free interest rates">0.28%</span>
    - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zKXqL9Ish2u2">0.71%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zUL6Ejt736V7">0.77%</span>
    - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zm1j5c8ajwF2">2.37%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zTa7ch8pmPZj" title="Volatility">87%</span>
    - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_ziVZpTGts1Ki">127%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zYHYFJV41tZa">86%</span>
    - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zC5IcFOdVVE6">103%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    life (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zxbZfBQ3IN0l" title="Expected Life (years)">5.0</span>
    - <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_z1TUxfEn4EG1">6.0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zRjo0fMiYtB4">5.0</span>
    - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zjseC5rpXBNk">6.0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Dividend
    yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zznV59JTlHzb">&#8212;%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zzPv2kfTG5L1">&#8212;%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p id="xdx_8AC_zuhRbsCVqLn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The fair values
of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to
establish the fair term of options as well as average volatility of three comparable organizations. The risk-free interest rate
was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date
for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid
dividends and has no intention to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts
for forfeitures as they occur.</span></p>




<p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_znsC7EV5wvie" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">A summary of <span id="xdx_8BD_zo1WcKMoXVka">stock option activity
</span>under the 2017 Plan is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zJSj4aqevOpc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Available</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted Average</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2019</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331_zLweyHt3pxQh" style="width: 8%; text-align: right" title="Shares available for grant, beginning">490,031</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVmGRDLvVbFb" style="width: 8%; text-align: right">509,969</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRzl68rEqYJl" style="width: 8%; text-align: right">2.56</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_c20190401__20200331_zhAdxgDFNffd" style="text-align: right">333,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_iN_di_c20190401__20200331_zPsMwIKwoQAc" style="text-align: right">(572,402</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMPyaRvRz9dd" style="text-align: right">572,402</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zng6yBVex3Pe" style="text-align: right">6.75</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20190401__20200331_zfYa8LQ4ZHWg" style="border-bottom: Black 1pt solid; text-align: right">23,056</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2NYijcemSPe" style="border-bottom: Black 1pt solid; text-align: right">(23,056</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlC05erYxvwe" style="border-bottom: Black 1pt solid; text-align: right">6.75</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Balance at March 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331_z15feRx4wrj7" style="text-align: right">274,019</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1nYosdl6G92" style="text-align: right">1,059,315</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5YLernKnlpk" style="text-align: right">4.74</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_iN_di_c20200401__20210331_zJggddizapdi" style="text-align: right">(163,492</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLCxmcLIOV75" style="text-align: right">163,492</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZXcbDKJQol3" style="text-align: right">8.64</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20200401__20210331_zkXgvpN0sYMi" style="border-bottom: Black 1pt solid; text-align: right">25,555</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZ7eE89lFage" style="border-bottom: Black 1pt solid; text-align: right">(25,555</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbhsQtPUzcSh" style="border-bottom: Black 1pt solid; text-align: right">6.75</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at March 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331_zye6aVSk8FA5" style="border-bottom: Black 2.5pt double; text-align: right">136,082</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znw72iivgn5k" style="border-bottom: Black 2.5pt double; text-align: right">1,197,252</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0YFfXOhuZWl" style="border-bottom: Black 2.5pt double; text-align: right">5.25</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A4_zCZ32lEJywa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">There were no
stock options exercised during the years ended March 31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z4MDAK8NLx19" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table <span id="xdx_8BD_z7khsmxDY1Ib">summarizes the range of outstanding and exercisable options</span> as of March 31, 2021:</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zjQ9JdEOW2z5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 3)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in Years)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt">$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zzRBzMxdOvJi">1.98</span> - $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zxDphhvUO3l4">9.48</span></td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zs1oFVpZzC45" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">1,197,252</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtYxH_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDF6lDyhHc4a" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="::XDX::P8Y4M">8.25</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zz6JFas6hN48" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">5.25</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhDEwU7OVCq4" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">742,913</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtYxH_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zD0TjOxu1WX7" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="::XDX::P3Y11M16D">3.96</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoZStRXd9JH2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">8,763,260</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AB_zRfPGIO5nMhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The intrinsic
value per share is calculated as the excess of the closing price of the common stock on the Company&#8217;s principal trading
market over the exercise price of the option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise
of stock options as financing cash flows in the consolidated statements of cash flows. For the years ended March 31, 2021 and
2020, there were no such tax benefits associated with the exercise of stock options.<b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295877763672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_zUEqCSby3s5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
7 &#8211; <span id="xdx_82D_zxkyS1vMVZte">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#8217;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to
affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that
all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management
believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company
has recorded a full valuation allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. All tax returns for fiscal
2016 to fiscal 2021 may be subject to examination by the U.S. federal and state tax authorities. As of December 31, 2021, the
Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295878852888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zl0wjrUeuXPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
8 &#8211; <span id="xdx_82B_z5GWTZLhenl5">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt"><span style="font-size: 10pt">In
February 2021, the Company&#8217;s chairman of the board of directors and president and an existing investor, who is represented by
a member of the Company&#8217;s board of directors, purchased $100,000 and $1,000,000, aggregate principal amount of the Original
Notes, respectively. Effective April 30, 2021, the related party holders entered into revocation agreements with the Company
pursuant to which their collective $<span id="xdx_907_ecustom--NotesCancelled_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember_zpEpvhCm5JPg">1,100,000</span>
aggregate principal amount of Original Notes and accrued interest of $<span id="xdx_904_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember_zcyifl49Z55f">50,091</span>
were replaced with Notes. At December 31, 2021, the investor and executive officer held Notes in an aggregate principal amount of
$<span id="xdx_902_eus-gaap--NotesPayable_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_z3CkvCUhqox5">1,026,630 </span></span><span style="font-size: 10pt; background-color: white">and
$<span id="xdx_906_eus-gaap--NotesPayable_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_z11Y8PN1Hqul">102,663</span></span><span style="font-size: 10pt; background-color: white">,
respectively, with $<span id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_z2tgfwXqwLbf">82,693 </span></span><span style="font-size: 10pt; background-color: white">and
$<span id="xdx_905_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_zOOV3VE30ppc">8,269 </span></span><span style="font-size: 10pt; background-color: white">of
interest payable thereon. For the three months ended December 31, 2021, the Company incurred interest expense of approximately
$<span id="xdx_906_eus-gaap--InterestExpense_c20211001__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zJlsPLO8Ucc3">31,052</span>
and $<span id="xdx_90E_eus-gaap--InterestExpense_c20201001__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zm29wzzYRPh5">3,105</span>,
respectively, and for the nine months ended December 31, 2021, the Company incurred interest expense of approximately $<span id="xdx_90F_eus-gaap--InterestExpense_c20200401__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zduk0yOy6uCg">82,693</span>
and $<span id="xdx_90C_eus-gaap--InterestExpense_c20210401__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zWDYuGmYOvei">8</span>,269,
respectively, on the related party holder Notes.</span></span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In May
2021, a member of the Board purchased $<span id="xdx_901_eus-gaap--NotesPayable_iI_c20210531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember_zCkH58G40yP9">200,000</span> aggregate principal amount of Notes (the Director Note). For the three and nine
months ended December 31, 2021, the Company incurred expense of approximately $<span id="xdx_90A_eus-gaap--InterestExpense_c20211001__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_zdzZyZbvd3t4">6,049</span> and $<span id="xdx_903_eus-gaap--InterestExpense_c20200401__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_zFDOKrRi1Gb4">16,110</span>, respectively, on the Director
Note. At December 31, 2021, approximately $<span id="xdx_90F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember_z7AmrHnUNT13">16,110</span> of interest was payable by the Company on the Director Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In
October 2021, the Company entered into purchase agreements with <span id="xdx_91E_esrt--ChiefExecutiveOfficerMember_zehMJcD8lkOc">Ellen O&#8217;Connor (Lynn) Vos</span>, the Company&#8217;s chief executive
officer, and <span id="xdx_916_esrt--BoardOfDirectorsChairmanMember_zy02JHBnJS12">Paul DiPerna</span>, the chairman of the Company&#8217;s board of directors and its president, chief financial officer and
treasurer, providing for the sale and issuance by the Company of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20211031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9rvwpXchzH8">30,864</span> shares of the Company&#8217;s common stock, par value
$0.001 per share at the closing market price on October 28, 2021 of $8.10 per share. The Company received proceeds of approximately
$250,000 from the sale of the shares, comprising $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20211031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zUBpGab4RsSe">150,000</span> from Ms. Vos and $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20211031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--BoardOfDirectorsChairmanMember_z80d6un24TL6">100,000</span> from Mr. DiPerna.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z5zBxWgYBylj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE&#160;11
&#8211; <span id="xdx_827_zfZkjWzcwctc">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Consulting
Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">During the year
ended March 31, 2020, the Company entered into consulting agreements with a member of its board of directors. Under the consulting
agreements, during the year ended March 31, 2020, the Company paid the director consulting fees of $140,625<span style="color: red">&#160;</span>in
cash, and the director was granted stock options with a fair value of $76,875. The options were for a total of 15,687 shares
of common stock, were fully vested on the grant dates and have terms of 10 years.<b>&#160;</b>&#160;The most recent consulting
agreement, which was entered into between the Company and the director in September 2019, was terminated in March 2020. At March
31, 2020, the Company had an outstanding payable to the director of $5,585, which was included in accounts payable in the consolidated
balance sheet. The Company paid the $5,585 to the director during fiscal 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>2021 Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">The
Company&#8217;s chief executive officer and an existing investor, which is represented by a member of the Company&#8217;s board
of directors, purchased $100,000 and $1,000,000, respectively, aggregate principal amount of the Notes (the Related Party Notes)
in the 2021 Placement. As of March 31, 2021, $1,677 and $16,767 of interest was payable by the Company on the Related Party Notes
to its chief executive officer and to the investor, respectively.</span></p>





<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295875096824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zbceCCTkrLKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
9 &#8211; <span id="xdx_824_zaPq6zvWTJl9">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><i>Litigations,
Claims and Assessments </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In the
normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course
of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable
settlements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"><span style="font-size: 10pt"><i>Indemnification</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In the
ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties
from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims
and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising
from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses.
The Company has also entered into indemnification agreements with its officers and directors. No amounts were reflected in the
Company&#8217;s consolidated financial statements for the nine months ended December 31, 2021 and 2020 related to these indemnifications.
The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited
history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has
not made any payments related to these indemnification agreements, and no claims for payment have been made under such agreements.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zeBo7ziYRPG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE 10 &#8211;
<span id="xdx_820_zkGXOVMGfxh7">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Litigations,
Claims and Assessments&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the normal
course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of
business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable
settlements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Indemnification</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the ordinary
course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties
from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims
and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising
from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses.
The Company has also entered into indemnification agreements with its officers and directors. No amounts were reflected in the
Company&#8217;s consolidated financial statements for the years ended March&#160;31, 2021 and 2020 related to these indemnifications.
The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited
history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has
not made any payments related to these indemnification agreements.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295880501992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_znpdYl2pAO33" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
10 &#8211; <span id="xdx_823_zAU6dGNwHE6e">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 9.05pt 0 0; text-align: justify"><span style="font-size: 10pt"><i>Bridge
Note</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 9.05pt 0 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 9.05pt 0 0; text-align: justify"><span style="font-size: 10pt">Subsequent
to December 31, 2021, the Company made additional draws totaling $<span id="xdx_901_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_c20220101__20220214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z7zukpg0ljG8">600,000</span> under the Bridge Note.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 9.05pt 0 0; text-align: justify"><span style="font-size: 10pt"><i><span id="xdx_91F_eus-gaap--IPOMember_zixvTgUUY3Zg">Public
Offering</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 9.05pt 0 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On February
9, 2022, the Company entered into an underwriting agreement (the Underwriting Agreement), with Oppenheimer &amp; Co. Inc.,
which acted as the representative of the several underwriters (the &#8220;Representative&#8221;), in a firm commitment underwritten
public offering (the Offering) pursuant to which the Company agreed to sell to the Representative an aggregate of 2,500,000 shares
of the Company&#8217;s common stock, par value $0.001 per share (the Common Stock), and 2,500,000 warrants (Warrants and, collectively
with the Common Stock, the Units), each to purchase one share of Common Stock, at a public offering price of $6.00 per Unit. The
Warrants included in the Units are exercisable immediately, have an exercise price of $6.60 per share and expire five years from
the date of issuance. The Common Stock was approved to list on the Nasdaq Capital Market under the symbol &#8220;MODD&#8221; and
began trading there on February 10, 2022. The gross proceeds from the Offering were $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_pdp0_dm_c20220209__20220210__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zj4ohTeyRNYf">15 million</span>, before deducting underwriting
discounts and commissions and other offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Units were
offered and sold to the public pursuant to the Company&#8217;s registration statement on Form S-1 (File No. 333-260682), initially
filed by the Company with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the Securities
Act), on November 2, 2021, and declared effective on February 9, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Underwriting
Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification
obligations of the Company and the Representative, including for liabilities under the Securities Act of 1933, as amended,
other obligations of the parties and termination provisions. In addition, pursuant to the terms of the Underwriting Agreement and
related &#8220;lock-up&#8221; agreements, the Company, each director and executive officer of the Company, and certain stockholders
have agreed with the Representative not to offer for sale, issue, sell, contract to
sell, pledge or otherwise dispose of any of our Common Stock or securities convertible into Common Stock for a period of 180 days
after February 9, 2022, the date of the final prospectus.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zJZhTqL9Pnwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE 12 &#8211;
<span id="xdx_822_zye6Msj6Q1d7">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Convertible
Promissory Notes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Subsequent to
March 31, 2021, the Company issued an additional $4,250,000 of the Notes in the 2021 Placement pursuant to a Securities Purchase
Agreement between the Company and each investor (the SPA) and warrants to purchase shares of its common stock (the Warrants).
The Notes are unsecured obligations of the Company with each Note having a stated maturity date of 12 months from its issue date
(the Issue Date). The Notes bear interest at a rate of 12% per annum, payable on maturity, provided that, if the Company fails
to pay any amounts when due under a Note, the interest rate increases to the greater of 16% or the maximum amount permitted by
law. Each Note may be prepaid at the Company&#8217;s option during the first 270 calendar days following its Issue Date (the 270<sup>th</sup>&#160;day,
the Trigger Date), subject to a 110% prepayment penalty on all principal and accrued but unpaid interest then outstanding. No
Notes may be prepaid in whole or in part after the Trigger Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If the Notes
remain outstanding after the Trigger Date, the Notes may be converted into shares of the Company&#8217;s common stock at an initial
conversion price of $8.61 per share; provided, that a Note holder may not convert any portion of its Note that would cause it
to beneficially own in excess of 4.99% of the Company&#8217;s outstanding common stock. The conversion price and number of
shares of Company common stock issuable upon conversion of the Notes will be subject to adjustment from time to time for any subdivision
or consolidation of shares and other standard dilutive and certain other corporate events, as provided in the Notes. Subject to
certain Exempt Issuances (as defined in the Notes), if at any time while a Note is outstanding, the Company sells, issues or grants
any shares of its common stock or other securities entitling the holder to acquire shares of the Company&#8217;s common stock
at a price per share less than the then conversion price, such conversion price shall be reduced to such lesser price, and the
number of shares of the Company&#8217;s common stock issuable upon conversion of the Notes shall be increased, as provided in
the Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">If the Company
completes an offering of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified Capital
Raise), each Note holder will be required to convert its Adjusted Note Amount into the securities of such Qualified Capital Raise.
For purposes hereof, Adjusted Note Amount equals the product of (i) the sum of all outstanding principal plus accrued but unpaid
interest on a Note, multiplied by (ii) 1.25.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Notes contain
a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal or interest
thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting requirements
under the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement, (v)
material restatements of the Company&#8217;s consolidated financial statements filed with the SEC, (vi) a holder&#8217;s inability
to rely on Rule 144 for sales of shares underlying the Notes, (vii) the Company&#8217;s common stock is suspended or halted from
trading and/or fails to be quoted or listed (as applicable) on the OTCQB, OTCQX, any tier of the Nasdaq Stock Market, the New
York Stock Exchange, or the NYSE American within 10 days thereafter, (viii) failure to file with the SEC a registration statement
covering the resale of shares of common stock underlying the Notes and Warrants within 60 calendar days following the Issue Date,
(ix) failure to cause such registration statement to become effective within 120 calendar days following the Issue Date, or (x)
certain merger consolidations, business combinations and sales of all or substantially all of the Company&#8217;s assets in the
event the Company is not the survivor of such transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Upon an Event
of Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will be required
to pay such Noteholder the product of (i) all then outstanding principal amount and accrued but unpaid interest thereon, multiplied
by (ii) 125%; and all collection costs including legal fees and expenses in connection therewith. At the option of a Note holder,
in the event the Company receive cash proceeds as a result of certain events including, but not limited to, from customers, issuances
of debt or equity securities, exercise of warrants or asset sales, the Company will be required to use such proceeds to repay
all or any lesser outstanding amounts due under such holder&#8217;s Note.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Notes also
includes various covenants, including negative covenants, representations, warranties, other payment obligations and agreements
by the Company including, without limitation, most-favored nation clauses, rights of participation and first refusal and exchange
rights. In connection with the issuance of the Notes, the Company issued Warrants to purchase 761,912 shares of its common
stock (Warrant Shares) at an initial exercise price of $24.00 per share. The Warrants may be exercised for a period of 5 years
from the Trigger Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In the event
that, prior to the Trigger Date, the Company (i) completes a Qualified Capital Raise, the outstanding Warrants shall be cancelled
or (ii) prepays a holder&#8217;s Note(s) in whole or in part, such holder&#8217;s pro-rata number of its Warrants shall be cancelled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Effective April
30, 2021, each of the holders of the $2,210,000 of Notes outstanding at March 31, 2021 entered into a revocation and replacement
agreement with the Company (the Revocation Agreement). Under the terms of the Revocation Agreement, the $2,210,000 of Notes and
accrued interest of $50,091 were replaced with new Notes consistent with the terms described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In May 2021,
a member of the Board purchased $200,000 of the Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>PPP Note</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">As a result
of the Company&#8217;s request for loan forgiveness, on May 29, 2021, the Company was notified that the outstanding principal
and accrued interest for the PPP Note was forgiven in full by the U.S. Small Business Administration.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295877799720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEET DETAIL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureConsolidatedBalanceSheetDetailAbstract', window );"><strong>Consolidated Balance Sheet Detail</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_ConsolidatedBalanceSheetDetailTextBlock', window );">CONSOLIDATED BALANCE SHEET DETAIL</a></td>
<td class="text"><p id="xdx_803_ecustom--ConsolidatedBalanceSheetDetailTextBlock_zFH8XpydeD68" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE&#160;2 &#8211; <span id="xdx_829_zEATFVQb0qp3">CONSOLIDATED
BALANCE SHEET DETAIL</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_892_eus-gaap--PropertyPlantAndEquipmentTextBlock_zndr6DZw71U1" style="margin: 0"><span style="font-size: 10pt"><span id="xdx_8BE_zHWRXpwdOD49" style="display: none">Schedule of
Property Plant And Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureConsolidatedBalanceSheetDetailsAbstract_z7p2IfHAlRqh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)">
<tr style="vertical-align: bottom">
    <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49F_20210331_zCz7v32xtXAa" style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49A_20200331_zD6jfVUXPyoa" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: left">Property and equipment, net:</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z3BPmqjQLSv9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Leasehold improvements</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">139,197</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">139,197</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zcwACcdJH1u3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,476</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,724</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zTWOHfvNRM33" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Computer equipment and software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,383</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,882</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zXXrzTWCcmC8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Machinery and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">202,993</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">112,198</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_zhStRP3g6Mdk" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td><span style="display: none">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">451,049</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">353,001</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_z8azUF3TJ1jj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(152,091</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(51,693</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td><span style="display: none">Property and equipment, net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">298,958</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">301,308</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A4_z8yDspHtdiad" style="margin: 0"/>

<p id="xdx_893_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zizSZirDdEgi" style="margin: 0"><span id="xdx_8B4_zcJkXV60NCF2" style="display: none">Schedule of Accrued Expenses</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureConsolidatedBalanceSheetDetails2Abstract_z3esqbaMX4Bg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49D_20210331_zahbdjG7U326" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_495_20200331_z11U9drwWqZ2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>

<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: left; padding-bottom: 1pt">Accrued expenses:</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedWagesAndBonusMember_zZVbo88qYMUi" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Accrued wages and bonus</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">372,563</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">198,160</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedPlacementFeesMember_zMdz7KVF6jZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued placement fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1075">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedInterestMember_zjTar9XFERn" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,538</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1078">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedOtherExpensesMember_zyN8mqgMrjL" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,047</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_zdCf18Aoa407" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt"><span style="display: none">Accrued expenses</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">499,948</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">202,160</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A6_zujoonP5i0A8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ConsolidatedBalanceSheetDetailTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ConsolidatedBalanceSheetDetailTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureConsolidatedBalanceSheetDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureConsolidatedBalanceSheetDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295880539560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">NOTES PAYABLE</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--DebtDisclosureTextBlock_zAiJa8bB4pD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
4 &#8211; <span id="xdx_82B_zDANrQwEOcLj">CONVERTIBLE PROMISSORY NOTES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">From
February through April 2021, the Company sold $2,310,000 of convertible promissory notes (each an Original Notes and, collectively,
the Original Notes), at par in a private placement transaction effected pursuant to an exemption from the registration requirements
under the Securities Act of 1933, as amended. Effective April 30, 2021, pursuant to a revocation and replacement agreement between
each holder of an Original Note and the Company (the Revocation Agreement), the $2,310,000 of Original Notes and accrued interest
thereon as of April 30, 2021 were replaced with $2,360,550 aggregate principal amount of new Notes (as defined below). The Company
accounted for the replacement of the Original Notes in accordance with ASC 470 and recorded a loss on extinguishment of $<span id="xdx_900_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20210401__20211231_z7Gjzm5a3EVg">1,321,450</span>
and interest expense of $<span id="xdx_906_eus-gaap--AmortizationOfFinancingCosts_c20210401__20211231_zshpgyKP037h">70,647</span> for unamortized debt issuance costs as of April 30, 2021.</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In April
and May 2021, pursuant to a Securities Purchase Agreement by and between the Company and each investor (the SPA), the Company
sold to investors $<span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_c20210531__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zaxJPRzXweH3">4,250,000</span> aggregate principal amount of convertible promissory notes (the Notes) and warrants to purchase shares
of its common stock (the Warrants). The Notes are unsecured obligations of the Company with each Note having a stated maturity
date of 12 months from its issue date (the Issue Date). The Notes bear interest at a rate of 12% per annum, payable on maturity,
provided that, if the Company fails to pay any amounts when due under a Note, the interest rate increases to the greater of 16%
or the maximum amount permitted by law. Each Note may be prepaid at the Company&#8217;s option during the first 270 calendar days
following its Issue Date (the 270<sup>th</sup> day, the Trigger Date), subject to a 110% prepayment penalty on outstanding principal
and accrued interest then outstanding. No Note may be prepaid in whole or in part after the Trigger Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Notes
outstanding after the Trigger Date may be converted into shares of the Company&#8217;s common stock at an initial conversion price
of $8.61 per share; provided that a Note holder may not convert any portion of its Note that would cause it to beneficially own
in excess of 4.99% of the Company&#8217;s outstanding common stock. The conversion price and number of shares of Company common
stock issuable upon conversion of the Notes are subject to adjustment from time to time for subdivisions and consolidations of
shares and other standard dilutive and corporate events, as provided in the Notes. Subject to certain Exempt Issuances (as defined
in the Notes), if while a Note is outstanding, the Company sells, issues or grants any shares of its common stock or other securities
to acquire shares of common stock at a price per share less than the then conversion price, such conversion price shall be reduced
to such lesser price, and the number of conversion shares issuable upon conversion of the Notes shall be increased, as provided
in the Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">If the
Company completes an offering of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified
Capital Raise, as defined in the Notes), each Note holder will be required to convert its Adjusted Note Amount (as defined below)
into the securities of such Qualified Capital Raise. Adjusted Note Amount equals the product of (i) the sum of all outstanding
principal plus accrued interest on a Note, multiplied by (ii) 1.25.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Notes
contain a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal
or interest thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting
requirements under the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement,
(v) material restatements of the Company&#8217;s consolidated financial statements filed with the SEC, (vi) a holder&#8217;s inability
to rely on Rule 144 for sales of shares underlying the Notes, (vii) the Company&#8217;s common stock is suspended or halted from
trading and/or fails to be quoted or listed (as applicable) on the OTCQB, OTCQX, any tier of the NASDAQ Stock Market, the New
York Stock Exchange, or the NYSE American within 10 days thereafter, (viii) failure to file with the SEC a registration statement
covering the resale of shares of common stock underlying the Notes and Warrants within 60 calendar days following the Issue Date,
(ix) failure to cause such registration statement to become effective within 120 calendar days following the Issue Date, or (x)
certain mergers consolidations, business combinations and sales of all or substantially all of the Company&#8217;s assets in the
event the Company is not the survivor of such transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">Upon
an Event of Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will
be required to pay such Note holder the sum of (i) the product of (a) all then outstanding principal amount and accrued interest
thereon, multiplied by (b) 125%; and (ii) all collection costs including legal fees and expenses in connection therewith. At the
option of a Note holder, in the event the Company receives cash proceeds as a result of certain events, including, but not limited
to, payments from customers, issuances of debt or equity securities, exercise of warrants or asset sales, the Company will be
required to use such proceeds to repay all or any lesser outstanding amounts due under such holder&#8217;s Note.</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Notes
include covenants, representations, warranties, other payment obligations and agreements by the Company including, without limitation,
most-favored nation rights, rights of participation and first refusal and exchange rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In connection
with the issuance of the Notes, the Company issued Warrants to purchase in the aggregate 767,796 shares of its common stock at
an initial exercise price of $24.00 per share. The Warrants may be exercised for a period of five years from the Trigger Date,
provided that, if prior to the Trigger Date, the Company (i) completes a Qualified Capital Raise, the outstanding Warrants shall
be cancelled or (ii) prepays a holder&#8217;s Note(s) in whole or in part, such holder&#8217;s pro-rata number of Warrants shall
be cancelled. The fair value of the Warrants was $3,700,632, of which $2,379,182 was recorded as a debt discount, which is being
amortized to interest expense over the term of the Warrants, and $1,321,450 was recorded as a loss on debt extinguishment. The
Company calculated the fair value of the Warrants utilizing the Black-Scholes valuation model with the following assumptions:
volatility of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_c20210401__20211231_zsRt4WHqRwy2">88.98%</span>, risk-free interest rate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20211231_zLknLX55GhKe">0.86%</span>, a term of <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20211231_zGJvvNpm3bWh" title="::XDX::P5Y9M">5.75</span> years and a dividend yield of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dcpxH_c20210401__20211231_zLx04zbKA4ge" title="::XDX::0">zero</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In connection
with the April and May 2021 sales of the $4,250,000 aggregate principal amount of the Notes, the Company incurred debt issuance
costs of $116,000, which were recorded as a debt discount and are being amortized to interest expense over the term of the Notes
using the effective interest rate method. The interest expense attributable to the debt discount, comprising the debt issuance
costs and Warrants, during the three and nine months ended December 31, 2021 was $630,323 and $1,454,762, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The $6,610,550
aggregate principal amount of Notes are due and payable in full in the first quarter of fiscal 2023. Subsequent to the Trigger
Date, the Notes can be converted into <span id="xdx_90C_ecustom--NotesAndAccuredInterestCouldBeConvertedIntoCommonStock_iI_c20211231_zAX49DWsrmre">767,783</span> shares of common stock at a conversion price of $8.61 per share.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_z239wqwiF2ui" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 3 &#8211; <span id="xdx_82D_zcREI3129Eqe">NOTES PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>PPP Note</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">On April 24,
2020, the Company received a $368,780 unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was
established under the U.S. government&#8217;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note
to the Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration
Paycheck Protection Program Note (the Agreement) with the Lender evidencing the PPP Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 73.35pt 0 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The full amount
of the PPP Note is due in April 2022. Interest will accrue on the outstanding principal balance of the PPP Note at a fixed rate
of 1.0% per annum, which shall be deferred for 10 months after the covered period during which the Company used the proceeds.
The Company may prepay principal of the PPP Note at any time in any amount without penalty. The Agreement contains customary events
of default relating to, among other things, payment defaults, breach of representations and warranties or provisions of the PPP
Note. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts
owing from the Company, and/or filing suit and obtaining judgment against the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
applied to the Lender for forgiveness of the PPP Note in October 2020, and the amount which may be forgiven will be equal to the
sum of the payroll and benefit costs and covered rent and utility payments incurred by the Company, as calculated in accordance
with the terms of the CARES Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Convertible
Promissory Notes</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">In
February and March 2021, the Company sold $2,210,000 of convertible promissory notes (the Notes), at par in a private placement
transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended
(the 2021 Placement). The Notes bear interest at an annual rate of 12%, and interest is accrued or payable monthly in cash. The
Notes mature on September 30, 2021 (the Maturity Date) and may be prepaid prior to the Maturity Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">The
aggregate principal amount of the Notes plus accrued but unpaid interest thereon shall automatically convert upon the closing
of an offering of the Company&#8217;s equity securities to investors or a strategic corporate investor resulting in aggregate
gross proceeds to the Company of at least $5,000,000 (excluding conversion of the Notes or other convertible securities issued
for capital raising purposes) (a Qualified Financing). In the event of a Qualified Financing, all such outstanding principal and
accrued interest shall convert into the same equity securities purchased by and on the same terms and conditions as the other
investors in such Qualified Financing at a conversion price equal to 80% (a 20% discount) of the lowest price paid per unit or
share by investors in the Qualified Financing. In the event that additional bridge financing is obtained by the Company, the Notes
shall convert into the same securities and on the same terms and conditions as the other investors therein and all such purchases
will be treated as one, single round of financing going forward. As of March 31, 2021, the Notes could be converted into 770,305
shares of common stock, excluding the effects of any payments of interest in kind.</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">At
any time on or following the Maturity Date, the holders of the Notes may demand repayment of the Notes, and the Company shall
repay the outstanding aggregate principal amount plus accrued but unpaid interest thereon. The holders of the Notes, however,
retain the right for 30 days after the Maturity Date to convert all or part of the aggregate principal amount plus accrued but
unpaid interest on the Notes into the Company&#8217;s common stock at the conversion price of $2.87 per share or at a 20% discount
to any financing consummated during the 30-day period following the Maturity Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">If
a Qualified Financing has not occurred immediately prior to the consummation of a Change of Control (as defined below), the Note
holders shall have the option of either (i) converting all or any portion of the aggregate principal amount of the Notes plus
accrued but unpaid interest thereon into common stock of the Company at a conversion price equal to $2.87 per share or (ii) having
the Company repay the aggregate principal amount of the Notes and accrued but unpaid interest. The term &#8220;Change of Control&#8221;
means (i) a consolidation or merger of the Company with or into any other corporation or other entity or person, or any other
corporate reorganization, other than any such consolidation, merger or reorganization in which the shares of capital stock of
the Company immediately prior to such consolidation, merger or reorganization continue to represent a majority of the voting power
of the surviving entity immediately after such consolidation, merger or reorganization; (ii) any transaction or series of related
transactions to which the Company is a party in which in excess of 50% of the Company&#8217;s voting power is transferred; (iii)
the sale or transfer of all or substantially all of the Company&#8217;s assets, or the exclusive license of all or substantially
all of the Company&#8217;s material intellectual property; or (iv) the dissolution and winding up of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
incurred debt issuance costs of $88,800, which were recorded as a debt discount and are being amortized to interest expense over
the term of the Notes using the effective interest rate method. The interest expense related to the debt discount during
the year ended March 31, 2021 was approximately $13,000.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295874846232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zQz1HdeI7FFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>NOTE
6 &#8211; <span id="xdx_82D_z6GULZVoIzo8">STOCKHOLDERS&#8217; DEFICIT AND STOCK-BASED COMPENSATION</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
the three months ended December 31, 2021, the Company sold 30,865 shares of common stock to its chief executive officer and its
chairman of the board of directors, president, chief financial officer and treasurer, issued 8,334 shares of common stock to a
service provider and issued 5,775 shares to its non-employee directors under the Company&#8217;s outside director compensation
plan. At December 31, 2021, the Company had an obligation to issue 16,666 shares of common stock to service providers, and the
value of these shares was recorded as common stock issuable in the condensed consolidated balance sheet.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Amended
2017 Equity Incentive Plan </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In October
2017, the Company&#8217;s board of directors (the Board) approved the 2017 Equity Incentive Plan (the Plan) with <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20171031_ztEmafj12tal">1,000,000</span> shares
of common stock reserved for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved
for issuance under the Plan by <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200131_zlXA0kJN12F2">333,334</span> and <span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200831_zMSDt8zLhQSk">1,333,334</span> shares, respectively. Under the Plan, eligible employees, directors and consultants
may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based
awards and restricted stock units. The Plan is administered by the Board or, in the alternative, a committee designated by the
Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Stock-Based
Compensation Expense</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The expense
relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period,
based on the grant date fair value. The unamortized compensation cost, as of December 31, 2021, was $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20211231_zlB1owsTyga">7,419,022</span> related to stock
options and is expected to be recognized as expense over a weighted-average period of approximately <span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dxH_c20210401__20211231_zHpVu1aRNWu" title="::XDX::P2Y">two</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">During
the nine months ended December 31, 2021, the Company granted options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zoRiL3V4EeLf">723,269</span> shares of its common stock to employees,
directors and consultants. The options had 10-year terms, and <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zUHxuUD5tbBj">85,484</span> options vested immediately when granted. The fair value of
the options was determined to be $<span id="xdx_909_ecustom--FairValueofOptionGranted_c20210401__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMgkdlr2ZUMk">8,108,043</span> of which $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20210401__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfNzWohm5oJ">1,769,805</span> was recorded as stock-based compensation expense and included
in the condensed consolidated statement of operations for the nine months ended December 31, 2021.</span></p>







<p id="xdx_891_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zvoaga1a89yd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
assumptions were used in the fair value method calculations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BC_zoHpYNToBpPe" style="display: none">Schedule of Fair Value Assumptions</span></p>



<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zBie8INYQvq1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Three
    Months Ended<br/> December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Nine
    Months Ended<br/> December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: left"><span style="font-size: 10pt">Risk-free
    interest rates</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_zJhiCTvtdor5">1.26%</span> - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zFYXEYTjgfXj">1.36%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20201001__20201231_zgrZ8UmxTHRa">0.38%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_z8xm6yEUn6ze">0.8%</span> - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_z4F0L9F5VYCg">1.36%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20201231__srt--RangeAxis__srt--MinimumMember_zMAGWA6uQjTh">0.28%</span> - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20201231__srt--RangeAxis__srt--MaximumMember_zmxRF2Rnv4Gk">0.38%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_zzxbc1ec0iya">197%</span>
                                         - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zX9wuplYzrge">253%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20201001__20201231_zzEbfdv7ehvb">87%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_zmHwQ5WCgu2d">89%</span>
                                         - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_zgALPDHRxh5b">370%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20201231__srt--RangeAxis__srt--MinimumMember_z3J24CnpuBAf">87%</span>
                                         - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20201231__srt--RangeAxis__srt--MaximumMember_zTf56EI8vHUa">127%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Expected life (years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_z3uH1IqRNXW8">5.0</span>
                                         &#8211; <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zUli8eAzzafj">6.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231__srt--RangeAxis__srt--MinimumMember_zRuCprlQIXoe">5.2</span>
                                         &#8211; <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231__srt--RangeAxis__srt--MaximumMember_zOj6Ji4p1sYa">5.7</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_zy0bHBwbcbmj">5.0</span>
                                         - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_zu1julJ9OpCf">6.2</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20201231__srt--RangeAxis__srt--MinimumMember_zgqyty753UOh">5.0</span>
                                         - <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20201231__srt--RangeAxis__srt--MaximumMember_z5K54pvMIsg">6.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20211001__20211231_zm1YAE8gfGAg">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20201001__20201231_zc9a5wEnzU71">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20210401__20211231_zWrUnJCVcVV8">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20201231_zgll00aypvEi">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>





<p id="xdx_8A0_zt8mvG0EWljf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The fair
values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods
to establish the fair term of options as well as average volatility of three comparable organizations. The risk-free interest
rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant
date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never
paid dividends and has no intention to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company
accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zgPewvRZSuA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">A summary
of stock option activity under the Plan is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BF_zMfIkSaPKpo3" style="display: none">Schedule of Stock Option activity</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zJgKjtBn1Yde" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares<br/> Available<br/> for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Prices</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2021</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zwC7l1Fa7005" style="width: 8%; text-align: right">136,082</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmpnLVcwY3H" style="width: 8%; text-align: right">1,197,252</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5b8iKkQzy1l" style="width: 8%; text-align: right">5.25</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zczvsn3JQKFi" style="text-align: right">(60,774</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoueppVNmd15" style="text-align: right">60,774</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSqVkRYMnjPh" style="text-align: right">12.69</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKnwKSq88j1h" style="text-align: right">(1,836</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgshN5RbEzDh" style="border-bottom: Black 1pt solid; text-align: right">7,547</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3cy1HgyK8jh" style="border-bottom: Black 1pt solid; text-align: right">(7,547</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT43tyNwyf" style="border-bottom: Black 1pt solid; text-align: right">8.61</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Balance at June 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLN21uVqY9e3" style="text-align: right">81,089</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWS7z1Hgdljk" style="text-align: right">1,250,479</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziGgmlnX6b1i" style="text-align: right">5.58</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztHm9HiOjxM" style="text-align: right">1,333,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zw75AdIoqDyd" style="text-align: right">(396,384</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAUosEMtvCBd" style="text-align: right">396,384</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyFNIXkQzrj5" style="text-align: right">12.15</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRLRhaCnjRf6" style="text-align: right">(3,636</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyad6u5ObVd3" style="border-bottom: Black 1pt solid; text-align: right">49,213</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zTxde3atswIb" style="border-bottom: Black 1pt solid; text-align: right">(49,213</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQHd0IPPrYek" style="border-bottom: Black 1pt solid; text-align: right">7.02</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at September 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2QiQGPgV8T3" style="text-align: right">1,063,546</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5KsGdZdFMok" style="text-align: right">1,597,650</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zr46KajKTuM2" style="text-align: right">7.17</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLCJHdBqM5kc" style="text-align: right">(266,112</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5ZRQE89Yb73" style="text-align: right">259,559</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBSJy6ClQVAc" style="text-align: right">9.99</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx4DAV7jxxii" style="text-align: right">(5,775</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmghZMF6l164" style="border-bottom: Black 1pt solid; text-align: right">29,073</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zV9lNSrU3La7" style="border-bottom: Black 1pt solid; text-align: right">(11,256</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBuKoN8LsIr9" style="border-bottom: Black 1pt solid; text-align: right">7.24</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at December 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zApvYc0926E8" style="border-bottom: Black 2.5pt double; text-align: right">820,732</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziAAAHiBLCc3" style="border-bottom: Black 2.5pt double; text-align: right">1,845,953</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDJsNb4lL4fc" style="border-bottom: Black 2.5pt double; text-align: right">7.57</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">There were no stock options exercised during the nine months ended December 31, 2021 and 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_zHfLqyJ8vjpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table summarizes the range of outstanding and exercisable options as of December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B0_zjWp49Tt5yt7" style="display: none">Schedule of
Outstanding and Exercisable Option, Range</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zhuv6eC9oSy" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number<br/> Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in Years)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number<br/> Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%; padding-bottom: 1pt">$<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zfOh8Nh6lWy3">1.98</span> - $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zxbrZpd0Al24">17.70</span></td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDlPIupeKgEh" style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1,845,953</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxH_c20210401__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGGy1zqdjbL1" style="width: 8%; padding-bottom: 1pt; text-align: right" title="::XDX::P8Y1M17D">8.13</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVj3UdAANCp3" style="width: 8%; padding-bottom: 1pt; text-align: right">7.57</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zketqRJJRft7" style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1,011,586</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znJSsM8zPE36" style="width: 8%; padding-bottom: 1pt; text-align: right">5.10</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6lN4x67ZMvb" style="border-bottom: Black 1pt solid; width: 8%; text-align: right">3,564,268</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A4_z8FJHdEPWO81" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The intrinsic
value per share is calculated as the excess of the closing price of the common stock on the Company&#8217;s principal trading
market over the exercise price of the option at December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise
of stock options as financing cash flows in the consolidated statements of cash flows. For the nine months ended December 31,
2021 and 2020, there were no such tax benefits associated with the exercise of stock options.<b> </b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_808_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zjUWhAWCd1K7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>NOTE 5 &#8211;
<span id="xdx_82A_zCTmmfmICWHf">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b>Equity Compensation
Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In October 2017,
the Company&#8217;s board of directors (the Board) approved the 2017 Equity Incentive Plan (the 2017 Plan) with 3,000,000 shares
of common stock reserved for issuance. In January 2020, the Board approved an amendment to the 2017 Plan to increase the number
of shares reserved for issuance by 1,000,000 shares. Under the 2017 Plan, eligible employees, directors and consultants may be
granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards
and restricted stock units. The 2017 Plan is administered by the Board or, in the alternative, a committee designated by the Board.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The exercise
or purchase price of a stock option shall be calculated as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
    the case of an incentive stock option, (a) granted to employees, who, at the time of the grant of such incentive stock option
    own stock representing more than 10% of the voting power of all classes of stock of the Company, the per share exercise price
    shall be not less than 110% of the fair market value per share on the date of grant; or (b) granted to employees, other than
    to employees, described in the preceding clause, the per share exercise price shall be not less than 100% of the fair market
    value per share on the date of grant;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
    the case of a non-qualified stock option, the per share exercise price shall be not less than 100% of the fair market value
    per share on the date of grant unless otherwise determined by the Board; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(iii) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
    the case of other grants, such price as determined by the Board.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Board
is responsible for determining the consideration to be paid for the shares of common stock to be issued upon exercise or purchase.
The 2017 Plan generally does not allow for the transfer of awards, and the Board may amend, suspend or terminate the 2017 Plan
at any time.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Stock-Based
Compensation Expense</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The expense
relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period,
based on the grant date fair value. The unamortized compensation cost, as of March 31, 2021 was $2,242,352 related to stock options
and is expected to be recognized as expense over a weighted-average period of approximately 2 years.&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">During
the year ended March 31, 2021, options granted to purchase shares of its common stock to employees, directors and consultants
had 10-year terms and a grant-date fair value of $1,101,737. Options to purchase 10,476 shares vested immediately on the respective
grant dates.&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zvYq7IF9JyI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The following <span id="xdx_8B5_zlf1rY5Degjc">assumptions were used
in the fair-value method calculations</span>:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zoHuDK6s0nT1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Year
    ended March 31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2021</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 75%"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rates</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z3WdONB4SZo3" title="Risk-free interest rates">0.28%</span>
    - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zKXqL9Ish2u2">0.71%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zUL6Ejt736V7">0.77%</span>
    - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zm1j5c8ajwF2">2.37%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zTa7ch8pmPZj" title="Volatility">87%</span>
    - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_ziVZpTGts1Ki">127%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zYHYFJV41tZa">86%</span>
    - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zC5IcFOdVVE6">103%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    life (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zxbZfBQ3IN0l" title="Expected Life (years)">5.0</span>
    - <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_z1TUxfEn4EG1">6.0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zRjo0fMiYtB4">5.0</span>
    - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zjseC5rpXBNk">6.0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Dividend
    yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zznV59JTlHzb">&#8212;%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zzPv2kfTG5L1">&#8212;%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p id="xdx_8AC_zuhRbsCVqLn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The fair values
of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to
establish the fair term of options as well as average volatility of three comparable organizations. The risk-free interest rate
was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date
for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid
dividends and has no intention to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts
for forfeitures as they occur.</span></p>




<p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_znsC7EV5wvie" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">A summary of <span id="xdx_8BD_zo1WcKMoXVka">stock option activity
</span>under the 2017 Plan is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zJSj4aqevOpc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Available</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted Average</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2019</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331_zLweyHt3pxQh" style="width: 8%; text-align: right" title="Shares available for grant, beginning">490,031</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVmGRDLvVbFb" style="width: 8%; text-align: right">509,969</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRzl68rEqYJl" style="width: 8%; text-align: right">2.56</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_c20190401__20200331_zhAdxgDFNffd" style="text-align: right">333,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_iN_di_c20190401__20200331_zPsMwIKwoQAc" style="text-align: right">(572,402</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMPyaRvRz9dd" style="text-align: right">572,402</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zng6yBVex3Pe" style="text-align: right">6.75</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20190401__20200331_zfYa8LQ4ZHWg" style="border-bottom: Black 1pt solid; text-align: right">23,056</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2NYijcemSPe" style="border-bottom: Black 1pt solid; text-align: right">(23,056</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlC05erYxvwe" style="border-bottom: Black 1pt solid; text-align: right">6.75</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Balance at March 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331_z15feRx4wrj7" style="text-align: right">274,019</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1nYosdl6G92" style="text-align: right">1,059,315</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5YLernKnlpk" style="text-align: right">4.74</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_iN_di_c20200401__20210331_zJggddizapdi" style="text-align: right">(163,492</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLCxmcLIOV75" style="text-align: right">163,492</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZXcbDKJQol3" style="text-align: right">8.64</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20200401__20210331_zkXgvpN0sYMi" style="border-bottom: Black 1pt solid; text-align: right">25,555</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZ7eE89lFage" style="border-bottom: Black 1pt solid; text-align: right">(25,555</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbhsQtPUzcSh" style="border-bottom: Black 1pt solid; text-align: right">6.75</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at March 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331_zye6aVSk8FA5" style="border-bottom: Black 2.5pt double; text-align: right">136,082</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znw72iivgn5k" style="border-bottom: Black 2.5pt double; text-align: right">1,197,252</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0YFfXOhuZWl" style="border-bottom: Black 2.5pt double; text-align: right">5.25</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A4_zCZ32lEJywa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">There were no
stock options exercised during the years ended March 31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z4MDAK8NLx19" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table <span id="xdx_8BD_z7khsmxDY1Ib">summarizes the range of outstanding and exercisable options</span> as of March 31, 2021:</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zjQ9JdEOW2z5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 3)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in Years)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt">$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zzRBzMxdOvJi">1.98</span> - $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zxDphhvUO3l4">9.48</span></td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zs1oFVpZzC45" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">1,197,252</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtYxH_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDF6lDyhHc4a" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="::XDX::P8Y4M">8.25</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zz6JFas6hN48" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">5.25</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhDEwU7OVCq4" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">742,913</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtYxH_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zD0TjOxu1WX7" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="::XDX::P3Y11M16D">3.96</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoZStRXd9JH2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">8,763,260</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AB_zRfPGIO5nMhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The intrinsic
value per share is calculated as the excess of the closing price of the common stock on the Company&#8217;s principal trading
market over the exercise price of the option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise
of stock options as financing cash flows in the consolidated statements of cash flows. For the years ended March 31, 2021 and
2020, there were no such tax benefits associated with the exercise of stock options.<b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295880588840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_ziV6Qcjuipug" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 6 &#8211; <span id="xdx_820_zIsr1RW0bfL9">STOCKHOLDERS&#8217;
EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><i>Private Placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Between March
and December 2020, the Company completed a private placement of shares of its common stock (the 2020 Placement). The Company sold
<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200401__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsybujndopYi">320,796</span> shares of common stock, at a purchase price of $8.61 per share, for gross proceeds of $2,762,054. The Company paid placement
agent fees on the 2020 Placement of $52,256 during fiscal 2021. Under the terms of the common stock purchase agreements between
the Company and the investors, the Company must use commercially reasonable efforts to file a registration statement with the
SEC to register for resale the shares of common stock sold.</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 &#8211; INCOME TAXES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"><span style="font-size: 10pt">The income tax provision (benefit)
consisted of the following:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Current portion:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.9pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; padding-bottom: 1pt; padding-left: 8.9pt">State</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1,600</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1,600</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Deferred portion:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.9pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,931,390</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,180,434</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 1pt; padding-left: 8.9pt">State</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(576,868</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(391,865</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,508,258</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,572,299</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,508,258</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,572,299</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,600</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"><span style="font-size: 10pt">As of March 31, 2021,
the Company had net operating loss carryforwards (NOLs) of approximately $13,954,000 for federal income tax purposes and $14,019,000
for state income tax purposes. These NOLs are available to reduce future taxable income and will expire at various times from 2037 through
2041, except federal NOLs from fiscal 2018, 2019 and 2020 which will never expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"><span style="font-size: 10pt">The Company
also had federal research and development tax credit carryforwards of approximately $535,000, which will begin expiring at various times
from 2038 through 2040, and state research and development credits of approximately $141,000, which do not have an expiration date.</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"><span style="font-size: 10pt">A reconciliation of
income taxes provided at the federal statutory rate (21% for fiscal 2021 and 2020) to the actual income tax provision is as follows:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Federal statutory rate</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">(21</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State tax rate, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Section 179 assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">34</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">31</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">Significant components of the Company&#8217;s
deferred tax assets and liabilities were:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Net operating loss carryforwards</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,909,434</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,965,118</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">554,892</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">364,989</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,039</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,842</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reserves, accruals &amp; other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(79,878</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,181</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt">Research and development tax credits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">646,296</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">237,716</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.9pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,012,705</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,567,484</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,012,705</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,567,484</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 8.9pt">Deferred tax assets, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Based on the available
information and other factors, management believes it is more likely than not that the net deferred tax assets at March 31, 2021 and
2020, will not be fully realizable. Accordingly, management has recorded a full valuation allowance against its net deferred tax assets
at March 31, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 0.5in"><span style="font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Management has evaluated
and concluded that there were no material uncertain tax positions requiring recognition in the Company&#8217;s consolidated financial
statements at March 31, 2021 and 2020. The Company does not expect any significant changes in its unrecognized tax benefits within twelve
months of the reporting date.</span></p>





<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295880535496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ROYALTY AGREEMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureRoyaltyAgreementAbstract', window );"><strong>Royalty Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_RoyaltyAgreementDisclosureTextBlock', window );">ROYALTY AGREEMENT</a></td>
<td class="text"><p id="xdx_803_ecustom--RoyaltyAgreementDisclosureTextBlock_zkaeltItnZK7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 8 &#8211; <span id="xdx_825_zCbrVhHYqJ95">ROYALTY AGREEMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">In July 2017,
the Company entered into a royalty agreement with its founder, chief executive officer and major shareholder (the Founder). Pursuant
to the agreement, the Founder assigned and transferred all of his rights in the intellectual property of Quasuras in return for
future royalty payments on the Company&#8217;s product. The Company is obligated to make royalty payments under the agreement
to the Founder on any sales of the royalty product sold or otherwise commercialized by the Company equal to (a) $0.75 on each
sale of a royalty product or (b) 5% of the gross sale price of the royalty product, whichever is less. The royalty payments will
cease, and the agreement will terminate, at such time as the total sum of royalty payments actually paid to the Founder, pursuant
to the agreement, reaches $10,000,000. The Company has the option to terminate the agreement at any time upon payment, to the
Founder, of the difference between total royalty payments actually made to him to date and the sum of $10,000,000. All payments
of the royalties, if due, for the preceding quarter, will be made by the Company to the Founder within thirty days after the end
of each calendar quarter.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureRoyaltyAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureRoyaltyAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_RoyaltyAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_RoyaltyAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295880618248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RETIREMENT SAVINGS PLAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureRetirementSavingsPlanAbstract', window );"><strong>Retirement Savings Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_RetirementSavingsPlanDisclosureTextBlock', window );">RETIREMENT SAVINGS PLAN</a></td>
<td class="text"><p id="xdx_802_ecustom--RetirementSavingsPlanDisclosureTextBlock_zX9EcFTxDFYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b>NOTE 9 &#8211; <span id="xdx_822_zQx4uQmdvPXg">RETIREMENT SAVINGS
PLAN</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Effective March
2020, the Company adopted the Modular Medical, Inc. 401(k) Plan (the Savings Plan), which qualifies as a thrift plan under Section&#160;401(k)
of the Internal Revenue Code. Full-time and part-time employees who are at least 21&#160;years of age are eligible to participate
in the Savings Plan at the time of hire. Participants may contribute up to 15% of their earnings to the Savings Plan. The Plan
became effective and began accepting participant contributions in April 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureRetirementSavingsPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureRetirementSavingsPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_RetirementSavingsPlanDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_RetirementSavingsPlanDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295874968216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p id="xdx_840_ecustom--LiquidityPolicyTextBlock_z9z2ekIUfun5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86B_zSn8fkw1P1Oc">Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Financial
Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15), <i>Going Concern</i>, requires management
to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#8217;s
ability to continue as a going concern within one year after the date that the financial statements are issued. If management
identifies conditions or events that raise substantial doubt about an entity&#8217;s ability to continue as a going concern, management
must consider if there are plans that are probable to be implemented, and whether it is probable that the plans will mitigate
the conditions or events raising the substantial doubt about the entity&#8217;s ability to continue as a going concern. If the
substantial doubt is not alleviated after consideration of management&#8217;s plans, the entity must include a statement in the
notes to the financial statements indicating that there is substantial doubt about the entity&#8217;s ability to continue as a
going concern within one year after the date that the financial statements are issued including: 1) the principal conditions or
events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern, 2) management&#8217;s evaluation
of the significance of those conditions or events in relation to the entity&#8217;s ability to meet its obligations, and 3) management&#8217;s
plans to attempt to mitigate the conditions or events causing the substantial doubt about the entity&#8217;s ability to continue
as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development
and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant
product revenues to achieve profitability. The Company&#8217;s expected operating losses and cash burn and the need to repay the
convertible promissory notes and accrued interest in the first half of 2022 raise substantial doubt about the Company&#8217;s
ability to continue as a going concern within one year after the date that these financial statements are issued. Implementation
of the Company&#8217;s plans and its ability to continue as a going concern will depend upon the Company&#8217;s ability to raise
additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no
assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and,
if available, that such capital will be offered on terms and conditions acceptable to the Company. As disclosed in note 9, the
Company recently sold shares of its common stock to two of its officers, obtained access to a credit facility and filed a registration
statement to offer shares of its common stock. The Company&#8217;s operating needs include the planned costs to operate its business,
including amounts required to repay its convertible promissory notes (if not converted), fund working capital and capital expenditures.
The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many factors, including
the Company&#8217;s ability to successfully commercialize its product, competing technological and market developments, and the
need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its
product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash. These condensed consolidated financial
statements do not include any adjustments that might result from this uncertainty.</span></p>






<span></span>
</td>
<td class="text"><p id="xdx_843_ecustom--LiquidityPolicyTextBlock_z4QrIhxBDxHj" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0"><span style="font-size: 10pt"><b><span id="xdx_86D_zDQdXEmUbbvb">Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="font-size: 10pt">Financial
Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15),&#160;<i>Going&#160;</i>Concern,
requires management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt
about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are
issued.&#160;If management identifies conditions or events that raise substantial doubt about an entity&#8217;s ability to continue
as a going concern, management must consider if there are plans that are probable to be implemented, and whether it is probable
that the plans will mitigate the conditions or events raising the substantial doubt about the entity&#8217;s ability to continue
as a going concern.&#160;If the substantial doubt is not alleviated after consideration of management&#8217;s plans, the entity
must include a statement in the notes to the financial statements indicating that there is substantial doubt about the entity&#8217;s
ability to continue as a going concern within one year after the date that the financial statements are issued including: 1) the
principal conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern, 2)
management&#8217;s evaluation of the significance of those conditions or events in relation to the entity&#8217;s ability to meet
its obligations, and 3) management&#8217;s plans to attempt to mitigate the conditions or events causing the substantial doubt
about the entity&#8217;s ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The Company
expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development
and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant
product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#8217;s ability to continue
as a going concern within one year after the date that these consolidated financial statements are issued. Implementation of the
Company&#8217;s plans and its ability to continue as a going concern will depend upon the Company&#8217;s ability to raise additional
capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance
that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available,
that such capital will be offered on terms and conditions acceptable to the Company.&#160; As discussed in notes 3 and 11, in
February 2021, the Company commenced a private placement of its convertible promissory notes to investors to fund its operations.
In addition, during fiscal 2021, the Company obtained additional equity financing through a private placement of its common stock
(see note 6), and the Company obtained a loan from Silicon Valley Bank in April 2020 (see notes 3 and 12).</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company&#8217;s
operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital
expenditures. The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many factors,
including the Company&#8217;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement
its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash. These consolidated financial statements
do not include any adjustments that might result from this uncertainty.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zg1kLg1u7ymh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: left"><span style="font-size: 10pt"><b><span id="xdx_866_zzUiA2s82eS6">Basis
of Presentation </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">The Company&#8217;s
fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in these notes to the condensed consolidated
financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2022 refers
to the fiscal year ending March 31, 2022). The condensed consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">The accompanying
condensed consolidated financial statements of the Company have been prepared without audit. The condensed consolidated balance
sheet as of March 31, 2021 has been derived from the audited consolidated financial statements at that date. Certain information
and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted
in the United States (GAAP) have been condensed or omitted in accordance with these rules and regulations of the Securities and
Exchange Commission (SEC).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">In the
opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting
only of normal recurring adjustments) necessary to summarize fairly the Company&#8217;s financial position, results of operations
and cash flows for the interim periods presented. The operating results for the three months ended December 31, 2021 are not necessarily
indicative of the results that may be expected for the year ending March 31, 2022 or for any other future period.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z2QiEAE6btr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_862_zgcZE7UT1anf">Basis of
Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The consolidated
financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany
transactions and balances have been eliminated in consolidation. The Company&#8217;s fiscal year ends on March 31 of each calendar
year.<b>&#160;</b>Certain prior year amounts have been reclassified for consistency with the current period presentation. These
reclassifications had no effect on the reported results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><p id="xdx_843_ecustom--ReverseStockSplitPolicyTextBlock_zLxBVkzxzg51" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><span style="font-size: 10pt"><b><i><span id="xdx_868_zzQnHUeQsOQa">Reverse Stock Split</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20211123__20211124_zbRbXZoxiQj8">On November
24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary
of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company&#8217;s shares of common stock.</span> Such amendment
and ratio were previously approved by a majority of the Company&#8217;s stockholders and the board of directors. As a result of
the reverse stock split, which was effective November 29, 2021, every three shares of the Company&#8217;s pre-reverse split outstanding
common stock were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common
stock holders were not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Split
were rounded up to the nearest whole share. All stock options outstanding and common stock reserved for issuance under the
Company&#8217;s equity incentive plans and warrants outstanding immediately prior to the reverse stock split were adjusted by
dividing the number of affected shares of common stock by three (3) and, as applicable, multiplying the exercise price by three
(3), as a result of the reverse stock split.</span></p>





<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--UseOfEstimates_zoPl13e0kP2d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_869_zxNVb9p9jHN6">Use
of Estimates </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">The preparation
of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of
the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates
may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--UseOfEstimates_zjb03aSEOl9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86E_zkVTFpwCYJTh">Use of Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The preparation
of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues
and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income
taxes. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Reportable Segment</a></td>
<td class="text"><p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWeoFIr7QlXe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_863_zvh4FPiSwkPe">Reportable
Segment </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">The Company
operates in <span id="xdx_906_eus-gaap--NumberOfOperatingSegments_dc_uNumber_c20210401__20211231_zevLYwcoxte5">one</span> business segment and uses one measurement of profitability for its business.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zEBGwLnCl838" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_861_zYSzqPmtkea">Reportable Segment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The Company operates in one business
segment and uses one measurement of profitability for its business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zZZNMr8lQ3V2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_865_zTNsevdrL2h3">Research
and Development</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">The Company
expenses research and development expenditures as incurred.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIDNnS7C5Ryi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86F_zIfOdHenFOg9">Research
and Development</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
expenses research and development expenditures as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative</a></td>
<td class="text"><p id="xdx_841_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z58yieOnj0u9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86A_zpfdCgZFzn8">General
and Administrative </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt">General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting
fees, and office and other administrative expenses.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84A_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zslkeDbN2qj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86D_zGAah61b4eJa">General and
Administrative</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">General and
administrative expense consists primarily of payroll and benefit related costs, rent, office expenses, equipment supplies and
meetings and travel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zzo1rW1DtNX7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86E_zPLJpIi6iP3g">Concentration
of Credit Risk </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Financial
instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains
its cash balances at high-quality financial institutions within the United States, which are insured by the Federal Deposit Insurance
Corporation up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss
due to financial institution failure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_z5RHgVDh9VL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_868_zhvjzB3hriT2">Concentration
of Credit Risk</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Financial instruments
that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents. Cash and
cash equivalents are deposited with high credit-quality institutions within the United States, which are insured by the Federal
Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p id="xdx_847_ecustom--RisksAndUncertaintiesPolicyTextBlock_z5k8Yx9Zt5I5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_861_zA1ZtrM00522">Risks
and Uncertainties </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing technology and customer requirements, limited operating history and the volatility
of public markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><i>COVID-19</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">The global
outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains,
significantly restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in-place&#8221;
and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#8217;s operational
and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions
taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company&#8217;s
control, and cannot be predicted.</span></p>





<span></span>
</td>
<td class="text"><p id="xdx_84F_ecustom--RisksAndUncertaintiesPolicyTextBlock_zU4HzJXoI7S" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86F_zvwI2K5ZXTqd">Risks and
Uncertainties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public
markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><i>COVID-19</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt">The global
outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply
chains, significantly restricted travel and transportation, resulted in mandated closures and orders to &#8220;shelter-in-place&#8221;
and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#8217;s operational
and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions
taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company&#8217;s
control, and cannot be predicted.</span></p>





<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zKjab441Int8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_865_zwxlbtu427x1">Cash
and Cash Equivalents </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Cash
and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and highly liquid debt instruments
with original maturities of three months or less.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zRAzlxQ0y94d" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_863_z90kSs4OLyka">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Cash and cash
equivalents include cash in hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with
original maturities of three months or less.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z9QabmbzvQBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86F_zJqlZcaMfrYg">Property
&amp; Equipment </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Property
and equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful
lives of the assets, generally <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxH_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_zaJ33kMbcei9" title="::XDX::P3Y">three</span> to <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxH_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_z7a40rLLRfAk" title="::XDX::P5Y">five</span> years. Depreciation is recorded in operating expenses in the condensed consolidated
statements of operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of
their estimated useful life or the lease term, and amortization is recorded in operating expenses in the condensed consolidated
statements of operations.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_844_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zk1Cd3Wid9k2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_867_zUcEsPUJ4DLc">Property and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Property and
equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxH_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z0PB92ihRM74" title="::XDX::P3Y">three</span> to <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxH_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zVoGulgcYkX2" title="::XDX::P5Y">five</span> years. Depreciation is recorded in operating expenses in the consolidated statements of
operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated
useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z6gGPV0CA5hh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86A_zU4nuxpUaHsj">Fair
Value of Financial Instruments </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Level
                                         1 inputs to the valuation methodology are quoted prices for identical assets or liabilities
                                         in active markets.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Level
                                         2 inputs to the valuation methodology include quoted prices for similar assets and liabilities
                                         in active markets, and inputs that are observable for the asset or liability, either
                                         directly or indirectly, for substantially the full term of the financial instrument.</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Symbol">&#183;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Level
                                         3 inputs to the valuation methodology are unobservable and significant to the fair value
                                         measurement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Due to
their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses approximate fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zhjQ4qzLxNwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_86B_z3q4LBjYHSv1">Fair Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs
    that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial
    instrument.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Symbol">&#183;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Due to their
short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Per-Share Amounts</a></td>
<td class="text"><p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zo9FYsK7bo2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_861_zUBEGqHISegh">Per-Share
Amounts </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Basic
net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding
during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period.
For the nine months ended December 31, 2021 and 2020, outstanding options to purchase <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20211231_zjB5ywqmGkoe">1,967,188</span> and <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20201231_zHT92n9jnntk">1,170,863</span> shares of common
stock, respectively, were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_z04lF1yOv96e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86B_zNciwlCAEoM4">Per-Share
Amounts&#160;</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Basic net loss
per share is computed by dividing net loss for the period by the weighted-average number of shares of common stock outstanding
during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period.
For the years ended March 31, 2021 and 2020, <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20210331_z7FZlwLQa8h7">1,197,252</span> and <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190401__20200331_zKybxb95oDpl">1,059,315</span> outstanding options to purchase common stock were excluded
from the calculation of diluted net loss per share because their effect would be anti-dilutive. &#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><p id="xdx_844_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zKt0uGP8yu0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_862_zncbUgeI7kCi">Reclassification
</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt">Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no
effect on the reported results of operations or cash flows.<b> </b></span></p>






<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zI1mPvysuMpd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_864_zjEy9Mo68f6d">Comprehensive
Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly,
comprehensive loss may include certain changes in equity that are excluded from net loss. For the three and nine months ended
December 31, 2021 and 2020, the Company&#8217;s comprehensive loss was the same as its net loss.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zkBl9gDn6xMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_86B_z6I11cISyor1">Comprehensive&#160;Loss</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly,
comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2021 and
2020, the Company&#8217;s comprehensive loss was the same as its net loss.</span></p>





<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncement</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zcNdW5Ao75f6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b>Recently
Adopted Accounting Pronouncement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">In August
2020, the FASB issued ASU No. 2020-06, <i>Debt</i> <i>with Conversion and Other Options</i> <i>(Subtopic 470-20) and Derivatives
and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments and Contracts in an
Entity&#8217;s Own Equity </i>(ASU 2020-06)<i>.</i> ASU 2020-06 simplifies the accounting for convertible instruments by removing
major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single
liability instrument with no separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions
that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts
to qualify for it. ASU 2020-06 also simplifies the diluted net income per share calculation in certain areas. The new guidance
is effective for annual and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years
beginning after December 15, 2020, and interim periods within those fiscal years. The Company early adopted ASU 2020-06 effective
April 1, 2021, and the impact of the adoption was not material to the Company&#8217;s consolidated financial statements.</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_849_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z3Tp69wE9iP" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_869_zNRpWSNYg7F3">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the
requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock
options on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards
on the date of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number
of highly complex and subjective variables. These variables include, but are not limited to, the expected stock price&#160;volatility
over the term of the awards, and projected stock option exercise behaviors.</span></p>





<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zPlCSJXYVvMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt"><b><span id="xdx_863_zszo70i8EdZa">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#8217;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to
affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that
all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management
believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company
has recorded a full valuation allowance.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
accounts for uncertain tax positions in accordance with FASB Accounting Standards Codification (ASC) Topic 740,&#160;<i>Income
Taxes</i>. When tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing
authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that
would be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements in the period
during which, based on all available evidence, management believes it is more likely than not that the position will be sustained
upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated
with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount
of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The
portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as
a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and
penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits
is classified as interest expense and penalties are classified in selling, general and administrative expenses in the consolidated
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company
files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. All tax returns
from 2016 to 2020 may be subject to examination by the U.S. federal and state tax authorities.&#160; As of March 31, 2021, the
Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295874948824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Future minimum payments under the facility operating lease, net of the lease incentive</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zJmxZubEG2ql" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8B0_zxWDKwGCiRO8">Future
minimum payments under the facility operating lease</span>, as of December 31, 2021, are listed in the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify"/>

<span></span>
</td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zwsEbf5hBpr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt"><span id="xdx_8B4_z4ymE4sowwz9">Future minimum
payments under the facility operating lease, net of the lease incentive</span>, as of March 31, 2021, are listed in the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureLeaseDetailsAbstract', window );">LEASES</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--DisclosureLeaseDetailsAbstract_zI3Kg6Yps0F5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Annual Fiscal Years</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20211231_z2XAUWdNaUfg" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Operating<br/> lease</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_maOLFMPz6XG_zdjbLZgmxOe3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 87%; text-align: left">2022</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">38,358</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_maOLFMPz6XG_zqAa2Rf3FnEd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158,028</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_maOLFMPz6XG_zzhclJCqGXo3" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,692</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_ecustom--OperatingLeasesImputedInterest_iI_maOLFMPz6XG_z073Amdjcmm7" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt; padding-bottom: 1pt">Imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(20,049</td><td style="text-align: left; padding-bottom: 1pt">)</td></tr>
<tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iTI_mtOLFMPz6XG_zN6ZgoIM8uQf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">217,029</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureLeasesDetailsAbstarct', window );">LEASES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureLeasesDetailsAbstarct_zaw73crHXSE8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - LEASES (Details)">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20210331_zrL4AFPyLXnl" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Operating</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><b>Annual
    Fiscal Years</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>lease</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_zVkfNZy9FY0h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 87%"><span style="font: 10pt Times New Roman, Times, Serif">2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">153,432</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_znDX2jMH8Bvk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">158,028</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_zuf1bKMgk1Tf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">40,692</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Less:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_402_ecustom--OperatingLeasesImputedInterest_iI_zAvxbfezdWk1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 17.3pt"><span style="font: 10pt Times New Roman, Times, Serif">Imputed
    interest</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(42,297</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_zBAFDAn0JDSa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Present value
    of lease liabilities</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">309,855</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureLeaseDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureLeaseDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureLeasesDetailsAbstarct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureLeasesDetailsAbstarct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295874895128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; DEFICIT AND STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zvoaga1a89yd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
assumptions were used in the fair value method calculations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BC_zoHpYNToBpPe" style="display: none">Schedule of Fair Value Assumptions</span></p>



<span></span>
</td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zvYq7IF9JyI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The following <span id="xdx_8B5_zlf1rY5Degjc">assumptions were used
in the fair-value method calculations</span>:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureStockBasedCompensationDetailsAbstract', window );">STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zBie8INYQvq1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Three
    Months Ended<br/> December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Nine
    Months Ended<br/> December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: left"><span style="font-size: 10pt">Risk-free
    interest rates</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_zJhiCTvtdor5">1.26%</span> - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zFYXEYTjgfXj">1.36%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20201001__20201231_zgrZ8UmxTHRa">0.38%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_z8xm6yEUn6ze">0.8%</span> - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_z4F0L9F5VYCg">1.36%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20201231__srt--RangeAxis__srt--MinimumMember_zMAGWA6uQjTh">0.28%</span> - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20201231__srt--RangeAxis__srt--MaximumMember_zmxRF2Rnv4Gk">0.38%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_zzxbc1ec0iya">197%</span>
                                         - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zX9wuplYzrge">253%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20201001__20201231_zzEbfdv7ehvb">87%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_zmHwQ5WCgu2d">89%</span>
                                         - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_zgALPDHRxh5b">370%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20201231__srt--RangeAxis__srt--MinimumMember_z3J24CnpuBAf">87%</span>
                                         - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20201231__srt--RangeAxis__srt--MaximumMember_zTf56EI8vHUa">127%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Expected life (years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_z3uH1IqRNXW8">5.0</span>
                                         &#8211; <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zUli8eAzzafj">6.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231__srt--RangeAxis__srt--MinimumMember_zRuCprlQIXoe">5.2</span>
                                         &#8211; <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231__srt--RangeAxis__srt--MaximumMember_zOj6Ji4p1sYa">5.7</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_zy0bHBwbcbmj">5.0</span>
                                         - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_zu1julJ9OpCf">6.2</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20201231__srt--RangeAxis__srt--MinimumMember_zgqyty753UOh">5.0</span>
                                         - <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20201231__srt--RangeAxis__srt--MaximumMember_z5K54pvMIsg">6.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20211001__20211231_zm1YAE8gfGAg">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20201001__20201231_zc9a5wEnzU71">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20210401__20211231_zWrUnJCVcVV8">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20201231_zgll00aypvEi">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zoHuDK6s0nT1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Year
    ended March 31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2021</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 75%"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rates</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z3WdONB4SZo3" title="Risk-free interest rates">0.28%</span>
    - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zKXqL9Ish2u2">0.71%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zUL6Ejt736V7">0.77%</span>
    - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zm1j5c8ajwF2">2.37%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zTa7ch8pmPZj" title="Volatility">87%</span>
    - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_ziVZpTGts1Ki">127%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zYHYFJV41tZa">86%</span>
    - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zC5IcFOdVVE6">103%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    life (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zxbZfBQ3IN0l" title="Expected Life (years)">5.0</span>
    - <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_z1TUxfEn4EG1">6.0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zRjo0fMiYtB4">5.0</span>
    - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zjseC5rpXBNk">6.0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Dividend
    yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zznV59JTlHzb">&#8212;%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zzPv2kfTG5L1">&#8212;%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option activity</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zgPewvRZSuA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">A summary
of stock option activity under the Plan is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BF_zMfIkSaPKpo3" style="display: none">Schedule of Stock Option activity</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_znsC7EV5wvie" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">A summary of <span id="xdx_8BD_zo1WcKMoXVka">stock option activity
</span>under the 2017 Plan is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureStockBasedCompensationDetails2Abstract', window );">STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zJgKjtBn1Yde" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares<br/> Available<br/> for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Prices</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2021</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zwC7l1Fa7005" style="width: 8%; text-align: right">136,082</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmpnLVcwY3H" style="width: 8%; text-align: right">1,197,252</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5b8iKkQzy1l" style="width: 8%; text-align: right">5.25</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zczvsn3JQKFi" style="text-align: right">(60,774</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoueppVNmd15" style="text-align: right">60,774</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSqVkRYMnjPh" style="text-align: right">12.69</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKnwKSq88j1h" style="text-align: right">(1,836</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgshN5RbEzDh" style="border-bottom: Black 1pt solid; text-align: right">7,547</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3cy1HgyK8jh" style="border-bottom: Black 1pt solid; text-align: right">(7,547</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT43tyNwyf" style="border-bottom: Black 1pt solid; text-align: right">8.61</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Balance at June 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLN21uVqY9e3" style="text-align: right">81,089</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWS7z1Hgdljk" style="text-align: right">1,250,479</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziGgmlnX6b1i" style="text-align: right">5.58</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztHm9HiOjxM" style="text-align: right">1,333,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zw75AdIoqDyd" style="text-align: right">(396,384</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAUosEMtvCBd" style="text-align: right">396,384</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyFNIXkQzrj5" style="text-align: right">12.15</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRLRhaCnjRf6" style="text-align: right">(3,636</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyad6u5ObVd3" style="border-bottom: Black 1pt solid; text-align: right">49,213</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zTxde3atswIb" style="border-bottom: Black 1pt solid; text-align: right">(49,213</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQHd0IPPrYek" style="border-bottom: Black 1pt solid; text-align: right">7.02</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at September 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2QiQGPgV8T3" style="text-align: right">1,063,546</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5KsGdZdFMok" style="text-align: right">1,597,650</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zr46KajKTuM2" style="text-align: right">7.17</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLCJHdBqM5kc" style="text-align: right">(266,112</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5ZRQE89Yb73" style="text-align: right">259,559</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBSJy6ClQVAc" style="text-align: right">9.99</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx4DAV7jxxii" style="text-align: right">(5,775</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmghZMF6l164" style="border-bottom: Black 1pt solid; text-align: right">29,073</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zV9lNSrU3La7" style="border-bottom: Black 1pt solid; text-align: right">(11,256</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBuKoN8LsIr9" style="border-bottom: Black 1pt solid; text-align: right">7.24</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at December 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zApvYc0926E8" style="border-bottom: Black 2.5pt double; text-align: right">820,732</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziAAAHiBLCc3" style="border-bottom: Black 2.5pt double; text-align: right">1,845,953</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDJsNb4lL4fc" style="border-bottom: Black 2.5pt double; text-align: right">7.57</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zJSj4aqevOpc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Available</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted Average</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2019</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331_zLweyHt3pxQh" style="width: 8%; text-align: right" title="Shares available for grant, beginning">490,031</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVmGRDLvVbFb" style="width: 8%; text-align: right">509,969</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRzl68rEqYJl" style="width: 8%; text-align: right">2.56</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_c20190401__20200331_zhAdxgDFNffd" style="text-align: right">333,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_iN_di_c20190401__20200331_zPsMwIKwoQAc" style="text-align: right">(572,402</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMPyaRvRz9dd" style="text-align: right">572,402</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zng6yBVex3Pe" style="text-align: right">6.75</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20190401__20200331_zfYa8LQ4ZHWg" style="border-bottom: Black 1pt solid; text-align: right">23,056</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2NYijcemSPe" style="border-bottom: Black 1pt solid; text-align: right">(23,056</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlC05erYxvwe" style="border-bottom: Black 1pt solid; text-align: right">6.75</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Balance at March 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331_z15feRx4wrj7" style="text-align: right">274,019</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1nYosdl6G92" style="text-align: right">1,059,315</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5YLernKnlpk" style="text-align: right">4.74</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_iN_di_c20200401__20210331_zJggddizapdi" style="text-align: right">(163,492</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLCxmcLIOV75" style="text-align: right">163,492</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZXcbDKJQol3" style="text-align: right">8.64</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20200401__20210331_zkXgvpN0sYMi" style="border-bottom: Black 1pt solid; text-align: right">25,555</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZ7eE89lFage" style="border-bottom: Black 1pt solid; text-align: right">(25,555</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbhsQtPUzcSh" style="border-bottom: Black 1pt solid; text-align: right">6.75</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at March 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331_zye6aVSk8FA5" style="border-bottom: Black 2.5pt double; text-align: right">136,082</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znw72iivgn5k" style="border-bottom: Black 2.5pt double; text-align: right">1,197,252</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0YFfXOhuZWl" style="border-bottom: Black 2.5pt double; text-align: right">5.25</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">Schedule of Outstanding and Exercisable Option, Range</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_zHfLqyJ8vjpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table summarizes the range of outstanding and exercisable options as of December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B0_zjWp49Tt5yt7" style="display: none">Schedule of
Outstanding and Exercisable Option, Range</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z4MDAK8NLx19" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table <span id="xdx_8BD_z7khsmxDY1Ib">summarizes the range of outstanding and exercisable options</span> as of March 31, 2021:</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureStockBasedCompensationDetails3Abstract', window );">STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zhuv6eC9oSy" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number<br/> Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in Years)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number<br/> Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%; padding-bottom: 1pt">$<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zfOh8Nh6lWy3">1.98</span> - $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zxbrZpd0Al24">17.70</span></td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDlPIupeKgEh" style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1,845,953</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxH_c20210401__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGGy1zqdjbL1" style="width: 8%; padding-bottom: 1pt; text-align: right" title="::XDX::P8Y1M17D">8.13</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVj3UdAANCp3" style="width: 8%; padding-bottom: 1pt; text-align: right">7.57</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zketqRJJRft7" style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1,011,586</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znJSsM8zPE36" style="width: 8%; padding-bottom: 1pt; text-align: right">5.10</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6lN4x67ZMvb" style="border-bottom: Black 1pt solid; width: 8%; text-align: right">3,564,268</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zjQ9JdEOW2z5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 3)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in Years)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt">$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zzRBzMxdOvJi">1.98</span> - $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zxDphhvUO3l4">9.48</span></td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zs1oFVpZzC45" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">1,197,252</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtYxH_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDF6lDyhHc4a" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="::XDX::P8Y4M">8.25</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zz6JFas6hN48" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">5.25</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhDEwU7OVCq4" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">742,913</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtYxH_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zD0TjOxu1WX7" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="::XDX::P3Y11M16D">3.96</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoZStRXd9JH2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">8,763,260</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureStockBasedCompensationDetails2Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureStockBasedCompensationDetails2Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureStockBasedCompensationDetails3Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureStockBasedCompensationDetails3Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureStockBasedCompensationDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureStockBasedCompensationDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295877788632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEET DETAIL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureConsolidatedBalanceSheetDetailAbstract', window );"><strong>Consolidated Balance Sheet Detail</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property Plant And Equipment</a></td>
<td class="text"><p id="xdx_892_eus-gaap--PropertyPlantAndEquipmentTextBlock_zndr6DZw71U1" style="margin: 0"><span style="font-size: 10pt"><span id="xdx_8BE_zHWRXpwdOD49" style="display: none">Schedule of
Property Plant And Equipment</span></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureConsolidatedBalanceSheetDetailsAbstract', window );">CONSOLIDATED BALANCE SHEET DETAIL</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureConsolidatedBalanceSheetDetailsAbstract_z7p2IfHAlRqh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)">
<tr style="vertical-align: bottom">
    <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49F_20210331_zCz7v32xtXAa" style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td style="white-space: nowrap; font-weight: bold; text-align: center"/>
    <td id="xdx_49A_20200331_zD6jfVUXPyoa" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: left">Property and equipment, net:</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z3BPmqjQLSv9" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Leasehold improvements</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">139,197</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">139,197</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zcwACcdJH1u3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,476</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,724</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zTWOHfvNRM33" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Computer equipment and software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,383</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,882</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zXXrzTWCcmC8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Machinery and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">202,993</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">112,198</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_zhStRP3g6Mdk" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td><span style="display: none">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">451,049</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">353,001</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_z8azUF3TJ1jj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 17.3pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(152,091</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(51,693</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td><span style="display: none">Property and equipment, net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">298,958</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">301,308</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zizSZirDdEgi" style="margin: 0"><span id="xdx_8B4_zcJkXV60NCF2" style="display: none">Schedule of Accrued Expenses</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureConsolidatedBalanceSheetDetails2Abstract', window );">CONSOLIDATED BALANCE SHEET DETAIL (Details 2)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureConsolidatedBalanceSheetDetails2Abstract_z3esqbaMX4Bg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_49D_20210331_zahbdjG7U326" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td id="xdx_495_20200331_z11U9drwWqZ2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>

<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: left; padding-bottom: 1pt">Accrued expenses:</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedWagesAndBonusMember_zZVbo88qYMUi" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 74%; text-align: left">Accrued wages and bonus</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">372,563</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">198,160</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedPlacementFeesMember_zMdz7KVF6jZj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued placement fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1075">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedInterestMember_zjTar9XFERn" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,538</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1078">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedOtherExpensesMember_zyN8mqgMrjL" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,047</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_zdCf18Aoa407" style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-bottom: 2.5pt"><span style="display: none">Accrued expenses</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">499,948</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">202,160</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureConsolidatedBalanceSheetDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureConsolidatedBalanceSheetDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureConsolidatedBalanceSheetDetails2Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureConsolidatedBalanceSheetDetails2Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureConsolidatedBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureConsolidatedBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295874863528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">assumptions were used in the fair-value method calculations</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zvoaga1a89yd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
assumptions were used in the fair value method calculations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BC_zoHpYNToBpPe" style="display: none">Schedule of Fair Value Assumptions</span></p>



<span></span>
</td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zvYq7IF9JyI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">The following <span id="xdx_8B5_zlf1rY5Degjc">assumptions were used
in the fair-value method calculations</span>:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureStockBasedCompensationDetailsAbstract', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zBie8INYQvq1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Three
    Months Ended<br/> December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Nine
    Months Ended<br/> December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: left"><span style="font-size: 10pt">Risk-free
    interest rates</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_zJhiCTvtdor5">1.26%</span> - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zFYXEYTjgfXj">1.36%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20201001__20201231_zgrZ8UmxTHRa">0.38%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_z8xm6yEUn6ze">0.8%</span> - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_z4F0L9F5VYCg">1.36%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20201231__srt--RangeAxis__srt--MinimumMember_zMAGWA6uQjTh">0.28%</span> - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20201231__srt--RangeAxis__srt--MaximumMember_zmxRF2Rnv4Gk">0.38%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_zzxbc1ec0iya">197%</span>
                                         - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zX9wuplYzrge">253%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20201001__20201231_zzEbfdv7ehvb">87%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_zmHwQ5WCgu2d">89%</span>
                                         - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_zgALPDHRxh5b">370%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20201231__srt--RangeAxis__srt--MinimumMember_z3J24CnpuBAf">87%</span>
                                         - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20201231__srt--RangeAxis__srt--MaximumMember_zTf56EI8vHUa">127%</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Expected life (years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_z3uH1IqRNXW8">5.0</span>
                                         &#8211; <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zUli8eAzzafj">6.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231__srt--RangeAxis__srt--MinimumMember_zRuCprlQIXoe">5.2</span>
                                         &#8211; <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231__srt--RangeAxis__srt--MaximumMember_zOj6Ji4p1sYa">5.7</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_zy0bHBwbcbmj">5.0</span>
                                         - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_zu1julJ9OpCf">6.2</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20201231__srt--RangeAxis__srt--MinimumMember_zgqyty753UOh">5.0</span>
                                         - <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20201231__srt--RangeAxis__srt--MaximumMember_z5K54pvMIsg">6.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">Dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20211001__20211231_zm1YAE8gfGAg">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20201001__20201231_zc9a5wEnzU71">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20210401__20211231_zWrUnJCVcVV8">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20201231_zgll00aypvEi">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zoHuDK6s0nT1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Year
    ended March 31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2021</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 75%"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rates</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z3WdONB4SZo3" title="Risk-free interest rates">0.28%</span>
    - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zKXqL9Ish2u2">0.71%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zUL6Ejt736V7">0.77%</span>
    - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zm1j5c8ajwF2">2.37%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zTa7ch8pmPZj" title="Volatility">87%</span>
    - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_ziVZpTGts1Ki">127%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zYHYFJV41tZa">86%</span>
    - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zC5IcFOdVVE6">103%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    life (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zxbZfBQ3IN0l" title="Expected Life (years)">5.0</span>
    - <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_z1TUxfEn4EG1">6.0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zRjo0fMiYtB4">5.0</span>
    - <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zjseC5rpXBNk">6.0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">Dividend
    yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zznV59JTlHzb">&#8212;%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zzPv2kfTG5L1">&#8212;%</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">stock option activity</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zgPewvRZSuA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">A summary
of stock option activity under the Plan is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BF_zMfIkSaPKpo3" style="display: none">Schedule of Stock Option activity</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_znsC7EV5wvie" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 10pt">A summary of <span id="xdx_8BD_zo1WcKMoXVka">stock option activity
</span>under the 2017 Plan is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureStockBasedCompensationDetails2Abstract', window );">STOCK-BASED COMPENSATION (Details 2)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zJgKjtBn1Yde" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares<br/> Available<br/> for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Prices</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2021</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zwC7l1Fa7005" style="width: 8%; text-align: right">136,082</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmpnLVcwY3H" style="width: 8%; text-align: right">1,197,252</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5b8iKkQzy1l" style="width: 8%; text-align: right">5.25</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zczvsn3JQKFi" style="text-align: right">(60,774</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoueppVNmd15" style="text-align: right">60,774</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSqVkRYMnjPh" style="text-align: right">12.69</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="padding-left: 8.65pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKnwKSq88j1h" style="text-align: right">(1,836</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgshN5RbEzDh" style="border-bottom: Black 1pt solid; text-align: right">7,547</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3cy1HgyK8jh" style="border-bottom: Black 1pt solid; text-align: right">(7,547</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT43tyNwyf" style="border-bottom: Black 1pt solid; text-align: right">8.61</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Balance at June 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLN21uVqY9e3" style="text-align: right">81,089</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWS7z1Hgdljk" style="text-align: right">1,250,479</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziGgmlnX6b1i" style="text-align: right">5.58</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztHm9HiOjxM" style="text-align: right">1,333,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zw75AdIoqDyd" style="text-align: right">(396,384</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAUosEMtvCBd" style="text-align: right">396,384</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyFNIXkQzrj5" style="text-align: right">12.15</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRLRhaCnjRf6" style="text-align: right">(3,636</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyad6u5ObVd3" style="border-bottom: Black 1pt solid; text-align: right">49,213</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zTxde3atswIb" style="border-bottom: Black 1pt solid; text-align: right">(49,213</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQHd0IPPrYek" style="border-bottom: Black 1pt solid; text-align: right">7.02</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at September 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2QiQGPgV8T3" style="text-align: right">1,063,546</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5KsGdZdFMok" style="text-align: right">1,597,650</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zr46KajKTuM2" style="text-align: right">7.17</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLCJHdBqM5kc" style="text-align: right">(266,112</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5ZRQE89Yb73" style="text-align: right">259,559</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBSJy6ClQVAc" style="text-align: right">9.99</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 8.65pt">Share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx4DAV7jxxii" style="text-align: right">(5,775</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmghZMF6l164" style="border-bottom: Black 1pt solid; text-align: right">29,073</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zV9lNSrU3La7" style="border-bottom: Black 1pt solid; text-align: right">(11,256</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBuKoN8LsIr9" style="border-bottom: Black 1pt solid; text-align: right">7.24</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at December 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zApvYc0926E8" style="border-bottom: Black 2.5pt double; text-align: right">820,732</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziAAAHiBLCc3" style="border-bottom: Black 2.5pt double; text-align: right">1,845,953</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDJsNb4lL4fc" style="border-bottom: Black 2.5pt double; text-align: right">7.57</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zJSj4aqevOpc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Available</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number of</td><td style="white-space: nowrap; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted Average</td><td style="white-space: nowrap; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">for Grant</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 61%">Balance at March 31, 2019</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331_zLweyHt3pxQh" style="width: 8%; text-align: right" title="Shares available for grant, beginning">490,031</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVmGRDLvVbFb" style="width: 8%; text-align: right">509,969</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRzl68rEqYJl" style="width: 8%; text-align: right">2.56</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Additional shares authorized under the Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_c20190401__20200331_zhAdxgDFNffd" style="text-align: right">333,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_iN_di_c20190401__20200331_zPsMwIKwoQAc" style="text-align: right">(572,402</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMPyaRvRz9dd" style="text-align: right">572,402</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zng6yBVex3Pe" style="text-align: right">6.75</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20190401__20200331_zfYa8LQ4ZHWg" style="border-bottom: Black 1pt solid; text-align: right">23,056</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2NYijcemSPe" style="border-bottom: Black 1pt solid; text-align: right">(23,056</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlC05erYxvwe" style="border-bottom: Black 1pt solid; text-align: right">6.75</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td>Balance at March 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331_z15feRx4wrj7" style="text-align: right">274,019</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1nYosdl6G92" style="text-align: right">1,059,315</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5YLernKnlpk" style="text-align: right">4.74</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 8.65pt">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_iN_di_c20200401__20210331_zJggddizapdi" style="text-align: right">(163,492</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLCxmcLIOV75" style="text-align: right">163,492</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZXcbDKJQol3" style="text-align: right">8.64</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="text-align: left; padding-left: 8.65pt">Options cancelled and returned to the Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20200401__20210331_zkXgvpN0sYMi" style="border-bottom: Black 1pt solid; text-align: right">25,555</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZ7eE89lFage" style="border-bottom: Black 1pt solid; text-align: right">(25,555</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbhsQtPUzcSh" style="border-bottom: Black 1pt solid; text-align: right">6.75</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at March 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331_zye6aVSk8FA5" style="border-bottom: Black 2.5pt double; text-align: right">136,082</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znw72iivgn5k" style="border-bottom: Black 2.5pt double; text-align: right">1,197,252</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0YFfXOhuZWl" style="border-bottom: Black 2.5pt double; text-align: right">5.25</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock', window );">summarizes the range of outstanding and exercisable options</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_zHfLqyJ8vjpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table summarizes the range of outstanding and exercisable options as of December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B0_zjWp49Tt5yt7" style="display: none">Schedule of
Outstanding and Exercisable Option, Range</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z4MDAK8NLx19" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt">The following
table <span id="xdx_8BD_z7khsmxDY1Ib">summarizes the range of outstanding and exercisable options</span> as of March 31, 2021:</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosureStockBasedCompensationDetails3Abstract', window );">STOCK-BASED COMPENSATION (Details 3)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zhuv6eC9oSy" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number<br/> Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in Years)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number<br/> Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%; padding-bottom: 1pt">$<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zfOh8Nh6lWy3">1.98</span> - $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zxbrZpd0Al24">17.70</span></td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDlPIupeKgEh" style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1,845,953</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxH_c20210401__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGGy1zqdjbL1" style="width: 8%; padding-bottom: 1pt; text-align: right" title="::XDX::P8Y1M17D">8.13</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVj3UdAANCp3" style="width: 8%; padding-bottom: 1pt; text-align: right">7.57</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zketqRJJRft7" style="border-bottom: Black 1pt solid; width: 8%; text-align: right">1,011,586</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znJSsM8zPE36" style="width: 8%; padding-bottom: 1pt; text-align: right">5.10</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6lN4x67ZMvb" style="border-bottom: Black 1pt solid; width: 8%; text-align: right">3,564,268</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zjQ9JdEOW2z5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 3)">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Options Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Range of Exercise Price</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Outstanding</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life<br/> (in Years)</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number<br/> Exercisable</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,204)">
    <td style="width: 22%; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt">$<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zzRBzMxdOvJi">1.98</span> - $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zxDphhvUO3l4">9.48</span></td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zs1oFVpZzC45" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">1,197,252</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtYxH_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDF6lDyhHc4a" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="::XDX::P8Y4M">8.25</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zz6JFas6hN48" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">5.25</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhDEwU7OVCq4" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">742,913</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtYxH_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zD0TjOxu1WX7" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="::XDX::P3Y11M16D">3.96</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 3%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoZStRXd9JH2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right">8,763,260</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureStockBasedCompensationDetails2Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureStockBasedCompensationDetails2Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureStockBasedCompensationDetails3Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureStockBasedCompensationDetails3Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosureStockBasedCompensationDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosureStockBasedCompensationDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295877724072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 24, 2021</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>Number </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">On November
24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary
of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company&#8217;s shares of common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments | Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,967,188<span></span>
</td>
<td class="nump">1,170,863<span></span>
</td>
<td class="nump">1,197,252<span></span>
</td>
<td class="nump">1,059,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295876697112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2022</a></td>
<td class="nump">$ 38,358<span></span>
</td>
<td class="nump">$ 153,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2023</a></td>
<td class="nump">158,028<span></span>
</td>
<td class="nump">158,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2024</a></td>
<td class="nump">40,692<span></span>
</td>
<td class="nump">40,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_OperatingLeasesImputedInterest', window );">Imputed interest</a></td>
<td class="num">(20,049)<span></span>
</td>
<td class="num">(42,297)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Present value of lease liabilities</a></td>
<td class="nump">217,029<span></span>
</td>
<td class="nump">309,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 217,029<span></span>
</td>
<td class="nump">$ 309,855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_OperatingLeasesImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_OperatingLeasesImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295876743992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Monthly Rent</a></td>
<td class="nump">$ 12,400<span></span>
</td>
<td class="nump">$ 26,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,844<span></span>
</td>
<td class="nump">$ 80,698<span></span>
</td>
<td class="nump">$ 80,654<span></span>
</td>
<td class="nump">$ 107,540<span></span>
</td>
<td class="nump">$ 35,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_OperatingLeasesAnnualRentIncreasePercentange', window );">Operating Lease Annual Rent Increase Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_LeaseIncentiveReceived', window );">Lease Incentive Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,000<span></span>
</td>
<td class="nump">$ 139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_CashPaidforLeaseLiabilities', window );">[custom:CashPaidforLeaseLiabilities-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_CashPaidforLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_CashPaidforLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_LeaseIncentiveReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_LeaseIncentiveReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_OperatingLeasesAnnualRentIncreasePercentange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_OperatingLeasesAnnualRentIncreasePercentange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295877653032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PPP NOTE (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Apr. 24, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_DisclosurePppNoteAbstract', window );"><strong>Ppp Note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebtCurrent', window );">Unsecured Debt, Current</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 368,780<span></span>
</td>
<td class="nump">$ 368,780<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_DisclosurePppNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_DisclosurePppNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295876616760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE PROMISSORY NOTES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,321,450<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.38%<span></span>
</td>
<td class="nump">0.86%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock', window );">[custom:NotesAndAccuredInterestCouldBeConvertedIntoCommonStock-0]</a></td>
<td class="nump">767,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">767,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295872524424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROMISSORY NOTE (Details Narrative) - Revolving Credit Facility [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet', window );">Line of Credit Facility, Increase (Decrease), Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest', window );">Line of Credit Facility, Increase, Accrued Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Secured Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Maturity Date</a></td>
<td class="text">Mar. 15,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Line of Credit Facility, Interest Rate During Period</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the credit facility for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=modd_SecuredPromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=modd_SecuredPromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295876535672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.38%<span></span>
</td>
<td class="nump">0.86%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">1.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.28%<span></span>
</td>
<td class="nump">0.28%<span></span>
</td>
<td class="nump">0.77%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">197.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">1.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.36%<span></span>
</td>
<td class="nump">0.38%<span></span>
</td>
<td class="nump">0.71%<span></span>
</td>
<td class="nump">2.37%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">253.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370.00%<span></span>
</td>
<td class="nump">127.00%<span></span>
</td>
<td class="nump">127.00%<span></span>
</td>
<td class="nump">103.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295868655368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,082<span></span>
</td>
<td class="nump">136,082<span></span>
</td>
<td class="nump">274,019<span></span>
</td>
<td class="nump">490,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,492<span></span>
</td>
<td class="nump">572,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,555)<span></span>
</td>
<td class="num">(23,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,082<span></span>
</td>
<td class="nump">274,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="nump">1,063,546<span></span>
</td>
<td class="nump">81,089<span></span>
</td>
<td class="nump">136,082<span></span>
</td>
<td class="nump">136,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance</a></td>
<td class="nump">1,597,650<span></span>
</td>
<td class="nump">1,250,479<span></span>
</td>
<td class="nump">1,197,252<span></span>
</td>
<td class="nump">1,197,252<span></span>
</td>
<td class="nump">1,059,315<span></span>
</td>
<td class="nump">509,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 7.17<span></span>
</td>
<td class="nump">$ 5.58<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
<td class="nump">$ 2.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant', window );">Granted</a></td>
<td class="num">(266,112)<span></span>
</td>
<td class="num">(396,384)<span></span>
</td>
<td class="num">(60,774)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">259,559<span></span>
</td>
<td class="nump">396,384<span></span>
</td>
<td class="nump">60,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,492<span></span>
</td>
<td class="nump">572,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 9.99<span></span>
</td>
<td class="nump">$ 12.15<span></span>
</td>
<td class="nump">$ 12.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.64<span></span>
</td>
<td class="nump">$ 6.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards', window );">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards]</a></td>
<td class="num">(5,775)<span></span>
</td>
<td class="num">(3,636)<span></span>
</td>
<td class="num">(1,836)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant', window );">Cancelled</a></td>
<td class="nump">29,073<span></span>
</td>
<td class="nump">49,213<span></span>
</td>
<td class="nump">7,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</a></td>
<td class="num">(11,256)<span></span>
</td>
<td class="num">(49,213)<span></span>
</td>
<td class="num">(7,547)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,555)<span></span>
</td>
<td class="num">(23,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 7.24<span></span>
</td>
<td class="nump">$ 7.02<span></span>
</td>
<td class="nump">$ 8.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.75<span></span>
</td>
<td class="nump">$ 6.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant', window );">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="nump">820,732<span></span>
</td>
<td class="nump">1,063,546<span></span>
</td>
<td class="nump">81,089<span></span>
</td>
<td class="nump">820,732<span></span>
</td>
<td class="nump">136,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance</a></td>
<td class="nump">1,845,953<span></span>
</td>
<td class="nump">1,597,650<span></span>
</td>
<td class="nump">1,250,479<span></span>
</td>
<td class="nump">1,845,953<span></span>
</td>
<td class="nump">1,197,252<span></span>
</td>
<td class="nump">1,059,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">$ 7.57<span></span>
</td>
<td class="nump">$ 7.17<span></span>
</td>
<td class="nump">$ 5.58<span></span>
</td>
<td class="nump">$ 7.57<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295872507128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,082<span></span>
</td>
<td class="nump">274,019<span></span>
</td>
<td class="nump">490,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">1,845,953<span></span>
</td>
<td class="nump">1,597,650<span></span>
</td>
<td class="nump">1,250,479<span></span>
</td>
<td class="nump">1,197,252<span></span>
</td>
<td class="nump">1,059,315<span></span>
</td>
<td class="nump">509,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 1 month 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 7.57<span></span>
</td>
<td class="nump">$ 7.17<span></span>
</td>
<td class="nump">$ 5.58<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
<td class="nump">$ 2.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</a></td>
<td class="nump">1,011,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="nump">$ 3,564,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</a></td>
<td class="nump">$ 1.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</a></td>
<td class="nump">$ 17.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295876183656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; DEFICIT AND STOCK-BASED COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,333,334<span></span>
</td>
<td class="nump">333,334<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 7,419,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,419,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,492<span></span>
</td>
<td class="nump">572,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">$ 1,221,735<span></span>
</td>
<td class="nump">$ 862,431<span></span>
</td>
<td class="nump">$ 655,920<span></span>
</td>
<td class="nump">$ 295,054<span></span>
</td>
<td class="nump">$ 300,604<span></span>
</td>
<td class="nump">$ 344,716<span></span>
</td>
<td class="nump">$ 2,740,086<span></span>
</td>
<td class="nump">$ 940,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">259,559<span></span>
</td>
<td class="nump">396,384<span></span>
</td>
<td class="nump">60,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,492<span></span>
</td>
<td class="nump">572,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_FairValueofOptionGranted', window );">[custom:FairValueofOptionGranted]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,108,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,769,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock [Member] | Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Employee Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">723,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_FairValueofOptionGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_FairValueofOptionGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295876194392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,010,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,204,917<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 39,791<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">30,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,865<span></span>
</td>
<td class="nump">77,497<span></span>
</td>
<td class="nump">243,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,796<span></span>
</td>
<td class="nump">320,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_CEOAndInvestorMember', window );">C E O And Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_modd_NotesCancelled', window );">Notes Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_CEOAndInvestorMember', window );">C E O And Investor [Member] | Notes Payable Other Payables 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,026,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,026,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">$ 82,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_CEOAndInvestorMember', window );">C E O And Investor [Member] | Notes Payable Other Payables 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_MemberOfBoardMember', window );">Member Of Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Ellen O&#8217;Connor (Lynn) Vos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember', window );">Paul DiPerna</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_modd_NotesCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">modd_NotesCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>modd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_CEOAndInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_CEOAndInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=modd_NotesPayableOtherPayables1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=modd_NotesPayableOtherPayables1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=modd_NotesPayableOtherPayables2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=modd_NotesPayableOtherPayables2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_MemberOfBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=modd_MemberOfBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295877726200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Feb. 14, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet', window );">Line of Credit Facility, Increase (Decrease), Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet', window );">Line of Credit Facility, Increase (Decrease), Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295872483160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEET DETAIL (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 451,049<span></span>
</td>
<td class="nump">$ 353,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(152,091)<span></span>
</td>
<td class="num">(51,693)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">139,197<span></span>
</td>
<td class="nump">139,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">56,476<span></span>
</td>
<td class="nump">49,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">52,383<span></span>
</td>
<td class="nump">51,882<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 202,993<span></span>
</td>
<td class="nump">$ 112,198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295872480440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEET DETAIL (Details 2) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterimPeriodCostsNotAllocableLineItems', window );"><strong>Interim Period, Costs Not Allocable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses</a></td>
<td class="nump">$ 1,124,499<span></span>
</td>
<td class="nump">$ 499,948<span></span>
</td>
<td class="nump">$ 202,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=modd_AccruedWagesAndBonusMember', window );">Accured Wages and Bonus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterimPeriodCostsNotAllocableLineItems', window );"><strong>Interim Period, Costs Not Allocable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372,563<span></span>
</td>
<td class="nump">198,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=modd_AccruedPlacementFeesMember', window );">Accured Placement Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterimPeriodCostsNotAllocableLineItems', window );"><strong>Interim Period, Costs Not Allocable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,800<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=modd_AccruedInterestMember', window );">Accured Interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterimPeriodCostsNotAllocableLineItems', window );"><strong>Interim Period, Costs Not Allocable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,538<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=modd_AccruedOtherExpensesMember', window );">Accrued Other Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterimPeriodCostsNotAllocableLineItems', window );"><strong>Interim Period, Costs Not Allocable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,047<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterimPeriodCostsNotAllocableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterimPeriodCostsNotAllocableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=modd_AccruedWagesAndBonusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=modd_AccruedWagesAndBonusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=modd_AccruedPlacementFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=modd_AccruedPlacementFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=modd_AccruedInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=modd_AccruedInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=modd_AccruedOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=modd_AccruedOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295868647512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.38%<span></span>
</td>
<td class="nump">0.86%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="nump">1.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.28%<span></span>
</td>
<td class="nump">0.28%<span></span>
</td>
<td class="nump">0.77%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">197.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="nump">1.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.36%<span></span>
</td>
<td class="nump">0.38%<span></span>
</td>
<td class="nump">0.71%<span></span>
</td>
<td class="nump">2.37%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">253.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370.00%<span></span>
</td>
<td class="nump">127.00%<span></span>
</td>
<td class="nump">127.00%<span></span>
</td>
<td class="nump">103.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295876135448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,082<span></span>
</td>
<td class="nump">136,082<span></span>
</td>
<td class="nump">274,019<span></span>
</td>
<td class="nump">490,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(163,492)<span></span>
</td>
<td class="num">(572,402)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,492<span></span>
</td>
<td class="nump">572,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,555<span></span>
</td>
<td class="nump">23,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,555)<span></span>
</td>
<td class="num">(23,056)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,082<span></span>
</td>
<td class="nump">274,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance</a></td>
<td class="nump">1,597,650<span></span>
</td>
<td class="nump">1,250,479<span></span>
</td>
<td class="nump">1,197,252<span></span>
</td>
<td class="nump">1,197,252<span></span>
</td>
<td class="nump">1,059,315<span></span>
</td>
<td class="nump">509,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 7.17<span></span>
</td>
<td class="nump">$ 5.58<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
<td class="nump">$ 2.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="num">(259,559)<span></span>
</td>
<td class="num">(396,384)<span></span>
</td>
<td class="num">(60,774)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(163,492)<span></span>
</td>
<td class="num">(572,402)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">259,559<span></span>
</td>
<td class="nump">396,384<span></span>
</td>
<td class="nump">60,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,492<span></span>
</td>
<td class="nump">572,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 9.99<span></span>
</td>
<td class="nump">$ 12.15<span></span>
</td>
<td class="nump">$ 12.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.64<span></span>
</td>
<td class="nump">$ 6.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</a></td>
<td class="nump">11,256<span></span>
</td>
<td class="nump">49,213<span></span>
</td>
<td class="nump">7,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,555<span></span>
</td>
<td class="nump">23,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</a></td>
<td class="num">(11,256)<span></span>
</td>
<td class="num">(49,213)<span></span>
</td>
<td class="num">(7,547)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,555)<span></span>
</td>
<td class="num">(23,056)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 7.24<span></span>
</td>
<td class="nump">$ 7.02<span></span>
</td>
<td class="nump">$ 8.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.75<span></span>
</td>
<td class="nump">$ 6.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance</a></td>
<td class="nump">1,845,953<span></span>
</td>
<td class="nump">1,597,650<span></span>
</td>
<td class="nump">1,250,479<span></span>
</td>
<td class="nump">1,845,953<span></span>
</td>
<td class="nump">1,197,252<span></span>
</td>
<td class="nump">1,059,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">$ 7.57<span></span>
</td>
<td class="nump">$ 7.17<span></span>
</td>
<td class="nump">$ 5.58<span></span>
</td>
<td class="nump">$ 7.57<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295868496264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">136,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,019<span></span>
</td>
<td class="nump">490,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">1,197,252<span></span>
</td>
<td class="nump">1,845,953<span></span>
</td>
<td class="nump">1,597,650<span></span>
</td>
<td class="nump">1,250,479<span></span>
</td>
<td class="nump">1,059,315<span></span>
</td>
<td class="nump">509,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="nump">$ 7.57<span></span>
</td>
<td class="nump">$ 7.17<span></span>
</td>
<td class="nump">$ 5.58<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
<td class="nump">$ 2.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</a></td>
<td class="nump">742,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">3 years 11 months 16 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 8,763,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 9.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140295877871608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">30,864<span></span>
</td>
<td class="nump">30,865<span></span>
</td>
<td class="nump">77,497<span></span>
</td>
<td class="nump">243,299<span></span>
</td>
<td class="nump">320,796<span></span>
</td>
<td class="nump">320,796<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>modular_s1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:modd="http://modular-medical.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="modd-20211231.xsd" xlink:type="simple"/>
    <context id="From2021-04-01to2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2021-10-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CommonStockIssuableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">modd:CommonStockIssuableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-11-232021-11-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2021-11-23</startDate>
            <endDate>2021-11-24</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-04-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-04-02</instant>
        </period>
    </context>
    <context id="From2020-04-012020-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-04-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-04-24</instant>
        </period>
    </context>
    <context id="AsOf2021-05-31_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="AsOf2021-10-28_us-gaap_RevolvingCreditFacilityMember_custom_SecuredPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">modd:SecuredPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-28</instant>
        </period>
    </context>
    <context id="From2021-10-272021-10-28_us-gaap_RevolvingCreditFacilityMember_custom_SecuredPromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">modd:SecuredPromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-27</startDate>
            <endDate>2021-10-28</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2017-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="AsOf2020-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="AsOf2020-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_us-gaap_CommonStockMember_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_us-gaap_StockOptionMember_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_StockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_StockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CEOAndInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-05-31_custom_MemberOfBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:MemberOfBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="From2021-10-012021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:CEOAndInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">modd:NotesPayableOtherPayables2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MemberOfBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">modd:MemberOfBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-10-012021-10-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-10-31_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="From2021-10-012021-10-31_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-02-14_us-gaap_SubsequentEventMember_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-02-14</endDate>
        </period>
    </context>
    <context id="From2022-02-092022-02-10_us-gaap_SubsequentEventMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_AccruedWagesAndBonusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedWagesAndBonusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_AccruedWagesAndBonusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedWagesAndBonusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_AccruedPlacementFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedPlacementFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_AccruedPlacementFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedPlacementFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_AccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_AccruedInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_AccruedOtherExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_AccruedOtherExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">modd:AccruedOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_StockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_StockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Number">
        <measure>modd:Number</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-04-01to2021-12-31">0001074871</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-04-01to2021-12-31">false</dei:AmendmentFlag>
    <us-gaap:UnsecuredDebtCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0074"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:PromissoryNotePayable
      contextRef="AsOf2021-03-31"
      id="xdx2ixbrl0078"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0092"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0104"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-03-31"
      id="xdx2ixbrl0105"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:CommonStockIssuable
      contextRef="AsOf2021-03-31"
      id="xdx2ixbrl0130"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2020-10-012020-12-31"
      id="xdx2ixbrl0172"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2020-04-012020-12-31"
      id="xdx2ixbrl0174"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-10-012021-12-31"
      id="xdx2ixbrl0176"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-10-012020-12-31"
      id="xdx2ixbrl0177"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-04-012020-12-31"
      id="xdx2ixbrl0179"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-10-012021-12-31"
      id="xdx2ixbrl0186"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-10-012020-12-31"
      id="xdx2ixbrl0187"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-04-012021-06-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0225"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0226"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2021-04-012021-06-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-012021-06-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0238"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0239"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0243"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0244"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0245"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0251"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-07-012021-09-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0257"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0258"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0262"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-10-012021-12-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-012021-12-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:SharesIssuableForServices
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:SharesIssuableForServices
      contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:SharesIssuableForServices
      contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:SharesIssuedForReverseStockSplit
      contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:SharesIssuedForReverseStockSplit
      contextRef="From2021-10-012021-12-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:SharesIssuedForReverseStockSplit
      contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-10-012021-12-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012021-12-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-04-012020-06-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-07-012020-09-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-012020-09-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-10-012020-12-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-10-012020-12-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-012020-12-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:GainOnPPPNoteForgiveness
      contextRef="From2020-04-012020-12-31"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-04-012020-12-31"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2020-04-012020-12-31"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:SharesIssuableForServices
      contextRef="From2020-04-012020-12-31"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2020-04-012020-12-31"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2020-04-012020-12-31"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:ProceedsFromIssuanceOfPromissoryNote
      contextRef="From2020-04-012020-12-31"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2021-04-01to2021-12-31"
      id="xdx2ixbrl0466"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2020-04-012020-12-31"
      id="xdx2ixbrl0488"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2021-04-012021-12-31_srt_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2021-04-012021-12-31_srt_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2020-04-02">P39M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-04-01to2021-12-31">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-04-01to2021-12-31"
      decimals="INF"
      id="xdx2ixbrl0568"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2021-04-01to2021-12-31">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-04-012021-12-31_us-gaap_StockOptionMember">P8Y1M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:UnsecuredDebtCurrent
      contextRef="AsOf2020-03-31"
      id="xdx2ixbrl0749"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="AsOf2020-03-31"
      id="xdx2ixbrl0752"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-03-31"
      id="xdx2ixbrl0772"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2020-03-31"
      id="xdx2ixbrl0773"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:CommonStockIssuable
      contextRef="AsOf2021-03-31"
      id="xdx2ixbrl0797"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0831"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-04-012020-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0861"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-04-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0862"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-04-012020-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0864"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-04-012020-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0870"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0871"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-04-012020-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0874"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-04-012020-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0876"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-04-012020-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0877"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012020-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0880"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0881"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012020-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0882"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0896"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0902"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0903"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0907"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0909"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0910"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0913"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0914"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0915"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_custom_CommonStockIssuableMember"
      id="xdx2ixbrl0921"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0939"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0942"
      unitRef="USD"
      xsi:nil="true"/>
    <modd:IncreaseDecreaseInLeaseLiability
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0945"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0948"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0951"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0959"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0984"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0987"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2020-04-012021-03-31_srt_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2020-04-012021-03-31_srt_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2020-03-31_custom_AccruedPlacementFeesMember"
      id="xdx2ixbrl1075"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2020-03-31_custom_AccruedInterestMember"
      id="xdx2ixbrl1078"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2020-04-02">P39M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember">P8Y4M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember">P3Y11M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <dei:DocumentType contextRef="From2021-04-01to2021-12-31">S-1</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="From2021-04-01to2021-12-31">MODULAR MEDICAL, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-04-01to2021-12-31">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-04-01to2021-12-31">87-0620495</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-04-01to2021-12-31">16772 W. Bernardo Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2021-04-01to2021-12-31">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-04-01to2021-12-31">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-04-01to2021-12-31">92127</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-04-01to2021-12-31">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-04-01to2021-12-31">800-3500</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="From2021-04-01to2021-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2021-04-01to2021-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-04-01to2021-12-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2021-04-01to2021-12-31">false</dei:EntityExTransitionPeriod>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">204098</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1468465</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">63607</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">178158</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">946</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2466</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">268651</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1649089</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">241468</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">298958</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">141720</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">200124</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DepositsAssets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">100000</us-gaap:DepositsAssets>
    <us-gaap:DepositsAssets contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">100000</us-gaap:DepositsAssets>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">483188</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">599082</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">751839</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2248171</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">671363</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">169284</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1124499</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">499948</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">139817</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">125500</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:UnsecuredDebtCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">368780</us-gaap:UnsecuredDebtCurrent>
    <modd:PromissoryNotePayable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1500000</modd:PromissoryNotePayable>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">5485583</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2133453</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">8921262</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">3296965</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">77212</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">184355</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">42000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">8998474</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">3523320</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">6373706</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">6373706</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">6302050</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">6302050</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">6374</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">6302</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">21602162</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">14665559</us-gaap:AdditionalPaidInCapital>
    <modd:CommonStockIssuable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">149994</modd:CommonStockIssuable>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-30005165</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-15947010</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-8246635</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-1275149</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">751839</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2248171</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">1849399</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">1086669</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">5742911</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">3150149</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">1981665</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">783898</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">5156152</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">2453808</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">3831064</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">1870567</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">10899063</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">5603957</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">-3831064</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">-1870567</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">-10899063</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">-5603957</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">4</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">22</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">368876</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">126</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestExpense
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">1010247</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">2204917</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">-1321450</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">-4841307</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">-1870545</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">-14056554</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">-5603831</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">-4841307</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">-1870545</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">-14058155</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">-5605431</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-10-012021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-10-012020-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-04-01to2021-12-31"
      decimals="INF"
      unitRef="USDPShares">-2.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-04-012020-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-10-012021-12-31"
      decimals="INF"
      unitRef="Shares">6354145</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-10-012020-12-31"
      decimals="INF"
      unitRef="Shares">6249038</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-04-01to2021-12-31"
      decimals="INF"
      unitRef="Shares">6331982</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-04-012020-12-31"
      decimals="INF"
      unitRef="Shares">6187526</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">6302050</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">6302</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">14665559</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-15947010</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-1275149</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">20000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">20</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">172180</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">172200</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3700632</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">3700632</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1836</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">655918</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">655920</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-4835091</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-4835091</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">6324</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">19194289</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-20782101</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">-1581488</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3635</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">4</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">862427</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">862431</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-4381757</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-4381757</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">6327521</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">6328</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">20056716</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-25163858</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">-5100814</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">30865</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">31</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">249969</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">8334</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">8</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">73748</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">73756</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <modd:SharesIssuableForServices
      contextRef="From2021-10-012021-12-31_custom_CommonStockIssuableMember"
      decimals="0"
      unitRef="USD">149994</modd:SharesIssuableForServices>
    <modd:SharesIssuableForServices
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">149994</modd:SharesIssuableForServices>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1211</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <modd:SharesIssuedForReverseStockSplit
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</modd:SharesIssuedForReverseStockSplit>
    <modd:SharesIssuedForReverseStockSplit
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">1</modd:SharesIssuedForReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5775</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-10-012021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">6</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-10-012021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1221729</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">1221735</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-4841307</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">-4841307</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">6373706</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">6374</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">21602162</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_CommonStockIssuableMember"
      decimals="0"
      unitRef="USD">149994</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-30005165</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-8246635</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5956754</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5957</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">10517505</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_custom_CommonStockIssuableMember"
      decimals="0"
      unitRef="USD">923994</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-8569034</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">2878422</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">243299</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">243</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2042385</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30_custom_CommonStockIssuableMember"
      decimals="0"
      unitRef="USD">-923994</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1118634</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">344716</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">344716</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1874157</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-1874157</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">6200053</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">6200</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">12904606</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-10443191</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">2467615</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">300604</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">300604</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1860729</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-1860729</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">6200053</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">6200</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">13205210</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-12303920</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">907490</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">77497</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">77</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">667171</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">667248</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">295054</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">295054</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1870545</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">-1870545</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">6277550</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">6277</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">14167435</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-14174465</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-753</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">-14058155</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">-5605431</us-gaap:NetIncomeLoss>
    <modd:GainOnPPPNoteForgiveness
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">-368780</modd:GainOnPPPNoteForgiveness>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">-1321450</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">2740086</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">940374</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">80268</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">82016</us-gaap:DepreciationAndAmortization>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">388021</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <modd:SharesIssuableForServices
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">149994</modd:SharesIssuableForServices>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">58404</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">52994</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <modd:IncreaseDecreaseInLeaseLiability
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">-92826</modd:IncreaseDecreaseInLeaseLiability>
    <modd:IncreaseDecreaseInLeaseLiability
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">67092</modd:IncreaseDecreaseInLeaseLiability>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">1454762</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">-25995</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">15964</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">1223983</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">-123722</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">-7128787</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">-4570713</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">22779</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">109541</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">-22779</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">-109541</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">250000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">1785882</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">4137199</us-gaap:ProceedsFromConvertibleDebt>
    <modd:ProceedsFromIssuanceOfPromissoryNote
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">1500000</modd:ProceedsFromIssuanceOfPromissoryNote>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">368780</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">5887199</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">2154662</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">-1264367</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">-2525592</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1468465</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">3122134</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">204098</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">596542</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">3700632</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zdcuY53cetG" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE
1 &#x2013; &lt;span id="xdx_826_zOZwgRE2vlhh"&gt;THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Modular
Medical, Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had
no material business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of
Quasuras, Inc., a Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and
Quasuras, the share exchange was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities
of Quasuras acquired in the merger, at their historical carrying amounts. Prior to the acquisition of Quasuras and since at least
2002, the Company was a shell company, as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange
Act). In June 2017, the Company changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
is a development-stage, medical-device company focused on the design, development, and commercialization of an innovative insulin
pump using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part,
patch pump product, the Company seeks to fundamentally alter the trade-offs between cost and complexity and access to the higher
standards of care that presently available insulin pumps provide. By simplifying and streamlining the user experience from introduction,
prescription, reimbursement, training and day-to-day use, the Company seeks to expand the wearable insulin delivery device market
beyond the highly motivated &#x201c;super users&#x201d; and expand the category into the mass market. The Company&#x2019;s pump product
seeks to serve both the type 1 and type 2 diabetes markets.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--LiquidityPolicyTextBlock_z9z2ekIUfun5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zSn8fkw1P1Oc"&gt;Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial
Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15), &lt;i&gt;Going Concern&lt;/i&gt;, requires management
to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#x2019;s
ability to continue as a going concern within one year after the date that the financial statements are issued. If management
identifies conditions or events that raise substantial doubt about an entity&#x2019;s ability to continue as a going concern, management
must consider if there are plans that are probable to be implemented, and whether it is probable that the plans will mitigate
the conditions or events raising the substantial doubt about the entity&#x2019;s ability to continue as a going concern. If the
substantial doubt is not alleviated after consideration of management&#x2019;s plans, the entity must include a statement in the
notes to the financial statements indicating that there is substantial doubt about the entity&#x2019;s ability to continue as a
going concern within one year after the date that the financial statements are issued including: 1) the principal conditions or
events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern, 2) management&#x2019;s evaluation
of the significance of those conditions or events in relation to the entity&#x2019;s ability to meet its obligations, and 3) management&#x2019;s
plans to attempt to mitigate the conditions or events causing the substantial doubt about the entity&#x2019;s ability to continue
as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development
and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant
product revenues to achieve profitability. The Company&#x2019;s expected operating losses and cash burn and the need to repay the
convertible promissory notes and accrued interest in the first half of 2022 raise substantial doubt about the Company&#x2019;s
ability to continue as a going concern within one year after the date that these financial statements are issued. Implementation
of the Company&#x2019;s plans and its ability to continue as a going concern will depend upon the Company&#x2019;s ability to raise
additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no
assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and,
if available, that such capital will be offered on terms and conditions acceptable to the Company. As disclosed in note 9, the
Company recently sold shares of its common stock to two of its officers, obtained access to a credit facility and filed a registration
statement to offer shares of its common stock. The Company&#x2019;s operating needs include the planned costs to operate its business,
including amounts required to repay its convertible promissory notes (if not converted), fund working capital and capital expenditures.
The Company&#x2019;s future capital requirements and the adequacy of its available funds will depend on many factors, including
the Company&#x2019;s ability to successfully commercialize its product, competing technological and market developments, and the
need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its
product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash. These condensed consolidated financial
statements do not include any adjustments that might result from this uncertainty.&lt;/span&gt;&lt;/p&gt;






&lt;p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zg1kLg1u7ymh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zzUiA2s82eS6"&gt;Basis
of Presentation &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company&#x2019;s
fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in these notes to the condensed consolidated
financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2022 refers
to the fiscal year ending March 31, 2022). The condensed consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The accompanying
condensed consolidated financial statements of the Company have been prepared without audit. The condensed consolidated balance
sheet as of March 31, 2021 has been derived from the audited consolidated financial statements at that date. Certain information
and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted
in the United States (GAAP) have been condensed or omitted in accordance with these rules and regulations of the Securities and
Exchange Commission (SEC).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In the
opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting
only of normal recurring adjustments) necessary to summarize fairly the Company&#x2019;s financial position, results of operations
and cash flows for the interim periods presented. The operating results for the three months ended December 31, 2021 are not necessarily
indicative of the results that may be expected for the year ending March 31, 2022 or for any other future period.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--ReverseStockSplitPolicyTextBlock_zLxBVkzxzg51" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zzQnHUeQsOQa"&gt;Reverse Stock Split&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20211123__20211124_zbRbXZoxiQj8"&gt;On November
24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary
of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company&#x2019;s shares of common stock.&lt;/span&gt; Such amendment
and ratio were previously approved by a majority of the Company&#x2019;s stockholders and the board of directors. As a result of
the reverse stock split, which was effective November 29, 2021, every three shares of the Company&#x2019;s pre-reverse split outstanding
common stock were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common
stock holders were not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Split
were rounded up to the nearest whole share. All stock options outstanding and common stock reserved for issuance under the
Company&#x2019;s equity incentive plans and warrants outstanding immediately prior to the reverse stock split were adjusted by
dividing the number of affected shares of common stock by three (3) and, as applicable, multiplying the exercise price by three
(3), as a result of the reverse stock split.&lt;/span&gt;&lt;/p&gt;





&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_zoPl13e0kP2d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zxNVb9p9jHN6"&gt;Use
of Estimates &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The preparation
of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of
the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates
may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWeoFIr7QlXe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zvh4FPiSwkPe"&gt;Reportable
Segment &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
operates in &lt;span id="xdx_906_eus-gaap--NumberOfOperatingSegments_dc_uNumber_c20210401__20211231_zevLYwcoxte5"&gt;one&lt;/span&gt; business segment and uses one measurement of profitability for its business.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zZZNMr8lQ3V2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zTNsevdrL2h3"&gt;Research
and Development&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
expenses research and development expenditures as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z58yieOnj0u9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zpfdCgZFzn8"&gt;General
and Administrative &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting
fees, and office and other administrative expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zzo1rW1DtNX7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zPLJpIi6iP3g"&gt;Concentration
of Credit Risk &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains
its cash balances at high-quality financial institutions within the United States, which are insured by the Federal Deposit Insurance
Corporation up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss
due to financial institution failure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_ecustom--RisksAndUncertaintiesPolicyTextBlock_z5k8Yx9Zt5I5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zA1ZtrM00522"&gt;Risks
and Uncertainties &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing technology and customer requirements, limited operating history and the volatility
of public markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;COVID-19&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The global
outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains,
significantly restricted travel and transportation, resulted in mandated closures and orders to &#x201c;shelter-in-place&#x201d;
and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#x2019;s operational
and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions
taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company&#x2019;s
control, and cannot be predicted.&lt;/span&gt;&lt;/p&gt;





&lt;p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zKjab441Int8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zwxlbtu427x1"&gt;Cash
and Cash Equivalents &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Cash
and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and highly liquid debt instruments
with original maturities of three months or less.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z9QabmbzvQBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zJqlZcaMfrYg"&gt;Property
&amp;amp; Equipment &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Property
and equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful
lives of the assets, generally &lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxH_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_zaJ33kMbcei9" title="::XDX::P3Y"&gt;three&lt;/span&gt; to &lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxH_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_z7a40rLLRfAk" title="::XDX::P5Y"&gt;five&lt;/span&gt; years. Depreciation is recorded in operating expenses in the condensed consolidated
statements of operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of
their estimated useful life or the lease term, and amortization is recorded in operating expenses in the condensed consolidated
statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z6gGPV0CA5hh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zU4nuxpUaHsj"&gt;Fair
Value of Financial Instruments &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level
                                         1 inputs to the valuation methodology are quoted prices for identical assets or liabilities
                                         in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level
                                         2 inputs to the valuation methodology include quoted prices for similar assets and liabilities
                                         in active markets, and inputs that are observable for the asset or liability, either
                                         directly or indirectly, for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level
                                         3 inputs to the valuation methodology are unobservable and significant to the fair value
                                         measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Due to
their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses approximate fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zo9FYsK7bo2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zUBEGqHISegh"&gt;Per-Share
Amounts &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Basic
net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding
during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period.
For the nine months ended December 31, 2021 and 2020, outstanding options to purchase &lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20211231_zjB5ywqmGkoe"&gt;1,967,188&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20201231_zHT92n9jnntk"&gt;1,170,863&lt;/span&gt; shares of common
stock, respectively, were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zKt0uGP8yu0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zncbUgeI7kCi"&gt;Reclassification
&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no
effect on the reported results of operations or cash flows.&lt;b&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;






&lt;p id="xdx_847_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zI1mPvysuMpd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zjEy9Mo68f6d"&gt;Comprehensive
Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly,
comprehensive loss may include certain changes in equity that are excluded from net loss. For the three and nine months ended
December 31, 2021 and 2020, the Company&#x2019;s comprehensive loss was the same as its net loss.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zcNdW5Ao75f6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Recently
Adopted Accounting Pronouncement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In August
2020, the FASB issued ASU No. 2020-06, &lt;i&gt;Debt&lt;/i&gt; &lt;i&gt;with Conversion and Other Options&lt;/i&gt; &lt;i&gt;(Subtopic 470-20) and Derivatives
and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments and Contracts in an
Entity&#x2019;s Own Equity &lt;/i&gt;(ASU 2020-06)&lt;i&gt;.&lt;/i&gt; ASU 2020-06 simplifies the accounting for convertible instruments by removing
major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single
liability instrument with no separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions
that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts
to qualify for it. ASU 2020-06 also simplifies the diluted net income per share calculation in certain areas. The new guidance
is effective for annual and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years
beginning after December 15, 2020, and interim periods within those fiscal years. The Company early adopted ASU 2020-06 effective
April 1, 2021, and the impact of the adoption was not material to the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <modd:LiquidityPolicyTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_840_ecustom--LiquidityPolicyTextBlock_z9z2ekIUfun5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zSn8fkw1P1Oc"&gt;Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial
Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15), &lt;i&gt;Going Concern&lt;/i&gt;, requires management
to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#x2019;s
ability to continue as a going concern within one year after the date that the financial statements are issued. If management
identifies conditions or events that raise substantial doubt about an entity&#x2019;s ability to continue as a going concern, management
must consider if there are plans that are probable to be implemented, and whether it is probable that the plans will mitigate
the conditions or events raising the substantial doubt about the entity&#x2019;s ability to continue as a going concern. If the
substantial doubt is not alleviated after consideration of management&#x2019;s plans, the entity must include a statement in the
notes to the financial statements indicating that there is substantial doubt about the entity&#x2019;s ability to continue as a
going concern within one year after the date that the financial statements are issued including: 1) the principal conditions or
events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern, 2) management&#x2019;s evaluation
of the significance of those conditions or events in relation to the entity&#x2019;s ability to meet its obligations, and 3) management&#x2019;s
plans to attempt to mitigate the conditions or events causing the substantial doubt about the entity&#x2019;s ability to continue
as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development
and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant
product revenues to achieve profitability. The Company&#x2019;s expected operating losses and cash burn and the need to repay the
convertible promissory notes and accrued interest in the first half of 2022 raise substantial doubt about the Company&#x2019;s
ability to continue as a going concern within one year after the date that these financial statements are issued. Implementation
of the Company&#x2019;s plans and its ability to continue as a going concern will depend upon the Company&#x2019;s ability to raise
additional capital, through the sale of additional equity or debt securities, to support its future operations. There can be no
assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and,
if available, that such capital will be offered on terms and conditions acceptable to the Company. As disclosed in note 9, the
Company recently sold shares of its common stock to two of its officers, obtained access to a credit facility and filed a registration
statement to offer shares of its common stock. The Company&#x2019;s operating needs include the planned costs to operate its business,
including amounts required to repay its convertible promissory notes (if not converted), fund working capital and capital expenditures.
The Company&#x2019;s future capital requirements and the adequacy of its available funds will depend on many factors, including
the Company&#x2019;s ability to successfully commercialize its product, competing technological and market developments, and the
need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement its
product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash. These condensed consolidated financial
statements do not include any adjustments that might result from this uncertainty.&lt;/span&gt;&lt;/p&gt;






</modd:LiquidityPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_84A_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zg1kLg1u7ymh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zzUiA2s82eS6"&gt;Basis
of Presentation &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company&#x2019;s
fiscal year ends on March 31 of each calendar year. Each reference to a fiscal year in these notes to the condensed consolidated
financial statements refers to the fiscal year ended March 31 of the calendar year indicated (for example, fiscal 2022 refers
to the fiscal year ending March 31, 2022). The condensed consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiary, Quasuras. All significant intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The accompanying
condensed consolidated financial statements of the Company have been prepared without audit. The condensed consolidated balance
sheet as of March 31, 2021 has been derived from the audited consolidated financial statements at that date. Certain information
and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted
in the United States (GAAP) have been condensed or omitted in accordance with these rules and regulations of the Securities and
Exchange Commission (SEC).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In the
opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting
only of normal recurring adjustments) necessary to summarize fairly the Company&#x2019;s financial position, results of operations
and cash flows for the interim periods presented. The operating results for the three months ended December 31, 2021 are not necessarily
indicative of the results that may be expected for the year ending March 31, 2022 or for any other future period.&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <modd:ReverseStockSplitPolicyTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_843_ecustom--ReverseStockSplitPolicyTextBlock_zLxBVkzxzg51" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zzQnHUeQsOQa"&gt;Reverse Stock Split&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20211123__20211124_zbRbXZoxiQj8"&gt;On November
24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary
of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company&#x2019;s shares of common stock.&lt;/span&gt; Such amendment
and ratio were previously approved by a majority of the Company&#x2019;s stockholders and the board of directors. As a result of
the reverse stock split, which was effective November 29, 2021, every three shares of the Company&#x2019;s pre-reverse split outstanding
common stock were combined and reclassified into one share of common stock. Proportionate voting rights and other rights of common
stock holders were not affected by the reverse stock split. Any fractional shares of common stock resulting from the Reverse Split
were rounded up to the nearest whole share. All stock options outstanding and common stock reserved for issuance under the
Company&#x2019;s equity incentive plans and warrants outstanding immediately prior to the reverse stock split were adjusted by
dividing the number of affected shares of common stock by three (3) and, as applicable, multiplying the exercise price by three
(3), as a result of the reverse stock split.&lt;/span&gt;&lt;/p&gt;





</modd:ReverseStockSplitPolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2021-11-232021-11-24">On November
24, 2021, the Company filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary
of State of the State of Nevada to effect a 1-for-3 reverse stock split of the Company&#x2019;s shares of common stock.</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:UseOfEstimates contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_zoPl13e0kP2d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zxNVb9p9jHN6"&gt;Use
of Estimates &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The preparation
of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of
the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Estimates
may include those pertaining to accruals, stock-based compensation and income taxes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zWeoFIr7QlXe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zvh4FPiSwkPe"&gt;Reportable
Segment &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
operates in &lt;span id="xdx_906_eus-gaap--NumberOfOperatingSegments_dc_uNumber_c20210401__20211231_zevLYwcoxte5"&gt;one&lt;/span&gt; business segment and uses one measurement of profitability for its business.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2021-04-01to2021-12-31"
      decimals="INF"
      unitRef="Number">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zZZNMr8lQ3V2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zTNsevdrL2h3"&gt;Research
and Development&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
expenses research and development expenditures as incurred.&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_841_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_z58yieOnj0u9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zpfdCgZFzn8"&gt;General
and Administrative &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;General
and administrative expenses consist primarily of payroll and benefit costs, rent, stock-based compensation, legal and accounting
fees, and office and other administrative expenses.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zzo1rW1DtNX7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zPLJpIi6iP3g"&gt;Concentration
of Credit Risk &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains
its cash balances at high-quality financial institutions within the United States, which are insured by the Federal Deposit Insurance
Corporation up to limits of approximately $250,000. No reserve has been made in the financial statements for any possible loss
due to financial institution failure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <modd:RisksAndUncertaintiesPolicyTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_847_ecustom--RisksAndUncertaintiesPolicyTextBlock_z5k8Yx9Zt5I5" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zA1ZtrM00522"&gt;Risks
and Uncertainties &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing technology and customer requirements, limited operating history and the volatility
of public markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;COVID-19&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The global
outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply chains,
significantly restricted travel and transportation, resulted in mandated closures and orders to &#x201c;shelter-in-place&#x201d;
and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#x2019;s operational
and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions
taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company&#x2019;s
control, and cannot be predicted.&lt;/span&gt;&lt;/p&gt;





</modd:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zKjab441Int8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_865_zwxlbtu427x1"&gt;Cash
and Cash Equivalents &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Cash
and cash equivalents include cash on hand and cash in demand deposits, certificates of deposit and highly liquid debt instruments
with original maturities of three months or less.&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z9QabmbzvQBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zJqlZcaMfrYg"&gt;Property
&amp;amp; Equipment &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Property
and equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful
lives of the assets, generally &lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxH_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_zaJ33kMbcei9" title="::XDX::P3Y"&gt;three&lt;/span&gt; to &lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxH_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_z7a40rLLRfAk" title="::XDX::P5Y"&gt;five&lt;/span&gt; years. Depreciation is recorded in operating expenses in the condensed consolidated
statements of operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of
their estimated useful life or the lease term, and amortization is recorded in operating expenses in the condensed consolidated
statements of operations.&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_847_eus-gaap--FairValueOfFinancialInstrumentsPolicy_z6gGPV0CA5hh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zU4nuxpUaHsj"&gt;Fair
Value of Financial Instruments &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level
                                         1 inputs to the valuation methodology are quoted prices for identical assets or liabilities
                                         in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level
                                         2 inputs to the valuation methodology include quoted prices for similar assets and liabilities
                                         in active markets, and inputs that are observable for the asset or liability, either
                                         directly or indirectly, for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level
                                         3 inputs to the valuation methodology are unobservable and significant to the fair value
                                         measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Due to
their short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses approximate fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zo9FYsK7bo2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zUBEGqHISegh"&gt;Per-Share
Amounts &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Basic
net loss per share is computed by dividing loss for the period by the weighted-average number of shares of common stock outstanding
during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period.
For the nine months ended December 31, 2021 and 2020, outstanding options to purchase &lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20211231_zjB5ywqmGkoe"&gt;1,967,188&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20201231_zHT92n9jnntk"&gt;1,170,863&lt;/span&gt; shares of common
stock, respectively, were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-04-01to2021-12-31"
      decimals="INF"
      unitRef="Shares">1967188</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-04-012020-12-31"
      decimals="INF"
      unitRef="Shares">1170863</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_844_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zKt0uGP8yu0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zncbUgeI7kCi"&gt;Reclassification
&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Certain
prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no
effect on the reported results of operations or cash flows.&lt;b&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;






</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_847_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zI1mPvysuMpd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zjEy9Mo68f6d"&gt;Comprehensive
Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly,
comprehensive loss may include certain changes in equity that are excluded from net loss. For the three and nine months ended
December 31, 2021 and 2020, the Company&#x2019;s comprehensive loss was the same as its net loss.&lt;/span&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zcNdW5Ao75f6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Recently
Adopted Accounting Pronouncement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In August
2020, the FASB issued ASU No. 2020-06, &lt;i&gt;Debt&lt;/i&gt; &lt;i&gt;with Conversion and Other Options&lt;/i&gt; &lt;i&gt;(Subtopic 470-20) and Derivatives
and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)-Accounting For Convertible Instruments and Contracts in an
Entity&#x2019;s Own Equity &lt;/i&gt;(ASU 2020-06)&lt;i&gt;.&lt;/i&gt; ASU 2020-06 simplifies the accounting for convertible instruments by removing
major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single
liability instrument with no separate accounting for embedded conversion features. ASU 2020-06 removes certain settlement conditions
that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts
to qualify for it. ASU 2020-06 also simplifies the diluted net income per share calculation in certain areas. The new guidance
is effective for annual and interim periods beginning after December 15, 2021, and early adoption is permitted for fiscal years
beginning after December 15, 2020, and interim periods within those fiscal years. The Company early adopted ASU 2020-06 effective
April 1, 2021, and the impact of the adoption was not material to the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_809_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zffH278fS3Q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE
2 &#x2013; &lt;span id="xdx_829_z4AbZHRlLxEk"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Effective April
1, 2019, the Company adopted ASU No. 2016-02, &lt;i&gt;Leases &lt;/i&gt;(ASC 842),&lt;i&gt; &lt;/i&gt;and related ASUs, as amended, using the alternative
transition method, which allowed the Company to initially apply the new lease standard at the adoption date (the &#x201c;effective
date method&#x201d;). In January 2020, the Company executed a lease for a new, larger corporate facility in San Diego, California
and paid a $100,000 security deposit. The &lt;span id="xdx_908_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxH_c20200402_zyp6c5dcFNR5" title="::XDX::P39M"&gt;39&lt;/span&gt;-month lease
term commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $&lt;span id="xdx_908_eus-gaap--LeaseAndRentalExpense_c20200401__20200430_zW6ATisQmqil" title="Monthly Rent"&gt;12,400&lt;/span&gt; annual rent increases of approximately &lt;span id="xdx_90D_ecustom--OperatingLeasesAnnualRentIncreasePercentange_iI_c20200402_zNBNpGf376D4" title="Operating Lease Annual Rent Increase Percentage"&gt;3%&lt;/span&gt;.&#160;In addition to the minimum lease payments, the Company
is responsible for property taxes, insurance and certain other operating costs. The right-to-use asset and corresponding liability
for the facility lease have been measured at the present value of the future minimum lease payments. A discount rate of 11%, which
approximated the Company&#x2019;s incremental borrowing rate, was used to measure the lease asset and liability. Lease expense
is recognized on a straight line basis over the lease term.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
obtained a right-of-use asset of $&lt;span id="xdx_905_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20210401__20211231_zC45oVTDftc8"&gt;270,950&lt;/span&gt; in exchange for its obligations under the operating lease. The landlord also provided
a lease incentive of approximately $&lt;span id="xdx_909_ecustom--LeaseIncentiveReceived_iI_c20200930_z7w1C4Im8Qc7"&gt;139,000&lt;/span&gt;, which was paid to the Company in June 2020, for the Company to make improvements
to the leased space.&lt;/span&gt;&lt;/p&gt;





&lt;p id="xdx_89E_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zJmxZubEG2ql" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8B0_zxWDKwGCiRO8"&gt;Future
minimum payments under the facility operating lease&lt;/span&gt;, as of December 31, 2021, are listed in the table below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--DisclosureLeaseDetailsAbstract_zI3Kg6Yps0F5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Annual Fiscal Years&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20211231_z2XAUWdNaUfg" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Operating&lt;br/&gt; lease&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_maOLFMPz6XG_zdjbLZgmxOe3" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 87%; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;38,358&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_maOLFMPz6XG_zqAa2Rf3FnEd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;158,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_maOLFMPz6XG_zzhclJCqGXo3" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,692&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--OperatingLeasesImputedInterest_iI_maOLFMPz6XG_z073Amdjcmm7" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt; padding-bottom: 1pt"&gt;Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(20,049&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iTI_mtOLFMPz6XG_zN6ZgoIM8uQf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;217,029&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;




&lt;p id="xdx_8A3_zPArM1EYkdH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Cash
paid for amounts included in the measurement of lease liabilities was $&lt;span id="xdx_90F_ecustom--CashPaidforLeaseLiabilities_iI_c20211231_zPgsconRLJA2"&gt;115,073&lt;/span&gt; for the nine months ended December 31, 2021. Rent
expense was $&lt;span id="xdx_907_eus-gaap--LeaseAndRentalExpense_c20210401__20211231_z9BHbeDJ2Tal"&gt;80,698&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--LeaseAndRentalExpense_c20200401__20201231_z5l2mr1N2Rke"&gt;80,654&lt;/span&gt; for the nine months ended December 31, 2021 and 2020, respectively, and $&lt;span id="xdx_90A_eus-gaap--LeaseAndRentalExpense_c20211001__20211231_zcADFxelGKi5"&gt;26,930&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--LeaseAndRentalExpense_c20201001__20201231_z4Wt8IcRaChh"&gt;26,844&lt;/span&gt; for
the three months ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2020-04-012020-04-30"
      decimals="0"
      unitRef="USD">12400</us-gaap:LeaseAndRentalExpense>
    <modd:OperatingLeasesAnnualRentIncreasePercentange contextRef="AsOf2020-04-02" decimals="INF" unitRef="Pure">0.03</modd:OperatingLeasesAnnualRentIncreasePercentange>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">270950</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <modd:LeaseIncentiveReceived contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">139000</modd:LeaseIncentiveReceived>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_89E_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zJmxZubEG2ql" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8B0_zxWDKwGCiRO8"&gt;Future
minimum payments under the facility operating lease&lt;/span&gt;, as of December 31, 2021, are listed in the table below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 9pt; text-align: justify"/&gt;

</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <modd:DisclosureLeaseDetailsAbstract contextRef="From2021-04-01to2021-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--DisclosureLeaseDetailsAbstract_zI3Kg6Yps0F5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASES (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Annual Fiscal Years&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20211231_z2XAUWdNaUfg" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Operating&lt;br/&gt; lease&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_maOLFMPz6XG_zdjbLZgmxOe3" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 87%; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;38,358&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_maOLFMPz6XG_zqAa2Rf3FnEd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;158,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_maOLFMPz6XG_zzhclJCqGXo3" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,692&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--OperatingLeasesImputedInterest_iI_maOLFMPz6XG_z073Amdjcmm7" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt; padding-bottom: 1pt"&gt;Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(20,049&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iTI_mtOLFMPz6XG_zN6ZgoIM8uQf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;217,029&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureLeaseDetailsAbstract>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">38358</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">158028</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">40692</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <modd:OperatingLeasesImputedInterest contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-20049</modd:OperatingLeasesImputedInterest>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">217029</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <modd:CashPaidforLeaseLiabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">115073</modd:CashPaidforLeaseLiabilities>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">80698</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2020-04-012020-12-31"
      decimals="0"
      unitRef="USD">80654</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2021-10-012021-12-31"
      decimals="0"
      unitRef="USD">26930</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2020-10-012020-12-31"
      decimals="0"
      unitRef="USD">26844</us-gaap:LeaseAndRentalExpense>
    <modd:PPPNotesPayableTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_805_ecustom--PPPNotesPayableTextBlock_z1pYskgfGTY9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE
3 &#x2013; &lt;span id="xdx_82B_zu9sua4qxjwh"&gt;PPP NOTE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On April
24, 2020, the Company received a $&lt;span id="xdx_902_eus-gaap--UnsecuredDebtCurrent_iI_c20200424_zuS4y3ofPMQa"&gt;368,780&lt;/span&gt; unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which
was established under the U.S. government&#x2019;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP
Note to the Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration
Paycheck Protection Program Note with the Lender evidencing the PPP Note. The full amount of the PPP Note was due in April 2022
and interest accrued on the outstanding principal balance of the PPP Note at a fixed rate of 1.0% per annum, which was deferred
for 10 months after the covered period during which the Company used the proceeds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
applied to the Lender for forgiveness of the PPP Note in October 2020, and, in May 2021, the Company was notified by the Lender
and the U.S. Small Business Administration that the outstanding principal and accrued interest for the PPP Note was forgiven in
full. The Company accounted for the forgiveness of the PPP Note in accordance with Accounting Standards Codification Topic 470:
Debt (ASC 470), and the amount forgiven was recorded as a gain on extinguishment and recognized in the other income line of the
condensed consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;

</modd:PPPNotesPayableTextBlock>
    <us-gaap:UnsecuredDebtCurrent contextRef="AsOf2020-04-24" decimals="0" unitRef="USD">368780</us-gaap:UnsecuredDebtCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_80C_eus-gaap--DebtDisclosureTextBlock_zAiJa8bB4pD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE
4 &#x2013; &lt;span id="xdx_82B_zDANrQwEOcLj"&gt;CONVERTIBLE PROMISSORY NOTES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;From
February through April 2021, the Company sold $2,310,000 of convertible promissory notes (each an Original Notes and, collectively,
the Original Notes), at par in a private placement transaction effected pursuant to an exemption from the registration requirements
under the Securities Act of 1933, as amended. Effective April 30, 2021, pursuant to a revocation and replacement agreement between
each holder of an Original Note and the Company (the Revocation Agreement), the $2,310,000 of Original Notes and accrued interest
thereon as of April 30, 2021 were replaced with $2,360,550 aggregate principal amount of new Notes (as defined below). The Company
accounted for the replacement of the Original Notes in accordance with ASC 470 and recorded a loss on extinguishment of $&lt;span id="xdx_900_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20210401__20211231_z7Gjzm5a3EVg"&gt;1,321,450&lt;/span&gt;
and interest expense of $&lt;span id="xdx_906_eus-gaap--AmortizationOfFinancingCosts_c20210401__20211231_zshpgyKP037h"&gt;70,647&lt;/span&gt; for unamortized debt issuance costs as of April 30, 2021.&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In April
and May 2021, pursuant to a Securities Purchase Agreement by and between the Company and each investor (the SPA), the Company
sold to investors $&lt;span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_c20210531__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zaxJPRzXweH3"&gt;4,250,000&lt;/span&gt; aggregate principal amount of convertible promissory notes (the Notes) and warrants to purchase shares
of its common stock (the Warrants). The Notes are unsecured obligations of the Company with each Note having a stated maturity
date of 12 months from its issue date (the Issue Date). The Notes bear interest at a rate of 12% per annum, payable on maturity,
provided that, if the Company fails to pay any amounts when due under a Note, the interest rate increases to the greater of 16%
or the maximum amount permitted by law. Each Note may be prepaid at the Company&#x2019;s option during the first 270 calendar days
following its Issue Date (the 270&lt;sup&gt;th&lt;/sup&gt; day, the Trigger Date), subject to a 110% prepayment penalty on outstanding principal
and accrued interest then outstanding. No Note may be prepaid in whole or in part after the Trigger Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Notes
outstanding after the Trigger Date may be converted into shares of the Company&#x2019;s common stock at an initial conversion price
of $8.61 per share; provided that a Note holder may not convert any portion of its Note that would cause it to beneficially own
in excess of 4.99% of the Company&#x2019;s outstanding common stock. The conversion price and number of shares of Company common
stock issuable upon conversion of the Notes are subject to adjustment from time to time for subdivisions and consolidations of
shares and other standard dilutive and corporate events, as provided in the Notes. Subject to certain Exempt Issuances (as defined
in the Notes), if while a Note is outstanding, the Company sells, issues or grants any shares of its common stock or other securities
to acquire shares of common stock at a price per share less than the then conversion price, such conversion price shall be reduced
to such lesser price, and the number of conversion shares issuable upon conversion of the Notes shall be increased, as provided
in the Notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;If the
Company completes an offering of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified
Capital Raise, as defined in the Notes), each Note holder will be required to convert its Adjusted Note Amount (as defined below)
into the securities of such Qualified Capital Raise. Adjusted Note Amount equals the product of (i) the sum of all outstanding
principal plus accrued interest on a Note, multiplied by (ii) 1.25.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Notes
contain a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal
or interest thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting
requirements under the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement,
(v) material restatements of the Company&#x2019;s consolidated financial statements filed with the SEC, (vi) a holder&#x2019;s inability
to rely on Rule 144 for sales of shares underlying the Notes, (vii) the Company&#x2019;s common stock is suspended or halted from
trading and/or fails to be quoted or listed (as applicable) on the OTCQB, OTCQX, any tier of the NASDAQ Stock Market, the New
York Stock Exchange, or the NYSE American within 10 days thereafter, (viii) failure to file with the SEC a registration statement
covering the resale of shares of common stock underlying the Notes and Warrants within 60 calendar days following the Issue Date,
(ix) failure to cause such registration statement to become effective within 120 calendar days following the Issue Date, or (x)
certain mergers consolidations, business combinations and sales of all or substantially all of the Company&#x2019;s assets in the
event the Company is not the survivor of such transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Upon
an Event of Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will
be required to pay such Note holder the sum of (i) the product of (a) all then outstanding principal amount and accrued interest
thereon, multiplied by (b) 125%; and (ii) all collection costs including legal fees and expenses in connection therewith. At the
option of a Note holder, in the event the Company receives cash proceeds as a result of certain events, including, but not limited
to, payments from customers, issuances of debt or equity securities, exercise of warrants or asset sales, the Company will be
required to use such proceeds to repay all or any lesser outstanding amounts due under such holder&#x2019;s Note.&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Notes
include covenants, representations, warranties, other payment obligations and agreements by the Company including, without limitation,
most-favored nation rights, rights of participation and first refusal and exchange rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In connection
with the issuance of the Notes, the Company issued Warrants to purchase in the aggregate 767,796 shares of its common stock at
an initial exercise price of $24.00 per share. The Warrants may be exercised for a period of five years from the Trigger Date,
provided that, if prior to the Trigger Date, the Company (i) completes a Qualified Capital Raise, the outstanding Warrants shall
be cancelled or (ii) prepays a holder&#x2019;s Note(s) in whole or in part, such holder&#x2019;s pro-rata number of Warrants shall
be cancelled. The fair value of the Warrants was $3,700,632, of which $2,379,182 was recorded as a debt discount, which is being
amortized to interest expense over the term of the Warrants, and $1,321,450 was recorded as a loss on debt extinguishment. The
Company calculated the fair value of the Warrants utilizing the Black-Scholes valuation model with the following assumptions:
volatility of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_c20210401__20211231_zsRt4WHqRwy2"&gt;88.98%&lt;/span&gt;, risk-free interest rate of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20211231_zLknLX55GhKe"&gt;0.86%&lt;/span&gt;, a term of &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20210401__20211231_zGJvvNpm3bWh" title="::XDX::P5Y9M"&gt;5.75&lt;/span&gt; years and a dividend yield of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dcpxH_c20210401__20211231_zLx04zbKA4ge" title="::XDX::0"&gt;zero&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In connection
with the April and May 2021 sales of the $4,250,000 aggregate principal amount of the Notes, the Company incurred debt issuance
costs of $116,000, which were recorded as a debt discount and are being amortized to interest expense over the term of the Notes
using the effective interest rate method. The interest expense attributable to the debt discount, comprising the debt issuance
costs and Warrants, during the three and nine months ended December 31, 2021 was $630,323 and $1,454,762, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The $6,610,550
aggregate principal amount of Notes are due and payable in full in the first quarter of fiscal 2023. Subsequent to the Trigger
Date, the Notes can be converted into &lt;span id="xdx_90C_ecustom--NotesAndAccuredInterestCouldBeConvertedIntoCommonStock_iI_c20211231_zAX49DWsrmre"&gt;767,783&lt;/span&gt; shares of common stock at a conversion price of $8.61 per share.&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">-1321450</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2021-04-01to2021-12-31"
      decimals="0"
      unitRef="USD">70647</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2021-05-31_us-gaap_ConvertibleNotesPayableMember"
      decimals="0"
      unitRef="USD">4250000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2021-04-01to2021-12-31"
      decimals="INF"
      unitRef="Pure">0.8898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-04-01to2021-12-31"
      decimals="INF"
      unitRef="Pure">0.0086</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <modd:NotesAndAccuredInterestCouldBeConvertedIntoCommonStock contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">767783</modd:NotesAndAccuredInterestCouldBeConvertedIntoCommonStock>
    <modd:PromissoryNoteTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_804_ecustom--PromissoryNoteTextBlock_zZLKfUWSVEFc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE
5 &#x2013; &lt;span id="xdx_82A_zXncvbeBDPdf"&gt;PROMISSORY NOTE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On
October 28, 2021, the Company issued a secured promissory note (the Bridge Note) to Manchester Explorer, L.P. (&#x201c;Manchester&#x201d;)
that provides the Company with a $&lt;span id="xdx_90E_eus-gaap--LineOfCredit_iI_c20211028__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--InvestmentTypeAxis__custom--SecuredPromissoryNotesMember_zEh8GdOS7zXk"&gt;3,000,000&lt;/span&gt; revolving credit facility with all amounts being drawn down by the Company thereunder
being due and payable, subject to acceleration in the event of a default, on &lt;span id="xdx_90A_eus-gaap--LineOfCreditFacilityExpirationDate1_c20211027__20211028__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--InvestmentTypeAxis__custom--SecuredPromissoryNotesMember_zDtbfLEgLYo2" title="Maturity Date"&gt;March 15, 2022&lt;/span&gt; (the &#x201c;Maturity Date&#x201d;).
Interest at the rate of &lt;span id="xdx_90E_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_c20211027__20211028__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--InvestmentTypeAxis__custom--SecuredPromissoryNotesMember_zV3wKkgD9ZS"&gt;12%&lt;/span&gt; is payable on each drawn down without regard to the draw down date or the date when interest is paid.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The
principal amount of the Bridge Note and interest due thereon is payable to Manchester no later than the earlier of: (i) the Maturity
Date and (ii) the date on which the Company has received proceeds in excess of $12,000,000 from a transaction or series of related
transactions occurring prior to the Maturity Date, which such transactions constitute equity financings or other issuances of
the Company&#x2019;s equity securities. Provided that no Event of Default (as such term is defined in the Bridge Note) has occurred,
on any date prior to the Maturity Date, upon no less than three days written notice by the Company specifying the draw amount,
Manchester will advance the draw amount to the Company. No draw amount can be in an amount less than $100,000 or exceed an amount
equal to $3,000,000 minus the aggregate principal amount outstanding under the Bridge Note at the time of such draw request. If
an Event of Default occurs and is continuing, Manchester may declare all of the Bridge Note, including any interest and other
amounts due, to be due and payable immediately.&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In
connection with the issuance of the Note, on October 28, 2021, the Company entered into a Security Agreement with Manchester (the
&#x201c;Security Agreement&#x201d;) under which the Company granted Manchester a continuing and unconditional first priority security
interest in and to any and all of the Company&#x2019;s property of any kind or description, tangible or intangible, wheresoever
located and whether now existing or hereafter arising or acquired.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;During
the quarter ended December 31, 2021, the Company made draws on the Bridge Note of $&lt;span id="xdx_90C_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_c20211001__20211231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zosYE3aCBPLk"&gt;1,500,000&lt;/span&gt; and incurred interest charges of
$&lt;span id="xdx_90E_eus-gaap--LineOfCreditFacilityIncreaseAccruedInterest_c20211001__20211231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zGfFez5D3hHk"&gt;180,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;



</modd:PromissoryNoteTextBlock>
    <us-gaap:LineOfCredit
      contextRef="AsOf2021-10-28_us-gaap_RevolvingCreditFacilityMember_custom_SecuredPromissoryNotesMember"
      decimals="0"
      unitRef="USD">3000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityExpirationDate1 contextRef="From2021-10-272021-10-28_us-gaap_RevolvingCreditFacilityMember_custom_SecuredPromissoryNotesMember">2022-03-15</us-gaap:LineOfCreditFacilityExpirationDate1>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="From2021-10-272021-10-28_us-gaap_RevolvingCreditFacilityMember_custom_SecuredPromissoryNotesMember"
      decimals="INF"
      unitRef="Pure">0.12</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet
      contextRef="From2021-10-012021-12-31_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      unitRef="USD">1500000</us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet>
    <us-gaap:LineOfCreditFacilityIncreaseAccruedInterest
      contextRef="From2021-10-012021-12-31_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      unitRef="USD">180000</us-gaap:LineOfCreditFacilityIncreaseAccruedInterest>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_80A_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zQz1HdeI7FFf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE
6 &#x2013; &lt;span id="xdx_82D_z6GULZVoIzo8"&gt;STOCKHOLDERS&#x2019; DEFICIT AND STOCK-BASED COMPENSATION&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;During
the three months ended December 31, 2021, the Company sold 30,865 shares of common stock to its chief executive officer and its
chairman of the board of directors, president, chief financial officer and treasurer, issued 8,334 shares of common stock to a
service provider and issued 5,775 shares to its non-employee directors under the Company&#x2019;s outside director compensation
plan. At December 31, 2021, the Company had an obligation to issue 16,666 shares of common stock to service providers, and the
value of these shares was recorded as common stock issuable in the condensed consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Amended
2017 Equity Incentive Plan &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In October
2017, the Company&#x2019;s board of directors (the Board) approved the 2017 Equity Incentive Plan (the Plan) with &lt;span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20171031_ztEmafj12tal"&gt;1,000,000&lt;/span&gt; shares
of common stock reserved for issuance. In January 2020 and August 2021, the Board approved increases in the number of shares reserved
for issuance under the Plan by &lt;span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200131_zlXA0kJN12F2"&gt;333,334&lt;/span&gt; and &lt;span id="xdx_904_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20200831_zMSDt8zLhQSk"&gt;1,333,334&lt;/span&gt; shares, respectively. Under the Plan, eligible employees, directors and consultants
may be granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based
awards and restricted stock units. The Plan is administered by the Board or, in the alternative, a committee designated by the
Board.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Stock-Based
Compensation Expense&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The expense
relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period,
based on the grant date fair value. The unamortized compensation cost, as of December 31, 2021, was $&lt;span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20211231_zlB1owsTyga"&gt;7,419,022&lt;/span&gt; related to stock
options and is expected to be recognized as expense over a weighted-average period of approximately &lt;span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dxH_c20210401__20211231_zHpVu1aRNWu" title="::XDX::P2Y"&gt;two&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;During
the nine months ended December 31, 2021, the Company granted options to purchase &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zoRiL3V4EeLf"&gt;723,269&lt;/span&gt; shares of its common stock to employees,
directors and consultants. The options had 10-year terms, and &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zUHxuUD5tbBj"&gt;85,484&lt;/span&gt; options vested immediately when granted. The fair value of
the options was determined to be $&lt;span id="xdx_909_ecustom--FairValueofOptionGranted_c20210401__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMgkdlr2ZUMk"&gt;8,108,043&lt;/span&gt; of which $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20210401__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zfNzWohm5oJ"&gt;1,769,805&lt;/span&gt; was recorded as stock-based compensation expense and included
in the condensed consolidated statement of operations for the nine months ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;







&lt;p id="xdx_891_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zvoaga1a89yd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The following
assumptions were used in the fair value method calculations:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8BC_zoHpYNToBpPe" style="display: none"&gt;Schedule of Fair Value Assumptions&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zBie8INYQvq1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp;amp; STOCK-BASED COMPENSATION (Details)"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Three
    Months Ended&lt;br/&gt; December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Nine
    Months Ended&lt;br/&gt; December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Risk-free
    interest rates&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_zJhiCTvtdor5"&gt;1.26%&lt;/span&gt; - &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zFYXEYTjgfXj"&gt;1.36%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20201001__20201231_zgrZ8UmxTHRa"&gt;0.38%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_z8xm6yEUn6ze"&gt;0.8%&lt;/span&gt; - &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_z4F0L9F5VYCg"&gt;1.36%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20201231__srt--RangeAxis__srt--MinimumMember_zMAGWA6uQjTh"&gt;0.28%&lt;/span&gt; - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20201231__srt--RangeAxis__srt--MaximumMember_zmxRF2Rnv4Gk"&gt;0.38%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_zzxbc1ec0iya"&gt;197%&lt;/span&gt;
                                         - &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zX9wuplYzrge"&gt;253%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20201001__20201231_zzEbfdv7ehvb"&gt;87%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_zmHwQ5WCgu2d"&gt;89%&lt;/span&gt;
                                         - &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_zgALPDHRxh5b"&gt;370%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20201231__srt--RangeAxis__srt--MinimumMember_z3J24CnpuBAf"&gt;87%&lt;/span&gt;
                                         - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20201231__srt--RangeAxis__srt--MaximumMember_zTf56EI8vHUa"&gt;127%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_z3uH1IqRNXW8"&gt;5.0&lt;/span&gt;
                                         &#x2013; &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zUli8eAzzafj"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231__srt--RangeAxis__srt--MinimumMember_zRuCprlQIXoe"&gt;5.2&lt;/span&gt;
                                         &#x2013; &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231__srt--RangeAxis__srt--MaximumMember_zOj6Ji4p1sYa"&gt;5.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_zy0bHBwbcbmj"&gt;5.0&lt;/span&gt;
                                         - &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_zu1julJ9OpCf"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20201231__srt--RangeAxis__srt--MinimumMember_zgqyty753UOh"&gt;5.0&lt;/span&gt;
                                         - &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20201231__srt--RangeAxis__srt--MaximumMember_z5K54pvMIsg"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20211001__20211231_zm1YAE8gfGAg"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20201001__20201231_zc9a5wEnzU71"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20210401__20211231_zWrUnJCVcVV8"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20201231_zgll00aypvEi"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;





&lt;p id="xdx_8A0_zt8mvG0EWljf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The fair
values of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods
to establish the fair term of options as well as average volatility of three comparable organizations. The risk-free interest
rate was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant
date for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never
paid dividends and has no intention to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company
accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zgPewvRZSuA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;A summary
of stock option activity under the Plan is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8BF_zMfIkSaPKpo3" style="display: none"&gt;Schedule of Stock Option activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zJgKjtBn1Yde" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp;amp; STOCK-BASED COMPENSATION (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;br/&gt; Available&lt;br/&gt; for Grant&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Prices&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 61%"&gt;Balance at March 31, 2021&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zwC7l1Fa7005" style="width: 8%; text-align: right"&gt;136,082&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmpnLVcwY3H" style="width: 8%; text-align: right"&gt;1,197,252&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5b8iKkQzy1l" style="width: 8%; text-align: right"&gt;5.25&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zczvsn3JQKFi" style="text-align: right"&gt;(60,774&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoueppVNmd15" style="text-align: right"&gt;60,774&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSqVkRYMnjPh" style="text-align: right"&gt;12.69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-left: 8.65pt"&gt;Share awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKnwKSq88j1h" style="text-align: right"&gt;(1,836&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgshN5RbEzDh" style="border-bottom: Black 1pt solid; text-align: right"&gt;7,547&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3cy1HgyK8jh" style="border-bottom: Black 1pt solid; text-align: right"&gt;(7,547&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT43tyNwyf" style="border-bottom: Black 1pt solid; text-align: right"&gt;8.61&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td&gt;Balance at June 30, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLN21uVqY9e3" style="text-align: right"&gt;81,089&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWS7z1Hgdljk" style="text-align: right"&gt;1,250,479&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziGgmlnX6b1i" style="text-align: right"&gt;5.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Additional shares authorized under the Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztHm9HiOjxM" style="text-align: right"&gt;1,333,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zw75AdIoqDyd" style="text-align: right"&gt;(396,384&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAUosEMtvCBd" style="text-align: right"&gt;396,384&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyFNIXkQzrj5" style="text-align: right"&gt;12.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 8.65pt"&gt;Share awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRLRhaCnjRf6" style="text-align: right"&gt;(3,636&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyad6u5ObVd3" style="border-bottom: Black 1pt solid; text-align: right"&gt;49,213&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zTxde3atswIb" style="border-bottom: Black 1pt solid; text-align: right"&gt;(49,213&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQHd0IPPrYek" style="border-bottom: Black 1pt solid; text-align: right"&gt;7.02&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Balance at September 30, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2QiQGPgV8T3" style="text-align: right"&gt;1,063,546&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5KsGdZdFMok" style="text-align: right"&gt;1,597,650&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zr46KajKTuM2" style="text-align: right"&gt;7.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLCJHdBqM5kc" style="text-align: right"&gt;(266,112&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5ZRQE89Yb73" style="text-align: right"&gt;259,559&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBSJy6ClQVAc" style="text-align: right"&gt;9.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 8.65pt"&gt;Share awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx4DAV7jxxii" style="text-align: right"&gt;(5,775&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmghZMF6l164" style="border-bottom: Black 1pt solid; text-align: right"&gt;29,073&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zV9lNSrU3La7" style="border-bottom: Black 1pt solid; text-align: right"&gt;(11,256&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBuKoN8LsIr9" style="border-bottom: Black 1pt solid; text-align: right"&gt;7.24&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Balance at December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zApvYc0926E8" style="border-bottom: Black 2.5pt double; text-align: right"&gt;820,732&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziAAAHiBLCc3" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,845,953&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDJsNb4lL4fc" style="border-bottom: Black 2.5pt double; text-align: right"&gt;7.57&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;There were no stock options exercised during the nine months ended December 31, 2021 and 2020.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_zHfLqyJ8vjpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The following
table summarizes the range of outstanding and exercisable options as of December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B0_zjWp49Tt5yt7" style="display: none"&gt;Schedule of
Outstanding and Exercisable Option, Range&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zhuv6eC9oSy" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp;amp; STOCK-BASED COMPENSATION (Details 3)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Range of Exercise Price&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number&lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;br/&gt; (in Years)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number&lt;br/&gt; Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 22%; padding-bottom: 1pt"&gt;$&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zfOh8Nh6lWy3"&gt;1.98&lt;/span&gt; - $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zxbrZpd0Al24"&gt;17.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDlPIupeKgEh" style="border-bottom: Black 1pt solid; width: 8%; text-align: right"&gt;1,845,953&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxH_c20210401__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGGy1zqdjbL1" style="width: 8%; padding-bottom: 1pt; text-align: right" title="::XDX::P8Y1M17D"&gt;8.13&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVj3UdAANCp3" style="width: 8%; padding-bottom: 1pt; text-align: right"&gt;7.57&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zketqRJJRft7" style="border-bottom: Black 1pt solid; width: 8%; text-align: right"&gt;1,011,586&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znJSsM8zPE36" style="width: 8%; padding-bottom: 1pt; text-align: right"&gt;5.10&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6lN4x67ZMvb" style="border-bottom: Black 1pt solid; width: 8%; text-align: right"&gt;3,564,268&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A4_z8FJHdEPWO81" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The intrinsic
value per share is calculated as the excess of the closing price of the common stock on the Company&#x2019;s principal trading
market over the exercise price of the option at December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise
of stock options as financing cash flows in the consolidated statements of cash flows. For the nine months ended December 31,
2021 and 2020, there were no such tax benefits associated with the exercise of stock options.&lt;b&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2017-10-31" decimals="INF" unitRef="Shares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2020-01-31" decimals="INF" unitRef="Shares">333334</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2020-08-31" decimals="INF" unitRef="Shares">1333334</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">7419022</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-04-012021-12-31_us-gaap_CommonStockMember_us-gaap_EmployeeStockMember"
      decimals="INF"
      unitRef="Shares">723269</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-04-012021-12-31_us-gaap_StockOptionMember_us-gaap_EmployeeStockMember"
      decimals="INF"
      unitRef="Shares">85484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <modd:FairValueofOptionGranted
      contextRef="From2021-04-012021-12-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">8108043</modd:FairValueofOptionGranted>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2021-04-012021-12-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">1769805</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zvoaga1a89yd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The following
assumptions were used in the fair value method calculations:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8BC_zoHpYNToBpPe" style="display: none"&gt;Schedule of Fair Value Assumptions&lt;/span&gt;&lt;/p&gt;



</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <modd:DisclosureStockBasedCompensationDetailsAbstract contextRef="From2021-04-01to2021-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zBie8INYQvq1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp;amp; STOCK-BASED COMPENSATION (Details)"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Three
    Months Ended&lt;br/&gt; December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Nine
    Months Ended&lt;br/&gt; December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Risk-free
    interest rates&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_zJhiCTvtdor5"&gt;1.26%&lt;/span&gt; - &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zFYXEYTjgfXj"&gt;1.36%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20201001__20201231_zgrZ8UmxTHRa"&gt;0.38%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_z8xm6yEUn6ze"&gt;0.8%&lt;/span&gt; - &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_z4F0L9F5VYCg"&gt;1.36%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20201231__srt--RangeAxis__srt--MinimumMember_zMAGWA6uQjTh"&gt;0.28%&lt;/span&gt; - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200401__20201231__srt--RangeAxis__srt--MaximumMember_zmxRF2Rnv4Gk"&gt;0.38%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_zzxbc1ec0iya"&gt;197%&lt;/span&gt;
                                         - &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zX9wuplYzrge"&gt;253%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20201001__20201231_zzEbfdv7ehvb"&gt;87%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_zmHwQ5WCgu2d"&gt;89%&lt;/span&gt;
                                         - &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_zgALPDHRxh5b"&gt;370%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20201231__srt--RangeAxis__srt--MinimumMember_z3J24CnpuBAf"&gt;87%&lt;/span&gt;
                                         - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200401__20201231__srt--RangeAxis__srt--MaximumMember_zTf56EI8vHUa"&gt;127%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231__srt--RangeAxis__srt--MinimumMember_z3uH1IqRNXW8"&gt;5.0&lt;/span&gt;
                                         &#x2013; &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20211001__20211231__srt--RangeAxis__srt--MaximumMember_zUli8eAzzafj"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231__srt--RangeAxis__srt--MinimumMember_zRuCprlQIXoe"&gt;5.2&lt;/span&gt;
                                         &#x2013; &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231__srt--RangeAxis__srt--MaximumMember_zOj6Ji4p1sYa"&gt;5.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20211231__srt--RangeAxis__srt--MinimumMember_zy0bHBwbcbmj"&gt;5.0&lt;/span&gt;
                                         - &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210401__20211231__srt--RangeAxis__srt--MaximumMember_zu1julJ9OpCf"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20201231__srt--RangeAxis__srt--MinimumMember_zgqyty753UOh"&gt;5.0&lt;/span&gt;
                                         - &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20201231__srt--RangeAxis__srt--MaximumMember_z5K54pvMIsg"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20211001__20211231_zm1YAE8gfGAg"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20201001__20201231_zc9a5wEnzU71"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20210401__20211231_zWrUnJCVcVV8"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20201231_zgll00aypvEi"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureStockBasedCompensationDetailsAbstract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-10-012021-12-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.0126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-10-012021-12-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-10-012020-12-31"
      decimals="INF"
      unitRef="Pure">0.0038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-04-012021-12-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-04-012021-12-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-04-012020-12-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.0028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-04-012020-12-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-10-012021-12-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">1.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-10-012021-12-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">2.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-10-012020-12-31"
      decimals="INF"
      unitRef="Pure">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-04-012021-12-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-04-012021-12-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">3.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-04-012020-12-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-04-012020-12-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">1.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-10-012021-12-31_srt_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-10-012021-12-31_srt_MaximumMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-10-012020-12-31_srt_MinimumMember">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-10-012020-12-31_srt_MaximumMember">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-04-012021-12-31_srt_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-04-012021-12-31_srt_MaximumMember">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-04-012020-12-31_srt_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-04-012020-12-31_srt_MaximumMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-10-012021-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-10-012020-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-04-01to2021-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-04-012020-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zgPewvRZSuA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;A summary
of stock option activity under the Plan is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8BF_zMfIkSaPKpo3" style="display: none"&gt;Schedule of Stock Option activity&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <modd:DisclosureStockBasedCompensationDetails2Abstract contextRef="From2021-04-01to2021-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zJgKjtBn1Yde" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp;amp; STOCK-BASED COMPENSATION (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;br/&gt; Available&lt;br/&gt; for Grant&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Prices&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 61%"&gt;Balance at March 31, 2021&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zwC7l1Fa7005" style="width: 8%; text-align: right"&gt;136,082&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmpnLVcwY3H" style="width: 8%; text-align: right"&gt;1,197,252&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5b8iKkQzy1l" style="width: 8%; text-align: right"&gt;5.25&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zczvsn3JQKFi" style="text-align: right"&gt;(60,774&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoueppVNmd15" style="text-align: right"&gt;60,774&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSqVkRYMnjPh" style="text-align: right"&gt;12.69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-left: 8.65pt"&gt;Share awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zKnwKSq88j1h" style="text-align: right"&gt;(1,836&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zgshN5RbEzDh" style="border-bottom: Black 1pt solid; text-align: right"&gt;7,547&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z3cy1HgyK8jh" style="border-bottom: Black 1pt solid; text-align: right"&gt;(7,547&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210401__20210630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zT43tyNwyf" style="border-bottom: Black 1pt solid; text-align: right"&gt;8.61&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td&gt;Balance at June 30, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLN21uVqY9e3" style="text-align: right"&gt;81,089&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWS7z1Hgdljk" style="text-align: right"&gt;1,250,479&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziGgmlnX6b1i" style="text-align: right"&gt;5.58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Additional shares authorized under the Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztHm9HiOjxM" style="text-align: right"&gt;1,333,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zw75AdIoqDyd" style="text-align: right"&gt;(396,384&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAUosEMtvCBd" style="text-align: right"&gt;396,384&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyFNIXkQzrj5" style="text-align: right"&gt;12.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 8.65pt"&gt;Share awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRLRhaCnjRf6" style="text-align: right"&gt;(3,636&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zyad6u5ObVd3" style="border-bottom: Black 1pt solid; text-align: right"&gt;49,213&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zTxde3atswIb" style="border-bottom: Black 1pt solid; text-align: right"&gt;(49,213&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQHd0IPPrYek" style="border-bottom: Black 1pt solid; text-align: right"&gt;7.02&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Balance at September 30, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2QiQGPgV8T3" style="text-align: right"&gt;1,063,546&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5KsGdZdFMok" style="text-align: right"&gt;1,597,650&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210701__20210930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zr46KajKTuM2" style="text-align: right"&gt;7.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLCJHdBqM5kc" style="text-align: right"&gt;(266,112&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5ZRQE89Yb73" style="text-align: right"&gt;259,559&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBSJy6ClQVAc" style="text-align: right"&gt;9.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 8.65pt"&gt;Share awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zx4DAV7jxxii" style="text-align: right"&gt;(5,775&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zmghZMF6l164" style="border-bottom: Black 1pt solid; text-align: right"&gt;29,073&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zV9lNSrU3La7" style="border-bottom: Black 1pt solid; text-align: right"&gt;(11,256&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBuKoN8LsIr9" style="border-bottom: Black 1pt solid; text-align: right"&gt;7.24&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Balance at December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iE_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zApvYc0926E8" style="border-bottom: Black 2.5pt double; text-align: right"&gt;820,732&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ziAAAHiBLCc3" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,845,953&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20211001__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDJsNb4lL4fc" style="border-bottom: Black 2.5pt double; text-align: right"&gt;7.57&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureStockBasedCompensationDetails2Abstract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">136082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1197252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant
      contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">-60774</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">60774</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">12.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards
      contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">-1836</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant
      contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">7547</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">7547</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-04-012021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">8.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">81089</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1250479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant
      contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1333334</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant
      contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">-396384</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">396384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">12.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards
      contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">-3636</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant
      contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">49213</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">49213</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">7.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1063546</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1597650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">7.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">-266112</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">259559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">9.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">-5775</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards>
    <modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">29073</modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">11256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-10-012021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">7.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">820732</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1845953</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">7.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_zHfLqyJ8vjpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The following
table summarizes the range of outstanding and exercisable options as of December 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B0_zjWp49Tt5yt7" style="display: none"&gt;Schedule of
Outstanding and Exercisable Option, Range&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
    <modd:DisclosureStockBasedCompensationDetails3Abstract contextRef="From2021-04-01to2021-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zhuv6eC9oSy" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp;amp; STOCK-BASED COMPENSATION (Details 3)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;Range of Exercise Price&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number&lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;br/&gt; (in Years)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number&lt;br/&gt; Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 22%; padding-bottom: 1pt"&gt;$&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zfOh8Nh6lWy3"&gt;1.98&lt;/span&gt; - $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zxbrZpd0Al24"&gt;17.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDlPIupeKgEh" style="border-bottom: Black 1pt solid; width: 8%; text-align: right"&gt;1,845,953&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtxH_c20210401__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGGy1zqdjbL1" style="width: 8%; padding-bottom: 1pt; text-align: right" title="::XDX::P8Y1M17D"&gt;8.13&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVj3UdAANCp3" style="width: 8%; padding-bottom: 1pt; text-align: right"&gt;7.57&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zketqRJJRft7" style="border-bottom: Black 1pt solid; width: 8%; text-align: right"&gt;1,011,586&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znJSsM8zPE36" style="width: 8%; padding-bottom: 1pt; text-align: right"&gt;5.10&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6lN4x67ZMvb" style="border-bottom: Black 1pt solid; width: 8%; text-align: right"&gt;3,564,268&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureStockBasedCompensationDetails3Abstract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">1.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">17.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1845953</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">7.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1011586</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2021-12-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">3564268</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_zUEqCSby3s5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE
7 &#x2013; &lt;span id="xdx_82D_zxkyS1vMVZte"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#x2019;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to
affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that
all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management
believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company
has recorded a full valuation allowance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. All tax returns for fiscal
2016 to fiscal 2021 may be subject to examination by the U.S. federal and state tax authorities. As of December 31, 2021, the
Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_80F_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zl0wjrUeuXPd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE
8 &#x2013; &lt;span id="xdx_82B_z5GWTZLhenl5"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;In
February 2021, the Company&#x2019;s chairman of the board of directors and president and an existing investor, who is represented by
a member of the Company&#x2019;s board of directors, purchased $100,000 and $1,000,000, aggregate principal amount of the Original
Notes, respectively. Effective April 30, 2021, the related party holders entered into revocation agreements with the Company
pursuant to which their collective $&lt;span id="xdx_907_ecustom--NotesCancelled_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember_zpEpvhCm5JPg"&gt;1,100,000&lt;/span&gt;
aggregate principal amount of Original Notes and accrued interest of $&lt;span id="xdx_904_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember_zcyifl49Z55f"&gt;50,091&lt;/span&gt;
were replaced with Notes. At December 31, 2021, the investor and executive officer held Notes in an aggregate principal amount of
$&lt;span id="xdx_902_eus-gaap--NotesPayable_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_z3CkvCUhqox5"&gt;1,026,630 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: white"&gt;and
$&lt;span id="xdx_906_eus-gaap--NotesPayable_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_z11Y8PN1Hqul"&gt;102,663&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: white"&gt;,
respectively, with $&lt;span id="xdx_90C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_z2tgfwXqwLbf"&gt;82,693 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: white"&gt;and
$&lt;span id="xdx_905_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_zOOV3VE30ppc"&gt;8,269 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: white"&gt;of
interest payable thereon. For the three months ended December 31, 2021, the Company incurred interest expense of approximately
$&lt;span id="xdx_906_eus-gaap--InterestExpense_c20211001__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zJlsPLO8Ucc3"&gt;31,052&lt;/span&gt;
and $&lt;span id="xdx_90E_eus-gaap--InterestExpense_c20201001__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zm29wzzYRPh5"&gt;3,105&lt;/span&gt;,
respectively, and for the nine months ended December 31, 2021, the Company incurred interest expense of approximately $&lt;span id="xdx_90F_eus-gaap--InterestExpense_c20200401__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zduk0yOy6uCg"&gt;82,693&lt;/span&gt;
and $&lt;span id="xdx_90C_eus-gaap--InterestExpense_c20210401__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables1Member_zWDYuGmYOvei"&gt;8&lt;/span&gt;,269,
respectively, on the related party holder Notes.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In May
2021, a member of the Board purchased $&lt;span id="xdx_901_eus-gaap--NotesPayable_iI_c20210531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember_zCkH58G40yP9"&gt;200,000&lt;/span&gt; aggregate principal amount of Notes (the Director Note). For the three and nine
months ended December 31, 2021, the Company incurred expense of approximately $&lt;span id="xdx_90A_eus-gaap--InterestExpense_c20211001__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_zdzZyZbvd3t4"&gt;6,049&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--InterestExpense_c20200401__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CEOAndInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--NotesPayableOtherPayables2Member_zFDOKrRi1Gb4"&gt;16,110&lt;/span&gt;, respectively, on the Director
Note. At December 31, 2021, approximately $&lt;span id="xdx_90F_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MemberOfBoardMember_z7AmrHnUNT13"&gt;16,110&lt;/span&gt; of interest was payable by the Company on the Director Note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In
October 2021, the Company entered into purchase agreements with &lt;span id="xdx_91E_esrt--ChiefExecutiveOfficerMember_zehMJcD8lkOc"&gt;Ellen O&#x2019;Connor (Lynn) Vos&lt;/span&gt;, the Company&#x2019;s chief executive
officer, and &lt;span id="xdx_916_esrt--BoardOfDirectorsChairmanMember_zy02JHBnJS12"&gt;Paul DiPerna&lt;/span&gt;, the chairman of the Company&#x2019;s board of directors and its president, chief financial officer and
treasurer, providing for the sale and issuance by the Company of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20211031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9rvwpXchzH8"&gt;30,864&lt;/span&gt; shares of the Company&#x2019;s common stock, par value
$0.001 per share at the closing market price on October 28, 2021 of $8.10 per share. The Company received proceeds of approximately
$250,000 from the sale of the shares, comprising $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20211031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zUBpGab4RsSe"&gt;150,000&lt;/span&gt; from Ms. Vos and $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20211031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--BoardOfDirectorsChairmanMember_z80d6un24TL6"&gt;100,000&lt;/span&gt; from Mr. DiPerna.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <modd:NotesCancelled
      contextRef="AsOf2021-12-31_custom_CEOAndInvestorMember"
      decimals="INF"
      unitRef="Shares">1100000</modd:NotesCancelled>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2021-12-31_custom_CEOAndInvestorMember"
      decimals="0"
      unitRef="USD">50091</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:NotesPayable
      contextRef="AsOf2021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member"
      decimals="0"
      unitRef="USD">1026630</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member"
      decimals="0"
      unitRef="USD">102663</us-gaap:NotesPayable>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member"
      decimals="0"
      unitRef="USD">82693</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member"
      decimals="0"
      unitRef="USD">8269</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestExpense
      contextRef="From2021-10-012021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member"
      decimals="0"
      unitRef="USD">31052</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-10-012020-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member"
      decimals="0"
      unitRef="USD">3105</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-04-012020-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member"
      decimals="0"
      unitRef="USD">82693</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-04-012021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member"
      decimals="0"
      unitRef="USD">8</us-gaap:InterestExpense>
    <us-gaap:NotesPayable
      contextRef="AsOf2021-05-31_custom_MemberOfBoardMember"
      decimals="0"
      unitRef="USD">200000</us-gaap:NotesPayable>
    <us-gaap:InterestExpense
      contextRef="From2021-10-012021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member"
      decimals="0"
      unitRef="USD">6049</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-04-012020-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables2Member"
      decimals="0"
      unitRef="USD">16110</us-gaap:InterestExpense>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2021-12-31_custom_MemberOfBoardMember"
      decimals="0"
      unitRef="USD">16110</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-10-012021-10-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">30864</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-10-012021-10-31_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-10-012021-10-31_srt_BoardOfDirectorsChairmanMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zbceCCTkrLKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE
9 &#x2013; &lt;span id="xdx_824_zaPq6zvWTJl9"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Litigations,
Claims and Assessments &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In the
normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course
of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable
settlements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Indemnification&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In the
ordinary course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties
from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims
and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising
from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses.
The Company has also entered into indemnification agreements with its officers and directors. No amounts were reflected in the
Company&#x2019;s consolidated financial statements for the nine months ended December 31, 2021 and 2020 related to these indemnifications.
The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited
history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has
not made any payments related to these indemnification agreements, and no claims for payment have been made under such agreements.&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2021-04-01to2021-12-31">&lt;p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_znpdYl2pAO33" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE
10 &#x2013; &lt;span id="xdx_823_zAU6dGNwHE6e"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 9.05pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Bridge
Note&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 9.05pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 9.05pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Subsequent
to December 31, 2021, the Company made additional draws totaling $&lt;span id="xdx_901_eus-gaap--LineOfCreditFacilityIncreaseDecreaseForPeriodNet_c20220101__20220214__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_z7zukpg0ljG8"&gt;600,000&lt;/span&gt; under the Bridge Note.&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 9.05pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_91F_eus-gaap--IPOMember_zixvTgUUY3Zg"&gt;Public
Offering&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0.25pt 9.05pt 0 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On February
9, 2022, the Company entered into an underwriting agreement (the Underwriting Agreement), with Oppenheimer &amp;amp; Co. Inc.,
which acted as the representative of the several underwriters (the &#x201c;Representative&#x201d;), in a firm commitment underwritten
public offering (the Offering) pursuant to which the Company agreed to sell to the Representative an aggregate of 2,500,000 shares
of the Company&#x2019;s common stock, par value $0.001 per share (the Common Stock), and 2,500,000 warrants (Warrants and, collectively
with the Common Stock, the Units), each to purchase one share of Common Stock, at a public offering price of $6.00 per Unit. The
Warrants included in the Units are exercisable immediately, have an exercise price of $6.60 per share and expire five years from
the date of issuance. The Common Stock was approved to list on the Nasdaq Capital Market under the symbol &#x201c;MODD&#x201d; and
began trading there on February 10, 2022. The gross proceeds from the Offering were $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_pdp0_dm_c20220209__20220210__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zj4ohTeyRNYf"&gt;15 million&lt;/span&gt;, before deducting underwriting
discounts and commissions and other offering expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Units were
offered and sold to the public pursuant to the Company&#x2019;s registration statement on Form S-1 (File No. 333-260682), initially
filed by the Company with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the Securities
Act), on November 2, 2021, and declared effective on February 9, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Underwriting
Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification
obligations of the Company and the Representative, including for liabilities under the Securities Act of 1933, as amended,
other obligations of the parties and termination provisions. In addition, pursuant to the terms of the Underwriting Agreement and
related &#x201c;lock-up&#x201d; agreements, the Company, each director and executive officer of the Company, and certain stockholders
have agreed with the Representative not to offer for sale, issue, sell, contract to
sell, pledge or otherwise dispose of any of our Common Stock or securities convertible into Common Stock for a period of 180 days
after February 9, 2022, the date of the final prospectus.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet
      contextRef="From2022-01-012022-02-14_us-gaap_SubsequentEventMember_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      unitRef="USD">600000</us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-02-092022-02-10_us-gaap_SubsequentEventMember_us-gaap_IPOMember"
      decimals="0"
      unitRef="USD">15000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1468465</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">3122134</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">178158</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">63853</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2466</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">306</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1649089</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">3186293</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">298958</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">301308</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">200124</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">270950</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DepositsAssets contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">100000</us-gaap:DepositsAssets>
    <us-gaap:DepositsAssets contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">100000</us-gaap:DepositsAssets>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">599082</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">672258</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2248171</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">3858551</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">169284</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">367019</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">499948</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">202160</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">125500</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">92214</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:UnsecuredDebtCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">368780</us-gaap:UnsecuredDebtCurrent>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2133453</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">3296965</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">661393</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">184355</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">178736</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">42000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">140000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">3523320</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">980129</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">6302050</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">6302050</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">5956754</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">5956754</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">6302</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">5957</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">14665559</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">10517505</us-gaap:AdditionalPaidInCapital>
    <modd:CommonStockIssuable contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">-923994</modd:CommonStockIssuable>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-15947010</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">-8569034</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-1275149</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">2878422</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2248171</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">3858551</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">4083303</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">3034152</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">3253412</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">2313870</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">7336715</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">5348022</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-7336715</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-5348022</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">130</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">28749</us-gaap:InterestIncomeOther>
    <us-gaap:InterestExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">39791</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-7376376</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-5319273</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-7377976</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-5320873</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">-1.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Shares">6211562</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="Shares">5954923</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5946754</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5947</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">9696471</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_custom_CommonStockIssuableMember"
      decimals="0"
      unitRef="USD">19800</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-3248161</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31" decimals="0" unitRef="USD">6474057</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-04-012020-03-31_custom_CommonStockIssuableMember"
      decimals="0"
      unitRef="USD">923994</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">923994</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2019-04-012020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-04-012020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">10</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-04-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">19790</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2019-04-012020-03-31_custom_CommonStockIssuableMember"
      decimals="0"
      unitRef="USD">-19800</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-04-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">801244</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">801244</us-gaap:ShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-5320873</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-5320873</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5956754</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5957</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">10517505</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_custom_CommonStockIssuableMember"
      decimals="0"
      unitRef="USD">923994</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-8569034</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">2878422</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">320796</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">321</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2709555</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012021-03-31_custom_CommonStockIssuableMember"
      decimals="0"
      unitRef="USD">-923994</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1785882</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">24500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">24</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">210920</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">210945</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1227578</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1227578</us-gaap:ShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-7377976</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-7377976</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">6302050</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">6302</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">14665559</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-15947010</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-1275149</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-7377976</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-5320873</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1227578</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">801244</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">111015</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">35431</us-gaap:DepreciationAndAmortization>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">68880</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">70826</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <modd:IncreaseDecreaseInLeaseLiability
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">38905</modd:IncreaseDecreaseInLeaseLiability>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">12253</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1004</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-25600</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">48391</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-92500</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-86747</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">530250</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-5908662</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-4094839</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">109669</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">260789</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-109669</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-260789</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1785882</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">923994</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">2210000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">368780</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">4364662</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">923994</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-1653669</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-3431634</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">3122134</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-03-31" decimals="0" unitRef="USD">6553768</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1468465</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">3122134</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">1600</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zGT6BSgYLNs4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Note&#160;1 &#x2013; &lt;span id="xdx_82E_zMUTozRktbd4"&gt;THE COMPANY
AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Modular Medical,
Inc. (the Company) was incorporated in Nevada in October 1998 under the name Bear Lake Recreation, Inc. The Company had no material
business operations from 2002 until approximately 2017 when it acquired all of the issued and outstanding shares of Quasuras,
Inc., a Delaware corporation (Quasuras). As the major shareholder of Quasuras retained control of both the Company and Quasuras,
the share exchange was accounted for as a reverse merger. As such, the Company recognized the assets and liabilities of Quasuras,
acquired in the merger, at their historical carrying amounts. Prior to the acquisition of Quasuras and, since at least 2002, the
Company was a shell company, as defined in Rule 12b-2 promulgated under the Securities Exchange Act of 1934 (the Exchange Act).
In June 2017, the Company changed its name from Bear Lake Recreation, Inc. to Modular Medical, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
is a development-stage medical device company focused on the design, development and eventual commercialization of an innovative
insulin pump to address shortcomings and problems represented by the relatively limited adoption of currently available pumps
for insulin-dependent people with diabetes. The Company has developed a hardware technology allowing people with insulin-dependent
diabetes to receive their daily insulin in two ways, through a continuous &#x201c;basal&#x201d; delivery allowing a small amount
of insulin to be in the blood at all times and a &#x201c;bolus&#x201d; delivery to address meal time glucose input and to address
when the blood glucose level becomes excessively high. By addressing the time and effort required to effectively treat their condition,
the Company believes it can address the less technically savvy, less motivated part of the market. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United
States of America. The following summarizes the more significant of such policies:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--LiquidityPolicyTextBlock_z4QrIhxBDxHj" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zDQdXEmUbbvb"&gt;Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial
Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15),&#160;&lt;i&gt;Going&#160;&lt;/i&gt;Concern,
requires management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt
about the entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are
issued.&#160;If management identifies conditions or events that raise substantial doubt about an entity&#x2019;s ability to continue
as a going concern, management must consider if there are plans that are probable to be implemented, and whether it is probable
that the plans will mitigate the conditions or events raising the substantial doubt about the entity&#x2019;s ability to continue
as a going concern.&#160;If the substantial doubt is not alleviated after consideration of management&#x2019;s plans, the entity
must include a statement in the notes to the financial statements indicating that there is substantial doubt about the entity&#x2019;s
ability to continue as a going concern within one year after the date that the financial statements are issued including: 1) the
principal conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern, 2)
management&#x2019;s evaluation of the significance of those conditions or events in relation to the entity&#x2019;s ability to meet
its obligations, and 3) management&#x2019;s plans to attempt to mitigate the conditions or events causing the substantial doubt
about the entity&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development
and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant
product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#x2019;s ability to continue
as a going concern within one year after the date that these consolidated financial statements are issued. Implementation of the
Company&#x2019;s plans and its ability to continue as a going concern will depend upon the Company&#x2019;s ability to raise additional
capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance
that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available,
that such capital will be offered on terms and conditions acceptable to the Company.&#160; As discussed in notes 3 and 11, in
February 2021, the Company commenced a private placement of its convertible promissory notes to investors to fund its operations.
In addition, during fiscal 2021, the Company obtained additional equity financing through a private placement of its common stock
(see note 6), and the Company obtained a loan from Silicon Valley Bank in April 2020 (see notes 3 and 12).&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company&#x2019;s
operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital
expenditures. The Company&#x2019;s future capital requirements and the adequacy of its available funds will depend on many factors,
including the Company&#x2019;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement
its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash. These consolidated financial statements
do not include any adjustments that might result from this uncertainty.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z2QiEAE6btr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zgcZE7UT1anf"&gt;Basis of
Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The consolidated
financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany
transactions and balances have been eliminated in consolidation. The Company&#x2019;s fiscal year ends on March 31 of each calendar
year.&lt;b&gt;&#160;&lt;/b&gt;Certain prior year amounts have been reclassified for consistency with the current period presentation. These
reclassifications had no effect on the reported results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zjb03aSEOl9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zkVTFpwCYJTh"&gt;Use of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The preparation
of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues
and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income
taxes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zEBGwLnCl838" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zYSzqPmtkea"&gt;Reportable Segment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;The Company operates in one business
segment and uses one measurement of profitability for its business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_z5RHgVDh9VL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zhvjzB3hriT2"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial instruments
that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents. Cash and
cash equivalents are deposited with high credit-quality institutions within the United States, which are insured by the Federal
Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--RisksAndUncertaintiesPolicyTextBlock_zU4HzJXoI7S" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zvwI2K5ZXTqd"&gt;Risks and
Uncertainties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public
markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;COVID-19&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The global
outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply
chains, significantly restricted travel and transportation, resulted in mandated closures and orders to &#x201c;shelter-in-place&#x201d;
and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#x2019;s operational
and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions
taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company&#x2019;s
control, and cannot be predicted.&lt;/span&gt;&lt;/p&gt;





&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zRAzlxQ0y94d" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_z90kSs4OLyka"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Cash and cash
equivalents include cash in hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with
original maturities of three months or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zk1Cd3Wid9k2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zUcEsPUJ4DLc"&gt;Property and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Property and
equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally &lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxH_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z0PB92ihRM74" title="::XDX::P3Y"&gt;three&lt;/span&gt; to &lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxH_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zVoGulgcYkX2" title="::XDX::P5Y"&gt;five&lt;/span&gt; years. Depreciation is recorded in operating expenses in the consolidated statements of
operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated
useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zhjQ4qzLxNwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_z3q4LBjYHSv1"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs
    that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial
    instrument.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Due to their
short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIDNnS7C5Ryi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zIfOdHenFOg9"&gt;Research
and Development&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
expenses research and development expenditures as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zslkeDbN2qj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zGAah61b4eJa"&gt;General and
Administrative&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;General and
administrative expense consists primarily of payroll and benefit related costs, rent, office expenses, equipment supplies and
meetings and travel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z3Tp69wE9iP" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zNRpWSNYg7F3"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the
requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock
options on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards
on the date of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number
of highly complex and subjective variables. These variables include, but are not limited to, the expected stock price&#160;volatility
over the term of the awards, and projected stock option exercise behaviors.&lt;/span&gt;&lt;/p&gt;





&lt;p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_z04lF1yOv96e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zNciwlCAEoM4"&gt;Per-Share
Amounts&#160;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Basic net loss
per share is computed by dividing net loss for the period by the weighted-average number of shares of common stock outstanding
during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period.
For the years ended March 31, 2021 and 2020, &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20210331_z7FZlwLQa8h7"&gt;1,197,252&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190401__20200331_zKybxb95oDpl"&gt;1,059,315&lt;/span&gt; outstanding options to purchase common stock were excluded
from the calculation of diluted net loss per share because their effect would be anti-dilutive. &#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zPlCSJXYVvMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zszo70i8EdZa"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#x2019;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to
affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that
all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management
believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company
has recorded a full valuation allowance.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
accounts for uncertain tax positions in accordance with FASB Accounting Standards Codification (ASC) Topic 740,&#160;&lt;i&gt;Income
Taxes&lt;/i&gt;. When tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing
authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that
would be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements in the period
during which, based on all available evidence, management believes it is more likely than not that the position will be sustained
upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated
with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount
of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The
portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as
a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and
penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits
is classified as interest expense and penalties are classified in selling, general and administrative expenses in the consolidated
statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. All tax returns
from 2016 to 2020 may be subject to examination by the U.S. federal and state tax authorities.&#160; As of March 31, 2021, the
Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zkBl9gDn6xMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_z6I11cISyor1"&gt;Comprehensive&#160;Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly,
comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2021 and
2020, the Company&#x2019;s comprehensive loss was the same as its net loss.&lt;/span&gt;&lt;/p&gt;





</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <modd:LiquidityPolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_843_ecustom--LiquidityPolicyTextBlock_z4QrIhxBDxHj" style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zDQdXEmUbbvb"&gt;Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial
Accounting Standards Board (FASB) Accounting Standard Update (ASU) No. 2014-15 (ASU 2014-15),&#160;&lt;i&gt;Going&#160;&lt;/i&gt;Concern,
requires management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt
about the entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are
issued.&#160;If management identifies conditions or events that raise substantial doubt about an entity&#x2019;s ability to continue
as a going concern, management must consider if there are plans that are probable to be implemented, and whether it is probable
that the plans will mitigate the conditions or events raising the substantial doubt about the entity&#x2019;s ability to continue
as a going concern.&#160;If the substantial doubt is not alleviated after consideration of management&#x2019;s plans, the entity
must include a statement in the notes to the financial statements indicating that there is substantial doubt about the entity&#x2019;s
ability to continue as a going concern within one year after the date that the financial statements are issued including: 1) the
principal conditions or events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern, 2)
management&#x2019;s evaluation of the significance of those conditions or events in relation to the entity&#x2019;s ability to meet
its obligations, and 3) management&#x2019;s plans to attempt to mitigate the conditions or events causing the substantial doubt
about the entity&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
expects to continue to incur operating losses for the foreseeable future and incur cash outflows from operations as it continues
to invest in the development and subsequent commercialization of its product. The Company expects that its research and development
and general and administrative expenses will continue to increase, and, as a result, it will eventually need to generate significant
product revenues to achieve profitability. These circumstances raise substantial doubt about the Company&#x2019;s ability to continue
as a going concern within one year after the date that these consolidated financial statements are issued. Implementation of the
Company&#x2019;s plans and its ability to continue as a going concern will depend upon the Company&#x2019;s ability to raise additional
capital, through the sale of additional equity or debt securities, to support its future operations. There can be no assurance
that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available,
that such capital will be offered on terms and conditions acceptable to the Company.&#160; As discussed in notes 3 and 11, in
February 2021, the Company commenced a private placement of its convertible promissory notes to investors to fund its operations.
In addition, during fiscal 2021, the Company obtained additional equity financing through a private placement of its common stock
(see note 6), and the Company obtained a loan from Silicon Valley Bank in April 2020 (see notes 3 and 12).&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company&#x2019;s
operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital
expenditures. The Company&#x2019;s future capital requirements and the adequacy of its available funds will depend on many factors,
including the Company&#x2019;s ability to successfully commercialize its product, competing technological and market developments,
and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement
its product offering. If the Company is unable to secure additional capital, it may be required to curtail its research and development
initiatives and take additional measures to reduce costs in order to conserve its cash. These consolidated financial statements
do not include any adjustments that might result from this uncertainty.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</modd:LiquidityPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z2QiEAE6btr1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zgcZE7UT1anf"&gt;Basis of
Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The consolidated
financial statements include the accounts of the Company and its wholly-owned subsidiary, Quasuras. All significant intercompany
transactions and balances have been eliminated in consolidation. The Company&#x2019;s fiscal year ends on March 31 of each calendar
year.&lt;b&gt;&#160;&lt;/b&gt;Certain prior year amounts have been reclassified for consistency with the current period presentation. These
reclassifications had no effect on the reported results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2020-04-012021-03-31">&lt;p id="xdx_841_eus-gaap--UseOfEstimates_zjb03aSEOl9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zkVTFpwCYJTh"&gt;Use of Estimates&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The preparation
of the accompanying consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues
and expenses during the reporting period. Estimates may include those pertaining to accruals, stock-based compensation and income
taxes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zEBGwLnCl838" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zYSzqPmtkea"&gt;Reportable Segment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;The Company operates in one business
segment and uses one measurement of profitability for its business.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2020-04-012021-03-31">&lt;p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_z5RHgVDh9VL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zhvjzB3hriT2"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Financial instruments
that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents. Cash and
cash equivalents are deposited with high credit-quality institutions within the United States, which are insured by the Federal
Deposit Insurance Corporation (FDIC) up to limits of approximately $250,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <modd:RisksAndUncertaintiesPolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_84F_ecustom--RisksAndUncertaintiesPolicyTextBlock_zU4HzJXoI7S" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zvwI2K5ZXTqd"&gt;Risks and
Uncertainties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
is subject to risks from, among other things, competition associated with the industry in general, other risks associated with
financing, liquidity requirements, rapidly changing customer requirements, limited operating history and the volatility of public
markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;COVID-19&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The global
outbreak of the coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization and a national emergency
by the U.S. government in March 2020. This has negatively affected the U.S. and global economy, disrupted global supply
chains, significantly restricted travel and transportation, resulted in mandated closures and orders to &#x201c;shelter-in-place&#x201d;
and created significant disruption of the financial markets. The full extent of the COVID-19 impact on the Company&#x2019;s operational
and financial performance will depend on future developments, including the duration and spread of the pandemic and related actions
taken by U.S. and foreign government agencies to prevent disease spread, all of which are uncertain, out of the Company&#x2019;s
control, and cannot be predicted.&lt;/span&gt;&lt;/p&gt;





</modd:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zRAzlxQ0y94d" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_z90kSs4OLyka"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Cash and cash
equivalents include cash in hand and cash in demand deposits, certificates of deposit and all highly liquid debt instruments with
original maturities of three months or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_844_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zk1Cd3Wid9k2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zUcEsPUJ4DLc"&gt;Property and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Property and
equipment are originally recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives
of the assets, generally &lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxH_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z0PB92ihRM74" title="::XDX::P3Y"&gt;three&lt;/span&gt; to &lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dxH_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zVoGulgcYkX2" title="::XDX::P5Y"&gt;five&lt;/span&gt; years. Depreciation is recorded in operating expenses in the consolidated statements of
operations. Leasehold improvements and assets acquired through capital leases are amortized over the shorter of their estimated
useful life or the lease term, and amortization is recorded in operating expenses in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2020-04-012021-03-31">&lt;p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zhjQ4qzLxNwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_z3q4LBjYHSv1"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
measures the fair value of financial instruments using a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into three broad levels:&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs
    that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial
    instrument.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 24px"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Due to their
short-term nature, the carrying values of cash equivalents, accounts payable and accrued expenses, approximate fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2020-04-012021-03-31">&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_zIDNnS7C5Ryi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zIfOdHenFOg9"&gt;Research
and Development&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
expenses research and development expenditures as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_84A_eus-gaap--SellingGeneralAndAdministrativeExpensesPolicyTextBlock_zslkeDbN2qj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zGAah61b4eJa"&gt;General and
Administrative&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;General and
administrative expense consists primarily of payroll and benefit related costs, rent, office expenses, equipment supplies and
meetings and travel.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_849_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z3Tp69wE9iP" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zNRpWSNYg7F3"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
recognizes stock-based compensation for stock options granted to employees and non-employees on a straight-line basis over the
requisite service period, usually the vesting period, based on the grant-date fair value. The Company estimates the value of stock
options on the date of grant using the Black-Scholes pricing model. The determination of fair value of share-based payment awards
on the date of grant using an option-pricing model is affected by the option price, as well as assumptions regarding a number
of highly complex and subjective variables. These variables include, but are not limited to, the expected stock price&#160;volatility
over the term of the awards, and projected stock option exercise behaviors.&lt;/span&gt;&lt;/p&gt;





</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_z04lF1yOv96e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zNciwlCAEoM4"&gt;Per-Share
Amounts&#160;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Basic net loss
per share is computed by dividing net loss for the period by the weighted-average number of shares of common stock outstanding
during the period. Diluted net loss per share gives effect to all potentially dilutive common shares outstanding during the period.
For the years ended March 31, 2021 and 2020, &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20210331_z7FZlwLQa8h7"&gt;1,197,252&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190401__20200331_zKybxb95oDpl"&gt;1,059,315&lt;/span&gt; outstanding options to purchase common stock were excluded
from the calculation of diluted net loss per share because their effect would be anti-dilutive. &#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Shares">1197252</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="Shares">1059315</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zPlCSJXYVvMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zszo70i8EdZa"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
determines deferred tax assets and liabilities based upon the differences between the financial statement and tax bases of the
Company&#x2019;s assets and liabilities using tax rates in effect for the year in which the Company expects the differences to
affect taxable income. A valuation allowance is established for any deferred tax assets for which it is more likely than not that
all or a portion of the deferred tax assets will not be realized. Based on the available information and other factors, management
believes it is more likely than not that its federal and state net deferred tax assets will not be fully realized, and the Company
has recorded a full valuation allowance.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
accounts for uncertain tax positions in accordance with FASB Accounting Standards Codification (ASC) Topic 740,&#160;&lt;i&gt;Income
Taxes&lt;/i&gt;. When tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing
authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that
would be ultimately sustained. The benefit of a tax position is recognized in the consolidated financial statements in the period
during which, based on all available evidence, management believes it is more likely than not that the position will be sustained
upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated
with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount
of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The
portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as
a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and
penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits
is classified as interest expense and penalties are classified in selling, general and administrative expenses in the consolidated
statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. All tax returns
from 2016 to 2020 may be subject to examination by the U.S. federal and state tax authorities.&#160; As of March 31, 2021, the
Company has not recorded any liability for unrecognized tax benefits related to uncertain tax positions.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zkBl9gDn6xMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_z6I11cISyor1"&gt;Comprehensive&#160;Loss&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Comprehensive
loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly,
comprehensive loss may include certain changes in equity that are excluded from net loss. For the years ended March 31, 2021 and
2020, the Company&#x2019;s comprehensive loss was the same as its net loss.&lt;/span&gt;&lt;/p&gt;





</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <modd:ConsolidatedBalanceSheetDetailTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_803_ecustom--ConsolidatedBalanceSheetDetailTextBlock_zFH8XpydeD68" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;2 &#x2013; &lt;span id="xdx_829_zEATFVQb0qp3"&gt;CONSOLIDATED
BALANCE SHEET DETAIL&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--PropertyPlantAndEquipmentTextBlock_zndr6DZw71U1" style="margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8BE_zHWRXpwdOD49" style="display: none"&gt;Schedule of
Property Plant And Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureConsolidatedBalanceSheetDetailsAbstract_z7p2IfHAlRqh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"/&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49F_20210331_zCz7v32xtXAa" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49A_20200331_zD6jfVUXPyoa" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;Property and equipment, net:&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z3BPmqjQLSv9" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;139,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;139,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zcwACcdJH1u3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,476&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zTWOHfvNRM33" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment and software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,383&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,882&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zXXrzTWCcmC8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;202,993&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;112,198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_zhStRP3g6Mdk" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td&gt;&lt;span style="display: none"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;451,049&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;353,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_z8azUF3TJ1jj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 17.3pt"&gt;Less: accumulated depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(152,091&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(51,693&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td&gt;&lt;span style="display: none"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;298,958&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;301,308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A4_z8yDspHtdiad" style="margin: 0"/&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zizSZirDdEgi" style="margin: 0"&gt;&lt;span id="xdx_8B4_zcJkXV60NCF2" style="display: none"&gt;Schedule of Accrued Expenses&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureConsolidatedBalanceSheetDetails2Abstract_z3esqbaMX4Bg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20210331_zahbdjG7U326" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20200331_z11U9drwWqZ2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Accrued expenses:&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedWagesAndBonusMember_zZVbo88qYMUi" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Accrued wages and bonus&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;372,563&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;198,160&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedPlacementFeesMember_zMdz7KVF6jZj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued placement fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1075"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedInterestMember_zjTar9XFERn" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Accrued interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,538&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1078"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedOtherExpensesMember_zyN8mqgMrjL" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,047&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_zdCf18Aoa407" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;499,948&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;202,160&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A6_zujoonP5i0A8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</modd:ConsolidatedBalanceSheetDetailTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_892_eus-gaap--PropertyPlantAndEquipmentTextBlock_zndr6DZw71U1" style="margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8BE_zHWRXpwdOD49" style="display: none"&gt;Schedule of
Property Plant And Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <modd:DisclosureConsolidatedBalanceSheetDetailsAbstract contextRef="From2020-04-012021-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureConsolidatedBalanceSheetDetailsAbstract_z7p2IfHAlRqh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"/&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49F_20210331_zCz7v32xtXAa" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;
    &lt;td id="xdx_49A_20200331_zD6jfVUXPyoa" style="white-space: nowrap; font-weight: bold; text-align: center"/&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;Property and equipment, net:&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z3BPmqjQLSv9" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;139,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;139,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zcwACcdJH1u3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,476&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zTWOHfvNRM33" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment and software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,383&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,882&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zXXrzTWCcmC8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;202,993&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;112,198&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_zhStRP3g6Mdk" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td&gt;&lt;span style="display: none"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;451,049&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;353,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_z8azUF3TJ1jj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 17.3pt"&gt;Less: accumulated depreciation and amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(152,091&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(51,693&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td&gt;&lt;span style="display: none"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;298,958&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;301,308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureConsolidatedBalanceSheetDetailsAbstract>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-03-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">139197</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-03-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">139197</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-03-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      unitRef="USD">56476</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-03-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      unitRef="USD">49724</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-03-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      unitRef="USD">52383</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-03-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      unitRef="USD">51882</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-03-31_us-gaap_MachineryAndEquipmentMember"
      decimals="0"
      unitRef="USD">202993</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-03-31_us-gaap_MachineryAndEquipmentMember"
      decimals="0"
      unitRef="USD">112198</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">451049</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">353001</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">152091</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">51693</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zizSZirDdEgi" style="margin: 0"&gt;&lt;span id="xdx_8B4_zcJkXV60NCF2" style="display: none"&gt;Schedule of Accrued Expenses&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <modd:DisclosureConsolidatedBalanceSheetDetails2Abstract contextRef="From2020-04-012021-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--DisclosureConsolidatedBalanceSheetDetails2Abstract_z3esqbaMX4Bg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20210331_zahbdjG7U326" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20200331_z11U9drwWqZ2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Accrued expenses:&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedWagesAndBonusMember_zZVbo88qYMUi" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Accrued wages and bonus&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;372,563&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;198,160&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedPlacementFeesMember_zMdz7KVF6jZj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued placement fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1075"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedInterestMember_zjTar9XFERn" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Accrued interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,538&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1078"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_hus-gaap--NatureOfExpenseAxis__custom--AccruedOtherExpensesMember_zyN8mqgMrjL" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;11,047&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_zdCf18Aoa407" style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;499,948&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;202,160&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureConsolidatedBalanceSheetDetails2Abstract>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2021-03-31_custom_AccruedWagesAndBonusMember"
      decimals="0"
      unitRef="USD">372563</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2020-03-31_custom_AccruedWagesAndBonusMember"
      decimals="0"
      unitRef="USD">198160</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2021-03-31_custom_AccruedPlacementFeesMember"
      decimals="0"
      unitRef="USD">88800</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2021-03-31_custom_AccruedInterestMember"
      decimals="0"
      unitRef="USD">27538</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2021-03-31_custom_AccruedOtherExpensesMember"
      decimals="0"
      unitRef="USD">11047</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2020-03-31_custom_AccruedOtherExpensesMember"
      decimals="0"
      unitRef="USD">4000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">499948</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">202160</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_z239wqwiF2ui" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 3 &#x2013; &lt;span id="xdx_82D_zcREI3129Eqe"&gt;NOTES PAYABLE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;PPP Note&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On April 24,
2020, the Company received a $368,780 unsecured loan (the PPP Note) under the Paycheck Protection Program (the PPP), which was
established under the U.S. government&#x2019;s Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The PPP Note
to the Company was made through Silicon Valley Bank (the Lender), and the Company entered into a U.S. Small Business Administration
Paycheck Protection Program Note (the Agreement) with the Lender evidencing the PPP Note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 73.35pt 0 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The full amount
of the PPP Note is due in April 2022. Interest will accrue on the outstanding principal balance of the PPP Note at a fixed rate
of 1.0% per annum, which shall be deferred for 10 months after the covered period during which the Company used the proceeds.
The Company may prepay principal of the PPP Note at any time in any amount without penalty. The Agreement contains customary events
of default relating to, among other things, payment defaults, breach of representations and warranties or provisions of the PPP
Note. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts
owing from the Company, and/or filing suit and obtaining judgment against the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
applied to the Lender for forgiveness of the PPP Note in October 2020, and the amount which may be forgiven will be equal to the
sum of the payroll and benefit costs and covered rent and utility payments incurred by the Company, as calculated in accordance
with the terms of the CARES Act.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Convertible
Promissory Notes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-size: 10pt"&gt;In
February and March 2021, the Company sold $2,210,000 of convertible promissory notes (the Notes), at par in a private placement
transaction effected pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended
(the 2021 Placement). The Notes bear interest at an annual rate of 12%, and interest is accrued or payable monthly in cash. The
Notes mature on September 30, 2021 (the Maturity Date) and may be prepaid prior to the Maturity Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-size: 10pt"&gt;The
aggregate principal amount of the Notes plus accrued but unpaid interest thereon shall automatically convert upon the closing
of an offering of the Company&#x2019;s equity securities to investors or a strategic corporate investor resulting in aggregate
gross proceeds to the Company of at least $5,000,000 (excluding conversion of the Notes or other convertible securities issued
for capital raising purposes) (a Qualified Financing). In the event of a Qualified Financing, all such outstanding principal and
accrued interest shall convert into the same equity securities purchased by and on the same terms and conditions as the other
investors in such Qualified Financing at a conversion price equal to 80% (a 20% discount) of the lowest price paid per unit or
share by investors in the Qualified Financing. In the event that additional bridge financing is obtained by the Company, the Notes
shall convert into the same securities and on the same terms and conditions as the other investors therein and all such purchases
will be treated as one, single round of financing going forward. As of March 31, 2021, the Notes could be converted into 770,305
shares of common stock, excluding the effects of any payments of interest in kind.&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-size: 10pt"&gt;At
any time on or following the Maturity Date, the holders of the Notes may demand repayment of the Notes, and the Company shall
repay the outstanding aggregate principal amount plus accrued but unpaid interest thereon. The holders of the Notes, however,
retain the right for 30 days after the Maturity Date to convert all or part of the aggregate principal amount plus accrued but
unpaid interest on the Notes into the Company&#x2019;s common stock at the conversion price of $2.87 per share or at a 20% discount
to any financing consummated during the 30-day period following the Maturity Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-size: 10pt"&gt;If
a Qualified Financing has not occurred immediately prior to the consummation of a Change of Control (as defined below), the Note
holders shall have the option of either (i) converting all or any portion of the aggregate principal amount of the Notes plus
accrued but unpaid interest thereon into common stock of the Company at a conversion price equal to $2.87 per share or (ii) having
the Company repay the aggregate principal amount of the Notes and accrued but unpaid interest. The term &#x201c;Change of Control&#x201d;
means (i) a consolidation or merger of the Company with or into any other corporation or other entity or person, or any other
corporate reorganization, other than any such consolidation, merger or reorganization in which the shares of capital stock of
the Company immediately prior to such consolidation, merger or reorganization continue to represent a majority of the voting power
of the surviving entity immediately after such consolidation, merger or reorganization; (ii) any transaction or series of related
transactions to which the Company is a party in which in excess of 50% of the Company&#x2019;s voting power is transferred; (iii)
the sale or transfer of all or substantially all of the Company&#x2019;s assets, or the exclusive license of all or substantially
all of the Company&#x2019;s material intellectual property; or (iv) the dissolution and winding up of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
incurred debt issuance costs of $88,800, which were recorded as a debt discount and are being amortized to interest expense over
the term of the Notes using the effective interest rate method. The interest expense related to the debt discount during
the year ended March 31, 2021 was approximately $13,000.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_804_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zI2D2UliU05h" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 4 &#x2013; &lt;span id="xdx_825_zi2Nz2cefmjg"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Effective April 1,
2019, the Company adopted ASC No. 842, as amended, using the alternative transition method, which allowed the Company to initially apply
the new lease standard at the adoption date (the &#x201c;effective date method&#x201d;). In January 2020, the Company executed a lease
for a new, larger corporate facility in San Diego, California&#160;&lt;span style="background-color: white"&gt;and paid a $100,000 security
deposit.&lt;/span&gt; The &lt;span id="xdx_900_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxH_c20200402_z1KFBhPCaoOa" title="::XDX::P39M"&gt;39-month&lt;/span&gt;
lease term commenced April 1, 2020, and the lease provides for an initial monthly rent of approximately $&lt;span id="xdx_905_eus-gaap--LeaseAndRentalExpense_c20200401__20200430_zSDH0uPGgrS6"&gt;12,400&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: white"&gt;&#160;with
annual rent increases of approximately &lt;span id="xdx_902_ecustom--OperatingLeasesAnnualRentIncreasePercentange_iI_c20200402_zZhDUxsMKzcl"&gt;3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt; background-color: white"&gt;.&#160;In
addition to the minimum lease payments, the Company is responsible for property taxes, insurance and certain other operating costs. The
right-to-use asset and corresponding liability for the facility lease have been measured at the present value of the future minimum lease
payments. A discount rate of 11%, which approximated the Company&#x2019;s incremental borrowing rate, was used to measure the lease asset
and liability. Lease expense is recognized on a straight line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
obtained a right-of-use asset of $&lt;span id="xdx_908_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20210401__20210630_z2G2AIje6xNg"&gt;270,950&lt;/span&gt; in exchange for its obligations under the operating lease. The landlord also provided
a lease incentive of approximately $&lt;span id="xdx_908_ecustom--LeaseIncentiveReceived_iI_c20200630_zKiJo3oTJbY7" title="Lease Incentive Received"&gt;139,000&lt;/span&gt;, which was paid to the Company in June 2020, for the Company to make improvements
to the leased space.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p id="xdx_893_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zwsEbf5hBpr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8B4_z4ymE4sowwz9"&gt;Future minimum
payments under the facility operating lease, net of the lease incentive&lt;/span&gt;, as of March 31, 2021, are listed in the table below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureLeasesDetailsAbstarct_zaw73crHXSE8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - LEASES (Details)"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20210331_zrL4AFPyLXnl" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Operating&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Annual
    Fiscal Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;lease&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_zVkfNZy9FY0h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 87%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;153,432&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_znDX2jMH8Bvk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;158,028&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_zuf1bKMgk1Tf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;40,692&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Less:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--OperatingLeasesImputedInterest_iI_zAvxbfezdWk1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 17.3pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Imputed
    interest&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(42,297&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_zBAFDAn0JDSa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Present value
    of lease liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;309,855&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_8A3_zaIbd7vh93P6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Rent expense
was $&lt;span id="xdx_90E_eus-gaap--LeaseAndRentalExpense_c20200401__20210331_zjo2lo5EhDg1"&gt;107,540&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--LeaseAndRentalExpense_c20190401__20200331_zu0OXP6pJkSg"&gt;35,766&lt;/span&gt; for the years ended March&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;





</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2020-04-012020-04-30"
      decimals="0"
      unitRef="USD">12400</us-gaap:LeaseAndRentalExpense>
    <modd:OperatingLeasesAnnualRentIncreasePercentange contextRef="AsOf2020-04-02" decimals="INF" unitRef="Pure">0.03</modd:OperatingLeasesAnnualRentIncreasePercentange>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">270950</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <modd:LeaseIncentiveReceived contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">139000</modd:LeaseIncentiveReceived>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zwsEbf5hBpr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_8B4_z4ymE4sowwz9"&gt;Future minimum
payments under the facility operating lease, net of the lease incentive&lt;/span&gt;, as of March 31, 2021, are listed in the table below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <modd:DisclosureLeasesDetailsAbstarct contextRef="From2020-04-012021-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureLeasesDetailsAbstarct_zaw73crHXSE8" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - LEASES (Details)"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20210331_zrL4AFPyLXnl" style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Operating&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Annual
    Fiscal Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;lease&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_zVkfNZy9FY0h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 87%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;153,432&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInThreeYears_iI_znDX2jMH8Bvk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;158,028&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInFourYears_iI_zuf1bKMgk1Tf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;40,692&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Less:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--OperatingLeasesImputedInterest_iI_zAvxbfezdWk1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 17.3pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Imputed
    interest&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(42,297&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iI_zBAFDAn0JDSa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Present value
    of lease liabilities&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;309,855&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureLeasesDetailsAbstarct>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">153432</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">158028</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">40692</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <modd:OperatingLeasesImputedInterest contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-42297</modd:OperatingLeasesImputedInterest>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">309855</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">107540</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">35766</us-gaap:LeaseAndRentalExpense>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_808_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zjUWhAWCd1K7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 5 &#x2013;
&lt;span id="xdx_82A_zCTmmfmICWHf"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Equity Compensation
Plan&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In October 2017,
the Company&#x2019;s board of directors (the Board) approved the 2017 Equity Incentive Plan (the 2017 Plan) with 3,000,000 shares
of common stock reserved for issuance. In January 2020, the Board approved an amendment to the 2017 Plan to increase the number
of shares reserved for issuance by 1,000,000 shares. Under the 2017 Plan, eligible employees, directors and consultants may be
granted a broad range of awards, including stock options, stock appreciation rights, restricted stock, performance-based awards
and restricted stock units. The 2017 Plan is administered by the Board or, in the alternative, a committee designated by the Board.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The exercise
or purchase price of a stock option shall be calculated as follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 5%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(i)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
    the case of an incentive stock option, (a) granted to employees, who, at the time of the grant of such incentive stock option
    own stock representing more than 10% of the voting power of all classes of stock of the Company, the per share exercise price
    shall be not less than 110% of the fair market value per share on the date of grant; or (b) granted to employees, other than
    to employees, described in the preceding clause, the per share exercise price shall be not less than 100% of the fair market
    value per share on the date of grant;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 5%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;(ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
    the case of a non-qualified stock option, the per share exercise price shall be not less than 100% of the fair market value
    per share on the date of grant unless otherwise determined by the Board; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(iii) &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
    the case of other grants, such price as determined by the Board.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Board
is responsible for determining the consideration to be paid for the shares of common stock to be issued upon exercise or purchase.
The 2017 Plan generally does not allow for the transfer of awards, and the Board may amend, suspend or terminate the 2017 Plan
at any time.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Stock-Based
Compensation Expense&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The expense
relating to stock options is recognized on a straight-line basis over the requisite service period, usually the vesting period,
based on the grant date fair value. The unamortized compensation cost, as of March 31, 2021 was $2,242,352 related to stock options
and is expected to be recognized as expense over a weighted-average period of approximately 2 years.&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;During
the year ended March 31, 2021, options granted to purchase shares of its common stock to employees, directors and consultants
had 10-year terms and a grant-date fair value of $1,101,737. Options to purchase 10,476 shares vested immediately on the respective
grant dates.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zvYq7IF9JyI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;The following &lt;span id="xdx_8B5_zlf1rY5Degjc"&gt;assumptions were used
in the fair-value method calculations&lt;/span&gt;:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zoHuDK6s0nT1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Year
    ended March 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 75%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free
    interest rates&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z3WdONB4SZo3" title="Risk-free interest rates"&gt;0.28%&lt;/span&gt;
    - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zKXqL9Ish2u2"&gt;0.71%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zUL6Ejt736V7"&gt;0.77%&lt;/span&gt;
    - &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zm1j5c8ajwF2"&gt;2.37%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zTa7ch8pmPZj" title="Volatility"&gt;87%&lt;/span&gt;
    - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_ziVZpTGts1Ki"&gt;127%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zYHYFJV41tZa"&gt;86%&lt;/span&gt;
    - &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zC5IcFOdVVE6"&gt;103%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expected
    life (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zxbZfBQ3IN0l" title="Expected Life (years)"&gt;5.0&lt;/span&gt;
    - &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_z1TUxfEn4EG1"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zRjo0fMiYtB4"&gt;5.0&lt;/span&gt;
    - &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zjseC5rpXBNk"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend
    yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zznV59JTlHzb"&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zzPv2kfTG5L1"&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_8AC_zuhRbsCVqLn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The fair values
of options at the grant date were estimated utilizing the Black-Scholes valuation model, which includes simplified methods to
establish the fair term of options as well as average volatility of three comparable organizations. The risk-free interest rate
was derived from the Daily Treasury Yield Curve Rates, as published by the U.S. Department of the Treasury as of the grant date
for terms equal to the expected terms of the options. A dividend yield of zero was applied because the Company has never paid
dividends and has no intention to pay dividends in the foreseeable future. In accordance with ASU No. 2016-09, the Company accounts
for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;




&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_znsC7EV5wvie" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;A summary of &lt;span id="xdx_8BD_zo1WcKMoXVka"&gt;stock option activity
&lt;/span&gt;under the 2017 Plan is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zJSj4aqevOpc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt"&gt;Shares&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Available&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;for Grant&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 61%"&gt;Balance at March 31, 2019&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331_zLweyHt3pxQh" style="width: 8%; text-align: right" title="Shares available for grant, beginning"&gt;490,031&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVmGRDLvVbFb" style="width: 8%; text-align: right"&gt;509,969&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRzl68rEqYJl" style="width: 8%; text-align: right"&gt;2.56&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Additional shares authorized under the Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_c20190401__20200331_zhAdxgDFNffd" style="text-align: right"&gt;333,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_iN_di_c20190401__20200331_zPsMwIKwoQAc" style="text-align: right"&gt;(572,402&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMPyaRvRz9dd" style="text-align: right"&gt;572,402&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zng6yBVex3Pe" style="text-align: right"&gt;6.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20190401__20200331_zfYa8LQ4ZHWg" style="border-bottom: Black 1pt solid; text-align: right"&gt;23,056&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2NYijcemSPe" style="border-bottom: Black 1pt solid; text-align: right"&gt;(23,056&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlC05erYxvwe" style="border-bottom: Black 1pt solid; text-align: right"&gt;6.75&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td&gt;Balance at March 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331_z15feRx4wrj7" style="text-align: right"&gt;274,019&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1nYosdl6G92" style="text-align: right"&gt;1,059,315&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5YLernKnlpk" style="text-align: right"&gt;4.74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_iN_di_c20200401__20210331_zJggddizapdi" style="text-align: right"&gt;(163,492&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLCxmcLIOV75" style="text-align: right"&gt;163,492&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZXcbDKJQol3" style="text-align: right"&gt;8.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20200401__20210331_zkXgvpN0sYMi" style="border-bottom: Black 1pt solid; text-align: right"&gt;25,555&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZ7eE89lFage" style="border-bottom: Black 1pt solid; text-align: right"&gt;(25,555&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbhsQtPUzcSh" style="border-bottom: Black 1pt solid; text-align: right"&gt;6.75&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Balance at March 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331_zye6aVSk8FA5" style="border-bottom: Black 2.5pt double; text-align: right"&gt;136,082&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znw72iivgn5k" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,197,252&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0YFfXOhuZWl" style="border-bottom: Black 2.5pt double; text-align: right"&gt;5.25&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A4_zCZ32lEJywa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;There were no
stock options exercised during the years ended March 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z4MDAK8NLx19" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The following
table &lt;span id="xdx_8BD_z7khsmxDY1Ib"&gt;summarizes the range of outstanding and exercisable options&lt;/span&gt; as of March 31, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zjQ9JdEOW2z5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 3)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left"&gt;Range of Exercise Price&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number&lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;br/&gt; (in Years)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number&lt;br/&gt; Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 22%; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt"&gt;$&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zzRBzMxdOvJi"&gt;1.98&lt;/span&gt; - $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zxDphhvUO3l4"&gt;9.48&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zs1oFVpZzC45" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;1,197,252&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtYxH_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDF6lDyhHc4a" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="::XDX::P8Y4M"&gt;8.25&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zz6JFas6hN48" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;5.25&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhDEwU7OVCq4" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;742,913&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtYxH_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zD0TjOxu1WX7" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="::XDX::P3Y11M16D"&gt;3.96&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoZStRXd9JH2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;8,763,260&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AB_zRfPGIO5nMhl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The intrinsic
value per share is calculated as the excess of the closing price of the common stock on the Company&#x2019;s principal trading
market over the exercise price of the option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
is required to present the tax benefits resulting from tax deductions in excess of the compensation cost recognized from the exercise
of stock options as financing cash flows in the consolidated statements of cash flows. For the years ended March 31, 2021 and
2020, there were no such tax benefits associated with the exercise of stock options.&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_89A_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zvYq7IF9JyI1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;The following &lt;span id="xdx_8B5_zlf1rY5Degjc"&gt;assumptions were used
in the fair-value method calculations&lt;/span&gt;:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <modd:DisclosureStockBasedCompensationDetailsAbstract contextRef="From2020-04-012021-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureStockBasedCompensationDetailsAbstract_zoHuDK6s0nT1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Year
    ended March 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 75%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free
    interest rates&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_z3WdONB4SZo3" title="Risk-free interest rates"&gt;0.28%&lt;/span&gt;
    - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_zKXqL9Ish2u2"&gt;0.71%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 8%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zUL6Ejt736V7"&gt;0.77%&lt;/span&gt;
    - &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zm1j5c8ajwF2"&gt;2.37%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zTa7ch8pmPZj" title="Volatility"&gt;87%&lt;/span&gt;
    - &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_ziVZpTGts1Ki"&gt;127%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zYHYFJV41tZa"&gt;86%&lt;/span&gt;
    - &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zC5IcFOdVVE6"&gt;103%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expected
    life (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zxbZfBQ3IN0l" title="Expected Life (years)"&gt;5.0&lt;/span&gt;
    - &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200401__20210331__srt--RangeAxis__srt--MaximumMember_z1TUxfEn4EG1"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zRjo0fMiYtB4"&gt;5.0&lt;/span&gt;
    - &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190401__20200331__srt--RangeAxis__srt--MaximumMember_zjseC5rpXBNk"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend
    yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20200401__20210331__srt--RangeAxis__srt--MinimumMember_zznV59JTlHzb"&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20190401__20200331__srt--RangeAxis__srt--MinimumMember_zzPv2kfTG5L1"&gt;&#x2014;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureStockBasedCompensationDetailsAbstract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-04-012021-03-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.0028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-04-012021-03-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-04-012020-03-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.0077</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-04-012020-03-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-04-012021-03-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-04-012021-03-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">1.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-04-012020-03-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-04-012020-03-31_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-04-012021-03-31_srt_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-04-012021-03-31_srt_MaximumMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-04-012020-03-31_srt_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-04-012020-03-31_srt_MaximumMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-04-012021-03-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-04-012020-03-31_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_znsC7EV5wvie" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;A summary of &lt;span id="xdx_8BD_zo1WcKMoXVka"&gt;stock option activity
&lt;/span&gt;under the 2017 Plan is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <modd:DisclosureStockBasedCompensationDetails2Abstract contextRef="From2020-04-012021-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--DisclosureStockBasedCompensationDetails2Abstract_zJSj4aqevOpc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; padding-bottom: 1pt"&gt;Shares&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Available&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;for Grant&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 61%"&gt;Balance at March 31, 2019&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331_zLweyHt3pxQh" style="width: 8%; text-align: right" title="Shares available for grant, beginning"&gt;490,031&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVmGRDLvVbFb" style="width: 8%; text-align: right"&gt;509,969&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zRzl68rEqYJl" style="width: 8%; text-align: right"&gt;2.56&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Additional shares authorized under the Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_c20190401__20200331_zhAdxgDFNffd" style="text-align: right"&gt;333,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_iN_di_c20190401__20200331_zPsMwIKwoQAc" style="text-align: right"&gt;(572,402&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMPyaRvRz9dd" style="text-align: right"&gt;572,402&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zng6yBVex3Pe" style="text-align: right"&gt;6.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20190401__20200331_zfYa8LQ4ZHWg" style="border-bottom: Black 1pt solid; text-align: right"&gt;23,056&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2NYijcemSPe" style="border-bottom: Black 1pt solid; text-align: right"&gt;(23,056&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlC05erYxvwe" style="border-bottom: Black 1pt solid; text-align: right"&gt;6.75&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td&gt;Balance at March 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331_z15feRx4wrj7" style="text-align: right"&gt;274,019&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z1nYosdl6G92" style="text-align: right"&gt;1,059,315&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20190401__20200331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5YLernKnlpk" style="text-align: right"&gt;4.74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_iN_di_c20200401__20210331_zJggddizapdi" style="text-align: right"&gt;(163,492&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLCxmcLIOV75" style="text-align: right"&gt;163,492&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZXcbDKJQol3" style="text-align: right"&gt;8.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-left: 8.65pt"&gt;Options cancelled and returned to the Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c20200401__20210331_zkXgvpN0sYMi" style="border-bottom: Black 1pt solid; text-align: right"&gt;25,555&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zZ7eE89lFage" style="border-bottom: Black 1pt solid; text-align: right"&gt;(25,555&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbhsQtPUzcSh" style="border-bottom: Black 1pt solid; text-align: right"&gt;6.75&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Balance at March 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331_zye6aVSk8FA5" style="border-bottom: Black 2.5pt double; text-align: right"&gt;136,082&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_znw72iivgn5k" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,197,252&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0YFfXOhuZWl" style="border-bottom: Black 2.5pt double; text-align: right"&gt;5.25&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureStockBasedCompensationDetails2Abstract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-03-31" decimals="INF" unitRef="Shares">490031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">509969</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">2.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="Shares">333334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="Shares">572402</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2019-04-012020-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">572402</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-04-012020-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="Shares">23056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2019-04-012020-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">23056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-04-012020-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">274019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1059315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Shares">163492</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">163492</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">8.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Shares">25555</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">25555</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-04-012021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">136082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1197252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock_z4MDAK8NLx19" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The following
table &lt;span id="xdx_8BD_z7khsmxDY1Ib"&gt;summarizes the range of outstanding and exercisable options&lt;/span&gt; as of March 31, 2021:&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock>
    <modd:DisclosureStockBasedCompensationDetails3Abstract contextRef="From2020-04-012021-03-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureStockBasedCompensationDetails3Abstract_zjQ9JdEOW2z5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 3)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left"&gt;Range of Exercise Price&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number&lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;br/&gt; (in Years)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Number&lt;br/&gt; Exercisable&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 22%; padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 8.65pt"&gt;$&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zzRBzMxdOvJi"&gt;1.98&lt;/span&gt; - $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zxDphhvUO3l4"&gt;9.48&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zs1oFVpZzC45" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;1,197,252&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtYxH_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zDF6lDyhHc4a" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="::XDX::P8Y4M"&gt;8.25&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zz6JFas6hN48" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;5.25&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhDEwU7OVCq4" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;742,913&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtYxH_c20200401__20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zD0TjOxu1WX7" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right" title="::XDX::P3Y11M16D"&gt;3.96&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_c20210331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zoZStRXd9JH2" style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"&gt;8,763,260&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</modd:DisclosureStockBasedCompensationDetails3Abstract>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">1.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">9.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">1197252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      unitRef="Shares">742913</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="AsOf2021-03-31_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">8763260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_ziV6Qcjuipug" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 6 &#x2013; &lt;span id="xdx_820_zIsr1RW0bfL9"&gt;STOCKHOLDERS&#x2019;
EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Private Placement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Between March
and December 2020, the Company completed a private placement of shares of its common stock (the 2020 Placement). The Company sold
&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200401__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsybujndopYi"&gt;320,796&lt;/span&gt; shares of common stock, at a purchase price of $8.61 per share, for gross proceeds of $2,762,054. The Company paid placement
agent fees on the 2020 Placement of $52,256 during fiscal 2021. Under the terms of the common stock purchase agreements between
the Company and the investors, the Company must use commercially reasonable efforts to file a registration statement with the
SEC to register for resale the shares of common stock sold.&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7 &#x2013; INCOME TAXES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"&gt;&lt;span style="font-size: 10pt"&gt;The income tax provision (benefit)
consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Current portion:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 8.9pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; padding-bottom: 1pt; padding-left: 8.9pt"&gt;State&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 8%; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 8%; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Deferred portion:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 8.9pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,931,390&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,180,434&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 8.9pt"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(576,868&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(391,865&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,508,258&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,572,299&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,508,258&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,572,299&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;As of March 31, 2021,
the Company had net operating loss carryforwards (NOLs) of approximately $13,954,000 for federal income tax purposes and $14,019,000
for state income tax purposes. These NOLs are available to reduce future taxable income and will expire at various times from 2037 through
2041, except federal NOLs from fiscal 2018, 2019 and 2020 which will never expire.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company
also had federal research and development tax credit carryforwards of approximately $535,000, which will begin expiring at various times
from 2038 through 2040, and state research and development credits of approximately $141,000, which do not have an expiration date.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;A reconciliation of
income taxes provided at the federal statutory rate (21% for fiscal 2021 and 2020) to the actual income tax provision is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Federal statutory rate&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State tax rate, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Section 179 assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;34&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;31&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;Significant components of the Company&#x2019;s
deferred tax assets and liabilities were:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;3,909,434&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;1,965,118&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;554,892&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;364,989&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(18,039&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,842&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Reserves, accruals &amp;amp; other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(79,878&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,181&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Research and development tax credits&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;646,296&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;237,716&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 8.9pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,012,705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,567,484&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,204)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,012,705&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,567,484&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 8.9pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Based on the available
information and other factors, management believes it is more likely than not that the net deferred tax assets at March 31, 2021 and
2020, will not be fully realizable. Accordingly, management has recorded a full valuation allowance against its net deferred tax assets
at March 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Management has evaluated
and concluded that there were no material uncertain tax positions requiring recognition in the Company&#x2019;s consolidated financial
statements at March 31, 2021 and 2020. The Company does not expect any significant changes in its unrecognized tax benefits within twelve
months of the reporting date.&lt;/span&gt;&lt;/p&gt;





</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-04-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">320796</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <modd:RoyaltyAgreementDisclosureTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_803_ecustom--RoyaltyAgreementDisclosureTextBlock_zkaeltItnZK7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 8 &#x2013; &lt;span id="xdx_825_zCbrVhHYqJ95"&gt;ROYALTY AGREEMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In July 2017,
the Company entered into a royalty agreement with its founder, chief executive officer and major shareholder (the Founder). Pursuant
to the agreement, the Founder assigned and transferred all of his rights in the intellectual property of Quasuras in return for
future royalty payments on the Company&#x2019;s product. The Company is obligated to make royalty payments under the agreement
to the Founder on any sales of the royalty product sold or otherwise commercialized by the Company equal to (a) $0.75 on each
sale of a royalty product or (b) 5% of the gross sale price of the royalty product, whichever is less. The royalty payments will
cease, and the agreement will terminate, at such time as the total sum of royalty payments actually paid to the Founder, pursuant
to the agreement, reaches $10,000,000. The Company has the option to terminate the agreement at any time upon payment, to the
Founder, of the difference between total royalty payments actually made to him to date and the sum of $10,000,000. All payments
of the royalties, if due, for the preceding quarter, will be made by the Company to the Founder within thirty days after the end
of each calendar quarter.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</modd:RoyaltyAgreementDisclosureTextBlock>
    <modd:RetirementSavingsPlanDisclosureTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_802_ecustom--RetirementSavingsPlanDisclosureTextBlock_zX9EcFTxDFYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 9 &#x2013; &lt;span id="xdx_822_zQx4uQmdvPXg"&gt;RETIREMENT SAVINGS
PLAN&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Effective March
2020, the Company adopted the Modular Medical, Inc. 401(k) Plan (the Savings Plan), which qualifies as a thrift plan under Section&#160;401(k)
of the Internal Revenue Code. Full-time and part-time employees who are at least 21&#160;years of age are eligible to participate
in the Savings Plan at the time of hire. Participants may contribute up to 15% of their earnings to the Savings Plan. The Plan
became effective and began accepting participant contributions in April 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</modd:RetirementSavingsPlanDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zeBo7ziYRPG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 10 &#x2013;
&lt;span id="xdx_820_zkGXOVMGfxh7"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Litigations,
Claims and Assessments&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In the normal
course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of
business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable
settlements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Indemnification&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In the ordinary
course of business, the Company enters into contractual arrangements under which it may agree to indemnify the counterparties
from any losses incurred relating to breach of representations and warranties, failure to perform certain covenants, or claims
and losses arising from certain events as outlined within the particular contract, which may include, for example, losses arising
from litigation or claims relating to past performance. Such indemnification clauses may not be subject to maximum loss clauses.
The Company has also entered into indemnification agreements with its officers and directors. No amounts were reflected in the
Company&#x2019;s consolidated financial statements for the years ended March&#160;31, 2021 and 2020 related to these indemnifications.
The Company has not estimated the maximum potential amount of indemnification liability under these agreements due to the limited
history of prior claims and the unique facts and circumstances applicable to each particular agreement. To date, the Company has
not made any payments related to these indemnification agreements.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z5zBxWgYBylj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE&#160;11
&#x2013; &lt;span id="xdx_827_zfZkjWzcwctc"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Consulting
Services&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;During the year
ended March 31, 2020, the Company entered into consulting agreements with a member of its board of directors. Under the consulting
agreements, during the year ended March 31, 2020, the Company paid the director consulting fees of $140,625&lt;span style="color: red"&gt;&#160;&lt;/span&gt;in
cash, and the director was granted stock options with a fair value of $76,875. The options were for a total of 15,687 shares
of common stock, were fully vested on the grant dates and have terms of 10 years.&lt;b&gt;&#160;&lt;/b&gt;&#160;The most recent consulting
agreement, which was entered into between the Company and the director in September 2019, was terminated in March 2020. At March
31, 2020, the Company had an outstanding payable to the director of $5,585, which was included in accounts payable in the consolidated
balance sheet. The Company paid the $5,585 to the director during fiscal 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;2021 Placement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font-size: 10pt"&gt;The
Company&#x2019;s chief executive officer and an existing investor, which is represented by a member of the Company&#x2019;s board
of directors, purchased $100,000 and $1,000,000, respectively, aggregate principal amount of the Notes (the Related Party Notes)
in the 2021 Placement. As of March 31, 2021, $1,677 and $16,767 of interest was payable by the Company on the Related Party Notes
to its chief executive officer and to the investor, respectively.&lt;/span&gt;&lt;/p&gt;





</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2020-04-012021-03-31">&lt;p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zJZhTqL9Pnwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;NOTE 12 &#x2013;
&lt;span id="xdx_822_zye6Msj6Q1d7"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;Convertible
Promissory Notes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Subsequent to
March 31, 2021, the Company issued an additional $4,250,000 of the Notes in the 2021 Placement pursuant to a Securities Purchase
Agreement between the Company and each investor (the SPA) and warrants to purchase shares of its common stock (the Warrants).
The Notes are unsecured obligations of the Company with each Note having a stated maturity date of 12 months from its issue date
(the Issue Date). The Notes bear interest at a rate of 12% per annum, payable on maturity, provided that, if the Company fails
to pay any amounts when due under a Note, the interest rate increases to the greater of 16% or the maximum amount permitted by
law. Each Note may be prepaid at the Company&#x2019;s option during the first 270 calendar days following its Issue Date (the 270&lt;sup&gt;th&lt;/sup&gt;&#160;day,
the Trigger Date), subject to a 110% prepayment penalty on all principal and accrued but unpaid interest then outstanding. No
Notes may be prepaid in whole or in part after the Trigger Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;If the Notes
remain outstanding after the Trigger Date, the Notes may be converted into shares of the Company&#x2019;s common stock at an initial
conversion price of $8.61 per share; provided, that a Note holder may not convert any portion of its Note that would cause it
to beneficially own in excess of 4.99% of the Company&#x2019;s outstanding common stock. The conversion price and number of
shares of Company common stock issuable upon conversion of the Notes will be subject to adjustment from time to time for any subdivision
or consolidation of shares and other standard dilutive and certain other corporate events, as provided in the Notes. Subject to
certain Exempt Issuances (as defined in the Notes), if at any time while a Note is outstanding, the Company sells, issues or grants
any shares of its common stock or other securities entitling the holder to acquire shares of the Company&#x2019;s common stock
at a price per share less than the then conversion price, such conversion price shall be reduced to such lesser price, and the
number of shares of the Company&#x2019;s common stock issuable upon conversion of the Notes shall be increased, as provided in
the Notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;If the Company
completes an offering of its common stock or other securities in excess of $12,000,000 of gross proceeds (a Qualified Capital
Raise), each Note holder will be required to convert its Adjusted Note Amount into the securities of such Qualified Capital Raise.
For purposes hereof, Adjusted Note Amount equals the product of (i) the sum of all outstanding principal plus accrued but unpaid
interest on a Note, multiplied by (ii) 1.25.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Notes contain
a number of Company events of default (Events of Default) including, without limitation (i) failure to pay any principal or interest
thereon when due, (ii) failure to timely deliver shares upon conversions, (iii) failure to comply with SEC reporting requirements
under the Exchange Act, (iv) certain breaches of the SPA, the Notes, the Warrants, and the Registration Rights Agreement, (v)
material restatements of the Company&#x2019;s consolidated financial statements filed with the SEC, (vi) a holder&#x2019;s inability
to rely on Rule 144 for sales of shares underlying the Notes, (vii) the Company&#x2019;s common stock is suspended or halted from
trading and/or fails to be quoted or listed (as applicable) on the OTCQB, OTCQX, any tier of the Nasdaq Stock Market, the New
York Stock Exchange, or the NYSE American within 10 days thereafter, (viii) failure to file with the SEC a registration statement
covering the resale of shares of common stock underlying the Notes and Warrants within 60 calendar days following the Issue Date,
(ix) failure to cause such registration statement to become effective within 120 calendar days following the Issue Date, or (x)
certain merger consolidations, business combinations and sales of all or substantially all of the Company&#x2019;s assets in the
event the Company is not the survivor of such transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Upon an Event
of Default, a Note holder may declare all amounts under its Note(s) due and payable, in which event the Company will be required
to pay such Noteholder the product of (i) all then outstanding principal amount and accrued but unpaid interest thereon, multiplied
by (ii) 125%; and all collection costs including legal fees and expenses in connection therewith. At the option of a Note holder,
in the event the Company receive cash proceeds as a result of certain events including, but not limited to, from customers, issuances
of debt or equity securities, exercise of warrants or asset sales, the Company will be required to use such proceeds to repay
all or any lesser outstanding amounts due under such holder&#x2019;s Note.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Notes also
includes various covenants, including negative covenants, representations, warranties, other payment obligations and agreements
by the Company including, without limitation, most-favored nation clauses, rights of participation and first refusal and exchange
rights. In connection with the issuance of the Notes, the Company issued Warrants to purchase 761,912 shares of its common
stock (Warrant Shares) at an initial exercise price of $24.00 per share. The Warrants may be exercised for a period of 5 years
from the Trigger Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In the event
that, prior to the Trigger Date, the Company (i) completes a Qualified Capital Raise, the outstanding Warrants shall be cancelled
or (ii) prepays a holder&#x2019;s Note(s) in whole or in part, such holder&#x2019;s pro-rata number of its Warrants shall be cancelled.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Effective April
30, 2021, each of the holders of the $2,210,000 of Notes outstanding at March 31, 2021 entered into a revocation and replacement
agreement with the Company (the Revocation Agreement). Under the terms of the Revocation Agreement, the $2,210,000 of Notes and
accrued interest of $50,091 were replaced with new Notes consistent with the terms described above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In May 2021,
a member of the Board purchased $200,000 of the Notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;i&gt;PPP Note&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;As a result
of the Company&#x2019;s request for loan forgiveness, on May 29, 2021, the Company was notified that the outstanding principal
and accrued interest for the PPP Note was forgiven in full by the U.S. Small Business Administration.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MZ,P44RI5U@8J&R/9][V!(H9#T:0ZP%[7\11DU-IY73,7I:B*4R'L]100A.L
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MX-HG.%PE=&*N[$57 @]?$*E52IN* 4GK*^[F/2 W8UT5G3AE$4@TH7I=8KX
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M!!>UZ=<;35ZWU&N+K0OF8LI5:QN[/"<]<%K0#=;&#Q>5W?"<P48JV)+IL,M
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MWRXGLAUSLH<%C+TF5R:,F#(6.8^J%\,[DTR"L&R:!#G4N( OC%L'^T9&J$.
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MWX;A,+3]VS#\T?96?T3+_N/?AHGY:/2MF/#EEF$;AD#(0")^2W-MN"?D(UZ
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M>N.*-/6#/1I!5:K-C<&3G?&)O_8TIRDJ&WK1+XRX(]XA8[VA9DM^B!:TG<4
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M;"]W;W)K<VAE971S+W-H965T,34N>&UL[5A-;QLW$+WOKR!4H"=!7W::+]N
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M.3; ^Y5%\=H;)MC_FW+V#U!+ P04    "  SA,94\&2)[D4.  #])0  &0
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ML>W%XY?58)ME!6G>8\%P9(?C$82Q/?;#P8I73:M07!AH:LDS=60"8>C;013
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MM03B2Z<,) ]NP",@J13>(4MS&(8IC 34Q60(#YX$9SX[/XLO+\:4=U!B^.F
M7.;917PQXD9S=-BD;7-MBWX17,QKY$V/UY(O4,:[2N!A#BUH'GQ,N.]5(A5[
MBMQ!Q*A%1#F**HK=GBKG@*O)OEG5P?D-#7B_+U=Z9EX?<>YU:W/$0QTU:88Z
MO1&1NKN[$Z[T,0^SF[,XPC6&?:_V3(FZX,\F%U<0;PAVP*P%'Z8%[L$-Z+#?
M2:>DOM,;E,U(7'<.WPA[PX\+I[-FT4D3#KJ,J H&(RB7V+K=YN?!_4 MR,-S
MPJ$&K&\*5^1Z;5V-PMHF,2IN<,^YH-PM5%MD=A8Z[1N>RO"I-]>?H C\ZF<(
M0?3(VZQA5YIR9F*:&=<]D ?;JE^0",Q&O=7Y%]GQ'^2O[J2M_9N."D>3MZZ6
MF]QGQ,/>AJ+F.LF0T4.1%1W2&=N+#VQG-BUDBA @JTC0<' ?7^%R/E?53>T1
M>9!H',$*];-Y.\L;$_OQ>,!<4[A_J+OWEPI3G79Y4;,_-T_G]A'J(-2A\T>#
MX7.F*SI'P@V>T#0I$S,WC*A$5%!X>W!HQQ1<.],$3RB,AQ79I6N&NO1I*G#B
M0=09'C$Q$@[1N<8^\;FSD+&.>!8C^!'X*/!2IY6'GG:8XSMNI:\(:&@J!474
M:;0Y0XF-;(9" OM28Y69,A75B[(I+L("*HNY*T5R;A%N]L*6<Q/I8=Y6^HY_
MN%?4^D4QX]SES:9]R=/M!)*.?&7DH9 5%N9@W9JVUZOOE'O]QR))[PW1],:(
MFT80@@W?EZB29#8Q)2W21[_5R<+/0DFOO<IN:RJXDFK4![:/$/(F_+< K.6^
M']T/A%Q]G%4%)1[!PQ#5P=[L7YY-AXV:;C/W>/V)D:^YV?7TQA5IZ@=[-(*J
M5)L;@R<[XQ-_[6E.4U0V]*)?&'%'O$/&>D/-EOP0+6@[BP$ !]BEF<5'=^TL
M7I+4^[R=\PMO0O%R8,8__MH9?[=M?W!@'_U_#^S5MPSL(Q:4B<==D.BD4_S"
MCKK3S98Q)T$9=73I'K3G^+DX4/.8;7OXA6MX!F-;NN%>ARZ70K;EE$Q7U)G#
M3>[-JO*,*(S76<0/] 1Y"]&,$S[.NR?#FDWZ95KO<3GI*QEO?P1!39 ZY_UW
M6OH"XKHFQ$/-S0VY,'SA]CWC-\H-JFD$<[HCI7U-NYV.27^\S<4L&QW&GW7F
ME<VD7/"+3B!O"S>.MJ9/6RR 9*M4:C0N]^R\F5H=F\?0MGIJV-9,P;K!T)V(
M<7L@(CB:^2+8::'1\/!542(^>K,P]8-T_?/%";<EVMX6M[[V/!<SXG*E^T1?
M+T^BG8F2V*X9E37C+YV9/48(+8TDO+;@C<N/"^[XP7-B?7Z2$1@K)VH-"*-L
MS=2:>PAYV)F?-EA[!1X!38WQ3RA+3H(Q4$?2I?S8EH,!-JES2VTXF7Z3Y#TY
M:-T>,;:T+N\F)'(M8C[.)@L39C/D9J5/6WM@NRW0#JF[H^=O5FWG2AR55EI>
MC4<$PY51R%T5*$4EQ6B1T]0:EX#/@OWFOD$4;K8H.'D7#CP#E>,UYQ;)#Z%8
MZY4[_!;&GH+G$J7<\#S:/^V@CF@(LK9^E89_WDF-U"MKT#577VQ.(E&SS/,U
MBDRW-8CH@:#(*LV@LA_%TKG/_'M8+>/I= &V6;]TBH10;O/D T#[M=@J&6B?
ML#$^?8!ONABG<^N:DR$U,IGU3/SPJF70/2UT!^2^5TRMLG#$-X@>;8M>=&;U
MK8O_V5M#PO&W@IX;G8.KR\XK& 3]!!#=^.?7.6",UF=IKD1O*)/W=3H0D^%W
M"3%_J2$.. F]$!'MA5F%,.)Q@.?1N'B6F<1B4;KIY]Y&B&9B<2/M9I[#YQ4X
MXIYW$-I8BH+=!366>FW$QYH9B+$<_-)QE<1#?M?V_COO2OV)67=2?_0UJ9_-
MVW\?I)?0_PS,]UB7V[RX*Y&%?G<BQ-C7WJ([P=IS"8DM;J*15XZ'+W?,PY^/
M7D:9 35E->O^R)($EEGF]L69CLL+$.*<@1\(5?%KY4/ #+<Y'6FBI/&:-Y^D
MS9;>0.=NH7/[AXQ"FKI12Y$:WCQJY8L;Z=S6XG;6R%FF!65/3X(U>S;8Z^K?
M="I5R#:OC9]422T+K6;ZM\+Y7B^=N"[8E5? .!?:%S*>I8^]PKKB",Y]BRPO
M_:"2,D>G]*#9,O!!M,&U.LW\V@>8->[V'8CJ,X1N6LWVWH,Z'S[YKF'WLK01
MGR;]D)?RNDLD5$#&&N'KOSX-;]Y[X*1;4ILX15SF,H_<MV=T8,_FU1:*+&X!
M4'2#9,.;J\U+">JUC*(3J@[I54,_E /\<JZL5UN[]ZO[_0UWU3;<KZ[BJ_]B
MOST*A74?8?[#?KOWKKVM=I^V^&":T_D^>9]W<=]2KZ#J1YM)'#P;3:AH&:A]
M?VEPVOF3$0X+^DL:IFQY)7\]TGS:_+'.-?^-RFG[N/RE#P194*<K-7,L'0XN
MSX^$?81?JF+%?X R+2H4AOSCTFCD,WH W\\+J-#_0@<T?\+TYO\ 4$L#!!0
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MTME)Z37#@PY>.$JE2R.9KS@(BS[,F((Y7L-W#_S[2IE1-%N7.X0N!H2TDFV
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M[OXZZEG@TZQ>VF"=>:SD&:PX81]491>&75:9R)X"]$"L99=LV)TE+R)^X/J
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MR,N"&T947!9#6)V,-#GNL /D7,Y6;EM":!N/3:]>09>+M,#^=2#RP8\.AO#
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M+U21I[DT1\].:D % 9ZD;MN7=MOICFV?\C>JJM>&OZXRF?6LGP^OGTP' )P
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M &$(A'>_(@G6TI'&AC/VN@+Y9G]K=PDB9N_5 5OP$K>OAHO*#9M9PM 54)Q
M(U5:JX*NE$43W\=T*5^CK(-'9FGGD(1,/#'G*G$]&(7(0-ZX.R2TK5?*8W[6
MN0> "K)E%-F04>PK@O9@BS5N2JQ%*>V%?=,BT6LE/Y?K_]\8-FSFV+?B3E=+
MV^&\R7TS=>[].;-,4>,@>N?$A5:5PG+RSI+9?K#9?;#Q'M&L636FCLB#K\!P
M;Q#@^&H+^ZZ+Z7@T?I1 .+"HK9V<TS5PXTOP[TA,WKDHX/"R6=1J P[YP>/Q
M:#H^<D.(=#F;:D/X^6>983MJ-,>:N$CMO/%KP+-NF?/NNJ(*%TA""_3)Y.'H
MP?AH%)T+I6 >W4R/LSHJT<9[B(KMWF:(O]-VS&\Z/)E'ES)&+VE(;AX-R?6^
M(W!O4"P&U<E6L:H'^0%FECL'@BF-L:&*X],*%+9VEY_+3:%NI6LM5:H:M=\@
MC^^4 !?VUI"K -H!;YR2X>B><>[-^LX$LN(F9$SX8H!VW#GA%D?G*@F7478W
MAXBGN=I1<9\[43IN[_3[,SEP?HR;P$:5S)>% .I<IF"R)(WVT0L$2I7AV!UN
MEDG,E?(JC!9U<W^*O1QU(2NR%=9K?(<,&]@9K*?%;]39$8/3T&%T@:=]SJ;"
M]+Z3:XGCAJ8S&J_E2FA[_=\%IEAM=:T >[_\QK_:!5O3:-FNA,XQB3,^A@E?
M>#,,'&GJ<+G-MX-K90U#N+IF98@0[,RM^')PG!-;TMCD')+$WV(([J3R!B_T
M&XS0(%"#X&W0Q$[;\<?I\/CCN;V9\0%GWWO5[@M&VF*8'?WS4H,3_GBOF2[?
MBYM=Y0LK/^'%*78&7])8XD+6UQBJ[ACM<]?S;PB$[SILO=-EQ[9.#6!U&%UW
M\6KG.B)\;?N:\=1=^ZZ?+KZU8OZ.AKBA(H&]=  !0%3> !N@KJG7"R*/U\D6
M16[6+@A'\'U4P]\L(GF-ZTH%HEGDGR39$T&O-Z$ @5$W5N.P -ZH:/O9?5"I
MV>SZKEK2BR0@/7L9VZ+V11;1?>1H<#F\!*V]S\(6LL 7"9G[<+7OJG$3HJ2B
M="FNHM=3#&-K7X'A<=YZ<0G#V86VO6,+5#TLZ!A5%FH\2.W0Q"84_-U;TW>A
MF>*$WG=IS546\B)\/=;\B'\@O_WX <085H78M@KAS41C^_+;Y&FO6<$)ZT9;
MG'Z#K-=@X[Q]2P<8-2IKX;+&M4S)DOEW N$ETP@,HW!R.IX\0B](+W)Q5W6C
MJ1Y\?X'W"/$LR3:>Q+D&(F7;9:4W\FS=G^^^2I$F3E0=<:ZZ;8N3CBW!OSOE
MMY/G)LPW )([>->?5IY$+W^F,1E\)S9=":IJ^Q[H\&UX[_:,WC9]TCYN7]H-
M9X,PSO!"+F'I^/CQPP.N[7NP[0<(VNA5T@M5UZJD/]=2 .7P ?A]J53M/^ &
MX6WD+_X-4$L#!!0    ( #.$QE2O+KX0\@(  $L(   9    >&PO=V]R:W-H
M965T<R]S:&5E=#(T+GAM;*U676_:,!1]SZ^XBOJP2E$3'*!0 1*EK5:ITZIV
M'YJF/9AP :N)G=E.6?_]KAU(/P11->V%^.L<WW-LW\MHH_2#62-:^%/DTHS#
MM;7E61R;;(T%-R>J1$DS2Z4+;JFK5[$I-?*%!Q5YS)*D'Q=<R' R\F.W>C)2
ME<V%Q%L-IBH*KI_.,5>;<=@)=P-W8K6V;B">C$J^PGNT7\M;3;VX85F( J41
M2H+&Y3B<=LYF?;?>+_@F<&->M,$IF2OUX#K7BW&8N( PQ\PZ!DZ?1YQAGCLB
M"N/WEC-LMG3 E^T=^Y773EKFW.!,Y=_%PJ['X2"$!2YYE=L[M?F(6ST]QY>I
MW/A?V&S7)B%DE;&JV((I@D+(^LO_;'UX#X!M >R]@'0+2+W0.C(OZX);/AEI
MM0'M5A.;:WAO/)K4".E.\=YJFA6$LY.;R^G]Y3U\^,+G.9KC46R)U$W%V9;@
MO"9@!PB&\$E)NS9P*1>XV(.?M>,[K(4@)C6-)+:3=,Y:&2\P.X&T$P%+6&=?
M0.WP3UP?@K\*)VT<3CU?>LAAI%MFX.=T;JRF6_NKA;/;<'8]9_< YU5E*XWN
M/HBB*J#D3_2PK(&*+-1@UPA+GHE<V">@]ZZY%7(%N0LD DFI02W](C\"0F8$
MIL>T[_#?$T?P#W'L.Y?6O5PZ.S,ESW <4KXRJ!\Q?&-$\)^,@)8CZC5'U&NU
MIGY8^RQMQ>V7.96RXCE<"9/1YP=R;>#S3D] %Y5!.HC2WL"U4^CT!E'"?*<+
MW23J#UEP@\:<!==%65E<D%2+Q&[A TNBI#N$X^#6[28M//*\0F=,;4HN^-P9
M*.@.'P'KG!+SL,V@?F-0_]\,FK7B]AOT;$9M5?#**J^DMNF(S$FC;LK>Z53P
M[%2716QX^M:IX(!3:3*,!KW>7J?B%_FZ0+WR9<Q IBIIZ]3=C#:5<NH+1/R\
MO"ZSE*U60CJ)2X(F)Z=TNW1=NNJ.5:7/_G-EJ9;XYIJJ/6JW@.:72ME=QVW0
M_'^8_ 502P,$%     @ ,X3&5)FQMB)6!@  C10  !D   !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&ULU5AM;]LV$/ZN7W'PFLX!5%FBWMLD@..X:[8UR>*T
M13'L V/1MA!9<BDJ3O;K=Z1DV4YES6FQ OL@B91XQ^>>>R'%HV7&[_(98P(>
MYDF:'W=F0BQ>]WKY>,;F-#>R!4OQRR3C<RJPRZ>]?,$9C930/.D1T_1Z<QJG
MG9,C]>Z*GQQEA4CBE%UQR(OYG/+'4Y9DR^..U5F]N(ZG,R%?]$Z.%G3*1DQ\
M6%QQ[/5J+5$\9VD>9REP-CGN]*W7@U".5P,^QFR9;[1!6G*;97>R<QX==TP)
MB"5L+*0&BH][-F!)(A4AC"^5SDX]I13<;*^TOU6VHRVW-&>#+/D41V)VW DZ
M$+$)+1)QG2W?L<H>5^H;9TFN[K LQ_IF!\9%+K)Y)8P(YG%:/NE#Q<.&0+!+
M@%0"9%\!NQ*PE:$E,F76&17TY(AG2^!R-&J3#<6-DD9KXE1Z<20X?HU13IR,
M;BX'O[V[_/UL>#UZ^5- +/\-G W?G@_.;Z!_<0;J^ZO3_FAX!H/+]U?#BU'_
MYOSR KHW]#9A^>%13R ,J:PWKJ8\+:<D.Z8,X7V6BED.PS1B48/\H%W>(BT*
M>FA_30)9D7!*6C6>L;$!MJ4#,8G5!*A=_#WEN\2WX-BU3VRES]ZA;_BEB,4C
M_-F_S07'./^K1:=3ZW243F>7GS']HR)AD$W@+8TY?*1)P:"?8_HN9$+E38YL
MUWDS8S#)$BP$<3K5Z%H5+!EG4.0L@C@%(8?)*>_5E',F9ED$8YJ,BX2J\:_A
MF^ -6N')^O<Z7] Q.^Y@@<L9OV>=;<S0B%G;P/QJ)V9H<8I;.\5M=\I&\OT,
MPS\^G-]\AFZ5?H?PDLX7;W9F8)._6J?;10AG3-M,*+A N:TWF@QL&=TFU"WM
M.L[O7DVD<)P*Y"X7P*E@.5@&\0[P;N/=-.Q WH/U"Q)4K[6/F>0RD;%NA?X!
M$-<^@  ;07@ MF^6'8OX!]KP88%U'[$E\81!]Y%1GA^":YC@X>4:!"^_ZI/5
M>^TLOH\CED;P&+,D E7?R)N=SZ80^P9&/R,XC2DFL3*,9[(T:'OPMJ+&M]1=
M$F+8_A9-*SX@D R;]IH8;0<QVT1H6T0<K!LMP>S5P>SM76%&(AO?P>5BO5(C
M^J: ;5?97VTN--29*YW9MDXHD&>NTO4JH2G$.2A'I#)6;N4>9;NV[ MLL"<P
MV 6LA5"_)M3_[ZH##F2"QDD.I'&);IVZ.:XOJT)Y68A<T#2217\TH_@=+HKY
M+;H!R?BD]DT8CZ<4_3%F0,4Z"\KJ8=F>;@8$+!VS7B<N@1<R@UUM-<&44^6_
MKF?JON_ (50-BQA>6,X)=$EYE$/7T@/;PR%/DKE6-I8HD@35(63<=XJ"I]@1
MV3IH?-UU?.B6CT,(#,_:A/]KD3*PS0I]8"'X$,$3U]0=/T3H;J#UHRB6\]$$
M\I(26N"2P>._<:XG,6KIMFWCY>S$7!-@AYYN!Y*!50LIL-PG%-BZ][T4.*%.
M+!NZU?,0?,,DFR2,V$(PY>2:"23"LY$S#ULN>M)S312S_*_-()ZG6[AM.\02
M'^JN&T)HA$\=Z:*+W;45ST%/0MWT$;TEO>(I],391(\;O K\*@@#@B%ERR ,
M'%</71ME7+]Q"?B&5*G2HBEC^O>8E7+KW) TT+]G'/^=-/P[@U\D>U!I&CXP
M/HYSM)?'8[8KN:P0'6GJIFV!:X9ZZ(6XA+C>LZ)S[]AT?:([IG3JJN49OOLL
MM]FZB>[J5L_#4L&NPH%[#]_1I8T8>!A&MN6"8_C.U\@L#$LGE,A6+4QIYUG(
M7(Q2%Y&5SW]!UE329$%K6U6#>A$(]EY5-\)(0:^"0@53:9P.US2=LJ:"WS[-
M]E9>*)7E$H<QDBMBN-0L861/8+ -&%G%,<WER*_2;FLQUK['GL$/M:?%D6'M
MR/!'K.9VXVK>.O7>JWE=KS8<H5VO:-HN0:OJ59>NNO'T0W\ZY6R*.USM!?X#
MA %8ON&;&X4W,'#%>5'67TQM+.)NX*D]@67B Y<8S]&)%S06Y_^5Y:'A!!LU
M(I UHMS[@.\0/50\V$8HK0]T'XL7\<S&*M+;./&9,SY5!V%8VK(B%>7A3_VV
M/FOKJR.FWGIX>5"'I6P:H^D)FZ H_GC@+P\O#[_*CL@6ZOSH-A,BFZOFC%%<
M-.0 _#[),K'JR GJ$\B3?P!02P,$%     @ ,X3&5.ROF "4 P  \ @  !D
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MK.[X\3,MXQEH/I_'TOS#L;3M6.#G4O&D!*,'"4N++WDN=;@&X)0 YPW &5X
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MK8/9WPE3H=ZP+VMHU?$_4$L#!!0    ( #.$QE3^62^Z%P0  ,$.   9
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;,57;6_B.!#^*U9T)[522]YX%R !
MH7>5^H*@V]6IV@\F&2!J$G.V@7*__L9.F@(;LKOMG=H/)7;\/#//>#(>=[:,
M/XLE@"0O<92(KK&4<M4V3>$O(::BPE:0X)LYXS&5..0+4ZPXT$"#XLAT+*MN
MQC1,C%Y'SXUYK\/6,@H3&',BUG%,^6X $=MV#=MXG9B$BZ54$V:OLZ(+F(+\
MLAIS')DY2Q#&D(B0)83#O&OT[?:5[2J 7O$8PE;L/1,E9<;8LQI<!UW#4AY!
M!+Y4%!1_-C"$*%),Z,??&:F1VU3 _>=7]BLM'L7,J( AB[Z&@5QVC:9! IC3
M=20G;/LG9()JBL]GD=#_R39;:QG$7PO)X@R,'L1ADO[2ERP0>P#D*08X&< Y
M!E1/ -P,X!X#&B< U0Q0_5D+M0Q0.P:X)P#U#%#7L4^#I2/M44E['<ZVA*O5
MR*8>]'9I- 8X3%1F327'MR'B9&]X?_<XFCQ<#VY&9#RYO[V>3N\G?Y&[^X?1
ME)QY(&D8"7)'.:<J!<[))?DR]<C9;^<=4Z)]Q6+ZF:U!:LLY8<LEMRR12T%&
M20!! =XKQ[=*\";JSL4[K^('3BFA!WZ%N/8%<2S'+O!G^/-PJTC.QZR//F;]
MJAQ^2W<GC!^$TLWSR-5T[@FZZ9)Q>2F!Q\2#F21/-[B 7$N(Q;<2^FI.7]7T
MU1/T?V"-)&<W3(AS@O5H]"+#9+$.Q1*+G"1LKHT6960IK2K;;;&B/G0-K,L"
M^ :,'BG*A/^(QTMY:II'5?U-SW8=NUK#'=SL[_W'[1W$N9;'N58:YWZ,VQC^
M0W75S\)*KH58T\0',F1"BB)5M>]4-:QZM9%K.O"EGOM2+_5ENJ0<+M6Q$:#E
M&,]2D?K5QV*4+$!O_6Q']M>-Z4Y/][>4!Q?DBH:</-)H#:2/(N*5PHL+\E4?
M.+B^OP&.!RAY9!%R1Z'<D0F54*2QW-EFL])J_EZR XU<=>.S5$]"\4RN..!W
MF>"7"D*>$CLL]]&JN,=:TQC]"-:LEX6HF8>H^5DA&KVLL.7!]0]8R8H4EGM6
M(SN@7) 6B?5)52*VE8MM?;I8+]R$ 23!J708E+MH52RK*!V&[X-Y[X.-?AEV
ML!^V]=8Q6:5,3VE;UKYC$D0_"?J^O^80O'Y30[:.@@&VN@G6%JGG&6X<)L14
M,O_YTOI6V#FE-NO[);3>:#3=PW/!^_&Z0U5[?:!=JBKS-YQ%0+0RE454C9YN
M(9X!+SO&;>?-C/-_] GV6Q]BN^_34=0B95S[!U?5J5GX=Q1.<Z_#CH$O]%U(
M$)^M$YDV2?EL?M_JZUO&T?S ;@_M@GG/;H_2V]0;?7JYNZ5\$2:"1#!'4U:E
M@=[R]+Z4#B1;Z?Y^QB2FI7Y<XAT3N%J [^<,PY -E('\UMK[%U!+ P04
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M)@4)3[,O>\KK< #PVT< 00X(?@4TCP :.:!A$\V4V;1&3+-!3XH]2.--T<S
MUL:B*1N>FEU<:$FKG'!Z,)M/;\>+Q73^%2;33^_A=(2:\5C!A$G)3(G/X!SF
MN!/QCJ<K&$J,N(8;%O*8ZV?X=HO) \I[<KI;C.#T[5G/U:3+1'?#7,-UIB$X
MHF$:ZCH$W1H$7N"7P(?5\!&&=6CX97"7JE&4)"A*$MAXC2/Q/I(-8ODZ5;LP
MUIBH^PJ:1D'3L#3-/Z.IP3@-Z3XJ-'N1C<YJ,$%=5IF,HF4IS(7=#?R69WX]
M=U>BK5EH:_Z;MAI<A:'<8D0S&B6J4G7-U^JZQ\6U"G&M2G$+#+>D"V92)%PI
M(9]A(C2JXBQ6;$Z[X&C_SS/0*6@ZU746Z>J<ZI? SX1E=ZCSJI@-KV*KNX6$
M;J6$6Z:WTJ1&[0/+>'\'EW7P6[4W)R=T_8**FEP4@B[^]NQE)PWFI!1&I)KZ
MT0PE%U&9[FH6/ZA[WKLRN>Y!,S4/&66XXJF"&)<4R:MW: MD]CADAA8;VU\?
MA*9N;8=K>D]1&@=:7PHZG;EA6G;Q0@]^ %!+ P04    "  SA,94-RW2FSD$
M  !K&   &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6S5F>V3HC88P/^5
M##/7]F;VA("O6W5&!#RG]=:JMYU.IQ^B9)59(#:)Y_K?-[PLNA8"QWWP[LL*
M(;_G-3P/R?:/A#ZS'<8<O 1^R ;*CO/]O:JRS0X'B#7('H?BR1.A >+BEFY5
MMJ<8N3$4^*JN:6TU0%ZH#/OQV)P.^^3 ?2_$<PK8(0@0/9G8)\>! I77@86W
MW?%H0!WV]VB+EYA_WL^IN%,S*:X7X)!Y) 04/PV4$;R?P%8$Q#,>/7QD%]<@
M<F5-R'-T,W4'BA99A'V\X9$()'Z^X#'V_4B2L./?5*B2Z8S R^M7Z4[LO'!F
MC1@>$_]/S^6[@=)5@(N?T,'G"W+\B%.'8@,WQ&?Q7W!,YVH*V!P8)T$*"PL"
M+TQ^T4L:B M R,D']!30KP"]"#!2P*@*-%.@>6U2LP!HI4#K&F@7 .T4:%?5
MT$F!3IRL)+IQ:BS$T;!/R1'0:+:0%EW$^8UID1$OC);BDE/QU!,<'RY7#^/?
M/C[\;MF+Y<_ _N/S=/47^,6RG>EXNGH/?D+!_E<03_I@CI:V!<8/L[G]:3E:
M31\^B8F8(\]G[_LJ%\9$(M5-JMA,%.L%B@TP(R'?,6"'+G9S>$O.]\IX1\Y#
M72) %5',0JF_AM+4I1(MO&D  ]X!7=-ACD'CZKB6%X]OTVY_FW9'CL\0E6J?
M5,<U22J,;%4;L;QFT:K>(8H_1"7*!6,2B+K-4%SY1I2B<(M%+>5@?0*7\^;H
M% ^/CHBZ=\!!'@6/R#]@,&*B4.\CGMV!A<>>@4,Q!M.08XH9!PO$<5Z^Y39J
M#:/[+B_/95BW_4X2HF86HN:M0F2_[$6C$?,?B2]D^AX_%<9(;F2WT] TF;>M
MS-O6S;U=81KDY5-N60N<,*(,]$ 0ER.)L^W,V?;-G;6\+YZ+0[<HL:;<1.W_
M>4W60SW,JH?97XV]R4<GRT='*F?FA5YP",#?,QRL,?U'(K*;B>Q^_P7.E-L(
M&_IUI4J2)<=$@<M/5AFFYY93IQXV*<,Z'=G2Z&5Y[-W\52VOPJ;<2-C+*<-)
M*N5@MU?TXI5P1?J<FMRDA&N7O.E0.W].:S=/:$&C,4M,2SM-7M6M1@(][5%
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M=^-?H/_'P^#^3WC7ZU\-NH/[]_ SB9:_0@8ZO^R,^SWH#F]&_=MQYWXPO)5
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MGS(%D,]G22*>+]0$Y<>?]C]02P,$%     @ ,X3&5#%BJ3*7!0  5AD  !D
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M0S#0?%#+-YPDV:PS)5Q,3MG2%\,MIM) /)\1PE<;.3Z5XW+G'U!+ P04
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MD^_;4+P4?J"OMS2;>=.VBTEEFOP_.SNN:@=LG/_>[A63/!+1<AW;TH]5'$%
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M"D@ + /(YPM*Q6LGFZ"XV>K]"U!+ P04    "  SA,94K@I]Q.X"  "V"
M&0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6REEFUOVC 0Q[^*E4E3*W5-
M2 (I'2"U/)6M+:RTFZ9J+TQRD*AQS&P'NF\_VPD9M"$@[4UB._?[W_G\<&FM
M*7OA(8! KR1.>-L(A5A>FB;W0R"8G],E)/++G#*"A>RRA<F7#'"@(1*;MF4U
M3(*CQ.BT]-B$=5HT%7&4P(0AGA*"V9]KB.FZ;=2,S<!#M B%&C [K25>P!3$
MTW+"9,\L5(*(0,(CFB &\[9Q5;L<UI6]-O@>P9IOM9&:R8S2%]49!6W#4@%!
M#+Y0"EB^5M"%.%9",HS?N:91N%3@=GNC/M!SEW.980Y=&O^( A&VC0L#!3#'
M:2P>Z/H&\OGH 'T:<_U$Z\RVWC20GW)!20[+"$B49&_\FN=A"Y ZY8"= _:Q
M@),#SEO W0.X.> >"]1SH'YL2(T<:+P%&GL +P<\O5A9=O72]+# G1:C:\24
MM513#;V^FI8K$B5J)TX%DU\CR8G.]''<_7HSONWU'Z8?/US8->\SZG][&CW^
M1"<]$#B*.;K'C&&U8T[1)\1#S("W3"&=*PG3SQU=9X[L/8YJZ(XF(N2HGP00
ME/#=:MXYQ ^J^>8A?G@@?KM"P)19+U)O;U)_;5<JCGUQCIS:&;(MNU:6D&K\
M2YI(W-J+]ZKQ'OB%=ZL$[Q_OO0P?_)_W835^A]F^U.TLA5.< D?KN7OTNI00
M>2].!?5?T/,=D!FP7Q6Z;J'K:EUGC^Z5[Z<DC;&  (U%" Q)3[)BA.HJ7P$:
M)3XE@$YN*>>GZ/E6XF@D@/ JY_7">;UR4MEL1IRGTGLO95&R0!-@$0W.T%2?
MXC-T+VN%MB@]T9E^0^NKDK;J.-9%PVV9J^UM6FY5W[7JO;?R/+?I[5KUWUO9
MKF,WF[MF@Q*7MN4U&[MFPX-F65[-K>N3 %OHRLB13]-$9,>Y&"V*[Y6N.6_&
MN[7+?E9#_\ED%5UNV$64<!3#7$I:YYX,C655,NL(NM27](P*>>7K9BA_+( I
M _E]3JG8=)2#XE>E\Q=02P,$%     @ ,X3&5-0K19$1 P  ,!$   T   !X
M;"]S='EL97,N>&ULW5AM;YLP$/XKB$Y3*TV%A)6%-43:D"I-6J=*[8=]JYQ@
MB"5C,^-TI+]^/DS(2WU5UP];-J(4^Q[?<X_OCAIEVN@UI[=+2K775EPTJ;_4
MNOX8!,UB22O2G,N:"H,44E5$FZDJ@Z96E.0-.%4\&(=A'%2$"7\V%:OJJM*-
MMY KH5,_&DR>O7W)4W\4O_<]2Y?)G*;^_>G;'RNI+]]X]G[R[N0DO#^[/+2?
M=L"9'SA)+UY >AZ&.#& &'G\,O+GN#OJH$_0;%I(L9\G,)C8I*+> ^&IGQ'.
MYHJ!5T$JQM?6/ ;#0G*I/&T*9,2,P-(\6GAD9U"[GJ=B0JHNMHU@_\[[Y0?
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( #.$QE0T-49_[@   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( #.$QE297)PC$ 8  )PG   3
M      "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ,X3&
M5'"7 T>^ P  0@T  !@              ("!#0@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( #.$QE2L?;H@*P<  &0?   8
M      " @0$,  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M"  SA,94J;>2[ 4#   A"P  &               @(%B$P  >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ ,X3&5 OIFDZU!0  >!D  !@
M             ("!G18  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( #.$QE3I;Q668 P  !5:   8              " @8@<  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  SA,94#GZ"-PX(   ;
M)   &               @($>*0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ ,X3&5!W\?P]&&@  "5\  !@              ("!8C$
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( #.$QE27QFFN
M/04  !X,   8              " @=Y+  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    "  SA,94;9S&H!@#  "@!@  &
M@(%140  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ ,X3&
M5%Q]^Z.)$@  [#0  !D              ("!GU0  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    "  SA,94FJO^=!0%  "-"P  &0
M        @(%?9P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( #.$QE2'^^:,)PT  ',I   9              " @:IL  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ ,X3&5!66. G- P  @P@
M !D              ("!"'H  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    "  SA,94/6\6?L $  #["P  &0              @($,?@
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( #.$QE3V]<J0
M$04  %D1   9              " @0.#  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ ,X3&5/!DB>Y%#@  _24  !D
M ("!2X@  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  S
MA,94;M*K=6$#   U!P  &0              @(''E@  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( #.$QE1(BJ?QB1(  ,XT   9
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M970R,BYX;6Q02P$"% ,4    "  SA,94#]LVFG 7  "97   &0
M    @($%R0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M #.$QE2O+KX0\@(  $L(   9              " @:S@  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ ,X3&5)FQMB)6!@  C10  !D
M             ("!U>,  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    "  SA,94[*^8 )0#  #P"   &0              @(%BZ@  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( #.$QE2:4UM8*P8
M !$4   9              " @2WN  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ ,X3&5%M^1@V\ P  M0H  !D              ("!
MC_0  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  SA,94
MKN8J>WP"  !>!P  &0              @(&"^   >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( #.$QE2VLNR%S ,  #H.   9
M      " @37[  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ ,X3&5-8A4P@E @  M@4  !D              ("!./\  'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  SA,94_EDONA<$  #!#@
M&0              @(&4 0$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( #.$QE18\J[+N@(  *T'   9              " @>(% 0!X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ ,X3&5#<MTILY
M!   :Q@  !D              ("!TP@! 'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    "  SA,949>7:ACL&   $'P  &0
M@(%##0$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( #.$
MQE23.DSO5P0   @2   9              " @;43 0!X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ ,X3&5#%BJ3*7!0  5AD  !D
M         ("!0Q@! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
M    "  SA,94DP_<K#8%  !9&0  &0              @($1'@$ >&PO=V]R
M:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( #.$QE2>Q"$%J0(   T(
M   9              " @7XC 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL
M4$L! A0#%     @ ,X3&5#D6+4XI P  .@L  !D              ("!7B8!
M 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    "  SA,94:F?3
MZ! #   Q"P  &0              @(&^*0$ >&PO=V]R:W-H965T<R]S:&5E
M=#0Q+GAM;%!+ 0(4 Q0    ( #.$QE0#YJ]Y% 0   05   9
M  " @04M 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
M,X3&5#!N--F)!0  7!X  !D              ("!4#$! 'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    "  SA,94D@#[GE,$  #E$@  &0
M            @($0-P$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    ( #.$QE2N"GW$[@(  +8(   9              " @9H[ 0!X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ ,X3&5-0K19$1 P
M,!$   T              ( !OSX! 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M"  SA,94EXJ[',     3 @  "P              @ '[00$ 7W)E;',O+G)E
M;'-02P$"% ,4    "  SA,94BLI'!Q$$  #Z'0  #P              @ 'D
M0@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ,X3&5+@VQ-RI 0  +AL
M !H              ( !(D<! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ ,X3&5%/9*RFR 0  4QL  !,              ( ! TD!
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #4 -0!J#@  YDH!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>161</ContextCount>
  <ElementCount>201</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>27</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - PPP NOTE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/PppNote</Role>
      <ShortName>PPP NOTE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - CONVERTIBLE PROMISSORY NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://modular-medical.com/role/ConvertiblePromissoryNotes</Role>
      <ShortName>CONVERTIBLE PROMISSORY NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - PROMISSORY NOTE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/PromissoryNote</Role>
      <ShortName>PROMISSORY NOTE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - STOCKHOLDERS??? DEFICIT AND STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensation</Role>
      <ShortName>STOCKHOLDERS??? DEFICIT AND STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/ConsolidatedBalanceSheetDetail</Role>
      <ShortName>CONSOLIDATED BALANCE SHEET DETAIL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://modular-medical.com/role/NotesPayable</Role>
      <ShortName>NOTES PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Stock-basedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - ROYALTY AGREEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/RoyaltyAgreement</Role>
      <ShortName>ROYALTY AGREEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - RETIREMENT SAVINGS PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/RetirementSavingsPlan</Role>
      <ShortName>RETIREMENT SAVINGS PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://modular-medical.com/role/Leases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - STOCKHOLDERS??? DEFICIT AND STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationTables</Role>
      <ShortName>STOCKHOLDERS??? DEFICIT AND STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables</Role>
      <ShortName>CONSOLIDATED BALANCE SHEET DETAIL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://modular-medical.com/role/ConsolidatedBalanceSheetDetail</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Stock-basedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://modular-medical.com/role/Stock-basedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/LeasesDetails</Role>
      <ShortName>LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/LeasesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/LeasesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - PPP NOTE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/PppNoteDetailsNarrative</Role>
      <ShortName>PPP NOTE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/PppNote</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative</Role>
      <ShortName>CONVERTIBLE PROMISSORY NOTES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/ConvertiblePromissoryNotes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - PROMISSORY NOTE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/PromissoryNoteDetailsNarrative</Role>
      <ShortName>PROMISSORY NOTE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/PromissoryNote</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - STOCKHOLDERS??? DEFICIT AND STOCK-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? DEFICIT AND STOCK-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/RelatedPartyTransactions</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/SubsequentEvents</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails</Role>
      <ShortName>CONSOLIDATED BALANCE SHEET DETAIL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2</Role>
      <ShortName>CONSOLIDATED BALANCE SHEET DETAIL (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - STOCK-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Stock-basedCompensationDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - STOCK-BASED COMPENSATION (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Stock-basedCompensationDetails2</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - STOCK-BASED COMPENSATION (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Stock-basedCompensationDetails3</Role>
      <ShortName>STOCK-BASED COMPENSATION (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="modular_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://modular-medical.com/role/StockholdersEquity</ParentRole>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="S-1" original="modular_s1.htm">modular_s1.htm</File>
    <File>ex10_33.htm</File>
    <File>ex23_1.htm</File>
    <File>ex5_1.htm</File>
    <File>ex_107.htm</File>
    <File>modd-20211231.xsd</File>
    <File>modd-20211231_cal.xml</File>
    <File>modd-20211231_def.xml</File>
    <File>modd-20211231_lab.xml</File>
    <File>modd-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>modular001.jpg</File>
    <File>modular002.jpg</File>
    <File>modular003.jpg</File>
    <File>modular004.jpg</File>
    <File>modular005.jpg</File>
    <File>modular006.jpg</File>
    <File>modular007.jpg</File>
    <File>modular008.jpg</File>
    <File>modular009.jpg</File>
    <File>modular010.jpg</File>
    <File>modular011.jpg</File>
    <File>modular012.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="733">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="16">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "modular_s1.htm": {
   "axisCustom": 0,
   "axisStandard": 11,
   "contextCount": 161,
   "dts": {
    "calculationLink": {
     "local": [
      "modd-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "modd-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "modular_s1.htm"
     ]
    },
    "labelLink": {
     "local": [
      "modd-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "modd-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "modd-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 344,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 115,
    "http://modular-medical.com/20211231": 13,
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 130
   },
   "keyCustom": 33,
   "keyStandard": 168,
   "memberCustom": 10,
   "memberStandard": 17,
   "nsprefix": "modd",
   "nsuri": "http://modular-medical.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://modular-medical.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - CONVERTIBLE PROMISSORY NOTES",
     "role": "http://modular-medical.com/role/ConvertiblePromissoryNotes",
     "shortName": "CONVERTIBLE PROMISSORY NOTES",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:PromissoryNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - PROMISSORY NOTE",
     "role": "http://modular-medical.com/role/PromissoryNote",
     "shortName": "PROMISSORY NOTE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:PromissoryNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - STOCKHOLDERS\u2019 DEFICIT AND STOCK-BASED COMPENSATION",
     "role": "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensation",
     "shortName": "STOCKHOLDERS\u2019 DEFICIT AND STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - INCOME TAXES",
     "role": "http://modular-medical.com/role/IncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://modular-medical.com/role/RelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://modular-medical.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://modular-medical.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:ConsolidatedBalanceSheetDetailTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL",
     "role": "http://modular-medical.com/role/ConsolidatedBalanceSheetDetail",
     "shortName": "CONSOLIDATED BALANCE SHEET DETAIL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:ConsolidatedBalanceSheetDetailTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - NOTES PAYABLE",
     "role": "http://modular-medical.com/role/NotesPayable",
     "shortName": "NOTES PAYABLE",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://modular-medical.com/role/Stock-basedCompensation",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://modular-medical.com/role/BalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "role": "http://modular-medical.com/role/StockholdersEquity",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:RoyaltyAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - ROYALTY AGREEMENT",
     "role": "http://modular-medical.com/role/RoyaltyAgreement",
     "shortName": "ROYALTY AGREEMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:RoyaltyAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:RetirementSavingsPlanDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - RETIREMENT SAVINGS PLAN",
     "role": "http://modular-medical.com/role/RetirementSavingsPlan",
     "shortName": "RETIREMENT SAVINGS PLAN",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:RetirementSavingsPlanDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:LiquidityPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:LiquidityPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - LEASES (Tables)",
     "role": "http://modular-medical.com/role/LeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - STOCKHOLDERS\u2019 DEFICIT AND STOCK-BASED COMPENSATION (Tables)",
     "role": "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationTables",
     "shortName": "STOCKHOLDERS\u2019 DEFICIT AND STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "modd:ConsolidatedBalanceSheetDetailTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Tables)",
     "role": "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables",
     "shortName": "CONSOLIDATED BALANCE SHEET DETAIL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "modd:ConsolidatedBalanceSheetDetailTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://modular-medical.com/role/Stock-basedCompensationTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "modd:ReverseStockSplitPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-11-232021-11-24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "role": "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "modd:ReverseStockSplitPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-11-232021-11-24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureLeaseDetailsAbstract",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - LEASES (Details)",
     "role": "http://modular-medical.com/role/LeasesDetails",
     "shortName": "LEASES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureLeaseDetailsAbstract",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://modular-medical.com/role/BalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012020-04-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - LEASES (Details Narrative)",
     "role": "http://modular-medical.com/role/LeasesDetailsNarrative",
     "shortName": "LEASES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-04-012020-04-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnsecuredDebtCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - PPP NOTE (Details Narrative)",
     "role": "http://modular-medical.com/role/PppNoteDetailsNarrative",
     "shortName": "PPP NOTE (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "modd:PPPNotesPayableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2020-04-24",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:UnsecuredDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - CONVERTIBLE PROMISSORY NOTES (Details Narrative)",
     "role": "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative",
     "shortName": "CONVERTIBLE PROMISSORY NOTES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "modd:PromissoryNoteTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-10-012021-12-31_us-gaap_RevolvingCreditFacilityMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - PROMISSORY NOTE (Details Narrative)",
     "role": "http://modular-medical.com/role/PromissoryNoteDetailsNarrative",
     "shortName": "PROMISSORY NOTE (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "modd:PromissoryNoteTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-10-012021-12-31_us-gaap_RevolvingCreditFacilityMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityIncreaseAccruedInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetailsAbstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-10-012020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Details)",
     "role": "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails",
     "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetails2Abstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Details 2)",
     "role": "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2",
     "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetails2Abstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-10-012021-12-31_us-gaap_StockOptionMember",
      "decimals": "INF",
      "lang": null,
      "name": "modd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetails2Abstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Details 3)",
     "role": "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3",
     "shortName": "STOCKHOLDERS' EQUITY (DEFICIT) & STOCK-BASED COMPENSATION (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetails3Abstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_StockOptionMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2020-08-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - STOCKHOLDERS\u2019 DEFICIT AND STOCK-BASED COMPENSATION (Details Narrative)",
     "role": "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative",
     "shortName": "STOCKHOLDERS\u2019 DEFICIT AND STOCK-BASED COMPENSATION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2020-08-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-10-012021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "role": "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-10-012021-12-31_custom_CEOAndInvestorMember_custom_NotesPayableOtherPayables1Member",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "modd:PromissoryNoteTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-10-012021-12-31_us-gaap_RevolvingCreditFacilityMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "role": "http://modular-medical.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2022-02-092022-02-10_us-gaap_SubsequentEventMember_us-gaap_IPOMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-10-012021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "role": "http://modular-medical.com/role/StatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-10-012021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureConsolidatedBalanceSheetDetailsAbstract",
       "modd:ConsolidatedBalanceSheetDetailTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details)",
     "role": "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails",
     "shortName": "CONSOLIDATED BALANCE SHEET DETAIL (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureConsolidatedBalanceSheetDetailsAbstract",
       "modd:ConsolidatedBalanceSheetDetailTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesAndOtherLiabilities",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - CONSOLIDATED BALANCE SHEET DETAIL (Details 2)",
     "role": "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2",
     "shortName": "CONSOLIDATED BALANCE SHEET DETAIL (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureConsolidatedBalanceSheetDetails2Abstract",
       "modd:ConsolidatedBalanceSheetDetailTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-03-31_custom_AccruedWagesAndBonusMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesAndOtherLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetailsAbstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2020-10-012020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - STOCK-BASED COMPENSATION (Details)",
     "role": "http://modular-medical.com/role/Stock-basedCompensationDetails",
     "shortName": "STOCK-BASED COMPENSATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetails2Abstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - STOCK-BASED COMPENSATION (Details 2)",
     "role": "http://modular-medical.com/role/Stock-basedCompensationDetails2",
     "shortName": "STOCK-BASED COMPENSATION (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetails2Abstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2019-04-012020-03-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetails2Abstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - STOCK-BASED COMPENSATION (Details 3)",
     "role": "http://modular-medical.com/role/Stock-basedCompensationDetails3",
     "shortName": "STOCK-BASED COMPENSATION (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "modd:DisclosureStockBasedCompensationDetails3Abstract",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2021-03-31_us-gaap_StockOptionMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-10-012021-10-31_us-gaap_CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "role": "http://modular-medical.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2019-03-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)",
     "role": "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "AsOf2019-03-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://modular-medical.com/role/StatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": "0",
      "lang": null,
      "name": "modd:GainOnPPPNoteForgiveness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies",
     "shortName": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - LEASES",
     "role": "http://modular-medical.com/role/Leases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:PPPNotesPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - PPP NOTE",
     "role": "http://modular-medical.com/role/PppNote",
     "shortName": "PPP NOTE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "modular_s1.htm",
      "contextRef": "From2021-04-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "modd:PPPNotesPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 27,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r380",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "modd_AccruedInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accured Interest [Member]"
       }
      }
     },
     "localname": "AccruedInterestMember",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_AccruedOtherExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Other Expenses [Member]"
       }
      }
     },
     "localname": "AccruedOtherExpensesMember",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_AccruedPlacementFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accured Placement Fees [Member]"
       }
      }
     },
     "localname": "AccruedPlacementFeesMember",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_AccruedWagesAndBonusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accured Wages and Bonus [Member]"
       }
      }
     },
     "localname": "AccruedWagesAndBonusMember",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_CEOAndInvestorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "C E O And Investor [Member]"
       }
      }
     },
     "localname": "CEOAndInvestorMember",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_CashPaidforLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:CashPaidforLeaseLiabilities-0]"
       }
      }
     },
     "localname": "CashPaidforLeaseLiabilities",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_CommonStockIssuable": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issuable",
        "negatedLabel": "Common stock issuable"
       }
      }
     },
     "localname": "CommonStockIssuable",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_CommonStockIssuableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Issuable"
       }
      }
     },
     "localname": "CommonStockIssuableMember",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_ConsolidatedBalanceSheetDetailTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEET DETAIL"
       }
      }
     },
     "localname": "ConsolidatedBalanceSheetDetailTextBlock",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureConsolidatedBalanceSheetDetailAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheet Detail"
       }
      }
     },
     "localname": "DisclosureConsolidatedBalanceSheetDetailAbstract",
     "nsuri": "http://modular-medical.com/20211231",
     "xbrltype": "stringItemType"
    },
    "modd_DisclosureConsolidatedBalanceSheetDetails2Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEET DETAIL (Details 2)"
       }
      }
     },
     "localname": "DisclosureConsolidatedBalanceSheetDetails2Abstract",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureConsolidatedBalanceSheetDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisclosureConsolidatedBalanceSheetDetailsAbstract",
        "verboseLabel": "CONSOLIDATED BALANCE SHEET DETAIL"
       }
      }
     },
     "localname": "DisclosureConsolidatedBalanceSheetDetailsAbstract",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureLeaseDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisclosureLeaseDetailsAbstract",
        "verboseLabel": "LEASES"
       }
      }
     },
     "localname": "DisclosureLeaseDetailsAbstract",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureLeasesDetailsAbstarct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisclosureLeasesDetailsAbstarct",
        "verboseLabel": "LEASES"
       }
      }
     },
     "localname": "DisclosureLeasesDetailsAbstarct",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosurePppNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ppp Note"
       }
      }
     },
     "localname": "DisclosurePppNoteAbstract",
     "nsuri": "http://modular-medical.com/20211231",
     "xbrltype": "stringItemType"
    },
    "modd_DisclosurePromissoryNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note"
       }
      }
     },
     "localname": "DisclosurePromissoryNoteAbstract",
     "nsuri": "http://modular-medical.com/20211231",
     "xbrltype": "stringItemType"
    },
    "modd_DisclosureRetirementSavingsPlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Savings Plan"
       }
      }
     },
     "localname": "DisclosureRetirementSavingsPlanAbstract",
     "nsuri": "http://modular-medical.com/20211231",
     "xbrltype": "stringItemType"
    },
    "modd_DisclosureRoyaltyAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Agreement"
       }
      }
     },
     "localname": "DisclosureRoyaltyAgreementAbstract",
     "nsuri": "http://modular-medical.com/20211231",
     "xbrltype": "stringItemType"
    },
    "modd_DisclosureStockBasedCompensationDetails2Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 2)",
        "verboseLabel": "STOCK-BASED COMPENSATION (Details 2)"
       }
      }
     },
     "localname": "DisclosureStockBasedCompensationDetails2Abstract",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationTables",
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureStockBasedCompensationDetails3Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION (Details 3)",
        "verboseLabel": "STOCK-BASED COMPENSATION (Details 3)"
       }
      }
     },
     "localname": "DisclosureStockBasedCompensationDetails3Abstract",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationTables",
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_DisclosureStockBasedCompensationDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY (DEFICIT) &amp; STOCK-BASED COMPENSATION",
        "verboseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureStockBasedCompensationDetailsAbstract",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationTables",
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_FairValueofOptionGranted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:FairValueofOptionGranted]"
       }
      }
     },
     "localname": "FairValueofOptionGranted",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_GainOnPPPNoteForgiveness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on PPP note forgiveness"
       }
      }
     },
     "localname": "GainOnPPPNoteForgiveness",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_IncreaseDecreaseInLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiability",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_LeaseIncentiveReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Incentive Received"
       }
      }
     },
     "localname": "LeaseIncentiveReceived",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_MemberOfBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Member Of Board [Member]"
       }
      }
     },
     "localname": "MemberOfBoardMember",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_NotesAndAccuredInterestCouldBeConvertedIntoCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:NotesAndAccuredInterestCouldBeConvertedIntoCommonStock-0]"
       }
      }
     },
     "localname": "NotesAndAccuredInterestCouldBeConvertedIntoCommonStock",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_NotesCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Cancelled"
       }
      }
     },
     "localname": "NotesCancelled",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_NotesPayableOtherPayables1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable Other Payables 1 [Member]"
       }
      }
     },
     "localname": "NotesPayableOtherPayables1Member",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_NotesPayableOtherPayables2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable Other Payables 2 [Member]"
       }
      }
     },
     "localname": "NotesPayableOtherPayables2Member",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_OperatingLeasesAnnualRentIncreasePercentange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Annual Rent Increase Percentage"
       }
      }
     },
     "localname": "OperatingLeasesAnnualRentIncreasePercentange",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "pureItemType"
    },
    "modd_OperatingLeasesImputedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/LeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Imputed interest"
       }
      }
     },
     "localname": "OperatingLeasesImputedInterest",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_PPPNotesPayableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PPP NOTE"
       }
      }
     },
     "localname": "PPPNotesPayableTextBlock",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/PppNote"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_ProceedsFromIssuanceOfPromissoryNote": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of promissory note"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPromissoryNote",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_PromissoryNotePayable": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory note payable"
       }
      }
     },
     "localname": "PromissoryNotePayable",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_PromissoryNoteTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROMISSORY NOTE"
       }
      }
     },
     "localname": "PromissoryNoteTextBlock",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNote"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_RetirementSavingsPlanDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RETIREMENT SAVINGS PLAN"
       }
      }
     },
     "localname": "RetirementSavingsPlanDisclosureTextBlock",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/RetirementSavingsPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_ReverseStockSplitPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Stock Split"
       }
      }
     },
     "localname": "ReverseStockSplitPolicyTextBlock",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_RisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_RoyaltyAgreementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ROYALTY AGREEMENT"
       }
      }
     },
     "localname": "RoyaltyAgreementDisclosureTextBlock",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/RoyaltyAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "modd_SecuredPromissoryNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Promissory Notes [Member]"
       }
      }
     },
     "localname": "SecuredPromissoryNotesMember",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAdditionalSharesAuthorizedAvailableForGrant",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesCancelledAvailableForGrant",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAvailableForGrant",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesGrantedAwards",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "modd_SharesIssuableForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issuable for services"
       }
      }
     },
     "localname": "SharesIssuableForServices",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "modd_SharesIssuedForReverseStockSplit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for reverse stock split"
       }
      }
     },
     "localname": "SharesIssuedForReverseStockSplit",
     "nsuri": "http://modular-medical.com/20211231",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paul DiPerna"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ellen O\u2019Connor (Lynn) Vos"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r157",
      "r175",
      "r194",
      "r195",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r340",
      "r341",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r157",
      "r175",
      "r194",
      "r195",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r340",
      "r341",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r157",
      "r175",
      "r191",
      "r194",
      "r195",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r340",
      "r341",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r157",
      "r175",
      "r191",
      "r194",
      "r195",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r340",
      "r341",
      "r366",
      "r367"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets",
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r30",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative",
      "http://modular-medical.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r51",
      "r52",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative",
      "http://modular-medical.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r22",
      "r217",
      "r285"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r214",
      "r215",
      "r216",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r60",
      "r67",
      "r166",
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r58",
      "r67",
      "r166",
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r75",
      "r116",
      "r124",
      "r128",
      "r133",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r240",
      "r242",
      "r254",
      "r283",
      "r285",
      "r311",
      "r326"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r44",
      "r75",
      "r133",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r240",
      "r242",
      "r254",
      "r283",
      "r285"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "TOTAL CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r75",
      "r133",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r240",
      "r242",
      "r254",
      "r283"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "TOTAL NON-CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r27",
      "r69"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents, at end of year",
        "periodStartLabel": "Cash and cash equivalents, at beginning of year"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets",
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r64",
      "r255"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r40",
      "r144",
      "r316",
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies (Note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r145",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r79",
      "r80",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative",
      "http://modular-medical.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r285"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, $0.001\u00a0par value, 50,000,000 shares authorized, 6,302,050 shares and 5,956,754 shares issued and outstanding as of March 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r106",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r19",
      "r313",
      "r328",
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r18",
      "r312",
      "r325",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative",
      "http://modular-medical.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative",
      "http://modular-medical.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r72",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r167",
      "r168",
      "r169",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "CONVERTIBLE PROMISSORY NOTES",
        "verboseLabel": "NOTES PAYABLE"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotes",
      "http://modular-medical.com/role/NotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepositsAssets": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.",
        "label": "Security deposit"
       }
      }
     },
     "localname": "DepositsAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r67",
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r47",
      "r245",
      "r246",
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r57",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r92",
      "r93",
      "r95",
      "r96",
      "r97",
      "r100",
      "r101",
      "r250",
      "r251",
      "r319",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares used in computing net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Per-Share Amounts"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r51",
      "r52",
      "r53",
      "r79",
      "r80",
      "r81",
      "r83",
      "r89",
      "r91",
      "r103",
      "r134",
      "r187",
      "r188",
      "r214",
      "r215",
      "r216",
      "r231",
      "r232",
      "r249",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r342",
      "r343",
      "r344",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative",
      "http://modular-medical.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r67",
      "r170",
      "r171"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Loss on debt extinguishment",
        "negatedLabel": "Loss on debt extinguishment",
        "negatedTerseLabel": "Gain (Loss) on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative",
      "http://modular-medical.com/role/StatementsOfCashFlows",
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r55",
      "r116",
      "r123",
      "r126",
      "r127",
      "r129",
      "r310",
      "r317",
      "r322",
      "r338"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Loss before income taxes",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r225",
      "r226",
      "r229",
      "r233",
      "r235",
      "r237",
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r77",
      "r90",
      "r91",
      "r115",
      "r224",
      "r234",
      "r236",
      "r339"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r50",
      "r222",
      "r223",
      "r226",
      "r227",
      "r228",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Other"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets and prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInSecurityDeposits": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in security deposits.",
        "label": "Security deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInSecurityDeposits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r54",
      "r114",
      "r263",
      "r265",
      "r321"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Other income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r315",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest Payable"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterimPeriodCostsNotAllocableDomain": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred."
       }
      }
     },
     "localname": "InterimPeriodCostsNotAllocableDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterimPeriodCostsNotAllocableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Interim Period, Costs Not Allocable [Line Items]"
       }
      }
     },
     "localname": "InterimPeriodCostsNotAllocableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterimPeriodCostsNotAllocableTable": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing the costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred.",
        "label": "Interim Period, Costs Not Allocable [Table]"
       }
      }
     },
     "localname": "InterimPeriodCostsNotAllocableTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Shares for services"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Monthly Rent"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "LEASES"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37",
      "r75",
      "r125",
      "r133",
      "r146",
      "r147",
      "r148",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r241",
      "r242",
      "r243",
      "r254",
      "r283",
      "r284"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r75",
      "r133",
      "r254",
      "r285",
      "r314",
      "r331"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r38",
      "r75",
      "r133",
      "r146",
      "r147",
      "r148",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r241",
      "r242",
      "r243",
      "r254",
      "r283",
      "r284",
      "r285"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LONG-TERM LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r19",
      "r313",
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationDate1": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the credit facility terminates, in YYYY-MM-DD format.",
        "label": "Maturity Date"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LineOfCreditFacilityIncreaseAccruedInterest": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase for accrued, but unpaid interest on the credit facility for the period.",
        "label": "Line of Credit Facility, Increase, Accrued Interest"
       }
      }
     },
     "localname": "LineOfCreditFacilityIncreaseAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of the credit facility.",
        "label": "Line of Credit Facility, Increase (Decrease), Net"
       }
      }
     },
     "localname": "LineOfCreditFacilityIncreaseDecreaseForPeriodNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative",
      "http://modular-medical.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate during the reporting period.",
        "label": "Line of Credit Facility, Interest Rate During Period"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r34",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfExpenseAxis": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cost or expense.",
        "label": "Nature of Expense [Axis]"
       }
      }
     },
     "localname": "NatureOfExpenseAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r64",
      "r65",
      "r68"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r48",
      "r49",
      "r53",
      "r56",
      "r68",
      "r75",
      "r82",
      "r84",
      "r85",
      "r86",
      "r87",
      "r90",
      "r91",
      "r94",
      "r116",
      "r123",
      "r126",
      "r127",
      "r129",
      "r133",
      "r146",
      "r147",
      "r148",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r251",
      "r254",
      "r318",
      "r336"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows",
      "http://modular-medical.com/role/StatementsOfOperations",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Adopted Accounting Pronouncement"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r19",
      "r313",
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Offsetting Assets [Line Items]"
       }
      }
     },
     "localname": "OffsettingAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OffsettingAssetsTable": {
     "auth_ref": [
      "r45",
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.",
        "label": "Offsetting Assets [Table]"
       }
      }
     },
     "localname": "OffsettingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r116",
      "r123",
      "r126",
      "r127",
      "r129"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r271"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Short-term lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r271"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Long-term lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right of use asset, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Amortization of lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r266",
      "r267"
     ],
     "calculation": {
      "http://modular-medical.com/role/LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Present value of lease liabilities",
        "totalLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r266",
      "r267"
     ],
     "calculation": {
      "http://modular-medical.com/role/LeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r266",
      "r267"
     ],
     "calculation": {
      "http://modular-medical.com/role/LeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r266",
      "r267"
     ],
     "calculation": {
      "http://modular-medical.com/role/LeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r3",
      "r78",
      "r112",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r43",
      "r285"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Bonus payable"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r20",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r20",
      "r285"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, $0.001\u00a0par value, 5,000,000 shares authorized, none issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r135",
      "r136"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from issuance of convertible notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from private placement, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from issuance of PPP note payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r30",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r29",
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r140",
      "r285",
      "r323",
      "r332"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment,\u00a0net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r28",
      "r140",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r13",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of Property Plant And Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r13",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r193",
      "r277",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r193",
      "r277",
      "r280",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r275",
      "r276",
      "r278",
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r221",
      "r296",
      "r368"
     ],
     "calculation": {
      "http://modular-medical.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r188",
      "r217",
      "r285",
      "r330",
      "r345",
      "r346"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r79",
      "r80",
      "r81",
      "r83",
      "r89",
      "r91",
      "r134",
      "r214",
      "r215",
      "r216",
      "r231",
      "r232",
      "r249",
      "r342",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/PromissoryNoteDetailsNarrative",
      "http://modular-medical.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r273",
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative",
      "http://modular-medical.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "Schedule of Fair Value Assumptions",
        "verboseLabel": "assumptions were used in the fair-value method calculations"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationTables",
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Future minimum payments under the facility operating lease, net of the lease incentive"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r30",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConsolidatedBalanceSheetDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r198",
      "r203",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of Stock Option activity",
        "verboseLabel": "stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationTables",
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.",
        "label": "Schedule of Outstanding and Exercisable Option, Range",
        "verboseLabel": "summarizes the range of outstanding and exercisable options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationTables",
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Reportable Segment"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "General and Administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation expense",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative",
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-free interest rates"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative",
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "negatedLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r200",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance",
        "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r208",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected Life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative",
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails3"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r190",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "STOCKHOLDERS\u2019 DEFICIT AND STOCK-BASED COMPENSATION",
        "verboseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensation",
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Shares, Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBankLoansAndNotesPayable": {
     "auth_ref": [
      "r32",
      "r335"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.",
        "label": "Convertible notes payable"
       }
      }
     },
     "localname": "ShortTermBankLoansAndNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative",
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/ConvertiblePromissoryNotesDetailsNarrative",
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r42",
      "r51",
      "r52",
      "r53",
      "r79",
      "r80",
      "r81",
      "r83",
      "r89",
      "r91",
      "r103",
      "r134",
      "r187",
      "r188",
      "r214",
      "r215",
      "r216",
      "r231",
      "r232",
      "r249",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r342",
      "r343",
      "r344",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative",
      "http://modular-medical.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r103",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/Stock-basedCompensationDetails",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of preferred stock and warrants for common stock issued.",
        "label": "Warrants issued with convertible notes",
        "verboseLabel": "Fair value of detachable warrants issued with convertible notes"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r187",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.",
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r20",
      "r21",
      "r187",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Shares issued for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r187",
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Placement of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r20",
      "r21",
      "r188",
      "r196",
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock-based compensation",
        "terseLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfCashFlows",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit",
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/Stock-basedCompensationDetails2",
      "http://modular-medical.com/role/Stock-basedCompensationDetails3",
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails2",
      "http://modular-medical.com/role/StockholdersEquityDeficitStock-basedCompensationDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r24",
      "r25",
      "r75",
      "r132",
      "r133",
      "r254",
      "r285"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "TOTAL STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 DEFICIT"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets",
      "http://modular-medical.com/role/StatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r73",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r188",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r262",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r262",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r262",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r262",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r286",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StockholdersDeficitAndStock-basedCompensationDetailsNarrative",
      "http://modular-medical.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnsecuredDebtCurrent": {
     "auth_ref": [
      "r18",
      "r312",
      "r327"
     ],
     "calculation": {
      "http://modular-medical.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer.",
        "label": "PPP note payable",
        "verboseLabel": "Unsecured Debt, Current"
       }
      }
     },
     "localname": "UnsecuredDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/BalanceSheets",
      "http://modular-medical.com/role/PppNoteDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r104",
      "r105",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r92",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://modular-medical.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e639-108305"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r369": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r371": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r372": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r373": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r374": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r375": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r376": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r377": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r378": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r379": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r381": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r382": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r383": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r384": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r385": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r386": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r387": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r388": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001019056-22-000444-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001019056-22-000444-xbrl.zip
M4$L#!!0    ( #.$QE1#"*4^/AT  /^%   +    97@Q,%\S,RYH=&WM76US
MV[:R_JX9_0?<W',ZR0S]GC1M[&;&L976,X[ML=UV^A$B(0G'%*$2I!W=7W_W
M!0!!B7;L1D[<TYS.22**!('%8O?99Q?0WB^7'X[?]GM[OPSV#^%O@?_;NSRZ
M/!Z\W=O@O^';#??UWKO3PS_$Q>4?QX.?GHU,4;T16YNS2ESJJ;+B1-V(<S.5
M1<(7$G&A2CUZ!@_B?WO_L[8FWFN59V_$>9VKM3,Y5F)M[>W>X=%OOM&I+,>Z
M6*O,#)K>GE6[PET9FJHRTS=B!Z_=Z*R:X+LW__VL]3CV:<WJ_U/P)=XX-&6F
M2F[N72[3*_$2NFM-KK/PI6^9O]_RWS][^UTQM+/=O0UH_ZW[,QK"1FL,;HAG
MR\+9*$PYE?G=,O+#?",VX3]\;%=4ZF.U)G,]AJNE'D\J&.K[TY/+KK'" _#M
MN[>#CQ,]U!5<6-_9V=MX!_W&1^"OL[>W=?!^/6,9;K:[E:JB4N72'+GN+';V
M?LH"H[@8_#8XWS\Y&/1[^S^?#P8?!M#0_LFA^'EP E\<B_/!\6#_8K#2 2Z)
M7A>9PB8VUU_IHCWN_]2VTJ/YIR;D<J(MO.1:E;)(%0QF7"HUA4:%+#+QLRK@
MBUR<JUQ)J\3S:J+$=WGV9VUVPYW?E?3YA<ADI3+Q7@W+6I9SL;V3B.W-[>U$
MP"MH%N!;751&#.?4^E!5-TH58I#G\.?SXWE1O.CW3K\K+;9W8 I02_&;L>*Y
M>R7\.[P,&_A@LCJ7I?B@,IW*/!%'1;J>" ERO):9%*DI9Z:4E39%J^L'9CJ3
MQ=RWM?Z4-'!QN>S]^O9\<'!TN7]\L;?QZ]NGKD_/Y0NV29__YUE=VEH65;\'
M*B-!3::SW,Q)-QLM5:.12BM]K<1^/88NBJTMTKJMUH1W/>IG/R$5FT@+^@AJ
MJ.A6T%2X$/2$%-+V>P<3K49B\%&E-;WS=#32J2I7IT"/,2/#%<P(B*C?PR6'
M0G5B$86Y$9FRNE0"9@AT?*H+, &"EBF+S(F3)%^JG):BG>@9N,=JTFJLGL$B
MQ0O8CJ7EG9HBT_2$F(#Q@,9'\&6_9U4E1J:L)E]*[I\2\<GI[]#L+X/SP?O3
M\T'2[^D".V\U^&ZV/F9$8YO650WF-#77J@#-MGA7)74!ZL8C3.BVF2PK#9V6
MJ*NHB".3Y^;&OGG\\6Y]>K1;JUK@\9]HYE2J*YE;-'/K_=XE",)?$F'*A1R"
M\(0$G4.)@2=1'V>ELC:?P] R^(:DQP('OQ.6^Q?0E:V_N$*W'TV@%KI!"LB+
M]](M4:>1C54DD<-2+-*Z+.$S"#,L4,76SBMQ+%,VG:2E%DV K8=30'8P,>+:
MY#6H-L" LM4+7-G>QBI:Y7 IL@/!<-QB:I/(XB\A#2$K\<.;S4TAUZ?KMYBA
M?H]&YLT.#"?#P62-_<KN_XK8Q\3"/81F&O_B[>8@ZD3CP>Q$YCGXGHY^@&A
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MB"WN]]#%!N3GVB<OP@ ""P<<DJ:J"6HPQ2(NHJ@]X^E4RM28;BBO<<A+;TW
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M_26CO@RF?*CJHE?_5 B:T*9T=GWD]7G$RM@D1)9LV1,N:>24W"VFV:\O6#^
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M'"_I.SJ@G.H;3O:"\<CV\TM[L2SW?:&KC6^;^KK+MW\&_@!02P,$%     @
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MQ$#91-K0B&.K;]1SFC"4B3C6:FH:X@APGQB;:"G>[79WWV[3C!+'3X' Z'"
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M7;[PLJQ5]]_"N//JQ@85^:-$U)C\79GBC9@VO3*4OT,T.C_K_Q]02P,$%
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M&O[W^_^?GFI7#G#MCUH/6J=];PX_:4-S"3YJ7X '?#. _B?MF^F&Y!-XY;C
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M@-+%N7@L4&VB9*/X!3.%R$5*@$:>\4!B(*&#%D2/1W/".QTW;M>;UPI@QW-
MQ+A0-%J'M[!8Z_X;;W"O',_T+,Q %R)6P([5JQ68<1E0U .AF(G"IK$5(+%H
M5S0LEW_+2"=%/.ZB-?[R\:D)YH=\I/\T??O*=/SH1K..4+A<15G@?P'G;A$
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MX)I#- H#%)B>C=>08<@!M>JII"4?%'5\:N+\T&)^66[_ L[= N_']'O@FW?
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M_9QDWMZ:I5E1>Q=1V4<H!'8OQ$[WW3JC/_+DT1#\C+YB+F B_66]H:4BOZ4
MDP)'G+1]2OPY^4&B _B3_P%02P,$%     @ ,X3&5'K"TA_+0   O<D# !4
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M)?2E&TA[EF$]BV)?\SB_9EH H)ZF/VK)_%"9NYHNT66E FSJ-D]K[LU=:2$
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ME$.S R6;.)^E>!5N5K*9%;V>U=DR4S-:4U\Z)>?,ZXM4Y\G8 #4L>WDRALG
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M$=K/TY4'^GVD,#4?J*OG]@L-DSA+HC"@A^!NO(@F&)T_8YR;-RG#$N!]Q;[
MY=_5L*1S.WG7GB(:O!!;Z+KM79*RHX5'7=G7O O:K,PI33S!VCPW25>_G=UY
MR-[O:G7R'-+MN?==)S-)=6-\\PT7J'X'&QLTWW+1?[*J^=.$_$5^KGXB_X^2
MF/SR_P%02P,$%     @ ,X3&5 8MO9IE-   ]XP# !4   !M;V1D+3(P,C$Q
M,C,Q7W!R92YX;6SM?6USXS:R[O=;=?^#[J1J*_O!F=C.VR2;>TJ6Y(EJ-9(B
M:29G[I<434$R3RA2 2F/M;_^ B0E\PU @R+5D*RMVLR,#8#HYVDT@$:C\:__
M>EZYK2=" \?W?GUS_<VW;UK$L_VYXRU_??-Q>M6>=OK]-ZT@M+RYY?H>^?6-
MY[_YK__[O_]7B_WO7__GZJIU[Q!W_G.KZ]M7?6_A_](:6BOR<^L]\0BU0I_^
MTOIDN1O^$__><0EM=?S5VB4A8;^(/_QSZ_MOKK^S6E=7@'8_$6_NTX^3_K[=
MQS!<!S^_??OERY=O//_)^N+3OX)O;'\%:W :6N$FV+?V[?.WR?_BZO]R'>^O
MG_E_'JR M!A>7O#S<^#\^H9_-_GLE]MO?+I\>_/MM]=O__O#8&H_DI5UY7@<
M-YN\V=7BK935NW[W[MW;Z+>[HH62SP_4W7WC]NVN._N6V6\=2?E43P+GYR#J
MWL"WK3"B7?F9EK $_]?5KM@5_]'5]<W5[?4WS\'\S0[\"$'JNV1"%BW^)V-O
M_]65/]^X%KU:D;EC6R[G[2TO\[;C,[UD'8YJ/U*R^/4-*SMG'[FYOKZ)/_%5
MIE"X73/]#!RN7F]:;P_[_)WE<L2FCX2$@:H;I86;Z\[8HL0+'TG(RVCUK;1F
MK1WEPXFLV$>"T6*TYB: Z9@20'FMQCHX#7W[KT??G3-#U/M[XX3;+EDXMA/J
M]%?92&/=[UC!X[WK?]&"MU"IUNYQXVYYV[8WGVY6*XMN&3[.TG,8()87MFW;
MWW@AFUW&OLL@(LJ>5VVO5J$&A%DW95>SI6KMP'B]'OHA4?4@5ZQF8CUF:D/G
MP25CZJ^<(/#IEG\-0*&J9KU89;ZAA*RT=,TC]L4^)):!JS/_Z16?-N=<QXD7
M1#9//9(K-%:K.'VV/ER1F?6L9KZD:*U=F1"7V;4YF]3"[8Q:3&H;--NHZM5M
M$5=.&!E?QA0;#-Q<L44VS/BIJM:KJ9N'@/R]8=_K/?&/*I514+YNPQ,PXS[G
MC*77,ET26HYR]0.K76N'(],VMK;6@ZLT/V5EZS<^%<W,D0Q*<?VD8P2S->HU
M+_[6<L-M>TE)M'A2FA5!^9IM7NC0J/FI]<3,03!F2JTV>))*J.N_IM:!1U@/
MSOB@!:X*LV7QEA>P/A_0Y!%-/TP6G3:.87DU&#@RUGH#+,8O&%J4;]:?E#-=
M7>TW,)"33\%&<JYP<]T!(RNOU<0^5+>'BFI'VJ?J:ZQN2PWN8[4A!]5N>!V7
MS!T"8P8<=@<V:X*(-PW)>&.2D+<-"7F+OVK2'7RU-'X43XFN9+KM-.J>T*8%
M6/^(:UB@#=1JY/C=5]HWO5:.L0S7F7P0YI@#IQ*,&>/ B0'1_N\FH^I&7MZ"
MK.-K2@)FBR*!!^P'F2KD.23>G,QW#?&>:QZ<AT[(ZR0A#=>M*Q[_L.&>(/;7
MN&32GUV/7-_.=,+E<0)^[B1^%W,110,$Q/YFZ3^]G1/G+8?H[^_X7Z_BOT98
ML7_^&7VL_1"$E,T9N]9<ZX&XT3?^9&5R1=X>J6<[1&:LU?*.94OD^Y7FL$WM
MED^93C#,=VU9U,XP5PRC2$J\74?'\U?VH^/N25^PE;P(H00-7]#1-%CL$\=#
MM,WZ,.?]N'>M93FDN2) 3*\Q0"V5!A/5+@ELZJS3'GD!N)F20(QO4#$ND0T!
MZMTXFI"EP_O,N[,/HI#;"$$5(/BWF%9#*BTB"VW/VUCNA*Q]J@ _6Q*(^7>8
MF)?)A@CU[QNVM2/4W4+0+A0& OX])N ""1$QCS;2#L<( GJQ-!#U'U 7) (9
M$6%G.U#738XE(,"7E0="_R,F]&(Y#0$_\L9TK5"Q^!94 5+PDRD4%*1%9&%,
MJ.//V51/ ?@7"@.1?X>)O$!"=,Q[WAR*^+XH>(^$#WA./$2X[YW MMRX5_?L
M9X$<\I+B4-A1]J9*,=&A_TPL"@8^51@*.\IV52$B NB=#:69#DDMC+@T%':4
MC:I*2 3<>U[HA%M^LVVX63V\.%ZS>!=+07%&V9R*A$+#=^>9\$)^:4^&<;XD
M%&>4/:E,.#2L.TPF:KE];TZ>_TVV,K +1:%HH^Q%I>*AP3VF#@^'FSJVVH 4
MRT(!1]F!R@5$0WQF/??G3+(H]I #I09>6 6*/\KV$R0N&@W\=A!=^REW<X?'
M@-)MQY]+3;RB(I02E'VIANAHQ+3G<P99D/PQ<#QR+:.CM#CXK F/!(F8!D%_
MHP?]#1QZE/VJ4DR#H+_5@_X6#CW*GE4I)C;T'?;7$9WY7P2GVL+"4-A1]JP*
M$;%!CV:?$1U3_\F),X2HD"_4@,*/N)65"XO-03+Y0[1^5Q**.>*VMEPX;*S'
M?A!:[O]SUJI59GEY*.Z(&UR9H!B.R9A_[N00A2OEBD Q1MG3EHJ# 2MGFA)+
MK,;9$E!043:J9<(@8#KP^1G*H^])?;G%4E!L47:<(J$P##&/9PZ$9B#U:W"T
M'(J9S8N! .4?U E9+WB&D(V7^'4$)VR"HE"(4;:)4O$0X)Y&MY+Y_>0/; 5)
MG9?D:5FLR\I!@4;9%(H%0T!Y3 EGG+"E>10SQB\_T-%B(;+$LO)0U%'VA&I!
M\='O!\&&4%T.2FI!F4#9'D*%QK YQ-XP,[B]OGF8\5L\ HM3* 7%&V5K*!(*
M =^A/Z,6SW0[W:X>?%=\5:6T(!1EE(V@1#0$H#-]*8<X5P0*+LH.L%0<1/O0
M>[8?+6])Q)$1Y26A(*/L"&7"H=KB)<@6+S5M,<K.4"04(KYQ?#H;7:,'UUEF
M<LZ50UU: 7SO!Q-UB:@8=PNC:T@\+SI=17VY9W\IAUY0% HZSA5.F7@8<&_F
M3DCF<;?N'<_R;+;U>DG3+$!>60M* LX=3Z#0:$<$?Q#7_;?G?_&FQ I\C\SC
M[8#LE$!8!<H$XIFD0EPT&C[Y[H8A1:, 5"H8"X*B4-@1SR(%XN'%>\9!U?OY
M*'X00X:ZJ 84?,1#2;FPB+%P(>']=IY(UPJMI)<R#D0UH!P@'E#*A46-X:<=
M-ADM??E9?*X@%''$$-Q2T=" GJXLU[W;!(Y' JF=R16$ HT8:ULJ&AK0O16A
M2V;DWE/_2_B8W#^5 2ZH  4>,:)6*BH> <\O]][CNWE2]$M*@S,J($(O%!(S
M9<@^H? T>KN,"I"7E8=BCWKQ4RPH OJC\)'0]-HJZE"?[>]D 17J6E F4+:U
M4*'QYMM4]@'I=)LI!\4<<0-;)AC>/:[-@^O8]ZYO2=?MF6)0C!%WJR5BH4%\
M9WE_T<TZM+=CZMN$\&.88#_R )LF8 -06A#WL5I0X+D6_-6*7W#R[;^FCTSP
M8+0)H[=$61^E#@9I/2@]F)=, 8(CKHZ"EPMH9'ZWG9 %H3P$8D:>PSOVL;_D
MBR5 =2A'J)F1P#"44/6OMP6Y!NP'32=W+7]I-)/D]:9UU=H[U:,LK^PS7D#F
MK70:YE;24BMNJO7U1\^*_?/_/#PC[,(*'B+>-L'5TK+6D4J^)6X8['X2:>;5
MM]?)6[%?)3_^<]_QT6)_0C#VX\V%)'EL4AU6^_#15EV^=A PM-62Y,MAY9S5
M C8[T 22-&#\#J4CF2ZAK!2*HR6OE4-<QH- 5$/HX&_3\I<.V1\\I?:3Y7(K
MW0X[%J5;-G5&;W2+Z0%61\N#"V+"KR*242R.*5E;SKSWS%.Y$_&R/"DO*(Z6
M,+<"2U*)#6$E<E-DA!)34E86+9EN!3[$LAI"!I"':A34ORVM0($*?=9WMMJF
M9#Z(I1;V,.I>Z(>6&Y7$-FW^FM!PR]_/Y&_Z<)N\YNNB(9%:.%DMM/2]E0R=
M6GY#AMB(==3BSI#H?;R)LWQDB]>/ 8G$E9@^>36TA+]5K" $ 4/8ZI(UWTX$
ML7QB>O+ET++_5N"C7$9#"(@[-?0]&S8II4NB)0*N/"\5Y3SYJ4DU<C1'3 -9
MA"NS=38<#1SKP7&=T"'![D' S M2:@\$O 6\M,6'^XQT<3+$AJ:Z#78IR>K@
MI4"NRH.01K/]3DD013"VMOR%;28K^PG=,.M2D$!B8'4:P4NS#.?&KRZ>:>SF
M^LDZ'[D(4C^2\@JICI?0^0!&X;@8PF5V3[/KYU;MT5+4PTL3794]&!*&T/;1
M"_BU-S+ODH=0259Y:;S<TE4IDDE]*#'%!TGY3_[,OON>V.H2I'EA05F\E-+:
M.$ND,$K]IX\^#6>$KGC8SL"W/&YI>7<#,4.[5;2Z*EX.ZJH# XR'(?SI+ ,/
M6>TUYB'19@BTJ#OY3?B+&TAKHU96#2_A=>U[-3$JA@Q'P=('XKP$5,7+GZU%
M!6@U*/5SHI]&EPJJ.)46U,'+O'T(:4H0#&$+M$^NLAMN("5W[>;P;"8^'I3L
MA%'@*P\I\J-;0\2SI:Q**^%E_JZ'90 BAHS *F<%-9P.-) _O![F3N9,8+PS
M%5&/%0&,I87Q4H[#L2Z$PXED-H25U/T,54QIH21>>O*J?(BD-82,]GP>'0I:
M[MARYGVO8ZV=L#3#[LYQ+:J E^2\*C4*V1OR$J84@N?\D?@(2TOBY3O7AEDH
M@U$C8$)"R_'(O&=1CU_D:]OV9K5Q^3V=+EGP!,WBP0"IBY=.O>JX@"-B"(5%
M"7469ICIV*M2));XY'=*JL5I]?@<S'3PM>^,I=C@*4$3D]Z?\(?U&D@I?R!S
M$IFJ<O4NYLHC2VZ2#1BRA]E?'7I-=6:42V74)-F<7=4AL#&?1H,1CU(J3;B+
M/HX >B0A+[/O:^9B^NVA%]-;7V>^<KFH?C2_%<-]1*-.SR,/PIC0**\%U)4E
MKG^Z%]OU$#+$ F<['><F:6_"1Y\Z_WD9_RHZB_6PK\#7QJ,($H/YB](V:W*W
MJX-]%[YFWK)0&,R9/!&21,(JF9 :VY#4S%[329)J.2_0GPI!E;&OUQ] I08X
MYM$)GP*EE;"OYM=#G^&37Z&GJIE/6 '[SGV==!DYYVEF_A/)5F6V:_#<M3[2
M8%,=TL;^Y4F6T2()+$P_OYK9U'\'V]2_--GR%ZV71DW).\<S :[(OI?J';RP
M@A&!L4DF(D"B.4D5Y*VY@A)1 *Q(=$,,XX1AR#K!DWIUR1-Q_2A]2M)IV2FO
MM!KV]EN-?OYX%X""(8R])QX3SN477N<KQW.X8/SM$B5GRHK8FV]=UH!(&,);
M03H-(XB_M=;E1BCMR1_&[R6+)X2!7_IH3!Z&=&'LO75E+HL2GSR;T>-/) AC
MT1) I-G3Q#6P-]UZ*Q25Y(:8S5TWE=-;H2#VIKH:'>+)ZU1#(=Y;CA=PH\&V
MF5[OF1N2C1,\QCM7?A5=LF115\7>A>NQ#,;"F-&WL_CW3/#X1LJ&/Q*\WS'?
MD85/25QN9CV3@$E%+8:ZXUETRY^=B>Z1L9H,4S>:1&)%5^UE&_HH=H8^7:O0
M./YG,(4GLB>F\XYM"Q:R$&5A!>S$@55T0RBW(1:$K2@@"^5<,?2L@'I4E IY
M\@-K%^R^.S53>^_$-=#3_^D1JA+=D,&5[^:=%3@VG)ZD.'I>/R7:<G(R4IO,
M#'<O.NZ&+<NCJ_9=)[!=/]A0B&.\<H/HJ?T.&WF:P!E"_Q^$I[<F\_836Z<M
M2?SRXFA1.&Q3#%C-9M!S_AU*GG^(] ?.NNPC#WY #)AWLYZ9"#2H.RHIC)X^
ML%Y%D !BR'@_MWVRQOV%YA(<&K-5-O&V0SHHHG@_(W\I-1,C\7V5&(GT-_YA
MK?W@EU;\J=;7R<?^:4KP1"HPIEJ>$E!UW-ME21=GBFR-N7*J(5U0\D;&M18_
MA5ME68G2C@ C&&'#FT2F!,!*JJQAS&3T2D1!JOOI=()&T! K$W^,V_>X"6L_
M.Q!&RJN=(CGEDJ0";U!WQ]G.=?V5Y7B2O6]Y<<-HD:E<?I-;+E#J@-B08-D/
MA.^YQ,R4%,6._:K"AU!B0[87@K0\*G84U;#CO:HP!4+B>&F*A P(<AQH0M_\
M32D(] I9C!HI^40]JB$B*H\=HU5E;,AE-X2@(R4F:GYZ*2STF\]'M";4\>>L
M!S0TP$VI<9&F^NV9YB<?)8^ "S(G3>/.II-Y=T.9?..H>]%]R?C']SZ=$OKD
MV+*89<UFC)D 0<-8%QZ3;&VQ[^E[>H=P*VS'F,FS(KD*@$QBM^W-_[ HM=C*
M0*"DV9OMJ?(*O@]J&3L46D\#:@#1))T0R+ [B"-\,<\CQB(VJEET45O8,=>U
MF'4Y4&8S'9NNFJB6-X8=>5V/E3\)LAL-HFPP^S20(%7XI('C+#(40_(E^DW%
M97&J.G;D<2UVLP"'V13&X[\ZAX7ZZ$'+]5C$VFD4N%-?5MG<FRC?B/ *DO+H
MT<5JY!42' GI:#\S(4^$!B1._[%V2Z]*9+LKJH8>.:R+NUS^4[!7A<Y7-5QE
M#:''"M=CP<08F<*P[OK\L"5X<P&_>EY4R#+[5(-VCY;PN[F@W0..-@[)W9[Q
MBO<\$ZXL'W*T843H;/73C0:9-"!2MF,%C_>N_T60/>R'*I&QO,U6U*B! ;![
M@;7B7DMJG:W[XPCI^80DG) ?I#W_GTT0OTTY\R?$]CW;<4FFQS.?"SJF_I/#
M!NG=]B,;.'UOGSVF;8?.4_RD@%(7F_F:,;$#<)5H$O:&=IL\Q\7(&X_'0S_D
MF]RE\T0\4CIP>7EQ<>P0@4:Q]R$(&&4!C,CCTMC.\QADP]&HN@(S+OG/B1Q(
M-K9!/J):U7*D>:K;[RYA/;>=F%=OWE[Y-'3^HU H:27L$(8C:@X /$/FH,AW
M[MDDN3F6"L1(>=-'M.-:CNP&EF8SV%$-1U2%2@"?S0%18[$*QUI*-G["5'<2
MU0%AD]*$YWD8+9C$;;8H"M/V1YGV4;\E[+"((X[FJC W-*"9@)1WI$OB/_M>
MU*_=8X-E'G->3UT-.WSB6,,;"J AHSRM8?'.AN?\\#=>.*9DY6Q6$@>0NBIZ
MN,41!S(824.8+RIJE+7E17!N@/C3HJF'1AEPH'<N#FL8/53DF(NY>E@P5J>8
M[J\M9]Y-MJS)),;DB<2,I=-1)5A[Z$$OJ!JD@[FQBM.V(]L9C*TM7R?S/:]M
MTPU)#P0=Q8&UAQY=@ZHX.I@;HC@,&2 :TD-)<!OFA/-HG5EJ8F0VN7WOB02Z
MQY55VC(GW.=@L@&8&4(Z,SZ)^6O;?V\<2I@H3%/#[=BUO)#9)![.%#W^)"9;
MIPWT0* #&/,K2WTVIU=P].JP#7!U:<Q/69NZZ"-W\NG2!2(G;W/6,J%(VX(J
M3_/WO0Z>4 "8F3*A4-\F9![E''TY.QE3YXEAP4RC3123"; ^E-S&7)P',)5_
M:5T',0-I[OC,B-'089L8>=2+M!(XN.FD"!5@T]!Y@DB5_)43!#[=\G@JP9D"
MK"J4I,:<A8>3!!?6V ''N[=S&\!&6[8&E,7&'':-#+4R5 PA#RYO'2L@.,&-
M.=9J(U@?N9-?-G-Y^?_Y_O')<OD><\+V"-2QV1Z0_X+M+;,_2)6,0]R*SD;;
MW<RC!T[M1\M;D@E;6O06"R);<A^['U"E-<G9A\/56:@X0R:'1YL-=4JW3/0H
M1%.NF8#J4(4RR:&HA<R9)-P[AC9H7$*\:?X28LWZ<&:735]2&N]0ZKGQ[4*&
MQ'2S7L?_>OEUWUOX=!7S"+A)54?K4%UJ/MF3SM6I^G U96'M>S;K[(L7U9OO
MEX;1+5^ 9Q'>!)3T!B,E:V30KPJ#41IP!DD?;YKS46J3VG@RR%.]3W/D#"6W
M#09I-F9#3B)UH" &,!>-HQUP6:@/);K!N,K&B-;#T&SB<\&?AT;:PHEO,!SR
MV,0+,#R#@(>BP%-BL_F/ORBX]@-IMC%(7:BR-!@">41E$6%GCH78O83)'],9
M$N5;H]FR4#)-\F"*93;G:4^^FK"\;:20JY5%MZ/%U%EZSH(5\\)DUN%+4M]U
M[/110":7T8^MJ];+$[OL'[/?>JW.Z,.X/?S<:@^[K>G'#Q_:D\^MT7UKVG\_
M[-_W.^WAK-7N=$8?A[/^\'UK/!KT._W>%#.7T8@N+2^Y^?*2A"F^J#Q.83]:
M)$M]RWU)SZ3>#M?4/.I=RD-$>-$0KFXR+9LQ9;YC<OS5$)B5>H*<XZE6Y<S?
MW42BU1P[&-UM%%BWG_+6;=!K3W$M5=Q=M<G)E\.T'7%?1HL!82M9\@(H8+ #
MJB*/SG)"<L,,C( YXV*\7F<B=C(#XUU^8(S'X]9P-.M5&AJ"P*N7#R1]D6@]
MKR I7VL\6)Q":[<AEREQ%!8E+(ZEN JLL@HL%\$TI4U%!F8#S\H-_/6W>3WN
MC(:?>I-9_V[0:XTGHP_]Z73$5J]<M5'-_NXR=C+=*LV_J#QN]J1TGP#&7U@!
MV>3+R2BD/9)*;<[8$41J9L;+=<'N9\=(0^8_TS/X+""H5G-P<.H;RKE 5-J0
MJ4"*<R[65R:V.4J=3B+>)6Q[XO!;9-%/KQZ$ARH9G;_)Z_QT-NK\^[?1H-N;
M3/_QU4\WUS_^TNKV[ON=_BQV>?#?7]VQG4(W<H7TAM/VK#\:8LX?<0)U];R1
M+X=^.IA) ,^IVQ^'[>\*JB<2_9:09YARNLI.!BO@8\[H3/E)R\?>;7[L]8=L
M1/5:L_9_XZ[']CW7691)*QGAH]=:GLEK(8\@ $$BI_U)K-8FQ.6G>6.+AML9
MM=@,9O/6!>/HN_PXFO0&[1F;G\;MR>QS:S9ILSFJPR<IU%$E$DH]M-0U,<>7
MJ'=:PTVK$>31!R4R-P0KX&3.B&0KR943[DYY.W[D ">>\.SL^ONB\^'#A_[L
M0V\XFT8+R<XH.B'K#;&/QR2BZ<Q_FLV@AL]#N@H8M+KM((_;2D3GH^LK06?.
M.)YN'@+R]X:UVGLBZ7C+S.#]H; K_'@W[?W^D0W>5N\3'\*H;_/D9 "\RR.L
M@;H%S/4*LM<35\%^JT=!2GY[IY+=G"&3?K?JSG+YS>_I(R%AEX26XY8/H$+D
M")OMIJ-!OQNM2^_:@_:PTVM-?^OU9JUN;];N#YIQ+LK[#G8V0INIT_DH_Z;*
M&0FN;89S4H^GM+-2$R9SAE7IY?O,("H$*$0'56Q7][E]-ZCFC;\<6%T.K( '
M5G5<.\$\%X"> !2B'2X>_HN'_T0\_*<^1DL?.\X,SYM"$$?9 1W;FO5GGR\#
M5'. %BC@:Q*M.5&CB9,8DKJ(F+.<G/A;RV4"+BG)9K_+C*9"B,=D]+D]F'UN
MM=]/>CWNG&QF'Y;O'7CG):Y8YUXK_Q78&.!5037-V&.I.$COJC0 ,6@(D-"A
M47>GUI/C+0.>5[A\'!3"/B:]67\2#8#6M/VI/WS/]EF#=K4UGWHTE'44/B3D
MM6L=%V6?TA@<X.J&C! (+YEAHHF/.6-%]X*8]*+832&2H_I%L=;7NT_]\W)G
MK)$[8X*Q/G#8@F?.ECP1_EO5V!87/\<+57*)A8,;0W/9YM$)1HO<$ :PFC0
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ME442UT/CF>CT2<2PGV,HL#"('5V;JEPUEP\ML5-V0OC"G3_!GJSF-Y;;5$Z
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M B<;QVG.TQQLW-P\/-S<YP4$!,X+_P,0$Q,3.QO[.4[.<S!>+EZ8\/\7Q^T
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M O_=!;QCXV"3 H"8F'>#[OX!'POS/VP &38.$S\YKKPNA16S5Q-(R-N :DQ
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M_/2# 5S<CL?(9<_\WC]U(CY_L5]Q=*,JNX'X(I7*6I^TB?O;$=-I!NW&EUO
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M]"Z%&P-C^*7HK'\F"KU:(GL[^S]02P,$%     @ ,X3&5"8=XJ:Z9   0&\
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M,[F)4?++R]V8HEY ,BNO1[G.VL:=5*4D"2-M8#7/0N!0I2=J4I(+G59[B.(
MB%4Y)J]W?&=/5KKA,EI/1 LCHMZ<YQ0FNR%,Q[M,JD^2J@=:M"^V($T(2UGX
M1J#ATZA<"BT/^*!E1\L>BUX[/MUX_V6.8WEW<2$;-KUND=JXU"T;RUY3U)!$
M9S14-(41C( V5^F6#&GIWMOVKH2V;V[87+W].KPI2!OP9JL(MT?@G8CL9XY
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M@IV7_6HU7]!<6OHK%B;L^1L)7QLF__0L'LJJ1A6,7U!VQ4OF(&=2AO]*+=>
M22ON'KU[.A/ %5OK78*0I&GXS0MZ=^7)-4WEZFQ6?6*2$.7G3C%!$6=^B9OD
M_A'P<L"P^FGD#,U5=WT%BWOBI4K#AF?(%1EJ9)_YJV/+PM[N6@$9U'YSY2<
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MDAY+2EP+0*G%U35,5BG!;G_Z[N@T8$FL%=[1D/X("&DNLC1WH.G[T+M#/<-
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MAXT=X!IS\JUB@3%R@T>B;:-CZQK*8:ZSR%DO%7-&U)E.!U$E2Y]VC^+QN,0
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MNSQ7R(!*Q_/$LS%1F.2,X&W_[5N:2KJ#S/O-^SK<&;S+X0>7=U ,N_"[[4>
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MY"$.TSBO+)6('>_M4M)G?6%=7>X]*[T:!Q&7-+N^*T6;U=L+_3)UR^7NNJF
MI"G+D:_B%B='V![+BFM1'W&)J>LE&YF<OTN\'@OL\UQ]"K>0-Q!,\TNQ=(GS
MJ5>+.0U#IK)DABQ:[.=**"L %#_$+TBTP,_G(OR]O$?T%XD,5]KM_3B!7ZJ)
M8Z@K<TL)\P G?YA;-3WQVD\HS)4K1MV),^<S9<"<5-GC@&_E_9R&MQ.7JKIC
ML]1:[[V;:@RL8"(F/_!X%7_G>40HP*HT*;0B&GGA(@UNH%$W Z^N+C/SLW(-
ME S5IM'U5BA-:XP%=+[/L_4;;G2K++ZP'/^61][$)^ZCEM[T8\@U(7N@LU=
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M_R\0^=HF_M\,#0!,_^=L9/Y,_0]02P,$%     @ ,X3&5/K_^@2V'0  EQ\
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MT9_YPYW4,WILHDSX\YSC\]?O;3Y3A0=J7#51SN@E]?%W12BR=RRN6\&&9,1
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MTV9/?YMA+=#A>*]M4F[!HYNY_P%02P,$%     @ ,X3&5.#1M&%5(@  <B,
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M^,PS<Z7TS[WTV-4C0J'(D,\T$Z6FG4HO?\_A22W&+"8<1[CS&3ZZC[:\<V$
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MO&9\3']F$[]+Z;>:&@VP?P;P:Z.1VDMI.D,$FZJ\87&&3R;(VKD\/\,'6+^
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MG$/@D'Z,;OUBO %=$S]V6MKLTC/$7'STC-?W2113F]3V#PSEE666)5&M^H$
M+6M*VU[#U!@R-2M_'*2)Z^( 0Q=K0\6M*OGR2$?5L9'/,W#G#=$?6)ME;SV^
MUV]7'"<*A<E![%CHO\L?7PM_'?+45B:=4/3[)C4>J:3U.XN>-%G<7P**T)M
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M@3\Z^D88I1-M?[LFK:PBE9T$"*LS8Q1)Q*-N;^97UP2LYI?2_\=JC%Y9CJ2
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M8C;JL::6YB=-IJ:"4*&^]).OLSL: L)<-CTR2=2_&:OV1;RV3T]L[/@TPG;
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M+5]Y9?( -"!]:SU:=GU>,.2V%J^09R%I$4@\,EWH6\RDU:S1?()416"287R
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ML_6^$5K&I KHTJ5T"I/$AUC-]*TITO+]$YJ\0T4-<5Q@Q<9Q5[KGL:=E7CF
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MMR5^CN%-#=^T%^7CCP^==JV-^B;S]:V:)M.NG0+-2.^1K!#_\\"V0 /.47&
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M-OG\C*S7&(91:] _UXO++O)F%/;N@BGR<RL@=G[Y#(3J;VB,^XF9**]MO;7
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M622A9/;!T:X2,>9R[N2/@G8\;IV;NAGZ%BQ=+7UFL_X,/=O\\0_>1**STPU
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M^JN>LM"@Q/+@!NHFFV7H!;>O9/A4DD 4E2EXQ2>6]D:C+N1Y:O1_!.,B0,;
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M1HR%@V'M6Y@^UW>FU 6Z^K91TUN]#O8CP?.@$+*<U4MGF$WE@DP<@G?H+L1
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M[ZV#X@Z^?<$A$$B"AP2"$S0$!M=!$@+!+88-$ER&P=TEP3W!W2&X#@P:W&V
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MSAF6PXV"/\7)Z4:;(,7:[LV4>-F5V;ONZ=4WM3L;2^W1]']>:8TW[*S< 5#
M[)G'+FPY=X B-K_L1-OQ!-34+:&\0:O\.#HE]"$W=WZ$Y@NV0B/96]/WU4;Q
M?ZV-NT8LHJK"9D^X58O:KN>&K\GATN_I0WUBS7]DL<8XT-UX,N4F!FBUOEJO
M2R,L(3/EQM.,".Z,Z5V;CO3*1.PY'5STT:Q>+P-()8<?VJ\0OO_SZE,ZZ"J=
MBZ&<;&^/@KZLP.B7<SAAKX]=4Y**<Z.J!.5%-;B/FA#/EBYMB= I#6(D7]BH
M>EW[T=U)USRFND7GG&7J/]Z3^!=B3J_S!>_?H"%*S*0)FT6!8T!09FEU!$*1
M-#$W0W%M5?E89BQVI/LIVK;*49#VT#MA_&W+^G<<PN<"*J,%0J[])&:X<K2Z
MQ+?.4)BM8#X%+]R@>I2)US3[R=NOQX]9>$J_!:R>*1TSP;O]"$OL6;$>&ZZM
M6G7R<Y;&D.CU8-/H0[>X_B#Y'T<RX]6G]M3 AA9,O5LS_][ T"\CNNC/+N^&
M+L0^BE$V?O:(84F(HC?P5CNW=X:D)C:^?^L8&HZ0'K-F-JO%(4_\7E;2>:U)
M1>.C[, <[WD:Y3+WBS'BNY+7;JX#F%L.3"BVEO .J)C?F?&I;8E'F4\X]!0W
MUD>5;XTU2=8++4#K2))=+J(6\WK-HV%L4.'X26?]U:_+@N:4-49N;HA)Q!A'
M]?@AL*6I(07"RM?8V .+?<KBM#6N0FNYW.\<X=M<PS;5" Z3_8)S JM<(2SI
M^KQ^57"\H6D/S1:L<A*_Y']L$MF[O_A;!#LAU4;Y]O,1$E)%_UJJ&&'X0.HI
M#@X!KZ,E]*@IO36ZDR<&)263U^"]X*+PK!B2]?I24^&HY;>YDP=:+.<SMD;"
MDEDY9;-1@*#Z[_Q."7RZ7MB9T_A*Z/A]6K\EORGK+_T$4Y((O_1LA#-APV,A
M2GBVW*E,<\1RDJY^5%*26ZTTE\?]WM&Q(LJ:RA#QM$6F9'&4!6ZH#<FGY/1G
M5U5,02JB<L.#.1%SY[G>VPYSD0P7PCWUD";( PPY??426MI$#U/I>&%?[UJQ
M>1O?#@'5#,V&--77]'Z9./K!060YDF[4(DXT(J+1E$X/L7>[H6P7VTB02)$;
M=7:-P_5HSG^WIF<5UB/VSG,_-LE"@.YC78_>*K#GO;SNDX#FBAUM)8BP0*RK
M)'U)DFIL%J78I2$/_Y<E>7O9BGPXS/=M8KK=><.^H[59X&KN8F8)WT;K:COT
ME/_8>+0-8;_'O96D^^Q2;[<E28;5>$28M" 14EJ(UVUJ+P8S?#JON+=92YPX
M>QAB(BRBDS8I(>878G(9ZVG-$O202?CO"GA^,^X]'#1JRA\=@WIVN )O<E/^
MXVP/880W5&XGUXOMN/VX#I0AOP.T]]-;2\YSZS21)FSM7=D6F>8GQIG3_@U:
MMKD!0TBJ++H);=ZM[_&KM9ZTJK+Y=L+' A8:0NK9'S)QXMMW$#.@5''RID>/
M@^N:?B\&$T;T+-<]VVW<.$[6=>K3H  YZ/83)8A42G.\7WD?)C9U=67-+S)[
M6=SO],LROR@-2-P46/M*)8VD6$Y.89?@"P,= M=00Y+-I4:)^!NU'4_Y?J7.
MEHBL+B_/WA9?NP"8XT_D1[N-U5YYII$"DM.0(?H(=[4QD(H%83"4OJ"VCRAF
MRI#('J\!E29&8B/?@,R<C=NT.Q[M;1X/4BDQB4?RU12@%/"J?."QTS5=&_C-
MB[D$>NB17W8.ET2%[>('P1)X=?+]PT_LHH^3^&MF-H11RQQ3^-]IFIGB/XOB
M>8;9,<RI"NB-08NCVA( 1WU*J]Z$::M%6L<$$\'E 8$?R>@G,2K5M)6V<DFJ
M"6/+E+_KL2&&62%]6Z$$(M\1\K[,P9FQIW")BTY@=2U<U^Z@7'^I58@"["(D
M1#-];N!<X+""F3A]P..>J74*)?2=@49^-[5H2Y@(-X.PNCCH#4M610%L5B[I
MR:PQ&[1SL<*TWWJ7]<$FPU6VE7M[;?,P,K@XH^^3#PI%;M\8O]9=]ALSQ 5'
MW@'\5GR3WIQ($O\,ZE1?PZH1RGXM<'^O.J5TU"HR,,'@%5I(),*XE9BA/;F^
MV:/,2XQM4J*U" O0'W;GJT?VK=D_(R0@PY&,ZR9B\)U;H#4F>70B*[5:#33-
M9U4A?6T@Y/C4A1=.C!C9=GTL8/ZJ=5P-$@=-Z5U:$-JNF.8/?2/LWJ*YB?Y)
M4BF]>DHY3.CK"I$J#UUD]CEPU0&5QTQY%[M\]9::J_ZF\9A8_/<TM&4S1%]H
MORE&*==6WMNX]&(%+K_#2_P$]ZMGSF*79Z#]MT&!P<8$_^8T+;T1A%;*:I0B
M=H"8D% VY<&AMZ;*SY)_8!>DK@;VWI9Q"<^#!Y]UN"IR!RE8N43CIAHS7?\(
M8K/'),D6D[::I*'#1J('.^<[^:1%I&V$6H5 -2[9=X!7N?@S_>DBJA%K8!_;
MDVX;^Y$J[W3&8%I"B]1.L=EBK3B)JR.9Z;'#%EOU=RD(FRMS;Q9_[0]@"KF3
M9_G."P=J IH4\Q^?\:,O)"MZ&Q(+2\PWD?HA@R^F9M$/]+%:4NI A^RNU^L:
MRE'X2Z?XW'T.:[2Q6=2R9O$(L881B*Y0O$@!X_"O;]W)CTIIW/QLT!H/TFQ=
M&B?2WWE<Z5]0*M#.;9L*B+E)Y;Q/7+,*UD*.ABREL,/ZDE]C#. ZUR."LX.=
M*H@H1Z9'30PHIJ4!SRBTQ=PR&A49I;:9V'O*@Y=FB%&0)'NC@[)&<+2)J*E+
M4^;L[/LN\GBM78C,@9:XJ!YDB\?'0C:8B^739MJ_/^;[)V^4!+' 86Y+W4;2
MXQS&CF*NK:*D:5RFDI:?NJ$KD=T]@[/?NE!>F@K%I[+#5.W6K(UIX#!>(HH^
M-$?JEXD>\YWF !MBVW<4)2>X$80GTE9[QR;SP&,8U<7E7M2S?8O%D2!.1JZ<
MG= F>OX^G>,SR/!7NJE@'M(14N )!DT=!?.I'-578X1'<E1+30I_ UGK@5>C
M)X?Z&Q4<6!*((=G\/I7.!:8Y"5RI@/K4FOE6=>3##9C( =%32,JNMEC]'0!A
M5ZDHRKSDIV^X4>&E-99T<J&["( VN[_;;[(#:;>HR= <",TL)RC)J(QN;8X)
MK#^/>89MVM\*NI Q,_N<]7H"\V:%<[H@ND2H9-/PA;CC5>CFB,5VRF^\.CV]
MD$71Y_3IM!;[;NJ#-=?]4;Z?8-*IPL0KP9 _ZY[VCBS[!C&II\.KMOSK&W'Z
MRHL4\!<//E-(91U/3RU)#LK OBSZ@>T(3ZU-8W?U#?7Z$S)/=)/JA:\C\2J=
M/924,SEFQH-(D@A9Z@6:(419XE/][L*M"6#==DXH:E(P,$&[!U,OHAURZDXE
MFJCPA((5[XES6.%]FR!<;\S8A+A_'9&H^^.WO@<?%KWKOM8+=#^!X6LK/8>X
MR $SMLA[WK<VY?RTQ_0G)U 9\G_KNN#'PBB&S;F(W/KXWB[$.,NG%$6DL;H3
M.&W]Q,_"];.5R&AG&">V!(YB+*Z/$8.2ZA%@I46ZJ:'MAOIMETP"(=%/+L<;
MP2Y7B9NSU#!@+2Q]AR?3[->>[89W06HN1CW.U*^AG%\\QODES:H<3>KB5LU1
MHXBG!#=N55[29*JW>,4^:NYLV!F/N&R AX)*L6LVY+'+!=-BYV$'#\^I6Y+'
M+[5V]:/1)_(J"NCFVGZ6GL9Q9]3BXV1YK)7DKZ#A<3XW.JKW\X0>&_WGQ0W#
M^G "@<6HFH8L)3I4[;>:K%U6(6N0/N(HI-S/Y.KC@.J)KO3PXK-A3[#CYTLC
M>WKT,*Z9*8INXK# PY?"Z U)^WSS?'.4Z])[.E8MRB2.16$#5*0G"'])/-K4
M6S:E:_X7@=4Z*OCS5B-A6%MR/G5SU(+W1N-A%*,KOC)<H2:_E,+F:$JVM.=>
MT B)I<W^K[TC2LS:BT(*?1',[CMO3)IBT?<%:LX72;J\LIG35NMZ$T?/N6O:
M8&WU(3OSO4?J$Y=9LNFEQ?'Y 9*:MDQ,ZP>.L-Y0L 3>A_F>"RO;ZO,_-0?$
MGVVAD"7]->O5!V(=T#W//.*D^7@%1^!H.MC1G(5FZYST4Z*/<7V2XEB6M*A3
M61!1U[IQP$)*R/RB1:O K]<J&<//*Z;=(I+ZJ+MG9/J#B*@DLHV]<YVOG?L)
MB<CT""V3X:(-8\ 043XJ>0RZ-5FT6QY4%"5$I+' 8.1]I@F:;#\QSGKL.R2;
M1S;6FKM5_.?#^;28!]T!(-E!QH=Z].NA1PLMH;?GLOL$-/G-\LZZ_>P@L5%A
MN4561@%?IK\B(@TO]0[ ,R8\JVY+4OUX&ZL-5M31Q_D^,##BQVYM^G=,N%=\
M/M['3_Q#.PR63:MO-:4'GJ\V#?'53"EOG:4ZF.)4.&<RJK,W"3D(Y:R1N=HY
MHQ][6QEG3NB#JU,^1[V^HA'NZ<X3J8FY?J>Z1'Q8G(L73&]O"<5S0+UF"J#(
M8Z\K(/ /"/AK6?X!->\HJ 5V&"7&:$T]+.2!E@NT,Y0-%PH161$[1]O8  I?
M:N"1MQ U]C77..\[KDU9P;,.YDP^-T$6NO0O1]ZBU%,"9_4YN^IEW*CX:VS=
MBFAFAUB<0SWN#:;1NYRRZ'<9R(?"+<\YCD&@R[)>_"45A[W;.GOA2*#>//!L
MC/]":\Q]5@QB12]RUE-)-$VC3R\__0COV;[ C0"$NTA^_1EW!0O<-_&\M[?4
M*DD^^$FEP^0?HUFI2N\F37@!D]%!Q5<K='I_UW!DE&VM*D;6FF5CMT?UL1(Y
M-PX*Y$7/) 255'\@4G5*R]Q??'^=*41Q_<8X_LPUQ,$G9+WS[VS_X0]5(WX9
M;'W3@H]NB60':8^:/^TYI>SG4&O?EN%2K;2RR"UWR]E8./!-S]OY Z8VYVZS
M$#C1UAW82C5Z*DG,C>02>J5F2K*%"F:7OP,8FQ4VQ!Q7-#V?7$3)HZVSD;M!
MSS#O!=A+7/5I]9Q=R5SXJ+GQ]2X@Z?CXBSJ@M5FWD.TI(S[(3^#1CF,#I+1,
M$_KR_IN'S/=(#->&3!PO0"<AC8B67 0YW 0K1E$@/[%V2*BT$1QLW^;V=''D
M7:\@$;**. R$TFH[2!([H^>) B4(*)XU14@D:AK?;-6SMYN1H:2WEC Q<VU)
M&U.0;T+JCVLZI7+;,;*#]N[2G>U2ZS6'E2D6'H)+Z)YYE97$8Q<SXOAHG]X0
M2M@NC8^<\]/<Y_>/#_;SN('.8I>W.P_M3/L5@*VD J*E9R[5@C\P[T.[EEAB
M69_^E94+;5LL<^U]3NPZ[9B"&L@D;W+>65E4VRH1J7?'[<7?++Q M P,1L$B
M1!>[[?,LSO2?H9U.%N]O9H*HZB=+6*Y&]ZN/DK4;84W;JPEBK%]&[:W+*G&B
M$[KM+L>*I8I6X>G=V5[$EIY5FYM1%#KID! Z9]-::'!.E)@"=_O>+Q3=$<VL
M"DEH:-)Q,:@QEP.%SK__K:.UWQ18"',-9M[9#9/KK@BH)P&%6^4(XTX:6K&N
M)_R3'(@'%]X6JZ<PS04C:@VE--"[ 9W^D*'!^8IZ#++GP:6F@ZU/\KP6NRRA
M7699Z>NKX1)66 ):\0C9_62,^ =1_U!;&KIL<#/&NJ@]B[ LF'L3D_3--<^2
M08J?)5Q8>*_B!9DVU-.Q]DA 9]&D 4EGQVBQSF5(@PZIY:1>Q=6T^EH!59+:
MQ"_P^[0O'J+L\V4T;9TW^487JS6&?3^?]A.7Q=@TL\0*3_*Q*Y7810ZJ_\JZ
MKKRN:E1O6+P9LIQ'ZCF#QX;H=V0QC?U&H,6>0/9!<--O:&B#M^K0B+]U\&U.
MTX*CZ4ODSM<JDB=E.%9N1;"3UZ6OFT^6S>-?)'B:0'LT?W+=[S351WM;<Z-<
MLFC@%,TQAZL+P7IW@*%,F*,-T%';:<YL;^FJ_ #,F:#(EA@OMXTK8WU-)I+X
M0M2M(_%2$J=7?;"2YY!?B[F/<\O_2S3(B"<&I(\Y8J*7#O+(V35QL^.@=B<>
MK2OB_9HI(J!$F/K7LJN)-U0"(<V(3$U%,C(PQ^??#YZ+,GS8NQ)\O+EE>]B:
M\+?OTN[B<)W!%!-0F4[6<*ILVIH'C<,#?E.?VCDWRF1^V*?>MMO\O2U1478U
M-R!$9T!V\ [PDI(/7_,(H\1>PM-S95U[+*I35J;+)KBFOVZQI8X21S3*5[=5
M$$/"S ZWC_9EWFU6]OKN88E('H^Z H\A=B]9XM?DQQ'X\&=;8]BV_)"ZCS3)
MWMK#+3>JZN)8)T)O,?/N>?YO22+R:)!X)NVBLEC?KD43*/\HY]>Z9,/\9>NN
MLUM\D^%Y);L=K&;4!?F^70'TM:',B*4;("F64ZL!;!3N0=Y3S!2BT)#J26+?
M'(.95N4E4'<S5S#;+AVS9!8E.K<! %M*&XT_4T=V!UT=3"9VLRK0V8<X,>6&
M)Z131(6T@P0*T/W,.OR7FTFIU+7/5+]6F$?L^)7X./'7G&>S_';AZ^H3RGKM
MI?E^V,2VQM/:TU[<M?>;@:4M9I"*X,%"UP0N8);9<V7)/]'0BA=^@K9;,&;M
M10VS.L"I]%S!['E]XA/-*)<)X>Y%W:+OB %-!QF!H!=K7^/[%KE-974F!X3S
M IC:< @D1,,:ATTK^;%VWM #<-Z;46$$2E*F^XAI56(XNHFW_%!!?]3X>=),
MD8&J*;PRY1&YX6.Q+/SB -: %[2/]VRY+R7H)#/E?\:&=5.L^JL=V$9-OG!<
M__.9O428^01+2@1U@6G+>_1E^SS^Y?W<_ET>CDP72/T.H%&@J<FG=^58NP\_
MD3.\WQF/$$?PA2H($C(@'8Y%OM# 6T.?T#:B-6S!AJCE;G%C&#^?_'S*'",W
M-S__N.EK:V]=MA<OQ!U6R(P8NCMK"T?3M&?V(1O?FT=-UQ(84OZ4Z0IV^WVD
M,FNTD+X#2(EH811"1RW0].270H&<WY7IK];CA%8>'KX@MR5N>[I'Y5"KN&BC
M\\L$,JZJV%<3I,;J*\4OY+^FJ=B)LWQ\.6$8$!"LP!;5V&'+G:WY2W4XS+#?
MVMDL*HW\Z#%I+L$]J>2&?891 6EJ_%("9("*EP7G2_K1&-.FZSB(Q,,Z?H<U
M_M',V5'>Y#T=-$]1?<"\H0DKV;.Q;P97.6EN.<L#4-^V^(ZL T_#+;4I*K)&
M^Q\NT=#GWNE]L1.'I/X]P4]:["%;-8)SX?3"!3"$@;+.#J,GC_N';=S.Q]:+
M<\$Z^Q69B?54Y/J#=._?\C\6\4N/HA)LMU:J(NMOP\3\1G3F].U93"Z(/[1T
M4UBJP =)Z'(+)\D;.[,75%4(:W%]ZZ];E>D@0:*U)E7(4\=\]]R)FM.4@K,%
M>5W"&4[N2^J!"Z;"!)3JCDYE@?7.&@1:.Q*K4]^%][/P!8"J)4)/K*;%'<\F
M"4#+PQ7I4-]#-R<E>Z=1LGY6Y^AW\.=J0%;Q&2"=C'2\NI7$G$%#=/>X)S"2
M;MP_;M2E:PT#?Z^_I2CS&V8SI>&L%UP;$/R!);JV@RRR"$)Y\C"7*2EI@ 9C
M<[]^S_,!4TN1$8^;]VK2>67(A8IN;V&&>AP<PR5A47,<8+-,Q"^<5^!UE=/?
M&)OX ;SV9Z3]RWB<S_MYOD5Q)$G2XKBW[EESG[GW@_U2&Z()V+"8@/N<TK4(
M\MFR6T,":LU$N/8=J:R*_GH)E7#4^9%,T+K$IAP?>+^C00CQ'(_2L9>U=W)Q
ML'2"/T$P[ [ '=B?C4>KYI_(38:ZS;?0E3QHA'U92$ (0;&6-=_=IX[?+6[%
M"M'60M7*(*):$DB4P?P]LTSDIP1*_2&&DW665GH#D&RL)2O=7M'2R68J5WF6
MW8Y$Y,@WL/L3^R:'29P$RM#7?:\4[;7$SJ7R8ZWS2+XU^@T,>>^RQ*D*I/$<
M4$/=KL6KG+,KHJ//R(>V]0UD"F=D9G[:MC4'MZ?=4%L?8"FZGY9E5AP4D#U2
MH, -)X9X!Y'L_+,T09P-S;?8D*GF<958'RK#[8,3J>0J*]9!:R[I6C)Q>@T(
M*<-/]"#!2\1P^K G<X)D)(M;_B%QQ'0MD.VHU45WUEWM''9_#!18ND)F-UK-
MY,?R,,HV[T7UY+-\_I[9&0PN66(.#?^HXZSXL4P?PSO$,]O4!&^&*X-#4:!9
MX2E8*J]&4D4RL/*O\9P=9>D^TW1UOF$XY<UP76F*6!J=?3,;PB%M,5BE"73P
MIID]/M9T/&.:B1WFEQIOW>0Q;8M+_?'7&_^)Y)$&;)L5Q:TJ'Z\$2\_/::>T
MS@\9&/3S?P9&%E/,<P>@97 $![8RC38>S^)?0D9RTOGHF3N.C__E'B<Q76\&
MMNFF1<?"M;ZNZW*]"2)[)KX/))G8"7W?&B9#!#OI\C@^:/![FR#>IZ"EXMXN
MDKR0'M#7<-JV)J /9E$9],#MX>P1D!BV;I](^,-UT>^TVV2'YI7_,,4O*IO_
M-<0O4@>S8X4OJLF >!.LQ_B2U4R>PTP&8IH@\7J@V H&V2VL"7:23>_9>;SK
M2(>;]B+H)IO;(IOZ?G8;6D31KLINZ6WLM-8?T>I&,55X>GZ9IFL62ZP3<;^M
MRJ^CU#):B5SZWH6HIF[5ZR:T"H7>KPU?A;#SX"Q,#$GIX0N^6"#1>Q%O\.23
MFK=0NJ=?QX[!T@\)MZ[[7&UNO.H]7'9<R>S!MLEO [.I#F60@BY$R>I?\"5_
MBH)5UB$A)8MG^A.KJQ6/2#YU)&H$#7$9^W4Q-<:@6 X*",)ZFYC=&M]-AR_]
M>A!E76C0<Y0#7;AR!?:B.43?R?UD,;R<AZH)98DWO#[(W5;Z 2+P:)7D?/?Q
ML5I=<.3#D%"Z_H=$=O'C<:+RQ0-8Q2WKLA;]X!__FDF=_#<BV72[4*"UP]1Z
M#WL^CS[1?NV,?FU0'"VER.QX9<S%&O:*F;7!%FH[\> %PZJ0$QFIYG94HQ1.
MAK6A.7[=[^(D+F]:B$H3'N6Q+-TBV%V\<$)WV,;<%AK?H<OQ$52XP(D*GLRS
M"$.-<2CBQDK?"^/]U[15ED"9APN&ABW"\?!F5[1IR'Y\S7X"+FLYO_SE-E&;
MO'7TH@8MH9K'1$1.>;L!6.U +4$>3DA=:1:QG+>(DRRHP!EV3Y'8*E*#Q/6R
M6_5*F[)E9[%YM 6.31-;Q$4(IE[S3CK1Z$T=EDW,6C^I\"1;[-T+/VYNL@=[
M_ADO%(-_(>9-T%94)<7L/,M/DI]M?QGS468D<E@U*9VD79EF3@\%KIV?/4A@
M.2@G)]L7D)V.,,#IK;P_*BELO1),^[N\UC7=L<-*1.(@LRS/VY1_<*H&  (I
M<+%N*]Z"NAF69:J>T!Z>=$U9#-[OB7+]?F$RMK8DHJ:=LN$3/UBI6\PBNUR:
MXU@E\!9 =$G*6]B+81Y:V#!K;\5JN#?%A3.3IH['GZC.BLC2RH68Z"/Y%V05
M'?;QT2<W>Y&756S-YL,KQN'19O3T'_$>FAU+MGN)!7,\BND,LIJ4#_".^X0#
MR FSWP]EV#$O\SV_4(>9+[P=B4[8,=^OV\^2])<+9-.#C.(Y_QDTQ<?4CD9N
M44 /VB *70BZK+4_Y3Q0.D(ZUF.QXZJ<8YET)T]ARXP%9'J0:D$CULDEVZ2O
MES8=[QA$]9#14. .$+=,&&=:?0*]< 3CI/O4Z6U 3_(LP7*$E<8"X82_% */
MQ\ R:JQ:Q0G$$%+F&I&D6E0=%_<7!7M[:A^'YLE>B"/=[$J@,CS>VKETK<*;
M3/E$XC&:+3'K#SA(ERO?V7B[H=-E"Y:Y[QU+%4JK24,Z69I'+.Y&*;!:/2]R
M)H;J9:60U^EOZF=#VYW%:3RBW#[[0IOB&VL9L^", 7/&(Q]+6\AAMLG;CAN9
M=60#BL)0G$6M-X\>NMO\7VKXOH+7/_YO_M?SO!_T':+<=>>9@:T^?'P*/Q:D
MY87'(E:_Q? G95-I*$DMQ%EW6&Z9F"Y"DA+''=OC5P_\PY%Z7XB,*Y[-R0 <
MSG(&86Z51HQQ_>.>KH?,2UR!+!G8MA&7?9B]6HQ_^"C/UW'6BZP';/^6G,B,
M3K>W%$A-YXKDPNKJRN!5?!<>(RBW^'K<\?JH/3IZO7<I6/G0%'.PFB#N#.-O
MHDW6&R9<ZD(.44]X;Y_!>8V%-B#JGV2RNJTQ4$%5.+5NIK$]2R81C_?2EMRM
M6=?U$9/X2BB#).<@/N>%EM/J2?-\<^[UX&8#67*]\,F#+VQ=Q9I1?>O%R>'W
M6>:I%?\V?5^[W?8K@B-)N3G&Q=9Y7+&MG?T>,N12_,.4I@'[\/"PLR!F3/^F
M%:'P/(@#!!+@YR,BP<__,F)]2!Y\%BYCZ_UH3TQRDY7T>Z>]F;DN:^67ZM9=
M!O9S/!>A0YFZ,!2U"E&+?<'(@G[_;/QA8^*8BZ_X<Z+MAN* @HK'?GB/>_X=
MIGZ3@*#I<65SV+VC"Y&8S36'!T+\\S?%FW[C;:;/L/4@JL8<&M@GL6LR15IE
MI^+<^YI6&-[>KU]@'Z<O^P,+)J@8/LDP)CMML9CA=9,G>:C^# #E #08I$9?
ML W\L]/@_R0]^1_?A8ISP"8?B+_29<0&$>O/9$5*<+<RN9:C*;(0@R,YC($$
M7GT[$F6*E2S"9A73RZ$U^%T/VO7\&P0U5]%W@.*H<!Y%C,I;ZR,'&=\YZ\4+
MU9RIY\XN%Q^*.?X\8/VGQ];_VR1^-6*;2N==D7),FX%IT<4++$#&R:3,AZ[?
M3AD"^5TR=KPX/]*IU7 G)6OK>&9JO]YW9#CR1&S*H :7;C*CD$)52@W$DB\]
M<8YSUO<E"!YD)V1']\[S/-UZXZ.P*M/,PZR]M39X#C"S!?)-("/UEWPZ. D,
M</[O)#S+$:(^!?+&@O9^I2FX;;R09$/54=N*1->* BM=!P\V\<(8J[-0%SB
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M^[]X__^?=W-+L#"^.\UOWST!0O?F*G9Q&N2G+V*.DTL4OX,ZG&_:@\^L;^X
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MG3ACW7FV1Z&U^I.M49L/\89[YLFKZH*AK\E[*AKITD)Y9K9*%^\K_+[/?UK
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M,_XV_]#38UN>2VO/&-O4Y )+J!5C%B9O#2SM;V^+3#]>\'46/L#RMB;=]"A
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M;[5*!.3'+>Q6#Q7V1E;%MG=H,?!"KZ'GA71=IGFQ3J ABW#3L(%EL@J7V>R
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MFIW-6?<L^\;?U,@*,#%+2)3>46JZFA%!6X<)"@+CVY<3"!^\$_6<>UY:?9=
M$8P>.K$F/#[CCO0(7Y56DM+P&KD+IJ-\"J:TYMQN;U'J-W:JT!ED>U*,Z$@>
MW):<9G0&P5:&BS/"*IZ]Y'00]N!COP  6\K9*XJH'C8F]P<N R>Y^6= 0BS4
M(\3N08?&>Y3 T!T(9X;6[Q<YIP%/4/%!^N>.$0YE+* *BBRXHW=GYZ+82CO,
MS&;(E75 @PY+UCR)#EE+*62N\W$TQBFRU$RR(*0T(]V"Z%U;'S"'27@%ER]
M(54"0$K1HT&)5[-X>'I'W2KG%6E"M(8O&:F*(U-[SBCF5=$1SJW)_25G2F\'
MV%@4''E5<GA1%U/=EZ,4- %I1JNU]+*K#D"4-1Z%%4(,^Q7+7U,]-Z*K<L.2
MVZ0L=Y7OH&'&9MSHKS[F81GRPF0S^IZ2\&41\T%,Z1:?XM"?.8&R<=GE3T61
M110#1+#\'JD1H8)N4+0753LG$8/'4Z^9CI_X<4?6AD,LRTL*!URE5(I\7GDN
M;MJCMV3GMB0B\\LHD9H-*]XT:P1 EQF$1XO\,V_K-&@\7*2HH%2F6T,Z$-ES
MZJ6F!IGAAVX9*;G]9A(A<4D&\\BO&=:)?;%_5P["C6TSMXW9=ON$@_%Z8E9>
M%BT5](>QXG(OO\$I/(M A\0?&+=ZW69/W(8FOL3(WK[3-=MF<LS*_1LNM;F(
M->$ID[<6N]5(^=Z!S-+B\O">J:1DU(Q@E'T@=#Y,[$V%K8U[@#)43C6YHV5<
M"A0V)EM"(=<]4A-^> +L+@JN;AU3H^A\:7PD(BP<YY3C<[5]5AQ68,PYF]H>
M5BU$88_]4M^NXF!O.,!.13FTHJU#)_>X 7UJ-GHP>_0F1V(?#?SEX#ME*4C,
M !DJ43Z01%VC3:CA6Y=KB.7=MA3S5K:V7Y.%WW=94&YIM^$_^N%C#6>^<DNO
M9=,-2A1)05DM..?55>Z6I.#<Q?0<JTN=[BK+1XE%];_!W2"7J!.T]ZQE+ZQU
MJNQ7W9\J>(7W<^_Y<VU E\_XL;R]S/.G;-'S76Z[P:6]W"$I2T$=!N&M55@F
MVJ1P01O+./%CG<DP(0V?J (\INJL?X":S-ZH&>+*$>LM7IW%:SY@[:GW>7%C
M5G2U!E<W!M:2,MK;QP^+EIBOE0>515E"&#FD5U:@A"I5A69VV7Q0EU8&I1H;
MRUEF[,!5)F[K-?9(8T]I#[SFF&)868&Y(36=?6VOY:+@\)RBEO@<17'V5S[?
M.CFWRB:O%ROCW6)).*9XC9\PVD&^;3Y*&$M1I'"<1W4[B%F.6KC>)Z> C+?=
MLA85H.5BBMP6?=-LU[>(?DY@=@D&^$#@[5!@54F$F=ZG.A&3*I_"1 B3^X>P
M.^"/'".+;[+3 ^)H5UNABSH"_,S)_? N-,ROBE_NW7PTXE#L*&LV[##FI>BD
M9\6$T_C55?>$X?1,-CW;16F_R+ W>-FHNFUFAC%J@57*Q!V0+D/8$-W\@0+V
M]0=[*C_:#]*3?)4;@5WE.0'MM7!8H/5ZZ'"XZN05A\6X)H(RS.9WA,'\JX(Y
MSZH#W3(3?3N/<ZYNW?@R626G6:037VF$20W]: \PK< &KY,8/??80<Q.2Q?(
MS(2-G @/$5V8_M4ZVDG:\I-]'"P<]C)P-R;@4T_6XZ"E]IZ9R8.@P,X@&RBS
MI_(ZR]N6[B&NY!B=H2GJ.N V9M\:,2AR=!?XIQ**&:VT3\,.02$?@6F;%32X
MHJ.Z%W&# C3#!HTSQHFFEI(2<*O']A'5L9"/TV/T3(K!"5\V@?RT74AD67_E
M7,7(&'UXH0%S2@V^E XUO;EP'S;]:ULBDBE];^6@=59]>0VC!-_@HSR^?OO'
MO<A,R7#+DC<XX2T]@;G=M<"B8;\<>ZP-RO HN=^&,ZB\I:2+DE&M;8#$+U^B
MD+D8:#S94;HE[9I^M@]S.[=:Z\R)*Z^:?$Z"P[VC;@O.WV#I209Q5Z]A)&IN
MC(%;"WXY)TI-UIYDSCA3J%!7H3;6=8<7G'8F!/9B+@"Q\Z_@<H3Y]:<G@MGB
M,V:(VPH5]V'01\&8=EA!6SQQ^<[D].$%X L" \:@S^=+4;_H]'[^*<R%?'&]
M.CCZG(#Q8%6-R;%(&-]@@YM4FV3$)%<T:T"92DJ6 H57,V[9JNSFK_NN&$[I
M%;@'%+A"]K(*(BX 6+PO*G7REEX8S=:3T7G?>SECJZNWU#QJCUG+!>NS7_&^
M8-2PV>2K3JTWXC6HUX=)^^C6YJ ZF%*O6#@LF/U\V$,8N4X'@+<[#V"^]QOZ
MZ$YX,#DZ%H:-63@ M[\\F"F:;VJ;W(3'<-79FSGZ<D+*OB7[!#T]";&;?":[
M<O>@W DRR\<^I$0*]WO8,F92F%M,XE:YE FOIUWO#2J1Y>KO-GOYZK$F<[!2
M[+!P_"[_K*CZ?#=>HOJIB][3*JR!25X5R!C@-1(1NH %JW?- E/<KQ\DS"(?
M=G89*;E'IRP\V9US@JG<$P:X>9/71]=Q^[EX/?6HRA;>[RRNV$%+W/9^_=QD
MR*PQ/+O/R9XV+G)1VS(WT-K)0R^[':%M9V4'19>V.H%9V/-QHK7)J(=F6]ZX
ME6Q.V9=!/G'+MWYA!28<#L9?G8/]E9Z)O^Y#><TXAB55EDJ\2X 6&+C!$-+"
M>G;H=ODARV0[3VNGV<88VR*)I##7.C[DK/68;5=_;YM##=PN#"DJ1I+STDB#
MPEH6E5?=^?8Q7G>DF,D3XQIYJJEI9S^:_.6U^U'AZ;Q*PP)>X^0L"C.W5<?I
M%-6=C(M+,*_ZBB!;;%)ANZ5:BQ$*<"RV7LD*9^,JZV\=ERC@;7E)FEQA]_J,
MX<9/UH]DID7;WAWKK79FMRCO4^YUX7R,)#"R$J..SH[:!7W4;!2@ @V)8?VI
M]I4PF<@1I_[BJUME568YSH^9IFCB]YW@S,R#XR\67 PA,@-U8RKH#T!? OZ(
MR;(U*JC;Z:?3@PH]]+>"K/KH_JI(4$.P.-,>J"K$<GPT$0PG0J'2'LHV[,JD
MC8@A6VW'Z,%B$TM,K3<+IMZMZ>T/ )^MA=_54!>E<NVO<Z__$<E'.!8*N)'[
M4^79H*5@>YQ#M=V["K\!KS^;[!)>AV6AHE_@(^XQ+FG9/VB!-W@8J>EU Z-5
MR=,>9-WA^?2*GIR4YX_"L]Q["E]U2'D^99&HDM[AN<-#3<\3I)ND2FY#^/3\
MT_/ /\_]R:\]RZ-5R,LB?7U'6_7Z#PH>QM>PG2\7 )O:,^W8?SO[T'QJ6]/E
M?.OK@7=/)^X-X,&#+#)G<FS?)X5_/[M RLZ9@:>=NUN_I+A?.33[F[%PW#ZY
M6BKKBP\7;HMR?ZG';%OWNY(=V+A=I*HH+3M*CA&U[8VSQ^H7%VJ=J!:W;O$C
M=T1W&Z3D=12K"LFUN4EOD +F/@;QW!%W?_!S;3K0Q>ULKS;6(.[^-7\1Y/7/
M-<,1$7@C.#Q!FBA:5_-2=+'=T)S?+'8T3J!P0"WQI6&QKW:D$:9+P*.;#FN,
MU+A:T-"7]CSM^<QXYKVK9*0/GZ?](R#G;_A-\ZX5Y8,LBM?_6V'99'*2CX-J
M9+:DY@R3IO[4[W:*,6U=^I!=\C.:\PWP.BN+)__ERS/:M5Z]\L_[)/@%J&]V
MY'[ZIQ12'ME[X=]Y%2*T?GQ2>OWVOP1O_IWR_R9XZ+^[_L]&C?[_P/_?!,ZN
M2.Q5^+=C2#MJ?RV.2N!JDM[-M0 +H;5_F*TRUY5G-S\^?WWC)N#_Z2 2S:M+
M>V_<B+T 9$4,SMY@/;+'"_OB?5UYVC?0]=D1>,<>?RT?U-G?.A=!.+%X.6,?
MO_,S>@KHI\&&GDJ^G7)@?ZP+USCJEY!9Q^\6[B=>-DX2ZU5[;>HE&?Y6E9S(
M4_^M46,KE[V4,(%9-B"*+2K,'50[#I3A_HJ'H\]X9;)/E\P/.DT&E8B8187+
MDG'[/X'^AU^^Y*[%^\;*67O_J_]+[CK#\P0Y^_] ?/F/JOWN?VIX CFV/D.?
M_N?^_Q)QJ44KD>HO#\=C_;.?_T"\ /Q#?>[_$,O^WP.$P_Y#&B)ET/<_Z_BO
M_MM#V_]>PJ.M6T^[C_K:-]RFLJW*IY)IXN3$8 YK1M-W?U4T35_/'MK<*S*V
M]*6HL]04E14QMF/N[76\[ :ESA^D;'#3>[)JM2AV.609,_J',=JYO3U_&V5I
M(X*T07(2=9<*'+K)<FIF_%M9]+\MN[*1MS;E#?U34.K_JER4FC1U.0JI7\P(
M.D9VIPLG&D>#?X%%RG82+SEJ,Q9ZJR:,'77OK3CVI+N.'L8P3B]\%O_2MJ._
MP"5CO"H@&YRK_+\RO:+*GPT!@=(-EZ:OR#(?^QO>.?$9Q0<=(NA[1..[2>6(
M?G%3OXMDONSD=3SSPUT ^.L_&<+)%M7C_]62K<ZV7]^Y,:V;\N=HD(MD_E_U
M3]UC94TNMW"FY?M:/1G5+!8TU'^_QU <0U?\-([&)M?I82'?$7G_V-R>+E1N
M;2R'S+PUP[+5S/.#EQR>\'3.?6'YYV%^F<V"MN-8K-26HQ:*HG\^(&[Q C!J
M?RF_**ED6E;OR$]K7/0O,D_\FTE]3U]2WX:_:#7=6PQ1D'5G)+K^Q\@ _5P3
M#G(]0.U6WA9MCA\[LA073MD>VB1:N,\=JV?']X7"Y@%+M\BBIHX!RGFY;*U7
M%Y@$AX3BF#(Z+AGGG00/CLI)CG:5-/V+Z)!ZO.$%X*EWG37'=!& N=WF:,AP
M2[\KDF&9\E4+;COVII=#$RZ.DG*0P8EL0-Y0>P[52J3(WW13MWQ8:_&KIJS6
MLMI.)"F,>6G0)+A %JGCYH-8^5/V*F^5XN=_IAC:V4)[R=&;;)U7Z_WI,D*3
M?FX;VUF18'S*DJ$O$37)]F3+)U)_13?:IDE"D-C[F#TQ&ZK[;3R,G8/*OT#3
M.R4WR6^FQ)BR?5]2-,7XR-&=/G;JEA6'%:JH>!8D>41;X_(>GS^4I&;N^6%^
MBZWB[ZP5CL4E/?<NWKX '%+D_/)U97C6RA];9ZS0<#"]ANOOJBQG^UHLAJ<-
M[8"H()HD^/!U;TK-:$IT/X8[+"?+L>C&K7C5VXGZL9<Q-.:1Q;&"QQ4Y VY9
M'DZT_ZF1U:DL=C$6TD6A-*P*GFW7=Z[X$LKWJ7IJFWI1]!^/3.8W+S7PN;2T
M=O_'IYCMA1M=43-/1UNV8"$V\EN%[A.T>U[(2DS&=]&#'_[&\4V&*<*4R^*8
MV?S!,VU=Z 7 OW7Y!!IGS :LJ4)\5MZ,#?] >TUX6XY\/'NIW 4" F,S2R\
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M'CK+/$E&U?O+KZ4FRXGYX6X2L*/MCB5.]X5N%&UNJ3P\C2U/;2E;2<9SKUP
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M97KF91M#T>2EQP<;#_"\2=%%#UR3Q-3+[#1@7YM[_26N?<Y0^^B2I.3.N/\
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M5,H;#LK1$NT0BIM<*1]K?0VA<4%S+4X%:]GFM^->=AHS;V3,W+9YE#7^1]C
MCS.PLPGVR-Z_DC)MVGHC?;T!9?6NB0"2NRL0;^Y:VVANYQ#TNTWZP9>6I*7:
MG@*%V<F=K56!5.>&=I)CR1ON5QE?4;&]"!F [+$N>Y2[EPD.V&JRWM8*YLN.
MH^2PI2#N%4:VHB51B]'@W=>&1M\?DQR&L](T'8OST[26R[0^RA>\%1?GWW!
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M00^R-.W>;0<%G#1N :FD]@E,=8]D,[O$7=_5;H4"+Q4/_:L]<DG)+JO"Y )
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ML&9'=_*J0C###%K#(J;SH*@7V_Q[)2O\$./#26'1CU,_;1_>3@=_$T=OG+C
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M5&L=.<]#20!B =U?N[$/DO[LS^XQHNWK,WE1_,<ZC+&&54#C'T$X>O+#)"\
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MT\XYRN3%NA+!'*&_RI0*",^<A+T^3@E9+PZD.XHQ24;R+"%,K:;WYC<::RK
M,'^/= Y"*XG*XLL9NN%D'2<W-2X43HMSH)<+GGV>@-!ZG$S: \=M/FO.?%I#
ML(G[6#7TG'\CQ@8X/Y$R,B!$[3!MP$L_+"^O,.)MPZ\5P5*."BEEOI,,XW/:
MVS=PLP1CY)[B.J>^TJ=2M,:)2>DH?=PXV>*O?!HH&056!P*DHH'JK4;+Z3&)
MW/W6.*\P&_S.B'*Y^V8&H'>IM@.)P@.XSO7VN]QHV :'XS9.0K_0<!UQYL22
MITG-!'"(>4#B[651N<O]4AVQ9 !%]$RR[K(PO5*G-K&",./ _;ERQ?GD[3>'
MSS3&* L;GZRRV)0[\9WKTXG J^T/BOOJ!:8ZVIRMV=.7O3I8Z<>HA*K)#M'3
M)LZ$DI!%!SW5:R4XZ<65">(CF.*QJJ"1.9KR^@CT]&I#Y@BEC,H+BJ+."BE+
MO(9NT;!3'F)ETT?@L8V$M_5IA<+#[K??O ^,TA!UNL4EJS3\^]O"Q5[<PC\_
M;S_.$O+7VC0L:BN^'JQ8G^V%)4&RS5ZC'G?(ED:6<;JA+RZ/:FI(MW>%CH+T
M1:J.R@2F^1-<31==RMOT'JXC>,^>$CX2U'YHW;ND)\FJ%YQVW499E[ S.J)[
MUQXT/Y#O"P^HK*I-?# 8]$UAC7[^@B+Y N;0S9&>YB#Q;@MDDB0-U!G:ML_V
MX/+],GEPOK1RXGH!(XJC?&2'F##SR-"C$U&TL@^R?AS/KWFE?#/O*VI[S;)K
MWFC"S;!(2K>-&?1 P9&V283L^$"C!S#OXS2_%E5393>$<)[_H3M9+_T&8]_*
MP9(^UW$]6^AL?R\9=MM_ RL?BV6E^W+4^+8Z6@Y*194Q;@2GXPC6M4% >;([
M_AP)>40DM6,9!OAM!PQD(H#A;1;F41B,9^,3TA8H%(\"CH.(3<?%B_,1 6^V
M]S1CJ4_C7-7M,P2N5?(5(E_NYJS:FM ^?&C!,Z(P/(N;M\5_RR+BT8 S^'B[
M<6#Y@W=;*L3:DJAJ=?A1\9<1 9,'?. L1[//H\&/7+-6!>U72Q; CRY[4=/T
ME1G8HGDMMT517C%["0JDY'G%'- W8D(TJ7NBX!N8:,<\_U[,Q46L/)6-IT8=
M+"<_1TEJWHU!MC&?V9&C0WY=3RA1O&W1FH83+[5R$O5Z5ZA^.66IE+@:;D*4
M_0E:/>BWS:KOCCQO:B[7\>'?,.PR7M7A*C4LI/"$BGTL,.BWW#;OZ+-P.$;M
MA'!"\C+4?]O2DI@82&<NL%T2]%9?CK^-2*<9^)J%/ F<S%&9</SZD!.'?NCX
M =!'XCQOZDH_;<[1SIE+J3Z^$\S@G_H2),$X VFQ;_Q#H1BO<<+6/;ZLET8G
MUEXK+[G.^[RZ$,7!)\PENL4FG'S1^[R0L06QSXCH1?WVN#FN*41G]L&P3L.Q
MZ9-JK\#:&IZ,#4XCNY#ZY,!(,TNETPSJ"*C77IP!+R<DS'"O H_[8105<[+X
MZA&C(Y#)SK:W;%(WM-3P]:FF+.[ 2&TLQ2B]]:$Z-N4ANG9G$(J_63RTA;F0
M*5FU:I)'*K@^03)O0K/EZ<.CTJ N?7"A!2%(N?U<5J-IW66E,^07FE]M1)P
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MU+1 ,R>$(5=ER(3\T%LA5_2\WR+_FOX_4$L#!!0    ( #.$QE3=]ZERA8T
M '":   .    ;6]D=6QA<C P."YJ<&>D>P58E$_7]Y*+=(,TDBHAW;&"@*"
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M<PO?4+S7\U5G/P$=+RBM<\DZ> 7O]",9[1QYXFT3AV!L8!.PO'K:^$2(T_L
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MMIXU63[ >*27_+R356U>TC2%M+(CK9EOA?!;3)WDUR$[TA-]%DX!4!3.E(>
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M(801:6+QP?2V?!T)';PH^L(R_1&86HC\\DJQ/?%:ENKRU/FK4P-&F6N^UCO
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M1A ')T=)"<D\5LEE?I*1+;B\QW9(R BF6H*?$?8JR$HR2"79#N?)#M>?+B#
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M4=%]84*\T?J*R"?ZP; 7'.Q<B7]0:NP$D/SIM2I1XC?P ZO32Q%Z=;=$68[
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M08>-]AP(6FS[A+J=))HE%,'RT%8O,C)XY1=  !2J26037^=7-%$D*).H3/M
MARYCXQ<@'I@0.M"LP<M\0FKTF9Y 9>-;WAI[2'*T0!>63&@.Z3H],>3*/01
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MX&N)ZVL*,++,\FPQS5EIL/&IL+0'+0:^'FK4>*TU+J)@_8%YR#R3K5&87$S
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MON9=:/LV;VOQ$D@X_ (([[S3?9+R0W_$37'5DX;\XY\RRA\DR.'X.<EY?O:
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M:WWNH<]3U*?)XV)4MW6#+$P*8D^DOG\UKK40^BMLB=U<P;XB1VP=H<T\1K*
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M')+M5W[ ]MV-\ZB$E)V3Z #;,*O^7FUG7Z&B E9.S!1BP/>9:=5<EN8>L1;
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MWIOSRVQ,3LH!EDM(>D-Z8!<'@4Q-?!</7(A)XB=22F4X3<[[:/[O9:Z!Y9/
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M@GJE@V:!;&H%$2:Y$L%N?=GF==@]5=1-'P,1H%:L48771YJN-LV.*FNJXEN
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M2I/UV5B>POL7:-Z,YT&NX839_P!02P,$%     @ ,X3&5%F9P+\M$   K1
M  X   !M;V1U;&%R,#$Q+FIP9Y579U03VK).(90 @4  J=(A5"F')J&WA(YT
M$"6" M*;% U=I+< BHA4(121%H(B(+VH2 P@33I2% 04E2*7]\Z[]WA_OF^O
M/3^^67O-K-DS:^_O],/I H 98X V  !! (#;V0*<?@; ]4*NW0P'  %4  !
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M#LN] 8T 8S8Y4'D+XA3>XJX>5R?QZ!X?*69$4_5H[YC)PT:W2NX4>7F4>V\
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MKN-V<F2\S;ZJ%>:A_'^<YNG4OP!02P,$%     @ ,X3&5#_0,W0^H@  R;$
M  X   !M;V1U;&%R,#$R+FIP9]2[!U14S[(O/$0!R4FBDF%(DB6+9(8\0XZ2
M&6! <A)!)$B4,.0D88 9DH09,B@Y(UFR)$F2!11$/O[GW'/7O?>==]9WUUOO
M>^_K6;/V[MK5U54U7;_=U=US^^7V*X <I*JA"L#"!@#L[SZ V^\ "F5?.]=
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M^,QC(5^E@%O^Y&K-S/2G_@GO FJFIW;X-BI;,'N,Q;[JOD1 ,QT+ KUD?,G
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MH?N^\[$S=65\[N+B\7#*!@29IN!S1>%NBJ/>4QVSP>\K<]]NF$I+#R_!>QQ
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MAC-B= O =8)"X,YPQV*!B%19W(M7YNQ!H%YVMS5RYS %5O7S:Z?KEHSK]%M
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MAS;1LQB"XW:-/W Q],+-B]9:OYHBPT_GTRW#? KJGET&S3Z$R5S!=LJ'L[>
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M#+TFXF<M%YJRZR8_#SI 80T<E12"*9CA3P\R4-8/@UB<@YW-#!HU8XE K\W
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M(Q<*WZ4\IMZL(/ LXQABTM&#2^86\GA**>JM>T44]FP1*L4,4493P3E)N7E
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M>02$R:/Y.4W?!LCIG=+J#!;RG"CXC38L:B,PDXPP ">!>HH"M@((N_P_GLH
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MT9IXY&6+QS@GS?VJA3>&*Z($*)>LR*I94]=P%YAA<T LH*EH@]79A]L^*<G
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MLJB'A47@=H95?1GMAO\/;>\!U>2S]8V&HM)%BC11E!IZ[R"=)$" )/0F)?0
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M=WC]W,X_G]0O$]__&,$?IV\^*VYPZSR]=<;6Q.@M*E:_,891GA>O-S9BI35
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M6E%!XX!/L22$Z7CU:-0'EF'5GZIN!5&<GYKVS1C[3/-QP-@M0$9;YA&PXYJ
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M87JSVLD_CE-;<MV83DEW/2+)RK]SCZ-YGC)5"O/V8\:GG@#AW?67-[U27/
MU3&9N%=Q34R[7-_P_=29@MY].5Y6MU"YY\_LQ\S)](QH20BA2V,=>P@IX=EK
M[]=!F4]ZOM]R$OV8T?27W-W^7W+W_3?@Z4GS+U#7Z/D[8@_:A4'\,Z$4; E?
M;/H ZVK31QKZ'/L-*?S,W7<?I(BF_@;DK?:$5;R/*5+</VU-ELZ36?3EL]).
M.K#I8Y=$Y^V&\#K^R7Y\S:UY"73ISY-D?^C(/UD\_UN)?2*V$VN,5[KMCX<
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M>K7&K3_&\=4==96Q]E=S@ZQG8W+0R3#AK[00;;K@T/%Y3P;B6GLS]HVIN?#
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MU_/W[WCD[>^@,!^+*@F)I#O?=)9#)KJ#-46R,Z$_E(HLV\ON^NSMYK_,1EX
MH?A/$->&6^.%Z*"!0S#A'MN7N:'F]1\79?"[>EGE=96%M*12?EL8M:8Y(EXH
MY U33OB5F;Z .&[.K$7FB J/NM^ 2%R0^ <Q&#KY'0 L04X.R=44@',X9Q=+
MMVAF$2K%T9TY+[0?^P%]D#S))1^2_:AY4Q2*N;"APO@YSH])\B+"7(XX(VAL
MM;R4YO,\LRM)MLX*+0'54WJ/FU6[F9@M8Y=*7.3-<]Y'76<(!/> 0?V9WU^.
M?P[('2LYH==MGD(UF+7U&+%"2+G&')L!*9D"!O9F(!&.:_(]7 Y3H50.GLL5
MNM;;.[1 'PQ/9#(N\^1,6'74<LI&I:75U",=-5#J6?C%4WO7X,5D13I@CN8Q
MK7Z\HD;%TV*#'4@ -($4VR*#*F]<<F-9]:NOC](YX^=C=&N7>I\Y>;B 8J^+
M6#1K(Y2)#4T]M(.5:"T:5#9DUIL\[Q(VG,S##([S5IRQY]N(&&W-/ZT^29A9
M]I@>'=8H:##?:>8!ZT9P"";OQ:^]$G,0_59<_1A'3D:&>:5X+RZ%_&^+"F6E
M^F$1B509Q"8,P51]WU?HOB1ED%@\K!7YM<L3E!049#?1;+[A,WG7H/B4OC*O
M1ETC:MOZ6$P8'"2\Q<#(89J:G'F^1.H%[^^\^>9D7L@D=JOPS]=:QK[Y:R V
M=_\:_(9_V6T8.N\ZGU?V&U!$*BO;V4>8@0EE#Z+&!)"TC@(^\E5*]Z6I-I*"
M%4A[J1#;K2!4S_[Q'J=U40&F$,IF(4W#M&511E88)>V/2CHZ<?H2A([YN_ED
M\/:0OQVP*,D!H(R\0<&5-)Y>9=4)Q%V3G\,O@V3E;F(^]^QP.$JH=FB#-/BI
MX1K/=R$SZ8Y#26^7\A[/6]6B/CRR-7>8,E]>/)7=]D!L^"I6UZY<AH(TN%+K
MKV.""T!DSUI8__Z(P[^>0U3[R[])\=>]/^Y-N1-T$K8GMU9ZWDLZ^[-+-1UH
M7QJ>LSR U D7>O@JYVMXUZ,UF9EI#A^GR;U(O;<H4U9!KV23\OQ-[7</ U1R
MC+&PBTEUL& ZG3-V:CJDWE\=M(U#'_GC_J_:O@,HJF7Y>PDB('$!)8@2EK!D
MR4DDLRQY61!8@N0<!0041.ZR2!#)23(L88F2DR Y(SD+DH. $D5 _0!]]_KN
M=]_[_ZN^^JJV9L[T]'3/GCIUIL]T_WJ<.H0FW%AISZ4^N10LY0;:&A!O+-TI
M^)ZF]P/P>^HPH^Z;<P&7H4* F'Y3X H<CQ5.'\XVF]:,)4:^'_P]_N@!,Y.4
MZ[WA8X;'B13W)!^?-2Z3FHR N\+NFKE,K;EM+X=&T9PSMEJG?$M(X+=0&F [
M,<&E*-6,KFS[ 5#Y@")*/._M=$[Y++T3]OSK!>V43YL)I$3.+Z%T?MF-7-&X
M&#+E;_&O6GZM3?4'8/I['R[>H+!H)'?JHZ,';!Q^+J;E \>,O7>)S#'\S&L4
MWWBW6JD%8I:5?HWZQQH73QD_R4?N@7]8\,?G>/*';3A,/HM8D7== 5VI-><:
M#65,6S4,Y0BJY9BL)1==^96CF<07"<_I"G)_8Y2&0&7H^5S]8]$L2CE8_KE_
M[^9G*V:@H=@/ )!%OC:C)CI79_&3-$%&]$^Z\TVO6-E1)%\1^P\,*$#&75?@
M0:Q+6/!,LD(CBN*<COM/$G&0GS*CDK(4N*L_TF8[5PAZ#:#'LMG5I5&PQ6_K
M'Q=J2GA75#<_RYF7 2WSUAND<BJ^@C^_='^_FY.B45/8M,MR8XNS,8#WWK,G
MWF_>U3C\)#3UMJ8<2;W;D5HH^P%HBS$I+?X!X"5Y-'EZK^84U?L# -3R:ZD_
M:Q";-]_ZOK3#R7NFK'!*^&GO\YKOR\ISEI#?6,Y(?U)X%Z'@IZY&WXW9>)\=
M67^Y[3+U=!'*.WG_:7SPH\Y,WY>SONV6/P#![$VFYSQ<>R:6IR;_ILOX/VFG
M^UU[^>G+O_\'I5E=D^/PET=4\S) 1]?))?X3ZWK%:7NYJ2G;@]&J.%#03!_P
M=<(B]G @J<>=_8;X@AV_>\.;:T-I ?P["3\7/Y&E[^?V' $#T,J""2F-W")G
M4,R3QR]ETD3*,B@NOU44W,E&S#*0Z<F\@EA:FQ'@"\K\GL>)*2)@F$F6^!%C
MB>>C#0+YF7J#(Z9/4\$0^RE(!!,2QQ1X5NJ?_VZ<L^-)#G8"KA[Y*UE!<BG&
MGV&B8#P(&.!_&>E]Y8[MIS/\@:=??P \#K\1*,A>O!L/&<88VABR+]\Q<]\
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MOP/:]R7_"Z!=6A4;JYN=1]<N;WUSD YC6H?$IB3;!);B3UJD/XC.W(0!(R)
MD?Z0R;M=!**]S64W\HF_4PCL!,OPR;?!*0- BE<=$ )W?'$%9QQ!C-FHP30A
M=AKI7:REP(^SL7 V&4(H7$:3$-P."HXP%3>,+VRQ8/2)3B? >QJ_@L0F8PE;
M\ ]-(O]]#X8 'P!P"-S$Q0;)MZ%YE.6CL=M9&@.""17H!>!=^AP&^K((W%08
M$'<Q=(\LGY7 C)1]:D<^TEF'T[$RF)M1&BH=O#5%1/@<=X!'&Q>UKAXB V+(
M_GO65%R<*E:<IRBP*0.3:T)G.MI1>)$R"'@],!C,08%+_Z&]'(Q$XT-E@1$Q
M_@#(6P ?#GX"O,M\(?09%OXU3@*:KDCXZXC/S7QI9PS9YRH"-XD8HRXCNK&2
MPY63&< 1P0&'+-<(!EN_JL*;&0GXJO,9B7"O8)*@T!QXNS9W8\_9:C)4-[HW
M!,+$>D6UM)68)0ZAHL:@3)R.FXW5!8C)#%6<<1(R*QTNGP'T<'C9+EJ^3]5'
M$PQ:D!&=W;F#+0N+ \8TX+$C,_ A4!@P9@L'P)   3@\\_=_RNO)HRKYI4GC
M@\+W@W<;2B:X7U/O]9^8B'WW.J% F! :YRTS1VR'"MK'PWAQ(GD@_1/7>N_B
M(,=0U(D+94)W@J2$AK(4X6#,E9".IHZB;#"(<\QUGS)?S_P/:]RM+^;QG/%9
M)B16.K691D3\59Q)>22]J)B,MU85L8)WU%GTA1UOEM:+W+N]F!.DQ(/>[/$8
MPY50U(R'0&,B7PT Z9FT/Y []EGY2:865-*RJ [/VO4W(X5D2U&OW&-$=[LH
MW4AQ/R=;IV4]73H<\"GE/7'1W\B_C@D7>!E/M@B+!3&D,\)H&K8,]U%7GZCI
MS[2/-+6C8QXMN0;15!NFQ4LBN!-4#[NY6'8ZK (G@W# R*W$S9.FNI(37XMO
M\P>QMP6ZWY^0=C1QEBR'.RN??V*:3E@D/515,<5VH:ZEI5;S"\-A?CRV_I9?
MY(WQ_^=+=<4O!4/^78P4U"D!V* 7:TE8(&?)00)F[U5_9;IW@MB0.>]TH.)^
M/R!*)-4&-[)A7_J_,6'5AJE/$L9'B[6]U?Y_D?,G$[SQUL/@&2S5__6 _\ D
MJOYUR%$W1+/8>S7_5$4 09S1_@[-$QK.GW;^7%)M[ONI)OLT4)2OYT=^>=%C
M;D.I"F0K<RMH<=V:<$R[95^LWI_Y T!6^RWPY;Z6MX/^7^VTB[:Y=KE-4QO/
M4U/KLU'5;5B_^KN_>GVBB3KMMTB94JIY'P6\YZKGO\(LP]U+D$Y8"GS")-"Q
MQA/O;45)FR)L8!OMT_ Y?\"*;NO%BFRN9!=]L;(4.;!'C:VF7_V5Z9AD_^;>
M3(&NAVB28DM(75M([0!7/,'1ZN,"JG% ? 1O=4,E]2A;N0C;O;3O NB=MB6#
M.@V/NMR*=AA"36?U\XD!1$YF6C$.&/D:W*]KP1C2/_SX]:EPZ)GLVM'UI_V*
M7QT&A"3^;,K%=?RO6O?Z91'(CEI?WO<9N>I!%:RQ]D:B5FK<H^AKS'?VAV-%
M8]*.PI[\ +!<.#K8;NA+A9V1!UDT7R0S;\/.:5ZYU\/ YP^\Q8Z+VDXXC: U
M>*&FVLZ!@0_'37-0J5=D9>=GJYLR RUW/=L:LW2</XFWFN@XHG.SBWEG0U#J
M *V<'@N)^\30#WWAAN;&3=LT3O8%9@B7([N8(@X8S35+0Q$W3HZX(*TV6< ]
ML9AC9J'\&QR5*65)7]6L=(2T8X6(KX9N"]Y7'61Z('Z$!=I3"!L7NN'EB>D1
M#XECYPS9V-16FH+WD&W.ZD<18L<!83Y3;[JJ0!CC3\#Q=DSQXG9=$S=31.I
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M1*Y VG*)G ITIS\9-7L,CPIY;OH\M1GT"E5K#@DL^P1A(191I]?>$%/F<4=
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ML#+>.LW&,'&N0;M(Y[.X=;Y$ S>L\0<UYPI65/=G9^#&/3]\ZS1^=G MU=W
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M_VALPP2@V//%E*'QB6?&^23P9!G4G/.PL^V\4L&@6S$>2DJE_F1S0WT4I5G
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MX18AA)8UB9U% "H4,V)!R@81VO#H.74[C(\A+8S/2-SO:F-%856"^@K5+"H
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MF;",/=>H@,E7TP.RT5"86DTXD65I%9]8$I6B9<R-_$"I 8*O0*7<: V*B+K
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MRPH5JOWQK"SI7C=&X FB[ E=I^(*%+#.^L=RH'MBQHN&EGQ[W$-\45F7=J6
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MNB;S;RIIPY:*D+2=Z1&O?]!R=4*(P'"F&%-,8\O<PBZA)P%LXL!/1I4^4,U
M!J"N0 6>X1:7'ZQZ:F!J66;E?97NZ+!?FE.]:GACNS5_K.]I1^C[WKS,X_MC
M].%MI/QP=2K_$@LXLV+.%3<#/P++!XZ=)&!U1X8NN@][@O/:(RI/P]"K*":P
M-9=Z*:O#IW++K8-;;H4KMOQ+]"+$X %HV9 3 F$#%VPJ&*<[@W#(N2_%/:Z1
M:K^H]HO'"^-1@R"X9IMP=NCO;(]0/DG84F+?ZPDYGS0N"U93/E%K[:X8*S/[
MO243LR]B$-TP%B^A9&SRR3""G,*=Z#!"'S3A%]W.=Y&LWUY661R5.JC4P4/4
MP>>(V*&("X&*E41!(&*#YE6'%2:QHKI0-?RC30QS(XUC8 K92DE42J)2$C^B
MDK@*_ %7WD2[E/+004?<"OSEOG!Q2=QXJP?HVS$ZC#(@SPQ&#HX'\'B,R_4Q
M(-;O,%YKA'PB.8:OO88S\(. L_MOB $4$^ZD\XK*6-WY Z8%:[[9P<=^W;[:
MSE_X6G/#*,PO1N$HH4/%03620#6MZ\<#Y_SJF!SC'EB)(;',$>'.! I/-1C;
MCIR$"I#00R(@ IO=N &1TL7H,-=)7H%)+-G<X(IM.H<O(UU4;F'*YH>W!FX:
M$NT0AN:81I'N),I4UVDU?H)!@]U(*/2( HXP*M /$LX?5!%/HN.)/!',Q:QR
M4.$7YL(OM"K\PN(3)3D4N;EQ$KA24F9 QA9TK</3BTY#+ >;G_W&4P/FD)B,
MJQ('.FI0D"P*=)=FAJ6D7TH%OVZ>TD_.W^6/6J<+C3@YS9U'H!Q7EOQ465SK
M97&!Q%(8G2BMH[H_&&#M0@,M4:Y .)*Y'209^T]&ZHM@=(-,#P72W1DJ/]@-
M70Y%*]YR1+EKD 5!;R@?5T/2$5#1"R,$,'DI060Z?3_P^E'$F$,O"H3L4.(/
M-^@<FG?C>ZD;*'@,=D/G-''.KT9T:!@I\;_&-V"OW L\?-+RW-\^J)9GM3P7
MM3Q;IS9>!:U:YPAL421A)B<J&)R^M1BRA32)&H,E=_]"SBU<M<'A^0)),)TT
M@:_^DT$&(Y4SHA<XPJ'\#H)FK+4>^HQ_JW%RC$[9IU4+O4,'SV!HY=&H!/RL
M\ -#PP>4V6<0U9XO$@6P1%89#>>&3]XH %7*S- 18?>(N\98,GB)'_[%J&&\
MJ!>D';<7A?7 _XY,E\/$]T2]Z;SZ[>-EO?G:\>(448O_C&X%\3LS>Y5%$P Z
MZH89VC646F&'&!\.;>_%"FJ6Y07E591/>#)DJ$8,>$?468\%4=BK8\$AZP:*
M$B+&D0]FG$HD0C9-'(U_Y)80!\GX Y12-"D^1L"0+&" 2#<\7UF(MP).'5V"
MPD':M0&=WYK;^^8HB7.K6H5IHRK.B0P+XVC_C M"D?=\#7VN$.<B <-2M34;
M4^M\_/\-1#="J!FE4\7^@+T 1&U+:6RAB'N,ZZ>-I69RPP;(ILI<?DBQH(B3
M51ZNFHIV@'LP+76/P2)#K/<(!^XA3GI ST26HX[)UV5O R[\S0U[L6OQJ:F'
M]KCA^H5XDD;@Y"T^T#B(N?* 92DPI-,A/B"$OM4P;<ZH"@1E<ZT.,,#C7C#J
MB('OUIA2E>X)HMO\+6C9(S/=:!CIZV&AV[=3!D9 9('$^$.,T+0LD<"';1[#
MO&S1SK9!N#VN:?/=AU]@6CQ05"Y.%DS*#1%+$](&8Z\TP)A0TH'[*2AVX\H.
M,7.IN^#+ /E$04D-VHX[&*::EE["8'T7F"H2>WXT?A^C$#U8>7WJF>DGH[9U
MSV!(NJE455&"B+F8$0K=P0ZKVCRDS:S,1N?&EUG% %#/<0_,M)$31]' 0?0Z
MKF\E68J^G_EKB=1?^/]!9![150_<FE;-W-1G7UDE6>#'L!YRFR:<,74%!I^+
M)ZEEKQ1SK=@2MDH'Z/FZ$FX/=U4L5-YTS)GW?9 *YWT4?:\Y8Q[ PY]LUAUH
MS>8&Z_E)O4V'W]WM [,A\%U9X[3Z?Y7'\\MT. Q&K\&R82R;V9IVMIOF603W
MI]N&L%BL'<]<;^]%KR>,BXS=Y[R@8M&MR%@>QT:><=YC)HQ%/V0UQ6S64@.]
MU2?U;/T4Z<<*[IUOQHDV#VJJXHV+1!,)@AZ5V&?V4[XZS</&^RWG<0R#\9.C
ML1#1K,9:HX'%$H=&,R86,*&@'.'C!=7U,*D$(I2*Q#1F0GR0A$_Z5:?TJG/]
M"B82/#W7EAE[D3(KMH"M2M'B%4@<)<*@_Q[37P+*@T$G/=S3%\&0>Z]W7[<-
M.P]S3[E=#+; 'M*.^B./F*@X$7%H]G;:.,&23&GO2ML=V()"$:72&C3>1$!%
M00].KLZM+N4&;]OY35<@J.6NHW.*RL#A<=-Y%3:[&-G;R$NI#D6YL6/!P %V
MP0BQC@ZHJ=3NU]%&!EGS,(A8+Y+.1'J_LNQ=3=L+\HM>?VVF]\4 -M.H#1<?
M-SO.JW^VX<=K_3!FOD+2)! >DF#0EHB!P3*C%&%X=7W^Y;7#),JYH=6SPT]"
MR544@;XN8X%I^ %N\U2Z ;V4T#)0\<36I*JS*<).57,';9,$8R[(G$CI3N.1
MES'2,>8K\X3BV=1M0JY]=4:L*;8LFM1L;FQ;JI8]@*O9X*R00(* =',G&NM9
M7>%./*DR" R2(L$E3$QJBD>!J@:8%5$;IUR  <XJ!^ MJDQ CD*'TJL-EX;.
M4,&E-H6ASY5LK.-"4/G9.*?JO*OSLU6@#/6QH<E4IV-5%F(\,YGB@MQ6P;6*
MJ"02)_!A=639==5Q@Z1],$%[1,DW,2C KKC5M0?[;H!YBW&GC[+H9FD^K/8(
M_JZK.XF[(5%>8+Z6L9&P_B]5--;GW=><Q662""7Z!M!,4NG2G'<VD]I/HKYQ
M'3#6>QB)[*D"6]0:U&A&!0VC81HH:Q_-#=M$*:)?-S;'<8#9F)L;E_ V)#N:
M8ES,"$L>5F')N<*2.VL6EEP^61^&%@<]1\8=4\JAT6AM_S7L;2$E\J];KWZ#
M?1L.-*^S^0TB-U$U=$T7 ]&%SUJH!)TW2G;+'%+]&7G_HOBM\T5XIF[%O=RJ
M'FS6</+AA>NH=8LKVO;SH@XHHBMEXPY4AX8I6#<IBM9;_*_A2],\F291V3(7
M^MK=R1@*J\@.;NCD[8!;1\RI*I0/ 4T8@857U=8TD") ,(GL1PFQJ8)RQK()
M"9PO,3>I'H5U/.E17@1RLZL^D%77:C2R#'*[_\A+AT^A35"-P="%\<H2WXE)
M(XISV=PJ*UMO%IRFG4M-KZEM48[O3OTT3I#1HH,%.D5(VZRU>^8R. CI/$;E
M;=4](F/+BPEC@R-$M0QB@?XX;#/-WA\&J.()I)M%MCK3829Z(MI7.'T0/2YV
MFCPVL LD$<6?&8&BSOH#=CV[5%ZIAL2JR$>K:A:3P'&AK"PO5:5+9OF3G$=+
MMVBB;?-DK):(ZEOQ!2J+U$ZC!O%4QPN3XYP[B%]'#C.J4SL4WSK.CLG/)V,#
M36G_Q@0O\F)1F8BJ&1Q@S1SS7#QTI_63C0NS0J>4W5Q OK/MG" ;/#'Y<GT\
MQG QTT2F,_2)027"^ZCX.1A!0M,ZS+\8Z\LJ3Y;E+]W=_8D7.RH35'!98$ '
MGF!IU#0'4 ;&(.7X6M=G=E6.%:9UZ^X8(XQ:Y[\F0F)2 +C:#5#.>,".%3$1
MWM)+?3QJAXK-QM /Z_.0.D86*%PXY[!+6]72[@1P/=+4VZXH]9C-#>T'YZ67
MLDEJ,209I2(P\1S[=A,%N!+JK(6Y!L#XQI&5RE/<(QA]&4N(Y_7+%+]H*YJ%
MJV O*K;E94S\RFV-.@W^)H\\]R9J&Y^)S8B047H6T%AKIPX,+Y8591(1SD.R
MV)OU%)8_?;N*W5>Q>ZI;*I6;Y*VJC$(>G% (3YJL3^9A'S<?C*E0#*,OA1!D
M,_NT5(9%/&7*]%B/5F-7BG&K\J*SV)8B[%?+Y)9!WEQ32+,7Z"V&8&$1<M1-
M&.:T1\0NHS'['-/4YP\[^,(W_ 7;3"A&IDH8^Z0[VM#AC8L]5-7Z6^SZ*\4*
MK+:OAZU-(L=2C$*T*,Z\E&$.BL13+U=3Q"GLH5UK\SU*%P_ ?!XDAK/L3-C6
ML5Y:V-8Q X\&72S[RS>KRM<^/TC7D^)DB^A6P:TXKD?X#.$P 51?NS84?MMI
MNS$<DN.<-<DF*-G'7-5:F;-4)ZI:_-7B?Z&+_PI]<1T^;U[!*H4#I]F>N26T
M9EQ:PG@:#46"[$%6L"BKA*3.AG^GZ)#01\,.8ASC\/GP?8LK*?,L-(<^XVHQ
MP0V,)7)-3!2C\IGASF6/P) \ B;,E(64G"#B\JRS\9>+2%YA=/PZN]9R[@N&
M*H"&DI0K,8RC#N'D:">T "=47&RDG>VQ:(^T(U-1$+++7><.6KLD;[ 9\2R7
M+^& NMG$QJ.*FQL<&54!5_*GV0"F#+1$/N<8^H,NJG0(SYH PVB'SK9C)T6Y
M&EVHDC:'0SB^HKB12QJ3)LF/"SHA\,@U%E,<2Y=!0[>8%D0NNDB08K0)HHX?
M"1A5L/@[.)3:Z"!8(OJP=,5+<B41Q)CQ$(0MGD3*D.N3VL?.<(3,C_G(YHB&
M'E71T+FBH;MK%@TM=T21BQAC0=IS)>,HPHNN9JQV3?AEV<78EMG*>V,D(2%.
M"8:$*=P>.Q@H8%=#5M@A8:J+JKWD"%@UC-Z08BOK!H,"RE$N%0EWSPUU!KJP
ME3PA9TR]72PC V.[[7PE+FZ;@5NY)G!Q>HJ.6]K:7R'/N/8NFFOD6E?6F)"=
M/I-,FU)@ X&Y[KX<&%B9YXX8+>_S\/#06!GT615<I@HG; [33Q*JB*! 2'5K
M"DAB69@ -I$X@B.>M,8/;Z? "@PWKF[ML:'HZXW<!MM&)1:X= ;M8.Q)G]@D
M1W$SJR6G]5%)"H4JLZ@."%N&IT/8CE,J&(S5I?.W<@ATL6;/$T6U?(N'ZR*+
M^M 4@N92W8&Q80QA<6YP.<OCEF/9O4C/"8(7F0E?!=<H6[,]R%(+/F#*",[G
M:9SVG&,/5HA/X$4-GOUP>DQ A<V-#GK2R=-'JY4,"XI3%YJW:$0@:( "X_JE
M#*H?%WC=E--C?-0G-^[T$3G?TE8/K1*ARU.#B6/RYYU7T,*]9N/5]]>O'64E
M.J_05T$U454B6N(G&.=_Y&9!"?R_H0,C)+/J"U<5H*FQ$O;!>(7Q9T0'F'!P
M=I!6CA?VC<: /]5-M4H&4@;>ZVWGF&!SV;6D;[*!-.;M+?P>P70SWI.JP(=:
M5Z@WLI*U I)^PG9OXGX78RD(T@>M!6/2)UN.:R@XV8S;C]5MA >/7P>:)?=^
M59N76X=Y4VE<4+#>F/?(6\)#EZF?!4[BR?B;-S>N"*?;@]LO,F\XOO;<N+7_
MJ?S@XW--$FZ .00<OXFPB+E5KL;$ED%54N:8M" ;&>Z$-RF*8*GP+E.N=!AZ
M,@Y9TF6.L3P/K 2U<[W1.,\WQ.V2DRM:L1I;HFE8<*80#&D*VY1)$9;D5,IX
M&8-"A2GU&.*4^K)/0 <-XREK_'P)*$2%OHL)?;<P"UPU?Q+1N&,A&AF@^,P#
M#2=4JI-J8%3NYH;RHRLR8DJN4'G).I_$RENRL=JF#J"?</75S*8S\!^JY<(O
M@%6,6PRJE C3%-&V=@?V^F9EDN6-Y&L>4OY7S]0^<(:8^4B9:4F$7HU7'R_?
M7W/=%^2> *L.SG*DL]/0;+J?/YR\1BJ)H33Q@MP["+&H[Q *E<3.2CG .C3#
M?A0B) U-Z(3,#)5:$;7]@,WHE%'GL-,B Q;M#;1C@<V.;%'/+@0E45 M6Q:1
M@5XBZE%QT',F.9I10HQQ$6<TQ"I'19K9Z_J4N9O+)>]2^BBCE)AGA%&,2I9)
MB%1N-.<SL;AB BIEJJ+10?XLE!64=;)ETM"8>/B8PT:]3R:NWS75GTPSJQE7
MS=CA&8\%NPLEVL2OR._7CVXQ)Q/'&>T2L,SH@JB;./O.8$#^05"I/$-A5B8U
MUEE]@GD)C,Z0WTT*$7(.ZZI39*D$PF1,@0T5RBX6.C4\"%8^VAQ.P&:C\@+.
MY07<J[R ]ZZ775@O;,91E4J57IV#W6N/CZX19>UCM[@))KJBKJZ.:&K>P/IJ
MH[-^2 F#K&\U^?8KM2#I3)@D;J=OI8CK/%?E<S%@<+RX'P4Z <UDI5K-^IFB
MZ;>QR]LO7JU(*J8<K,U]K)IO1-")(R0W<(=J;\[U0J9^8G)]\37L?:/3)L>]
MX@$'#7I:(:@WL &C0*QTTM3&CXL;OR*@4+F8,:'2F28"YX/RSFL*#8_WFO34
MW$%UK_&3?FL"%E!@I3YF;@Y]1"*_'STL58F245BG(<T,-5?Y/%!_J0S?FL5-
MQVN"AXZ.O9@77"'B;8>5 B??""X/A[43OXLI(JGQ)C#N'<[LI[G"&_JP/&O6
M!1EPDXZ_AC\'$YNSJU+.D.'B<]F2490-FQN4#Y('JEL4/SI[@F RN,&E"=>R
M??:!?<;Y?4(,Y=J&N&]N'&?9Y(L.IJS;H(XO&CO('(K;S0V0RMBMVV[^+%^
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MF,:\6^4BYCI"#\N3(\HY^WT\+4ZAY\BH@[]#YQ5;;K!0M594B\3PWR%;AB+
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MX6U*LVB^+"(QC;AEG3Y8=D$5O7AL].)) -$JP)%/I.Q%Z(Z1G"&!-IDO^YJ
M3&'@VNCK4=Y=W#H-=ZA)=:<%9@?WE/?/0%3&L+&OKC-_(OW:>FU.X/!T2DU@
MF!PH=]@_U$D8=P.=;8_NQK'<.?9D4<"#4N#)]5K$ZV6P5,2IEAE:2(ME3D.T
M_U,*H6?*PID.3U8QR8CXLF3^LB[PBJRI2GB?8+O(:B-,!$^(8R(EU: "=C(+
MO"G'@B\+$" !@FO1]*4R../I8^2;,>$+.A$A1)79)QF!F#*-!CS XV:0EP23
M$8SJH?@=[M[H>:.'<-(P6HEHV;*Y/W1'6H.@"X0<01D,@;9M.,>D0SB?A DW
M ='!&G/OO%<YRHJ6IZM[K0!&54VU$BWU@U:UU&= D6%=8OH.'9=OJ 8(>SY?
M78)(OU: ,(+C#$WY!K ,DE26M?9\-?,/FOE3#1%1>*QAWXT';F>4$3 P-6<,
MHO#^TVO0@AX?GEP+D5Y6&:B(Y7(U$LA(QPDD6Y;GG/S^_J"=QI*+GG'5[[+.
M:+6J'\95Y"*1MJD>D:M(^(]F8[_U1EDQ;T8(HD"-KVRN91HMU6FE.JTL3>15
M5%8CEH@GSV,:"6Q&ST>XBF6^:TBB%Z$7'4'QQN\8HC)4+#N4 ,"0=84TLN$&
M5.H/#A!]00%-]2D<-XRK@L\WWX6I&AWV!&-QP'R*,7KZ7:=V$_0:_B#V6PU
MR3@XJ:P)$EPI:$G(Q!69[P+ZC!1%HYQ+1&#EE5#?8^C#37.,(_(^3E#%7<T
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MUBO6G;$GP])D>"!U/*L[C<F?S.!C>DU C#XM+BSQ2JL==0QE(E.T<@SS#K-
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M]D..&/GH!AJXFB1FK"?V09(X"?P0-(!/>?4P"@,[>(=>?1)?.*^Q:UVEA8M
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MIPB>*4]5G;^K-5NMV86L6;4EZ;S-;*_0%BD9J?0[F;#9#F-[:=.A"5+BZ6^
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M2YC,A'_FG</;4\#Z)/2A<GHP4J*,0QVM%0=0_:\"KK@G\<9_T]PHRY91;P%
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M3*V>2#.,.0O$H-"V<<6N95</>9D"*/&8KX94P7"/:25+)ETJ%P&]?^1*6=N
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MHN<TW[:D_4-C1COQ24R&>\N&ZT1VS&Z=9CNRDPTJ/8(-+@H#GZ8G]*>](F^
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M@)/61<[\]LO9@_Q[ :>F=')8I*Y#.=!3F#U(OR<O6Q35A;4V+_,E"_66 $E
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M<6%-KW\K-/+,8,.T(NMT$W"//V"U.O)\4):"I,GW_X^]=UUNV\JV1O^K2N^
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ME8%'LKZKCXO5JJ\BV2(ZJ-E4? =2X!AQ/QJO?!=6E6>-[V.E%$8$]=&S(P]
MH><L7X7V*]1@%U7=.NBH"5M,ET4Y6]:UXLUG=9FW4VTQ?2XCNRAF?59:11V/
MX1IGE<C!E3M=]P!INIL+.5]O(!)FW.+C%O]T6_S\651IM@("@'N/3[^C6R8.
M5Q%M*+\9]X!59-N^W1@,-K\>K$:<&U"&#@]M!"R--Q) 8133@E01WEZ0Q;1$
MGR8!TX[+A3M?G@XA\VH=]9T:,TNP8-I5M&(+NF_&F15YYU(^P':!&4P1U=\;
M]J%7UM^:D"%2CWD'ZGO*R?QA\E#RH4793[-%71V7Q6L)#  2G^7'9\G17__Q
M\OCL3C)K>H"E_E9?YC+Y9(P>\L?84&87Y 5/0]5?6XL<4EW!DZZ/=FCF"L)8
M0*&/]J%I?JRVL*RKQ3&X;*,O,"\/:)4&(]IZFU?J$3FPJ6&O2#6U?0&'*W0M
ML1[* !*9%: KB# BH,T>2C33B9&0H=61S)*SDP<N?-)1X 7;T$C/3.J=[4:Q
M0!)DD,Y_56Q4>@4PVDVD$/CL,<Q?97G6K>E6*5VSA)*J5<K6[BIO%MKVQ7,H
M]?W2["Z@C!O"O&D.Q8;*D4+8=$]*'-.QW(+*6E&J:H5P4J[I^S04+L(H&IL;
M,H9A0[LEDMI%%SIP=T/')WJ)"_JTFK941!Z%HL42XH !3 &Y?S '@'M6V"1+
M<?(;!_(U.5U^IZPOAU]!T""WB4'!LIGCKQ,ZC-C<N-N*6@)W;CU0L:EOY"Q(
M+"8RD04\4UF5UX7\0U[+3.Q0AI<E+^4"E]%*+2H?G&#T&T[E^\Q17V3ME.2)
M]BWYHXQ>COJR6$V2;+7N%3.<RMIHZM<Y.@F;65%O?R\UX0VBG/\6/:<"0MV3
MR93,>\*!T%%I-/I 64[QP/H<:K&B;O_DHFB+SH&UQ00W"_'D-DE3@Y._(4^
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M7!BSS%?BB-03"/J>39.COTWD/W?<Q;3]U?7ETO/[7:WPX<%OK$$<_?[\MSM
MQ9-S-)I:]W;T2E2<5*+<HE45&=+ZE%-*E.MA@9')Z4EN0VW;<'S4$YGG>0$>
M"/%RHB:44(S!.\JVFF&PTN!:S7*CD79CNI"9M1@ZC3OEPKN)_= T7( Q%M?Y
MK#:]H#C@TTMI#X5K5QMXM%\\3+E9-);_K#OL9*<RRXFCLK?;&.DVDY-,--ZJ
M.J]85%[-98MX>^HINAP$'SON"H;;K-5X!_M!@AF-4WQ:P#&@6#T-=MB31EL2
MP62[MKD_N%2]0!;"JKK2&%IB @A6M0#XTS)QT:]B&D/MBS(.K*-Y?LFN$]1'
MLW(>5).RT,<09'<OT2I5=6SJ)),6NFF\%_HR:[H*5W5I@3O:8^-;O%JD4."(
M&B&)KN@W,N.RAIHE$N\L4+)<.$DW?!&&S5NB=;TV#8N4'E[L%18[7F,2W+PG
M)7KE#@_0K0O>PBO\N2]!PJQJ'8F.,+$!TD5]MP.;$T'*W$O\O^\1,MK<H@F]
M<=X4\HVYAA5\(VMC"@8DN+ FXE9"!GBM"67J7C$)3-AT:IH!4XI1QG(B?.^:
MT+(6YK=R1J?N),@UG48Y>1<D*!U/R'.IPQ&=?J.9W.W44Z6I$N)_TUZ-T [A
M=6']RKH,UUR&?B^&?9>4]=1I5KTAE_>Y]'-03%\MDK:9>M64T]-[)W^L%]]
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M1PP$.EZ/=1BH'EF<N9%O7<J!2(5K10CD6;<UI!-F&5J5W$*2!BA7ZG;)1"L
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MDH,RZGES8ZS3[SQ%" >0 X+([\CH.&82S0_J8?F6'.@5R/!A DJ9/&1: &T
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MZO,K#7 E$[:J9WE)UC@FJ^5<2TPY.):;D$$?DQ\8^ ]Y9G+QM#I!@27!DNB
M%:[0V($+L&2&,\W!@ $M\D(93**=_0BZHV,CF "*A#8%VAY5YWAZZ%]Q]G2D
MEZ#>:#1V8=CS_3(W>'-]67'OZNMQ_/SV?LJ\&5F,;X0!>GC^E1B@MR+!9HK
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M='"U<#G["*GZ]EYCKRZ4^?%%G+4TKOD?DV5]*=:T27U(X/"_+KG-/+P]PLZ
MKO%,&L4?'H"/ W'*M&ADMEM:=2T59)8[CV-Q%#V0S-H['29Q1<'D_0/P8IQX
M,DTCO,JG.A_&M16)O"5'YV<,MIZ>)# '#W],[C[0P"<6$[1 *[B)2"[MH^PR
M"+.^AW(3 G\[.R,=;W_5;0:P[<F(GSEZMFPF,ZV%K; %MX7RK*#@Y5&#;^SV
MYY#6,:@?NGU*A(A]6&:<8J;.=_"?H> 1#(\8%N0B*U/5(Q-D\B39_B(_O"N5
MZ*(,=SV<X5'-E7'?*L\J.FQ'Q9W@[*L0KJSCG6OZ_?$BVR3GC]+D[/'#!\E1
M>*)C.9NJF3,"T6/=T7 G&-H,(W#C<M$ !K(S$J_#WN11+,>M$P(S&5,<L?'_
MY%K;%SL\P'/-ZYX4D%=)5491O:TG+PK^?![6#"*^-HFDW=W;>),(INUV?8.>
MIM((P8N0S+,X0JDTKC18@5Y<+1!*$5,K"9.">#_1<&<M"WIW9-K@,W=!$-+?
M?,L6YH/8[.451F.KO$\!RWF>A_Q"%F3M0X; G/\;DZ;55\U3^O"@JH.-"!LP
M"I0'Y.TX>"FXTKBZQ,!DI%?9$2#J8'R4=25:[4SK<H$?'CSW)ER6HQ6,IUG+
M<-QGM.+1T.:A!02X/>+2:%"0-6N*1=T P(?-&)_X-+Z9GD!YR^*N./>N06>0
M6L BCBJU7F_5/59%LM-F-HR3+8-U1=KJ4RR"]V;1"7@#1:[$M:U)SI@L"3&9
M"],B*>K4'[D^OK,ZHL(7!W_=$V<-PBR^"&;1EEFS8FZRR=\WXHMBO9TAVH%Q
MM9SO'CLVM/%ORK_@ZA/SF$$@5)<HYYOQV_7"8:^WW5MJ_(!SE[B7L#M.DE>1
M>Q!5A)S_1^OM$KJQM<<NV),+'1RT>T\Y3M8F[P98GBR&=H2,S6XB5K,BT<UQ
M)^Y/<4$RS3/*:ZGVGDB_,/SG<6[JNW[G'QYPZP_5F_5IF7,DW HRZ7%=FK+I
M/%W7.' +%59M._FK.?W,H#8Z0/^!COF==,]Q>'B =7"%*+,W@D':/<P&1\_$
MD,FX._!R) J_E8 A"JMKH^ZZU+Z$-;KSK54N7CKB($NCN4?T:XR<W&P8&-:W
M+,.E8W=9,+P,]"=@&F7N<KF7YEWQ,-%1K?D]K,*02Y4MDUL:U9^_B@F*8T0C
MJZ8*+4)0'MLQ!P+5J9!A';HJTVF^[MKM:Q\>S(E1P.=10*6K=?;H5-; IMTJ
M&SJ<'F^-&8X2]"'G%C_$]OEF25??7C$?^/<69Z'&+R:):Y26"U5CG)AZ0.&6
MB&AD\28=)1L"'$OF1F+U!8(Q706\(S_5KY7Y[()692.N4.O](-9Q:IGFMD=D
MJ&1*,S$U>%426UA]28>MP V_V1C^AH(SM<0USL8RDHTB)PF#"LH2V[H;:L9$
M"\^-R"5N25@.\Q@EFL6!=2?H_[SZ[5IYM?MC7NU:>;4'IV->[5V44SZXE GO
M^EUJF:[Y:\O9OF0*3RZ1E^_B2K,(. @<S<>5 Z*^K(ZG.W6SR)D-7XWK@JD'
M#V5 7FT?@>;1M>C]UH-SIBA:>'(L\:"=I915"P\:BDZ4#G0G":YD=*W1N-VU
MLVX)U&)P+[JAZI2OYUPH<:,>1M$A,*BBUK7B09XU_>+PX$F06\2E7@5W[KGX
M;Q?ZVR=3'G+GIV?GP2@6$<USYYW\30A0#'=U=FZ'S7S?P?GA5?*W+BT7W]#A
MR:H0^6ZE]IA!P]#$]\4#[A2J%S4 8H2L6PI'(J&BG=IY<WAP?GI^EO*[C,Y-
MF"(^>MRAXR?GODT.JLIN5BHQY-_Q1<I%/L;D)-'L[)^<5N^.,SM2-L-3F3N8
M/#SED#[VN[KR_M'$RL([/_?.SL PH/VMC;)&SJ&*#4 :RMY10.M6!1U0ET$'
M^"R;=^;7  HB>WFWP.?#)Y_;C&H%V3M6&8?QDL-,; /:/$!K10OPAT-97K'&
M"YBRD&K:FS7<22YJ,E!AU\Y[,\$<+3Q:/#)(2]5-[-GNR9"QO"G64-7@@S7T
MR.W=RCN&0#IH<=!<)L8H>@"9(-1;KG!%K!@B3H.OY;//0:'C3N^/<(</2&$\
M'09I6E9187#S1@;6VI'YRD$1-:G4$BMQJ/L^:HM @X&]B9UP)*%:(;;+18YX
MH1= $2Y"TXS/1<3U_"NS"=RE$S8ZP&_6=,"^G%,,P!C<-!(,\OE(HJ.>/_LY
M'0 O='&R VC[$FYY1]#'IEX6$U97# M!=V+OUUKC7-?$*+8SQO\ZS]=;V T"
M'$.OB=%)%9YY"ID@"=8W"7_O6-KU5^'6I,%Y/M_KIF2'!ZZ@$3>[P%EQ18HL
MX.H#'FN0@K958F0X\8!TW; "(VM69G@0[H:B3.HP\/9^)0C*HPS"L%97(; P
M!,-63D+-).ZC!^_ ,=RY[%T[<\72YXT[=F-8[" QI#%\Y42;XP>1P:E-='/@
MGMY9P\$Z(&JC$I^CG!F$=9.HP9+=+W?LBE)A?.XRGB$(6U"QO.0Y".6K;%+W
M^^[$ 0S%IO6=^;TA&VDJ"WQ8[M@RZ Z.HRA!34],"T4$^F8#7L43*^ 56'>-
MYN'B=B1_!F*I!$<2\^"S',,7:^?J- =L69,5D0@C .>#])J[&J-TOIG-_O=B
M6Z6-B""B/)7'@CIHGZ]DV#&+T<0/=I+\HAW:*[:115L$H\$EQ*VX'/KH.E?Z
M3%<4?)]7X+<I.E_ZT6$[6^C&B)6;NI266<>0V($=:T'B+G=-#7K>%5UO$VBN
M[:0F-1[,X6\_I3SVB6<,R<&BRZ^V)L2,19;$<$*N%F;  K77U@7HA<WW:,<;
MRMVQY'6VMR,CG;*^I&]513L7KM-EL(#D#.0FKYW<383RM52,+K3)9I#SE%G0
M18W]U>;L'LJW4*HQ3%BA75IY[F""F,[9V+Z83##-&=>-/DB,NW M&9'%W]G1
MZ9:\_/ #. &L.*[601G66M]_Z,XK1X\JK^'8SITA"N1:V:8'8[;I>MFFLZ\M
MV_21FQ=> LGTPF&(T?^HS8.^U?KGT'A[D_H7GM &N<0(>YBLJ#5 ?D#?9Y6S
M5AMUM Y*MFR&/C$PF$6M:GL"HG1%]%)7?[TRDB.OT>WB-=)0P8<^_7JF>"SO
M&BAK 8:T X%W$9DBX-M!)/A5"E^,B_]V+?Y]'2;H"]%1N.X7B[2'2$=?0V 3
M?84>=6NXB+HV+3^6>NRN.93J!FJ#3%Y9Z[N'"$2_-I[8N?JT^+U3R<@T$1-'
MGO.BM#R'A8C_U[I@0B;4)^RB3/.P8&K%H''[CMOWQF_?OD+:N:_@S8GKUA4:
M18H?>LR>.T=+RE/*=W(%N$ [R*Y9-BS;^)($.IJ9_REDQUOZ)D(4?+4",^,^
MN5W[Q*<@!ED<:_NC#(O+I!L^)F33/7D%B5 JXIPU32>;SR7JT(-M*>UZ/C_F
M[1PP'1 O8^]:(<5G1U,3AX^.H<I3UL?-C4 H7>A^&_?:N-=N^EX3QZ[)H[1(
MDZ^8\O05)A]+;>U$G[9GDG'H;.J7XXZ:.5)&27PS0@UYKQ:E:&:A@<ZK%(,#
MT@:#F>,7"DVVW<_,^R2"CVCE!XF/&7Y[4=3EH(J@B$4=YR:"5 ^O/IZ/XYZ]
M%7OVZB[-*[:JYT5TU:-!<U34 WB)MI!MJ$KG@"3K?E(64]LMMND\E,5K+>@H
MKBS/*Z#<"BK;5$P??]-]*#6=KZJYHJ(O10Y)8[R]9&7LQ;/?TN&+V.:8&=A+
M)&1C',6N_8PJN=;#YXT?4-I6VJ)4,T.)F;9+5M8A.3,VZCS3%]=".;UOK1\?
MO\%55EGI"-@,-1$H$!5P8UR2%JT,;J'HC/W7+QP<J]PF> L&//-$>>YW<RUW
M#=&=*#)SAJ9]P^0VH!H&E$.. \W#\D;E!2#; !)/U!S_Z&<+=KE8 !5?<UC6
M+EIKY/,)EOBSOB8^Z'%*M1:/[WN,><3K:51G-Z:3#>5OS$]<+0  J*VU#V06
MCL2$)*L1*)UKH6^WL6>MHO-A"LB5E#6QH)G2#IG'[5C(V 7H+^R@))[HT$+:
M9=VNBXZM)-EJXNH<8O06O'MT@:3J&XJM+FO.F,37KIAL+(AR4 V^0"9@_R%/
M<AA_YO  ]1+R72PW+3C@L7+GA399)WN>Q6KNMH/!ZV<M[RX'IGL$O6)UR#X[
M$H!]YD$I8/9<:6N3F;48;!>)=-*P^Z(_@$6O>EW5EU4:F9D['FL:H*;X$_O%
M3A)'"+;U[GP]:8\)\\_C=WY[E3U)KFE.0!$4[,G ,&B%74R7&("^ZK*F8+L7
M1V0V93 >;8)ZD<_^G773I8>;^-UN4.?G,9P&*F1*FG-X\#/F)_G-@[)>-O6B
MR58W597O"^$.'>R&EL:($61AQ\P((:; @3BEJ.M\V'(\VSY*?<AOJ XN5NVL
M49JA'4"2_)S;%S0%SJ,LVA\*$=H[LLR-RT%KM >6*\(B'=^AU_F.X2'25T8\
M\23>0S2LV#]N#-T1;MT[=B9GE('74$" /8_LDY/DQ9#:(-ND =M3-%1O(V5H
M!E\L=<^1!69-Y2$-O HS!X-L9;<7I1)RB\\9PW <WLEC;9H\XG];%>VDR=@=
MBR-^UJ.M(1NBCI2K#0V QH/*A,ONR]NP&,YF_9B+TN,*P0?MP%$#L*E#S,O3
M@CK #(&:*6=_S>ZAD>RR;EYKYZ/'_47+$0V,-HM[,,-O@L \'"$PUX/ G']M
M$)CWMJK8G7V3FTAMA"8+['-7H42TJ]^1K.]ZK6\I.1AQ,3[A>W;0X6MGZX@K
M&7,JMR.G<IFIB$>9=V*^T *NE)9P.6TQ6W%;O-3B0D[#=5[):?P.>?YQQ8TK
M;L^3FT>2,I=0^:1XFQ?_*[;<K;90TGK[,AL7V;C(MI[<M$JT,\A7,,>E-"ZE
M:R^E65XB(K(HVS&K:T9ZRU0%LG6M4HSK;5QOUUYO78T6MEKUNI ):/MV#9:B
MW04GOQJ7V+C$WL^D*1)AWK?:;6?!KG?V'?['PF<B:?=S*::.2X--8VTD 16X
M[(=M87(I\"Z.'MZXAM\_<+664>!HF/3V+4\8Q6"]48MK7&/C&KON&C.?CPP1
MKB:A'*,ZCFE3K$B4)I:LS:?]L-S]"9!4-Z08]GX)VZMYW*Y(TKX#>B3BU]TG
M=T5^0KPXN4Q*SLIVNLQG?6F"7Q$R'>6-_8!SJU&W^0"2'F>#=]LSHBJQ<I*R
MPDNI]R]+[?N!DIHJ2GQX\'N3R7,_K5>.8"N2R/K5M=/?-,5-B@@'@1;E?:0R
M;JRRZZ5UE<+:+2_38TZH W-<5,?1E52/UJG'^<5CW]B>*R=&E?SR^U/PGLDF
M,&T;)4OF,:046JAXHM_5P=$PT[C7@*WLBMN DHRWDMOHO^V>>+!\M:X!'9@-
MQ(L L3+UHCHYRNXXRES9)_.L:!Q/J&MTDO/68P+L$ZS*@F43)"+95!F4'7VE
M:NTVIH1)P(Q6N/,?DZ/)'3)5H<4_[S)(?\KH&B<4X;S1LLCG1IE9:?$6T @:
M9F5!XG1IRT=R-+V3++).I2MG'#)@4L46G"%<:D# $]#N%M/7S2*K'$&GU_5-
MP^,YV;TJ6WB%2V0X:0;R:B&_GIEF-)_:RKGR1H *H+SAI*FSV; <Y:KQIOMI
M-2\"VR9 (-IJ&W*?QA36<__B05(79O.JQ;55&\LB^KN+G*"</_I906(I7PN(
M^^*VR@2#6D+T[LUH5GDST"EW#%<)MT%DU]VVK,-^]7(4\[ZC>BL6QAO/Y)NL
M5_PW+^]]>/"/3#EE/ZE\\>V7:AR*)W\B/H/WA/T\5ZG-%[\^>W86M&&G(+*>
MP;;;V:-[41=PLO,I]7)\!\\^]14*GI/3B3#8K5+X1:;6$8(D<N#96:%<6!@%
M-GR:-.(1[0JJKQ568FPTD?K\O,EZ=: R,8-#/6>Q0,>OB^GK"5 <7J<]P C;
MO)P?-_D\;^A(O.'^)\G_<0T-WHIMW=EN@)GKQ48M:3,@M.Z, .T[[9&OS4>C
MI7@S*-WH_"FG$#14Y<^MIZ]A&FY:K#.C34QV)S&:FK5"X 8&\06]V$;=4?VA
MF#F&"CZ!.9+*B.T!!3LH@C?!;!Z-,)OKP6SNWCJ8S9BA&#,4V\4"V NS1T]@
M>O]NIE>'@1.BIU:+-HZV^[5*Q="W,+*T=T!'RZ]+;6+!P0+=@ W-Q+2P5@_Q
MXAIC9 0GK0E^!"2\.)]]E2L'B25+9@5ZX,J-ZB&ZGVB"IUF[U%\GK^5/##^*
MBJUP3%)?9HTXQ46W])A$/3Z,)0Y7D_OVRECFPZMUWTS%L:9;2-$PRVR#U0%<
MB;/,.C)2PKD68'U6T+6JTP0%CW6VH2^N-&KRGQG//'!NE[D-',>$ YYF_IWL
MG@S6)F2$9GN/AK&!=K0\M\KR_)*5+?5LBY7A=Q!I:B-YNQL/FFJ($G?./;!,
M]EK;E?FD1&8"NTJ"V*3+5H;(Q!<7&?RT:,,S'/0Q-J[ES9=KF6?3JVM0 [[<
M_-F)9V?,9[X9Q#V1<MNJBN*4S\6+.T/@Z:WG?'*06< Q[2D*1$S]:]7(X-]M
MR\-57#G5H(NZF $"-04^WO6 3'.ZE4D]*3U-*;J)-LR*;*X>Y&@Q1HMQJRR&
MYCJ2YY4Q'NE(7D*MRQI$V&@TG=;H8[)?F<;"V>/'#[B9__;\Y9,G:; SNT%?
M6;CODJ[U3^:#N#%1!UA9MY4+*LUD1&?V)*_RN3)7X^R.MK9N?+^G0[IP*U1>
M9<35CAMTW* W?H/:?H(2RTJE_32WK*/P6S9DSW_/I\NJ+NN%[J^?Y0BK5\64
M&]"S[=OW7.X9,C*0_>.VV2&[88^<V]#A&(S3*3J:%;2;66YRE36X_VA.1D),
MBXHLUI%G/9O+33(C5B9W3G&1327X0(:X<>9&+E.UKGI"BGKG9DC4X@0CN&MB
M6HZHG##N\G&7W_A='A_#VZ=8\%0'68,K<P+XOMS2D2C"?[54P!2^*?[=KZE4
M95V-J)#'#G*U\7^SRT7#<?L+EZZL0!4IIY8%2V:R42//''9H]P"'_9!KME%\
M/Q[)XV:]79N5QQ/$E-D3C%$,ZKRAL_BE+[:\U%W1)J_ZJEV"=Q''L!>>&,!I
M9!_]\NS)L:\US9I^T7I5WC29%#CIBZG6:0R9X[)9*EJMNU[]!I_9 BV,);8"
M04)JG>-95>'<IF*<#\*?04R@<Q5T\Q]PT[]1V.25!VC$Y# Z'\H0H4&ST8'[
M>C?G;VZ/>H%:"3_H)@OWAZ"#<FD$^@T$$]9?G<TN,K)80LLAE+0BSA"7=$#*
M@GPRS7;]J[[$+Y?%6KTA8@[XJ""31;/*R%<Y&J?;89PR";;K!:K+6@8UV>N<
MS!(8B"__#GQ\E_MV7XH+QHIP@1=@63>M#U.QQI%YM5F9&_63AY<WLK<7>=CQ
MTR@7J7Q(W-;!,=AQ!V2,Q6K2-\:Q)SL\I->HCUTTLV/8I0UL2]T,*KR,)U3B
MEL9T!(%>,8Q7D)D*R -W%!T>K"'CGDWSGMN8;W>(_20V3B6FA@@'+0B5^45&
M(SJ3@31!Q,DQX6PBU&FRZ NXCY5A#N(K'!YL?8[_ -%I7RYXN!C>:C<)JV I
MI4T+U"FDU)"C-&;B7VU3E!M'S^! VW>8#<ZKZ&B+6:LLL]YL;9'\SW4.42CT
MV-X82JY7NW9#;0;2 *8O%\7KAL^TD%U.<7ON&-%GB(ZA4!0LB#(V:$%O5J"
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M7GX26;(Y368@6OKS4L^]+L0W-V;C^;RK^*K[*C9M-* 22_=0E)0F8"Z^\65
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M<7ZM^)!1P4-=.-TE!.>A?=.59-H1X$H&&@N@ZQ[)Q'B+*4Y&Z'F6,I8/3TO
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M;];"Y<&9Q74=S+QT(F>^35[0,1SIFB-;7HF741@,;%-)5;;JL+,!"+R__/G
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MJ=X4J57#G^IGG3L4]=&_"7@3'& 67H *UI3.&&N+BSYS^_QIU\T12G(Q@X'
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M*AHX$'4%7)0X&D?B*<!+B2H3D!-41&MQ/0F5BJ&5:;Y34.Y[PQ+>2"Y]L>E
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M<!9BQF(N@=7JP;3^<A")=1CSK!N,X\W#V*^&]>5L'#KZ@ L )AG"JKX.>5&
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M,HDLJ48A9%9T,=HA]R^,G5IO.@XK@##\V65I@^$RC+)QKA4?*-6TG(Y?#\(
M5UJ*F7![X_"KP+#7*F6UYR-HH)&9O)*4N0!,78SFB4R??V#,V*LT^T+V%3U7
MBH=-X;2AUOB.@TK@D"0M8=Q&[-P:5L(5,CO!UW$X#**LEB=AP?2F/F.RX.[
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ML.F4C EJSN=\?3[+NF467=2Y8[K-63@F5YZ32I=!%$, RU^J>-6P+,I,5%.
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M["^KA+"VUN"2-;1LF$EJP?'"/06\#MH,-34V_'[RI3WY5I85Y?Y4D--9R^3
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MT*N1;=E@S()*G'WR5=E\O+ALGCW*E>5Y;Q9<IJF."]^:@Y?)DR#//C1*3.:
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MY'7X*$MU)IEZKX#W YW!VH"'XBAA^_  "1R$G9P;D &V%<<,3AZ/+BL]@E6
M[V8$QIB8ZQSE2,WY2+LG;.HQ8TOI@N>(A^2< @"NUB6FJ5C-%RB_.W\Y/( _
M 7&;.O=EI"N$M8(@T<_!JP&)A,\);RY@=D $DS0N(&AI40,^83P\4!'?,K"5
M9I"&^2,0EGN%!PX@D!_!GU32<$:1T3.ZI&O;H'PB*U@ P?L?P-.<AS$ 'L);
MPS?5EC@+NO$$OWC",B%KI*GZX<%P-!ARJ /N.; 7%).QKM+MZV"5W8\1H2HK
M\>#(AR79&)*',G:5@:\5=$D /P^*39IP4.F ;7=/)<\A$0$#_!< E[.?C2/T
M67@ 0;*[??ILX"EYU+6#/& IR@/9L]D#-I-HX!7TD*39C.=L4Y*5(Z/7LSB
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M$(Q$7A%<&F'P7TW,P*%F+M/7),%) Q]=0X.C&,[E2BI_Z/(4&M-#WPA%C$:
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M%@FV.B>E&I( SSTK)'^L/*G&R,*+&(LFG^CH.HG6+9(8\!PP?+1Q(V,=4KN
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MH['(=-3YXWA73B"<5JIY!R7.$SVGB><,E0VWG,U]S #KS.#_P)-QZMV\T@
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MY!-?\C?Z<M:YQ#8U2Z#)S/&LP8MS^;I$A4KLO43Q(1P\ITFXU-I=[ZUX&W9
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MX=\O6^ENR[M))OXW#7]%ZJP$P)W=<8Z^?ZK%DK$4+>NL['_;$.W&X;,-P!&
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MFA,SUQ]=<J5'Y7FK.><+^N';2PVAY_[F\P. FJPAT@8=_D$(BA',V2F&9*0
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MI44K=WTVO$OZ"H^LILDC+-I:ZZC<6 O62S5_5#17__/P<O=THS[7>A'27'B
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M!(]TZB&R(+S</VF;G6)D!M&(*'=1"5_:K#PF*QZJ'@4]H_FIA04+'0*N=5-
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MSS>=%U-^O8IC5K7E*1NX":+)=E+Y&3"DD<_&-BCC2^M]312_^E!%.$1NP (
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M*92.97\+!O)K,\+L\ P;_C^3CZ5J*7TU?CUP0'#X<\U)[6;238Q[:>E6>K>
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MSFA"'3S'<@$\DO<G=?8%YGF?[P#=>>A&$M+@L=]J?*$=Q%\.&=SAF5L+W.J
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MI99Y+AMM($VSIDM]>=BWQ'Q7D^7?;Y5'/1LO,2_"BDD'/%)2T]8,<\^&STJ
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M;)B:CF3#M*U8.0Y'PHY>ITQ-EV&%ID;?AX\R9+L5N@,96 #+ *;!CH.GXD
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M;:/?B> _Z#AF3MCOD3WL2\_]=@3>NMWCK6WW^L4A0!BUA41+R N__N12)95
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M>V=ZCJRLY&@N:AX,HEH^M:<X6#O,_0X<$1'M:O1]JI^B[6DF:#"W\ZCC5KR
M0C/B+U@)8\.+X8Y:6+ZGQ*UMO,\24UD#4P=;->A&8@2;G$"NP."P <>J.UA[
M3? /'&3A4 @ESRBM)OI*L#6M9WK /-M4:"%:3#@F0HU@&%U78NABX4I=8Q1W
MD7* 6PD"K.YZZ EOBLPV<6)8Y6M$P>7!&'H86$9^P'5$;X"_$ (+]S_$4KXB
MBQQ+NVKQQ&\S\*)S][NPNZ9<6L@S^">JO:2H&=EQ&)VY-1UDI_ \L9X J*+R
MAH&L(Q*P70HN]4*.Y9?ILJLS,O_";**.58$#N8XHCR_Z+W5AMSJ8O*Q3$+%)
M7#%[<4IV79SRU.*4PJLO3EEX0" 1F'*\I3T9TWO(UKZH]>V'SYG':J&YY%!<
M_KI?S=Q>^H6SX\=;0X&/I7\H:_X30G(SZ?P8X&XZI;K:,JQ./CBHLC:I:>FP
MPR] 4G-)";G(:%5C'2.E,+FG3?R%]3N(7/34J5\5[6.N E6"#<*0=CT+]D-J
MK"<;KDD>>R;VOSF]-B4Z[77P;W!X6O)P^O'7O1"?F#?5(Z[[M]F]9OZ;U:S>
MYI9\X\O@VC<._/,OGPK[QPV:FT=K)AX+%[R^[B-6HY*+;[OH8<""-G'Q;$9[
M\' 8F=&CBJ\=;1\[T-'A1;O-HNK?;D  "5$W"MC!6*NU;5L4Q>^U7;#K[D01
MOLR54: ?C%(->Z?]*.=*R49=29K&3[Z:*4[#J5_HV<=6R[QN/GQ,Q,RZ]KW>
M]O8%HB_4'BQ?_'QB.58GZ)R8G;KI7?<SY[O5G-6^."D7-K2>U4-BOGOW??_[
MNW?G^1\;[TD:B=-$0W-PL>7%+M9X4!?[U?T0V#>-'[??<T.++<)B6T!IN5:L
M9/&'CS,\<$S1A&&',!DKHJ>Q/&^L93HL<:5^@6,TMA''!#T,#U@@2@++I+*$
M!I&%YK+J%"$\)*1>!Q. B#@2,A$A)# X"G>RAUR53H5LU:*"2^Y91Z,?2__9
M8A=/G-NNU2K\EY8S+Z-U#@W+([]% 90ZBE0Z*XX!E5-2[L94W[_NMW]]+OSN
M'S^<WM\L6=_L7O?SOPO'N[]^?+R\RX*O @MF3PW//TJ:*(M>*Y]IXK51;3$&
M*9"J=Y*JK:14E% TAOK9M@77SVNT'[D(AFKUK%X(ED#(&Q0'B)I &<'B-]6;
M$+ +=6[24M0G4T$XFYQUSS6:#,SAOUN%2N/(A5==]D&7_CDN_+^:B#9027S7
MAP7)?VW$46ZG?_P@'B[XU2/0Y)^TW%RA^S 3,P[0-@GG=J;%)+QWFF>,_MKE
M8Z?NVK3@2CY:\%S6/1W=IEO_,=X07DM6N7J4K@BO'UN% BL(KMSOP"74&-!&
MHG67L1.HB8--!?3UE/(S E^AAM>A=$<26/"*Z.'UG5W?V=6^L[FI[JR,"0W?
M6]_J6(A--Z)J=.C:ZJ+N$M_)*PBQ2-PZ-A1Q5YFPY.FIJBAXU#73HGQL$_R(
M!B9G"-9,_J3SHJ(^<YLS290.08]@*&W"BX@LCK5<6<N5M5QYMES)3VT+!(YR
M\2DUJ.0[)7Q.9*(K9:*OXJHNW=W:#R2L@>6E4Q0ZV2;)YV!@W614@!!WE8CJ
MAX5Y\=%[L@>L:SR&IT.5]694L:^K96_*0:V#]%&XY$*TXM:<YGZ4(#]@"B8&
M2ZI*L&2*;U_WC_9/G<OR7O'B<8X3 9Y5^7;4.FM^-)W#LYLJ5LOS'KBB0-G&
MJI>^K<BE'@)&HDCEJ!9O3>WZUQB$&[L1APL55IC&BV]8L6V0@!\X\P"7JQ8#
M5A+W:T+:O!;K8)GE@==]W[XU]^NGN=^_5J+8?O^Z_Z%FM$O9>L'\9&R\_Q!A
M3Z53\2VM^N5=K3AHC)#)*%ZR9-Z/U\R#_O5<FZO.ZO"4%E;8BRHI0F; XC.G
MIR.L!*)81[HY2O51A9OH_L,P+.%G^+*0#43'6C:H+351H^ %$WH/Z3Q>&%1C
M[353/>&ZG[_JEJKW!U7K?!4N?_6Z?WK1_79Y^N.F?)C?>'])W9.[V#W)V&=R
M3ZM^]5=1;X?#%/S17:D4OL _:JYH]+WQ# * 1V"93M=V'TU130H<OQW]!NLJ
M!W+Q=<;,$%E4T6B,'30:^ELH*+BQ5M<"/PA#)0@[%C7=ZAHO4A2+TF*VFP.F
M?AS:,&S2E7X?97<$8)C<E036%^W$]%REJ(#J'+<O&VT7.Z4QWH1_Z;A-D%/T
MMJ:)/HW%Q<.4/8KEDF@$AJ O2$\N=KA'O&18PNA7&XX@^W;LE9@T#@N+16VR
MP-RG4!B!*][CE G#CS5I(ZBQQ^A-FA-@VIXJ'T1!%(,#/4@DR5\,V@Z;\"QT
MMWR)J!/^0L;AX% "CIEA):KL&^BY J"6L"4I:8U\1"ODZQ#U#\ R9')=C8HQ
MB70YA>"7^ARQ8?,!09E\A,)H&W>6ZPWGP*>N?LVMJU^?6OU:7%>_3M#=!X:'
M* #^N>E=HA08K[/5\J()W[SN9PKV8?;Q[*Y:,E=!6>^"LFY8]_9>[< ]*6R\
MAW5OT\+!3F<0B $MN-;5XY:!$%,-S3%[!"F<3H$"%*.4U,(W$/_ ]E:34?WX
MLV&^0F#]"!7!X]'-YC:8UQ[>"58!H7[BL)N"IZD.F$JG%"@,"8"Q;]FTB/#%
MT1IO",Y-X 8A @9H([6!MXE?1?4B7RA6H(RT&GYA.G4H=D8%9(BI!&^7B$HZ
MP8R2LL!KJ@^5PZD&<0T6(M<0S50Z8.G0Q*N^1R0V>$[=X%UDADZ>AED^_&G?
M'W\V*NWRQH31PW-9Q5SG21^='BKSBNDM/HXLSE;+>JZ82QA;S!5]2/5!>N\N
M@M[9:DCO#-/[O\?Z0[U:=/>[]HO1>^;IT*/HG2E6]7RV.)+>ZD611BRV&@5P
M%PS?C-_C>Y,'L-$NTRF!'8-A=[L1V*'-VAQ]G>LF(K[+Z4CB6M\3($T= _$]
M:UO2=4=;F !]!:YZ.$Q\O)[?5Z[&J*]<]\_MO<M/WW]\O3LQEM_2XO?=<L:J
M'#1_&AOO>8T:#4E?Z^^G^]K2/S1IVI_I4=&Q\3"J3H$]Q1"+G3&?3((CK)N]
M>U-,[4H N1((J@_T" F7.(P3/^*]PN.%KX=0.>*NMQ3%B[_FID45?B.:(1!?
M<,]-IR0PF/% K@_C7.UH-24/2T/2J)43S!MPVN&#EM^6$R+A^4ETP[_Q2G@B
M# VFLJU;&C76-@@JG2HZ8 G8;.EA0S!67T<-JTF/I692T54)?@DB_H*ULZM&
M'B+(8<MA02];2;D_7\(-*RAJZ90ZV6S<:AD!G\$_V!W'XR6Y/&FY#%8L%SV$
M@9Y.M0VEXMS@2I2$4]A9TBUZ*Q<\3$XC2X9]O'1*U'U&"CIA9!O.R4H:D^7#
MHYLA$"?.QMK;TJ[<+BBI<B$33<<Z$I!Q0C);[W>T;S34#^^PV0L\A]L86I:-
M[,",%_$<ABY KD=+Y.;F4+/[0 K&S"=A9#X889!+>!7P(G(/C*#7=N4P![B3
MML"FYM<KH!@*9+(R;P/U;P3O*M<CEB/+KT*TOOAGZ'Z'2P[LGL2\"5?/03J9
MJT!LG-C)R"X,,5HVJ>-B%.9BY)V$'A())"5021,?0W%AWF%M*0;I%'S%J05#
M;./1F JQS71J\)0&F][!NG3M()P(VNV"H!#%K3TQ+0@C;0A[CN>(,RX<G*$2
M8V,^%!GO<ULM4147CDV#A2BXY>$7AYY#P-JF*3@ -KW-F][&36_CP\6IB'.&
MU5,_#[Y:%-Y@+P]WV<!=QM$XRFQ-4H/BS%FL"M(238L9/#@,ADE2XSQC$RDE
MQ2<S/>RNQZ#I$3*+@=FK!@.CTP70)/_SQ!EPU^-J1JQC"+)E0$(P:6FQ.'83
M4?H5SE?WW 0KU+/J^$/=O3.9A5LVAT@-Q+&,JA2%4%*G)T>D"=EX-."HP$+&
MT<5D-=@(9<,3)Q&#.=H182K3*6!6KVLZADUV!6THO*&R?D=44PT0D.R0 3;>
MT8[")P_0;^2V"(Q'04:FN@/Q$)G?I,!RN$H:$1A]P<*CIQRZ/M7$HP2QD4XM
MLU/K;6I6U%P^8VT,FT1L2<:T'1S#+Q#$/F)A1",4[@PN,,.O!:(QG#(5XC@(
M'EQYC/"2P;,O(9_2(!@QX4#190GZ<,1"R5R+.%P9[0,+B4>P!J:&$Z*,$(5L
MM#F/4U]MF997]6Y<Y,QY;,&(\Y:,M<2$N6>"'81CB]E$F@8 =G<@8S[-(Z[[
MM[MV]6;?*3V</*LM<(YA^-)1-MLXNGQTO2RB4RH;X7,X=OVU%S\E,H5*O72*
MPF+A''16S@2D)IQE,=^L)2:GFEX7))&IA[AOAB- FQF=B49DH9RA.!W:-O@I
M913!#OD&E+.U'W6$_E&6PT$Z%7M:WO#A)85M#3(,R.^5H;X=;;K(>CK%H?4D
MI*:$M=T+X\PW.B;/,_2C5\Z<I\VO\[1/S=.6WER>=J'8H'N*#;?+QN\EVK[[
M)LXS&J$^,LJH\2D?<-T__%CYWGULFONE10.(GYY='? )Y CO+9O]=R!C4\E5
MK_L'M:O#KY_KF=_=/$B_L]/+L^.C_=K5P7XZM5L[KIWN'6B7'P\.KK3]@ZO:
MT?%K:3-?&M#-".:HYJ;!XE 8PVEZI?V?]^7LEV@ TO3''3_7W8/K_L=O%]^[
M]\VS_4(U?%[3\KNV\?@.:[?,C?>7C;;9#&AH)\XU$A@MM$BME@ALLYS<"EW)
M_7!"Q/B[Y=?JZ)HUIA?@(9DJR@5^\NNN^^5N[JCUL69?_&X#A8,.G-8C/?F=
M%CU-V];42Z4EW2EM4SQ[:P:1,+)/;D"1Q)KF!EOA6&XG=,,-ZZ<-H4'BS5[;
M7&R 3[)!X0KR1_J F#2Q5>R^;?7,;3P?$_GRWC.Z_VH)CQRYDNB)\F +U4,E
M/;_7+]_E<P^][[4HJ3;'E_Z93XQ(75,R\_NE7ZVO7[Z?/[IS)/6D#23P6L(+
M-M['VO3F=!6D_IGM0BC?CMX&UQ>E[/_=*&V,-6^SD7G['!*')O]<::W297:*
MS[(OVVP- (Y%30@Z^B+OIMKH?(XPMY0C1%&WL--[6W3*#&[J>0P=2L%,;1IK
M[X,';O"U=73=GOS9W4?T\!A]+?QTB'!VI "<23RV_.YYY_>OS\>7=Y'!EWS5
MP&@ LMYX;N TT7!PO7>:=U/?S&4*>BY?T>&_6TG7D<V)<N'OI"N7C+XVQ$3\
MC/S?(U@B_K%LXIO^&O'0RL"G/3S 215BXP\K7OI5\\]:D>TJC^5ZS*E,6126
M44K"OESN;[S/YJM8@9=0#9:X\V0ZC;C&;^ $,J_P!)*DQOY2I,89=>6%GY'R
MHG%?VVLT/WW,!OD9Y,4W%,03K"0FPIEH"HR<2:;@6/:;EIM?XKXGTG-6/BN6
M]$*Y-)'-)M'CU1!S\.K.E9B%JE[.%9Y)S)=3[UR+;'I#5_7JV]G'UMWIQ4E^
MEJLZA6H?IHA<B]+"2\E-M]6[-SSSU?'=X"4>0>N9KW%.SU?R?^XUGC<YLWJE
MDM1\\-R+G%G*13XQ&FW+,;U']9/R,G__[L&%WFMT]BH+U;OA(N).\!0>T'C+
M<)*+-BV;/N4YRY(*8PYN5E:&M^C5ZF31D.B)3DO+/_H0!V71 @XQF\V!-U!9
MQ"$F2:G*DZ14OWW9NSC/WY1.FK?S-0_B6:>![-&H&-N-IU:;O#*]]K3FN6$#
M%!17IE#]X^R 6>F5+^;U3":[ $6OSO:N-1I!)Z#".'4" ?S;-O$?B)6D8/2/
M),.U=7ITW;2N^Q6C_^4P?_4I^^O7 E5X%$K%GT"8E'?R78JT^?X[K-Z5F\*)
M-]%<A<&1 Z]95VQ.:.^<T\$N0A1DP27(5">S]I0J8VM]C+,=XS,E% CTTORL
MMZTGI<26H:T=LS>@JT=M*;=3G(G%Z'M:TPWJMCE5,/F)3Q$\EJM6]&JQ,M4N
M9C>L5YP(^4Q6SV?F0X0XH.U@L8^H^ IK:6H%4(N/^W[W8Z]I&<W$$J9%U6;)
M.J:SEFBL\\^YXP0%!^/%'D=-KU?XEU%56WD54/$9C[WN6_W+GY:WWSRXL4;7
M<T456T"^QJ?;[U]+F=.]P]P4%5N:6((F@1U7LSHK]XSRK.P,Y5FYJ#XK;_J_
MZ\;)]\+NS9SJL[3<ZZC0FNP/)'QREB='94#[2L65T:XW?WTH?\GGHAJ6N2US
M61LJ*G5-V>R7:M.[__;[9VX!&V)!NRY*>MM%22/(71O ,U^7)[WF\J05J$2J
MQ ,? U8*F"YGV)JD_"J>Z#@EE/ZSEK J.+$AM;!XWC?CAIZTZSI!6'[T\VO=
MK51^_SCY8KU$^9&\1_>X-D8JQM6M?/7+5$<T-G?!AW,]^FQF#LZ5<WJQ--GW
M?0M%2+,?0V;1QY %QQ9(M-A*I.+BI<8Y"$NJS#HTS5!JG#3[Y?^^'I9^_5QD
M)#42#UVY"*UEFJ%T>)EP^[RO?@*!9^6Y2D6O9":SW(NE,=1 U[9O-K:MA^VV
MU6R:\!E@Z)SU4/?L;*9<Q(=6<MG<OR."7$^_*87%WQ2)?2$OR:\KPZM^/SRX
M<)95_2.OBP30>%L7)4[?F1/[9;V8GYP27OD[4IG_'<DO_H[0$V3H2UZ4Q]-*
MY_?-B??K>([*)-%AH->_YI3,<F]<PFG-7HJA9PJ3Z[+7Y30+L6OG>) %/3.%
MB3&GBIJ9M':_N=?*5FJN4<B4%Z-Y1Z27QB7R!@-&;R-[MV!Q-'M!>56O%IY>
M]_6VLXP+%CG/J;2<QE%>1C:T=-T/?KFN<UZT,K6%(GV\#.SUOEGO14FT$=G4
M6!'6B&]<]W/YZOWO>^LP%SQK=.24B"A:?B08ROYUOW%Q<)3/YJH'OT'2XL<O
MM?/:C]KN\<%KP3U9.F#6_ZSWY^?GVJG;,Q&.=A76(ZFS JLY<[1:U[-L+5?0
M$["T$.3/M.X(F?FO?*FBERL9D&H^CBJ 7]HN/'H3/R])O 5_;8K)2>?&8Z-M
M@L ^]^ O+(KAGS>>T0F_M*4+O.Q[A A58;:CYQ""X0T.9'(P>A3B>^VYGNL8
M=Y87^%K-:NK:!:+6MAAC^@!DB-L!62+&*CQJM4:/7[M7NX![ S]N,0RO7'LZ
M)0! Y>81+:QC-!&?%0RGF[9V"=H!GHMH7[;YJ.T:SBT_\ACQR;RM(7AKQESC
M0(4+-*2M7'80@7<7L<U-'Y:NP'>Z3CHUCFRX3'YC[<8S*9BV%8' \BHDHJ^$
MV)7;FRO"IU;.[^11#6?>'L0>\@3!D*O0O0HA$=JV&2#6I[P[F5Q.080E&&2>
M RW1V=7I&/ 5.)RN88<PMH//1V0\K64] -\@[#TM(+N3^9OF7Q@.6!SRUOAM
M@R&70QAVA-_,9K0.;*J-4]EZXA(U\/Y@@)E'\*C0T#&&#1 DFE"=$779;/H[
MZ90ZO@[1_;J>V:7_R(TD;0 ^VX-#(8QQ!.5EQ&#D58389I!;QB:.>)D4OV$Y
MOL9>G>'!#;K#9FFB 6S2"&PQVY/8V]7QP3AR1. 9XG04/1QI)[X OT&8.-@I
M/"0$2V2@5;JQ]X:'4^X0<Q?(ARW:EL]C^,*-I5-TAVB];H/&!8NC0V1%7*.F
MK!"IQ(B*$H672-81'S-"YHI-&-*I\D9<^?C'8/_W(3BC<EXD<?Z!1;<LF^!D
M XL;(=TZ$A)_]2MHWG!_Y V2MJ=^?8WZ.S6>/HV';4J,:"%J\;;!_W"X%,GR
M(4GA:&>-GHM3K5BW2OT@KP/=/X'C*Q\4XJB;OP.X7/S&=,H/PCF$20-O:= M
M_49>=4\VQ08\U%!>BVC>M<0(CIC)#V?P,.!T-!Y 0*C+D8CA7D-MNN:E\5;?
MGNM0; ;\,T*SZUB^[X* 0T;QEV0,#L >+^"$AL-,]QRW'D^?(S!\#LVZ%QBB
M'Y1+K$+XZ5#_^(C@\E=.SV4S&)_C$7$A85%V2[HZ2%<VEHC$:)V!XN%Q,09J
MKSL$P@XSKF#^14"W8LP,*LS \P-$'$0#CN9[\O322!1[YDUHOFDT1-83".N1
M#1L-]R([%!5Z-9^G"P=^JT-CL&BI!&P;9DJ%A4KKAYM.:Y>X\WBWR1H &>&)
M8:W9W-\L8\*/X6A6$9%#U2:0[LD\L!&G%^Z[WQ8C O@U'<INH.5R:79[%$+5
M\AD!N4MK/,%/H$#9-]#BQ_<)$4:6@87#42V$[V59&?OXRTB)F?ER:5-G9EP?
MG5LXYT(QR>*S2?ADNW80<0..R T<.JV06="(,GGX(6J7 $TP"B;3-%ZZ9=$0
M*(R4T*05MH%<G+!$T]]:B6C, O?9CRX"L(?EX#AEU_-Y%!+=(KA-& 'RNJ['
MB/K\$06A&N^OW'(Z1?V<H;FJ#?APN+B>9IL&;.^O(HH,$AN;C.<K)DO QGQE
M-@93"U[)5J4J7Y3E@Y@):'H=?+!A=*T>W4.+)E:!T.BZ/L@<;=/0/L,-Y0D.
MASRTQ;G90G>!IQ%+TS'Q<SK9@'Z IFNB"T$0V,9 -ER<GSPQ\CU#U.OA<Y S
M^L@<(-O1B3[.NI[-"GBYL)D919O(DTY%AX@3*G"M"3MAIT:A-<U=CDR<"K@W
M0*L<_*=I^=3.L"7/PW;O<5?\#98OID?!53@D,(QX(N"C%EL(?C%A'0.$9QCR
M)F\,73+/:MZ$@\R0UWQA2B=82R&OT!I&4EPA]9.IJ^R)+J<E^B<E5\BS\]$\
M8ZNQ!ZX.SUR!5YFZA@P)G$NRA2:!AWN[<<FE<#T<:[TS>O:#N! -.2]%;%.&
M-<KEC)[/%,5!#$UMU;7HKA'A2;/Z[#HI1BG\'&DM1[L% 3X[)'MA#<G^5$CV
M\JN'9%\=M5S# 7\R N+2P+"6BZ/LY"6(V41\R7C:@A]70FA7-<T.WOE8!"'\
MQ'#(D411.L4QFL'@TQA385KK@$W2I-7J\-M[D*N>CJ_GT2YH'V-6CESE?$9K
M C,H8:D8'5 /2!$JQB."N1[N]PEK3Z<&%R^D+E,UE,\)(R.B*;5BO-F0SH+E
M_)7;J925<;1HO:!^4]47A9/Q0"*!BZ.8L,^+>N*C:=+YS'83XVD<FAO#*,LP
MGD=P_ K[WK,[G2V<2I9DK,@91R+2AYBA';-I\12_F',3'JF,V6E[-.L$_PT>
M?\]S;;!K:,HJVQ F'.Y6I%;3*7F3V(1H&W<FW]JN?*1ID26P:6V%IBC>9#$_
M%%5H?+3;4]R!R'@<YP_0?8E/8H\9^9.,NX3KLFG!=F"SY$'$,TY2;DV[#S*(
M1N^"Y15:6I19S67^'3HA^GWVWW2J8QI@@"&E#65NFL42O&-Z-SR>/I8DHL&"
MGLCPH,<AG 9V8,1W^9<X;1['\7A("Q^G(8H3%)9TY/4 V;T;PQ&( K%Y/23C
MT?:++5 /E^<-?#D^'5>QT83/(@\T?@R)#/^DUV(LWW("DNIAT!WHVC%^T5Q"
M2<@[E_BY"ZK#"W,M?N#=6<@<DF;J>EA]/&4Q_S*_D4I6@CSP.1\D#--#C":+
MA8'(G1Q.DF!0A5338T1<'&WTT!!!X"+H@1%^L+I=?!"]C9,WM$IKBP_"-VRZ
M*/+O,B& :P[JJ-![%CGF],OD=_$\7EW.*R6#B8<AP?7$>8,CGBFF$R<_%-67
MAX-'\8)1N@)O>5?@-_S+E_MNB[[;Q%B<F.])B1:+S9"@._#TM69[=H8B#.HW
MS7J/HA.47.2\ -HLW#01)MQ!."HS_)"CZ8O2?&&QBHXUC2 5B#V< 1F:6XD9
M!V9;DK,Q\2QF>(>>'_)?^  2=AVSUW;%3-RA1RL3 XFC8FMD(XK?3)/ $^>$
M81[?Z *'/LA!O']E$=<I,^=9@S-QS1**H0A^VC]K(3"3:4XNBU*+42=^][I_
ME-O/?;&M+YEB>QD%4H61!5+%Z[Z5.^WG&F:K\^MFX_WQ0>WRX')=&35B-0?A
M=>0RABQ5 &6K\82+T01+%.Y4[7(/+O2.5BGDU+2%KMQOPX:[Z_ 46E);/">9
MK[>4.S31W8R[K"12+*G/NEW40/AW!S:.H5O0AF(,N73*:%7X<,39X*R$,.XB
M(=.,9(LP\#CL^LEP*,TT7.UD/IB-@&)G_%H.[AJX#IT'.GM*9+IE-#BO"JK_
M$NB\;YDWKJ[MH3OA>HYEB+-6#V&DIT*3?]%L-4 XB2"U"!P",9HFS4>5\HHD
M99S[JS'H6+ZM9SS=U[FA2WP%DOFL118OPH]81]?-AX_7#4*1*&1RU_WL?X>[
M[?,]PSTS-C0PNG"][]Y]W__^[MUYOGJR\3Y?W:;$D5A%.L5G0R(?O0.,%S5#
M9AK(>/-GJ;:B:?)8>EP^'WN8D/)D-#PNK@?W6AR44#6G>8$U';:H_0_WE;UF
MG(Q"/G/=O]S_F G./]QXEZ5)5<*)3]T8+XSI7_G,S)TC.;V0V'$0&VXVYDJ/
M<829%=%7P< 4YPR1U& T>"3AAXD^2/-<A'839RR_1@]$2AV)QYWS('-TLY#1
M%";[V=[_\N"?_-=OV*..@ !\GO**4<7:<"RY*0_CZ/00=%?#H&:TG'(RYZ#K
M@/.'3N7ON1R+&+N,V6^9A)"&#A8%=H*.O#<B2JX/^B%@*W7!3Z'D5(N+EQA'
MK6<\H*:P'-#69 A2ED',8V5WTI4T9B-19($I7+?=<[<#'$B.'H1(4'C\+C+@
MX_.><4VA-.0%4QRC;IJ.,B2^)PK+V!.\P_B\-!5; 26=8YM.I^2N=[1:9/.%
MN>[LWZ%.B1BWF>BS$)MWZ"HCW)''\36/8J]H'7+5FRO7J@@L(@#>F6:TYQV-
MF#(T4>D8PGG7Z.I0)I/"GK;E !T,'_-(=R+H&8G-=<W,M-Y-F(0S.)Z\[;84
M!D7W9E!>J4 C%_B5L]87$.GX^3/QL"/GX(%'$Q^Z7ESBR%Z01Q)>V5"39#,E
MU"2Y#[G:T2^S]'!Z,TF3/./=B?HFJQK_I6?HFUPYHU>+(Q6.B&APK QO.0Y+
M=NMPA*)R,JINB00)L39[<C;<&9!UF*ST7:GX,5LM^!_N),9V[LPI]'TETCU$
MH2/YW0M1GQYI&3J>_ZQ/;MZ]^E3_40Y-&;ZSX3<U^=6Q:BCY;:,4SG-. P?Z
M)#<<TFDH=?)L)P[4.<!A?0H<4QA=4B@K!G;'N#5CHZ_"<G<ZCJ9&T$2+%TBS
M.LF+ V4\)-USPJJ'[;USH7B&KN8LZ(S/>/YU_]X_J+>*[=VN5WZ.<SU;T>(P
M!F3AL7-0\-W[^WYUX_UA3&E'ZEJ1#*%5," B"-@UK.^(RX.0XXW$@@2,2=F6
M+PI4*>9$27C*K"R"?^>@.Y>$=<DLI P"!M+%JQ34JH3!JH4(V+*6!&R9^/#K
MOG%?SC>\C]\O#RIC42PY&/.L4<)*E<,8U,H!H,KI'S\UQ-ZTCWPBKR2UT2[C
M52J.7(0O654 ,[WC0NWP_/'XNV//<FQ)R'=)L'-#6YARY_7WH1"-!=:>0]#$
M93^=RL- C@O@QX%:IGH2ZM\\]SSUL;#7SNL]M-"]UGZ8AN<O]I1&C?>>RP59
M!LGG?3M(O\Z1YG,A[\3Q5P.&4<R*DO;3?@#&^=6]2UQ%D!A?;UNG/Q^KAS\R
MLR0CY@J>\63%5BG_/?,Q8P_BO*Y4!'ZX-/T5*??92?#7?%<R"J=QQFLX-D;P
M9%Y?S$20O%[()TVU6_@!SR(K<C/)BK9GFI&T</:_YWZ=?*SLWMTN5%J,PNYZ
MAGDWM5C(O[B!N;JO6L4;'G+H8NYX1<_DD@"#7N3@$B]V;9:+?>@&7G2O@U:V
M_M_)S6WVJO5:K(#G7/'":[MW?_85#WEU(9!@&;U479 27P7_=Z74*XVZ>VTW
M8N4NW^IL=)2A.:+PX8B&2H=XO:1Z:G</]9;9;WZ[S;X6U3-JD..,ET)0A9<3
M(32O3NAA80&T%5K*/-7>B/&(274Z S=B/@K.ASW\WXWM(4V7TW/5)*3=)7+:
M= 3<FBAC#IYN\Y*TV:T=[M><S*?]2^-M.K#G:K40O]YMB8RA'>%U+NC0D_!N
MYW:K<SLY%<ATX:0<'Q^;YQ)7SN9>A*&=SU3U2K&X+/DS(RM.!(:-P<+FK_O&
M4;U9OFM7\^>E.10<O.+R>*S4D"5^Z136W0R5)1T\L0Q9I%-_N3G;+1ZT]V^R
MBRA#?FZ(*%/6BX7196%8"CE$B?UI*)&M*@791(D@<_;]O-3]='LYL8QN:DID
MJVI!]O.FO^OE4FDD(621%38>^6KG$3-QV'Z$!..R+"R@Y>8$>[CC;6ILB^(:
MV^*IV!:55X]ML>@>L4OL"Q:MZ <$$01WC7ZYB]6!4I>.:AE3BVV?^B@0B%^^
MM6O?]IK9_UZ@R$VTE15E6QD0.U[WEJM=]_>N.IU6YVCOVT<P22ZOSO;^V]ZM
M71[L:WMG)^<'IY>UJZ.ST\5VFKV9NFZ@.+,%E:>"&#<$\+%M.&O:3<))5 !%
MLV4]UK0?MCO476R50SQ:RP-]@^A1U"*WB[_?XF+K.]$J@8_1Q'E$Q=%X%MIF
M^'?\40!-YT,,-882H);]&#8$>FS>G< BEGW((SKO:$71@A#> /L*">9&E">'
M"^ V0>[^H;^ )J\+S  !:Y#X:L3MR@ZL>D?[$M:HAB_0-1,.@UIIS$[7=A]-
M/+>(A@*G"V'H#"QS9=!#1*"#'ZDUH>ZY!H(V"W@) X&UJ E' F )L 7J780_
M"* 9V#Y8(08#2**WY).MT /1CL\5,%K@ZI = UO:KE/)-C^?NU,&/T^V#/?T
M*"1$Y *!-VXJ +!\#*ZGRY):I953)RR,3L?J]4SLO\9H##7:J-_=61K6RZN]
MNE>$P&!Z#0O]"6S5$MAM$:R0$>./"-U;P>0U? $0Y+][=22?K@QYU<N"P<J;
M1[%7\47*JXI_3\N[4X:&K:WY+K":F?,*L;<2%T5@388O(=NC[B/URNG:IK&E
M27D.^D;1 _=M5Y<]C#VK$[8NTJ?Q!P*D27ZN"%S>1RI2=$&B3NBXU'$(B\I&
ML#$QF!@!T]*PL=N-FB*24)A8HT8H2U+8L'SA)80B!=&M;$2KX1<K;VX9EH<B
MX=:4/9H*<!-KAZ9HP:2M,^)+?139(N0B<0ZQOX(Z:7A6/>KE0$UH,BZK;02^
M.7Y3(_>32=P/KV"J38V)H3T?)60M$-^L0.0U(MK4:Y2+.,-O^W<(B!<7C7.\
MB&HZ9_Q%!#.6GD9BY![?US2Q<UH%Y"4+]%\TSQ=5>O(\%E\N7T_J)WB^RD<H
MM064ARR"HUG[$">ANT60R<2O!,F8R$@[BQ/]J^&]P/_AYV=V8HA*Z50"^(2D
MJ 0$0F?9:IH"!A$T?UW@=\O0>3)BM/@D ZPSX'PH;12_24PFBIS;&].!=R&&
M4-,U&<"3T(;"U\6P](1O+O%IV 5&EYXB$,@L?M=T:&P"[XH0:M47@N,=#3I:
M@ ?\G(/Z7_W])=)RFV*NZ90::M-$]F0ETFSL%HLLFS+9*1XJ&8>QL9V$L4%S
M.'P0A8CP>$? \02OBWA5 ?$(6=FFSV8V_RV=XKB*4$2L@)J,]02ZBY061U0"
M)P+$:ZBD1225Y,YE:MW'R26%G)XOYE1@N]A6.9P#>T&J-,0GZJ:Z?<./(>\!
M+>Y-I(39W#;@9TPD"##A(6B%'*>KDKGUA?#O7NJ.[$^#'JB'+*CX-V'H)A)@
MB(XQ*,2FB2*F4VVC"0O:IA5$ P$,?M_V /L1U$E6SV:R>CE?WM'.NB%.:;BH
M;$8OE$MR;<CC PC&KIQ))M.1(H9)O#Z"-Q8(P% #0<]#=?PO</W&0BS4$B$6
MQC[ANG_WXW?YZ+#ZZ?%HEIK,J?D;!4.$WCV(GE"\[MNMK/>CN&_>_&ILO#>B
M-3,89T""6OC!>.+;?.(,81<& ?$+XFP6%P)\/9@'I.5(R:DJ3H$IP+3]#!@(
MN20,A*E>=MUW/P;[_Y7\C'.5'8N),"J1^$>A),RIT_ZU]) 77V</.?:K\&X&
ME.2KZ.5?"@S#FN'?$F@"JJ$7X.TIM_$G'4/F#Q4QBX>=2"*&,!_*B>'XZ8[M
MPO)OMUN>:<9;@ AO<UZ5^N/6OFSDBC%+F07M8$%+F3.>Q4 !<'FP '#(2JYY
M5!>#I3V[CT/E@#4,QQV"TT.EK8H_A\QT"+PD6XHN@(D2RZJO?:^WO7V![Z@]
M6+[X6?0"G- <T^M^_EOS['2W</G3S8? D"&[#G#JI(KDA6]SNCIOW.=U;)OS
MP3S.["3@!$C88^;1[2&0Z/RJLH'QH++!?]]_'U>/_'8NR+VJ4U9W,:]3+F<G
M@ELO6U8_)=6Z%N*O6(@/=81,)<2_')<.?O7*^=+7\DK>WN$.E,7)Z/)P ^PD
M&;V_JJ<<E]&=[*]BHV+\NC]<31D]ZI3G+Z-S._G1I_Q2\F]6&?TZ$$'F"X7Y
MU<6X/>(@KQ(VZ=MZ_R+UXN&B).:!2/%&#/(\]^;**#?:E6[G_.>OT+V)GKU4
M,9J\M9=U:2I/5Y8+<VB>?_1Q=6E]_=F]^M#SL_]9K^R<YZ\PL[F7T)<KZ\B\
M9='\ O=S-J?EQ\<?AY^^%K*]G\:*WL_EN2V5X:;Z27)XJ,%X=<XY+H?WBD>-
MP[/FUZ\'$V?,K=@Y+T .9R8/3EMI.?PVDCHS$T3R%"_'MEJFMDGE@W-K;E@]
M9?72[U^DLCP8%*+UR<*G_A3A@S-&L]?-WH_979B'^L_6[N?\T6G&#ET8^7CM
M6&'!C5E*RB9HM&W?;+QK!AZ^(1$A8R$$VWA?W,D,U<L]41^NQ%'&56'VZLM#
MZ\ I''S(/N.P1JJEESJLTLC#>KM2Z:7?OTBIF%WJ59K->[CXY69:)]:/WFYA
MBJOT9$O^]<B]O94\K+C<^^6;>T6O^WWW]/89A[66>RLR<6OU\PO[%LY6=82=
M_HB 8JMT)&_K_8M41:5%1SDDIU",H]G-S&ZG]YVOQ>JG*_MCO_XB<0YU)_/)
M*O1-SVT:?OL) 0Y"W,K]^[J#'.OK.;.EN(SK.9O!V#^_R]VVKCX4CR=BS+[(
M]7QZL/E/O9Y/0W#>N^X'[8NZO_?U][%363:"\PI!K44MLPQ1*+MX!8*3TMM-
MS9?8"-ZA?NP H^=]"6% X+G8:>K:V$L+SZ/;H77<IFG+H>R,[P=_]ZU.5V"G
M<-<F-N:F4_!P.#O+;T<X*-CHJZG+PB90V\;_RA;NNS"2SP@J6*&,O>:&1ZV,
MKG=C.%:?EB-P_KSD2F9&KVX"90D:$>X?K6/?L.Q'[0KQ%,&9T'Z@V:CM!=Z=
MJ>&M]:F-O1O0PB.,C"\[ESO:O@FKZ!%*HP!W"1_#K>]Q$J=3+5?V-IL(+R.Q
M':,6=_J;^**@R8Y6TYI"C+!1BQ] ,4"M]$872(WK,AL(%!6;=]^&OSLFML8C
MW$0Z)1_#K=7T5Y=HY$ADBJ[QJ$6?DDVX+J)TF43N%D'+$XRET6BX7I.@)0D2
MLW;Y13MU=Q 8HK2=J>JQI>"' ^KS1AK _UJFA4^B(X</PN$V&H$W.QQT:0T'
M_50XZ.KKAH->8"M^LBU ;<\"::"&@ $@D\9VZ5<3N_1G??AUW_'WR@=?B_=W
MEKG(!OZ:;-9&03/8O[]_W7>SWQK_G;C?O]X:&^]C4)V&6#CJ:;K'P3"\+&)Z
M"-@_$ENV>_]N :KRC;3NYQ)[]\>)GJAW/__DWOU<U+S_Z?)7P?AMWIUU&\]K
MWM=RL[3OC^S8'Q!]L1#7U#W*2<V9D@=0\L7-WVV&E<'GV<T1?9+*M\=VG2:Z
M:@DO29+YB2\F:>(/+GOZ/MNA=X^BQ+0KGX$\I5%-N;N#3;FSDV_CO<2(.0MZ
M8(@ZN,B%D6TH^CHU:T[=3/R<4UH&OX(>N8/[CS)K#HM<T2V>$O8ZZ,FWN\5O
M E-+J[%#-H^=KOCU>*:,7Z000^_I WJ4KUOB+X=8;T$W+H=2!Q)8\AQA00>W
MMT -.&,AH+ !2]B3M6O8%(0P>C',NFQUZ)2B7MM$FL<_EAWH,<6AL$/G'P;%
M*T,9^5E"R<)$42P45C#7UF7RY+#C>_/Q8R_???C<#LO$F.LU0VI?POVD*)0.
M[A8X20A,NC&PVU$=M8L)F8_:9]* 0@R1/V%\&<7"PP XTV+C?:&:T3/YX1;O
M$2PRU=DO@ZOF4N_]5*ZZ#E^YC\%2 Z$1CQQP# -\)#:&<L(E6ED4NY")EZ^=
M#Q?[QW=?ZX?UU\=J<F?70QM[%A,6,U6]6JJ^.B;,+88)I6$I[$JI@D@#+9(U
M+_IVJ>(=_/[QR5XUUAQ'DB4R[)?+_7/)M+F=8M+LQQDY]AE6P:A:H\$7#HYQ
MK^R4:&1L#7Z)BS=L"0EK!+VVZQ&4<!2GY/%KO+VQ=^D)%Z@PSPN$4.Y'8OZ7
MOV^*?QPYYP1UG&PFM&O-AYO]P]-6J[F1M/[E\/GXE<]UB&FR ,[G\WH^7YC(
MSI..]GE\,9K^8:+^%2]GL7;_M)==QOH$6/6\+_0\C7WRYL-;\,%S??_:.KUN
M6LE7^=P_N3_Z[][]7&N,N\J;B[W+"8M>POTMEG-Z(9.;X?YNS9L#AGJ(YLP!
MBS)^3LX?C8N[BWZU^8*:8&;N691A/C-?S5,01\SU)&@B_TG$'FMT+XKIG)O2
MX^Y7\R%_;BZ0Z>9'B!=A1M7H+NV4B\_DQA>TM*7R;6!8SK9IH"U.9NT%GL.#
M(P8-[3&!QO$.[:28Z!,NW5S0;<36#Z/ZIIK3/'CH6CS\9X*9WOIA5(X_%WY^
M_'8S==1WZ<)[XMZ68 CD\GIF"K=T(K#T.(/X)7FQME1>'&UMSD/XYTY_6+\:
M9N=2$?XS,/6"#=HY<?6"#)3Y\OO6*K%Z<9FL_B+6C[V7*9K>CX>[^V==@!?F
M_]=O+\V@#183S!B5L42(_Q=T))Z>/CI(-F.RQ99Y\5"X]WZ57S#:.$W"9S[&
M2+F@4[9Y1;S'>1H/4Q_Z/ 1EUOGA^DV[]*&:>R5\LR!UGP5M7]7SV>?Z@*L9
M\)PZ!;@X3BO^.#8]YS_'[MZN!*<]->^W!)5:V"D_-U&R B&(!<7_=Y<5_Q]J
M2N]_NKF!#?>-;M-:_?A_4D?$<^1B*:\7JBL1_U\T!R0"$LQ!\AWO/70:QT=G
M7\O%E8__)V 7+$C?SLQ7*Z!MYQO_7PC3_?S>J.__]^FS:^=?;?Q_X<RH*E]0
M8R^H?!>0AW]=J8"Y#(!Y2BI@6,W??K^YZYYF_!\GUBL.&BW!)L@5]6)Q(<&?
MU>#%N2![/ST5L!@]4#8/*E7[$.3M6TL%+,U6F2^_KU0JH+I*J8"%7(!ZV__<
M.__2;URV7[%47VG3:053 8/!C)'Q_^RD=>9VBC/=1_J>UG2#NFV^6'9N5"QY
MV/AY-$O&U\O;RF%MY)CX2?M:H5CQ7"(?^9*>J4SV4!,99G9#9^G\-A=HN:?R
MVUQ*W.[+.<NZNW&*MV^'91>6WLA6RWJN^/;9.?-B:9.%,'GFQV'K^UD[^/G-
M?BU,_N3,RN(ME.).[ND6RE2</PDB<0 DL7#=W_N9S]D'GQ[OC=P,(#WCX0E?
M-W*B)Q 1'3>=4C&N?,T4/-34FH$G 1)I&(=FPEZ; S8=1;SP0@YAV\U]6_.C
M^(M"JSE-^K'6[7IPG>CO%WB+?;KC4R&OE6=%7IOEW=?]PLE^[;_*Z?%#MOJ<
M:P3_AY^?'>S3M6WW'E@RG6*LL 3PMO)MV^\\[/_('M4WWC.N%SR%,!@UDJ\$
MQQD)4&)?P?(,N,F4$APC@"[C+#^$Y[8*2&KY9R"I59^,I):/D-1^?:Y^:AZ<
M?<OUB\]$4LNOD=2RF:7@H2P3*VPI,#)+IMM!)# 61K?90:0600&VQBZD!!T/
MJ//J\8+8=_Q?W=/^>?]V+LER:"==$D$]":O&/UV8'<-"@![Q\QX\$]5(8-CB
M-SC\3?QSTW*T'V(0X9KNSZ*[O*_BQ^EO[1].U)@@6(;4?T.T6S/D HA:N[GQ
MS!NC)PEW!/+3<GRK(7ZF60A3Y8-6 > NE_M[F-9J+$CZ^MM<<3.J#N>OA0P,
M%];>5]/'"!OE"GE2FHN_4J3!^(#E$04LYQ:FG&XPS,5N_^2A>7;WR5IT-/)Y
MY)DM2/F\D>6)8<OL3K62$+;D*,"V-L1A\TP=O@X.BX\_?-COMMMW7\[R=N'M
M<MBLP](3.:RZ4QC)84-Z2@+>C1"/S\[RS :5MZ"$C\Q?SIF/^W[6/?S:_=G?
M*SPIT;XB:'FO((&I<-$S<YFOA>%GF;HZ7HR-SN:%SK+B)8>#:Q\^+BP/NG]8
MLO<?VQ\;!2-$W7WW[OO^]W?OSBL_"B?SNTL5RA6^39[Z:WGU1DNU#OK]TJ=#
MPR^U3PN55RA57VO&_*U<BZ741DVV&!=E<K3W#^Z_E,^^[OTNO);+,2VQ7L 2
M*1=R>C6;_V,N1Y+.&()BG+\),MJ3>C$3)'/UZ^PAR'[[7AXR0?(_LMF3;&E_
M?O<KOU,M_4DL-4_$\\DL%88LPU@E3;*<O^QU?U[V+KXWJY\^3HC%OB;9.X)Z
M"Q7&F;BA G:Z7B[E]5PILW!)_,0:O]WK_D7K_,/16=$Y:=MSK_&+UO:20XXM
M>?+I%(7WM:[I,<@[#IML&'8CL&FH,<^:U<R'ANF'<W:Q @<+G;IHX8:_=#L=
M%]]*E7^..LN68+'+_^(42\MI6%V<X^L932J[@KW<FCW-O1-H\K)6,/YP+J%Z
M3?6 +W*L@M[I%!RB9_X.+(];AL7T4")ESWC0ZJ9CMJP>?L@/[!Z>)4]WAK\U
MS6;0X)H4RQD\>$4BP0\X)MILN#<.300(YT/+(Z3QV?%*4&"GEN48#E:, 9OY
M;:UEN_?AW&000)30(M8#]ZK';>KX^NC#.]JAZTU10II.H25!0Y6CTE3-#^!C
M,1H8ON]BX2(\A*8RQ[AP< <[_ZN'!UY_/\]#UTH[5=0AF86SYJ)J"T,-A@1K
MNS9H2?\ F+#W>.KVS*AR;T0):B8&PS7M,Z[[UM?2Y\:OP.H&-\^1UI-H"0=_
M>G9UH)4T$F?9?P=K17.9Z_Z1[V4OOF7JK>/JQGLJ3_QX=KQ_<'$I1& Z=?#Y
MR]'5C_!(YLM#<V.<A7'Y3*+M?];[<[+@"/B@04(!N'@9"WMI9;UK]NY-TV'Q
MEDYA:?&^V2#+2PO%6S@S'N6S;9+>1OU)%.M*BI$L(R\8_X62+Z:R-WGF="X3
MT7AK1U.T"M8:@% =S%KN#M[:(]\/S.8^5?IS^RO[WD A^M,@5 \(EIBU?BGE
M/M][?+OKH!H8,-?W:/7TRC [\U@/?CE-M_MC<HYZJJ5.:,[-;&=SJG4\M*3G
M#5^!XRU7DT!L.84<':9ZD#HVR<+Q!\ PAFI'_579*64C0T\74^Y<'^TRMV&:
M37K67SFPS'-ZIEB(GW[7L)H1,P$KWB!/M4Q<@:,-,P\]JYC3<\62;/MH@?@&
MVP_UR([V)1P@U /OWT\T(\--&."Q"%N@SC<BG5(9'^]%C^S:._!U7,^/WXL.
M7#8M\/GIJ-D-VW[4<)J.ZU!AN]D"8L##P59J6?"S 7^\L; >G5@G-$5""R&=
MNCS8PX_SYV G2$TX#@.^C:]./ARZ0T-F+)POV%EVT 3WY/_9WM8.+=-NOM/.
M@<3_@ACY'9@.UO5D<^5_-7+5X-_:]K;T[)O6W7C?-*H38F&TW7.[^#CTG<1O
MY#=*W>FK_9\L"F/5\_\#MVQL6?S YP^W5=I(JORK73UV@1XUSZA;C7^U4[CD
M3+E3%TF4SZC?^D=^#?\4>8>1;PBD3*!J%QZW70=VN=VNFW#.\ ;#OC<>_3A!
M2PGT1")'6D1YO+HJ7"ZO2.$$Y(QGZYPD]=(R.I;]^&[2,T890.E4.;2 CD[W
MSDX.M*O:]X/+.5L*)3:%IW-FX8JQ8P."[,[R\<IN"OM^*YU"KP+O:%/*F+#K
M9ZCM9D&,/WU'"0;J%M%3,G6EX=,>M< G<]AF4?28;X]-:2F%FEBXKAW$O=T%
M]XK,1OX_?>1X$C#)NO(XD4Z9P4TME%?GA-VW\7XO\#PT![M@-8*V>3<?/,N$
MSX6#!2=]<+EC#I^^FF>=T2APX\'2[2IR]J$)#&O8,Q+AKZGVOXRIDPM;R:*O
MBS!IRH6$C$TVJ>*>CHW<_B<D.I^-LS;#T.@I'SDB[Y?52YDA>3<FN_4DQ,4U
MI98H?Y8D9Q/)\%)"?X;%+%\O[YLMT\.DUUHQOS7%/#41-K-Z%3RC?'4*;IT3
MROW8Q60K&;V ,[2G7,RB;\TS5?+R\4YG>(ZD?K%<TBNERE1.QDIBO3YC[_EJ
M%O8^5 S_M+V_1K6YF=.+&6#_XM"YOXP P&')N6IU903 X(M'6(Q[;8+FL!SJ
M .9$B(&!4T1B?<TW8R1[O#+(\]DI,)(G7]JPGIY%19WK>1CPQ_Q;E DP_4E;
M6Q2TY9#;/AO>8Z*Y_4K0/5>.!"&/BD3?/')KE3&U6I.R5K4$"#@]GM%N&TW-
MP<+(KHE):.=&LS%3WS \[Q%8'0M^?6WS].S8W\)G&=VNYSY8'3#8[$?MKVQ>
MKQ8+>B:3H7O18LL[EBD+O*[KPT8Q=?Y7E@8RXN?3*?P");R3/DXU ;ZIX8LU
M+!<U[@S+IJP9)<.;0</46@%BH>/WZ _B,?BB>\NV-1,!T@G+^\[P+#?PM1Z1
MG H(<YE\6>NU04K<M+&"KP#DP2+$;B_<!;V;/AP6%&0K2,1L-82.Q+@T$)?>
MYYA87,IOG6<)Z7,X(%:M:=B^2P<N=XCEFL0<N)TF+-]VNU1^@$?1 "I;O0%.
M&&:!8KZ(YZFKE*B;-U33"90@H,*!$X"S%T=0D4< /Q3@&;@.YHF12^-E):TD
M"V>HK*3I:H[;@_W>(4_P:MBZP+K/P0-ZT6M*Y:U.P[(9UQ+VEDZI.H;SS9B0
M,[BX5AX@TBKHN=ZCYB'1-G/9O_DB1A4P(:MNR:$^W N3G,ZVN':6$M?^.FV]
M3ENOT];KM/4Z;;U.6T^9AQNVCP\35=7(M-)X-V&&#-'X#-!F BN.>\?6WZ]]
MY4OQHT5,EXP+/&Z=?8Q6:+B(JKF%1\7*4T3#_EZE52P_EW5N>F"3H6G=M%HM
MT\.Z57_1))FZH&#AA_/4E2SI_EQ,=LT6?DB;0ZWE+W)[\JM\>RY-[OK(EJO8
MX6<N_E365V>=95 .83CC.V5P?<B2>56[GCB1;_RN7S[W)8+B!Z!R<79)+ J:
M9"&_T,BL9T761PB(J6/K$UGT#R)"4FYA[CT[B\4;F/3&2]BUU8([B&'>L!U3
M=M,,@#RD4TU9A(57AG4O64NV9=0MV^I9L"ALQU^',==AS-<3QES'+E<\)K>.
M7?XQL<O3"8GQ1<0"AXH:)@# Z=5,-:GN<_: XS*7G]6KI:*>S0[52$V]_*7%
M,]W&[3:A$\;AB<P'_+<Y7E$^W]<N%@MZI9J;[&LOI_8Q7RKHU<H4M88O6Z=_
M[N'U[3%P P)5=1G39<$1JVQ%S^2G+\1<W$I*>J7P1)Y98GS3NT/KV6@TO,"P
M?>W_-3J@8%S$T5I\1+ZJ5\HK4;=;UK.5(9-BU6MVGQ*=?HWAI5*AI.>&D57_
MF,+=7+ZLE[/SV/^28[ZQOI(KMV?86D*88.'*6L]D<WHY,]04\5+J.J<72V6]
M4)FB.^@E%?8(:7-L^OZ[MQ:WWQS))']$U]!(CGS!OJ$G!N]'2)W]87E#Y0\O
M%<N>4Y7\<\/8;Z)58)Y$F'M ?Z;:X_E'^6?#GR3'6@#\A;7^6 7-P(8D]L'6
M).] :QD-!M^#=1B,5J[53=L"0]37K!Y6,7=<S]1LZQ8KPWMM>#/6@L,_N'X:
MJY$2TP>],0"_7.3OXJNT5B"0_6RKCRO=T6J-!K 4<(']&%M7V_"IO-NC\FWZ
M8I(JTXP;PW+\'@%FCEA>.I6X/JKN7ES#P=, 75^:D4[BE#>9U&:3,4VQRAY1
M[YHA*RB0S=A'X%E@,09P'E[/0+!H+(YW?8M1I1GJ&D.! HZ:CM!*QB"/84P+
M,&K#3J<4N.DQIQF#Q&RZ0"]D/).@]C4"255S953;0.C6R#V!HZ!EQR"H$542
MEWMOVG=PN3I O':87_-, C. W27U1TP/'EE9@T<^%3PR^^K!(Q>%]=UQF\UW
M%^ZC8?<>:Q*<=3+$=_[:;("\<#O;VU-\^;I_:YAV[ZCG_/ROO QL[\I(;._B
M=7^O[GUM?_SQ^U.UN/'^XNQ'[?CJAU;[<'%P<')P>K7JB-XK8D\<.=JG #1T
M+I,M#W0\TKT%R6@Y/1<!>)D_(NA?QMY%<=E"9\'T=!"PEME"L/Y&0*4Z;@LD
M+]@A**X[QB]70!TSCCPC7!_R=[=VM// \P,#H8QE_Y5\$X,'BT^BCH<=HI&
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M50==^*Q8GBX6E$Z%*Q($C4K.)>"VV.?H#7:,)C4!MZT._@>-E9"B@CJQK=2
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MMZB<$&90$B:6AM0"P^32[/;D:-]L5:<'A2D=,EWX<+D2I=:3D=7DPT9 43A
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M)52]'RT1V1&9=NCE&KU[!SL)O&BX&/9QNBT]^?G4$^*+VG[1\-'2-JTMM66
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MMVMBP]"AW9$M10?RYKL6_69'V!4&H*E.UU0HZ\-3&DZT>=."Y\.8DFYMP?R
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M,2YH=&U02P$"% ,4    "  SA,94QAU67DP(   $)0  "0
M@ $O(0  97@U7S$N:'1M4$L! A0#%     @ ,X3&5)OPN+$M!P  ^:D   H
M             ( !HBD  &5X7S$P-RYH=&U02P$"% ,4    "  SA,94.R$Z
MZ$$,   #?@  $0              @ 'W,   ;6]D9"TR,#(Q,3(S,2YX<V10
M2P$"% ,4    "  SA,94/7Q<*2 -   CF@  %0              @ %G/0
M;6]D9"TR,#(Q,3(S,5]C86PN>&UL4$L! A0#%     @ ,X3&5 A=16MA'0
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M9'5L87(P,#$N:G!G4$L! A0#%     @ ,X3&5)&^V94.'@  L1\   X
M         ( !-^T  &UO9'5L87(P,#(N:G!G4$L! A0#%     @ ,X3&5"8=
MXJ:Z9   0&\   X              ( !<0L! &UO9'5L87(P,#,N:G!G4$L!
M A0#%     @ ,X3&5/K_^@2V'0  EQ\   X              ( !5W ! &UO
M9'5L87(P,#0N:G!G4$L! A0#%     @ ,X3&5.#1M&%5(@  <B,   X
M         ( !.8X! &UO9'5L87(P,#4N:G!G4$L! A0#%     @ ,X3&5#55
M^YL>90  ,VX   X              ( !NK ! &UO9'5L87(P,#8N:G!G4$L!
M A0#%     @ ,X3&5"*,Q.H8/@$ 2U0!  X              ( !!!8" &UO
M9'5L87(P,#<N:G!G4$L! A0#%     @ ,X3&5-WWJ7*%C0  <)H   X
M         ( !2%0# &UO9'5L87(P,#@N:G!G4$L! A0#%     @ ,X3&5%/:
M7.I<%P  @!<   X              ( !^>$# &UO9'5L87(P,#DN:G!G4$L!
M A0#%     @ ,X3&5+2C("/:%@  "Q<   X              ( !@?D# &UO
M9'5L87(P,3 N:G!G4$L! A0#%     @ ,X3&5%F9P+\M$   K1    X
M         ( !AQ $ &UO9'5L87(P,3$N:G!G4$L! A0#%     @ ,X3&5#_0
M,W0^H@  R;$   X              ( !X" $ &UO9'5L87(P,3(N:G!G4$L!
M A0#%     @ ,X3&5*7:NF;:+ , NH$9  X              ( !2L,$ &UO
B9'5L87)?<S$N:'1M4$L%!@     6 !8 -P4  %#P!P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
